US20230010358A1 - Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein - Google Patents
Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein Download PDFInfo
- Publication number
- US20230010358A1 US20230010358A1 US17/404,808 US202117404808A US2023010358A1 US 20230010358 A1 US20230010358 A1 US 20230010358A1 US 202117404808 A US202117404808 A US 202117404808A US 2023010358 A1 US2023010358 A1 US 2023010358A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- optionally substituted
- cycloalkyl
- heterocycloalkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title claims description 30
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title claims description 30
- 229940124530 sulfonamide Drugs 0.000 title description 49
- 239000003112 inhibitor Substances 0.000 title description 24
- 108090000623 proteins and genes Proteins 0.000 title description 6
- 102000004169 proteins and genes Human genes 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 224
- 238000000034 method Methods 0.000 claims abstract description 77
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 188
- -1 substituted Chemical class 0.000 claims description 167
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 161
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 151
- 125000001072 heteroaryl group Chemical group 0.000 claims description 110
- 125000003118 aryl group Chemical group 0.000 claims description 104
- 229910052799 carbon Inorganic materials 0.000 claims description 84
- 125000005843 halogen group Chemical group 0.000 claims description 78
- 150000001721 carbon Chemical group 0.000 claims description 72
- 125000004432 carbon atom Chemical group C* 0.000 claims description 66
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 66
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 56
- 150000003839 salts Chemical class 0.000 claims description 51
- 229910052805 deuterium Inorganic materials 0.000 claims description 47
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 46
- 239000008194 pharmaceutical composition Substances 0.000 claims description 46
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 44
- 229910052739 hydrogen Inorganic materials 0.000 claims description 44
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 43
- 125000005549 heteroarylene group Chemical group 0.000 claims description 42
- 125000000732 arylene group Chemical group 0.000 claims description 33
- 239000012453 solvate Substances 0.000 claims description 33
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 30
- 125000005724 cycloalkenylene group Chemical group 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 125000002950 monocyclic group Chemical group 0.000 claims description 28
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 24
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 21
- 229910052717 sulfur Inorganic materials 0.000 claims description 21
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 20
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 19
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 18
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 16
- 125000002619 bicyclic group Chemical group 0.000 claims description 15
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 14
- 125000004450 alkenylene group Chemical group 0.000 claims description 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
- 229910052701 rubidium Inorganic materials 0.000 claims description 13
- 125000004419 alkynylene group Chemical group 0.000 claims description 12
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 11
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims description 11
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 8
- 125000001475 halogen functional group Chemical group 0.000 claims description 8
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 125000005717 substituted cycloalkylene group Chemical group 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 125000005038 alkynylalkyl group Chemical group 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 229910018830 PO3H Inorganic materials 0.000 claims description 3
- 230000001594 aberrant effect Effects 0.000 claims description 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 107
- 238000002360 preparation method Methods 0.000 abstract description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 134
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 92
- 239000000243 solution Substances 0.000 description 82
- 125000001424 substituent group Chemical group 0.000 description 69
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 58
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 53
- 238000006243 chemical reaction Methods 0.000 description 53
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 48
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 42
- 230000002829 reductive effect Effects 0.000 description 39
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 37
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 35
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Substances C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 35
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 229910001868 water Inorganic materials 0.000 description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 31
- MPVDXIMFBOLMNW-UHFFFAOYSA-N chembl1615565 Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1N=NC1=CC=CC=C1 MPVDXIMFBOLMNW-UHFFFAOYSA-N 0.000 description 31
- 206010028980 Neoplasm Diseases 0.000 description 30
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- 235000019439 ethyl acetate Nutrition 0.000 description 30
- 229910052938 sodium sulfate Inorganic materials 0.000 description 30
- 125000003003 spiro group Chemical group 0.000 description 30
- 239000003795 chemical substances by application Substances 0.000 description 29
- 238000005160 1H NMR spectroscopy Methods 0.000 description 28
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 28
- 235000019441 ethanol Nutrition 0.000 description 28
- 239000012044 organic layer Substances 0.000 description 27
- 239000002904 solvent Substances 0.000 description 27
- 239000002253 acid Substances 0.000 description 26
- 235000014113 dietary fatty acids Nutrition 0.000 description 26
- 229930195729 fatty acid Natural products 0.000 description 26
- 239000000194 fatty acid Substances 0.000 description 26
- 125000004429 atom Chemical group 0.000 description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 24
- 125000005842 heteroatom Chemical group 0.000 description 24
- 239000000741 silica gel Substances 0.000 description 24
- 229910002027 silica gel Inorganic materials 0.000 description 24
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 23
- 125000004093 cyano group Chemical group *C#N 0.000 description 23
- 239000000047 product Substances 0.000 description 23
- 125000003710 aryl alkyl group Chemical group 0.000 description 22
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 22
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 22
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000007832 Na2SO4 Substances 0.000 description 21
- 239000012267 brine Substances 0.000 description 21
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 21
- 239000004094 surface-active agent Substances 0.000 description 21
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 20
- 229910052760 oxygen Inorganic materials 0.000 description 20
- 229920001223 polyethylene glycol Polymers 0.000 description 20
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 19
- 239000002585 base Substances 0.000 description 19
- 201000011510 cancer Diseases 0.000 description 19
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 239000004480 active ingredient Substances 0.000 description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- 229910052757 nitrogen Inorganic materials 0.000 description 18
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 17
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 16
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 239000002202 Polyethylene glycol Substances 0.000 description 14
- 150000001299 aldehydes Chemical class 0.000 description 14
- 239000003054 catalyst Substances 0.000 description 14
- 239000002552 dosage form Substances 0.000 description 14
- 229940093499 ethyl acetate Drugs 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 14
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 12
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 12
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 12
- 150000001408 amides Chemical class 0.000 description 12
- 150000003456 sulfonamides Chemical class 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 150000001412 amines Chemical class 0.000 description 11
- 239000000969 carrier Substances 0.000 description 11
- 238000004440 column chromatography Methods 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- 125000004122 cyclic group Chemical group 0.000 description 10
- 238000003818 flash chromatography Methods 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 235000013772 propylene glycol Nutrition 0.000 description 10
- 239000012279 sodium borohydride Substances 0.000 description 10
- 229910000033 sodium borohydride Inorganic materials 0.000 description 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 9
- 229930182558 Sterol Natural products 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000003085 diluting agent Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 9
- 235000011152 sodium sulphate Nutrition 0.000 description 9
- 150000003432 sterols Chemical class 0.000 description 9
- 235000003702 sterols Nutrition 0.000 description 9
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 8
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 8
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 8
- 125000004966 cyanoalkyl group Chemical group 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 238000006798 ring closing metathesis reaction Methods 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 7
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- DWLVWMUCHSLGSU-UHFFFAOYSA-N dimethylcarbamic acid Chemical compound CN(C)C(O)=O DWLVWMUCHSLGSU-UHFFFAOYSA-N 0.000 description 7
- 239000007884 disintegrant Substances 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 229910052731 fluorine Inorganic materials 0.000 description 7
- 238000005984 hydrogenation reaction Methods 0.000 description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- 238000006268 reductive amination reaction Methods 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 235000010443 alginic acid Nutrition 0.000 description 6
- 229920000615 alginic acid Polymers 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 description 6
- 235000010216 calcium carbonate Nutrition 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- 229940049964 oleate Drugs 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 125000004193 piperazinyl group Chemical group 0.000 description 6
- 125000003386 piperidinyl group Chemical group 0.000 description 6
- 229920005862 polyol Polymers 0.000 description 6
- 150000003077 polyols Chemical class 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 125000003226 pyrazolyl group Chemical group 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 6
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 description 6
- 239000008158 vegetable oil Substances 0.000 description 6
- UHRLAAAKTOXQRK-UHFFFAOYSA-N (6-chloro-1-formyl-3,4-dihydro-2H-naphthalen-1-yl)methyl benzoate Chemical compound C(C1=CC=CC=C1)(=O)OCC1(CCCC2=CC(=CC=C12)Cl)C=O UHRLAAAKTOXQRK-UHFFFAOYSA-N 0.000 description 5
- 150000000185 1,3-diols Chemical class 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
- 239000007821 HATU Substances 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 239000003638 chemical reducing agent Substances 0.000 description 5
- 238000004296 chiral HPLC Methods 0.000 description 5
- 235000015165 citric acid Nutrition 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 5
- 239000000787 lecithin Chemical class 0.000 description 5
- 235000010445 lecithin Nutrition 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 235000010356 sorbitol Nutrition 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 4
- RSFGNJDWJXWITH-UMSFTDKQSA-N (4S)-7-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,3-dihydro-1H-naphthalene-4,3'-4,5-dihydro-2H-1,5-benzoxazepine]-7'-sulfonamide Chemical compound ClC=1C=C2CCC[C@@]3(C2=CC=1)COC1=C(NC3)C=C(C=C1)S(=O)(=O)N(CC1=CC=C(C=C1)OC)CC1=CC=C(C=C1)OC RSFGNJDWJXWITH-UMSFTDKQSA-N 0.000 description 4
- ZICHRRJLIHXMPQ-XIFFEERXSA-N (4S)-7-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,3-dihydrochromene-4,3'-4,5-dihydro-2H-1,5-benzoxazepine]-7'-sulfonamide Chemical compound ClC1=CC=C2[C@@]3(CCOC2=C1)CNC1=C(OC3)C=CC(=C1)S(=O)(=O)N(CC1=CC=C(C=C1)OC)CC1=CC=C(C=C1)OC ZICHRRJLIHXMPQ-XIFFEERXSA-N 0.000 description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 4
- HFFXLYHRNRKAPM-UHFFFAOYSA-N 2,4,5-trichloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=N1 HFFXLYHRNRKAPM-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- WPOJJAFRKRSBLW-UHFFFAOYSA-N 4-fluoro-N,N-bis[(4-methoxyphenyl)methyl]-3-nitrobenzenesulfonamide Chemical compound FC1=C(C=C(C=C1)S(=O)(=O)N(CC1=CC=C(C=C1)OC)CC1=CC=C(C=C1)OC)[N+](=O)[O-] WPOJJAFRKRSBLW-UHFFFAOYSA-N 0.000 description 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 4
- 102000051485 Bcl-2 family Human genes 0.000 description 4
- 108700038897 Bcl-2 family Proteins 0.000 description 4
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical class CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
- 239000000783 alginic acid Substances 0.000 description 4
- 229960001126 alginic acid Drugs 0.000 description 4
- 150000004781 alginic acids Chemical class 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 4
- 230000002424 anti-apoptotic effect Effects 0.000 description 4
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 4
- 125000004350 aryl cycloalkyl group Chemical group 0.000 description 4
- 125000002393 azetidinyl group Chemical group 0.000 description 4
- 150000005347 biaryls Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229920001429 chelating resin Polymers 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229940125758 compound 15 Drugs 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 230000000155 isotopic effect Effects 0.000 description 4
- 229940070765 laurate Drugs 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 201000005962 mycosis fungoides Diseases 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 229960002621 pembrolizumab Drugs 0.000 description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000008117 stearic acid Chemical group 0.000 description 4
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 4
- 125000000335 thiazolyl group Chemical group 0.000 description 4
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 4
- 238000005809 transesterification reaction Methods 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical class CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 3
- PNKMKZLRCHQXLY-VRTXHTCJSA-N (4S)-7-chloro-5'-[[(1R,2R)-2-(hydroxymethyl)cyclobutyl]methyl]-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,3-dihydro-1H-naphthalene-4,3'-2,4-dihydro-1,5-benzoxazepine]-7'-sulfonamide Chemical compound ClC=1C=C2CCC[C@@]3(C2=CC=1)COC1=C(N(C3)C[C@H]2[C@@H](CC2)CO)C=C(C=C1)S(=O)(=O)N(CC1=CC=C(C=C1)OC)CC1=CC=C(C=C1)OC PNKMKZLRCHQXLY-VRTXHTCJSA-N 0.000 description 3
- UZFDQGFKBBDRFU-VRTXHTCJSA-N (4S)-7-chloro-5'-[[(1R,2R)-2-formylcyclobutyl]methyl]-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,3-dihydro-1H-naphthalene-4,3'-2,4-dihydro-1,5-benzoxazepine]-7'-sulfonamide Chemical compound ClC=1C=C2CCC[C@@]3(C2=CC=1)COC1=C(N(C3)C[C@H]2[C@@H](CC2)C=O)C=C(C=C1)S(=O)(=O)N(CC1=CC=C(C=C1)OC)CC1=CC=C(C=C1)OC UZFDQGFKBBDRFU-VRTXHTCJSA-N 0.000 description 3
- SXHNBNKFGAHCNM-UMSFTDKQSA-N (4S)-7-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,3-dihydro-1H-naphthalene-4,3'-2H-1,5-benzoxazepine]-7'-sulfonamide Chemical compound ClC=1C=C2CCC[C@]3(C2=CC=1)C=NC1=C(OC3)C=CC(=C1)S(=O)(=O)N(CC1=CC=C(C=C1)OC)CC1=CC=C(C=C1)OC SXHNBNKFGAHCNM-UMSFTDKQSA-N 0.000 description 3
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- DKXWZNRWVNVJEP-UHFFFAOYSA-N 2-(2-bromo-5-chlorophenoxy)ethoxy-tert-butyl-dimethylsilane Chemical compound BrC1=C(OCCO[Si](C(C)(C)C)(C)C)C=C(C=C1)Cl DKXWZNRWVNVJEP-UHFFFAOYSA-N 0.000 description 3
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- HUPWYUWVTIMLTR-UHFFFAOYSA-N 4-[(6-chloro-1-formyl-3,4-dihydro-2H-naphthalen-1-yl)methoxy]-3-nitrobenzenesulfonamide Chemical compound ClC=1C=C2CCCC(C2=CC=1)(C=O)COC1=C(C=C(C=C1)S(=O)(=O)N)[N+](=O)[O-] HUPWYUWVTIMLTR-UHFFFAOYSA-N 0.000 description 3
- FIYITACXGADVLU-BHVANESWSA-N 4-[[(1R)-6-chloro-1-(dimethoxymethyl)-3,4-dihydro-2H-naphthalen-1-yl]methoxy]-N,N-bis[(4-methoxyphenyl)methyl]-3-nitrobenzenesulfonamide Chemical compound COC1=CC=C(C=C1)CN(S(=O)(=O)C1=CC(=C(C=C1)OC[C@]1(CCCC2=CC(=CC=C12)Cl)C(OC)OC)[N+](=O)[O-])CC1=CC=C(C=C1)OC FIYITACXGADVLU-BHVANESWSA-N 0.000 description 3
- WQUBIBBJYUYLMS-UMSFTDKQSA-N 4-[[(1R)-6-chloro-1-formyl-3,4-dihydro-2H-naphthalen-1-yl]methoxy]-N,N-bis[(4-methoxyphenyl)methyl]-3-nitrobenzenesulfonamide Chemical compound COC1=CC=C(C=C1)CN(S(=O)(=O)C1=CC(=C(C=C1)OC[C@]1(CCCC2=CC(=CC=C12)Cl)C=O)[N+](=O)[O-])CC1=CC=C(C=C1)OC WQUBIBBJYUYLMS-UMSFTDKQSA-N 0.000 description 3
- KNRPPFFJHAJMTP-DHUJRADRSA-N 4-[[(4R)-7-chloro-4-(dimethoxymethyl)-2,3-dihydrochromen-4-yl]methoxy]-N,N-bis[(4-methoxyphenyl)methyl]-3-nitrobenzenesulfonamide Chemical compound COC1=CC=C(C=C1)CN(S(=O)(=O)C1=CC(=C(C=C1)OC[C@]1(CCOC2=CC(=CC=C12)Cl)C(OC)OC)[N+](=O)[O-])CC1=CC=C(C=C1)OC KNRPPFFJHAJMTP-DHUJRADRSA-N 0.000 description 3
- SFTDZGDFJJXIFH-XIFFEERXSA-N 4-[[(4R)-7-chloro-4-formyl-2,3-dihydrochromen-4-yl]methoxy]-N,N-bis[(4-methoxyphenyl)methyl]-3-nitrobenzenesulfonamide Chemical compound ClC1=CC=C2[C@@](CCOC2=C1)(C=O)COC1=C(C=C(C=C1)S(=O)(=O)N(CC1=CC=C(C=C1)OC)CC1=CC=C(C=C1)OC)[N+](=O)[O-] SFTDZGDFJJXIFH-XIFFEERXSA-N 0.000 description 3
- JWDPLTKMKZDKED-UHFFFAOYSA-N 4-[[6-chloro-1-(dimethoxymethyl)-3,4-dihydro-2H-naphthalen-1-yl]methoxy]-3-nitrobenzenesulfonamide Chemical compound ClC=1C=C2CCCC(C2=CC=1)(C(OC)OC)COC1=C(C=C(C=C1)S(=O)(=O)N)[N+](=O)[O-] JWDPLTKMKZDKED-UHFFFAOYSA-N 0.000 description 3
- FAYVDRRKPVJSPE-UHFFFAOYSA-N 4-fluoro-3-nitrobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(F)C([N+]([O-])=O)=C1 FAYVDRRKPVJSPE-UHFFFAOYSA-N 0.000 description 3
- DFCXJYJCPFUTKB-UHFFFAOYSA-N 6-chloro-1,2,3,4-tetrahydronaphthalene-1-carbaldehyde Chemical compound O=CC1CCCC2=CC(Cl)=CC=C21 DFCXJYJCPFUTKB-UHFFFAOYSA-N 0.000 description 3
- QIHWGQCNKILACI-UHFFFAOYSA-N 7-chlorospiro[2,3-dihydro-1H-naphthalene-4,3'-4,5-dihydro-2H-1,5-benzoxazepine]-7'-sulfonamide Chemical compound ClC=1C=C2CCCC3(C2=CC=1)COC1=C(NC3)C=C(C=C1)S(=O)(=O)N QIHWGQCNKILACI-UHFFFAOYSA-N 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- FFOGPJSXIZQGIV-UHFFFAOYSA-N COC(OC)C1(CO)CCCc2cc(Cl)ccc12 Chemical compound COC(OC)C1(CO)CCCc2cc(Cl)ccc12 FFOGPJSXIZQGIV-UHFFFAOYSA-N 0.000 description 3
- FFOGPJSXIZQGIV-AWEZNQCLSA-N COC(OC)[C@]1(CO)CCCC2=C1C=CC(Cl)=C2 Chemical compound COC(OC)[C@]1(CO)CCCC2=C1C=CC(Cl)=C2 FFOGPJSXIZQGIV-AWEZNQCLSA-N 0.000 description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- AIGNHNLQDXEPCJ-UHFFFAOYSA-N ClC1=CC2=C(C=C1)C1(CO1)CCC2 Chemical compound ClC1=CC2=C(C=C1)C1(CO1)CCC2 AIGNHNLQDXEPCJ-UHFFFAOYSA-N 0.000 description 3
- FCJQTMQPGXXCLO-UHFFFAOYSA-N ClC=1C=C2CCCC(C2=CC=1)(CO)CO Chemical compound ClC=1C=C2CCCC(C2=CC=1)(CO)CO FCJQTMQPGXXCLO-UHFFFAOYSA-N 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 3
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 3
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 208000003445 Mouth Neoplasms Diseases 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 3
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- 229940079156 Proteasome inhibitor Drugs 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 238000006859 Swern oxidation reaction Methods 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- RFHLIJNPHLBJLO-BFKHEBHZSA-N [(1R,2R)-2-[[(4S)-7'-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-7-chlorospiro[2,3-dihydro-1H-naphthalene-4,3'-2,4-dihydro-1,5-benzoxazepine]-5'-yl]methyl]cyclobutyl]methyl acetate Chemical compound C(C)(=O)OC[C@H]1[C@@H](CC1)CN1C[C@@]2(CCCC3=CC(=CC=C23)Cl)COC2=C1C=C(C=C2)S(N(CC1=CC=C(C=C1)OC)CC1=CC=C(C=C1)OC)(=O)=O RFHLIJNPHLBJLO-BFKHEBHZSA-N 0.000 description 3
- CCXDKRARVPSIKO-IBGZPJMESA-N [(1S)-6-chloro-1-(hydroxymethyl)-3,4-dihydro-2H-naphthalen-1-yl]methyl benzoate Chemical compound C(C1=CC=CC=C1)(=O)OC[C@]1(CCCC2=CC(=CC=C12)Cl)CO CCXDKRARVPSIKO-IBGZPJMESA-N 0.000 description 3
- LZVXBAUMMJOEMT-ZDUSSCGKSA-N [(4R)-7-chloro-4-(dimethoxymethyl)-2,3-dihydrochromen-4-yl]methanol Chemical compound ClC1=CC=C2[C@@](CCOC2=C1)(C(OC)OC)CO LZVXBAUMMJOEMT-ZDUSSCGKSA-N 0.000 description 3
- VFSIOARCMKUOFB-FQEVSTJZSA-N [(4R)-7-chloro-4-(dimethoxymethyl)-2,3-dihydrochromen-4-yl]methyl 4-bromobenzoate Chemical compound BrC1=CC=C(C(=O)OC[C@]2(CCOC3=CC(=CC=C23)Cl)C(OC)OC)C=C1 VFSIOARCMKUOFB-FQEVSTJZSA-N 0.000 description 3
- SUXVDNWDWGQUPM-SFHVURJKSA-N [(4R)-7-chloro-4-formyl-2,3-dihydrochromen-4-yl]methyl 4-bromobenzoate Chemical compound BrC1=CC=C(C(=O)OC[C@]2(CCOC3=CC(=CC=C23)Cl)C=O)C=C1 SUXVDNWDWGQUPM-SFHVURJKSA-N 0.000 description 3
- YDAAFRJPHHCHQI-SFHVURJKSA-N [(4S)-7-chloro-4-(hydroxymethyl)-2,3-dihydrochromen-4-yl]methyl 4-bromobenzoate Chemical compound BrC1=CC=C(C(=O)OC[C@]2(CCOC3=CC(=CC=C23)Cl)CO)C=C1 YDAAFRJPHHCHQI-SFHVURJKSA-N 0.000 description 3
- UMKFEFLYVSSFCM-UHFFFAOYSA-N [7-chloro-4-(hydroxymethyl)-2,3-dihydrochromen-4-yl]methanol Chemical compound ClC1=CC=C2C(CCOC2=C1)(CO)CO UMKFEFLYVSSFCM-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000005215 alkyl ethers Chemical class 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical class ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 3
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 239000004327 boric acid Substances 0.000 description 3
- 235000010338 boric acid Nutrition 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 3
- VPLSLSHRQBYVQU-UHFFFAOYSA-N diethyl 2-[2-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]-4-chlorophenyl]propanedioate Chemical compound [Si](C)(C)(C(C)(C)C)OCCOC1=C(C=CC(=C1)Cl)C(C(=O)OCC)C(=O)OCC VPLSLSHRQBYVQU-UHFFFAOYSA-N 0.000 description 3
- HUAZXYKTGJMDCC-UHFFFAOYSA-N diethyl 7-chloro-2,3-dihydrochromene-4,4-dicarboxylate Chemical compound ClC1=CC=C2C(CCOC2=C1)(C(=O)OCC)C(=O)OCC HUAZXYKTGJMDCC-UHFFFAOYSA-N 0.000 description 3
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical class CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 3
- 229940113088 dimethylacetamide Drugs 0.000 description 3
- 239000003968 dna methyltransferase inhibitor Substances 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 3
- 229940093471 ethyl oleate Drugs 0.000 description 3
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 235000011087 fumaric acid Nutrition 0.000 description 3
- HNJBEVLQSNELDL-UHFFFAOYSA-N gamma-butyrolactam Natural products O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000000174 gluconic acid Chemical group 0.000 description 3
- 235000012208 gluconic acid Nutrition 0.000 description 3
- 125000005456 glyceride group Chemical class 0.000 description 3
- 239000001087 glyceryl triacetate Substances 0.000 description 3
- 235000013773 glyceryl triacetate Nutrition 0.000 description 3
- 150000002334 glycols Chemical class 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 125000005343 heterocyclic alkyl group Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 150000002466 imines Chemical class 0.000 description 3
- 229940126546 immune checkpoint molecule Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000002563 ionic surfactant Substances 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 229960004942 lenalidomide Drugs 0.000 description 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
- 150000002678 macrocyclic compounds Chemical class 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000013160 medical therapy Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 3
- 229960001924 melphalan Drugs 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 108020004017 nuclear receptors Proteins 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- CZYFDZPOVORIRJ-UHFFFAOYSA-N oxiran-2-amine Chemical class NC1CO1 CZYFDZPOVORIRJ-UHFFFAOYSA-N 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical class [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 3
- 230000000861 pro-apoptotic effect Effects 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 239000003207 proteasome inhibitor Substances 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 229960001367 tartaric acid Drugs 0.000 description 3
- 150000003899 tartaric acid esters Chemical class 0.000 description 3
- 230000037317 transdermal delivery Effects 0.000 description 3
- 229960002622 triacetin Drugs 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- WJTCHBVEUFDSIK-NWDGAFQWSA-N (2r,5s)-1-benzyl-2,5-dimethylpiperazine Chemical compound C[C@@H]1CN[C@@H](C)CN1CC1=CC=CC=C1 WJTCHBVEUFDSIK-NWDGAFQWSA-N 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 2
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- ZRPFJAPZDXQHSM-UHFFFAOYSA-L 1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazole;dichloro-[(2-propan-2-yloxyphenyl)methylidene]ruthenium Chemical compound CC(C)OC1=CC=CC=C1C=[Ru](Cl)(Cl)=C1N(C=2C(=CC(C)=CC=2C)C)CCN1C1=C(C)C=C(C)C=C1C ZRPFJAPZDXQHSM-UHFFFAOYSA-L 0.000 description 2
- HBKPDEWGANZHJO-UHFFFAOYSA-N 1-(4-methoxyphenyl)-n-[(4-methoxyphenyl)methyl]methanamine Chemical compound C1=CC(OC)=CC=C1CNCC1=CC=C(OC)C=C1 HBKPDEWGANZHJO-UHFFFAOYSA-N 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 2
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 2
- OEZPKXDBWNXBRE-UHFFFAOYSA-N 2,3-bis(2-hydroxyethoxy)propyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(OCCO)COCCO OEZPKXDBWNXBRE-UHFFFAOYSA-N 0.000 description 2
- OXPIFHNJGOJJQZ-UHFFFAOYSA-N 2,7-diazaspiro[3.4]octane Chemical compound C1NCC11CNCC1 OXPIFHNJGOJJQZ-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- KHICUSAUSRBPJT-UHFFFAOYSA-N 2-(2-octadecanoyloxypropanoyloxy)propanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C(O)=O KHICUSAUSRBPJT-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- QPEJAHMNOVMSOZ-UHFFFAOYSA-N 2-azaspiro[3.3]heptane Chemical compound C1CCC21CNC2 QPEJAHMNOVMSOZ-UHFFFAOYSA-N 0.000 description 2
- PSNDWZOXFDKLLH-UHFFFAOYSA-N 2-azaspiro[3.4]octane Chemical compound C1NCC11CCCC1 PSNDWZOXFDKLLH-UHFFFAOYSA-N 0.000 description 2
- ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 2-dodecanoyloxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCC ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 2
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 240000004178 Anthoxanthum odoratum Species 0.000 description 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 2
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 2
- 102100027308 Apoptosis regulator BAX Human genes 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 239000012664 BCL-2-inhibitor Substances 0.000 description 2
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 2
- YIIMEMSDCNDGTB-UHFFFAOYSA-N Dimethylcarbamoyl chloride Chemical compound CN(C)C(Cl)=O YIIMEMSDCNDGTB-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000001263 FEMA 3042 Substances 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- 208000021309 Germ cell tumor Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000757232 Homo sapiens Protein arginine N-methyltransferase 2 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 2
- 206010023825 Laryngeal cancer Diseases 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N N,N′-Dicyclohexylcarbodiimide Substances C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229910020889 NaBH3 Inorganic materials 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 108010038807 Oligopeptides Chemical class 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102100035548 Protein Bop Human genes 0.000 description 2
- 108050008794 Protein Bop Proteins 0.000 description 2
- 102000003708 Protein arginine N-methyltransferase Human genes 0.000 description 2
- 108020000912 Protein arginine N-methyltransferase Proteins 0.000 description 2
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 2
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 201000005969 Uveal melanoma Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- CCXDKRARVPSIKO-LJQANCHMSA-N [(1R)-6-chloro-1-(hydroxymethyl)-3,4-dihydro-2H-naphthalen-1-yl]methyl benzoate Chemical compound C(C1=CC=CC=C1)(=O)OC[C@@]1(CCCC2=CC(=CC=C12)Cl)CO CCXDKRARVPSIKO-LJQANCHMSA-N 0.000 description 2
- UHRLAAAKTOXQRK-IBGZPJMESA-N [(1R)-6-chloro-1-formyl-3,4-dihydro-2H-naphthalen-1-yl]methyl benzoate Chemical compound C(C1=CC=CC=C1)(=O)OC[C@]1(CCCC2=CC(=CC=C12)Cl)C=O UHRLAAAKTOXQRK-IBGZPJMESA-N 0.000 description 2
- OYQHJCMXKSAHIL-YUMQZZPRSA-N [(1r,2r)-2-formylcyclobutyl]methyl acetate Chemical compound CC(=O)OC[C@@H]1CC[C@H]1C=O OYQHJCMXKSAHIL-YUMQZZPRSA-N 0.000 description 2
- AKZWRTCWNXHHFR-PDIZUQLASA-N [(3S)-oxolan-3-yl] N-[(2S,3S)-4-[(5S)-5-benzyl-3-[(2R)-2-carbamoyloxy-2,3-dihydro-1H-inden-1-yl]-4-oxo-3H-pyrrol-5-yl]-3-hydroxy-1-phenylbutan-2-yl]carbamate Chemical compound NC(=O)O[C@@H]1Cc2ccccc2C1C1C=N[C@](C[C@H](O)[C@H](Cc2ccccc2)NC(=O)O[C@H]2CCOC2)(Cc2ccccc2)C1=O AKZWRTCWNXHHFR-PDIZUQLASA-N 0.000 description 2
- OXLURKCRXVAJQS-UHFFFAOYSA-L [1,3-bis(2,4,6-trimethylphenyl)imidazolidin-2-ylidene]-dichloro-[[5-(dimethylsulfamoyl)-2-propan-2-yloxyphenyl]methylidene]ruthenium Chemical compound CC(C)OC1=CC=C(S(=O)(=O)N(C)C)C=C1C=[Ru](Cl)(Cl)=C1N(C=2C(=CC(C)=CC=2C)C)CCN1C1=C(C)C=C(C)C=C1C OXLURKCRXVAJQS-UHFFFAOYSA-L 0.000 description 2
- CCXDKRARVPSIKO-UHFFFAOYSA-N [6-chloro-1-(hydroxymethyl)-3,4-dihydro-2H-naphthalen-1-yl]methyl benzoate Chemical compound C(C1=CC=CC=C1)(=O)OCC1(CCCC2=CC(=CC=C12)Cl)CO CCXDKRARVPSIKO-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 125000004036 acetal group Chemical group 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000005865 alkene metathesis reaction Methods 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000008051 alkyl sulfates Chemical class 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 150000004808 allyl alcohols Chemical class 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 238000010640 amide synthesis reaction Methods 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 125000003725 azepanyl group Chemical group 0.000 description 2
- 108700000711 bcl-X Proteins 0.000 description 2
- 102000055104 bcl-X Human genes 0.000 description 2
- 229960002707 bendamustine Drugs 0.000 description 2
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- PNPBGYBHLCEVMK-UHFFFAOYSA-N benzylidene(dichloro)ruthenium;tricyclohexylphosphanium Chemical compound Cl[Ru](Cl)=CC1=CC=CC=C1.C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1.C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1 PNPBGYBHLCEVMK-UHFFFAOYSA-N 0.000 description 2
- FCDPQMAOJARMTG-UHFFFAOYSA-M benzylidene-[1,3-bis(2,4,6-trimethylphenyl)imidazolidin-2-ylidene]-dichlororuthenium;tricyclohexylphosphanium Chemical compound C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1.CC1=CC(C)=CC(C)=C1N(CCN1C=2C(=CC(C)=CC=2C)C)C1=[Ru](Cl)(Cl)=CC1=CC=CC=C1 FCDPQMAOJARMTG-UHFFFAOYSA-M 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960002645 boric acid Drugs 0.000 description 2
- 229960001467 bortezomib Drugs 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- 238000002725 brachytherapy Methods 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 2
- 108010021331 carfilzomib Proteins 0.000 description 2
- 229960002438 carfilzomib Drugs 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 150000004696 coordination complex Chemical class 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 150000001942 cyclopropanes Chemical group 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 238000003618 dip coating Methods 0.000 description 2
- ROORDVPLFPIABK-UHFFFAOYSA-N diphenyl carbonate Chemical compound C=1C=CC=CC=1OC(=O)OC1=CC=CC=C1 ROORDVPLFPIABK-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000010894 electron beam technology Methods 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 235000010350 erythorbic acid Nutrition 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 206010016629 fibroma Diseases 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 201000010175 gallbladder cancer Diseases 0.000 description 2
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 229940074046 glyceryl laurate Drugs 0.000 description 2
- 239000011984 grubbs catalyst Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 201000009277 hairy cell leukemia Diseases 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 2
- 239000011987 hoveyda–grubbs catalyst Substances 0.000 description 2
- 102000046485 human PRMT2 Human genes 0.000 description 2
- 235000011167 hydrochloric acid Nutrition 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- ONUFESLQCSAYKA-UHFFFAOYSA-N iprodione Chemical compound O=C1N(C(=O)NC(C)C)CC(=O)N1C1=CC(Cl)=CC(Cl)=C1 ONUFESLQCSAYKA-UHFFFAOYSA-N 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 229940026239 isoascorbic acid Drugs 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000002690 malonic acid derivatives Chemical class 0.000 description 2
- 208000008585 mastocytosis Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 229940095102 methyl benzoate Drugs 0.000 description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
- 239000003697 methyltransferase inhibitor Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004957 naphthylene group Chemical group 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- AKRYBBWYDSDZHG-UHFFFAOYSA-N nitrosobis(2-oxopropyl)amine Chemical compound CC(=O)CN(N=O)CC(C)=O AKRYBBWYDSDZHG-UHFFFAOYSA-N 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- YYZUSRORWSJGET-UHFFFAOYSA-N octanoic acid ethyl ester Natural products CCCCCCCC(=O)OCC YYZUSRORWSJGET-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 229940116315 oxalic acid Drugs 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 150000002924 oxiranes Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- MXQOYLRVSVOCQT-UHFFFAOYSA-N palladium;tritert-butylphosphane Chemical compound [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 2
- 229960005184 panobinostat Drugs 0.000 description 2
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Chemical class 0.000 description 2
- 229960000688 pomalidomide Drugs 0.000 description 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001686 pro-survival effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Chemical class 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000002661 proton therapy Methods 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 2
- 229960000215 ruxolitinib Drugs 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical class [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 229960004274 stearic acid Drugs 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 125000004089 sulfido group Chemical group [S-]* 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229920002258 tannic acid Polymers 0.000 description 2
- 235000015523 tannic acid Nutrition 0.000 description 2
- 229940033123 tannic acid Drugs 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 2
- 229960001183 venetoclax Drugs 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- PGOLTJPQCISRTO-UHFFFAOYSA-N vinyllithium Chemical compound [Li]C=C PGOLTJPQCISRTO-UHFFFAOYSA-N 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- 229960000237 vorinostat Drugs 0.000 description 2
- 239000011992 zhan catalyst-1B Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- FCYOMJQCOIIEMU-MSVYEENVSA-N (4S)-7-chloro-5'-[[(1R,2R)-2-formylcyclobutyl]methyl]-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,3-dihydrochromene-4,3'-2,4-dihydro-1,5-benzoxazepine]-7'-sulfonamide Chemical compound ClC1=CC=C2[C@]3(CCOC2=C1)COC1=C(N(C3)C[C@H]2[C@@H](CC2)C=O)C=C(C=C1)S(=O)(=O)N(CC1=CC=C(C=C1)OC)CC1=CC=C(C=C1)OC FCYOMJQCOIIEMU-MSVYEENVSA-N 0.000 description 1
- MPMGKVKBEUYUBR-VSJLXWSYSA-N (4r)-5,5-dibutyl-2-[6-[(4r)-5,5-dibutyl-4-phenyl-4h-1,3-oxazol-2-yl]pyridin-2-yl]-4-phenyl-4h-1,3-oxazole Chemical compound C1([C@H]2N=C(OC2(CCCC)CCCC)C=2N=C(C=CC=2)C=2OC(CCCC)(CCCC)[C@@H](C=3C=CC=CC=3)N=2)=CC=CC=C1 MPMGKVKBEUYUBR-VSJLXWSYSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 description 1
- 125000006587 (C5-C10) heteroarylene group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- XGQXULJHBWKUJY-LYIKAWCPSA-N (z)-but-2-enedioic acid;n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound OC(=O)\C=C/C(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C XGQXULJHBWKUJY-LYIKAWCPSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- WDQFELCEOPFLCZ-UHFFFAOYSA-N 1-(2-hydroxyethyl)pyrrolidin-2-one Chemical compound OCCN1CCCC1=O WDQFELCEOPFLCZ-UHFFFAOYSA-N 0.000 description 1
- AOWCOHYBGYRYGE-UHFFFAOYSA-N 1-[2,3-bis(2-oxopropoxy)propoxy]propan-2-one Chemical compound CC(=O)COCC(OCC(C)=O)COCC(C)=O AOWCOHYBGYRYGE-UHFFFAOYSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 1
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 1
- QIZPVNNYFKFJAD-UHFFFAOYSA-N 1-chloro-2-prop-1-ynylbenzene Chemical compound CC#CC1=CC=CC=C1Cl QIZPVNNYFKFJAD-UHFFFAOYSA-N 0.000 description 1
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
- ZPDQFUYPBVXUKS-YADHBBJMSA-N 1-stearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OC[C@H](N)C(O)=O ZPDQFUYPBVXUKS-YADHBBJMSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 238000004293 19F NMR spectroscopy Methods 0.000 description 1
- YTORMSBGFMQNEO-UHFFFAOYSA-N 2,3-dihydroxypropyl decanoate;2,3-dihydroxypropyl octanoate;(3-hydroxy-2-octanoyloxypropyl) octanoate;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC(=O)OCC(O)CO.CCCCCCCCCC(=O)OCC(O)CO.CCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCC YTORMSBGFMQNEO-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- UGDAWAQEKLURQI-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethanol;hydrate Chemical compound O.OCCOCCO UGDAWAQEKLURQI-UHFFFAOYSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- MQFYRUGXOJAUQK-UHFFFAOYSA-N 2-[2-[2-(2-octadecanoyloxyethoxy)ethoxy]ethoxy]ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCOCCOCCOC(=O)CCCCCCCCCCCCCCCCC MQFYRUGXOJAUQK-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- FMRKYXVZQWHGDA-UHFFFAOYSA-N 2-bromo-5-chlorophenol Chemical compound OC1=CC(Cl)=CC=C1Br FMRKYXVZQWHGDA-UHFFFAOYSA-N 0.000 description 1
- KDPAWGWELVVRCH-ZDOIIHCHSA-N 2-bromoacetic acid Chemical class O[13C](=O)[13CH2]Br KDPAWGWELVVRCH-ZDOIIHCHSA-N 0.000 description 1
- JBKINHFZTVLNEM-UHFFFAOYSA-N 2-bromoethoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCBr JBKINHFZTVLNEM-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- PPPFYBPQAPISCT-UHFFFAOYSA-N 2-hydroxypropyl acetate Chemical compound CC(O)COC(C)=O PPPFYBPQAPISCT-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- DUIOKRXOKLLURE-UHFFFAOYSA-N 2-octylphenol Chemical class CCCCCCCCC1=CC=CC=C1O DUIOKRXOKLLURE-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- DENKGPBHLYFNGK-UHFFFAOYSA-N 4-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Br)C=C1 DENKGPBHLYFNGK-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- RRONENSZKCGROA-UHFFFAOYSA-N 4-fluoro-3-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC(S(Cl)(=O)=O)=CC=C1F RRONENSZKCGROA-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- FMXSYRBHGUMFBA-UHFFFAOYSA-N 6-amino-3-azaniumylidene-9-[2-carboxy-4-[6-[4-[4-[4-[4-[3-carboxy-6-[4-(trifluoromethyl)phenyl]naphthalen-1-yl]phenyl]piperidin-1-yl]butyl]triazol-1-yl]hexylcarbamoyl]phenyl]-5-sulfoxanthene-4-sulfonate Chemical compound Nc1ccc2c(-c3ccc(cc3C(O)=O)C(=O)NCCCCCCn3cc(CCCCN4CCC(CC4)c4ccc(cc4)-c4cc(cc5cc(ccc45)-c4ccc(cc4)C(F)(F)F)C(O)=O)nn3)c3ccc(=[NH2+])c(c3oc2c1S(O)(=O)=O)S([O-])(=O)=O FMXSYRBHGUMFBA-UHFFFAOYSA-N 0.000 description 1
- WQKHERPPDYPMNX-UHFFFAOYSA-N 6-chloro-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=CC(Cl)=CC=C21 WQKHERPPDYPMNX-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- LKQJKSXWQLJJRG-UHFFFAOYSA-N 7-chlorospiro[2,3-dihydro-1H-naphthalene-4,3'-2H-1,5-benzoxazepine]-7'-sulfonamide Chemical compound ClC=1C=C2CCCC3(C2=CC=1)COC1=C(N=C3)C=C(C=C1)S(=O)(=O)N LKQJKSXWQLJJRG-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 208000007876 Acrospiroma Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 208000001783 Adamantinoma Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 description 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 206010002240 Anaplastic thyroid cancer Diseases 0.000 description 1
- 206010051810 Angiomyolipoma Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010073360 Appendix cancer Diseases 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010060971 Astrocytoma malignant Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 201000008271 Atypical teratoid rhabdoid tumor Diseases 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 108091012583 BCL2 Proteins 0.000 description 1
- 229940124291 BTK inhibitor Drugs 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 102000004072 Beclin-1 Human genes 0.000 description 1
- 108090000524 Beclin-1 Proteins 0.000 description 1
- 206010004453 Benign salivary gland neoplasm Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 208000007690 Brenner tumor Diseases 0.000 description 1
- 206010073258 Brenner tumour Diseases 0.000 description 1
- 102000001805 Bromodomains Human genes 0.000 description 1
- 108050009021 Bromodomains Proteins 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
- 206010070487 Brown tumour Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 1
- FFOGPJSXIZQGIV-CQSZACIVSA-N COC(OC)[C@@]1(CO)CCCc2cc(Cl)ccc12 Chemical compound COC(OC)[C@@]1(CO)CCCc2cc(Cl)ccc12 FFOGPJSXIZQGIV-CQSZACIVSA-N 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 208000037138 Central nervous system embryonal tumor Diseases 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 206010008583 Chloroma Diseases 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000004378 Choroid plexus papilloma Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 206010052012 Congenital teratoma Diseases 0.000 description 1
- 229920001634 Copolyester Polymers 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- 238000006942 Corey-Chaykovsky ring formation reaction Methods 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 1
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000008334 Dermatofibrosarcoma Diseases 0.000 description 1
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 description 1
- 208000001154 Dermoid Cyst Diseases 0.000 description 1
- 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 description 1
- 206010064581 Desmoplastic small round cell tumour Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 description 1
- 208000033832 Eosinophilic Acute Leukemia Diseases 0.000 description 1
- 201000008228 Ependymoblastoma Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 206010014968 Ependymoma malignant Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 201000005231 Epithelioid sarcoma Diseases 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000012468 Ewing sarcoma/peripheral primitive neuroectodermal tumor Diseases 0.000 description 1
- 208000017259 Extragonadal germ cell tumor Diseases 0.000 description 1
- 208000010368 Extramammary Paget Disease Diseases 0.000 description 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical group F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010016935 Follicular thyroid cancer Diseases 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 201000004066 Ganglioglioma Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 206010061183 Genitourinary tract neoplasm Diseases 0.000 description 1
- 208000000527 Germinoma Diseases 0.000 description 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 201000005409 Gliomatosis cerebri Diseases 0.000 description 1
- 206010068601 Glioneuronal tumour Diseases 0.000 description 1
- 206010018381 Glomus tumour Diseases 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 208000005234 Granulosa Cell Tumor Diseases 0.000 description 1
- 238000007015 Grubbs metathesis reaction Methods 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 208000006050 Hemangiopericytoma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102000008157 Histone Demethylases Human genes 0.000 description 1
- 108010074870 Histone Demethylases Proteins 0.000 description 1
- 102000003893 Histone acetyltransferases Human genes 0.000 description 1
- 108090000246 Histone acetyltransferases Proteins 0.000 description 1
- 102100025210 Histone-arginine methyltransferase CARM1 Human genes 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 101000757216 Homo sapiens Protein arginine N-methyltransferase 1 Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 208000007666 Klatskin Tumor Diseases 0.000 description 1
- 208000000675 Krukenberg Tumor Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 206010024218 Lentigo maligna Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 201000002171 Luteoma Diseases 0.000 description 1
- 206010025219 Lymphangioma Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 description 1
- 201000003791 MALT lymphoma Diseases 0.000 description 1
- 206010064281 Malignant atrophic papulosis Diseases 0.000 description 1
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
- 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 description 1
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010027462 Metastases to ovary Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 206010028767 Nasal sinus cancer Diseases 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 206010048757 Oncocytoma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 206010033268 Ovarian low malignant potential tumour Diseases 0.000 description 1
- 206010073261 Ovarian theca cell tumour Diseases 0.000 description 1
- 208000002063 Oxyphilic Adenoma Diseases 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 208000025618 Paget disease of nipple Diseases 0.000 description 1
- 201000010630 Pancoast tumor Diseases 0.000 description 1
- 208000015330 Pancoast tumour Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 208000037064 Papilloma of choroid plexus Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- 208000003937 Paranasal Sinus Neoplasms Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 description 1
- 208000000360 Perivascular Epithelioid Cell Neoplasms Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 description 1
- 101710204747 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 description 1
- 241001483078 Phyto Species 0.000 description 1
- 206010050487 Pinealoblastoma Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000021308 Pituicytoma Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- NKSOSPOXQKNIKJ-CLFAGFIQSA-N Polyoxyethylene dioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOC(=O)CCCCCCC\C=C/CCCCCCCC NKSOSPOXQKNIKJ-CLFAGFIQSA-N 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Chemical class 0.000 description 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 1
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 102100022985 Protein arginine N-methyltransferase 1 Human genes 0.000 description 1
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 description 1
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 description 1
- 208000006930 Pseudomyxoma Peritonei Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000034541 Rare lymphatic malformation Diseases 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 208000008938 Rhabdoid tumor Diseases 0.000 description 1
- 208000005678 Rhabdomyoma Diseases 0.000 description 1
- 208000025316 Richter syndrome Diseases 0.000 description 1
- 208000025280 Sacrococcygeal teratoma Diseases 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 208000006938 Schwannomatosis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 208000002669 Sex Cord-Gonadal Stromal Tumors Diseases 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 206010041329 Somatostatinoma Diseases 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 239000001833 Succinylated monoglyceride Substances 0.000 description 1
- XZAGBDSOKNXTDT-UHFFFAOYSA-N Sucrose monopalmitate Chemical compound CCCCCCCCCCCCCCCC(O)=O.OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(CO)O1 XZAGBDSOKNXTDT-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
- 208000020982 T-lymphoblastic lymphoma Diseases 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 201000000331 Testicular germ cell cancer Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 229910003074 TiCl4 Inorganic materials 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 208000009311 VIPoma Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000021146 Warthin tumor Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- PCWZKQSKUXXDDJ-UHFFFAOYSA-N Xanthotoxin Natural products COCc1c2OC(=O)C=Cc2cc3ccoc13 PCWZKQSKUXXDDJ-UHFFFAOYSA-N 0.000 description 1
- 208000012018 Yolk sac tumor Diseases 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 description 1
- KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
- 229960002184 abarelix Drugs 0.000 description 1
- 108010023617 abarelix Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 description 1
- 229950009821 acalabrutinib Drugs 0.000 description 1
- 206010059394 acanthoma Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000006336 acinar cell carcinoma Diseases 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 206010000583 acral lentiginous melanoma Diseases 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 125000002252 acyl group Chemical class 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 208000026562 adenomatoid odontogenic tumor Diseases 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 208000015230 aggressive NK-cell leukemia Diseases 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- RJZNFXWQRHAVBP-UHFFFAOYSA-I aluminum;magnesium;pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Al+3] RJZNFXWQRHAVBP-UHFFFAOYSA-I 0.000 description 1
- 208000008524 alveolar soft part sarcoma Diseases 0.000 description 1
- 230000002707 ameloblastic effect Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000002622 anti-tumorigenesis Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 230000005756 apoptotic signaling Effects 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 229960002594 arsenic trioxide Drugs 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- GSCLMSFRWBPUSK-UHFFFAOYSA-N beta-Butyrolactone Chemical compound CC1CC(=O)O1 GSCLMSFRWBPUSK-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 201000009076 bladder urachal carcinoma Diseases 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011143 bone giant cell tumor Diseases 0.000 description 1
- 208000012172 borderline epithelial tumor of ovary Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical class CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 201000007335 cerebellar astrocytoma Diseases 0.000 description 1
- 208000030239 cerebral astrocytoma Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 108700043024 cholylsarcosine Proteins 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000762 chronic effect Toxicity 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 201000006778 chronic monocytic leukemia Diseases 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- 201000010903 chronic neutrophilic leukemia Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 108010030886 coactivator-associated arginine methyltransferase 1 Proteins 0.000 description 1
- 201000010276 collecting duct carcinoma Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000008271 cosmetic emulsion Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- TXWRERCHRDBNLG-UHFFFAOYSA-N cubane Chemical compound C12C3C4C1C1C4C3C12 TXWRERCHRDBNLG-UHFFFAOYSA-N 0.000 description 1
- 208000017563 cutaneous Paget disease Diseases 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229940018872 dalteparin sodium Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- XLIDPNGFCHXNGX-UHFFFAOYSA-N dialuminum;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Al+3].[Al+3].[Si+4] XLIDPNGFCHXNGX-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- UYAAVKFHBMJOJZ-UHFFFAOYSA-N diimidazo[1,3-b:1',3'-e]pyrazine-5,10-dione Chemical compound O=C1C2=CN=CN2C(=O)C2=CN=CN12 UYAAVKFHBMJOJZ-UHFFFAOYSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229940018602 docusate Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229940125436 dual inhibitor Drugs 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000004428 dysembryoplastic neuroepithelial tumor Diseases 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 208000001991 endodermal sinus tumor Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 208000027858 endometrioid tumor Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 208000032099 esthesioneuroblastoma Diseases 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 201000010972 female reproductive endometrioid cancer Diseases 0.000 description 1
- 229960004207 fentanyl citrate Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- 229960001048 fluorometholone Drugs 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- GKDRMWXFWHEQQT-UHFFFAOYSA-N fostamatinib Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP(O)(O)=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 GKDRMWXFWHEQQT-UHFFFAOYSA-N 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 201000008361 ganglioneuroma Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 201000011587 gastric lymphoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 201000008822 gestational choriocarcinoma Diseases 0.000 description 1
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000004220 glutamic acid Chemical group 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 208000003064 gonadoblastoma Diseases 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 206010066957 hepatosplenic T-cell lymphoma Diseases 0.000 description 1
- 201000011045 hereditary breast ovarian cancer syndrome Diseases 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 208000018060 hilar cholangiocarcinoma Diseases 0.000 description 1
- 239000003234 histone lysine methyltransferase inhibitor Substances 0.000 description 1
- 229960003911 histrelin acetate Drugs 0.000 description 1
- BKEMVGVBBDMHKL-VYFXDUNUSA-N histrelin acetate Chemical compound CC(O)=O.CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 BKEMVGVBBDMHKL-VYFXDUNUSA-N 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 201000004653 inflammatory breast carcinoma Diseases 0.000 description 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 201000002529 islet cell tumor Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229960001320 lapatinib ditosylate Drugs 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000011080 lentigo maligna melanoma Diseases 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-M linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC([O-])=O DTOSIQBPPRVQHS-PDBXOOCHSA-M 0.000 description 1
- 229940040452 linolenate Drugs 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000006138 lithiation reaction Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000016992 lung adenocarcinoma in situ Diseases 0.000 description 1
- 208000024169 luteoma of pregnancy Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000030883 malignant astrocytoma Diseases 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
- 208000015179 malignant superior sulcus neoplasm Diseases 0.000 description 1
- 201000001117 malignant triton tumor Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000000516 mast-cell leukemia Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 201000000349 mediastinal cancer Diseases 0.000 description 1
- 208000029586 mediastinal germ cell tumor Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 201000008203 medulloepithelioma Diseases 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229960000901 mepacrine Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 238000003328 mesylation reaction Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 208000037970 metastatic squamous neck cancer Diseases 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004469 methoxsalen Drugs 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 229940037959 monooctanoin Drugs 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 208000022669 mucinous neoplasm Diseases 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 201000005987 myeloid sarcoma Diseases 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- AZBFJBJXUQUQLF-UHFFFAOYSA-N n-(1,5-dimethylpyrrolidin-3-yl)pyrrolidine-1-carboxamide Chemical compound C1N(C)C(C)CC1NC(=O)N1CCCC1 AZBFJBJXUQUQLF-UHFFFAOYSA-N 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- 229960001133 nandrolone phenpropionate Drugs 0.000 description 1
- UBWXUGDQUBIEIZ-QNTYDACNSA-N nandrolone phenpropionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@H]4CCC(=O)C=C4CC3)CC[C@@]21C)C(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-QNTYDACNSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 208000014761 nasopharyngeal type undifferentiated carcinoma Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 1
- 229950004847 navitoclax Drugs 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- 208000018280 neoplasm of mediastinum Diseases 0.000 description 1
- 208000028732 neoplasm with perivascular epithelioid cell differentiation Diseases 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 201000009494 neurilemmomatosis Diseases 0.000 description 1
- 208000027831 neuroepithelial neoplasm Diseases 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical class CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 125000005482 norpinyl group Chemical group 0.000 description 1
- 231100001143 noxa Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 206010073131 oligoastrocytoma Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 201000011130 optic nerve sheath meningioma Diseases 0.000 description 1
- 208000022982 optic pathway glioma Diseases 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 125000005961 oxazepanyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 201000011116 pancreatic cholera Diseases 0.000 description 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000029211 papillomatosis Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 201000007052 paranasal sinus cancer Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 229940077412 peg-12 laurate Drugs 0.000 description 1
- 229940008456 peg-32 oleate Drugs 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 229960001373 pegfilgrastim Drugs 0.000 description 1
- 108010044644 pegfilgrastim Proteins 0.000 description 1
- 229960003349 pemetrexed disodium Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 208000030940 penile carcinoma Diseases 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 201000005207 perivascular epithelioid cell tumor Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008251 pharmaceutical emulsion Substances 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 201000004119 pineal parenchymal tumor of intermediate differentiation Diseases 0.000 description 1
- 201000003113 pineoblastoma Diseases 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001693 poly(ether-ester) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 125000004585 polycyclic heterocycle group Chemical group 0.000 description 1
- 208000024246 polyembryoma Diseases 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229940097941 polyglyceryl-10 laurate Drugs 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Chemical class 0.000 description 1
- 150000007519 polyprotic acids Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Chemical class 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 229940116423 propylene glycol diacetate Drugs 0.000 description 1
- OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical compound [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- HNJBEVLQSNELDL-YZRHJBSPSA-N pyrrolidin-2-one Chemical group O=C1CC[14CH2]N1 HNJBEVLQSNELDL-YZRHJBSPSA-N 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 229960000424 rasburicase Drugs 0.000 description 1
- 108010084837 rasburicase Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 208000030859 renal pelvis/ureter urothelial carcinoma Diseases 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229940053174 restasis Drugs 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229940061341 retisert Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 1
- 229940066675 ricinoleate Drugs 0.000 description 1
- 229960001487 rimexolone Drugs 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 208000028467 sex cord-stromal tumor Diseases 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229950007213 spartalizumab Drugs 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 208000037959 spinal tumor Diseases 0.000 description 1
- LBJQKYPPYSCCBH-UHFFFAOYSA-N spiro[3.3]heptane Chemical compound C1CCC21CCC2 LBJQKYPPYSCCBH-UHFFFAOYSA-N 0.000 description 1
- IWDANOJGJIFBEL-UHFFFAOYSA-N spiro[3.4]octane Chemical compound C1CCC21CCCC2 IWDANOJGJIFBEL-UHFFFAOYSA-N 0.000 description 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 229940071209 stearoyl lactylate Drugs 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000019327 succinylated monoglyceride Nutrition 0.000 description 1
- 229940032085 sucrose monolaurate Drugs 0.000 description 1
- 229940035023 sucrose monostearate Drugs 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 208000030457 superficial spreading melanoma Diseases 0.000 description 1
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 208000001644 thecoma Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 238000007070 tosylation reaction Methods 0.000 description 1
- 201000007363 trachea carcinoma Diseases 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- VFJYIHQDILEQNR-UHFFFAOYSA-M trimethylsulfanium;iodide Chemical compound [I-].C[S+](C)C VFJYIHQDILEQNR-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 208000018417 undifferentiated high grade pleomorphic sarcoma of bone Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 208000023747 urothelial carcinoma Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 208000008662 verrucous carcinoma Diseases 0.000 description 1
- 229940055059 vexol Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/10—Spiro-condensed systems
Definitions
- the disclosure is directed to MCL-1 inhibitors and methods of their use.
- Apoptosis (programmed cell death) is a highly conserved cellular process that is required for embryonic development and normal tissue homeostasis (Ashkenazi A. et al, Nat. Rev. Drug Discov. 2017, 16, 273-284).
- Apoptotic-type cell death involves morphological changes such as condensation of the nucleus, DNA fragmentation as well as biochemical phenomena such as the activation of caspases which cause damage to key structural components of the cell, resulting in its disassembly and death.
- Regulation of the process of apoptosis is complex and involves the activation or repression of several intracellular signaling pathways (Cory S. et al, Nature Review Cancer 2002, 2, 647-656; Thomas L. W. et al, FEBS Lett. 2010, 584, 2981-2989; Adams J. M. et al., Oncogene 2007, 26, 1324-1337)
- the Bcl-2 protein family which includes both pro-apoptotic and anti-apoptotic members, plays a pivotal role in the regulation of the apoptosis process (Youle R. J. et al, Nat. Rev. Mol. Cell Biol. 2008, 9, 47-59; Kelly G. L. et al, Adv. Cancer Res. 2011, 111, 39-96).
- Bcl-2, Bcl-XL, Bcl-W, Mcl-1 and A1 are anti-apoptotic proteins and they share a common BH regions.
- the pro-apoptotic family members are divided into two groups.
- the multi-region pro-apoptotic proteins such as Bax, Bak and Bok
- the BH3-only proteins are proposed to share homology in the BH3 region only.
- Members of BH3-only proteins include Bad, Bim, Bid, Noxa, Puma, Bik/Blk, Bmf, Hrk/DP5, Beclin-1 and Mule (Xu G. et al, Bioorg. Med. Chem. 2017, 25, 5548-5556; Hardwick J. M. et al, Cell. 2009, 138, 404; Reed J. C., Cell Death Differ. 2018, 25, 3-6; Kang M. H. et al, Clin Cancer Res 2009, 15, 1126-1132).
- the pro-apoptotic members upon activation, form a homo-oligomer in the outer mitochondrial membrane that leads to pore formation and the escape of mitochondrial contents, a step into triggering apoptosis.
- Antiapoptotic members of the Bcl-2 family (such as Bcl-2, Bel-XL, and Mcl-1) block the activity of BAX and BAK. In normal cells, this process is tightly regulated. Abnormal cells can dysregulate this process to avoid cell death.
- One of the ways that cancer cells can accomplish this is by upregulating the antiapoptotic members of the Bcl-2 family of proteins. Overexpression or up-regulation of the anti-apoptotic Bcl-2 family proteins enhance cancer cell survival and cause resistance to a variety of anticancer therapies.
- Aberrant expression or function of the proteins responsible for apoptotic signaling contributes to numerous human pathologies including auto-immune diseases, neurodegeneration (such as Parkinson's disease, Alzheimer's disease and ischaemia), inflammatory diseases, viral infections and cancer (such as colon cancer, breast cancer, small-cell lung cancer, non-small-cell lung cancer, bladder cancer, ovarian cancer, prostate cancer, chronic lymphoid leukemia, lymphoma, myeloma, acute myeloid leukemia, pancreatic cancer, etc.) (Hanahan D. et al, Cell 2000, 100. 57-70).
- it is prospective to target key apoptosis regulators for cancer treatment (Kale J. et al, Cell Death Differ. 2018, 25, 65-80; Vogler M. et al, Cell Death Differ. 2009, 16, 360-367).
- Mcl-1 Myeloid Cell Leukemia-1
- Mcl-1 has the distinct trait of being essential for embryonic development as well as the survival of all hematopoietic lineages and progenitor populations. Mcl-1 is one of the most common genetic aberrations in human cancer and is highly expressed in many tumor types. Mcl-1 overexpression in human cancers is associated with high tumor grade and poor survival (Beroukhim R. et al, Nature 2010, 463, 899-905).
- Mcl-1 overexpression prevents cancer cells from undergoing programmed cell death (apoptosis), allowing the cells to survive despite widespread genetic damage. Further, its amplification is associated with both intrinsic and acquired resistance to a wide variety of antitumorigenic agents including chemotherapeutic agents such as microtubule binding agents, paclitaxel and gemcitabine, as well as apoptosis-inducing agents such as TRAIL, the Bcl-2 inhibitor, venetoclax, and the Bcl-2/Bcl-XL dual inhibitor navitoclax.
- chemotherapeutic agents such as microtubule binding agents, paclitaxel and gemcitabine
- apoptosis-inducing agents such as TRAIL, the Bcl-2 inhibitor, venetoclax, and the Bcl-2/Bcl-XL dual inhibitor navitoclax.
- Mcl-1 silencing approaches that specifically target Mcl-1 circumvent this resistance phenotype, but certain cancer cell types frequently undergo cell death in response to Mcl-1 silencing, indicating a dependence on Mcl-1 for survival. Consequently, approaches that inhibit Mcl-1 function are of considerable interest for cancer therapy (Wertz I. E et al, Nature 2011, 777, 110-114; Zhang B. et al., Blood 2002, 99, 1885-1893).
- Stereoisomers of the compounds of Formula I and the pharmaceutical salts and solvates thereof, are also contemplated, described, and encompassed herein. Methods of using compounds of Formula I are described, as well as pharmaceutical compositions including the compounds of Formula I.
- FIG. 1 shows an ORTEP representation of the compound of Example 34.
- compositions and methods which are described herein in the context of separate aspects, may also be provided in combination in a single aspect.
- alkyl when used alone or as part of a substituent group, refers to a straight- or branched-chain hydrocarbon group having from 1 to 12 carbon atoms (“C 1 -C 12 ”), preferably 1 to 6 carbons atoms (“C 1 -C 6 ”), in the group.
- alkyl groups include methyl (Me, C 1 alkyl), ethyl (Et, C 2 alkyl), n-propyl (C 3 alkyl), isopropyl (C 3 alkyl), butyl (C 4 alkyl), isobutyl (C 4 alkyl), sec-butyl (C 4 alkyl), tert-butyl (C 4 alkyl), pentyl (C 5 alkyl), isopentyl (C 5 alkyl), tert-pentyl (C 5 alkyl), hexyl (C 6 alkyl), isohexyl (C 6 alkyl), and the like.
- haloalkyl when used alone or as part of a substituent group, refers to a straight- or branched-chain hydrocarbon group having from 1 to 12 carbon atoms (“C 1 -C 12 ”), preferably 1 to 6 carbons atoms (“C 1 -C 6 ”), in the group, wherein one or more of the hydrogen atoms in the group have been replaced by a halogen atom.
- haloalkyl groups include trifluoromethyl (—CF 3 , C 1 haloalkyl), trifluoroethyl (—CH 2 CF 3 , C 2 haloalkyl), and the like.
- alkylene when used alone or as part of a substituent group, refers to an alkyl diradical, i.e., a straight- or branched-chain hydrocarbon group having from 1 to 12 carbon atoms (“C 1 -C 12 ”), preferably 1 to 6 carbons atoms (“C 1 -C 6 ”), in the group, wherein the group is directly attached to two other variable groups.
- cycloalkyl refers to non-aromatic cyclic hydrocarbons including cyclized alkyl and/or alkenyl groups. Cycloalkyl groups thus also encompass cycloalkenyl groups. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2 fused rings) groups, spirocycles, and bridged rings (e.g., a bridged bicycloalkyl group). Ring-forming carbon atoms of a cycloalkyl group can be optionally substituted by oxo or sulfido (e.g., C(O) or C(S)).
- oxo or sulfido e.g., C(O) or C(S)
- cycloalkyl moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo or thienyl derivatives of cyclopentane, cyclohexane, and the like.
- a cycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring.
- Cycloalkyl groups can have 3, 4, 5, 6, 7, 8, 9, or 10 ring-forming carbons (C 3-10 ).
- the cycloalkyl is a C 3-10 monocyclic or bicyclic cyclocalkyl.
- the cycloalkyl is a C 3-10 monocyclic or bicyclic cycloalkyl which is optionally substituted by CH 2 F, CHF 2 , CF 3 , and CF 2 CF 3 . In some embodiments, the cycloalkyl is a C 3-7 monocyclic cycloalkyl. In some embodiments, the cycloalkyl is a C 4-10 spirocycle or bridged cycloalkyl.
- Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, cubane, adamantane, bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, bicyclo[2.2.2]octanyl, spiro[3.3]heptanyl, and the like.
- cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
- cycloalkyl are cyclic-containing, non-aromatic hydrocarbon groups having from 3 to 12 carbon atoms (“C 3 -C 12 ”), preferably from 3 to 6 carbon atoms (“C 3 -C 6 ”).
- cycloalkyl groups include, for example, cyclopropyl (C 3 ; 3-membered), cyclobutyl (C 4 ; 4-membered), cyclopropylmethyl (C 4 ), cyclopentyl (C 5 ), cyclohexyl (C 6 ), 1-methylcyclopropyl (C 4 ), 2-methylcyclopentyl (C 4 ), adamantanyl (C 10 ), and the like.
- cycloalkylene when used alone or as part of a substituent group refers to a cycloalkyl diradical, i.e., a cyclic-containing, non-aromatic hydrocarbon group having from 3 to 14 carbon atoms (“C 3 -C 14 ”; or 3-14 membered), for example 3 to 12 carbon atoms (“C 3 -C 12 ”), preferably from preferably from 3 to 7 carbon atoms (“C 3 -C 7 ”, or 3-7 membered) or 3 to 6 carbon atoms (“C 3 -C 6 ”), wherein the group is directly attached to two other variable groups.
- Cycloalkylene groups include spirocycloalkylene groups.
- cycloalkenylene refers to a cycloalkenylene diradical.
- spirocycloalkyl when used alone or as part of a substituent group refers to a non-aromatic hydrocarbon group containing two cycloalkyl rings, and wherein the two cycloalyl rings share a single carbon atom in common.
- spirocycloalkylene when used alone or as part of a substituent group refers to a spirocycloalkyl diradical, i.e., a non-aromatic hydrocarbon group containing two cycloalkyl rings, and wherein the two cycloalyl rings share a single carbon atom in common, and wherein the group is directly attached to two other variable groups.
- heterocycloalkyl refers to monocyclic or polycyclic heterocycles having at least one non-aromatic ring (saturated or partially unsaturated ring), wherein one or more of the ring-forming carbon atoms of the heterocycloalkyl is replaced by a heteroatom selected from N, O, S and B, and wherein the ring-forming carbon atoms and heteroatoms of the heterocycloalkyl group can be optionally substituted by one or more oxo or sulfido (e.g., C(O), S(O), C(S), or S(0)2, etc.).
- oxo or sulfido e.g., C(O), S(O), C(S), or S(0)2, etc.
- Heterocycloalkyl groups include monocyclic and polycyclic (e.g., having 2 fused rings) systems. Included in heterocycloalkyl are monocyclic and polycyclic 3-10, 4-10, 3-7, 4-7, and 5-6 membered heterocycloalkyl groups. Heterocycloalkyl groups can also include spirocycles and bridged rings (e.g., a 5-10 membered bridged biheterocycloalkyl ring having one or more of the ring-forming carbon atoms replaced by a heteroatom independently selected from N, O, S and B). The heterocycloalkyl group can be attached through a ring-forming carbon atom or a ring-forming heteroatom.
- the heterocycloalkyl group contains 0 to 3 double bonds. In some embodiments, the heterocycloalkyl group contains 0 to 2 double bonds. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the non-aromatic heterocyclic ring, for example, benzo or thienyl derivatives of piperidine, morpholine, azepine, etc.
- a heterocycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring.
- the heterocycloalkyl group contains 3 to 10 ring-forming atoms, 4 to 10 ring-forming atoms, 3 to 7 ring-forming atoms, or 5 to 6 ring-forming atoms. In some embodiments, the heterocycloalkyl group has 1 to 4 heteroatoms, 1 to 3 heteroatoms, 1 to 2 heteroatoms or 1 heteroatom. In some embodiments, the heterocycloalkyl is a monocyclic 4-6 membered heterocycloalkyl having 1 or 2 heteroatoms independently selected from N, O, S and B and having one or more oxidized ring members.
- Example heterocycloalkyl groups include pyrrolidin-2-one, 1,3-isoxazolidin-2-one, pyranyl, tetrahydropyran, oxetanyl, azetidinyl, morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, azepanyl, benzazapene, 1,2,3,4-tetrahydroisoquinoline, azabicyclo[3.1.O]hexanyl, diazabicyclo[3.1.O]hexanyl, oxabicyclo[2.1.l]hexanyl, azabicyclo[2.2.l]heptanyl
- heterocycloalkyl refers to any three to ten membered monocyclic or bicyclic, saturated ring structure containing at least one heteroatom selected from the group consisting of O, N and S.
- the heterocycloalkyl group may be attached at any heteroatom or carbon atom of the ring such that the result is a stable structure.
- heterocycloalkyl groups include, but are not limited to, azepanyl, aziridinyl, azetidinyl, pyrrolidinyl, dioxolanyl, imidazolidinyl, pyrazolidinyl, piperazinyl, piperidinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, oxazepanyl, oxiranyl, oxetanyl, quinuclidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperazinyl, and the like.
- heterocycloalkylene when used alone or as part of a substituent group refers to a heterocycloalkyl diradical.
- heterocycloalkylene any three to ten membered monocyclic or bicyclic, saturated ring structure containing at least one heteroatom selected from the group consisting of O, N and S, wherein the ring structure is directly attached to two other variable groups.
- the term “spiroheterocycloalkyl” when used alone or as part of a substituent group refers to a non-aromatic group containing two rings, at least one of which is a heterocycloalkyl ring, and wherein the two rings share a single carbon atom in common.
- spirocycloalkylene when used alone or as part of a substituent group refers to a spirocycloalkyl diradical.
- spirocycloalkylene is a non-aromatic group containing two rings, at least one of which is a heterocycloalkyl ring, and wherein the two rings share a single carbon atom in common, and wherein the group is directly attached to two other variable groups.
- alkenyl when used alone or as part of a substituent group refers to a straight- or branched-chain group having from 2 to 12 carbon atoms (“C 2 -C 12 ”), preferably 2 to 4 carbons atoms (“C 2 -C 4 ”), in the group, wherein the group includes at least one carbon-carbon double bond.
- alkenyl groups include vinyl (—CH ⁇ CH 2 ; C 2 alkenyl), allyl (—CH 2 —CH ⁇ CH 2 ; C 3 alkenyl), propenyl (—CH ⁇ CHCH 3 ; C 3 alkenyl); isopropenyl (—C(CH 3 ) ⁇ CH 2 ; C 3 alkenyl), butenyl (—CH ⁇ CHCH 2 CH 3 ; C 4 alkenyl), sec-butenyl (—C(CH 3 ) ⁇ CHCH 3 ; C 4 alkenyl), iso-butenyl (—CH ⁇ C(CH 3 ) 2 ; C 4 alkenyl), 2-butenyl (—CH 2 CH ⁇ CHCH 3 ; C 4 alkyl), pentenyl (CH ⁇ CHCH 2 CH 2 CH 3 or CH2 ⁇ CHCH 2 CH 2 CH 2 —; C 5 alkenyl), and the like.
- alkenylene when used alone or as part of a substituent group refers to a alkenyl diradical, i.e., a straight- or branched-chain group having from 2 to 12 carbon atoms (“C 2 -C 12 ”), preferably 2 to 4 carbons atoms (“C 2 -C 4 ”), in the group, wherein the group includes at least one carbon-carbon double bond, and wherein the group is directly attached to two other variable groups.
- alkynyl when used alone or as part of a substituent group refers to a straight- or branched-chain group having from 2 to 12 carbon atoms (“C 2 -C 12 ”), preferably 2 to 4 carbons atoms (“C 2 -C 4 ”), in the group, wherein the group includes at least one carbon-carbon triple bond.
- alkynyl groups include ethynyl (—C ⁇ CH; C 2 alkynyl), propragyl (—CH 2 —CH ⁇ CH; C 3 alkynyl), and the like.
- alkynylene when used alone or as part of a substituent group refers to an alkynyl diradical, i.e., a straight- or branched-chain group having from 2 to 12 carbon atoms (“C 2 -C 12 ”), preferably 2 to 4 carbons atoms (“C 2 -C 4 ”), in the group, wherein the group includes at least one carbon-carbon triple bond, and wherein the group is directly attached to two other variable groups.
- aryl when used alone or as part of a substituent group refers to a monocyclic all carbon aromatic ring or a multicyclic all carbon ring system wherein the rings are aromatic. Thus, aryl also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 aryl rings) having about 9 to 14 carbon atoms. In some embodiments, “aryl” refers to a mono- or bicyclic-aromatic hydrocarbon ring structure having 6 or 10 carbon atoms in the ring, wherein one or more of the carbon atoms in the ring is optionally substituted.
- substituents include halogen atoms, —C 1 -C 3 alkyl groups, and C 1 -C 3 haloalkyl groups.
- Halogen atoms include chlorine, fluorine, bromine, and iodine.
- C 1 -C 3 haloalkyl groups include, for example, —CF 3 , —CH 2 CF 3 , and the like.
- arylene when used alone or as part of a substituent group refers to an aryl diradical.
- arylene refers to a mono- or bicyclic-aromatic hydrocarbon ring structure having 6 or 10 carbon atoms in the ring, wherein one or more of the carbon atoms in the ring is optionally substituted, and wherein the ring structure is directly attached to two other variable groups.
- heteroaryl when used alone or as part of a substituent group, the term “heteroaryl” as used herein refers to a monocyclic aromatic ring that has at least one atom other than carbon in the ring, wherein the atom is selected from the group consisting of oxygen, nitrogen and sulfur; “heteroaryl” also includes multicyclic ring systems that have at least one such aromatic ring. Thus, “heteroaryl” includes single aromatic rings of from about 1 to 6 carbon atoms and about 1-4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur. The sulfur and nitrogen atoms may also be present in an oxidized form provided the ring is aromatic.
- Heteroaryl also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) wherein a heteroaryl group is condensed with one or more rings selected from heteroaryls or aryls.
- a heteroaryl a single aromatic ring or multiple condensed ring system
- a heteroaryl a monocyclic aromatic ring or multicyclic condensed ring system
- the rings of a multicyclic ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
- heteroaryl refers to a mono- or bicyclic-aromatic ring structure including carbon atoms as well as up to four heteroatoms selected from nitrogen, oxygen, and sulfur.
- heteroaryl rings can include a total of 5, 6, 9, or 10 ring atoms.
- the heteroaryl moiety can be optionally substituted.
- substituents include halogen atoms; —C 1 -C 3 alkyl groups, and C 1 -C 3 haloalkyl groups. Halogen atoms include chlorine, fluorine, bromine, and iodine.
- heteroarylene when used alone or as part of a substituent group refers to a heteroaryl diradical.
- heteroarylene is a mono- or bicyclic-aromatic ring structure including carbon atoms as well as up to four heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the ring structure is directly attached to two other variable groups.
- halo refers to a halogen substituent (i.e., —F, —Cl, —Br, or —I).
- oxo refers to an oxygen substituent that is connected by a double bond (i.e., ⁇ O).
- alkoxy when used alone or as part of a substituent group refers to an oxygen radical attached to an alkyl group by a single bond.
- alkoxy groups include methoxy (—OCH 3 ), ethoxy (—OCH 2 CH 3 ), isopropoxy (—OCH(CH 3 ) 2 ) and the like.
- haloalkoxy when used alone or as part of a substituent group refers to an oxygen radical attached to a haloalkyl group by a single bond.
- haloalkoxy groups include —OCF 3 , —OCH 2 CF 3 , —OCH(CF 3 ) 2 , and the like.
- C 1 -C 6 When a range of carbon atoms is used herein, for example, C 1 -C 6 , all ranges, as well as individual numbers of carbon atoms are encompassed.
- C 1 -C 3 includes C 1 -C 3 , C 1 -C 2 , C 2 -C 3 , C 1 , C 2 , and C 3 .
- C 1 -C 6 alk when used alone or as part of a substituent group refers to an aliphatic linker having 1, 2, 3, 4, 5, or 6 carbon atoms and includes, for example, —CH 2 —, —CH(CH 3 )—, —CH(CH 3 )—CH 2 —, and —C(CH 3 ) 2 —.
- —C 0 alk- refers to a bond.
- the C 1 -C 6 alk can be substituted with one or more substituents.
- the optional substituent may be one or more of D, halo, oxo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkyl-NR c1 R d1 ,
- each R a1 is independently H, D, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, wherein said C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C
- each R b1 is independently H, D, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, wherein said C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1
- R c1 or R d1 is independently H, C 1 -C 10 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylcycloalkyl, arylheterocycloalkyl, arylheteroaryl, biaryl, heteroarylcycloalkyl, heteroarylheterocycloalkyl, heteroaryl aryl, and biheteroaryl, wherein said C 1 -C 10 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, heteroaryl, cycloalkyl,
- these optional substituents R c2 and R d2 together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, hydroxyalkyl, cyanoalkyl, aryl, heteroaryl, C(O)OR a1 , C(O)R b1 , S(O) 2 R b1 , alkoxyalkyl, and alkoxyalkoxy;
- R e1 is independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, (C 1 -C 6 alkoxy)-C 1 -C 6 alkyl, C 2 -C 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl.
- R f1 is independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl.
- R g1 is independently H, CN, or NO 2 .
- “Pharmaceutically acceptable” means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, e.g., in humans.
- “Pharmaceutically acceptable salt” refers to a salt of a compound of the disclosure that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound.
- such salts are non-toxic may be inorganic or organic acid addition salts and base addition salts.
- such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxy ethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic
- Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the compound contains a basic functionality, salts of non-toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.
- non-toxic organic or inorganic acids such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.
- a “pharmaceutically acceptable excipient” refers to a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith.
- excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
- a “solvate” refers to a physical association of a compound of Formula I with one or more solvent molecules.
- Subject includes humans.
- the terms “human,” “patient,” and “subject” are used interchangeably herein.
- Treating” or “treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (i.e., arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, “treating” or “treatment” refers to delaying the onset of the disease or disorder.
- Compounds of the present disclosure are meant to embrace compounds of Formula I or Formula II as described herein, as well as their respective subgenera, which expression includes the stereoisomers (e.g., entaniomers, diastereomers) and constitutional isomers (e.g., tautomers) of compounds of Formula I or Formula II as well as the pharmaceutically acceptable salts, where the context so permits.
- stereoisomers e.g., entaniomers, diastereomers
- constitutional isomers e.g., tautomers
- isotopic variant refers to a compound that contains proportions of isotopes at one or more of the atoms that constitute such compound that is greater than natural abundance.
- an “isotopic variant” of a compound can be radiolabeled, that is, contain one or more radioactive isotopes, or can be labeled with non-radioactive isotopes such as for example, deuterium ( 2 H or D), carbon-13 ( 13 C), nitrogen-15 ( 15 N), or the like.
- any hydrogen may be 2 H/D
- any carbon may be 13 C
- any nitrogen may be 15 N, and that the presence and placement of such atoms may be determined within the skill of the art.
- isomers compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers.” Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers,” for example, diastereomers, enantiomers, and atropisomers.
- the compounds of this disclosure may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)-stereoisomers at each asymmetric center, or as mixtures thereof. Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include all stereoisomers and mixtures, racemic or otherwise, thereof.
- the disclosure is directed to a compound of Formula I:
- Z in Formula I is CH or N. In some embodiments, Z is CH. In other embodiments, Z is N.
- Q in Formula I is —O—, —S—, —S(O)—, or —S(O) 2 —.
- Q is —O—.
- Q is —S—.
- Q is —S(O)—.
- Q is —S(O) 2 —.
- the moiety -W 1 -W 2 -W 3 in Formula I is —CR 2 R 2A —CR 2 R 2A —CR 2 R 2A —, —O—CR 2B R 2C —CR 2 R 2A —, —CR 2 R 2A —CR 2B R 2C —O—, —NR 2B —CR 2B R 2C —CR 2 R 2A —, —CR 2 R 2A —CR 2B R 2C — NR 2B —, —S—CR 2B R 2C —CR 2 R 2A , or —CR 2 R 2A —CR 2B R 2C —S—.
- the moiety -W 1 -W 2 -W 3 in Formula I is —CR 2 R 2A —CR 2 R 2A —CR 2 R 2A —. In some embodiments, the moiety -W 1 -W 2 -W 3 in Formula I is —O—CR 2B R 2C —CR 2 R 2A —. In some embodiments, the moiety -W 1 -W 2 -W 3 in Formula I —CR 2 R 2A —CR 2B R 2C —O—. In some embodiments, the moiety -W 1 -W 2 -W 3 in Formula I is —NR 2B —CR 2B R 2C —CR 2 R 2A —.
- the moiety -W 1 -W 2 -W 3 in Formula I —CR 2 R 2A —CR 2B R 2C — NR 2B
- the moiety -W 1 -W 2 -W 3 in Formula I is —S—CR 2B R 2C —CR 2 R 2A .
- the moiety -W 1 -W 2 -W 3 in Formula I is —CR 2 R 2A —CR 2B R 2C —S—.
- L 1 in Formula I is absent, or is —C 1 -C 6 alkylene-, for example, —C 1 alkylene, —C 2 alkylene, —C 3 alkylene, —C 4 alkylene, —C 5 alkylene, or —C 6 alkylene, wherein the C 1 -C 6 alkylene is optionally substituted.
- L 1 in Formula I is —C 1 -C 6 alkylene-, for example, —C 1 alkylene, —C 2 alkylene, —C 3 alkylene, —C 4 alkylene, —C 5 alkylene, or —C 6 alkylene, wherein the C 1 -C 6 alkylene is optionally substituted.
- L 1 in Formula I is optionally substituted —C 1 alkylene.
- L 1 in Formula I is —CH 2 —.
- L 2 in Formula I is optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, or optionally substituted heteroaryl ene.
- L 2 in Formula I is 3-7 membered cycloalkylene, 4-7 membered heterocycloalkylene, arylene, or heteroarylene; each optionally substituted.
- L 2 is optionally substituted cycloalkylene or optionally substituted heterocycloalkylene.
- L 2 is optionally substituted cyclobutylene or optionally substituted pyrrolidinyl.
- L 2 in Formula I is 3-7 membered cycloalkylene, for example, 3-membered cycloalkylene, 4-membered cycloalkylene, 5-membered cycloalkylene, 6-membered cycloalkylene, or 7-membered cycloalkylene.
- L 2 is 4-membered cycloalkylene.
- L 2 is cyclobutylenyl.
- L 2 in Formula I is 4-7 membered heterocycloalkylene, for example, 4-membered heterocycloalkylene, 5-membered heterocycloalkylene, 6-membered heterocycloalkylene, or 7-membered heterocycloalkylene.
- L 2 in Formula I is 5-membered heterocycloalkylene.
- L 2 is pyrrolidinyl.
- L 2 in Formula I is heteroarylene.
- the heteroarylene is pyrazolyl.
- L 3 in Formula I is absent, or is —(CR 4 R 5 ) p —, —(CR 4 R 5 ) p O—, —O—, —S—, —S(O)—, —S(O) 2 —, —C( ⁇ O)—, —NR 6 —, —OC( ⁇ O)—, —C( ⁇ O)O—, —NR 6A C(O)—, —C( ⁇ O)NR 6A —, —OC( ⁇ O)N(R 6A )—, —NR 6A C(O)O—, —S( ⁇ O)NR 6A —, —NR 6A S(O)—, —S( ⁇ O) 2 NR 6A —, or —NR 6A S(O) 2 —.
- L 3 in Formula I is absent. In some embodiments, L 3 is —(CR 4 R 5 ) p —. In some embodiments, L 3 is —(CR 4 R 5 ) p O—. In some embodiments, L 3 is —O—. In some embodiments, L 3 is —S—. In some embodiments, L 3 is —S(O)—. In some embodiments, L 3 is —S(O) 2 —. In some embodiments, L 3 is —C( ⁇ O)—. In some embodiments, L 3 is —NR 6 —. In some embodiments, L 3 is —OC( ⁇ O)—. In some embodiments, L 3 is —C( ⁇ O)O—.
- L 3 is —NR 6A C(O). In some embodiments, L 3 is —C( ⁇ O)NR 6A —. In some embodiments, L 3 is —OC( ⁇ O)N(R 6A )—. In some embodiments, L 3 is —NR 6A C(O)O—. In some embodiments, L 3 is —S( ⁇ O)NR 6A —. In some embodiments, L 3 is —NR 6A S(O)—. In some embodiments, L 3 is —S( ⁇ O) 2 NR 6A —. In some embodiments, L 3 is —NR 6A S(O) 2 —.
- L 4 in Formula I is absent, or is —(CR 4 R 5 ) p Q 1 (CR 4 R 5 ) q —, wherein Q 1 is absent, —CR 4A ⁇ CR 4B —, —O—, —S—, —S(O)—, —S(O) 2 —, —C( ⁇ O)—, —NR 6 —, —OC( ⁇ O)—, —C( ⁇ O)O—, —NR 6A C(O)—, —C( ⁇ O)NR 6A —, —NR 6A C(O)R 6B —, —OC( ⁇ O)N(R 6A )—, —NR 6A C(O)O—, —S( ⁇ O)NR 6A —, —NR 6A S(O)—, —S( ⁇ O) 2 NR 6A —, or —NR 6A S(O) 2 —; or is —(CR 4 R 5 ) p
- L 4 in Formula I is absent. In other embodiments, L 4 in Formula I is —(CR 4 R 5 ) p —(CR 4A ⁇ CR 4B )—(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula I is —(CR 4 R 5 ) p —O—(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula I is —(CR 4 R 5 ) p —S—(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula I is —(CR 4 R 5 ) p —S(O)—(CR 4 R 5 ) q —.
- L 4 in Formula I is —(CR 4 R 5 ) p —S(O) 2 —(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula I is —(CR 4 R 5 ) p —C( ⁇ O)—(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula I is —(CR 4 R 5 ) p —NR 6 —(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula I is —(CR 4 R 5 ) p —OC( ⁇ O)—(CR 4 R 5 ) q —.
- L 4 in Formula I is —(CR 4 R 5 ) p —C( ⁇ O)O—(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula I is —(CR 4 R 5 ) p —NR 6A C(O)—(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula I is —(CR 4 R 5 ) p —C( ⁇ O)NR 6A —(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula I is —(CR 4 R 5 ) p —NR 6A C(O)R 6B —CR 4 R 5 ) q —.
- L 4 in Formula I is —(CR 4 R 5 ) p —OC( ⁇ O)N(R 6A )—(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula I is —(CR 4 R 5 ) p —NR 6A C(O)O—(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula I is —(CR 4 R 5 ) p —S( ⁇ O)NR 6A —(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula I is —(CR 4 R 5 ) p —NR 6A S(O)—(CR 4 R 5 ) q —.
- L 4 in Formula I is —(CR 4 R 5 ) p —S( ⁇ O) 2 NR 6A —(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula I is —(CR 4 R 5 ) p —NR 6A S(O) 2 —(CR 4 R 5 ) q —. In some embodiments, L 4 is —(CR 4 R 5 ) p —(CR 4A ⁇ CR 4B )—(CR 4 R 5 ) q —O—.
- L 5 in Formula I is absent, or is —C 1 -C 6 alkylene-, —C 2 -C 6 alkenylene-, —C 2 -C 6 alkynylene-, -arylene-, -heteroarylene-, -cycloalkenylene-, -cycloalkylene-, -heterocycloalkylene-, wherein the C 1 -C 6 alkylene, C 2 -C 6 alkenylene, C 2 -C 6 alkynylene, arylene, heteroaryl ene, cycloalkenylene, cycloalkylene, or heterocycloalkylene groups are optionally substituted.
- L 5 in Formula I is absent. In other embodiments, L 5 in Formula I is C 1 -C 6 alkylene, for example, C 1 alkylene, C 2 alkylene, C 3 alkylene, C 4 alkylene, C 5 alkylene, or C 6 alkylene, each optionally substituted.
- L 5 in Formula I is C 2 -C 6 alkenylene, for example, C 2 alkenylene, C 3 alkenylene, C 4 alkenylene, C 5 alkenylene, or C 6 alkenylene, each optionally substituted.
- L 5 in Formula I is C 2 -C 6 alkynylene, for example, C 2 alkynylene, C 3 alkynylene, C 4 alkynylene, C 5 alkynylene, or C 6 alkynylene, each optionally substituted.
- L 5 in Formula I is an optionally substituted arylene.
- L 5 in Formula I is a 6- to 10-membered arylene, for example phenylene or naphthylene.
- L 5 in Formula I is a phenylene.
- L 5 in Formula I is an optionally substituted heteroarylene.
- L 5 in Formula I is a 5- to 10-membered heteroarylene, for example, pyrazolyl, thiazolyl, imidazolyl, or pyridinyl.
- L 5 in Formula I is pyrazolyl.
- L 5 in Formula I is thiazolyl.
- L 5 in Formula I is imidazolyl.
- L 5 in Formula I is pyridinyl.
- L 5 in Formula I is an optionally substituted cycloalkenylene.
- L 5 in Formula I is a 3- to 12-membered cycloalkenylene, for example, cyclohexenyl.
- L 5 in Formula I is an optionally substituted cycloalkylene.
- L 5 in Formula I is a 3- to 7-membered monocyclic cycloalkylene, for example, cyclopentanyl, cyclohexanyl, and the like.
- L 5 in Formula I is cyclopentanyl.
- L 5 in Formula I is a 6- to 12-membered bicyclic cycloalkylene.
- L 5 in Formula I is an optionally substituted heterocycloalkylene.
- L 5 in Formula I is an optionally substituted 3- to 7-membered monocyclic heterocycloalkylene group, for example, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, and the like.
- L 5 in Formula I is pyrrolidinyl.
- L 5 in Formula I is tetrahydrofuranyl.
- L 5 in Formula I is piperidinyl.
- L 5 in Formula I is piperazinyl.
- L 5 in Formula I is an optionally substituted 6- to 12-membered bicyclic heterocycloalkylene group.
- L 5 is absent, or is —C 1 -C 6 alkylene-, —C 2 -C 6 alkenylene-, —C 2 -C 6 alkynylene-, a 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, or 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene group.
- L 6 in Formula I is absent, or is (CR 7 R 8 ) s , (CR 7 R 8 ) s O(CR 7 R 8 ) t , (CR 7 R 8 ) s NR 9 (CR 7 R 8 ) t , (CR 7 R 8 ) s S(CR 7 R 8 ) t , (CR 7 R 8 ) s S(O)(CR 7 R 8 ) t , (CR 7 R 8 ) s S(O) 2 (CR 7 R 8 ) t , (CR 7 R 8 ) s NR 9A C(O)(CR 7 R 8 ) t , (CR 7 R 8 ) s OC(O)NR 9A (CR 7 R 8 ) t , (CR 7 R 8 ) s NR 9A C(O)O(CR 7 R 8 ) t , (CR 7 R 8 ) s NR 9A C(O)NR 9B (CR 7 R 8 ) t ,
- L 6 in Formula I is absent. In other embodiments, L 6 in Formula I is (CR 7 R 8 ) s . In other embodiments, L 6 in Formula I is (CR 7 R 8 ) s O(CR 7 R 8 ) t . In other embodiments, L 6 in Formula I is (CR 7 R 8 ) s NR 9 (CR 7 R 8 ) t . In other embodiments, L 6 in Formula I is (CR 7 R 8 ) s S(CR 7 R 8 ) t . In other embodiments, L 6 in Formula I is (CR 7 R 8 ) s S(O)(CR 7 R 8 ) t .
- L 6 in Formula I is (CR 7 R 8 ) s S(O) 2 (CR 7 R 8 ) t . In other embodiments, L 6 in Formula I is (CR 7 R 8 ) s NR 9A C(O)(CR 7 R 8 ) t . In other embodiments, L 6 in Formula I is (CR 7 R 8 ) s OC(O)NR 9A (CR 7 R 8 ) t . In other embodiments, L 6 in Formula I is (CR 7 R 8 ) s NR 9A C(O)O(CR 7 R 8 ) t .
- L 6 in Formula I is (CR 7 R 8 ) s NR 9A C(O)NR 9B (CR 7 R 8 ) t . In other embodiments, L 6 in Formula I is (CR 7 R 8 ) s NR 9A S(O)(CR 7 R 8 ) t . In other embodiments, L 6 in Formula I is (CR 7 R 8 ) s NR 9A S(O) 2 (CR 7 R 8 ) t . In other embodiments, L 6 in Formula I is —(CR 7 R 8 ) s —CR 4A ⁇ CR 4B —(CR 7 R 8 ) t .
- L 6 in Formula I is (CR 7 R 8 ) s C( ⁇ O)(CR 7 R 8 ) t . In other embodiments, L 6 in Formula I is —(CR 7 R 8 ) s C( ⁇ O)(CR 7 R 8 ) t —O—. In other embodiments, L 6 in Formula I is —(CR 7 R 8 ) s C( ⁇ O)(CR 7 R 8 ) t —NR 6 —.
- L 6 is absent, or is —(CR 7 R 8 ) s —, —O(CR 7 R 8 ) t —, —NR 9 (CR 7 R 8 ) t —, —S(CR 7 R 8 ) t —, —S(O)(CR 7 R 8 ) t —, —S(O) 2 (CR 7 R 8 ) t —, —NR 9A C(O)(CR 7 R 8 ) t —, —C(O)NR 9A (CR 7 R 8 ) t —, —R 9A C(O)O(CR 7 R 8 ) t —, —NR 9A C(O)NR 9B (CR 7 R 8 ) t —, —NR 9A S(O)(CR 7 R 8 ) t —, —NR 9A S(O) 2 (CR 7 R 8 ) t —; —CR 4A ⁇ CR 4B —(CR 7
- each R in Formula I is independently -D, -halo, —CN, —NO 2 , —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 1 -C 6 alkoxy, -cycloalkyl, —OR a , —SR a , —C(O)R b , —C(O)OR a , —NR c R d , —C(O)NR c R d , or —S(O) 2 R a ; wherein said —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 1 -C 6 alkoxy, or -cycloalkyl is optionally substituted.
- R is halo, for example, Cl or F.
- R is —SR a , for example —SCH 3 .
- R is —C 1 -C 6 alkyl, for example —CH 3 .
- each R 1 in Formula I is independently -D, -halo, —CN, —NO 2 , —C 1 -C 6 alkyl, —C 1 -C 6 alkenyl, —C 1 -C 6 alkynyl, —OR a , —SR a , —NR c R d , —C(O)R b , —OC(O)R b , —C(O)OR a , —C(O)NR c R d , —S(O) 2 R a ; -aryl, -heteroaryl, -cycloalkyl, or -heterocycloalkyl, wherein the —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 2 -C 6 alkynyl, -cycloalkyl, -heterocycloalkyl, -aryl, or -
- R 1 in Formula I is halo, for example, Cl or F. In other embodiments, R 1 in Formula I is —C 1 -C 6 alkyl substituted with fluorine, for example —CF 3 . In other embodiments, R 1 in Formula I is —C 1 -C 6 alkyl, for example, —C 6 alkyl, —C 5 alkyl, —C 4 alkyl, —C 3 alkyl, —C 2 alkyl, —C 1 alkyl. In some embodiments, R 1 in Formula I is —C 1 alkyl substituted with —CN.
- R 1 in Formula I is cycloalkyl, for example, cyclopropane, cyclobutane, cyclopentane, and the like. In other embodiments, R 1 in Formula I is cyclopropane substituted with —CN.
- each R 2 , R 2A , or R 2a is independently H, D, halo, OR a , optionally substituted C 1 -C 6 alkyl, or R 2 and R 2A that are attached to the same carbon atom may, together with the carbon atom to which they are both attached, form an optionally substituted cycloalkyl ring.
- R 2 , R 2A , and R 2a in Formula I are each H.
- R 2 , R 2A , or R 2a in Formula I is C 1 -C 6 alkyl, for example —CH 3 or —CH 2 CH 3 .
- R 2 and R 2a that are attached to the same carbon atom, together with the carbon atom to which they are both attached form an optionally substituted 3-6 membered cycloalkyl ring.
- R 2 and R 2a that are attached to the same carbon atom, together with the carbon atom to which they are both attached form a cyclopropane ring.
- each R 2B and R 2C in Formula I is independently H, D, optionally substituted C 1 -C 6 alkyl, or R 2B and R 2C may, together with the carbon atom to which they are both attached, form an optionally substituted cycloalkyl ring.
- R 2B and R 2C in Formula I are each H.
- R 3 in Formula I is H, D, —C 1 -C 6 alkyl, —C 3 -C 6 alkenyl, —C 3 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, C(O)R b , C(O)OR a , or C(O)NR c R d ; wherein said C 1 -C 6 alkyl, —C 3 -C 6 alkenyl, —C 3 -C 6 alkynyl, cycloalkyl, or heterocycloalkyl is optionally substituted; or R 3 is —C 1 -C 6 alkyl substituted at the C 1 carbon atom with —OR 3A wherein R 3A is C 1 -C 6 alkyl, —PO 3 H, —C(O)OR 2C , or —C(O)NR 3A R 3B wherein R 3A and R 3B are each independently H, D, optionally substituted C
- R 3 in Formula I is H. In other embodiments, R 3 in Formula I is —C 1 -C 6 alkyl, for example, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, C 1 alkyl, —CH3, and the like.
- each R 4 or R 7 in Formula I is independently H, D, halo, —OH, —CN, —NO 2 , —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 2 -C 6 alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, —OR a , —SR a , —NR c R d , —NR a R c , —C(O)R b , —OC(O)R a , —C(O)OR a , —C(O)NR c R d , —S(O)R b , or —S(O) 2 R b , wherein said C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 2 -C 6 alkyny
- R 4 is Formula I is H. In some embodiments, R 4 is Formula I is —OH. In other embodiments, R 4 in Formula I is —C 1 -C 6 alkyl, for example, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, C 1 alkyl, —CH 3 , and the like. In other embodiments, R 4 is Formula I is —OR a , for example, —OCH 3 .
- R 7 in Formula I is H. In other embodiments, R 7 in Formula I is —C 1 -C 6 alkyl, for example, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, C 1 alkyl, —CH 3 , and the like. In some embodiments, R 7 in Formula I is —CH 3 . In other embodiments, R 7 in Formula I is —OR a , for example, —OCH 3 .
- each R 4A or R 4B in Formula I is independently H, D, -Me, —CF 3 or —F.
- R 4A is H.
- R 4B is H.
- each R 5 or R 8 in Formula I is independently H, D, fluoro, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 2 -C 6 alkynyl, —C(O)R b , —C(O)OR a , —C(O)NR c R d , aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein the C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 2 -C 6 alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted.
- R 5 in Formula I is H. In other embodiments, R 5 in Formula I is —C 1 -C 6 alkyl, for example, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, C 1 alkyl, —CH 3 , and the like. In some embodiments, R 5 in Formula I is —CH 3 .
- R 8 in Formula I is H. In other embodiments, R 8 in Formula I is —C 1 -C 6 alkyl, for example, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, C 1 alkyl, —CH 3 , and the like. In some embodiments, R 8 in Formula I is —CH 3 .
- each R 7 and each R 8 is independently, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted —C 1 -C 6 alkyl.
- each R 7 and each R 8 is independently H, optionally substituted 3-7 membered cycloalkyl, 4-7 membered heterocycloalkyl, or optionally substituted —C 1 -C 6 alkyl.
- each R 7 and each R 8 is independently H, —CH 3 , -cyclopropyl, —CH 2 CH 3 , or —CH(CH 3 ) 2 .
- each R 7 and each R 8 is independently H, or a —C 1 -C 6 alkyl group optionally substituted with —OH, optionally substituted —OC 1 -C 6 alkyl, optionally substituted —(CH 2 CH 2 O) o C 1 -C 6 alkyl wherein o is 1-10, or —C(O)NR c1 R d1 wherein R c1 and R d1 are independently H, optionally substituted —C 1 -C 6 alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl.
- each R 7 and each R 8 is independently H, or —C 1 -C 6 alkyl group is optionally substituted with —OH, —OC 1 -C 6 alkyl, —(CH 2 CH 2 O) o C 1 -C 6 alkyl wherein o is 1-10, or —C(O)NR c1 R d1 wherein R c1 and R d1 are independently H, C 1 -C 6 alkyl, or 4-7 membered heterocycloalkyl; or wherein or R c1 and R d1 , together with the N atom to which they are both attached, form a multicyclic 4-7 membered heterocycloalkyl ring optionally substituted with halo, —OC 1 -C 6 alkyl, or —C 1 -C 6 alkyl optionally substituted with —OH or —OC 1 -C 6 alkyl.
- R 4 and R 5 together with the C atom to which they are attached form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted.
- each R 7 and each R 8 is independently H, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted —C 1 -C 6 alkyl; or R 7 and R 8 attached to the same carbon atom, together with that carbon atom, form an optionally substituted cycloalkyl ring or an optionally substituted heterocycloalkyl ring; or R 7 and R 8 attached to adjacent carbon atoms, together with those carbon atoms, form an optionally substituted cycloalkyl ring or and optionally substituted heterocycloalkyl ring.
- each R 7 and each R 8 is independently H, optionally substituted 3-7 membered cycloalkyl, 4-7 membered heterocycloalkyl, or optionally substituted —C 1 -C 6 alkyl; or wherein R 7 and R 8 attached to the same carbon atom, together with that carbon atom, form an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocycloalkyl ring; or R 7 and R 8 attached to adjacent carbon atoms, together with those carbon atoms, form an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocycloalkyl ring.
- R 7 or R 8 are each independently H, —CH 3 , -cyclopropyl, —CH 2 CH3, or —CH(CH 3 ) 2 .
- R 7 and R 8 attached to the same carbon atom, together with that carbon atom, form a cyclopropyl ring, a cyclobutyl ring, or azetidinyl ring.
- each R 7 and each R 8 is independently H, or a —C 1 -C 6 alkyl group optionally substituted with —OH; optionally substituted —OC 1 -C 6 alkyl; optionally substituted —(CH 2 CH 2 O) o C 1 -C 6 alkyl wherein o is 1-10; or —C(O)NR c1 R d1 wherein R c1 and R d1 are independently H, optionally substituted —C 1 -C 6 alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl; or wherein or R c1 and R d1 , together with the N atom to which they are both attached, form an optionally substituted monocyclic or multicyclic heterocycloalkyl ring.
- the —C 1 -C 6 alkyl group is optionally substituted with —OH; —OC 1 -C 6 alkyl; —(CH 2 CH 2 O) o C 1 -C 6 alkyl wherein o is 1-10; or —C(O)NR c1 R d1 wherein R c1 and R d1 are independently H, C 1 -C 6 alkyl, or 4-7 membered heterocycloalkyl; or wherein or R c1 and R d1 , together with the N atom to which they are both attached, form a monocyclic or multicyclic 4-7 membered heterocycloalkyl ring optionally substituted with halo; —OC 1 -C 6 alkyl; or —C 1 -C 6 alkyl optionally substituted with —OH or —OC 1 -C 6 alkyl.
- R 7 and R 8 together with the C atom to which they are both attached form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted, each optionally substituted.
- R 7 and R 8 together with the C atom to which they are both attached form a cycloalkyl ring, for example, a cyclopropyl ring, a cyclobutyl ring, or a cyclopentyl ring.
- R 7 and R 8 attached to the same carbon atom, together with that carbon atom, form an optionally substituted cycloalkyl ring or an optionally substituted heterocycloalkyl ring.
- R 7 and R 8 attached to adjacent carbon atoms, together with those carbon atoms, form an optionally substituted cycloalkyl ring or and optionally substituted heterocycloalkyl ring.
- R 7 and R 8 attached to the same carbon atom, together with that carbon atom, form an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocycloalkyl ring;
- R 7 and R 8 attached to adjacent carbon atoms, together with the atoms to which they are attached, form a 3-7 membered cycloalkyl ring or 4-7 membered heterocycloalkyl ring.
- R 7 and R 8 attached to the same carbon atom, together with that carbon atom, form a cyclopropyl ring, a cyclobutyl ring, or azetidinyl ring.
- each R 6 or R 9 is independently H, D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 2 -C 6 alkynyl, —OC 1 -C 6 alkyl, —C(O)R b , —C(O)OR a , —C(O)NR c R d , —S(O)R b or —S(O) 2 R b , aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group, wherein the C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 2 -C 6 alkynyl, —OC 1 -C 6 alkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group, where
- R 6 is H. In other embodiments, R 6 is —C 1 -C 6 alkyl, for example, —CH 3 or —CH 2 CH 3 .
- R 9 is H; optionally substituted —C 1 -C 6 alkyl; optionally substituted —C(O)OC 1 -C 6 alkyl; optionally substituted —SO 2 C 1 -C 6 alkyl; optionally substituted —C(O)C 1 -C 6 alkyl; optionally substituted —C(O)NR c R d ; or wherein R 9 together with either R 7 or R 8 form an optionally substituted heterocyclic alkylene.
- R 9 is H; —C 1 -C 6 alkyl, optionally substituted with deuterium; —C(O)OC 1 -C 6 alkyl; —SO 2 C 1 -C 6 alkyl; —C(O)C 1 -C 6 alkyl; or wherein R 9 together with either R 7 or R 8 forms an optionally heterocyclic alkylene.
- R 9 is H; —C 1 -C 6 alkyl, optionally substituted with deuterium; —C(O)OC 1 -C 6 alkyl; —SO 2 C 1 -C 6 alkyl; —C(O)C 1 -C 6 alkyl.
- R 9 is H; —CH 3 ; —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —CD 3 , —C(O)OCH 3 ; —C(O)OC(CH 3 ) 3 , —SO 2 CH 3 ; or —C(O)CH 3 .
- R 9 together with either an R 7 or an R 8 forms an optionally substituted heterocyclic alkylene. In some embodiments, R 9 together with either R 7 or R 8 form a heterocyclic alkylene. In some embodiments, R 9 together with either an R 7 or an R 8′ forms a C 3 -C 9 heterocyclic alkylene.
- each R 6A , R 6B , R 9A , or R 9B in Formula I is independently H, D, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 2 -C 6 alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein the C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 2 -C 6 alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted.
- R 6A and R 6B together with the N atoms to which they are attached form an optionally substituted heterocycloalkyl or heterocycloalkenyl ring.
- R 9A and R 9B together with the N atoms to which they are attached form an optionally substituted heterocycloalkyl or heterocycloalkenyl ring;
- each R a in Formula I is independently H, D, —C(O)R b , —C(O)OR c , —C(O)NR c R d , —P(OR c ) 2 , —P(O)R c R b , —P(O)OR c OR b , —S(O)R b , —S(O)NR c R d , —S(O) 2 R b , —S(O) 2 NR c R d , —B(OR c )(OR b ), SiR b 3 , —C 1 -C 10 alkyl, —C 2 -C 10 alkenyl, —C 2 -C 10 alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl wherein said C 1 -C 10 alkyl,
- R a is H, —C(O)R b , —C(O)NR c R d , optionally substituted C 1 -C 10 alkyl, optionally substituted C 2 -C 10 alkenyl, optionally substituted C 2 -C 10 alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl
- R a is H, —C(O)R b , —C(O)NR c R d , or optionally substituted C 1 -C 10 alkyl.
- R a is H.
- R a is —C(O)R b .
- R a is —C(O)R b wherein R b is optionally substituted —C 1 -C 6 alkyl.
- R a is —C(O)R b wherein R b is —C 1 -C 6 alkyl.
- R a is —C(O)R b wherein R b is —CH 3 .
- R a is —C(O)NR c R d .
- R a is —C(O)NR c R d wherein R c and R d are independently H; optionally substituted —OC 1 -C 6 alkyl; optionally substituted cycloalkyl; optionally substituted —C 1 -C 6 alkyl, or optionally substituted heterocycloalkyl.
- R a is —C(O)NR c R d wherein R c and R d are independently H; optionally substituted 3-7 membered cycloalkyl; —OC 1 -C 6 alkyl; or —C 1 -C 6 alkyl optionally substituted with deuterium, halo, optionally substituted cycloalkyl, optionally substituted —OC 1 -C 6 alkyl, —NR c1 R d1 wherein R c1 and R d1 are independently H or optionally substituted —C 1 -C 6 alkyl, optionally substituted 4-7 membered heterocycloalkyl, or optionally substituted 5-6 membered heteroaryl; or optionally substituted 4-7 membered heterocycloalkyl.
- R a is —C(O)NR c R d wherein R c and R d are independently H; 3-7 membered cycloalkyl; —C 1 -C 6 alkyl optionally substituted with deuterium, halo, —OC 1 -C 6 alkyl, cycloalkyl, —NR c1 R d1 wherein R c1 and R d1 are independently H or —C 1 -C 6 alkyl, 4-7 membered heterocycloalkyl (optionally substituted with halo, —C 1 -C 6 alkyl, —OH, or —OC 1 -C 6 alkyl), or -5-6 membered heteroaryl, —OC 1 -C 6 alkyl; or -4-7 membered heterocycloalkyl optionally substituted with —C 1 -C 6 alkyl or —OH.
- R a is —C(O)NR c R d wherein R c and R d , together with the nitrogen atom to which they are both attached, form an optionally substituted monocyclic or multicyclic heterocycloalkyl group.
- R a is —C(O)NR c R d wherein R c and R d , together with the nitrogen atom to which they are both attached, form a monocyclic or multicyclic heterocycloalkyl group optionally substituted with -halo, —OH, optionally substituted -4-7 membered heterocycle, optionally substituted 5-6 membered heteroaryl, optionally substituted —OC 1 -C 6 alkyl, optionally substituted —C 1 -C 6 alkyl; or —NR c1 R d1 wherein R c1 and R d1 are independently H or optionally substituted C 1 -C 6 alkyl.
- R a is —C(O)NR c R d wherein R c and R d , together with the nitrogen atom to which they are both attached, form a monocyclic or multicyclic -4-10 membered heterocycloalkyl group optionally substituted with -halo, —OH, -4-7 membered heterocycle, 5-6 membered heteroaryl, —OC 1 -C 6 alkyl, —C 1 -C 6 alkyl (optionally substituted with —OH, —OC 1 -C 6 alkyl, or NR c1 R d1 wherein R c1 and R d1 are independently H or C 1 -C 6 alkyl); or —NR c1 R d1 wherein R c1 and R d1 are independently H or C 1 -C 6 alkyl.
- R a is optionally substituted —C 1 -C 10 alkyl.
- R a is —C 1 -C 10 alkyl optionally substituted with —C(O)NR c1 R d1 , wherein R c1 and R d1 are independently H, optionally substituted C 1 -C 6 alkyl, or optionally substituted heterocyclyl; or wherein or R c1 and R d1 , together with the N atom to which they are both attached, form an optionally substituted monocyclic or multicyclic -4-10 membered heterocycloalkyl group; —NR c1 R d1 wherein R c1 and R d1 are independently H, optionally substituted C 1 -C 6 alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl; optionally substituted heteroaryl; —C(O)OH; or optionally substituted -heterocycloalkyl.
- R a is —C 1 -C 10 alkyl optionally substituted with —C(O)NR c1 R d1 , wherein R c1 and R d1 are independently H, C 1 -C 6 alkyl, or 4-7 membered heterocycloalkyl; or wherein or R c1 and R d1 , together with the N atom to which they are both attached, form a monocyclic or multicyclic -4-10 membered heterocycloalkyl group (optionally substituted with halo, —OC 1 -C 6 alkyl, or —C 1 -C 6 alkyl optionally substituted with —OH or —OC 1 -C 6 alkyl); —NR c1 R d1 wherein R c1 and R d1 are independently H, or optionally substituted C 1 -C 6 alkyl; —C 4 -C 5 heteroaryl; —C(O)OH; or -4-7 membered heterocyclo
- R a is —C(O)NR c R d wherein R c and R d are independently H; —OCH 3 , —CH 3 , —CD 3 , —CH 2 CH 2 OCH 3 , —CH 2 CH 3 , —CH 2 -cyclopropyl, -cyclobutyl, cyclopropyl, —CH(CH 3 ) 2 , —CH 2 —CH(CH 3 ) 2 , —CH 2 CH 2 NH 2J —CH 2 CH 2 N(CH 3 ) 2 , —CH 2 CH 2 NH(CH 3 ), —CH 2 CHF 2 ,
- R a is —C(O)NR c R d wherein R c and R d , together with the nitrogen atom to which they are both attached, are
- R a is —C 1 -C 6 alkyl optionally substituted with —N(CH 3 ) 2 , —CO 2 H, —CONH 2 , —CON(CH 3 )(CH 2 CH 2 OCH 3 ),
- each R b in Formula I is independently H, D, —C 1 -C 6 alkyl, —C 1 -C 6 alkenyl, —C 2 -C 6 alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl wherein the —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 2 -C 6 alkynyl, aryl, cycloalkyl, cycloalkeneyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted.
- each R c or R d in Formula I is independently H, D, —C 1 -C 10 alkyl, —C 2 -C 6 alkenyl, —C 2 -C 6 alkynyl, —OC 1 -C 6 alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein the C 1 -C 10 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, —OC 1 -C 6 alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl are each optionally substituted.
- R c and R d together with the N atom to which they are both attached, form an optionally substituted monocyclic or multicyclic heterocycloalkyl, or optionally substituted monocyclic or multicyclic heterocycloalkenyl group.
- compounds of Formula I are those having the Formula IA-0:
- compounds of Formula I are those having the Formula IA:
- the compounds of Formula IA are those wherein W 1 is —CH 2 — and W 3 is —O—, or W 1 is —O— and W 3 is —CH 2 —, or W 1 is —CH 2 — and W 3 is —S—, or W 1 is —S— and W 3 is —CH 2 —, or W 1 is —CH 2 — and W 3 is —NR 2B —, or W 1 is —NR 2B — and W 3 is —CH 2 —, or W 1 is —CH 2 — and W 3 is —CH 2 —.
- the compounds of Formula I are those having Formula IA-1:
- the compounds of Formula IA-1 are those wherein W 1 is —CH 2 — or —O—.
- the compounds of Formula I are those having the Formula IA-2:
- the compound of formula IA-2 are those wherein W 3 is —CH 2 — or —O—.
- the compounds of Formula I are those of Formula IA-3 wherein W 1 is —CH 2 — and W 3 is O, or W 1 is —O— and W 3 is —CH 2 —, or W 1 is —CH 2 — and W 3 is —CH 2 —:
- the compounds of Formula I are compound of Formula IA-4:
- W 1 is —CH 2 — and W 3 is O, or W 1 is —O— and W 3 is —CH 2 —, or W 1 is —CH 2 — and W 3 is —CH 2- ;
- L 3 is absent, or is —(CR 4 R 5 ) p —;
- L 4 is absent, or —(CR 4 R 5 ) p Q 1 (CR 4 R 5 ) q —, wherein Q 1 is absent, —CR 4A ⁇ CR 4B —, —O—, —S—, —S(O)—, —S(O) 2 —, —C( ⁇ O)—, —NR 6 —, —OC( ⁇ O)—, —C( ⁇ O)O—, —NR 6A C(O), —C( ⁇ O)NR 6A —, —NR 6A C(O)R 6B —, —OC( ⁇ O)N(R 6A )
- L 3 absent; L 4 is —(CR 4 R 5 ) p Q 1 (CR 4 R 5 ) q —, wherein Q 1 is absent, —CR 4A ⁇ CR 4B —, —O—, —S—, —S(O)—, —S(O) 2 —, —C( ⁇ O)—, —NR 6 —, —OC( ⁇ O)—, —C( ⁇ O)O—, —NR 6A C(O), —C( ⁇ O)NR 6A —, —NR 6A C(O)R 6B —, —OC( ⁇ O)N(R 6A )—, —NR 6A C(O)O—, —S( ⁇ O)NR 6A —, —NR 6A S(O)—, —S( ⁇ O) 2 NR 6A —, or —NR 6A S(O) 2 —; and L 5 is absent.
- L 6 is absent, or is —(CR 7 R 8 ) s —, —O(CR 7 R 8 ) t —, —NR 9 (CR 7 R 8 ) t —, —S(CR 7 R 8 ) t —, —S(O)(CR 7 R 8 ) t —, —S(O) 2 (CR 7 R 8 ) t —, —NR 9A C(O)(CR 7 R 8 ) t —, —C(O)NR 9A (CR 7 R 8 ) t —, —R 9A C(O)O(CR 7 R 8 ) t —, —NR 9A C(O)NR 9B (CR 7 R 8 ) t —, —NR 9A S(O)(CR 7 R 8 ) t —, —NR 9A S(O) 2 (CR 7 R 8 ) t —; —CR 4
- Q 1 is —CR 4A ⁇ CR 4B —; and L 6 is absent, —O(CR 7 R 8 ) t , or —NR 9 (CR 7 R 8 ) t ;
- L 3 absent;
- L 4 is —(CR 4 R 5 ) p Q 1 (CR 4 R 5 ) q —, wherein Q 1 is absent, —CR 4A ⁇ CR 4B —, —O—, —S—, —S(O)—, —S(O) 2 —, —C( ⁇ O)—, —NR 6 —, —OC( ⁇ O)—, —C( ⁇ O)O—, —NR 6A C(O), —C( ⁇ O)NR 6A —, —NR 6A C(O)R 6B —, —OC( ⁇ O)N(R 6A )—, —NR 6A C(O)O—, —S( ⁇ O)NR 6A —, —NR 6A S(O)—, —S( ⁇ O) 2 NR 6A —, or —NR 6A S( ⁇ O) 2 —;
- L 5 is a
- the compounds of Formula I or Formula IA-4 are those wherein Q 1 is —CR 4A ⁇ CR 4B —, —O—, —S—, —S(O)—, —S(O) 2 —, —C( ⁇ O)—, —OC( ⁇ O)—, —C( ⁇ O)O—, —OC( ⁇ O)N(R 6A )—, or —NR 6A C(O)O—;
- L 5 is a 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 7-membered monocyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, wherein the 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 7-membered monocyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene is optionally substituted; and L 6 is absent,
- the compounds of Formula I are those of Formula IA-5
- R is halo or C 1 -C 6 alkyl; represents a carbon-carbon single bond in which each carbon atom in the bond is substituted with R 4 and R 5 , an (E)-carbon-carbon double bond substituted with R 4A and R 4B , or a (Z)-carbon-carbon double bond substituted with R 4A and R 4B ; and R a* is R a wherein R a is H, —C(O)R b , —C(O)OR c , —C(O)NR c R d , P(OR c ) 2 , P(O)R c R b , P(O)OR c OR b , S(O)R b , S(O)NR c R d , S(O) 2 R b , S(O) 2 NR c R d , B(OR c
- the compound Formula IA-5 represents a carbon-carbon single bond in which each carbon atom in the bond is substituted with R 4 and R 5 .
- X is O, NR 9 , or CR 7 R 8 .
- R a* is R a wherein R a is H, —C(O)R b , —C(O)NR c R d , or optionally substituted C 1 -C 10 alkyl, optionally substituted C 2 -C 10 alkenyl, optionally substituted C 2 -C 10 alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl.
- the compounds of Formula I are those of Formula IA-6:
- X is —O—, —NR 9 —, or —CR 7 R 8 —; and W 1 is —CH 2 — and W 3 is O, or W 1 is —O— and W 3 is —CH 2 —, or W 1 is —CH 2 — and W 3 is —CH 2 ; R a* is R a .
- the compounds of Formula IA-6 are those wherein X is —CR 7 R 8 —.
- the compounds of Formula IA-6 are those wherein X is —O—.
- the compounds of Formula IA-6 are those wherein X is —NR 9 —.
- X is —NR 9 — wherein R 9 is H; optionally substituted —C 1 -C 6 alkyl; optionally substituted —C(O)OC 1 -C 6 alkyl; optionally substituted —SO 2 C 1 -C 6 alkyl; optionally substituted —C(O)C 1 -C 6 alkyl; optionally substituted —C(O)NR c R d ; or wherein R 9 together with either R 7 or R 8 form an optionally substituted C 1 -C 6 alkylene group.
- X is —NR 9 — wherein R 9 is H; —C 1 -C 6 alkyl, optionally substituted with deuterium; —C(O)OC 1 -C 6 alkyl; —SO 2 C 1 -C 6 alkyl; —C(O)C 1 -C 6 alkyl; or wherein R 9 together with either R 7 or R 8 form a C 1 -C 6 alkylene group.
- the compounds of Formula IA-6 are those having the structure (LA-7):
- the compounds of Formula IA-7 are those wherein W 1 is —CH 2 — and W 3 is —CH 2 —.
- the compounds of Formula I are those of Formula IA-8
- X is O, NR 9 , CR 7 R 8 , S, S(O), SO 2 ;
- W 1 is —CH 2 — and W 3 is O, or W 1 is —O— and W 3 is —CH 2 —, or W 1 is —CH 2 — and W 3 is —CH 2 —;
- R a* is R a wherein R a is H, —C(O)R b , —C(O)OR c , —C(O)NR c R d , P(OR c ) 2 , P(O)R c R b , P(O)OR c OR b , S(O)R b , S(O)NR
- the compound Formula IA-8 represents a carbon-carbon single bond in which each carbon atom in the bond is substituted with R 4 and R 5 .
- R a * is R a and R c * is R c .
- R a * is R a wherein R a is H, —C(O)R b , —C(O)OR c , —C(O)NR c R d , —S(O) 2 R b , or optionally substituted C 1 -C 10 alkyl; and R c * is R c wherein R c is H or optionally substituted C 1 -C 10 alkyl.
- R is —Cl
- each R 4 and R 5 is independently H or C 1 -C 6 alkyl.
- X is O, NR 9 , or CR 7 R 8 .
- the compounds of Formula I are those of Formula IA-9:
- X is —O—, —NR 9 —, or —CR 7 R 8 —; and 1 is —CH 2 — and W 3 is O, or W 1 is —O— and W 3 is —CH 2 —, or W 1 is —CH 2 — and W 3 is —CH 2- ; R a * is R a and R c * is R c .
- R a * is R a wherein R a is H, —C(O)R b , —C(O)OR c , —C(O)NR c R d , —S(O) 2 R b , or optionally substituted C 1 -C 10 alkyl; and R c * is R c wherein R c is H or optionally substituted C 1 -C 10 alkyl.
- the compounds of Formula IA-9 are those wherein X is —CR 7 R 8 —.
- the compounds of Formula IA-9 are those wherein X is —O—.
- the compounds of Formula IA-9 are those wherein X is —NR 9 —.
- X is —NR 9 — wherein R 9 is H; optionally substituted —C 1 -C 6 alkyl; optionally substituted —C(O)OC 1 -C 6 alkyl; optionally substituted —SO 2 C 1 -C 6 alkyl; optionally substituted —C(O)C 1 -C 6 alkyl; optionally substituted —C(O)NR c R d ; or wherein R 9 together with either R 7 or R 8 form an optionally substituted C 1 -C 6 alkylene group.
- X is —NR 9 — wherein R 9 is H; —C 1 -C 6 alkyl, optionally substituted with deuterium; —C(O)OC 1 -C 6 alkyl; —SO 2 C 1 -C 6 alkyl; —C(O)C 1 -C 6 alkyl; or wherein R 9 together with either R 7 or R 8 form a C 1 -C 6 alkylene group.
- the compounds of Formula IA-9 are those having the structure (IA-10):
- the disclosure is directed to compounds of Formula II:
- Z in Formula II is C or N. In some embodiments, Z is C. In other embodiments, Z is N.
- Q in Formula II is —O—, —S—, —S(O)—, or —S(O) 2 —.
- Q is —O—.
- Q is —S—.
- Q is —S(O)—.
- Q is —S(O) 2 —.
- the moiety -W 1 -W 2 -W 3 in Formula II is —CR 2 R 2A —CR 2 R 2A —CR 2 R 2A —, —O—CR 2B R 2C —CR 2 R 2A —, —CR 2 R 2A —CR 2B R 2C —O—, —S—CR 2B R 2C —CR 2 R 2A , or —CR 2 R 2A —CR 2B R 2C —S—.
- the moiety -W 1 -W 2 -W 3 in Formula II is —CR 2 R 2A —CR 2 R 2A —CR 2 R 2A —. In some embodiments, the moiety -W 1 -W 2 -W 3 in Formula II is —O—CR 2B R 2C —CR 2 R 2A —. In some embodiments, the moiety -W 1 -W 2 -W 3 in Formula II —CR 2 R 2A —CR 2B R 2C —O—. In some embodiments, the moiety -W 1 -W 2 -W 3 in Formula II is —S—CR 2B R 2C —CR 2 R 2A . In some embodiments, the moiety -W 1 -W 2 -W 3 in Formula II is —CR 2 R 2A —CR 2B R 2C —S—.
- L 1 in Formula II is —C 1 -C 6 alkylene-, for example, —C 1 alkylene, —C 2 alkylene, —C 3 alkylene, —C 4 alkylene, —C 5 alkylene, or —C 6 alkylene, wherein the C 1 -C 6 alkylene is optionally substituted with 1, 2, or 3 substituents independently selected from halo, oxo, CN, OR a1 , SR a1 , NR c1 C(O)R b1 , NR c1 C(O)OR a1 , and NR c1 S(O) 2 R b1 .
- L 1 in Formula II is —C 1 alkylene.
- L 1 in Formula II is —CH 2 —.
- L 2 in Formula II is C 3 -C 7 cycloalkylene, C 4 -C 7 heterocycloalkylene, or heteroarylene; wherein the C 3 -C 7 cycloalkylene, C 4 -C 7 heterocycloalkylene, or heteroarylene is optionally substituted with 1, 2, or 3 substituents independently selected from halo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, oxo, CN, NO 2 , N 3 , OR a2 , SR a2 , C(O)R b2 , C(O)NR c2 R d2 , C(O)OR a2 , OC(O)R b2 , NR c2 R d2 , NR c2 C(O)R b2 , NR c2 C(O)OR a2 ,
- L 2 in Formula II is C 3 -C 7 cycloalkylene, for example, C 3 cycloalkylene, C 4 cycloalkylene, C 5 cycloalkylene, C 6 cycloalkylene, or C 7 cycloalkylene. In some embodiments, L 2 is C 4 cycloalkylene. In some embodiments, L 2 is cyclobutylen-yl.
- L 2 in Formula II is C 4 -C 7 heterocycloalkylene, for example, C 4 heterocycloalkylene, C 5 heterocycloalkylene, C 6 heterocycloalkylene, or C 7 heterocycloalkylene. In some embodiments, L 2 in Formula II is C 4 heterocycloalkylene. In some embodiments, L 2 is pyrrolidinyl.
- L 2 in Formula II is heteroarylene.
- the heteroarylene is pyrazolyl.
- L 3 in Formula II is absent, or is —(CR 4 R 5 ) p —, —(CR 4 R 5 ) p O—, —O—, —S—, —S(O)—, —S(O) 2 —, —C( ⁇ O)—, —NR 6 —, —OC( ⁇ O)—, —C( ⁇ O)O—, —NR 6A C(O), —C( ⁇ O)NR 6A —, —OC( ⁇ O)N(R 6A )—, —NR 6A C(O)O—, —S( ⁇ O)NR 6A —, —NR 6A S(O)—, —S( ⁇ O) 2 NR 6A —, or —NR 6A S(O) 2 —.
- L 3 in Formula II is absent.
- L 3 is —(CR 4 R 5 ) p —.
- L 3 is —(CR 4 R 5 ) p O—.
- L 3 is —O—.
- L 3 is —S—.
- L 3 is —S(O)—.
- L 3 is —S(O) 2 —.
- L 3 is —C( ⁇ O)—.
- L 3 is —NR 6 —.
- L 3 is —OC( ⁇ O)—.
- L 3 is —C( ⁇ O)O—.
- L 3 is —NR 6A C(O). In some embodiments, L 3 is —C( ⁇ O)NR 6A —. In some embodiments, L 3 is —OC( ⁇ O)N(R 6A )—. In some embodiments, L 3 is —NR 6A C(O)O—. In some embodiments, L 3 is —S( ⁇ O)NR 6A —. In some embodiments, L 3 is —NR 6A S(O)—. In some embodiments, L 3 is —S( ⁇ O) 2 NR 6A —. In some embodiments, L 3 is —NR 6A S(O) 2 —.
- L 4 in Formula II is absent, or is —(CR 4 R 5 ) p Q 1 (CR 4 R 5 ) q —, wherein Q 1 is —CR 4A ⁇ CR 4B —, —O—, —S—, —S(O)—, —S(O) 2 —, —C( ⁇ O)—, —NR 6 —, —OC( ⁇ O)—, —C( ⁇ O)O—, —NR 6A C(O), —C( ⁇ O)NR 6A —, —NR 6A C(O)R 6B —, —OC( ⁇ O)N(R 6A )—, —NR 6A C(O)O—, —S( ⁇ O)NR 6A —, —NR 6A S(O)—, —S( ⁇ O) 2 NR 6A —, or —NR 6A S(O) 2 —; or is —(CR 4 R 5 ) p —(CR 4 R 5
- L 4 in Formula II is absent. In other embodiments, L 4 in Formula II is —(CR 4 R 5 ) p —(CR 4A ⁇ CR 4B )—(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula II is —(CR 4 R 5 ) p —O—(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula II is —(CR 4 R 5 ) p —S—(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula II is —(CR 4 R 5 ) p —S(O)—(CR 4 R 5 ) q —.
- L 4 in Formula II is —(CR 4 R 5 ) p —S(O) 2 —(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula II is —(CR 4 R 5 ) p —C( ⁇ O)—(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula II is —(CR 4 R 5 ) p —NR 6 —(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula II is —(CR 4 R 5 ) p —OC( ⁇ O)—(CR 4 R 5 ) q —.
- L 4 in Formula II is —(CR 4 R 5 ) p —C( ⁇ O)O—(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula II is —(CR 4 R 5 ) p —NR 6A C(O)—(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula II is —(CR 4 R 5 ) p —C( ⁇ O)NR 6A —(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula II is —(CR 4 R 5 ) p —NR 6A C(O)R 6B —CR 4 R 5 ) q —.
- L 4 in Formula II is —(CR 4 R 5 ) p —OC( ⁇ O)N(R 6A )—(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula II is —(CR 4 R 5 ) p —NR 6A C(O)O—(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula II is —(CR 4 R 5 ) p —S( ⁇ O)NR 6A —(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula II is —(CR 4 R 5 ) p —NR 6A S(O)—(CR 4 R 5 ) q —.
- L 4 in Formula II is —(CR 4 R 5 ) p —S( ⁇ O) 2 NR 6A —(CR 4 R 5 ) q —. In other embodiments, L 4 in Formula II is —(CR 4 R 5 ) p —NR 6A S(O) 2 —(CR 4 R 5 ) q —. In some embodiments, L 4 is —(CR 4 R 5 ) p —(CR 4A ⁇ CR 4B )—(CR 4 R 5 ) q —O—.
- L 5 in Formula II is absent, or is C 1 -C 6 alkylene, C 2 -C 6 alkenylene, C 2-6 alkynylene, a 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 5- to 12-membered spirocycloalkylene, a 5- to 12-membered spiroheterocycloalkylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, or a 6- to 12-membered bicyclic cycloalkylene, or a 3- to 7-membered monocyclic heterocycloalkylene or a 6 to 12-membered bicyclic heterocycloalkylene group, wherein the heteroarylene, spiroheterocycloalkylene or heterocycloalkylene group have 1, 2, 3 or 4, heteroatoms independently selected from O, N or S; wherein the cycloalkylene, spirohe
- L 5 in Formula II is absent. In other embodiments, L 5 in Formula II is C 1 -C 6 alkylene, for example, C 1 alkylene, C 2 alkylene, C 3 alkylene, C 4 alkylene, C 5 alkylene, or C 6 alkylene.
- L 5 in Formula II is C 2 -C 6 alkenylene, for example, C 2 alkenylene, C 3 alkenylene, C 4 alkenylene, C 5 alkenylene, or C 6 alkenylene.
- L 5 in Formula II is C 2 -C 6 alkynylene, for example, C 2 alkynylene, C 3 alkynylene, C 4 alkynylene, C 5 alkynylene, or C 6 alkynylene.
- L 5 in Formula II is a 6- to 10-membered arylene, for example phenylene or naphthylene. In some embodiments, L 5 in Formula II is a phenylene.
- L 5 in Formula II is a 5- to 10-membered heteroarylene, for example, pyrazolyl, thiazolyl, imidazolyl, or pyridinyl.
- L 5 in Formula II is pyrazolyl.
- L 5 in Formula II is thiazolyl.
- L 5 in Formula II is imidazolyl.
- L 5 in Formula II is pyridinyl.
- L 5 in Formula II is a 5- to 12-membered spirocycloalkylene, for example, spiro[3.4]octane, or spiro[3.3]heptane.
- L 5 in Formula II is a 5- to 12-membered spiroheterocycloalkylene, for example, 2,6-diazaspiro[3.4]octane, 2-azaspiro[3.4]octane, or 2-azaspiro[3.3]heptane.
- L 5 in Formula II is 2,6-diazaspiro[3.4]octane.
- L 5 in Formula II is 2-azaspiro[3.4]octane.
- L 5 in Formula II is 2-azaspiro[3.3]heptane.
- L 5 in Formula II is a 3- to 12-membered cycloalkenylene, for example, cyclohexenyl.
- L 5 in Formula II is a 3- to 7-membered monocyclic cycloalkylene, for example, cyclopentanyl, cyclohexanyl, and the like. In some embodiments, L 5 in Formula II is cyclopentanyl.
- L 5 in Formula II is a 6- to 12-membered bicyclic cycloalkylene.
- L 5 in Formula II is a 3- to 7-membered monocyclic heterocycloalkylene group, for example, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, and the like.
- L 5 in Formula II is pyrrolidinyl.
- L 5 in Formula II is tetrahydrofuranyl.
- L 5 in Formula II is piperidinyl.
- L 5 in Formula II is piperazinyl.
- L 5 in Formula II is a 6- to 12-membered bicyclic heterocycloalkylene group.
- L 6 in Formula II is absent, or is (CR 7 R 8 ) s , (CR 7 R 8 ) s O(CR 7 R 8 ) t , (CR 7 R 8 ) s NR 9 (CR 7 R 8 ) t , (CR 7 R 8 ) s S(CR 7 R 8 ) t , (CR 7 R 8 ) s S(O)(CR 7 R 8 ) t , (CR 7 R 8 ) s S(O) 2 (CR 7 R 8 ) t , (CR 7 R 8 ) s NR 9A C(O)(CR 7 R 8 ) t , (CR 7 R 8 ) s OC(O)NR 9A (CR 7 R 8 ) t , (CR 7 R 8 ) s NR 9A C(O)O(CR 7 R 8 ) t , (CR 7 R 8 ) s NR 9A C(O)NR 9B (CR 7 R 8 ) t ,
- L 6 in Formula II is absent. In other embodiments, L 6 in Formula II is (CR 7 R 8 ) s . In other embodiments, L 6 in Formula II is (CR 7 R 8 ) s O(CR 7 R 8 ) t . In other embodiments, L 6 in Formula II is (CR 7 R 8 ) s NR 9 (CR 7 R 8 ) t . In other embodiments, L 6 in Formula II is (CR 7 R 8 ) s S(CR 7 R 8 ) t . In other embodiments, L 6 in Formula II is (CR 7 R 8 ) s S(O)(CR 7 R 8 ) t .
- L 6 in Formula II is (CR 7 R 8 ) s S(O) 2 (CR 7 R 8 ) t . In other embodiments, L 6 in Formula II is (CR 7 R 8 ) s NR 9A C(O)(CR 7 R 8 ) t . In other embodiments, L 6 in Formula II is (CR 7 R 8 ) s OC(O)NR 9A (CR 7 R 8 ) t . In other embodiments, L 6 in Formula II is (CR 7 R 8 ) s NR 9A C(O)O(CR 7 R 8 ) t .
- L 6 in Formula II is (CR 7 R 8 ) s NR 9A C(O)NR 9B (CR 7 R 8 ) t . In other embodiments, L 6 in Formula II is (CR 7 R 8 ) s NR 9A S(O)(CR 7 R 8 ) t . In other embodiments, L 6 in Formula II is (CR 7 R 8 ) s NR 9A S(O) 2 (CR 7 R 8 ) t . In other embodiments, L 6 in Formula II is —(CR 7 R 8 ) s —CR 4A ⁇ CR 4B —(CR 7 R 8 ) t .
- L 6 in Formula II is (CR 7 R 8 ) s C( ⁇ O)(CR 7 R 8 ) t . In other embodiments, L 6 in Formula II is —(CR 7 R 8 ) s C( ⁇ O)(CR 7 R 8 ) t —O—. In other embodiments, L 6 in Formula II is —(CR 7 R 8 ) s C( ⁇ O)(CR 7 R 8 ) t —NR 6 —.
- each R in Formula II is independently selected from halo, CN, —NO 2 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, —(CH 2 CH 2 O) o R a , C 1 -C 6 haloalkoxy, C 3 -C 6 cycloalkyl, OR a , SR a , C(O)R b , C(O)OR a , NR c R d , C(O)NR c R d , and S(O) 2 R a ; wherein said C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl is optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, OR a1 , NR c1 R d1 and C(O)NR c1 R d1 .
- R is halo, for example, Cl or F. In some embodiments, R is —SR a , for example —SCH 3 .
- each R 1 in Formula II is independently selected from halo, —CN, Nitro, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, —(CH 2 CH 2 O) o R a , —C 1 -C 6 alkylC 3 -C 7 cycloalkyl, OR a , SR a , NR c R d , C(O)R b , OC(O)R b , C(O)OR a , C(O)NR c R d , or S(O) 2 R a ; aryl, heteroaryl, spirocycloalkyl, spiroheterocycloalkyl, cycloalkyl, or heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl or hetero
- R 1 in Formula II is halo, for example, Cl or F. In other embodiments, R 1 in Formula II is —C 1 -C 6 haloalkyl, for example —CF 3 . In other embodiments, R 1 in Formula II is —C 1 -C 6 alkyl, for example, —C 6 alkyl, —C 5 alkyl, —C 4 alkyl, —C 3 alkyl, —C 2 alkyl, —C 1 alkyl. In some embodiments, R 1 in Formula II is —C 1 alkyl substituted with —CN.
- R 1 in Formula II is cycloalkyl, for example, cyclopropane, cyclobutane, cyclopentane, and the like. In other embodiments, R 1 in Formula II is cyclopropane substituted with —CN.
- R 2 and R 2A in Formula II are each independently H, halo, OR a , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl. In some embodiments, R 2 and R 2A in Formula II are each H.
- R 2 and R 2A that are attached to the same carbon atom, together with the carbon atom to which they are both attached form an optionally substituted C 3 -C 6 cycloalkyl ring.
- R 2 and R 2A that are attached to the same carbon atom, together with the carbon atom to which they are both attached form a cyclopropane ring.
- R 2 and R 2a in Formula II are each independently H, halo, OR a , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl. In some embodiments, R 2 and R 2a in Formula II are each H.
- R 2 and R 2a that are attached to the same carbon atom, together with the carbon atom to which they are both attached form an optionally substituted C 3 -C 6 cycloalkyl ring.
- R 2 and R 2a that are attached to the same carbon atom, together with the carbon atom to which they are both attached form a cyclopropane ring.
- R 2B and R 2C in Formula II are each independently H, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl. In some embodiments, R 2B and R 2C in Formula II are each H.
- R 2B and R 2C may, together with the carbon atom to which they are both attached, form an optionally substituted C 3 -C 6 cycloalkyl ring. In some embodiments, R 2B and R 2C that are attached to the same carbon atom together with the carbon atom to which they are both attached, form a cyclopropane ring.
- R 3 in Formula II is H, —C 1 -C 6 alkyl, —C 3 -C 6 alkenyl, —C 3 -C 6 alkynyl, —(CH 2 CH 2 O) o R a , —C 3 -C 7 cycloalkyl, —C 3 -C 7 heterocycloalkyl, —C 1 -C 6 alkylC 3 -C 7 cycloalkyl, —C 1 -C 6 alkylC 3 -C 7 heterocycloalkyl, C(O)R b , C(O)OR a , or C(O)NR c R d ; wherein the C 1 -C 6 alkyl, —C 3 -C 6 alkenyl, —C 3 -C 6 alkynyl, cycloalkyl, and heterocycloalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, halo, C
- R 3 in Formula II is H. In other embodiments, R 3 in Formula II is —C 1 -C 6 alkyl, for example, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, C 1 alkyl, —CH 3 , and the like.
- R 4 and R 7 in Formula II are independently selected from H, halo, OH, CN, NO 2 , —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 2 -C 6 alkynyl, —C 1 -C 6 haloalkyl, —(CH 2 CH 2 O) o R a , C 3 -C 7 cycloalkyl, —C 1 -C 6 alkylC 3 -C 7 cycloalkyl, cyanoC 1 -C 6 alkyl-, heterocycloalkyl, C 1 -C 6 alk-NRHC 1 , OR a , SR a , NR c R d , C(O)R b , OC(O)R a , C(O)OR a , C(O)NR c R d , and S(O) 2 R a , wherein said C 1 -C 6 alkyl,
- R 4 is Formula II is H.
- R 4 in Formula II is —C 1 -C 6 alkyl, for example, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, C 1 alkyl, —CH 3 , and the like.
- R 4 is Formula II is —OR a , for example, —OCH 3 .
- R 7 in Formula II is H.
- R 7 in Formula II is —C 1 -C 6 alkyl, for example, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, C 1 alkyl, —CH 3 , and the like.
- R 7 is Formula II is —OR a , for example, —OCH 3 .
- R 4A and R 4B in Formula II are independently selected from H, Me, CF 3 and F. In some embodiments, R 4A is H. In some embodiments, R 4B is H.
- R 5 and R 8 in Formula II are independently selected from H, halo, OH, CN, NO 2 , —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 2 -C 6 alkynyl, —C 1 -C 6 haloalkyl, —(CH 2 CH 2 O) o R a , —C 1 -C 6 alkylC 3 -C 7 cycloalkyl, cyanoC 1 -C 6 alkyl-, C 1 -C 6 alk-NR c R d , OR c , SR C , NR c R d , C(O)R c , OC(O)R c , C(O)OR c , C(O)NR c R d , S(O)R c , S(O) 2 R C , aryl, heteroaryl, spirocycloalkyl, spir
- R 5 in Formula II is H.
- R 5 in Formula II is —C 1 -C 6 alkyl, for example, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, C 1 alkyl, —CH 3 , and the like.
- R 5 in Formula II is —OR a , for example, —OCH 3 .
- R 8 in Formula II is H. In other embodiments, R 8 in Formula II is —C 1 -C 6 alkyl, for example, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, C 1 alkyl, —CH 3 , and the like. In other embodiments, R 8 in Formula II is —OR a , for example, —OCH 3 .
- R 4 and R 5 in Formula II together with the carbon atom to which they are both attached form a 3, 4, 5, 6, or 7-membered cycloalkyl, heterocycloalkyl or spiroheterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from halo, OH, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, alkoxyalkyl, cyanoalkyl, heterocycloalkyl, cycloalkyl, C 1 -C 6 haloalkyl, CN, and NO 2 .
- R 7 and R 8 in Formula II together with the carbon atom to which they are both attached form a 3, 4, 5, 6, or 7-membered cycloalkyl, heterocycloalkyl or spiroheterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from halo, OH, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, alkoxyalkyl, cyanoalkyl, heterocycloalkyl, cycloalkyl, C 1-6 haloalkyl, CN, and NO 2 .
- R 6 and R 9 in Formula II are independently selected from H, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 2 -C 6 alkynyl, —C 1 -C 6 haloalkyl, —(CH 2 CH 2 O) o R a , —C 1 -C 6 alkylC 3 -C 7 cycloalkyl, cyanoC 1 -C 6 alkyl-, C 1 -C 6 alk-NR c R d , C(O)R b , C(O)OR a , C(O)NR c R d , S(O)R b S(O) 2 R b , aryl, heteroaryl, spirocycloalkyl, spiroheterocycloalkyl, cycloalkyl, and heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl,
- R 6 in Formula II is H. In other embodiments, R 6 in Formula II is —C 1 -C 6 alkyl, for example, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, or C 1 alkyl.
- R 9 in Formula II is H.
- R 6 in Formula II is —C 1 -C 6 alkyl, for example, C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, or C 1 alkyl.
- R 10 in Formula II is aryl, heteroaryl, spirocycloalkyl, spiroheterocycloalkyl, cycloalkyl, or heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl or heterocycloalkyl group have 1, 2, 3 or 4, heteroatoms independently selected from O, N or S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl groups may include a C ⁇ O group, and further wherein the spiroheterocycloalkyl, and heterocycloalkyl groups may include a S ⁇ O or SO 2 , wherein said aryl, cycloalkyl, cycloalkenyl, spirocycloalkyl, spiroheterocycloalkyl, heteroaryl, and heterocycloalkyl is optionally substituted with 1, 2, or
- R 6A , R 6B , R 9A , and R 9B in Formula II are each independently H, C i-C 6 alkyl, —C 2 -C 6 alkenyl, —C 2 -C 6 alkynyl, —(CH 2 CH 2 O) o R a , C 3 -C 7 cycloalkyl, —C 1 -C 6 alkylC 3 -C 7 cycloalkyl, C 4 -C 7 heterocycloalkyl, —C 1 -C 6 alkylC 4 -C 7 heterocycloalkyl, wherein said C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 2 -C 6 alkynyl, —C 3 -C 7 cycloalkyl, —C 1 -C 6 alkylC 3 -C 7 cycloalkyl, —C 4 -C 7 heterocycloalkyl, —C 1 -
- R 6A and R 6B in Formula II together with the N atom to which they are attached form a 5, 6, 7, 8 or 9-membered heterocycloalkyl ring or spiroheterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from halo, OH, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, alkoxyalkyl, cyanoalkyl, heterocycloalkyl, cycloalkyl, C 1 -C 6 haloalkyl, CN, and NO 2 .
- R 9A and R 9B in Formula II together with the N atom to which they are attached form a 5, 6, 7, 8 or 9-membered heterocycloalkyl ring or spiroheterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from halo, OH, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, alkoxyalkyl, cyanoalkyl, heterocycloalkyl, cycloalkyl, C 1 -C 6 haloalkyl, CN, and NO 2 .
- R a , R a1 , R 32 , R a3 , and R a4 in Formula II are independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3
- R a is H. In other embodiments, R a is —C 1 -C 6 alkyl, for example C 6 alkyl, C 5 alkyl, C 4 alkyl, C 3 alkyl, C 2 alkyl, or C 1 alkyl. In some embodiments, R a is —CH 3 .
- R b , R b1 , R b2 , R b3 , and R b4 in Formula II are independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, wherein said C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1, 2,
- R c and R d in Formula II are independently H, C 1 -C 10 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein said C 1 -C 10 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1 -C 6
- R c and R d in Formula II together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, and C 1 -C 6 haloalkoxy.
- R c1 and R d1 in Formula II are independently H, C 1 -C 10 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein said C 1 -C 10 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C
- R c1 and R d1 in Formula II together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, and C 1 -C 6 haloalkoxy.
- R c2 and R d2 in Formula II are independently H, C 1 -C 10 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylcycloalkyl, arylheterocycloalkyl, arylheteroaryl, biaryl, heteroarylcycloalkyl, heteroarylheterocycloalkyl, heteroaryl aryl, or biheteroaryl, wherein said C 1 -C 10 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, heteroaryl, cycloalkyl, wherein
- R c2 and R d2 in Formula II together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, hydroxyalkyl, cyanoalkyl, aryl, heteroaryl, C(O)OR a4 , C(O)R b4 , S(O) 2 R b3 , alkoxyalkyl, and alkoxyalkoxy.
- R c3 and R d3 in Formula II are independently H, C 1-10 alkyl, C 1-6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein said C 1 -C 10 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1 -C 6 alkyl,
- R c3 and R d3 in Formula II together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, and C 1 -C 6 haloalkoxy.
- R c4 and R d4 in Formula II are independently H, C 1 -C 10 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein said C 1 -C 10 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C
- R c4 and R d4 in Formula II together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, and C 1 -C 6 haloalkoxy.
- R e1 , R e2 , and R e3 in Formula II are independently H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, (C 1 -C 6 alkoxy)-C 1 -C 6 alkyl, C 2 -C 6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl.
- R f1 , R f2 , and R G in Formula II are independently selected from H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl.
- R g1 in Formula II is H, CN, or NO 2 .
- the disclosure is directed to compounds of Formula IIA:
- the disclosure is directed to compounds of Formula IIA-1:
- the disclosure is directed to compounds of Formula IIA-2:
- the disclosure is directed to compounds of Formula IIA-3:
- the compounds of Formula IIA-3 are those wherein
- L 4 is —(CR 4 R 5 ) p Q 1 (CR 4 R 5 ) q —, wherein Q 1 is —O— or —S—,
- L 5 is phenyl
- L 6 is —(CR 7 R 8 ) s —
- each R 4 is independently H, OH, or —OC 1 -C 6 alkyl
- each R 5 is independently selected from is H, OH, or —OC 1 -C 6 alkyl
- each R 7 is H, —C 1 alkyl, or —OC 1 alkyl
- each R 8 is H, —C 1 alkyl, or —OC 1 alkyl.
- the compounds of Formula IIA-3 are those wherein
- L 4 is —(CR 4 R 5 ) p Q 1 (CR 4 R 5 ) q —, wherein Q 1 is —O— or —S—;
- L 5 is phenyl
- L 6 is —(CR 7 R 8 ) s —
- each R 4 is independently H, OH, or —OC 1 -C 6 alkyl
- each R 5 is independently selected from is H, OH, or —OC 1 -C 6 alkyl
- each R 7 is H, —C 1 alkyl, or —OC 1 alkyl
- each R 8 is H, —C 1 alkyl, or —OC 1 alkyl.
- the disclosure is directed to compounds of Formula IIB:
- the disclosure is directed to compounds of Formula IIB-1:
- the disclosure is directed to compounds of Formula IIB-2:
- the disclosure is directed to compounds of Formula IIB-3:
- the disclosure is directed to compounds of Formula IIB-4:
- the disclosure is directed to compounds of Formula IIB-5:
- the disclosure is directed to compounds of Formula IIB-6:
- R 1 is halo, —CH 2 —CN, —C 1 -C 6 haloalkyl, —OC 1 -C 6 haloalkyl, —OC 1 -C 6 haloalkyl, —C 1 -C 6 haloalkyl, —C 1 -C 6 alk-OH, —C 1 -C 6 alk-O—C 1 -C 6 alkyl, —O—C 1 -C 6 alk-O—C 1 -C 6 alkyl, —C 1 -C 6 alk-O—C 3 -C 6 cycloalkyl, —C 1 -C 6 alk-O—C 1 -C 6 haloalkyl, or
- L 4 is —(CR 4 R 5 ) p —CR 4A ⁇ CR 4B —(CR 4 R 5 ) q —;
- R 4 is independently H, —OC 1 -C 6 alkyl, or —C 1 -C 6 alkyl;
- R 5 is independently H, —OC 1 -C 6 alkyl, or —C 1 -C 6 alkyl;
- R 4A and R 4B are H.
- the disclosure is directed to compounds of Formula IIB-7:
- R 4 is independently H, —OC 1 -C 6 alkyl, or —C 1 -C 6 alkyl;
- R 5 is independently H, —OC 1 -C 6 alkyl, or —C 1 -C 6 alkyl;
- R 4A and R 4B are H.
- the disclosure is directed to compounds of Formula IIC-1:
- the disclosure is directed to compounds of Formula IIC-2:
- the disclosure is directed to compounds of Formula IIC-3:
- compositions are typically formulated to provide a therapeutically effective amount of a compound of the present disclosure as the active ingredient, or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof.
- the pharmaceutical compositions contain pharmaceutically acceptable salt and/or coordination complex thereof, and one or more pharmaceutically acceptable excipients, carriers, including inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.
- compositions can be administered alone or in combination with one or more other agents, which are also typically administered in the form of pharmaceutical compositions.
- the one or more compounds of the invention and other agent(s) may be mixed into a preparation or both components may be formulated into separate preparations to use them in combination separately or at the same time.
- the concentration of one or more compounds provided in the pharmaceutical compositions of the present invention is less than 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% (or a number in the range defined by and including any two numbers above) w/w/w/w
- the concentration of one or more compounds of the invention is greater than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19.75%, 19.50%, 19.25%, 19%, 18.75%, 18.50%, 18.25% 18%, 17.75%, 17.50%, 17.25% 17%, 16.75%, 16.50%, 16.25%, 16%, 15.75%, 15.50%, 15.25% 15%, 14.75%, 14.50%, 14.25% 14%, 13.75%, 13.50%, 13.25%, 13%, 12.75%, 12.50%, 12.25%, 12%, 11.75%, 11.50%, 11.25% 11%, 10.75%, 10.50%, 10.25% 10%, 9.75%, 9.50%, 9.25%, 9%, 8.75%, 8.50%, 8.25% 8%, 7.75%, 7.50%, 7.25%, 7%, 6.75%, 6.50%, 6.25%, 6%, 5.75%, 5.50%, 5.25%, 5%, 4.75%,
- the concentration of one or more compounds of the invention is in the range from approximately 0.0001% to approximately 50%, approximately 0.001% to approximately 40%, approximately 0.01% to approximately 30%, approximately 0.02% to approximately 29%, approximately 0.03% to approximately 28%, approximately 0.04% to approximately 27%, approximately 0.05% to approximately 26%, approximately 0.06% to approximately 25%, approximately 0.07% to approximately 24%, approximately 0.08% to approximately 23%, approximately 0.09% to approximately 22%, approximately 0.1% to approximately 21%, approximately 0.2% to approximately 20%, approximately 0.3% to approximately 19%, approximately 0.4% to approximately 18%, approximately 0.5% to approximately 17%, approximately 0.6% to approximately 16%, approximately 0.7% to approximately 15%, approximately 0.8% to approximately 14%, approximately 0.9% to approximately 12%, approximately 1% to approximately 10% w/w, w/v or v/v.
- the concentration of one or more compounds of the invention is in the range from approximately 0.001% to approximately 10%, approximately 0.01% to approximately 5%, approximately 0.02% to approximately 4.5%, approximately 0.03% to approximately 4%, approximately 0.04% to approximately 3.5%, approximately 0.05% to approximately 3%, approximately 0.06% to approximately 2.5%, approximately 0.07% to approximately 2%, approximately 0.08% to approximately 1.5%, approximately 0.09% to approximately 1%, approximately 0.1% to approximately 0.9% w/w, w/v or v/v.
- the amount of one or more compounds of the invention is equal to or less than 10 g, 9.5 g, 9.0 g, 8.5 g, 8.0 g, 7.5 g, 7.0 g, 6.5 g, 6.0 g, 5.5 g, 5.0 g, 4.5 g, 4.0 g, 3.5 g, 3.0 g, 2.5 g, 2.0 g, 1.5 g, 1.0 g, 0.95 g, 0.9 g, 0.85 g, 0.8 g, 0.75 g, 0.7 g, 0.65 g, 0.6 g, 0.55 g, 0.5 g, 0.45 g, 0.4 g, 0.35 g, 0.3 g, 0.25 g, 0.2 g, 0.15 g, 0.1 g, 0.09 g, 0.08 g, 0.07 g, 0.06 g, 0.05 g, 0.04 g, 0.03 g, 0.02 g, 0.01 g, 0.009 g, 0.00
- the amount of one or more compounds of the invention is more than 0.0001 g, 0.0002 g, 0.0003 g, 0.0004 g, 0.0005 g, 0.0006 g, 0.0007 g, 0.0008 g, 0.0009 g, 0.001 g, 0.0015 g, 0.002 g, 0.0025 g, 0.003 g, 0.0035 g, 0.004 g, 0.0045 g, 0.005 g, 0.0055 g, 0.006 g, 0.0065 g, 0.007 g, 0.0075 g, 0.008 g, 0.0085 g, 0.009 g, 0.0095 g, 0.01 g, 0.015 g, 0.02 g, 0.025 g, 0.03 g, 0.035 g, 0.04 g, 0.045 g, 0.05 g, 0.055 g, 0.06 g, 0.065 g, 0.07 g, 0.075
- the amount of one or more compounds of the invention is in the range of 0.0001-10 g, 0.0005-9 g, 0.001-8 g, 0.005-7 g, 0.01-6 g, 0.05-5 g, 0.1-4 g, 0.5-4 g, or 1-3 g.
- the compounds according to the invention are effective over a wide dosage range.
- dosages from 0.01 to 1000 mg, from 0.5 to 100 mg, from 1 to 50 mg per day, and from 5 to 40 mg per day are examples of dosages that may be used.
- An exemplary dosage is 10 to 30 mg per day. The exact dosage will depend upon the route of administration, the form in which the compound is administered, the subject to be treated, the body weight of the subject to be treated, and the preference and experience of the attending physician.
- a pharmaceutical composition of the invention typically contains an active ingredient (i.e., a compound of the disclosure) of the present invention or a pharmaceutically acceptable salt and/or coordination complex thereof, and one or more pharmaceutically acceptable excipients, carriers, including but not limited to inert solid diluents and fillers, diluents, sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.
- an active ingredient i.e., a compound of the disclosure
- a pharmaceutically acceptable salt and/or coordination complex thereof include but not limited to inert solid diluents and fillers, diluents, sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.
- compositions and methods for preparing the same are non-limiting exemplary pharmaceutical compositions and methods for preparing the same.
- compositions for Oral Administration are provided.
- the invention provides a pharmaceutical composition for oral administration containing a compound of the invention, and a pharmaceutical excipient suitable for oral administration.
- the invention provides a solid pharmaceutical composition for oral administration containing: (i) an effective amount of a compound of the invention; optionally (ii) an effective amount of a second agent; and (iii) a pharmaceutical excipient suitable for oral administration.
- the composition further contains: (iv) an effective amount of a third agent.
- the pharmaceutical composition may be a liquid pharmaceutical composition suitable for oral consumption.
- Pharmaceutical compositions of the invention suitable for oral administration can be presented as discrete dosage forms, such as capsules, cachets, or tablets, or liquids or aerosol sprays each containing a predetermined amount of an active ingredient as a powder or in granules, a solution, or a suspension in an aqueous or non-aqueous liquid, an oil-in-water emulsion, or a water-in-oil liquid emulsion.
- Such dosage forms can be prepared by any of the methods of pharmacy, but all methods include the step of bringing the active ingredient into association with the carrier, which constitutes one or more necessary ingredients.
- compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.
- a tablet can be prepared by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granules, optionally mixed with an excipient such as, but not limited to, a binder, a lubricant, an inert diluent, and/or a surface active or dispersing agent.
- Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- This invention further encompasses anhydrous pharmaceutical compositions and dosage forms comprising an active ingredient, since water can facilitate the degradation of some compounds.
- water may be added (e.g., 5%) in the pharmaceutical arts as a means of simulating long-term storage in order to determine characteristics such as shelf-life or the stability of formulations over time.
- Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions.
- Pharmaceutical compositions and dosage forms of the invention which contain lactose can be made anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected.
- An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained.
- anhydrous compositions may be packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits.
- suitable packaging include, but are not limited to, hermetically sealed foils, plastic or the like, unit dose containers, blister packs, and strip packs.
- An active ingredient can be combined in an intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
- the carrier can take a wide variety of forms depending on the form of preparation desired for administration.
- any of the usual pharmaceutical media can be employed as carriers, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like in the case of oral liquid preparations (such as suspensions, solutions, and elixirs) or aerosols; or carriers such as starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents can be used in the case of oral solid preparations, in some embodiments without employing the use of lactose.
- suitable carriers include powders, capsules, and tablets, with the solid oral preparations. If desired, tablets can be coated by standard aqueous or nonaqueous techniques.
- Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, microcrystalline cellulose, and mixtures thereof.
- natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrol
- suitable fillers for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.
- talc calcium carbonate
- microcrystalline cellulose e.g., powdere., powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.
- Disintegrants may be used in the compositions of the invention to provide tablets that disintegrate when exposed to an aqueous environment. Too much of a disintegrant may produce tablets which may disintegrate in the bottle. Too little may be insufficient for disintegration to occur and may thus alter the rate and extent of release of the active ingredient(s) from the dosage form. Thus, a sufficient amount of disintegrant that is neither too little nor too much to detrimentally alter the release of the active ingredient(s) may be used to form the dosage forms of the compounds disclosed herein. The amount of disintegrant used may vary based upon the type of formulation and mode of administration, and may be readily discernible to those of ordinary skill in the art.
- Disintegrants that can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums or mixtures thereof.
- Lubricants which can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, or mixtures thereof.
- Additional lubricants include, for example, a syloid silica gel, a coagulated aerosol of synthetic silica, or mixtures thereof.
- a lubricant can optionally be added, in an amount of less than about 1 weight percent of the pharmaceutical composition.
- the active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying and/or suspending agents, together with such diluents as water, ethanol, propylene glycol, glycerin and various combinations thereof.
- the tablets can be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate can be employed.
- Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
- Surfactant which can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. That is, a mixture of hydrophilic surfactants may be employed, a mixture of lipophilic surfactants may be employed, or a mixture of at least one hydrophilic surfactant and at least one lipophilic surfactant may be employed.
- a suitable hydrophilic surfactant may generally have an HLB value of at least 10, while suitable lipophilic surfactants may generally have an HLB value of or less than about 10.
- An empirical parameter used to characterize the relative hydrophilicity and hydrophobicity of non-ionic amphiphilic compounds is the hydrophilic-lipophilic balance (“HLB” value).
- HLB hydrophilic-lipophilic balance
- Surfactants with lower HLB values are more lipophilic or hydrophobic, and have greater solubility in oils, while surfactants with higher HLB values are more hydrophilic, and have greater solubility in aqueous solutions.
- Hydrophilic surfactants are generally considered to be those compounds having an HLB value greater than about 10, as well as anionic, cationic, or zwitterionic compounds for which the HLB scale is not generally applicable.
- lipophilic (i.e., hydrophobic) surfactants are compounds having an HLB value equal to or less than about 10.
- HLB value of a surfactant is merely a rough guide generally used to enable formulation of industrial, pharmaceutical and cosmetic emulsions.
- Hydrophilic surfactants may be either ionic or non-ionic. Suitable ionic surfactants include, but are not limited to, alkylammonium salts; fusidic acid salts; fatty acid derivatives of amino acids, oligopeptides, and polypeptides; glyceride derivatives of amino acids, oligopeptides, and polypeptides; lecithins and hydrogenated lecithins; lysolecithins and hydrogenated lysolecithins; phospholipids and derivatives thereof; lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkylsulfates; fatty acid salts; sodium docusate; acyl lactylates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides; and mixture
- ionic surfactants include, by way of example: lecithins, lysolecithin, phospholipids, lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkylsulfates; fatty acid salts; sodium docusate; acylactylates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides; and mixtures thereof.
- Ionic surfactants may be the ionized forms of lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, lysophosphatidylserine, PEG-phosphatidylethanolamine, PVP—phosphatidylethanolamine, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, cholylsarcosine, caproate, caprylate, caprate,
- Hydrophilic non-ionic surfactants may include, but are not limited to, alkylglucosides; alkylmaltosides; alkylthioglucosides; lauryl macrogolglycerides; polyoxyalkylene alkyl ethers such as polyethylene glycol alkyl ethers; polyoxyalkylene alkylphenols such as polyethylene glycol alkyl phenols; polyoxyalkylene alkyl phenol fatty acid esters such as polyethylene glycol fatty acids monoesters and polyethylene glycol fatty acids diesters; polyethylene glycol glycerol fatty acid esters; polyglycerol fatty acid esters; polyoxyalkylene sorbitan fatty acid esters such as polyethylene glycol sorbitan fatty acid esters; hydrophilic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids, and sterols; polyoxyethylene sterols,
- hydrophilic-non-ionic surfactants include, without limitation, PEG-10 laurate, PEG-12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, PEG-32 distearate, PEG-40 stearate, PEG-100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 glyceryl oleate
- Suitable lipophilic surfactants include, by way of example only: fatty alcohols; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acids esters; propylene glycol fatty acid esters; sorbitan fatty acid esters; polyethylene glycol sorbitan fatty acid esters; sterols and sterol derivatives; polyoxyethylated sterols and sterol derivatives; polyethylene glycol alkyl ethers; sugar esters; sugar ethers; lactic acid derivatives of mono- and di-glycerides; hydrophobic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids and sterols; oil-soluble vitamins/vitamin derivatives; and mixtures thereof.
- preferred lipophilic surfactants include glycerol fatty acid esters, propylene glycol fatty acid esters, and mixtures thereof, or are hydrophobic transesterification products of a polyol with at least one member of the group consisting of vegetable oils, hydrogenated vegetable oils, and triglycerides.
- the composition may include a solubilizer to ensure good solubilization and/or dissolution of the compound of the present invention and to minimize precipitation of the compound of the present invention. This can be especially important for compositions for non-oral use, e.g., compositions for injection.
- a solubilizer may also be added to increase the solubility of the hydrophilic drug and/or other components, such as surfactants, or to maintain the composition as a stable or homogeneous solution or dispersion.
- solubilizers include, but are not limited to, the following: alcohols and polyols, such as ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediols and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives; ethers of polyethylene glycols having an average molecular weight of about 200 to about 6000, such as tetrahydrofurfuryl alcohol PEG ether (glycofurol) or methoxy PEG; amides and other nitrogen-containing compounds such as 2-pyrrolidone, 2-piperidone, 8-caprolactam,
- solubilizers may also be used. Examples include, but not limited to, triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrins, ethanol, polyethylene glycol 200-100, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide.
- Particularly preferred solubilizers include sorbitol, glycerol, triacetin, ethyl alcohol, PEG-400, glycofurol and propylene glycol.
- the amount of solubilizer that can be included is not particularly limited.
- the amount of a given solubilizer may be limited to a bioacceptable amount, which may be readily determined by one of skill in the art.
- the solubilizer can be in a weight ratio of 10%, 25% o, 50%), 100% o, or up to about 200%> by weight, based on the combined weight of the drug, and other excipients.
- solubilizer may also be used, such as 5%>, 2%>, 1%) or even less.
- the solubilizer may be present in an amount of about 1%> to about 100%, more typically about 5%> to about 25%> by weight.
- the composition can further include one or more pharmaceutically acceptable additives and excipients.
- additives and excipients include, without limitation, detackifiers, anti-foaming agents, buffering agents, polymers, antioxidants, preservatives, chelating agents, viscomodulators, toniciflers, flavorants, colorants, odorants, opacifiers, suspending agents, binders, fillers, plasticizers, lubricants, and mixtures thereof.
- an acid or a base may be incorporated into the composition to facilitate processing, to enhance stability, or for other reasons.
- pharmaceutically acceptable bases include amino acids, amino acid esters, ammonium hydroxide, potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, synthetic hydrocalcite, magnesium aluminum hydroxide, diisopropylethylamine, ethanolamine, ethylenediamine, triethanolamine, triethylamine, triisopropanolamine, trimethylamine, tris(hydroxymethyl)aminomethane (TRIS) and the like.
- bases that are salts of a pharmaceutically acceptable acid, such as acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid, and the like.
- a pharmaceutically acceptable acid such as acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids
- Salts of polyprotic acids such as sodium phosphate, disodium hydrogen phosphate, and sodium dihydrogen phosphate can also be used.
- the cation can be any convenient and pharmaceutically acceptable cation, such as ammonium, alkali metals, alkaline earth metals, and the like.
- Example may include, but not limited to, sodium, potassium, lithium, magnesium, calcium and ammonium.
- Suitable acids are pharmaceutically acceptable organic or inorganic acids.
- suitable inorganic acids include hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid, boric acid, phosphoric acid, and the like.
- suitable organic acids include acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acids, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic
- compositions for Injection are provided.
- the invention provides a pharmaceutical composition for injection containing a compound of the present invention and a pharmaceutical excipient suitable for injection.
- a pharmaceutical composition for injection containing a compound of the present invention and a pharmaceutical excipient suitable for injection.
- Components and amounts of agents in the compositions are as described herein.
- Aqueous solutions in saline are also conventionally used for injection.
- Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed.
- the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, for the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
- Sterile injectable solutions are prepared by incorporating the compound of the present invention in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- certain desirable methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- compositions for Topical e.g. Transdermal Delivery.
- the invention provides a pharmaceutical composition for transdermal delivery containing a compound of the present invention and a pharmaceutical excipient suitable for transdermal delivery.
- compositions of the present invention can be formulated into preparations in solid, semisolid, or liquid forms suitable for local or topical administration, such as gels, water soluble jellies, creams, lotions, suspensions, foams, powders, slurries, ointments, solutions, oils, pastes, suppositories, sprays, emulsions, saline solutions, dimethylsulfoxide (DMSO)-based solutions.
- DMSO dimethylsulfoxide
- carriers with higher densities are capable of providing an area with a prolonged exposure to the active ingredients.
- a solution formulation may provide more immediate exposure of the active ingredient to the chosen area.
- compositions also may comprise suitable solid or gel phase carriers or excipients, which are compounds that allow increased penetration of, or assist in the delivery of, therapeutic molecules across the stratum corneum permeability barrier of the skin.
- suitable solid or gel phase carriers or excipients which are compounds that allow increased penetration of, or assist in the delivery of, therapeutic molecules across the stratum corneum permeability barrier of the skin.
- humectants e.g., urea
- glycols e.g., propylene glycol
- alcohols e.g., ethanol
- fatty acids e.g., oleic acid
- surfactants e.g., isopropyl myristate and sodium lauryl sulfate
- pyrrolidones e.g., isopropyl myristate and sodium lauryl sulfate
- pyrrolidones e.glycerol monolaurate, sulfoxides, terpenes (e.g., menthol)
- amines amides, alkanes, alkanols, water, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
- transdermal delivery devices Such transdermal patches may be used to provide continuous or discontinuous infusion of a compound of the present invention in controlled amounts, either with or without another agent.
- transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Pat. Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
- compositions for Inhalation are provided.
- compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
- the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra.
- the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
- Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a face mask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.
- compositions may also be prepared from compositions described herein and one or more pharmaceutically acceptable excipients suitable for sublingual, buccal, rectal, intraosseous, intraocular, intranasal, epidural, or intraspinal administration. Preparations for such pharmaceutical compositions are well-known in the art.
- Administration of the compounds or pharmaceutical composition of the present invention can be effected by any method that enables delivery of the compounds to the site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, intraarterial, subcutaneous, intramuscular, intravascular, intraperitoneal or infusion), topical (e.g. transdermal application), rectal administration, via local delivery by catheter or stent or through inhalation. Compounds can also be administered intraadiposally or intrathecally.
- the compounds or pharmaceutical composition of the present invention are administered by intravenous injection.
- an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to 7 g/day, preferably about 0.05 to about 2.5 g/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, e.g. by dividing such larger doses into several small doses for administration throughout the day.
- a compound of the invention is administered in a single dose.
- Such administration will be by injection, e.g., intravenous injection, in order to introduce the agent quickly.
- injection e.g., intravenous injection
- other routes may be used as appropriate.
- a single dose of a compound of the invention may also be used for treatment of an acute condition.
- a compound of the invention is administered in multiple doses. Dosing may be about once, twice, three times, four times, five times, six times, or more than six times per day. Dosing may be about once a month, once every two weeks, once a week, or once every other day. In another embodiment a compound of the invention and another agent are administered together about once per day to about 6 times per day. In another embodiment the administration of a compound of the invention and an agent continues for less than about 7 days. In yet another embodiment the administration continues for more than about 6, 10, 14, 28 days, two months, six months, or one year. In some cases, continuous dosing is achieved and maintained as long as necessary.
- a compound of the invention is administered for more than 1, 2, 3, 4, 5, 6, 7, 14, or 28 days. In some embodiments, a compound of the invention is administered for less than 28, 14, 7, 6, 5, 4, 3, 2, or 1 day. In some embodiments, a compound of the invention is administered chronically on an ongoing basis, e.g., for the treatment of chronic effects.
- An effective amount of a compound of the invention may be administered in either single or multiple doses by any of the accepted modes of administration of agents having similar utilities, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant.
- compositions of the invention may also be delivered via an impregnated or coated device such as a stent, for example, or an artery-inserted cylindrical polymer.
- a method of administration may, for example, aid in the prevention or amelioration of restenosis following procedures such as balloon angioplasty.
- compounds of the invention may slow or inhibit the migration and proliferation of smooth muscle cells in the arterial wall which contribute to restenosis.
- a compound of the invention may be administered, for example, by local delivery from the struts of a stent, from a stent graft, from grafts, or from the cover or sheath of a stent.
- a compound of the invention is admixed with a matrix.
- Such a matrix may be a polymeric matrix, and may serve to bond the compound to the stent.
- Polymeric matrices suitable for such use include, for example, lactone-based polyesters or copolyesters such as polylactide, polycaprolactonglycolide, polyorthoesters, polyanhydrides, polyaminoacids, polysaccharides, polyphosphazenes, poly (ether-ester) copolymers (e.g. PEO-PLLA); polydimethylsiloxane, poly(ethylene-vinylacetate), acrylate-based polymers or copolymers (e.g.
- Compounds of the invention may be applied to the surface of the stent by various methods such as dip/spin coating, spray coating, dip-coating, and/or brush-coating.
- the compounds may be applied in a solvent and the solvent may be allowed to evaporate, thus forming a layer of compound onto the stent.
- the compound may be located in the body of the stent or graft, for example in microchannels or micropores.
- stents When implanted, the compound diffuses out of the body of the stent to contact the arterial wall.
- stents may be prepared by dipping a stent manufactured to contain such micropores or microchannels into a solution of the compound of the invention in a suitable solvent, followed by evaporation of the solvent. Excess drug on the surface of the stent may be removed via an additional brief solvent wash.
- compounds of the invention may be covalently linked to a stent or graft.
- a covalent linker may be used which degrades in vivo, leading to the release of the compound of the invention. Any bio-labile linkage may be used for such a purpose, such as ester, amide or anhydride linkages.
- Compounds of the invention may additionally be administered intravascularly from a balloon used during angioplasty. Extravascular administration of the compounds via the pericard or via advential application of formulations of the invention may also be performed to decrease restenosis.
- the compounds of the invention may be administered in dosages. It is known in the art that due to intersubject variability in compound pharmacokinetics, individualization of dosing regimen is necessary for optimal therapy. Dosing for a compound of the invention may be found by routine experimentation in light of the instant disclosure.
- a compound of the invention When a compound of the invention is administered in a composition that comprises one or more agents, and the agent has a shorter half-life than the compound of the invention unit dose forms of the agent and the compound of the invention may be adjusted accordingly.
- the subject pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
- the pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages.
- the pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.
- Exemplary parenteral administration forms include solutions or suspensions of active compound in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.
- the method typically comprises administering to a subject a therapeutically effective amount of a compound of the invention.
- the therapeutically effective amount of the subject combination of compounds may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
- the term also applies to a dose that will induce a particular response in target cells, e.g., reduction of proliferation or downregulation of activity of a target protein.
- the specific dose will vary depending on the particular compounds chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.
- IC 50 refers to the half maximal inhibitory concentration of an inhibitor in inhibiting biological or biochemical function. This quantitative measure indicates how much of a particular inhibitor is needed to inhibit a given biological process (or component of a process, i.e. an enzyme, cell, cell receptor or microorganism) by half. In other words, it is the half maximal (50%) inhibitory concentration (IC) of a substance (50% IC, or IC50).
- IC50 refers to the plasma concentration required for obtaining 50%> of a maximum effect in vivo.
- the subject methods utilize a MCL-1 inhibitor with an IC50 value of about or less than a predetermined value, as ascertained in an in vitro assay.
- the MCL-1 inhibitor inhibits MCL-1 a with an IC50 value of about 1 nM or less, 2 nM or less, 5 nM or less, 7 nM or less, 10 nM or less, 20 nM or less, 30 nM or less, 40 nM or less, 50 nM or less, 60 nM or less, 70 nM or less, 80 nM or less, 90 nM or less, 100 nM or less, 120 nM or less, 140 nM or less, 150 nM or less, 160 nM or less, 170 nM or less, 180 nM or less, 190 nM or less, 200 nM or less, 225 nM or less, 250 nM or less, 275 nM or less, 300 nM or less,
- the MCL-1 inhibitor selectively inhibits MCL-1 a with an IC50 value that is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, or 1000 times less (or a number in the range defined by and including any two numbers above) than its IC50 value against one, two, or three other MCL-1s.
- the MCL-1 inhibitor selectively inhibits MCL-1 a with an IC50 value that is less than about 1 nM, 2 nM, 5 nM, 7 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, 120 nM, 140 nM, 150 nM, 160 nM, 170 nM, 180 nM, 190 nM, 200 nM, 225 nM, 250 nM, 275 nM, 300 nM, 325 nM, 350 nM, 375 nM, 400 nM, 425 nM, 450 nM, 475 nM, 500 nM, 550 nM, 600 nM, 650 nM, 700 nM, 750 nM, 800 nM, 850 nM, 900 nM,
- the subject methods are useful for treating a disease condition associated with MCL-1. Any disease condition that results directly or indirectly from an abnormal activity or expression level of MCL-1 can be an intended disease condition.
- MCL-1 has been implicated, for example, auto-immune diseases, neurodegeneration (such as Parkinson's disease, Alzheimer's disease and ischaemia), inflammatory diseases, viral infections and cancer such as, for example, colon cancer, breast cancer, small-cell lung cancer, non-small-cell lung cancer, bladder cancer, ovarian cancer, prostate cancer, chronic lymphoid leukemia, lymphoma, myeloma, acute myeloid leukemia, or pancreatic cancer.
- auto-immune diseases such as Parkinson's disease, Alzheimer's disease and ischaemia
- inflammatory diseases such as, viral infections and cancer
- cancer such as, for example, colon cancer, breast cancer, small-cell lung cancer, non-small-cell lung cancer, bladder cancer, ovarian cancer, prostate cancer, chronic lymphoid leukemia, lymphoma, myeloma, acute myeloid leukemia, or pancreatic cancer.
- Non-limiting examples of such conditions include but are not limited to Acanthoma, Acinic cell carcinoma, Acoustic neuroma, Acral lentiginous melanoma, Acrospiroma, Acute eosinophilic leukemia, Acute lymphoblastic leukemia, Acute lymphocytic leukemia, Acute megakaryoblastic leukemia, Acute monocytic leukemia, Acute myeloblasts leukemia with maturation, Acute myeloid dendritic cell leukemia, Acute myeloid leukemia, Acute myelogenous leukemia, Acute promyelocytic leukemia, Adamantinoma, Adenocarcinoma, Adenoid cystic carcinoma, Adenoma, Adenomatoid odontogenic tumor, Adrenocortical carcinoma, Adult T-cell leukemia, Aggressive NK-cell leukemia, AIDS-Related Cancers, AIDS-related lymphoma, Alveolar soft part sar
- said method is for treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, eczema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.
- a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, eczema, and scleroderma
- diabetes diabetic retinopathy, retinopathy of prematurity
- age-related macular degeneration hemangio
- said method is for treating a disease selected from breast cancer, lung cancer, pancreatic cancer, prostate cancer, colon cancer, ovarian cancer, uterine cancer, or cervical cancer.
- said method is for treating a disease selected from leukemia such as acute myeloid leukemia (AML), acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, myelodysplasia, myeloproliferative disorders, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), mastocytosis, chronic lymphocytic leukemia (CLL), multiple myeloma (MM), myelodysplastic syndrome (MDS) or epidermoid cancer.
- AML acute myeloid leukemia
- AML acute lymphocytic leukemia
- chronic lymphocytic leukemia chronic myeloid leukemia
- CML chronic myelogenous leukemia
- mastocytosis chronic lymphocytic leukemia
- CLL multiple myeloma
- MDS myelodysplastic syndrome
- Medical therapies include, for example, surgery and radiotherapy (e.g., gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, systemic radioactive isotopes).
- radiotherapy e.g., gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, systemic radioactive isotopes.
- compounds of the disclosure as well as pharmaceutical compositions comprising them, can be administered to treat any of the described diseases, alone or in combination with one or more other agents.
- the compounds of the disclosure as well as pharmaceutical compositions comprising them, can be administered in combination with agonists of nuclear receptors agents.
- the compounds of the disclosure as well as pharmaceutical compositions comprising them, can be administered in combination with antagonists of nuclear receptors agents.
- the compounds of the disclosure as well as pharmaceutical compositions comprising them, can be administered in combination with an anti-proliferative agent.
- the compounds of the invention can be used in combination with chemotherapeutic agents, agonists or antagonists of nuclear receptors, or other anti-proliferative agents.
- the compounds of the invention can also be used in combination with a medical therapy such as surgery or radiotherapy, e.g., gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes.
- chemotherapeutic agents include any of: abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, all-trans retinoic acid, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bendamustine, bevacizumab, bexarotene, bleomycin, bortezombi, bortezomib, busulfan intravenous, busulfan oral, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, dasatinib, daunorubicin, decitabine, denileukin, denileukin difti
- the compounds of the invention can be used in combination with a therapeutic agent that targets an epigenetic regulator.
- epigenetic regulators include bromodomain inhibitors, the histone lysine methyltransferase inhibitors, histone arginine methyl transferase inhibitors, histone demethylase inhibitors, histone deacetylase inhibitors, histone acetylase inhibitors, and DNA methyltransferase inhibitors.
- Histone deacetylase inhibitors include, e.g., vorinostat.
- Histone arginine methyl transferase inhibitors include inhibitors of protein arginine methyltransferases (PRMTs) such as PRMT5, PRMT1 and PRMT4.
- DNA methyltransferase inhibitors include inhibitors of DNMT1 and DNMT3.
- the compounds of the invention can be used in combination with targeted therapies, including JAK kinase inhibitors (e.g. Ruxolitinib), PI3 kinase inhibitors including PI3K-delta selective and broad spectrum PI3K inhibitors, MEK inhibitors, Cyclin Dependent kinase inhibitors, including CDK4/6 inhibitors and CDK9 inhibitors, BRAF inhibitors, mTOR inhibitors, proteasome inhibitors (e.g. Bortezomib, Carfilzomib), HDAC inhibitors (e.g.
- JAK kinase inhibitors e.g. Ruxolitinib
- PI3 kinase inhibitors including PI3K-delta selective and broad spectrum PI3K inhibitors
- MEK inhibitors Cyclin Dependent kinase inhibitors
- CDK4/6 inhibitors and CDK9 inhibitors including CDK4/6 inhibitors and CDK9 inhibitors
- BRAF inhibitors e.g. Bortez
- panobinostat panobinostat, vorinostat
- DNA methyl transferase inhibitors dexamethasone, bromo and extra terminal family member (BET) inhibitors, BTK inhibitors (e.g. ibrutinib, acalabrutinib), BCL2 inhibitors (e.g. venetoclax), dual BCL2 family inhibitors (e.g. BCL2/BCLxL), PARP inhibitors, FLT3 inhibitors, or LSD 1 inhibitors.
- BTK inhibitors e.g. ibrutinib, acalabrutinib
- BCL2 inhibitors e.g. venetoclax
- dual BCL2 family inhibitors e.g. BCL2/BCLxL
- PARP inhibitors FLT3 inhibitors, or LSD 1 inhibitors.
- the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1, e.g., an anti-PD-1 monoclonal antibody.
- the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), or PDR001.
- the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab.
- the anti-PD1 antibody is pembrolizumab.
- the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1, e.g., an anti-PD-L1 monoclonal antibody.
- the anti-PD-L1 monoclonal antibody is atezolizumab, durvalumab, or BMS-935559.
- the inhibitor of an immune checkpoint molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody.
- the anti-CTLA-4 antibody is ipilimumab.
- the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatory agent.
- an alkylating agent include cyclophosphamide (CY), melphalan (MEL), and bendamustine.
- the proteasome inhibitor is carfilzomib.
- the corticosteroid is dexamethasone (DEX).
- the immunomodulatory agent is lenalidomide (LEN) or pomalidomide (POM).
- the compound of the invention can be administered in combination with a corticosteroid such as triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, or flumetholone.
- a corticosteroid such as triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, or flumetholone.
- the compound of the invention can be administered in combination with an immune suppressant such as fluocinolone acetonide (Retisert®), rimexolone (AL-2178, Vexol, Alcon), or cyclosporine (Restasis®).
- an immune suppressant such as fluocinolone acetonide (Retisert®), rimexolone (AL-2178, Vexol, Alcon), or cyclosporine (Restasis®).
- Compounds of the disclosure also include, for example, the compounds and genera identified m Tables A, B, and C.
- n 0, 1 or 2
- NR R H or C 1 -C 6 alkyl
- R H or C 1 -C 6 alkyl
- X OH, F, OMe, OCF 3
- Compounds of the disclosure also include, for example, the compounds described as Examples below.
- Johnson-Corey-Chaykovsky reaction of the substituted ketone 1 with sulfur ylide can form the corresponding epoxide 2 which can be converted to the aldehyde 3 under Lewis acid (e.g., boron trifluoride diethyl etherate or TiCl 4 ).
- the aldehyde 3 can be transformed to the 1,3-diol derivative 4 by treatment with formaldehyde under basic conditions (e.g., KOH).
- a series of 1,3-diol derivatives of formula 12 can be prepared by the methods outlined in Scheme 2.
- Compound 7 can be obtained by protecting the alcohol group (e.g., TBS or other silyl group) in 6 obtained from the reduction of the acid 5 using a suitable reductive reagent including, (e.g., BH 3 , NaBH 4 , LiBH 4 , LiAlH 4 ).
- a suitable agent e.g., BuLi or another lithium reagent
- Mono-protection of the hydroxyl group 13 can be achieved by reaction of 4 or 12 with substituted benzoyl chloride in the presence of a base (e.g, TEA, DIEA, or NaOH).
- Oxidation of the hydroxyl group of 13 using a suitable oxidant e.g., Dess-Martin or Swern oxidation conditions
- p-TsOH p-toluenesulfonic acid
- Reaction of compound 15 with 4-fluoro-3-nitrobenzenesulfonamide 16 in the presence of base can afford the corresponding compound 17.
- base e.g., potassium tert-butoxide, sodium tert-butoxide, LiHMDS or NaLiHMDS
- De-protection of the acetal group in 17 to the aldehyde 18 can be achieved under acid conditions (e.g., Amberlyst, p-TsOH, HCl in dioxane or TFA).
- Reduction of the nitro group in 18 using a suitable reducing agent can yield the imine intermediate 19 which can be further reduced to the amine derivative 20 by using suitable reductive reagent (e.g., NaBH 4 or NaBH(OAc) 3 ).
- suitable reductive reagent e.g., NaBH 4 or NaBH(OAc) 3
- the amine derivative 20 can be obtained by direct hydrogenation of the nitro compound 18 in the presence of a palladium catalyst (e.g., Pd/C or Pd(OH) 2 /C in an appropriate solvent such as methanol or ethanol).
- Reductive amination of the amine derivative 20 can afford the corresponding derivative 21 which can be transformed into the desired product 22 by reaction with the suitable acid using standard amide coupling conditions (e.g., EDCI, CDI, BOP, HATU or HBTU in the presence of a suitable base, TEA or DIEA).
- suitable acid e.g., EDCI, CDI, BOP, HATU or HBTU in the presence of a suitable base, TEA or DIEA.
- acid e.g., TFA in DCM
- hydrogenation conditions e.g., palladium catalyzed hydrogenation Pd/C with H 2 ).
- a suitable reducing agent such as NaBH 3 (CN) or NaBH(OAc) 3
- a suitable reducing agent such as NaBH 3 (CN) or NaBH(OAc) 3
- a suitable reducing agent such as NaBH 3 (CN) or NaBH(OAc) 3
- a suitable base e.g. TEA or DIEA
- RCM ring closing metathesis
- the amide coupling of the sulfonamide 33 with the appropriate acid 37 using a coupling agent (e.g. EDC, DCC, or HATU) in the presence of a suitable base (e.g. TEA or DIEA) can provide the sulfonamide derivative 38 which can be then converted to the corresponding macrocyclic sulfonamide derivative 39 in the presence of an RCM catalyst as described in Scheme 4.
- a coupling agent e.g. EDC, DCC, or HATU
- a suitable base e.g. TEA or DIEA
- the sulfonamide 33 can react with the appropriate chloroformate derivative 40 in the presence of a suitable base (e.g. DIEA, TEA, or NaOH) to produce the corresponding sulfonyl carbamate 41 which can be transformed into the desired macrocycle of formula 42 in the presence of an RCM catalyst as described in Scheme 4.
- a suitable base e.g. DIEA, TEA, or NaOH
- Intermolecular olefin metathesis reaction of compound 33 with the vinyl derivative 43 in the presence of suitable olefin metathesis catalyst e.g., Grubbs catalyst, Grubbs-II catalyst, Grubbs-III catalyst, Hoveyda-Grubbs catalyst or Zhan catalyst 1B under suitable reaction conditions
- suitable olefin metathesis catalyst e.g., Grubbs catalyst, Grubbs-II catalyst, Grubbs-III catalyst, Hoveyda-Grubbs catalyst or Zhan catalyst 1B under suitable reaction conditions
- suitable olefin metathesis catalyst e.g., Grubbs catalyst, Grubbs-II catalyst, Grubbs-III catalyst, Hoveyda-Grubbs catalyst or Zhan catalyst 1B under suitable reaction conditions
- Intra-molecular amide formation of 45 can afford compound 36 using a suitable amide coupling reagent (e.g., EDCI, CDI, BOP, HATU, or HBTU) and base (e.g., DMAP, Et 3 N, or Hunig's base).
- a suitable amide coupling reagent e.g., EDCI, CDI, BOP, HATU, or HBTU
- base e.g., DMAP, Et 3 N, or Hunig's base.
- Grubbs metathesis reaction of compound 33 with the vinyl derivative 46 can provide the corresponding olefin compound 47.
- Removal the protecting Boc-group in 47 by using acid e.g., TFA in DCM, HCl in dioxane
- acid e.g., TFA in DCM, HCl in dioxane
- Treatment of 48 with a suitable reagent such as CDI, phosgene or triphosgene and a base can provide the macrocyclic sulfonyl urea derivative 49.
- the sulfonyl urea derivatives 49 can be obtained by treatment of the sulfonamide 33 with diphenyl carbonate or 4-nitrophenyl chloroformate in the presence of DMAP and triethylamine or Hunig's base, follow by the addition of the appropriate amine 50.
- the alcohol derivative 54 can be obtained by hydrolysis of the acetate ester 53 which can be produced by the reductive amination of 29 with the aldehyde 52.
- Mitsunobo reaction e.g., DEAD and triphenylphospine
- Removal of the PMB groups in 56 under acid conditions e.g.
- TFA, HCl TFA, HCl
- hydrogenation conditions e.g., palladium catalyzed hydrogenation Pd/C with H 2
- hydrolysis of the ester group in 57 under basic conditions e.g., LiOH or NaOH in water/THF
- Intra-molecular amide formation of 58 can form the macro-cyclic sulfonamide derivative 59 by methods provided above.
- a series of spiro-cyclic sulfonamide derivatives of formula 60 can be prepared by the methods outlined in Scheme 12. Alkylation of phenol compound 61 with a bromide 62 can give the corresponding ether 63 in the presence of a base (e.g., NaH or NaOH) which can react with diethyl malonate 64 or other dialkyl malonate in the presence of a suitable palladium catalyst (e.g., Pd(PtButyl) 3 or other Pd catalyst) to afford the malonate derivative 65.
- a base e.g., NaH or NaOH
- Pd(PtButyl) 3 or other Pd catalyst e.g., Pd(PtButyl) 3 or other Pd catalyst
- 1,3-diol derivative 67 can be obtained by reduction (e.g., DIBAL, LAH, or NaBH 4 ) of the diethyl ester 66 provided by treatment of the malonate derivative 65 with 4-nitrobenzenesulfonyl fluoride in the presence of a base (e.g., DBU or DIEA).
- Asymmetric mono-protecting of the OH-group 68 can be achieved by reaction of 67 with substituted benzoyl chloride in the presence of a suitable chiral catalyst, such as (R,R)-Kang Catalyst.
- Dess-Martin oxidation or Swern oxidation of the hydroxyl group of 68 can afford the corresponding aldehyde 69 which can be transformed to compound 70 by reaction with trimethyl orthoformate in the presence of acid (e.g., p-TsOH in methanol). Hydrolysis of compound 70 can yield the alcohol 71 which can be transformed into the spiro-cyclic sulfonamide derivatives 60 in a similar manner as the those described above for compound 15 to compound 20 in Scheme 3.
- Reaction of the alcohol 71 with 4-fluoro-3-nitrobenzenesulfonamide 25 in the presence of base can afford the corresponding compound 72.
- base e.g., potassium tert-butoxide, sodium tert-butoxide, LiHMDS or NaLiHMDS
- De-protection of the acetal group in 72 to the aldehyde 73 can be achieved under acid conditions (e.g., Amberlyst, p-TsOH, HCl in dioxane or TFA).
- Reduction of the nitro group in 73 by using a suitable reducing agent e.g., iron in acetic acid, iron or zinc and NH 4 Cl in ethanol
- a suitable reducing agent e.g., iron in acetic acid, iron or zinc and NH 4 Cl in ethanol
- suitable reductive reagent e.g., NaBH 4 or NaBH(OAc)
- a series of allyl alcohol derivatives of formula 81 or 82 can be prepared by the methods outlined in Scheme 13. Reductive amination of the spiro-sulfonamide 74 with aldehyde 75 using reductive agent (e.g., NaBH 4 , NaBH(OAc) 3 , or NaBCNH 3 ) can afford the corresponding product 76 which can be transformed into the alcohol 77 under saponification conditions (e.g. acid or base). Swern oxidation or Dess-Martin oxidation of the alcohol 77 can afford the aldehyde 78.
- reductive agent e.g., NaBH 4 , NaBH(OAc) 3 , or NaBCNH 3
- Alkylation of 78 with a suitable reagent can yield a mixture of the allyl alcohol 79 and 80.
- a suitable reagent e.g., vinylmagnesium bromide or vinyllithium
- the diastereomers can be separated by chromatography (e.g., silica gel column, or preparative HPLC on a Cl8 column, or by SFC using a suitable column) using suitable conditions.
- Removal of the protecting group PMB in 79 or 80 under acid conditions e.g., TFA in DCM or HCl in dioxane or phosphoric acid in water
- acid conditions e.g., TFA in DCM or HCl in dioxane or phosphoric acid in water
- the allyl alcohol derivatives of formula 81 or 82 can be prepared by the methods outlined in Scheme 14 via reductive amination of the spiro-sulfonamide 74 with the aldehyde 85 or 86 by methods described in Scheme 13.
- the aldehyde 85 or 86 can be prepared by the methods outlined in Scheme 15. Alkylation of 75 with a suitable agent (e.g., vinylmagnesium bromide or vinyllithium) can produce a mixture of the allyl alcohol 83 or 84 that can be separated by chromatographic methods as described above. Oxidation of 83 or 84 under suitable conditions (e.g., Dess-Martin or Swern conditions) can afford the 85 or 86, respectively.
- a suitable agent e.g., vinylmagnesium bromide or vinyllithium
- Oxidation of 83 or 84 under suitable conditions e.g., Dess-Martin or Swern conditions
- suitable conditions e.g., Dess-Martin or Swern conditions
- a series of carbamate derivatives of formula 92 can be prepared by the methods outlined in Scheme 16. Reaction of the allyl alcohol 81 or 82 with acid 87 can yield the amide 88 under amide coupling conditions (e.g., BOP, HATU, HBTU, or EDCI, and an organic base such as DMAP, Et 3 N, or Hunig's base). Hydrolysis under basic conditions (e.g., LiOH or NaOH) of 88 can give the alcohol 89. Macrocyclic alcohol 90 can be obtained by a RCM reaction of 89 using RCM reaction conditions described above.
- amide coupling conditions e.g., BOP, HATU, HBTU, or EDCI
- organic base such as DMAP, Et 3 N, or Hunig's base
- Hydrolysis under basic conditions e.g., LiOH or NaOH
- Macrocyclic alcohol 90 can be obtained by a RCM reaction of 89 using RCM reaction conditions described above.
- Macrocyclic alcohol 90 can be transformed into the desired carbamate derivative 92 by reaction with a suitable dialkylcarbamoyl chloride 93, or by reaction with diphenyl carbonate or CDI followed by treatment with suitable amine R c R d NH.
- a series of carbamate derivatives of formula 98 can be prepared by the methods outlined in Scheme 17. Reaction of the allyl alcohol 81 or 82 with 3-allyl-oxazolidine-2,5-dione 94 in the presence of a suitable base (e.g., DBU or DIEA) can afford the amide 95 which can undergo a RCM reaction to yield the corresponding macrocycles 96. Reductive amination of 96 with an aldehyde RCHO with a suitable reducing agent (e.g., NaBH 3 (CN) or NaBH(OAc) 3 ) can afford 97 which can be transformed into the desired carbamate derivative 98 by methods similar to those shown for conversion of 90 to 92 as described in Scheme 16.
- a suitable base e.g., DBU or DIEA
- Reductive amination of 96 with an aldehyde RCHO with a suitable reducing agent e.g., NaBH 3 (CN) or NaBH(OAc) 3
- a series of 2-aminoethylene ether of formula 102 can be prepared by the methods outlined in Scheme 18.
- a suitable base e.g. NaH or DBU
- Reduction of the anhydride 108 with a suitable reducing agent (e.g., DIBAL or NaBH 4 ) at low temperature can provide the aldehyde 109 which can be transformed into the 2-aminoethylene ether 110 by reductive amination with R c R d NH using reductive agent (e.g., NaBH 4 , NaBH(OAc) 3 , or NaBCNH 3 ).
- a suitable reducing agent e.g., DIBAL or NaBH 4
- Reductive agent e.g., NaBH 4 , NaBH(OAc) 3 , or NaBCNH 3
- reaction of the anhydride 108 with amine R c R d NH can yield the corresponding amide 111.
- Step 7 4-[[6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methoxy]-3-nitro-benzenesulfonamide
- Step 8 4-[(6-chloro-1-formyl-tetralin-1-yl)methoxy]-3-nitro-benzenesulfonamide
- the Amberlyst 16 wet catalyst was rinsed with acetone and dried under high vacuum before use.
- a 500 mL RBF with septum containing crude 4-[[6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methoxy]-3-nitro-benzenesulfonamide (1.42 g, 3.02 mmol) and pre-treated Amberlyst 16 wet (1 g, ⁇ 7.44 mmol) under N 2 was charged with acetone (30 mL). The reaction mixture was heated at 50° C. for 2 h., filtered through cotton and rinsed with DCM.
- the filtrate was concentrated under reduced pressure, dissolved in DCM (30 mL), cooled to 0° C., and charged with sodium triacetoxyborohydride (1.99 g, 9.44 mmol) over 1 min.
- the reaction mixture was stirred at 0° C. for 1 min, then stirred at RT for 80 min.
- the reaction mixture was quenched with 10% citric acid (30 mL), diluted with water (30 mL), and extracted with EtOAc (125 mL).
- the organic layer was washed with 10% citric acid (10 mL) and water (40 mL), washed with brine (2 ⁇ 40 mL), dried over Na 2 SO 4 , and filtered.
- the mixture was neutralized with 1 N HCl to pH about 4-5 and diluted with EtOAc (100 mL). The organic layer was separated, washed with 1 N HCl (10 mL), 7.5% NaHCO 3 aqueous solution (20 mL), and brine, dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure. The residue was treated with DCM (30 mL), and hexane was added to the suspension until it became cloudy. The resulting suspension was sonicated for 2 min. and left at r.t. for 1 h. The mixture was filtered. and washed with hexane to afford the desired title product (6.85 g) without further purification. The mother liquid was concentrated under reduced pressure.
- Step 2 [(1S)-6-chloro-1-(hydroxymethyl)tetralin-1-yl]methyl benzoate and [(1R)-6-chloro-1-(hydroxymethyl)tetralin-1-yl]methyl benzoate
- This compound was prepared using procedures analogous to those described for Intermediate 1 using [(1S)-6-chloro-1-(hydroxymethyl)tetralin-1-yl]methyl benzoate (Step 2, P1) to replace the racemic [6-chloro-1-(hydroxymethyl)tetralin-1-yl]methyl benzoate in Step 5.
- Method A This compound was prepared using procedures analogous to those described for Intermediate 1 using [(1R)-6-chloro-1-formyl-tetralin-1-yl]methyl benzoate to replace the racemic (6-chloro-1-formyl-tetralin-1-yl)methyl benzoate in Step 6.
- the separated products were determined by chiral HPLC on Berger Analytical SFC.
- Chiral HPLC conditions Chiral Column: ChiralPak IC, 5 um, 4.6 mm ⁇ 250 mm (Daicel); Mobile phase: i-PrOH/Supercritical CO 2 /EtOH 1/3; Flow rate: 3.0 mL/min and Run time: 7 min.; Detector Wavelength (UV length): 220 nm, 254 nm, and 280 nm; Column temperature: 30° C.; Back pressure: 120 bar.
- Step 5 N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-4-[[(1R)-6-chloro-1-(dimethoxymethyl)-tetralin--yl]methoxy]benzenesulfonamide
- Step 6 N,N-bis[(4-methoxyphenyl) methyl]-3-nitro-4-[[(1R)-6-chloro-1-formyl-tetralin-1-yl]methoxy]benzenesulfonamide
- Step 7 (S)-6′-chloro-N,N-bis(4-methoxybenzyl)-3′,4′-dihydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-sulfonamide
- Step 8 (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[4,5-dihydro-2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide
- Step 1 [(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl acetate
- 2,2,2-trifluoroacetic acid (7.0 mL, 92 mmol) was dropwise added to a stirred solution of sodium borohydride (3.48 g, 92.0 mmol) in DCM (200 mL) at 0° C. The resulting mixture was stirred at 0° C. for 10 min.
- Step 2 (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-(hydroxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide
- Step 3 (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-formylcyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide
- DMSO (20.5 mL, 289 mmol) was slowly added to a cooled ( ⁇ 78° C.) solution of oxalyl chloride (12.4 mL, 144.9 mmol) in DCM (1000 mL). Gas was produced during this addition. The mixture was stirred at ⁇ 78° C. for 30 min.
- Step 4 (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide and (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide
- Step 5 (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 3)
- Step 6 (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 4)
- Step 1 [(1S)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] acetate
- Step 2 [(1S)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] acetate
- Step 1 (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide
- Step 2 (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide
- Step 1 [(1S)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] N,N-dimethylcarbamate
- Step 2 [(1S)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] N,N-dimethylcarbamate
- Step 1 [(1R)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] N,N-dimethylcarbamate
- Step 2 [(1R)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] N,N-dimethylcarbamate
- Step 2 diethyl 2-(2-(2-((tert-butyldimethylsilyl)oxy)ethoxy)-4-chlorophenyl)malonate
- Dess-Martin periodinane (5.07 g, 11.95 mmol) was added to a stirring solution of [(4S)-7-chloro-4-(hydroxymethyl)chroman-4-yl]methyl 4-bromobenzoate (4.10 g, 9.96 mmol) in DCM (130 mL) at 10° C. After addition, the cooling bath was removed and the reaction mixture was stirred for 30 min. at ambient temperature. Water (17 ml) was then added slowly and the reaction mixture was stirred further at ambient temperature for 30 min. The reaction was cooled to 0° C., quenched with a 1:1 mixture of 10% Na 2 S 2 O 3 and saturated NaHCO 3 (20 mL) solution and stirred further at r.t. for 1 h.
- Step 9 N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-4-[[(4R)-7-chloro-4-(dimethoxymethyl)chroman-4-yl]methoxy]benzenesulfonamide
- reaction was quenched with saturated NH 4 Cl solution (50 mL) and extracted with ethyl acetate (3 ⁇ 100 mL). The combined organic layers were washed with NH 4 Cl (50 mL) and brine (50 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure.
- Step 10 (R)-4-((7-chloro-4-formylchroman-4-yl)methoxy)-N,N-bis(4-methoxybenzyl)-3-nitrobenzenesulfonamide
- Step 11 (S)-7′-chloro-N,N-bis(4-methoxybenzyl)-4,5-dihydro-2H-spiro[benzo[b][1,4]oxazepine-3,4′-chromane]-7-sulfonamide
- Step 1 (3S)-7′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-formylcyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide
- Step 2 (3S)-7′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide and (3S)-7′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide
- This compound was prepared using procedures analogous to those described for Intermediate 3 Step 4 using vinylmagnesium bromide (1.0 M solution THF solution). The reaction was quenched with sat. NH 4 Cl solution (300 mL) and extracted with (EA 300 mL ⁇ 3).
- tert-Butylchlorodimethylsilane (25.34 g, 168 mmol) was slowly added to a solution of imidazole (17.34 g, 254 mmol) and 2-(2-bromo-5-chloro-phenyl)ethanol (60.0 g, 254 mmol) in dry DCM (400 mL) at 0° C. over 30 min. After addition, the reaction mixture was stirred at r.t. for 18 h., and treated with 5% of NaHCO 3 aqueous. The mixture was extracted with EA (200 mL ⁇ 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure.
- Step 3 5-(2-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-chlorophenyl)-2,2-dimethyl-1,3-dioxan-5-ol
- Step 4 5-(4-chloro-2-(2-hydroxyethyl)phenyl)-2,2-dimethyl-1,3-dioxan-5-ol (LGY001-75-1)
- Step 5 6′-chloro-2,2-dimethylspiro[[1,3]dioxane-5,1′-isochroman] (LGY001-80-1)
- Step 7 (R)-(6-chloro-1-(hydroxymethyl)isochroman-1-yl)methyl 4-bromobenzoate (LGY001-98-1)
- R,R-Kang catalyst (2,6-bis((R)-5,5-dibutyl-4-phenyl-4,5-dihydrooxazol-2-yl)pyridine) (908.93 mg, 1.53 mmol) in dry DCM (25 mL) was added Copper(II) chloride (205.79 mg, 1.53 mmol). The resulting green solution was stirred at ambient temperature for 3 h. This solution was transferred via cannula to a solution of 4-bromobenzoyl chloride (5.76 g, 26.2 mmol) in dry DCM (25 mL). The resulting solution was cooled to ⁇ 78° C. and light green colored precipitation was observed in the reaction after some time.
- Step 8 (S)-(6-chloro-1-formylisochroman-1-yl)methyl 4-bromobenzoate (LGY001-100-1)
- Step 9 (S)-(6-chloro-1-(dimethoxymethyl)isochroman-1-yl)methanol (LGY001-91-1)
- Step 10 (S)-4-((6-chloro-1-(dimethoxymethyl)isochroman-1-yl)methoxy)-N,N-bis(4-methoxybenzyl)-3-nitrobenzenesulfonamide
- Step 11 (S)-4-((6-chloro-1-formylisochroman-1-yl)methoxy)-N,N-bis(4-methoxybenzyl)-3-nitrobenzenesulfonamide
- Step 12 (R)-6′-chloro-N,N-bis(4-methoxybenzyl)-4,5-dihydro-2H-spiro[benzo[b][1,4]oxazepine-3,1′-isochroman]-7-sulfonamide
- Step 1 (3R)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-formylcyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-isochromane]-7-sulfonamide
- Step 2 (3R)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-isochromane]-7-sulfonamide and (3R)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-isochromane]-7-sulfonamide
- This compound was prepared using procedures analogous to those described for Intermediate 3 Step 4 using vinylmagnesium bromide (1.0 M solution THF solution). The reaction was quenched with sat. NH 4 Cl solution (300 mL) and extracted with (EA 300 mL ⁇ 3).
- Step 3 (3R)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-isochromane]-7-sulfonamide (Intermediate 15)
- Step 4 (3R)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-isochromane]-7-sulfonamide (Intermediate 16)
- Step 1 6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide
- Step 2 N-[6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylacetamide
- Step 1 6′-chloro-5-(cyclopropylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide
- Step 2 N-[6′-chloro-5-(cyclopropylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylacetamide
- the reaction mixture was charged with additional phenylacetyl chloride (23 ⁇ L, 0.17 mmol) and N,N-diisopropylethylamine (60 uL, 0.34 mmol), and heated at 40° C. for 1 h.
- the reaction mixture was diluted with EtOAc (40 mL), washed with sat. NH 4 Cl (20 mL), water (20 mL) and sat. NH 4 Cl (20 mL), and brine (30 mL).
- the organic layer was dried over Na 2 SO 4 , filtered, concentrated under reduced pressure, and purified by FCC (30 g C18, 10 ⁇ 100% MeCN in water, wet-loaded in DMSO).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
- This application claims the benefit of priority to U.S. Provisional Application No. 62/758,202, filed on Nov. 9, 2018; U.S. Provisional Application No. 62/907,451, filed on Sep. 27, 2019; and U.S. Provisional Application No. 62/909,635, filed on Oct. 2, 2019. Each of these applications is incorporated by reference in its entirety herein.
- The disclosure is directed to MCL-1 inhibitors and methods of their use.
- Apoptosis (programmed cell death) is a highly conserved cellular process that is required for embryonic development and normal tissue homeostasis (Ashkenazi A. et al, Nat. Rev. Drug Discov. 2017, 16, 273-284). Apoptotic-type cell death involves morphological changes such as condensation of the nucleus, DNA fragmentation as well as biochemical phenomena such as the activation of caspases which cause damage to key structural components of the cell, resulting in its disassembly and death. Regulation of the process of apoptosis is complex and involves the activation or repression of several intracellular signaling pathways (Cory S. et al, Nature Review Cancer 2002, 2, 647-656; Thomas L. W. et al, FEBS Lett. 2010, 584, 2981-2989; Adams J. M. et al., Oncogene 2007, 26, 1324-1337)
- The Bcl-2 protein family, which includes both pro-apoptotic and anti-apoptotic members, plays a pivotal role in the regulation of the apoptosis process (Youle R. J. et al, Nat. Rev. Mol. Cell Biol. 2008, 9, 47-59; Kelly G. L. et al, Adv. Cancer Res. 2011, 111, 39-96). Bcl-2, Bcl-XL, Bcl-W, Mcl-1 and A1 are anti-apoptotic proteins and they share a common BH regions. In contrast, the pro-apoptotic family members are divided into two groups. The multi-region pro-apoptotic proteins, such as Bax, Bak and Bok, are conventionally thought to have BH1-3 regions, whereas the BH3-only proteins are proposed to share homology in the BH3 region only. Members of BH3-only proteins include Bad, Bim, Bid, Noxa, Puma, Bik/Blk, Bmf, Hrk/DP5, Beclin-1 and Mule (Xu G. et al, Bioorg. Med. Chem. 2017, 25, 5548-5556; Hardwick J. M. et al, Cell. 2009, 138, 404; Reed J. C., Cell Death Differ. 2018, 25, 3-6; Kang M. H. et al, Clin Cancer Res 2009, 15, 1126-1132). The pro-apoptotic members (such as BAX and BAK), upon activation, form a homo-oligomer in the outer mitochondrial membrane that leads to pore formation and the escape of mitochondrial contents, a step into triggering apoptosis. Antiapoptotic members of the Bcl-2 family (such as Bcl-2, Bel-XL, and Mcl-1) block the activity of BAX and BAK. In normal cells, this process is tightly regulated. Abnormal cells can dysregulate this process to avoid cell death. One of the ways that cancer cells can accomplish this is by upregulating the antiapoptotic members of the Bcl-2 family of proteins. Overexpression or up-regulation of the anti-apoptotic Bcl-2 family proteins enhance cancer cell survival and cause resistance to a variety of anticancer therapies.
- Aberrant expression or function of the proteins responsible for apoptotic signaling contributes to numerous human pathologies including auto-immune diseases, neurodegeneration (such as Parkinson's disease, Alzheimer's disease and ischaemia), inflammatory diseases, viral infections and cancer (such as colon cancer, breast cancer, small-cell lung cancer, non-small-cell lung cancer, bladder cancer, ovarian cancer, prostate cancer, chronic lymphoid leukemia, lymphoma, myeloma, acute myeloid leukemia, pancreatic cancer, etc.) (Hanahan D. et al, Cell 2000, 100. 57-70). Herein, it is prospective to target key apoptosis regulators for cancer treatment (Kale J. et al, Cell Death Differ. 2018, 25, 65-80; Vogler M. et al, Cell Death Differ. 2009, 16, 360-367).
- By overexpressing one or more of these pro-survival proteins, cancer cells can evade elimination by normal physiological processes and thus gain a survival advantage. Myeloid Cell Leukemia-1 (Mcl-1) is a member of the pro-survival Bcl-2 family of proteins. Mcl-1 has the distinct trait of being essential for embryonic development as well as the survival of all hematopoietic lineages and progenitor populations. Mcl-1 is one of the most common genetic aberrations in human cancer and is highly expressed in many tumor types. Mcl-1 overexpression in human cancers is associated with high tumor grade and poor survival (Beroukhim R. et al, Nature 2010, 463, 899-905). Mcl-1 overexpression prevents cancer cells from undergoing programmed cell death (apoptosis), allowing the cells to survive despite widespread genetic damage. Further, its amplification is associated with both intrinsic and acquired resistance to a wide variety of antitumorigenic agents including chemotherapeutic agents such as microtubule binding agents, paclitaxel and gemcitabine, as well as apoptosis-inducing agents such as TRAIL, the Bcl-2 inhibitor, venetoclax, and the Bcl-2/Bcl-XL dual inhibitor navitoclax. Not only do gene silencing approaches that specifically target Mcl-1 circumvent this resistance phenotype, but certain cancer cell types frequently undergo cell death in response to Mcl-1 silencing, indicating a dependence on Mcl-1 for survival. Consequently, approaches that inhibit Mcl-1 function are of considerable interest for cancer therapy (Wertz I. E et al, Nature 2011, 777, 110-114; Zhang B. et al., Blood 2002, 99, 1885-1893).
- The disclosure is directed to compounds of Formula I:
- or a pharmaceutically acceptable salt or solvate thereof;
- wherein
-
- Z is CH or N;
- Q is —O—, —S—, —S(O)—, or —S(O)2—;
- the moiety -W1-W2-W3 is —CR2R2A—CR2R2A—CR2R2A—, —O—CR2BR2C—CR2R2A—, —CR2R2A—CR2BR2C—O—, —NR2B—CR2BR2C—CR2R2A—, —CR2R2A—CR2BR2C—NR2B—, —S—CR2BR2C—CR2R2A, or —CR2R2A—CR2BR2C—S—;
- L1 is absent or is optionally substituted —C1-C6alkylene-;
- L2 is absent or is optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, or optionally substituted heteroarylene;
- L3 is absent, or is —(CR4R5)p—, —(CR4R5)pO—, —O—, —S—, —S(O)—, —S(O)2—, —C(═O)—, —NR6—, —OC(═O)—, —C(═O)O—, —NR6AC(O)—, —C(═O)NR6A—, —OC(═O)N(R6A)—, —NR6AC(O)O—, —S(═O)NR6A—, —NR6AS(O)—, —S(═O)2NR6A—, or —NR6AS(O)2—;
- L4 is absent, or is —(CR4R5)pQ1(CR4R5)q—, wherein Q1 is absent, —CR4A═CR4B—, —O—, —S—, —S(O)—, —S(O)2—, —C(═O)—, —NR6—, —OC(═O)—, —C(═O)O—, —NR6AC(O)—, —C(═O)NR6A—, —NR6AC(O)R6B—, —OC(═O)N(R6A)—, —NR6AC(O)O—, —S(═O)NR6A—, —NR6AS(O)—, —S(═O)2NR6A—, or —NR6AS(O)2—; or is —(CR4R5)p—(CR4A═CR4B)—(CR4R5)q—O—;
- L5 is absent, or is —C1-C6 alkylene-, —C2-C6 alkenylene-, —C2-C6 alkynylene-, -arylene-, -heteroarylene-, -cycloalkenylene-, -cycloalkylene-, -heterocycloalkylene-, wherein said C1-C6 alkylene, C2-C6 alkenylene, C2-C6 alkynylene, arylene, heteroarylene, cycloalkenylene, cycloalkylene, or heterocycloalkylene groups are optionally substituted;
- L6 is absent, or is —(CR7R8)s—, —(CR7R8)sO(CR7R8)t—, —(CR7R8)sNR9(CR7R8)t—, —(CR7R8)sS(CR7R8)t—, —(CR7R8)sS(O)(CR7R8)t—, —(CR7R8)sS(O)2(CR7R8)t—, —(CR7R8)sNR9AC(O)(CR7R8)t—, —(CR7R8)sOC(O)NR9A(CR7R8)t—, —(CR7R8)SNR9AC(O)O(CR7R8)t—, —(CR7R8)sNR9AC(O)NR9B(CR7R8)t—, —(CR7R8)SNR9AS(O)(CR7R8)t—, —(CR7R8)sNR9AS(O)2(CR7R8)t—; —(CR7R8)s—CR4A═CR4B—(CR7R8)t—, —(CR7R8)sC(═O)(CR7R8)t—; —(CR7R8)sC(═O)(CR7R8)t—O—, or —(CR7R8)sC(═O)(CR7R8)t—NR6—;
- each n is independently 0-3;
- each m is independently 0-2;
- each p is independently 0-4;
- each q is independently 0-4;
- each s is independently 0-3;
- each t is independently 0-4;
- each R is independently -D, -halo, —CN, —NO2, —C1-C6alkyl, —C2-C6alkenyl, —C1-C6alkoxy, -cycloalkyl, —ORa, —SRa, —C(O)Rb, —C(O)ORa, —NRcRd, —C(O)NRcRd, or —S(O)2Ra; wherein said —C1-C6alkyl, —C2-C6alkenyl, —C1-C6alkoxy, or -cycloalkyl is optionally substituted;
- each R1 is independently -D, -halo, —CN, —NO2, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —ORa, —SRa, —NRcRd, —C(O)Rb, —OC(O)Rb, —C(O)ORa, —C(O)NRcRd, —S(O)2Ra; -aryl, -heteroaryl, -cycloalkyl, or -heterocycloalkyl, wherein said —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, -cycloalkyl, -heterocycloalkyl, -aryl, or -heteroaryl is optionally substituted;
- each R2, R2A, or R2a is independently H, D, halo, ORa, optionally substituted C1-C6alkyl, or R2 and R2A that are attached to the same carbon atom may, together with the carbon atom to which they are both attached, form an optionally substituted cycloalkyl ring;
- each R2B and R2C is independently H, D, optionally substituted C1-C6alkyl, or R2B and R2C may, together with the carbon atom to which they are both attached, form an optionally substituted cycloalkyl ring;
- R3 is H, D, —C1-C6alkyl, —C3-C6alkenyl, —C3-C6alkynyl, cycloalkyl, heterocycloalkyl, C(O)Rb, C(O)ORa, or C(O)NRcRd; wherein said C1-C6alkyl, —C3-C6alkenyl, —C3-C6alkynyl, cycloalkyl, or heterocycloalkyl is optionally substituted; or R3 is —C1-C6alkyl substituted at the C1 carbon atom with —OR3A wherein R3A is C1-C6alkyl, —PO3H, —C(O)OR2C, or —C(O)NR3AR3B wherein R3A and R3B are each independently H, D, optionally substituted C1-C6alkyl;
- each R4 or R7 is independently H, D, halo, —OH, —CN, —NO2, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, —ORa, —SRa, —NRcRd, —NRaRc, —C(O)Rb, —OC(O)Ra, —C(O)ORa, —C(O)NRcRd, —S(O)Rb, or —S(O)2Rb, wherein said C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkenyl, or heterocycloalkyl is optionally substituted;
- each R4A or R4B is independently H, D, -Me, —CF3 or —F;
- each R5 or R8 is independently H, D, fluoro, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —C(O)Rb, —C(O)ORa, —C(O)NRcRd, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein said C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted;
- or R4 and R5 together with the C atom to which they are attached form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted;
- or an R4 and an R5 attached to adjacent carbon atoms, together with the C atoms to which they are attached, form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted;
- or R7 and R8 together with the C atom to which they are both attached form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted, each optionally substituted;
- or an R7 and an R8 attached to adjacent carbon atoms, together with the C atoms to which they are attached, form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted;
- each R6 or R9 is independently H, D, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —OC1-C6alkyl, —C(O)Rb, —C(O)ORa, —C(O)NRcRd, —S(O)Rb or —S(O)2Rb, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group, wherein said C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —OC1-C6alkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, is optionally substituted;
- or R9 together with an R7 or an R8 forms an optionally substituted heterocyclic alkylene;
- each R6A, R6B, R9A, or R9B is independently H, D, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein said C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted;
- or R6A and R6B together with the N atoms to which they are attached form an optionally substituted heterocycloalkyl or heterocycloalkenyl ring;
- or R9A and R9B together with the N atoms to which they are attached form an optionally substituted heterocycloalkyl or heterocycloalkenyl ring; each Ra is independently H, D, —C(O)Rb, —C(O)ORc, —C(O)NRcRd, —P(ORc)2, —P(O)RcRb, —P(O)ORcORb, —S(O)Rb, —S(O)NRcRd, —S(O)2Rb, —S(O)2NRcRd, —B(ORc)(ORb), SiRb 3, —C1-C10alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl wherein said C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted;
- each Rb, is independently H, D, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl wherein said —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, aryl, cycloalkyl, cycloalkeneyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted;
- each Rc or Rd is independently H, D, —C1-C10 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —OC1-C6alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein said C1-C10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, —OC1-C6alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl are each optionally substituted;
- or Rc and Rd, together with the N atom to which they are both attached, form an optionally substituted monocyclic or multicyclic heterocycloalkyl, or optionally substituted monocyclic or multicyclic heterocycloalkenyl group.
- Stereoisomers of the compounds of Formula I and the pharmaceutical salts and solvates thereof, are also contemplated, described, and encompassed herein. Methods of using compounds of Formula I are described, as well as pharmaceutical compositions including the compounds of Formula I.
-
FIG. 1 shows an ORTEP representation of the compound of Example 34. - The disclosure may be more fully appreciated by reference to the following description, including the following definitions and examples. Certain features of the disclosed compositions and methods which are described herein in the context of separate aspects, may also be provided in combination in a single aspect. Alternatively, various features of the disclosed compositions and methods that are, for brevity, described in the context of a single aspect, may also be provided separately or in any subcombination.
- The term “alkyl,” when used alone or as part of a substituent group, refers to a straight- or branched-chain hydrocarbon group having from 1 to 12 carbon atoms (“C1-C12”), preferably 1 to 6 carbons atoms (“C1-C6”), in the group. Examples of alkyl groups include methyl (Me, C1alkyl), ethyl (Et, C2alkyl), n-propyl (C3alkyl), isopropyl (C3alkyl), butyl (C4alkyl), isobutyl (C4alkyl), sec-butyl (C4alkyl), tert-butyl (C4alkyl), pentyl (C5alkyl), isopentyl (C5alkyl), tert-pentyl (C5alkyl), hexyl (C6alkyl), isohexyl (C6alkyl), and the like.
- The term “haloalkyl,” when used alone or as part of a substituent group, refers to a straight- or branched-chain hydrocarbon group having from 1 to 12 carbon atoms (“C1-C12”), preferably 1 to 6 carbons atoms (“C1-C6”), in the group, wherein one or more of the hydrogen atoms in the group have been replaced by a halogen atom. Examples of haloalkyl groups include trifluoromethyl (—CF3, C1haloalkyl), trifluoroethyl (—CH2CF3, C2haloalkyl), and the like.
- The term “alkylene” when used alone or as part of a substituent group, refers to an alkyl diradical, i.e., a straight- or branched-chain hydrocarbon group having from 1 to 12 carbon atoms (“C1-C12”), preferably 1 to 6 carbons atoms (“C1-C6”), in the group, wherein the group is directly attached to two other variable groups.
- As used herein, “cycloalkyl” refers to non-aromatic cyclic hydrocarbons including cyclized alkyl and/or alkenyl groups. Cycloalkyl groups thus also encompass cycloalkenyl groups. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2 fused rings) groups, spirocycles, and bridged rings (e.g., a bridged bicycloalkyl group). Ring-forming carbon atoms of a cycloalkyl group can be optionally substituted by oxo or sulfido (e.g., C(O) or C(S)). Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo or thienyl derivatives of cyclopentane, cyclohexane, and the like. A cycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring. Cycloalkyl groups can have 3, 4, 5, 6, 7, 8, 9, or 10 ring-forming carbons (C3-10). In some embodiments, the cycloalkyl is a C3-10 monocyclic or bicyclic cyclocalkyl. In some embodiments, the cycloalkyl is a C3-10 monocyclic or bicyclic cycloalkyl which is optionally substituted by CH2F, CHF2, CF3, and CF2CF3. In some embodiments, the cycloalkyl is a C3-7 monocyclic cycloalkyl. In some embodiments, the cycloalkyl is a C4-10 spirocycle or bridged cycloalkyl. Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, cubane, adamantane, bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, bicyclo[2.2.2]octanyl, spiro[3.3]heptanyl, and the like. In some embodiments, cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, cycloalkyl are cyclic-containing, non-aromatic hydrocarbon groups having from 3 to 12 carbon atoms (“C3-C12”), preferably from 3 to 6 carbon atoms (“C3-C6”). Examples of cycloalkyl groups include, for example, cyclopropyl (C3; 3-membered), cyclobutyl (C4; 4-membered), cyclopropylmethyl (C4), cyclopentyl (C5), cyclohexyl (C6), 1-methylcyclopropyl (C4), 2-methylcyclopentyl (C4), adamantanyl (C10), and the like.
- The term “cycloalkylene” when used alone or as part of a substituent group refers to a cycloalkyl diradical, i.e., a cyclic-containing, non-aromatic hydrocarbon group having from 3 to 14 carbon atoms (“C3-C14”; or 3-14 membered), for example 3 to 12 carbon atoms (“C3-C12”), preferably from preferably from 3 to 7 carbon atoms (“C3-C7”, or 3-7 membered) or 3 to 6 carbon atoms (“C3-C6”), wherein the group is directly attached to two other variable groups. Cycloalkylene groups include spirocycloalkylene groups.
- The term “cycloalkenylene” refers to a cycloalkenylene diradical.
- The term “spirocycloalkyl” when used alone or as part of a substituent group refers to a non-aromatic hydrocarbon group containing two cycloalkyl rings, and wherein the two cycloalyl rings share a single carbon atom in common.
- The term “spirocycloalkylene” when used alone or as part of a substituent group refers to a spirocycloalkyl diradical, i.e., a non-aromatic hydrocarbon group containing two cycloalkyl rings, and wherein the two cycloalyl rings share a single carbon atom in common, and wherein the group is directly attached to two other variable groups.
- As used herein, “heterocycloalkyl” refers to monocyclic or polycyclic heterocycles having at least one non-aromatic ring (saturated or partially unsaturated ring), wherein one or more of the ring-forming carbon atoms of the heterocycloalkyl is replaced by a heteroatom selected from N, O, S and B, and wherein the ring-forming carbon atoms and heteroatoms of the heterocycloalkyl group can be optionally substituted by one or more oxo or sulfido (e.g., C(O), S(O), C(S), or S(0)2, etc.). Heterocycloalkyl groups include monocyclic and polycyclic (e.g., having 2 fused rings) systems. Included in heterocycloalkyl are monocyclic and polycyclic 3-10, 4-10, 3-7, 4-7, and 5-6 membered heterocycloalkyl groups. Heterocycloalkyl groups can also include spirocycles and bridged rings (e.g., a 5-10 membered bridged biheterocycloalkyl ring having one or more of the ring-forming carbon atoms replaced by a heteroatom independently selected from N, O, S and B). The heterocycloalkyl group can be attached through a ring-forming carbon atom or a ring-forming heteroatom. In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds. In some embodiments, the heterocycloalkyl group contains 0 to 2 double bonds. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the non-aromatic heterocyclic ring, for example, benzo or thienyl derivatives of piperidine, morpholine, azepine, etc. A heterocycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring. In some embodiments, the heterocycloalkyl group contains 3 to 10 ring-forming atoms, 4 to 10 ring-forming atoms, 3 to 7 ring-forming atoms, or 5 to 6 ring-forming atoms. In some embodiments, the heterocycloalkyl group has 1 to 4 heteroatoms, 1 to 3 heteroatoms, 1 to 2 heteroatoms or 1 heteroatom. In some embodiments, the heterocycloalkyl is a monocyclic 4-6 membered heterocycloalkyl having 1 or 2 heteroatoms independently selected from N, O, S and B and having one or more oxidized ring members. Example heterocycloalkyl groups include pyrrolidin-2-one, 1,3-isoxazolidin-2-one, pyranyl, tetrahydropyran, oxetanyl, azetidinyl, morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, azepanyl, benzazapene, 1,2,3,4-tetrahydroisoquinoline, azabicyclo[3.1.O]hexanyl, diazabicyclo[3.1.O]hexanyl, oxabicyclo[2.1.l]hexanyl, azabicyclo[2.2.l]heptanyl, diazabicyclo[2.2.1]heptanyl, azabicyclo[3.1.1]heptanyl, diazabicyclo[3.1.l]heptanyl, azabicyclo[3.2.l]octanyl, diazabicyclo[3.2.1]octanyl, oxabicyclo[2.2.2]octanyl, azabicyclo[2.2.2]octanyl, azaadamantanyl, diazaadamantanyl, oxa-adamantanyl, azaspiro[3.3]heptanyl, diazaspiro[3.3]heptanyl, oxa-azaspiro[3.3]heptanyl, azaspiro[3.4]octanyl, diazaspiro[3.4]octanyl, oxa-azaspiro[3.4]octanyl, azaspiro[2.5]octanyl, diazaspiro[2.5]octanyl, azaspiro[4.4]nonanyl, diazaspiro[4.4]nonanyl, oxa-azaspiro[4.4]nonanyl, azaspiro[4.5]decanyl, diazaspiro[4.5]decanyl, diazaspiro[4.4]nonanyl, oxa-diazaspiro[4.4]nonanyl and the like.
- In some embodiments, heterocycloalkyl refers to any three to ten membered monocyclic or bicyclic, saturated ring structure containing at least one heteroatom selected from the group consisting of O, N and S. The heterocycloalkyl group may be attached at any heteroatom or carbon atom of the ring such that the result is a stable structure. Examples of suitable heterocycloalkyl groups include, but are not limited to, azepanyl, aziridinyl, azetidinyl, pyrrolidinyl, dioxolanyl, imidazolidinyl, pyrazolidinyl, piperazinyl, piperidinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, oxazepanyl, oxiranyl, oxetanyl, quinuclidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperazinyl, and the like.
- The term “heterocycloalkylene” when used alone or as part of a substituent group refers to a heterocycloalkyl diradical. In some embodiments heterocycloalkylene any three to ten membered monocyclic or bicyclic, saturated ring structure containing at least one heteroatom selected from the group consisting of O, N and S, wherein the ring structure is directly attached to two other variable groups.
- In some embodiments, the term “spiroheterocycloalkyl” when used alone or as part of a substituent group refers to a non-aromatic group containing two rings, at least one of which is a heterocycloalkyl ring, and wherein the two rings share a single carbon atom in common.
- In some embodiments, the term “spirocycloalkylene” when used alone or as part of a substituent group refers to a spirocycloalkyl diradical. In some embodiments, spirocycloalkylene is a non-aromatic group containing two rings, at least one of which is a heterocycloalkyl ring, and wherein the two rings share a single carbon atom in common, and wherein the group is directly attached to two other variable groups.
- The term “alkenyl” when used alone or as part of a substituent group refers to a straight- or branched-chain group having from 2 to 12 carbon atoms (“C2-C12”), preferably 2 to 4 carbons atoms (“C2-C4”), in the group, wherein the group includes at least one carbon-carbon double bond. Examples of alkenyl groups include vinyl (—CH═CH2; C2alkenyl), allyl (—CH2—CH═CH2; C3alkenyl), propenyl (—CH═CHCH3; C3alkenyl); isopropenyl (—C(CH3)═CH2; C3alkenyl), butenyl (—CH═CHCH2CH3; C4alkenyl), sec-butenyl (—C(CH3)═CHCH3; C4alkenyl), iso-butenyl (—CH═C(CH3)2; C4alkenyl), 2-butenyl (—CH2CH═CHCH3; C4alkyl), pentenyl (CH═CHCH2CH2CH3 or CH2═CHCH2CH2CH2—; C5alkenyl), and the like.
- The term “alkenylene” when used alone or as part of a substituent group refers to a alkenyl diradical, i.e., a straight- or branched-chain group having from 2 to 12 carbon atoms (“C2-C12”), preferably 2 to 4 carbons atoms (“C2-C4”), in the group, wherein the group includes at least one carbon-carbon double bond, and wherein the group is directly attached to two other variable groups.
- The term “alkynyl” when used alone or as part of a substituent group refers to a straight- or branched-chain group having from 2 to 12 carbon atoms (“C2-C12”), preferably 2 to 4 carbons atoms (“C2-C4”), in the group, wherein the group includes at least one carbon-carbon triple bond. Examples of alkynyl groups include ethynyl (—C≡CH; C2alkynyl), propragyl (—CH2—CH═CH; C3alkynyl), and the like.
- The term “alkynylene” when used alone or as part of a substituent group refers to an alkynyl diradical, i.e., a straight- or branched-chain group having from 2 to 12 carbon atoms (“C2-C12”), preferably 2 to 4 carbons atoms (“C2-C4”), in the group, wherein the group includes at least one carbon-carbon triple bond, and wherein the group is directly attached to two other variable groups.
- The term “aryl” when used alone or as part of a substituent group refers to a monocyclic all carbon aromatic ring or a multicyclic all carbon ring system wherein the rings are aromatic. Thus, aryl also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 aryl rings) having about 9 to 14 carbon atoms. In some embodiments, “aryl” refers to a mono- or bicyclic-aromatic hydrocarbon ring structure having 6 or 10 carbon atoms in the ring, wherein one or more of the carbon atoms in the ring is optionally substituted. Exemplary substituents include halogen atoms, —C1-C3 alkyl groups, and C1-C3haloalkyl groups. Halogen atoms include chlorine, fluorine, bromine, and iodine. C1-C3haloalkyl groups include, for example, —CF3, —CH2CF3, and the like.
- The term “arylene” when used alone or as part of a substituent group refers to an aryl diradical. In some embodiments, “arylene” refers to a mono- or bicyclic-aromatic hydrocarbon ring structure having 6 or 10 carbon atoms in the ring, wherein one or more of the carbon atoms in the ring is optionally substituted, and wherein the ring structure is directly attached to two other variable groups.
- The term “heteroaryl” when used alone or as part of a substituent group, the term “heteroaryl” as used herein refers to a monocyclic aromatic ring that has at least one atom other than carbon in the ring, wherein the atom is selected from the group consisting of oxygen, nitrogen and sulfur; “heteroaryl” also includes multicyclic ring systems that have at least one such aromatic ring. Thus, “heteroaryl” includes single aromatic rings of from about 1 to 6 carbon atoms and about 1-4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur. The sulfur and nitrogen atoms may also be present in an oxidized form provided the ring is aromatic. “Heteroaryl” also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) wherein a heteroaryl group is condensed with one or more rings selected from heteroaryls or aryls. Thus, a heteroaryl (a single aromatic ring or multiple condensed ring system) has about 1-20 carbon atoms and about 1-6 heteroatoms within the heteroaryl ring system. A heteroaryl (a monocyclic aromatic ring or multicyclic condensed ring system) can also have about 5 to 12 or about 5 to 10 members within the heteroaryl ring. The rings of a multicyclic ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. In some embodiments, “heteroaryl” refers to a mono- or bicyclic-aromatic ring structure including carbon atoms as well as up to four heteroatoms selected from nitrogen, oxygen, and sulfur. In such embodiments, heteroaryl rings can include a total of 5, 6, 9, or 10 ring atoms. The heteroaryl moiety can be optionally substituted. Exemplary substituents include halogen atoms; —C1-C3 alkyl groups, and C1-C3haloalkyl groups. Halogen atoms include chlorine, fluorine, bromine, and iodine.
- The term “heteroarylene” when used alone or as part of a substituent group refers to a heteroaryl diradical. In some embodiments, heteroarylene is a mono- or bicyclic-aromatic ring structure including carbon atoms as well as up to four heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the ring structure is directly attached to two other variable groups.
- The term “halo” refers to a halogen substituent (i.e., —F, —Cl, —Br, or —I).
- The term “oxo” refers to an oxygen substituent that is connected by a double bond (i.e., ═O).
- The term “alkoxy” when used alone or as part of a substituent group refers to an oxygen radical attached to an alkyl group by a single bond. Examples of alkoxy groups include methoxy (—OCH3), ethoxy (—OCH2CH3), isopropoxy (—OCH(CH3)2) and the like.
- The term “haloalkoxy” when used alone or as part of a substituent group refers to an oxygen radical attached to a haloalkyl group by a single bond. Examples of haloalkoxy groups include —OCF3, —OCH2CF3, —OCH(CF3)2, and the like.
- When a range of carbon atoms is used herein, for example, C1-C6, all ranges, as well as individual numbers of carbon atoms are encompassed. For example, “C1-C3” includes C1-C3, C1-C2, C2-C3, C1, C2, and C3.
- The term “C1-C6alk” when used alone or as part of a substituent group refers to an aliphatic linker having 1, 2, 3, 4, 5, or 6 carbon atoms and includes, for example, —CH2—, —CH(CH3)—, —CH(CH3)—CH2—, and —C(CH3)2—. The term “—C0alk-” refers to a bond. In some aspects, the C1-C6alk can be substituted with one or more substituents.
- In some embodiments wherein a group is described as “optionally substituted” (e.g., when a C1-C6alkyl, —C1-C6alkylene-, C1-C10 alkyl, —C2-C10alkenyl, —C2-C10alkynyl, —C2-C6 alkenylene-, —C2-C6 alkynylene-, cycloalkyl, cycloalkylene, heterocycloalkyl, heterocycloalkylene, aryl, arylene, heteroaryl, or heteroarylene group is optionally substituted), the optional substituent may be one or more of D, halo, oxo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkyl-NRc1Rd1, —(CH2CH2O)oC1-C6alkyl wherein o is 1-10; C2-6 alkenyl-NRc1Rd1, C2-6 alkynyl-NRc1Rd1, OC2-6 alkyl-NRc1Rd1, CN, NO2, N3, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, —CH2C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, —NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(═NRg1)NRc1Rd1, NRc1C(═NRg1)NRc1Rd1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rb1, >SO(═NRb1); S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2Rb1, S(O)2NRc1Rd1; aryl, heteroaryl, spirocycloalkyl, spiroheterocycloalkyl, cycloalkyl, or heterocycloalkyl, wherein the aryl, heteroaryl, spirocycloalkyl, spiroheterocycloalkyl, cycloalkyl, or heterocycloalkyl are optionally substituted with D, halo, oxo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkyl-NRc1Rd1, C2-6 alkenyl-NRc1Rd1, C2-6 alkynyl-NRc1Rd1, OC2-6 alkyl-NRc1Rd1, CN, NO2, N3, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, —CH2C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, —NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(═NRg1)NRc1Rd1, NRc1C(═NRg1)NRc1Rd1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2Rb1, S(O)2NRc1Rd1.
- In these optional substituents, each Ra1 is independently H, D, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, wherein said C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6haloalkoxy.
- In these optional substituents each Rb1 is independently H, D, C1-C6alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, wherein said C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6haloalkoxy.
- In these optional substituents Rc1 or Rd1 is independently H, C1-C10 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylcycloalkyl, arylheterocycloalkyl, arylheteroaryl, biaryl, heteroarylcycloalkyl, heteroarylheterocycloalkyl, heteroaryl aryl, and biheteroaryl, wherein said C1-C10 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylcycloalkyl, arylheterocycloalkyl, arylheteroaryl, biaryl, heteroarylcycloalkyl, heteroarylheterocycloalkyl, heteroaryl aryl, and biheteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxyalkyl, cyanoalkyl, aryl, heteroaryl, C(O)ORa1, C(O)Rb1, S(O)2Rb1, alkoxyalkyl, and alkoxyalkoxy;
- Alternatively, in some embodiments, these optional substituents Rc2 and Rd2 together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxyalkyl, cyanoalkyl, aryl, heteroaryl, C(O)ORa1, C(O)Rb1, S(O)2Rb1, alkoxyalkyl, and alkoxyalkoxy;
- In these optional substituents Re1 is independently H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, (C1-C6 alkoxy)-C1-C6 alkyl, C2-C6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl.
- In these optional substituents Rf1 is independently H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl.
- In these optional substituents Rg1 is independently H, CN, or NO2.
- “Pharmaceutically acceptable” means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, e.g., in humans.
- “Pharmaceutically acceptable salt” refers to a salt of a compound of the disclosure that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. In particular, such salts are non-toxic may be inorganic or organic acid addition salts and base addition salts. Specifically, such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxy ethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine and the like. Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the compound contains a basic functionality, salts of non-toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.
- A “pharmaceutically acceptable excipient” refers to a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith. Examples of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
- A “solvate” refers to a physical association of a compound of Formula I with one or more solvent molecules.
- “Subject” includes humans. The terms “human,” “patient,” and “subject” are used interchangeably herein.
- “Treating” or “treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (i.e., arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, “treating” or “treatment” refers to delaying the onset of the disease or disorder.
- “Compounds of the present disclosure,” and equivalent expressions, are meant to embrace compounds of Formula I or Formula II as described herein, as well as their respective subgenera, which expression includes the stereoisomers (e.g., entaniomers, diastereomers) and constitutional isomers (e.g., tautomers) of compounds of Formula I or Formula II as well as the pharmaceutically acceptable salts, where the context so permits.
- As used herein, the term “isotopic variant” refers to a compound that contains proportions of isotopes at one or more of the atoms that constitute such compound that is greater than natural abundance. For example, an “isotopic variant” of a compound can be radiolabeled, that is, contain one or more radioactive isotopes, or can be labeled with non-radioactive isotopes such as for example, deuterium (2H or D), carbon-13 (13C), nitrogen-15 (15N), or the like. It will be understood that, in a compound where such isotopic substitution is made, the following atoms, where present, may vary, so that for example, any hydrogen may be 2H/D, any carbon may be 13C, or any nitrogen may be 15N, and that the presence and placement of such atoms may be determined within the skill of the art.
- It is also to be understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers.” Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers,” for example, diastereomers, enantiomers, and atropisomers. The compounds of this disclosure may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)-stereoisomers at each asymmetric center, or as mixtures thereof. Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include all stereoisomers and mixtures, racemic or otherwise, thereof. Where one chiral center exists in a structure, but no specific stereochemistry is shown for that center, both enantiomers, individually or as a mixture of enantiomers, are encompassed by that structure. Where more than one chiral center exists in a structure, but no specific stereochemistry is shown for the centers, all enantiomers and diastereomers, individually or as a mixture, are encompassed by that structure. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art.
- In some aspects, the disclosure is directed to a compound of Formula I:
- or a pharmaceutically acceptable salt or solvate thereof.
- In some aspects, Z in Formula I is CH or N. In some embodiments, Z is CH. In other embodiments, Z is N.
- In some aspects, Q in Formula I is —O—, —S—, —S(O)—, or —S(O)2—. In some embodiments, Q is —O—. In some embodiments, Q is —S—. In some embodiments, Q is —S(O)—. In some embodiments, Q is —S(O)2—.
- In some aspects, the moiety -W1-W2-W3 in Formula I is —CR2R2A—CR2R2A—CR2R2A—, —O—CR2BR2C—CR2R2A—, —CR2R2A—CR2BR2C—O—, —NR2B—CR2BR2C—CR2R2A—, —CR2R2A—CR2BR2C— NR2B—, —S—CR2BR2C—CR2R2A, or —CR2R2A—CR2BR2C—S—.
- In some embodiments, the moiety -W1-W2-W3 in Formula I is —CR2R2A—CR2R2A—CR2R2A—. In some embodiments, the moiety -W1-W2-W3 in Formula I is —O—CR2BR2C—CR2R2A—. In some embodiments, the moiety -W1-W2-W3 in Formula I —CR2R2A—CR2BR2C—O—. In some embodiments, the moiety -W1-W2-W3 in Formula I is —NR2B—CR2BR2C—CR2R2A—. In some embodiments, the moiety -W1-W2-W3 in Formula I —CR2R2A—CR2BR2C— NR2B In some embodiments, the moiety -W1-W2-W3 in Formula I is —S—CR2BR2C—CR2R2A. In some embodiments, the moiety -W1-W2-W3 in Formula I is —CR2R2A—CR2BR2C—S—.
- In some aspects, L1 in Formula I is absent, or is —C1-C6alkylene-, for example, —C1alkylene, —C2alkylene, —C3alkylene, —C4alkylene, —C5alkylene, or —C6alkylene, wherein the C1-C6alkylene is optionally substituted. In some embodiments, L1 in Formula I is —C1-C6alkylene-, for example, —C1alkylene, —C2alkylene, —C3alkylene, —C4alkylene, —C5alkylene, or —C6alkylene, wherein the C1-C6alkylene is optionally substituted. In some embodiments, L1 in Formula I is optionally substituted —C1alkylene. In some embodiments, L1 in Formula I is —CH2—.
- In some aspects, L2 in Formula I is optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, or optionally substituted heteroaryl ene.
- In some embodiments, L2 in Formula I is 3-7 membered cycloalkylene, 4-7 membered heterocycloalkylene, arylene, or heteroarylene; each optionally substituted.
- In some embodiments, L2 is optionally substituted cycloalkylene or optionally substituted heterocycloalkylene.
- In some embodiments, L2 is optionally substituted cyclobutylene or optionally substituted pyrrolidinyl.
- In some embodiments, L2 in Formula I is 3-7 membered cycloalkylene, for example, 3-membered cycloalkylene, 4-membered cycloalkylene, 5-membered cycloalkylene, 6-membered cycloalkylene, or 7-membered cycloalkylene. In some embodiments, L2 is 4-membered cycloalkylene. In some embodiments, L2 is cyclobutylenyl.
- In some embodiments, L2 in Formula I is 4-7 membered heterocycloalkylene, for example, 4-membered heterocycloalkylene, 5-membered heterocycloalkylene, 6-membered heterocycloalkylene, or 7-membered heterocycloalkylene. In some embodiments, L2 in Formula I is 5-membered heterocycloalkylene. In some embodiments, L2 is pyrrolidinyl.
- In other embodiments, L2 in Formula I is heteroarylene. In some embodiments, the heteroarylene is pyrazolyl.
- In some aspects, L3 in Formula I is absent, or is —(CR4R5)p—, —(CR4R5)pO—, —O—, —S—, —S(O)—, —S(O)2—, —C(═O)—, —NR6—, —OC(═O)—, —C(═O)O—, —NR6AC(O)—, —C(═O)NR6A—, —OC(═O)N(R6A)—, —NR6AC(O)O—, —S(═O)NR6A—, —NR6AS(O)—, —S(═O)2NR6A—, or —NR6AS(O)2—.
- In some embodiments, L3 in Formula I is absent. In some embodiments, L3 is —(CR4R5)p—. In some embodiments, L3 is —(CR4R5)pO—. In some embodiments, L3 is —O—. In some embodiments, L3 is —S—. In some embodiments, L3 is —S(O)—. In some embodiments, L3 is —S(O)2—. In some embodiments, L3 is —C(═O)—. In some embodiments, L3 is —NR6—. In some embodiments, L3 is —OC(═O)—. In some embodiments, L3 is —C(═O)O—. In some embodiments, L3 is —NR6AC(O). In some embodiments, L3 is —C(═O)NR6A—. In some embodiments, L3 is —OC(═O)N(R6A)—. In some embodiments, L3 is —NR6AC(O)O—. In some embodiments, L3 is —S(═O)NR6A—. In some embodiments, L3 is —NR6AS(O)—. In some embodiments, L3 is —S(═O)2NR6A—. In some embodiments, L3 is —NR6AS(O)2—.
- In some aspects, L4 in Formula I is absent, or is —(CR4R5)pQ1(CR4R5)q—, wherein Q1 is absent, —CR4A═CR4B—, —O—, —S—, —S(O)—, —S(O)2—, —C(═O)—, —NR6—, —OC(═O)—, —C(═O)O—, —NR6AC(O)—, —C(═O)NR6A—, —NR6AC(O)R6B—, —OC(═O)N(R6A)—, —NR6AC(O)O—, —S(═O)NR6A—, —NR6AS(O)—, —S(═O)2NR6A—, or —NR6AS(O)2—; or is —(CR4R5)p—(CR4A═CR4B)—(CR4R5)q—O—.
- In some embodiments, L4 in Formula I is absent. In other embodiments, L4 in Formula I is —(CR4R5)p—(CR4A═CR4B)—(CR4R5)q—. In other embodiments, L4 in Formula I is —(CR4R5)p—O—(CR4R5)q—. In other embodiments, L4 in Formula I is —(CR4R5)p—S—(CR4R5)q—. In other embodiments, L4 in Formula I is —(CR4R5)p—S(O)—(CR4R5)q—. In other embodiments, L4 in Formula I is —(CR4R5)p—S(O)2—(CR4R5)q—. In other embodiments, L4 in Formula I is —(CR4R5)p—C(═O)—(CR4R5)q—. In other embodiments, L4 in Formula I is —(CR4R5)p—NR6—(CR4R5)q—. In other embodiments, L4 in Formula I is —(CR4R5)p—OC(═O)—(CR4R5)q—. In other embodiments, L4 in Formula I is —(CR4R5)p—C(═O)O—(CR4R5)q—. In other embodiments, L4 in Formula I is —(CR4R5)p—NR6AC(O)—(CR4R5)q—. In other embodiments, L4 in Formula I is —(CR4R5)p—C(═O)NR6A—(CR4R5)q—. In other embodiments, L4 in Formula I is —(CR4R5)p—NR6AC(O)R6B—CR4R5)q—. In other embodiments, L4 in Formula I is —(CR4R5)p—OC(═O)N(R6A)—(CR4R5)q—. In other embodiments, L4 in Formula I is —(CR4R5)p—NR6AC(O)O—(CR4R5)q—. In other embodiments, L4 in Formula I is —(CR4R5)p—S(═O)NR6A—(CR4R5)q—. In other embodiments, L4 in Formula I is —(CR4R5)p—NR6AS(O)—(CR4R5)q—. In other embodiments, L4 in Formula I is —(CR4R5)p—S(═O)2NR6A—(CR4R5)q—. In other embodiments, L4 in Formula I is —(CR4R5)p—NR6AS(O)2—(CR4R5)q—. In some embodiments, L4 is —(CR4R5)p—(CR4A═CR4B)—(CR4R5)q—O—.
- In some aspects, L5 in Formula I is absent, or is —C1-C6 alkylene-, —C2-C6 alkenylene-, —C2-C6 alkynylene-, -arylene-, -heteroarylene-, -cycloalkenylene-, -cycloalkylene-, -heterocycloalkylene-, wherein the C1-C6 alkylene, C2-C6 alkenylene, C2-C6 alkynylene, arylene, heteroaryl ene, cycloalkenylene, cycloalkylene, or heterocycloalkylene groups are optionally substituted.
- In some embodiments, L5 in Formula I is absent. In other embodiments, L5 in Formula I is C1-C6 alkylene, for example, C1alkylene, C2alkylene, C3alkylene, C4alkylene, C5alkylene, or C6alkylene, each optionally substituted.
- In other embodiments, L5 in Formula I is C2-C6 alkenylene, for example, C2alkenylene, C3alkenylene, C4alkenylene, C5alkenylene, or C6alkenylene, each optionally substituted.
- In other embodiments, L5 in Formula I is C2-C6 alkynylene, for example, C2alkynylene, C3alkynylene, C4alkynylene, C5alkynylene, or C6alkynylene, each optionally substituted.
- In other embodiments, L5 in Formula I is an optionally substituted arylene. In some embodiments, L5 in Formula I is a 6- to 10-membered arylene, for example phenylene or naphthylene. In some embodiments, L5 in Formula I is a phenylene.
- In other embodiments, L5 in Formula I is an optionally substituted heteroarylene. In some embodiments, L5 in Formula I is a 5- to 10-membered heteroarylene, for example, pyrazolyl, thiazolyl, imidazolyl, or pyridinyl. In some embodiments, L5 in Formula I is pyrazolyl. In other embodiments, L5 in Formula I is thiazolyl. In other embodiments, L5 in Formula I is imidazolyl. In some embodiments, L5 in Formula I is pyridinyl.
- In other embodiments, L5 in Formula I is an optionally substituted cycloalkenylene. In some embodiments, L5 in Formula I is a 3- to 12-membered cycloalkenylene, for example, cyclohexenyl.
- In other embodiments, L5 in Formula I is an optionally substituted cycloalkylene. In some embodiments, L5 in Formula I is a 3- to 7-membered monocyclic cycloalkylene, for example, cyclopentanyl, cyclohexanyl, and the like. In some embodiments, L5 in Formula I is cyclopentanyl.
- In other embodiments, L5 in Formula I is a 6- to 12-membered bicyclic cycloalkylene.
- In other embodiments, L5 in Formula I is an optionally substituted heterocycloalkylene. In some embodiments, L5 in Formula I is an optionally substituted 3- to 7-membered monocyclic heterocycloalkylene group, for example, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, and the like. In some embodiments, L5 in Formula I is pyrrolidinyl. In some embodiments, L5 in Formula I is tetrahydrofuranyl. In some embodiments, L5 in Formula I is piperidinyl. In some embodiments, L5 in Formula I is piperazinyl.
- In other embodiments, L5 in Formula I is an optionally substituted 6- to 12-membered bicyclic heterocycloalkylene group.
- In some embodiments, L5 is absent, or is —C1-C6 alkylene-, —C2-C6 alkenylene-, —C2-C6 alkynylene-, a 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, or 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene group.
- In some aspects, L6 in Formula I is absent, or is (CR7R8)s, (CR7R8)sO(CR7R8)t, (CR7R8)sNR9(CR7R8)t, (CR7R8)sS(CR7R8)t, (CR7R8)sS(O)(CR7R8)t, (CR7R8)sS(O)2(CR7R8)t, (CR7R8)sNR9AC(O)(CR7R8)t, (CR7R8)sOC(O)NR9A(CR7R8)t, (CR7R8)sNR9AC(O)O(CR7R8)t, (CR7R8)sNR9AC(O)NR9B(CR7R8)t, (CR7R8)sNR9AS(O)(CR7R8)t, (CR7R8)sNR9AS(O)2(CR7R8)t; —(CR7R8)s—CR4A═CR4B—(CR7R8)t, (CR7R8)sC(═O)(CR7R8)t; —(CR7R8)sC(═O)(CR7R8)t—O—, or —(CR7R8)sC(═O)(CR7R8)t—NR6—.
- In some embodiments, L6 in Formula I is absent. In other embodiments, L6 in Formula I is (CR7R8)s. In other embodiments, L6 in Formula I is (CR7R8)sO(CR7R8)t. In other embodiments, L6 in Formula I is (CR7R8)sNR9(CR7R8)t. In other embodiments, L6 in Formula I is (CR7R8)sS(CR7R8)t. In other embodiments, L6 in Formula I is (CR7R8)sS(O)(CR7R8)t. In other embodiments, L6 in Formula I is (CR7R8)sS(O)2(CR7R8)t. In other embodiments, L6 in Formula I is (CR7R8)sNR9AC(O)(CR7R8)t. In other embodiments, L6 in Formula I is (CR7R8)sOC(O)NR9A(CR7R8)t. In other embodiments, L6 in Formula I is (CR7R8)sNR9AC(O)O(CR7R8)t. In other embodiments, L6 in Formula I is (CR7R8)sNR9AC(O)NR9B(CR7R8)t. In other embodiments, L6 in Formula I is (CR7R8)sNR9AS(O)(CR7R8)t. In other embodiments, L6 in Formula I is (CR7R8)sNR9AS(O)2(CR7R8)t. In other embodiments, L6 in Formula I is —(CR7R8)s—CR4A═CR4B—(CR7R8)t. In other embodiments, L6 in Formula I is (CR7R8)sC(═O)(CR7R8)t. In other embodiments, L6 in Formula I is —(CR7R8)sC(═O)(CR7R8)t—O—. In other embodiments, L6 in Formula I is —(CR7R8)sC(═O)(CR7R8)t—NR6—.
- In some embodiments, L6 is absent, or is —(CR7R8)s—, —O(CR7R8)t—, —NR9(CR7R8)t—, —S(CR7R8)t—, —S(O)(CR7R8)t—, —S(O)2(CR7R8)t—, —NR9AC(O)(CR7R8)t—, —C(O)NR9A(CR7R8)t—, —R9AC(O)O(CR7R8)t—, —NR9AC(O)NR9B(CR7R8)t—, —NR9AS(O)(CR7R8)t—, —NR9AS(O)2(CR7R8)t—; —CR4A═CR4B—(CR7R8)t—, —C(═O)(CR7R8)t—; —C(═O)(CR7R8)t—O—, or —C(═O)(CR7R8)t—NR6—.
- In some aspects, in Formula I, each n is independently 0-3. In some embodiments, n=0. In other embodiments, n=1. In other embodiments, n=2. In other embodiments, n=3.
- In some aspects, in Formula I, each m is independently 0-2. In some embodiments, m=0. In other embodiments, m=1. In other embodiments, m=2.
- In some aspects, in Formula I, each p is independently 0-4. In some embodiments, p=0. In other embodiments, p=1. In other embodiments, p=2. In other embodiments, p=3. In other embodiments, p=4.
- In some aspects, in Formula I, each q is independently 0-4. In some embodiments, q=0. In other embodiments, q=1. In other embodiments, q=2. In other embodiments, q=3. In yet other embodiments, q=4.
- In some aspects, in Formula I, each s is independently 0-3. In some embodiments, s=0. In other embodiments, s=1. In other embodiments, s=2. In other embodiments, s=3.
- In some aspects, in Formula I, each t is independently 0-4. In some embodiments, t=0. In other embodiments, t=1. In other embodiments, t=2. In other embodiments, t=3. In other embodiments, t=4.
- In some aspects, each R in Formula I is independently -D, -halo, —CN, —NO2, —C1-C6alkyl, —C2-C6alkenyl, —C1-C6alkoxy, -cycloalkyl, —ORa, —SRa, —C(O)Rb, —C(O)ORa, —NRcRd, —C(O)NRcRd, or —S(O)2Ra; wherein said —C1-C6alkyl, —C2-C6alkenyl, —C1-C6alkoxy, or -cycloalkyl is optionally substituted.
- In some embodiments, R is halo, for example, Cl or F. In some embodiments, R is —SRa, for example —SCH3. In other embodiments, R is —C1-C6alkyl, for example —CH3.
- In some aspects, each R1 in Formula I is independently -D, -halo, —CN, —NO2, —C1-C6alkyl, —C1-C6alkenyl, —C1-C6alkynyl, —ORa, —SRa, —NRcRd, —C(O)Rb, —OC(O)Rb, —C(O)ORa, —C(O)NRcRd, —S(O)2Ra; -aryl, -heteroaryl, -cycloalkyl, or -heterocycloalkyl, wherein the —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, -cycloalkyl, -heterocycloalkyl, -aryl, or -heteroaryl is optionally substituted.
- In some embodiments, R1 in Formula I is halo, for example, Cl or F. In other embodiments, R1 in Formula I is —C1-C6alkyl substituted with fluorine, for example —CF3. In other embodiments, R1 in Formula I is —C1-C6alkyl, for example, —C6alkyl, —C5alkyl, —C4alkyl, —C3alkyl, —C2alkyl, —C1alkyl. In some embodiments, R1 in Formula I is —C1 alkyl substituted with —CN. In other embodiments, R1 in Formula I is cycloalkyl, for example, cyclopropane, cyclobutane, cyclopentane, and the like. In other embodiments, R1 in Formula I is cyclopropane substituted with —CN.
- In some aspects, each R2, R2A, or R2a is independently H, D, halo, ORa, optionally substituted C1-C6alkyl, or R2 and R2A that are attached to the same carbon atom may, together with the carbon atom to which they are both attached, form an optionally substituted cycloalkyl ring.
- In some embodiments, R2, R2A, and R2a in Formula I are each H.
- In other embodiments, R2, R2A, or R2a in Formula I is C1-C6alkyl, for example —CH3 or —CH2CH3.
- In other embodiments, R2 and R2A that are attached to the same carbon atom, together with the carbon atom to which they are both attached, form an optionally substituted 3-6 membered cycloalkyl ring. In some embodiments, R2 and R2A that are attached to the same carbon atom, together with the carbon atom to which they are both attached, form a cyclopropane ring.
- In other aspects, R2 and R2a that are attached to the same carbon atom, together with the carbon atom to which they are both attached, form an optionally substituted 3-6 membered cycloalkyl ring. In some embodiments, R2 and R2a that are attached to the same carbon atom, together with the carbon atom to which they are both attached, form a cyclopropane ring.
- In some aspects, each R2B and R2C in Formula I is independently H, D, optionally substituted C1-C6alkyl, or R2B and R2C may, together with the carbon atom to which they are both attached, form an optionally substituted cycloalkyl ring.
- In some embodiments, R2B and R2C in Formula I are each H.
- In other embodiments, R2B and R2C that are attached to the same carbon atom together with the carbon atom to which they are both attached, form a cyclopropane ring.
- In some aspects, R3 in Formula I is H, D, —C1-C6alkyl, —C3-C6alkenyl, —C3-C6alkynyl, cycloalkyl, heterocycloalkyl, C(O)Rb, C(O)ORa, or C(O)NRcRd; wherein said C1-C6alkyl, —C3-C6alkenyl, —C3-C6alkynyl, cycloalkyl, or heterocycloalkyl is optionally substituted; or R3 is —C1-C6alkyl substituted at the C1 carbon atom with —OR3A wherein R3A is C1-C6alkyl, —PO3H, —C(O)OR2C, or —C(O)NR3AR3B wherein R3A and R3B are each independently H, D, optionally substituted C1-C6alkyl.
- In some embodiments, R3 in Formula I is H. In other embodiments, R3 in Formula I is —C1-C6alkyl, for example, C6alkyl, C5alkyl, C4alkyl, C3alkyl, C2alkyl, C1alkyl, —CH3, and the like.
- In some aspects, each R4 or R7 in Formula I is independently H, D, halo, —OH, —CN, —NO2, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, —ORa, —SRa, —NRcRd, —NRaRc, —C(O)Rb, —OC(O)Ra, —C(O)ORa, —C(O)NRcRd, —S(O)Rb, or —S(O)2Rb, wherein said C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl is optionally substituted.
- In some embodiments, R4 is Formula I is H. In some embodiments, R4 is Formula I is —OH. In other embodiments, R4 in Formula I is —C1-C6alkyl, for example, C6alkyl, C5alkyl, C4alkyl, C3alkyl, C2alkyl, C1alkyl, —CH3, and the like. In other embodiments, R4 is Formula I is —ORa, for example, —OCH3.
- In some embodiments, R7 in Formula I is H. In other embodiments, R7 in Formula I is —C1-C6alkyl, for example, C6alkyl, C5alkyl, C4alkyl, C3alkyl, C2alkyl, C1alkyl, —CH3, and the like. In some embodiments, R7 in Formula I is —CH3. In other embodiments, R7 in Formula I is —ORa, for example, —OCH3.
- In some aspects, each R4A or R4B in Formula I is independently H, D, -Me, —CF3 or —F. In some embodiments, R4A is H. In some embodiments, R4B is H.
- In some aspects, each R5 or R8 in Formula I is independently H, D, fluoro, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —C(O)Rb, —C(O)ORa, —C(O)NRcRd, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein the C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted.
- In some embodiments, R5 in Formula I is H. In other embodiments, R5 in Formula I is —C1-C6alkyl, for example, C6alkyl, C5alkyl, C4alkyl, C3alkyl, C2alkyl, C1alkyl, —CH3, and the like. In some embodiments, R5 in Formula I is —CH3.
- In some embodiments, R8 in Formula I is H. In other embodiments, R8 in Formula I is —C1-C6alkyl, for example, C6alkyl, C5alkyl, C4alkyl, C3alkyl, C2alkyl, C1alkyl, —CH3, and the like. In some embodiments, R8 in Formula I is —CH3.
- In some embodiments each R7 and each R8 is independently, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted —C1-C6alkyl.
- In other embodiments, each R7 and each R8 is independently H, optionally substituted 3-7 membered cycloalkyl, 4-7 membered heterocycloalkyl, or optionally substituted —C1-C6alkyl.
- In other embodiments, each R7 and each R8 is independently H, —CH3, -cyclopropyl, —CH2CH3, or —CH(CH3)2.
- In other embodiments, each R7 and each R8 is independently H, or a —C1-C6alkyl group optionally substituted with —OH, optionally substituted —OC1-C6alkyl, optionally substituted —(CH2CH2O)oC1-C6alkyl wherein o is 1-10, or —C(O)NRc1Rd1 wherein Rc1 and Rd1 are independently H, optionally substituted —C1-C6alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl.
- In other embodiments, each R7 and each R8 is independently H, or —C1-C6alkyl group is optionally substituted with —OH, —OC1-C6alkyl, —(CH2CH2O)oC1-C6alkyl wherein o is 1-10, or —C(O)NRc1Rd1 wherein Rc1 and Rd1 are independently H, C1-C6alkyl, or 4-7 membered heterocycloalkyl; or wherein or Rc1 and Rd1, together with the N atom to which they are both attached, form a multicyclic 4-7 membered heterocycloalkyl ring optionally substituted with halo, —OC1-C6alkyl, or —C1-C6alkyl optionally substituted with —OH or —OC1-C6alkyl.
- In some aspects, R4 and R5 together with the C atom to which they are attached form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted.
- In other aspects, R4 and an R5 attached to adjacent carbon atoms, together with the C atoms to which they are attached, form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted.
- In some embodiments, each R7 and each R8 is independently H, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted —C1-C6alkyl; or R7 and R8 attached to the same carbon atom, together with that carbon atom, form an optionally substituted cycloalkyl ring or an optionally substituted heterocycloalkyl ring; or R7 and R8 attached to adjacent carbon atoms, together with those carbon atoms, form an optionally substituted cycloalkyl ring or and optionally substituted heterocycloalkyl ring.
- In some embodiments, each R7 and each R8 is independently H, optionally substituted 3-7 membered cycloalkyl, 4-7 membered heterocycloalkyl, or optionally substituted —C1-C6alkyl; or wherein R7 and R8 attached to the same carbon atom, together with that carbon atom, form an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocycloalkyl ring; or R7 and R8 attached to adjacent carbon atoms, together with those carbon atoms, form an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocycloalkyl ring.
- In some embodiments, R7 and R8 attached to the same carbon atom, together with that carbon atom, form a 3-7 membered cycloalkyl ring or 4-7 membered heterocycloalkyl ring; or R7 and R8 attached to adjacent carbon atoms, together with the atoms to which they are attached, form a 3-7 membered cycloalkyl ring or 4-7 membered heterocycloalkyl ring.
- In some embodiments, R7 or R8 are each independently H, —CH3, -cyclopropyl, —CH2CH3, or —CH(CH3)2.
- In some embodiments, R7 and R8 attached to the same carbon atom, together with that carbon atom, form a cyclopropyl ring, a cyclobutyl ring, or azetidinyl ring.
- In some embodiments, each R7 and each R8 is independently H, or a —C1-C6alkyl group optionally substituted with —OH; optionally substituted —OC1-C6alkyl; optionally substituted —(CH2CH2O)oC1-C6alkyl wherein o is 1-10; or —C(O)NRc1Rd1 wherein Rc1 and Rd1 are independently H, optionally substituted —C1-C6alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl; or wherein or Rc1 and Rd1, together with the N atom to which they are both attached, form an optionally substituted monocyclic or multicyclic heterocycloalkyl ring.
- In some embodiments, the —C1-C6alkyl group is optionally substituted with —OH; —OC1-C6alkyl; —(CH2CH2O)oC1-C6alkyl wherein o is 1-10; or —C(O)NRc1Rd1 wherein Rc1 and Rd1 are independently H, C1-C6alkyl, or 4-7 membered heterocycloalkyl; or wherein or Rc1 and Rd1, together with the N atom to which they are both attached, form a monocyclic or multicyclic 4-7 membered heterocycloalkyl ring optionally substituted with halo; —OC1-C6alkyl; or —C1-C6alkyl optionally substituted with —OH or —OC1-C6alkyl.
- In some aspects, R7 and R8 together with the C atom to which they are both attached form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted, each optionally substituted.
- In some embodiments, R7 and R8 together with the C atom to which they are both attached form a cycloalkyl ring, for example, a cyclopropyl ring, a cyclobutyl ring, or a cyclopentyl ring.
- In some embodiments, R7 and R8 attached to the same carbon atom, together with that carbon atom, form an optionally substituted cycloalkyl ring or an optionally substituted heterocycloalkyl ring.
- In other embodiments, R7 and R8 attached to adjacent carbon atoms, together with those carbon atoms, form an optionally substituted cycloalkyl ring or and optionally substituted heterocycloalkyl ring.
- In other embodiments, R7 and R8 attached to the same carbon atom, together with that carbon atom, form an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocycloalkyl ring;
- In other embodiments, R7 and R8 attached to adjacent carbon atoms, together with those carbon atoms, form an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocycloalkyl ring.
- In other embodiments, R7 and R8 attached to adjacent carbon atoms, together with the atoms to which they are attached, form a 3-7 membered cycloalkyl ring or 4-7 membered heterocycloalkyl ring.
- In other embodiments, R7 and R8 attached to the same carbon atom, together with that carbon atom, form a cyclopropyl ring, a cyclobutyl ring, or azetidinyl ring.
- In some aspects, an R7 and an R8 attached to adjacent carbon atoms, together with the C atoms to which they are attached, form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted.
- In some aspects, each R6 or R9 is independently H, D, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —OC1-C6alkyl, —C(O)Rb, —C(O)ORa, —C(O)NRcRd, —S(O)Rb or —S(O)2Rb, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group, wherein the C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —OC1-C6alkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, is optionally substituted.
- In some embodiments, R6 is H. In other embodiments, R6 is —C1-C6alkyl, for example, —CH3 or —CH2CH3.
- In some embodiments, R9 is H; optionally substituted —C1-C6alkyl; optionally substituted —C(O)OC1-C6alkyl; optionally substituted —SO2C1-C6alkyl; optionally substituted —C(O)C1-C6alkyl; optionally substituted —C(O)NRcRd; or wherein R9 together with either R7 or R8 form an optionally substituted heterocyclic alkylene.
- In some embodiments, R9 is H; —C1-C6alkyl, optionally substituted with deuterium; —C(O)OC1-C6alkyl; —SO2C1-C6alkyl; —C(O)C1-C6alkyl; or wherein R9 together with either R7 or R8 forms an optionally heterocyclic alkylene.
- In other embodiments, R9 is H; —C1-C6alkyl, optionally substituted with deuterium; —C(O)OC1-C6alkyl; —SO2C1-C6alkyl; —C(O)C1-C6alkyl.
- In yet other embodiments, R9 is H; —CH3; —CH2CH3, —CH2CH2CH3, —CD3, —C(O)OCH3; —C(O)OC(CH3)3, —SO2CH3; or —C(O)CH3.
- In some aspects, R9 together with either an R7 or an R8 forms an optionally substituted heterocyclic alkylene. In some embodiments, R9 together with either R7 or R8 form a heterocyclic alkylene. In some embodiments, R9 together with either an R7 or an R8′ forms a C3-C9 heterocyclic alkylene.
- In some aspects, each R6A, R6B, R9A, or R9B in Formula I is independently H, D, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein the C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted.
- In some aspects, R6A and R6B together with the N atoms to which they are attached form an optionally substituted heterocycloalkyl or heterocycloalkenyl ring.
- In some aspects, R9A and R9B together with the N atoms to which they are attached form an optionally substituted heterocycloalkyl or heterocycloalkenyl ring;
- In some aspects, each Ra in Formula I is independently H, D, —C(O)Rb, —C(O)ORc, —C(O)NRcRd, —P(ORc)2, —P(O)RcRb, —P(O)ORcORb, —S(O)Rb, —S(O)NRcRd, —S(O)2Rb, —S(O)2NRcRd, —B(ORc)(ORb), SiRb 3, —C1-C10alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl wherein said C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted.
- In some embodiments, Ra is H, —C(O)Rb, —C(O)NRcRd, optionally substituted C1-C10alkyl, optionally substituted C2-C10alkenyl, optionally substituted C2-C10 alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl
- In some embodiments, Ra is H, —C(O)Rb, —C(O)NRcRd, or optionally substituted C1-C10alkyl.
- In some embodiments, Ra is H.
- In some embodiments, Ra is —C(O)Rb.
- In some embodiments, Ra is —C(O)Rb wherein Rb is optionally substituted —C1-C6alkyl.
- In some embodiments, Ra is —C(O)Rb wherein Rb is —C1-C6alkyl.
- In some embodiments, Ra is —C(O)Rb wherein Rb is —CH3.
- In some embodiments, Ra is —C(O)NRcRd.
- In some embodiments, Ra is —C(O)NRcRd wherein Rc and Rd are independently H; optionally substituted —OC1-C6alkyl; optionally substituted cycloalkyl; optionally substituted —C1-C6alkyl, or optionally substituted heterocycloalkyl.
- In some embodiments, Ra is —C(O)NRcRd wherein Rc and Rd are independently H; optionally substituted 3-7 membered cycloalkyl; —OC1-C6alkyl; or —C1-C6alkyl optionally substituted with deuterium, halo, optionally substituted cycloalkyl, optionally substituted —OC1-C6alkyl, —NRc1Rd1 wherein Rc1 and Rd1 are independently H or optionally substituted —C1-C6alkyl, optionally substituted 4-7 membered heterocycloalkyl, or optionally substituted 5-6 membered heteroaryl; or optionally substituted 4-7 membered heterocycloalkyl.
- In some embodiments, Ra is —C(O)NRcRd wherein Rc and Rd are independently H; 3-7 membered cycloalkyl; —C1-C6alkyl optionally substituted with deuterium, halo, —OC1-C6alkyl, cycloalkyl, —NRc1Rd1 wherein Rc1 and Rd1 are independently H or —C1-C6alkyl, 4-7 membered heterocycloalkyl (optionally substituted with halo, —C1-C6alkyl, —OH, or —OC1-C6alkyl), or -5-6 membered heteroaryl, —OC1-C6alkyl; or -4-7 membered heterocycloalkyl optionally substituted with —C1-C6alkyl or —OH.
- In some embodiments, Ra is —C(O)NRcRd wherein Rc and Rd, together with the nitrogen atom to which they are both attached, form an optionally substituted monocyclic or multicyclic heterocycloalkyl group.
- In some embodiments, Ra is —C(O)NRcRd wherein Rc and Rd, together with the nitrogen atom to which they are both attached, form a monocyclic or multicyclic heterocycloalkyl group optionally substituted with -halo, —OH, optionally substituted -4-7 membered heterocycle, optionally substituted 5-6 membered heteroaryl, optionally substituted —OC1-C6alkyl, optionally substituted —C1-C6alkyl; or —NRc1Rd1 wherein Rc1 and Rd1 are independently H or optionally substituted C1-C6alkyl.
- In some embodiments, Ra is —C(O)NRcRd wherein Rc and Rd, together with the nitrogen atom to which they are both attached, form a monocyclic or multicyclic -4-10 membered heterocycloalkyl group optionally substituted with -halo, —OH, -4-7 membered heterocycle, 5-6 membered heteroaryl, —OC1-C6alkyl, —C1-C6alkyl (optionally substituted with —OH, —OC1-C6alkyl, or NRc1Rd1 wherein Rc1 and Rd1 are independently H or C1-C6alkyl); or —NRc1Rd1 wherein Rc1 and Rd1 are independently H or C1-C6alkyl.
- In some embodiments, Ra is optionally substituted —C1-C10alkyl.
- In some embodiments, Ra is —C1-C10alkyl optionally substituted with —C(O)NRc1Rd1, wherein Rc1 and Rd1 are independently H, optionally substituted C1-C6alkyl, or optionally substituted heterocyclyl; or wherein or Rc1 and Rd1, together with the N atom to which they are both attached, form an optionally substituted monocyclic or multicyclic -4-10 membered heterocycloalkyl group; —NRc1Rd1 wherein Rc1 and Rd1 are independently H, optionally substituted C1-C6alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl; optionally substituted heteroaryl; —C(O)OH; or optionally substituted -heterocycloalkyl.
- In some embodiments, Ra is —C1-C10alkyl optionally substituted with —C(O)NRc1Rd1, wherein Rc1 and Rd1 are independently H, C1-C6alkyl, or 4-7 membered heterocycloalkyl; or wherein or Rc1 and Rd1, together with the N atom to which they are both attached, form a monocyclic or multicyclic -4-10 membered heterocycloalkyl group (optionally substituted with halo, —OC1-C6alkyl, or —C1-C6alkyl optionally substituted with —OH or —OC1-C6alkyl); —NRc1Rd1 wherein Rc1 and Rd1 are independently H, or optionally substituted C1-C6alkyl; —C4-C5heteroaryl; —C(O)OH; or -4-7 membered heterocycloalkyl optionally substituted with halo, C1-C6alkyl, or —OC1-C6alkyl.
- In some embodiments, Ra is —C(O)NRcRd wherein Rc and Rd are independently H; —OCH3, —CH3, —CD3, —CH2CH2OCH3, —CH2CH3, —CH2-cyclopropyl, -cyclobutyl, cyclopropyl, —CH(CH3)2, —CH2—CH(CH3)2, —CH2CH2NH2J—CH2CH2N(CH3)2, —CH2CH2NH(CH3), —CH2CHF2,
- In some embodiments, Ra is —C(O)NRcRd wherein Rc and Rd, together with the nitrogen atom to which they are both attached, are
- In some embodiments, Ra is —C1-C6alkyl optionally substituted with —N(CH3)2, —CO2H, —CONH2, —CON(CH3)(CH2CH2OCH3),
- In some aspects, each Rb in Formula I is independently H, D, —C1-C6 alkyl, —C1-C6 alkenyl, —C2-C6 alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl wherein the —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, aryl, cycloalkyl, cycloalkeneyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted.
- In some aspects, each Rc or Rd in Formula I is independently H, D, —C1-C10 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —OC1-C6alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein the C1-C10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, —OC1-C6alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl are each optionally substituted.
- In some aspects, Rc and Rd, together with the N atom to which they are both attached, form an optionally substituted monocyclic or multicyclic heterocycloalkyl, or optionally substituted monocyclic or multicyclic heterocycloalkenyl group.
- In some embodiments, compounds of Formula I are those having the Formula IA-0:
- In some embodiments, compounds of Formula I are those having the Formula IA:
- In some embodiments, the compounds of Formula IA are those wherein W1 is —CH2— and W3 is —O—, or W1 is —O— and W3 is —CH2—, or W1 is —CH2— and W3 is —S—, or W1 is —S— and W3 is —CH2—, or W1 is —CH2— and W3 is —NR2B—, or W1 is —NR2B— and W3 is —CH2—, or W1 is —CH2— and W3 is —CH2—.
- In other embodiments, the compounds of Formula I are those having Formula IA-1:
- In some embodiments, the compounds of Formula IA-1 are those wherein W1 is —CH2— or —O—.
- In some embodiments, the compounds of Formula I are those having the Formula IA-2:
- In some embodiments, the compound of formula IA-2 are those wherein W3 is —CH2— or —O—.
- In some embodiments, the compounds of Formula I are those of Formula IA-3 wherein W1 is —CH2— and W3 is O, or W1 is —O— and W3 is —CH2—, or W1 is —CH2— and W3 is —CH2—:
- In some embodiments, the compounds of Formula I are compound of Formula IA-4:
- or a pharmaceutically acceptable salt or solvate thereof; wherein W1 is —CH2— and W3 is O, or W1 is —O— and W3 is —CH2—, or W1 is —CH2— and W3 is —CH2-; L3 is absent, or is —(CR4R5)p—; L4 is absent, or —(CR4R5)pQ1(CR4R5)q—, wherein Q1 is absent, —CR4A═CR4B—, —O—, —S—, —S(O)—, —S(O)2—, —C(═O)—, —NR6—, —OC(═O)—, —C(═O)O—, —NR6AC(O), —C(═O)NR6A—, —NR6AC(O)R6B—, —OC(═O)N(R6A)—, —NR6AC(O)O—, —S(═O)NR6A—, —NR6AS(O)—, —S(═O)2NR6A—, or —NR6AS(O)2—; L5 is absent, or is a 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 12-membered cycloalkenylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, a 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene group, wherein the 6- to 10-membered arylene, 5- to 10-membered heteroaryl ene, a 3- to 12-membered cycloalkenylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, a 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene group is optionally substituted; and L6 is absent, or is (CR7R8)s, —O(CR7R8)t, —NR9(CR7R8)t, —S(CR7R8)t, —S(O)(CR7R8)t, —S(O)2(CR7R8)t, —NR9AC(O)(CR7R8)t, —C(O)NR9A(CR7R8)t, —R9AC(O)O(CR7R8)t, —NR9AC(O)NR9B(CR7R8)t, —NR9AS(O)(CR7R8)t, —NR9AS(O)2(CR7R8)t; —CR4A═CR4B—(CR7R8)t, —C(═O)(CR7R8>; —C(═O)(CR7R8)t—O—, or —C(═O)(CR7R8)t—NR6—.
- In some embodiments of the compounds of Formula I or Formula IA-4, L3 absent; L4 is —(CR4R5)pQ1(CR4R5)q—, wherein Q1 is absent, —CR4A═CR4B—, —O—, —S—, —S(O)—, —S(O)2—, —C(═O)—, —NR6—, —OC(═O)—, —C(═O)O—, —NR6AC(O), —C(═O)NR6A—, —NR6AC(O)R6B—, —OC(═O)N(R6A)—, —NR6AC(O)O—, —S(═O)NR6A—, —NR6AS(O)—, —S(═O)2NR6A—, or —NR6AS(O)2—; and L5 is absent.
- In some embodiments of the compounds of Formula I or Formula IA-4, L6 is absent, or is —(CR7R8)s—, —O(CR7R8)t—, —NR9(CR7R8)t—, —S(CR7R8)t—, —S(O)(CR7R8)t—, —S(O)2(CR7R8)t—, —NR9AC(O)(CR7R8)t—, —C(O)NR9A(CR7R8)t—, —R9AC(O)O(CR7R8)t—, —NR9AC(O)NR9B(CR7R8)t—, —NR9AS(O)(CR7R8)t—, —NR9AS(O)2(CR7R8)t—; —CR4A═CR4B—(CR7R8)t—, —C(═O)(CR7R8)t—; —C(═O)(CR7R8)t—O—, or —C(═O)(CR7R8)t—NR6—.
- In other embodiments of the compounds of Formula I or Formula IA-4, Q1 is —CR4A═CR4B—; and L6 is absent, —O(CR7R8)t, or —NR9(CR7R8)t;
- In other embodiments of the compounds of Formula I or Formula IA-4, p=1; q=1-4; and t=1.
- In other embodiments of the compounds for Formula I or Formula IA-4, L3 absent; L4 is —(CR4R5)pQ1(CR4R5)q—, wherein Q1 is absent, —CR4A═CR4B—, —O—, —S—, —S(O)—, —S(O)2—, —C(═O)—, —NR6—, —OC(═O)—, —C(═O)O—, —NR6AC(O), —C(═O)NR6A—, —NR6AC(O)R6B—, —OC(═O)N(R6A)—, —NR6AC(O)O—, —S(═O)NR6A—, —NR6AS(O)—, —S(═O)2NR6A—, or —NR6AS(═O)2—; L5 is a 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 12-membered cycloalkenylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, a 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene group, wherein the 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 12-membered cycloalkenylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, a 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene group is optionally substituted; and L6 is absent, or is (CR7R8)s.
- In other embodiments, the compounds of Formula I or Formula IA-4 are those wherein Q1 is —CR4A═CR4B—, —O—, —S—, —S(O)—, —S(O)2—, —C(═O)—, —OC(═O)—, —C(═O)O—, —OC(═O)N(R6A)—, or —NR6AC(O)O—; L5 is a 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 7-membered monocyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, wherein the 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 7-membered monocyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene is optionally substituted; and L6 is absent, or is (CR7R8)s.
- In some embodiments, the compounds of Formula I or Formula IA-4 are those wherein L4 is —(CR4R5)pQ1(CR4R5)q— wherein p=1; q=1-3, Q1 is absent, or —CR4A═CR4B—; L6 is (CR7R8)s wherein s=1-2, —O(CR7R8)t, —NR9(CR7R8)t, —S(CR7R8)t, —S(O)(CR7R8)t, or —S(O)2(CR7R8)t, wherein t=1.
- In some embodiments, the compounds of Formula I are those of Formula IA-5
- wherein X is O, NR9, CR7R8, S, S(O), SO2; R is halo or C1-C6alkyl; represents a carbon-carbon single bond in which each carbon atom in the bond is substituted with R4 and R5, an (E)-carbon-carbon double bond substituted with R4A and R4B, or a (Z)-carbon-carbon double bond substituted with R4A and R4B; and Ra* is Ra wherein Ra is H, —C(O)Rb, —C(O)ORc, —C(O)NRcRd, P(ORc)2, P(O)RcRb, P(O)ORcORb, S(O)Rb, S(O)NRcRd, S(O)2Rb, S(O)2NRcRd, B(ORc)(ORb), SiRb 3, C1-C10alkyl, C2-C10 alkenyl, C2-C10 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, wherein said C1-C10 alkyl, C2-C10alkenyl, C2-C10 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted.
-
-
- In some embodiments of the compound Formula IA-5, X is O, NR9, or CR7R8.
- In some embodiments of the compound Formula IA-5, Ra* is Ra wherein Ra is H, —C(O)Rb, —C(O)NRcRd, or optionally substituted C1-C10alkyl, optionally substituted C2-C10alkenyl, optionally substituted C2-C10 alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl.
- In some aspects, the compounds of Formula I are those of Formula IA-6:
- or a pharmaceutically acceptable salt or solvate thereof; wherein X is —O—, —NR9—, or —CR7R8—; and W1 is —CH2— and W3 is O, or W1 is —O— and W3 is —CH2—, or W1 is —CH2— and W3 is —CH2; Ra* is Ra.
- In some embodiments, the compounds of Formula IA-6 are those wherein X is —CR7R8—.
- In other embodiments, the compounds of Formula IA-6 are those wherein X is —O—.
- In some embodiments, the compounds of Formula IA-6 are those wherein X is —NR9—.
- In some embodiments X is —NR9— wherein R9 is H; optionally substituted —C1-C6alkyl; optionally substituted —C(O)OC1-C6alkyl; optionally substituted —SO2C1-C6alkyl; optionally substituted —C(O)C1-C6alkyl; optionally substituted —C(O)NRcRd; or wherein R9 together with either R7 or R8 form an optionally substituted C1-C6alkylene group.
- In other embodiments, X is —NR9— wherein R9 is H; —C1-C6alkyl, optionally substituted with deuterium; —C(O)OC1-C6alkyl; —SO2C1-C6alkyl; —C(O)C1-C6alkyl; or wherein R9 together with either R7 or R8 form a C1-C6alkylene group.
- In some embodiments, the compounds of Formula IA-6 are those having the structure (LA-7):
-
- wherein W1 is —CH2— and W3 is —O—; or W1 is —O— and W3 is —CH2—; or W1 is —CH2— and W3 is —CH2—.
- In some embodiments, the compounds of Formula IA-7 are those wherein W1 is —CH2— and W3 is —CH2—.
- In some embodiments, the compounds of Formula I are those of Formula IA-8
- wherein X is O, NR9, CR7R8, S, S(O), SO2; W1 is —CH2— and W3 is O, or W1 is —O— and W3 is —CH2—, or W1 is —CH2— and W3 is —CH2—; is halo or C1-C6alkyl; represents a carbon-carbon single bond in which each carbon atom in the bond is substituted with R4 and R5, an (E)-carbon-carbon double bond, or a (Z)-carbon-carbon double bond; and Ra* is Ra wherein Ra is H, —C(O)Rb, —C(O)ORc, —C(O)NRcRd, P(ORc)2, P(O)RcRb, P(O)ORcORb, S(O)Rb, S(O)NRcRd, S(O)2Rb, S(O)2NRcRd, B(ORc)(ORb), SiRb 3, C1-C10alkyl, C2-C10 alkenyl, C2-C10 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, wherein said C1-C10 alkyl, C2-C10alkenyl, C2-C10 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted; and Rc* is Rc wherein Rc is H, D, —C1-C10 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —OC1-C6alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein said C1-C10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, —OC1-C6alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl are each optionally substituted.
-
-
-
- In some embodiments of the compound of Formula IA-8, Ra* is Ra and Rc* is Rc.
- In other embodiments of the compound Formula IA-8, Ra* is Ra wherein Ra is H, —C(O)Rb, —C(O)ORc, —C(O)NRcRd, —S(O)2Rb, or optionally substituted C1-C10alkyl; and Rc* is Rc wherein Rc is H or optionally substituted C1-C10alkyl.
- In other embodiments of the compound Formula IA-8, R is —Cl.
- In other embodiments of the compound Formula IA-8, each R4 and R5 is independently H or C1-C6alkyl.
- In some embodiments of the compound Formula IA-8, X is O, NR9, or CR7R8.
- In some aspects, the compounds of Formula I are those of Formula IA-9:
- or a pharmaceutically acceptable salt or solvate thereof; wherein X is —O—, —NR9—, or —CR7R8—; and 1 is —CH2— and W3 is O, or W1 is —O— and W3 is —CH2—, or W1 is —CH2— and W3 is —CH2-; Ra* is Ra and Rc* is Rc.
- In other embodiments of the compound Formula IA-9, Ra* is Ra wherein Ra is H, —C(O)Rb, —C(O)ORc, —C(O)NRcRd, —S(O)2Rb, or optionally substituted C1-C10alkyl; and Rc* is Rc wherein Rc is H or optionally substituted C1-C10alkyl.
- In some embodiments, the compounds of Formula IA-9 are those wherein X is —CR7R8—.
- In other embodiments, the compounds of Formula IA-9 are those wherein X is —O—.
- In some embodiments, the compounds of Formula IA-9 are those wherein X is —NR9—.
- In some embodiments, X is —NR9— wherein R9 is H; optionally substituted —C1-C6alkyl; optionally substituted —C(O)OC1-C6alkyl; optionally substituted —SO2C1-C6alkyl; optionally substituted —C(O)C1-C6alkyl; optionally substituted —C(O)NRcRd; or wherein R9 together with either R7 or R8 form an optionally substituted C1-C6alkylene group.
- In other embodiments, X is —NR9— wherein R9 is H; —C1-C6alkyl, optionally substituted with deuterium; —C(O)OC1-C6alkyl; —SO2C1-C6alkyl; —C(O)C1-C6alkyl; or wherein R9 together with either R7 or R8 form a C1-C6alkylene group.
- In some embodiments, the compounds of Formula IA-9 are those having the structure (IA-10):
- In some aspects, the disclosure is directed to compounds of Formula II:
- or a pharmaceutically acceptable salt or solvate thereof.
- In some aspects, Z in Formula II is C or N. In some embodiments, Z is C. In other embodiments, Z is N.
- In some aspects, Q in Formula II is —O—, —S—, —S(O)—, or —S(O)2—. In some embodiments, Q is —O—. In some embodiments, Q is —S—. In some embodiments, Q is —S(O)—. In some embodiments, Q is —S(O)2—.
- In some aspects, the moiety -W1-W2-W3 in Formula II is —CR2R2A—CR2R2A—CR2R2A—, —O—CR2BR2C—CR2R2A—, —CR2R2A—CR2BR2C—O—, —S—CR2BR2C—CR2R2A, or —CR2R2A—CR2BR2C—S—.
- In some embodiments, the moiety -W1-W2-W3 in Formula II is —CR2R2A—CR2R2A—CR2R2A—. In some embodiments, the moiety -W1-W2-W3 in Formula II is —O—CR2BR2C—CR2R2A—. In some embodiments, the moiety -W1-W2-W3 in Formula II —CR2R2A—CR2BR2C—O—. In some embodiments, the moiety -W1-W2-W3 in Formula II is —S—CR2BR2C—CR2R2A. In some embodiments, the moiety -W1-W2-W3 in Formula II is —CR2R2A—CR2BR2C—S—.
- In some aspects, L1 in Formula II is —C1-C6alkylene-, for example, —C1alkylene, —C2alkylene, —C3alkylene, —C4alkylene, —C5alkylene, or —C6alkylene, wherein the C1-C6alkylene is optionally substituted with 1, 2, or 3 substituents independently selected from halo, oxo, CN, ORa1, SRa1, NRc1C(O)Rb1, NRc1C(O)ORa1, and NRc1S(O)2Rb1. In some embodiments, L1 in Formula II is —C1alkylene. In some embodiments, L1 in Formula II is —CH2—.
- In some aspects, L2 in Formula II is C3-C7cycloalkylene, C4-C7heterocycloalkylene, or heteroarylene; wherein the C3-C7cycloalkylene, C4-C7heterocycloalkylene, or heteroarylene is optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, oxo, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, P(O)ORe1ORf1, S(O)2Ra2, NRc2S(O)2Rb2, and S(O)2NRc2Rd2.
- In some embodiments, L2 in Formula II is C3-C7cycloalkylene, for example, C3cycloalkylene, C4cycloalkylene, C5cycloalkylene, C6cycloalkylene, or C7cycloalkylene. In some embodiments, L2 is C4cycloalkylene. In some embodiments, L2 is cyclobutylen-yl.
- In some embodiments, L2 in Formula II is C4-C7heterocycloalkylene, for example, C4heterocycloalkylene, C5heterocycloalkylene, C6heterocycloalkylene, or C7heterocycloalkylene. In some embodiments, L2 in Formula II is C4heterocycloalkylene. In some embodiments, L2 is pyrrolidinyl.
- In other embodiments, L2 in Formula II is heteroarylene. In some embodiment, the heteroarylene is pyrazolyl.
- In some aspects, L3 in Formula II is absent, or is —(CR4R5)p—, —(CR4R5)pO—, —O—, —S—, —S(O)—, —S(O)2—, —C(═O)—, —NR6—, —OC(═O)—, —C(═O)O—, —NR6AC(O), —C(═O)NR6A—, —OC(═O)N(R6A)—, —NR6AC(O)O—, —S(═O)NR6A—, —NR6AS(O)—, —S(═O)2NR6A—, or —NR6AS(O)2—.
- In some embodiments, L3 in Formula II is absent. In some embodiments, L3 is —(CR4R5)p—. In some embodiments, L3 is —(CR4R5)pO—. In some embodiments, L3 is —O—. In some embodiments, L3 is —S—. In some embodiments, L3 is —S(O)—. In some embodiments, L3 is —S(O)2—. In some embodiments, L3 is —C(═O)—. In some embodiments, L3 is —NR6—. In some embodiments, L3 is —OC(═O)—. In some embodiments, L3 is —C(═O)O—. In some embodiments, L3 is —NR6AC(O). In some embodiments, L3 is —C(═O)NR6A—. In some embodiments, L3 is —OC(═O)N(R6A)—. In some embodiments, L3 is —NR6AC(O)O—. In some embodiments, L3 is —S(═O)NR6A—. In some embodiments, L3 is —NR6AS(O)—. In some embodiments, L3 is —S(═O)2NR6A—. In some embodiments, L3 is —NR6AS(O)2—.
- In some aspects, L4 in Formula II is absent, or is —(CR4R5)pQ1(CR4R5)q—, wherein Q1 is —CR4A═CR4B—, —O—, —S—, —S(O)—, —S(O)2—, —C(═O)—, —NR6—, —OC(═O)—, —C(═O)O—, —NR6AC(O), —C(═O)NR6A—, —NR6AC(O)R6B—, —OC(═O)N(R6A)—, —NR6AC(O)O—, —S(═O)NR6A—, —NR6AS(O)—, —S(═O)2NR6A—, or —NR6AS(O)2—; or is —(CR4R5)p—(CR4A═CR4B)—(CR4R5)q—O—.
- In some embodiments, L4 in Formula II is absent. In other embodiments, L4 in Formula II is —(CR4R5)p—(CR4A═CR4B)—(CR4R5)q—. In other embodiments, L4 in Formula II is —(CR4R5)p—O—(CR4R5)q—. In other embodiments, L4 in Formula II is —(CR4R5)p—S—(CR4R5)q—. In other embodiments, L4 in Formula II is —(CR4R5)p—S(O)—(CR4R5)q—. In other embodiments, L4 in Formula II is —(CR4R5)p—S(O)2—(CR4R5)q—. In other embodiments, L4 in Formula II is —(CR4R5)p—C(═O)—(CR4R5)q—. In other embodiments, L4 in Formula II is —(CR4R5)p—NR6—(CR4R5)q—. In other embodiments, L4 in Formula II is —(CR4R5)p—OC(═O)—(CR4R5)q—. In other embodiments, L4 in Formula II is —(CR4R5)p—C(═O)O—(CR4R5)q—. In other embodiments, L4 in Formula II is —(CR4R5)p—NR6AC(O)—(CR4R5)q—. In other embodiments, L4 in Formula II is —(CR4R5)p—C(═O)NR6A—(CR4R5)q—. In other embodiments, L4 in Formula II is —(CR4R5)p—NR6AC(O)R6B—CR4R5)q—. In other embodiments, L4 in Formula II is —(CR4R5)p—OC(═O)N(R6A)—(CR4R5)q—. In other embodiments, L4 in Formula II is —(CR4R5)p—NR6AC(O)O—(CR4R5)q—. In other embodiments, L4 in Formula II is —(CR4R5)p—S(═O)NR6A—(CR4R5)q—. In other embodiments, L4 in Formula II is —(CR4R5)p—NR6AS(O)—(CR4R5)q—. In other embodiments, L4 in Formula II is —(CR4R5)p—S(═O)2NR6A—(CR4R5)q—. In other embodiments, L4 in Formula II is —(CR4R5)p—NR6AS(O)2—(CR4R5)q—. In some embodiments, L4 is —(CR4R5)p—(CR4A═CR4B)—(CR4R5)q—O—.
- In some aspects, L5 in Formula II is absent, or is C1-C6 alkylene, C2-C6 alkenylene, C2-6 alkynylene, a 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 5- to 12-membered spirocycloalkylene, a 5- to 12-membered spiroheterocycloalkylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, or a 6- to 12-membered bicyclic cycloalkylene, or a 3- to 7-membered monocyclic heterocycloalkylene or a 6 to 12-membered bicyclic heterocycloalkylene group, wherein the heteroarylene, spiroheterocycloalkylene or heterocycloalkylene group have 1, 2, 3 or 4, heteroatoms independently selected from O, N or S; wherein the cycloalkylene, spirocycloalkylene, spiroheterocycloalkylene, and heterocycloalkylene groups may include a C═O group; wherein the spiroheterocycloalkylene, and heterocycloalkylene groups may include a S═O or SO2; wherein said C1-C6 alkylene, C2-C6 alkenylene, C2-C6 alkynylene, cycloalkylene, spirocycloalkylene, heterocycloalkylene, spiroheterocycloalkylene, arylene or heteroarylene are optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from halo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkyl NRc3Rd3, C2-C6 alkenyl NRc3Rd3, C2-C6 alkynyl NRc3Rd3, OC2-C6 alkyl NRc3Rd3, CN, NO2, N3, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, —CH2C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)NRc3Rd3, NRc3C(O)ORa3, C(═NRg1)NRc2Rd2, NRc3C(═NRg1)NRc3Rd3, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O)ORe2ORf2, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, NRc3S(O)2Rb3, and S(O)2NRc3Rd3.
- In some embodiments, L5 in Formula II is absent. In other embodiments, L5 in Formula II is C1-C6 alkylene, for example, C1alkylene, C2alkylene, C3alkylene, C4alkylene, C5alkylene, or C6alkylene.
- In other embodiments, L5 in Formula II is C2-C6 alkenylene, for example, C2alkenylene, C3alkenylene, C4alkenylene, C5alkenylene, or C6alkenylene.
- In other embodiments, L5 in Formula II is C2-C6 alkynylene, for example, C2alkynylene, C3alkynylene, C4alkynylene, C5alkynylene, or C6alkynylene.
- In other embodiments, L5 in Formula II is a 6- to 10-membered arylene, for example phenylene or naphthylene. In some embodiments, L5 in Formula II is a phenylene.
- In other embodiments, L5 in Formula II is a 5- to 10-membered heteroarylene, for example, pyrazolyl, thiazolyl, imidazolyl, or pyridinyl. In some embodiments, L5 in Formula II is pyrazolyl. In some embodiments, L5 in Formula II is thiazolyl. In some embodiments, L5 in Formula II is imidazolyl. In some embodiments, L5 in Formula II is pyridinyl.
- In other embodiments, L5 in Formula II is a 5- to 12-membered spirocycloalkylene, for example, spiro[3.4]octane, or spiro[3.3]heptane.
- In other embodiments, L5 in Formula II is a 5- to 12-membered spiroheterocycloalkylene, for example, 2,6-diazaspiro[3.4]octane, 2-azaspiro[3.4]octane, or 2-azaspiro[3.3]heptane. In some embodiments, L5 in Formula II is 2,6-diazaspiro[3.4]octane. In some embodiments, L5 in Formula II is 2-azaspiro[3.4]octane. In some embodiments, L5 in Formula II is 2-azaspiro[3.3]heptane.
- In other embodiments, L5 in Formula II is a 3- to 12-membered cycloalkenylene, for example, cyclohexenyl.
- In other embodiments, L5 in Formula II is a 3- to 7-membered monocyclic cycloalkylene, for example, cyclopentanyl, cyclohexanyl, and the like. In some embodiments, L5 in Formula II is cyclopentanyl.
- In other embodiments, L5 in Formula II is a 6- to 12-membered bicyclic cycloalkylene.
- In other embodiments, L5 in Formula II is a 3- to 7-membered monocyclic heterocycloalkylene group, for example, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, and the like. In some embodiments, L5 in Formula II is pyrrolidinyl. In some embodiments, L5 in Formula II is tetrahydrofuranyl. In some embodiments, L5 in Formula II is piperidinyl. In some embodiments, L5 in Formula II is piperazinyl.
- In other embodiments, L5 in Formula II is a 6- to 12-membered bicyclic heterocycloalkylene group.
- In some aspects, L6 in Formula II is absent, or is (CR7R8)s, (CR7R8)sO(CR7R8)t, (CR7R8)sNR9(CR7R8)t, (CR7R8)sS(CR7R8)t, (CR7R8)sS(O)(CR7R8)t, (CR7R8)sS(O)2(CR7R8)t, (CR7R8)sNR9AC(O)(CR7R8)t, (CR7R8)sOC(O)NR9A(CR7R8)t, (CR7R8)sNR9AC(O)O(CR7R8)t, (CR7R8)sNR9AC(O)NR9B(CR7R8)t, (CR7R8)sNR9AS(O)(CR7R8)t, (CR7R8)sNR9AS(O)2(CR7R8)t; —(CR7R8)s—CR4A═CR4B—(CR7R8)t, (CR7R8)sC(═O)(CR7R8)t; —(CR7R8)sC(═O)(CR7R8)t—O—, or —(CR7R8)sC(═O)(CR7R8)t—NR6—.
- In some embodiments, L6 in Formula II is absent. In other embodiments, L6 in Formula II is (CR7R8)s. In other embodiments, L6 in Formula II is (CR7R8)sO(CR7R8)t. In other embodiments, L6 in Formula II is (CR7R8)sNR9(CR7R8)t. In other embodiments, L6 in Formula II is (CR7R8)sS(CR7R8)t. In other embodiments, L6 in Formula II is (CR7R8)sS(O)(CR7R8)t. In other embodiments, L6 in Formula II is (CR7R8)sS(O)2(CR7R8)t. In other embodiments, L6 in Formula II is (CR7R8)sNR9AC(O)(CR7R8)t. In other embodiments, L6 in Formula II is (CR7R8)sOC(O)NR9A(CR7R8)t. In other embodiments, L6 in Formula II is (CR7R8)sNR9AC(O)O(CR7R8)t. In other embodiments, L6 in Formula II is (CR7R8)sNR9AC(O)NR9B(CR7R8)t. In other embodiments, L6 in Formula II is (CR7R8)sNR9AS(O)(CR7R8)t. In other embodiments, L6 in Formula II is (CR7R8)sNR9AS(O)2(CR7R8)t. In other embodiments, L6 in Formula II is —(CR7R8)s—CR4A═CR4B—(CR7R8)t. In other embodiments, L6 in Formula II is (CR7R8)sC(═O)(CR7R8)t. In other embodiments, L6 in Formula II is —(CR7R8)sC(═O)(CR7R8)t—O—. In other embodiments, L6 in Formula II is —(CR7R8)sC(═O)(CR7R8)t—NR6—.
- In some aspects, in Formula II, n=0-3. In some embodiments, n=0. In other embodiments, n=1. In other embodiments, n=2. In other embodiments, n=3.
- In some aspects, in Formula II, m=0-2. In some embodiments, m=0. In other embodiments, m=1. In other embodiments, m=2.
- In some aspects, in Formula II, o=1-3. In some embodiments, o=0. In other embodiments, o=1. In other embodiments, o=2. In other embodiments, o=3.
- In some aspects, in Formula II, p=0-4. In some embodiments, p=0. In other embodiments, p=1. In other embodiments, p=2. In other embodiments, p=3. In other embodiments, p=4.
- In some aspects, in Formula II, q=0-3. In some embodiments, q=0. In other embodiments, q=1. In other embodiments, q=2. In other embodiments, q=3.
- In some aspects, in Formula II, s=0-3. In some embodiments, s=0. In other embodiments, s=1. In other embodiments, s=2. In other embodiments, s=3.
- In some aspects, in Formula II, t=0-4. In some embodiments, t=0. In other embodiments, t=1. In other embodiments, t=2. In other embodiments, t=3. In other embodiments, t=4.
- In some aspects, each R in Formula II is independently selected from halo, CN, —NO2, C1-C6alkyl, C2-C6alkenyl, C1-C6haloalkyl, C1-C6alkoxy, —(CH2CH2O)oRa, C1-C6haloalkoxy, C3-C6cycloalkyl, ORa, SRa, C(O)Rb, C(O)ORa, NRcRd, C(O)NRcRd, and S(O)2Ra; wherein said C1-C6alkyl or C3-C6cycloalkyl is optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa1, NRc1Rd1 and C(O)NRc1Rd1.
- In some embodiments, R is halo, for example, Cl or F. In some embodiments, R is —SRa, for example —SCH3.
- In some aspects, each R1 in Formula II is independently selected from halo, —CN, Nitro, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, C1-C6haloalkyl, —(CH2CH2O)oRa, —C1-C6alkylC3-C7cycloalkyl, ORa, SRa, NRcRd, C(O)Rb, OC(O)Rb, C(O)ORa, C(O)NRcRd, or S(O)2Ra; aryl, heteroaryl, spirocycloalkyl, spiroheterocycloalkyl, cycloalkyl, or heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl or heterocycloalkyl group have 1, 2, 3 or 4, heteroatoms independently selected from O, N or S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl groups may include a C═O group, and further wherein the spiroheterocycloalkyl, and heterocycloalkyl groups may include a S═O or SO2; wherein said C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, P(ORe3)2, P(O)Re3RG, P(O)ORe3ORG, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, and S(O)2NRc4Rd4.
- In some embodiments, R1 in Formula II is halo, for example, Cl or F. In other embodiments, R1 in Formula II is —C1-C6haloalkyl, for example —CF3. In other embodiments, R1 in Formula II is —C1-C6alkyl, for example, —C6alkyl, —C5alkyl, —C4alkyl, —C3alkyl, —C2alkyl, —C1alkyl. In some embodiments, R1 in Formula II is —C1alkyl substituted with —CN. In other embodiments, R1 in Formula II is cycloalkyl, for example, cyclopropane, cyclobutane, cyclopentane, and the like. In other embodiments, R1 in Formula II is cyclopropane substituted with —CN.
- In some aspects, R2 and R2A in Formula II are each independently H, halo, ORa, C1-C6alkyl, C1-C6haloalkyl. In some embodiments, R2 and R2A in Formula II are each H.
- In other aspects, R2 and R2A that are attached to the same carbon atom, together with the carbon atom to which they are both attached, form an optionally substituted C3-C6cycloalkyl ring. In some embodiments, R2 and R2A that are attached to the same carbon atom, together with the carbon atom to which they are both attached, form a cyclopropane ring.
- In some aspects, R2 and R2a in Formula II are each independently H, halo, ORa, C1-C6alkyl, C1-C6haloalkyl. In some embodiments, R2 and R2a in Formula II are each H.
- In other aspects, R2 and R2a that are attached to the same carbon atom, together with the carbon atom to which they are both attached, form an optionally substituted C3-C6cycloalkyl ring. In some embodiments, R2 and R2a that are attached to the same carbon atom, together with the carbon atom to which they are both attached, form a cyclopropane ring.
- In some aspects, R2B and R2C in Formula II are each independently H, C1-C6alkyl, or C1-C6haloalkyl. In some embodiments, R2B and R2C in Formula II are each H.
- In some aspects, R2B and R2C may, together with the carbon atom to which they are both attached, form an optionally substituted C3-C6cycloalkyl ring. In some embodiments, R2B and R2C that are attached to the same carbon atom together with the carbon atom to which they are both attached, form a cyclopropane ring.
- In some aspects, R3 in Formula II is H, —C1-C6alkyl, —C3-C6alkenyl, —C3-C6alkynyl, —(CH2CH2O)oRa, —C3-C7cycloalkyl, —C3-C7heterocycloalkyl, —C1-C6alkylC3-C7cycloalkyl, —C1-C6alkylC3-C7heterocycloalkyl, C(O)Rb, C(O)ORa, or C(O)NRcRd; wherein the C1-C6alkyl, —C3-C6alkenyl, —C3-C6alkynyl, cycloalkyl, and heterocycloalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, halo, C1-6 alkyl, CN, —OP(O)ORe3ORG, and ORa4.
- In some embodiments, R3 in Formula II is H. In other embodiments, R3 in Formula II is —C1-C6alkyl, for example, C6alkyl, C5alkyl, C4alkyl, C3alkyl, C2alkyl, C1alkyl, —CH3, and the like.
- In some aspects, R4 and R7 in Formula II are independently selected from H, halo, OH, CN, NO2, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —C1-C6haloalkyl, —(CH2CH2O)oRa, C3-C7cycloalkyl, —C1-C6alkylC3-C7cycloalkyl, cyanoC1-C6alkyl-, heterocycloalkyl, C1-C6alk-NRHC1, ORa, SRa, NRcRd, C(O)Rb, OC(O)Ra, C(O)ORa, C(O)NRcRd, and S(O)2Ra, wherein said C1-C6alkyl, C3-C7cycloalkyl, heterocycloalkyl, or —C1-C6alkylC3-C7cycloalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, P(ORe3)2, P(O)Re3RG, P(O)ORe3ORG S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, and S(O)2NRc4Rd4.
- In some embodiments, R4 is Formula II is H. In other embodiments, R4 in Formula II is —C1-C6alkyl, for example, C6alkyl, C5alkyl, C4alkyl, C3alkyl, C2alkyl, C1alkyl, —CH3, and the like. In other embodiments, R4 is Formula II is —ORa, for example, —OCH3.
- In some embodiments, R7 in Formula II is H. In other embodiments, R7 in Formula II is —C1-C6alkyl, for example, C6alkyl, C5alkyl, C4alkyl, C3alkyl, C2alkyl, C1alkyl, —CH3, and the like. In other embodiments, R7 is Formula II is —ORa, for example, —OCH3.
- In some aspects, R4A and R4B in Formula II are independently selected from H, Me, CF3 and F. In some embodiments, R4A is H. In some embodiments, R4B is H.
- In some aspects, R5 and R8 in Formula II are independently selected from H, halo, OH, CN, NO2, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —C1-C6haloalkyl, —(CH2CH2O)oRa, —C1-C6alkylC3-C7cycloalkyl, cyanoC1-C6alkyl-, C1-C6alk-NRcRd, ORc, SRC, NRcRd, C(O)Rc, OC(O)Rc, C(O)ORc, C(O)NRcRd, S(O)Rc, S(O)2RC, aryl, heteroaryl, spirocycloalkyl, spiroheterocycloalkyl, cycloalkyl, and heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl or heterocycloalkyl group have 1, 2, 3 or 4, heteroatoms independently selected from O, N and S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl groups may include a C═O group, and further wherein the spiroheterocycloalkyl, and heterocycloalkyl groups may include a S═O or SO2, wherein said C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, or —C1-C6alkylC3-C7cycloalkyl, cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from R10, halo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, P(ORe3)2, P(O)Re3RG, P(O)ORe3ORG S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, and S(O)2NRc4Rd4.
- In some embodiments, R5 in Formula II is H. In other embodiments, R5 in Formula II is —C1-C6alkyl, for example, C6alkyl, C5alkyl, C4alkyl, C3alkyl, C2alkyl, C1alkyl, —CH3, and the like. In other embodiments, R5 in Formula II is —ORa, for example, —OCH3.
- In some embodiments, R8 in Formula II is H. In other embodiments, R8 in Formula II is —C1-C6alkyl, for example, C6alkyl, C5alkyl, C4alkyl, C3alkyl, C2alkyl, C1alkyl, —CH3, and the like. In other embodiments, R8 in Formula II is —ORa, for example, —OCH3.
- In some embodiments, R4 and R5 in Formula II, together with the carbon atom to which they are both attached form a 3, 4, 5, 6, or 7-membered cycloalkyl, heterocycloalkyl or spiroheterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from halo, OH, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, alkoxyalkyl, cyanoalkyl, heterocycloalkyl, cycloalkyl, C1-C6 haloalkyl, CN, and NO2.
- In some embodiments, R7 and R8 in Formula II, together with the carbon atom to which they are both attached form a 3, 4, 5, 6, or 7-membered cycloalkyl, heterocycloalkyl or spiroheterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from halo, OH, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, alkoxyalkyl, cyanoalkyl, heterocycloalkyl, cycloalkyl, C1-6 haloalkyl, CN, and NO2.
- In some aspects, R6 and R9 in Formula II are independently selected from H, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —C1-C6haloalkyl, —(CH2CH2O)oRa, —C1-C6alkylC3-C7cycloalkyl, cyanoC1-C6alkyl-, C1-C6alk-NRcRd, C(O)Rb, C(O)ORa, C(O)NRcRd, S(O)Rb S(O)2Rb, aryl, heteroaryl, spirocycloalkyl, spiroheterocycloalkyl, cycloalkyl, and heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl or heterocycloalkyl group have 1, 2, 3 or 4, heteroatoms independently selected from O, N or S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl groups may include a C═O group, and further wherein the spiroheterocycloalkyl, and heterocycloalkyl groups may include a S═O or SO2, wherein said C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —C1-C6alkylC3-C7cycloalkyl, aryl, heteroaryl, cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, CN, N3, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, P(ORe3)2, P(O)Re3RG, P(O)ORe3ORG S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, and S(O)2NRc4Rd4.
- In some embodiments, R6 in Formula II is H. In other embodiments, R6 in Formula II is —C1-C6alkyl, for example, C6alkyl, C5alkyl, C4alkyl, C3alkyl, C2alkyl, or C1alkyl.
- In some embodiments, R9 in Formula II is H. In other embodiments, R6 in Formula II is —C1-C6alkyl, for example, C6alkyl, C5alkyl, C4alkyl, C3alkyl, C2alkyl, or C1alkyl.
- In some aspects, R10 in Formula II is aryl, heteroaryl, spirocycloalkyl, spiroheterocycloalkyl, cycloalkyl, or heterocycloalkyl group, wherein the heteroaryl, spiroheterocycloalkyl or heterocycloalkyl group have 1, 2, 3 or 4, heteroatoms independently selected from O, N or S, wherein the cycloalkyl, spirocycloalkyl, spiroheterocycloalkyl, and heterocycloalkyl groups may include a C═O group, and further wherein the spiroheterocycloalkyl, and heterocycloalkyl groups may include a S═O or SO2, wherein said aryl, cycloalkyl, cycloalkenyl, spirocycloalkyl, spiroheterocycloalkyl, heteroaryl, and heterocycloalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —CH2CH2ORa, CN, N3, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, P(ORe3)2, P(O)Re3RG, P(O)ORe3ORG, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, and S(O)2NRc4Rd4.
- In some aspects R6A, R6B, R9A, and R9B in Formula II are each independently H, C i-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —(CH2CH2O)oRa, C3-C7cycloalkyl, —C1-C6alkylC3-C7cycloalkyl, C4-C7heterocycloalkyl, —C1-C6alkylC4-C7heterocycloalkyl, wherein said C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —C3-C7cycloalkyl, —C1-C6alkylC3-C7cycloalkyl, —C4-C7heterocycloalkyl, —C1-C6alkylC3-C7heterocycloalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, CN, N3, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, P(ORe3)2, P(O)Re3RG, P(O)ORe3ORf3, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, and S(O)2NRc4Rd4.
- In some embodiments, R6A and R6B in Formula II, together with the N atom to which they are attached form a 5, 6, 7, 8 or 9-membered heterocycloalkyl ring or spiroheterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from halo, OH, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, alkoxyalkyl, cyanoalkyl, heterocycloalkyl, cycloalkyl, C1-C6 haloalkyl, CN, and NO2.
- In some embodiments, R9A and R9B in Formula II, together with the N atom to which they are attached form a 5, 6, 7, 8 or 9-membered heterocycloalkyl ring or spiroheterocycloalkyl ring, each optionally substituted by 1, 2, or 3 substituents independently selected from halo, OH, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, alkoxyalkyl, cyanoalkyl, heterocycloalkyl, cycloalkyl, C1-C6 haloalkyl, CN, and NO2.
- In some aspects, Ra, Ra1, R32, Ra3, and Ra4 in Formula II are independently H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6haloalkoxy.
- In some embodiments, Ra is H. In other embodiments, Ra is —C1-C6 alkyl, for example C6alkyl, C5alkyl, C4alkyl, C3alkyl, C2alkyl, or C1alkyl. In some embodiments, Ra is —CH3.
- In some aspects, Rb, Rb1, Rb2, Rb3, and Rb4 in Formula II are independently H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl, wherein said C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6haloalkoxy.
- In some aspects, Rc and Rd in Formula II are independently H, C1-C10 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein said C1-C10 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6haloalkoxy, or heterocycloalkyl group.
- In some embodiments, Rc and Rd in Formula II, together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, and C1-C6haloalkoxy.
- In some aspects, Rc1 and Rd1 in Formula II are independently H, C1-C10 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein said C1-C10 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6haloalkoxy.
- In some embodiments, Rc1 and Rd1 in Formula II, together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, and C1-C6haloalkoxy.
- In some aspects, Rc2 and Rd2 in Formula II are independently H, C1-C10 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylcycloalkyl, arylheterocycloalkyl, arylheteroaryl, biaryl, heteroarylcycloalkyl, heteroarylheterocycloalkyl, heteroaryl aryl, or biheteroaryl, wherein said C1-C10 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, arylcycloalkyl, arylheterocycloalkyl, arylheteroaryl, biaryl, heteroarylcycloalkyl, heteroarylheterocycloalkyl, heteroaryl aryl, and biheteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxyalkyl, cyanoalkyl, aryl, heteroaryl, C(O)ORa4, C(O)Rb4, S(O)2Rb3, alkoxyalkyl, and alkoxyalkoxy.
- In some aspects, Rc2 and Rd2 in Formula II, together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, hydroxyalkyl, cyanoalkyl, aryl, heteroaryl, C(O)ORa4, C(O)Rb4, S(O)2Rb3, alkoxyalkyl, and alkoxyalkoxy.
- In some aspects, Rc3 and Rd3 in Formula II are independently H, C1-10 alkyl, C1-6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein said C1-C10 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6haloalkoxy.
- In some aspects, Rc3 and Rd3 in Formula II together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, and C1-C6haloalkoxy.
- In some aspects, Rc4 and Rd4 in Formula II are independently H, C1-C10 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl, wherein said C1-C10 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, and C1-C6haloalkoxy.
- In some aspects, Rc4 and Rd4 in Formula II together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, and C1-C6haloalkoxy.
- In some aspects, Re1, Re2, and Re3 in Formula II are independently H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, (C1-C6 alkoxy)-C1-C6 alkyl, C2-C6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocycloalkylalkyl.
- In some aspects, Rf1, Rf2, and RG in Formula II are independently selected from H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl.
- In some aspects, Rg1 in Formula II is H, CN, or NO2.
- In some aspects, the disclosure is directed to compounds of Formula IIA:
- or a pharmaceutically acceptable salt or solvate thereof;
- wherein
-
- Q is —O—, —S—, —S(O)—, or —S(O)2—;
- R is halo; n=1;
- the moiety -W1-W2-W3 is —CR2R2A—CR2R2A—CR2R2A—, —O—CR2BR2C—CR2R2A—, —CR2R2A—CR2BR2C—O—, —S—CR2BR2C—CR2R2A, or —CR2R2A—CR2BR2C—S—;
- R2 and R2A are each independently H, halo, or C1-C6alkyl, or R2 and R2A that are attached to the same carbon atom may, together with the carbon atom to which they are both attached, form a C3-C6cycloalkyl ring;
- R2B and R2C are each independently H or C1-C6alkyl, or R2B and R2C may, together with the carbon atom to which they are both attached, form a C3-C6cycloalkyl ring;
- R3 is H or C1-C6alkyl;
- L1 is —C1-C6alkylene-;
- L2 is C3-C7 cycloalkylene, C4-C7 heterocycloalkylene or heteroarylene;
- L3 is absent, or is —NR6AS(O)—, —S(═O)2NR6A—, —NR6AS(O)2—, —(CR4R5)p—, —(CR4R5)pO—, —NR6AC(O), —C(═O)NR6A—;
- L4 is absent, —(CR4R5)p—(CR4A═CR4B)—(CR4R5)q—O—, or —(CR4R5)pQ1(CR4R5)q—, wherein Q1 is —CR4A═CR4B—, or —O—, —S—, —S(O)—, —S(O)2—, —NR6—, —NR6AC(O), or —C(═O)NR6A—;
- L5 is absent, or is a 6-10 membered arylene or 5-10 membered heteroarylene, wherein said heteroarylene is optionally substituted with C1-C6 alkyl, OC2-C6 alkyl NRc3Rd3, or —C1-C6 alkyl-C(O)NRc3Rd3;
- L6 is absent, or is —(CR7R8)s—;
- p=0-4; q=0-3; s=1;
- each R4 is independently H, OH, —C1-C6alkyl, or —OC1-C6alkyl,
- each R5 is independently selected from is H, OH, —C1-C6alkyl, or —OC1-C6alkyl;
- each R6 is independently selected from is H or —C1-C6alkyl;
- each R6A is independently selected from H, or C1-C6alkyl;
- each R7 is H, —C1-C6alkyl, or —OC1-C6alkyl;
- each R4A and R4B is independently H, Me, CF3 or F; and
- each R8 is H, —C1-C6alkyl, or —OC1-C6alkyl;
- Rc3 and Rd3 together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from OH, C1-C6alkyl, C1-C6alkoxy, or C1-C6alk-C1-C6 alkoxy.
- In some aspects, the disclosure is directed to compounds of Formula IIA-1:
- or a pharmaceutically acceptable salt or solvate thereof;
- wherein
-
- L2 is C4 cycloalkylene, C5 heterocycloalkylene or heteroarylene;
- L3 is absent, or is —NR6AS(O)—, —S(═O)2NR6A—, —NR6AS(O)2—, —(CR4R5)p—, —(CR4R5)pO—, —NR6AC(O), —C(═O)NR6A—;
- L4 is absent, —(CR4R5)p—(CR4A═CR4B)—(CR4R5)q—O—, or —(CR4R5)pQ1(CR4R5)q—, wherein Q1 is —CR4A═CR4B—, or —O—, —S—, —S(O)—, —S(O)2—, —NR6—, —NR6AC(O), or —C(═O)NR6A—;
- L5 is absent, a 6-membered arylene, or a 5- or 6-membered heteroarylene, wherein said heteroarylene is optionally substituted with —C1-C6 alkyl, OC2-6 alkyl NRc3Rd3, or —C1-C6 alkyl-C(O)NRc3Rd3;
- L6 is absent, or is —(CR7R8)s—;
- p=0-4; and q=0-3; s=1;
- each R4 is independently selected from H, OH, —C1-C6alkyl, and —OC1-C6alkyl,
- each R5 is independently selected from H, OH, —C1-C6alkyl, and —OC1-C6alkyl;
- each R6 is independently selected from H and —C1-C6alkyl;
- each R6A is independently selected from H, and C1-C6alkyl;
- each R7 is H, —C1-C6alkyl, or —OC1-C6alkyl;
- each R4A and R4B is independently H, Me, CF3 or F; and
- each R8 is H, —C1-C6alkyl, or —OC1-C6alkyl; Rc3 and Rd3 together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from OH, C1-C6alkyl, C1-C6alkoxy, or C1-C6alk-C1-C6 alkoxy.
- In some embodiments, the compounds of Formula IIA-1 are those wherein L2 is heteroarylene, L3 is absent, L4 is —(CR4R5)pQ1(CR4R5)q—, wherein Q1 is —CR4A═CR4B—; L5 is absent, L6 is absent, p=1; and q=3, R4 and R5 are H; R4A and R4B are H.
- In some aspects, the disclosure is directed to compounds of Formula IIA-2:
- or a pharmaceutically acceptable salt or solvate thereof;
- wherein
-
- L3 is absent, or is —NR6AS(O)—, —S(═O)2NR6A—, —NR6AS(O)2—, —(CR4R5)p—, —(CR4R5)pO—, —NR6AC(O), —C(═O)NR6A—;
- L4 is absent, —(CR4R5)p—(CR4A═CR4B)—(CR4R5)q—O—, or —(CR4R5)pQ1(CR4R5)q—, wherein Q1 is —CR4A═CR4B—, or —O—, —S—, —S(O)—, —S(O)2—, —NR6—, —NR6AC(O), or —C(═O)NR6A—;
- L5 is 6-membered arylene or 5- or 6-membered heteroaryl ene, wherein said heteroarylene is optionally substituted with —C1-C6 alkyl, —OC2-C6alkyl NRc3Rd3, or —C1-C6 alkyl-C(O)NRc3Rd3;
- L6 is absent, or is —(CR7R8)s—;
- p=0-4; q=0-3; and s=1;
- each R4 is independently H, OH, or —OC1-C6alkyl;
- each R5 is independently selected from is H, OH, or —OC1-C6alkyl;
- each R6 is independently selected from is H or —C1-C6alkyl;
- each R6A is independently selected from H or C1alkyl;
- each R7 is H, —C1alkyl, or —OC1alkyl;
- each R4A and R4B is H;
- each R8 is H, —C1alkyl, or —OC1alkyl; Rc3 and Rd3 together with the N atom to which they are attached form a 6-membered heterocycloalkyl group optionally substituted with —C1-C6 alkoxy or —C1-C6 alk-C1-C6 alkoxy.
- In some aspects, the disclosure is directed to compounds of Formula IIA-3:
- or a pharmaceutically acceptable salt or solvate thereof;
- wherein
-
- L3 is absent, or is —NR6AS(O)—, —S(═O)2NR6A—, —NR6AS(O)2—, —(CR4R5)p—, —(CR4R5)pO—, —NR6AC(O), —C(═O)NR6A—;
- L4 is absent, —(CR4R5)p—(CR4A═CR4B)—(CR4R5)q—O—, or —(CR4R5)pQ1(CR4R5)q—, wherein Q1 is —CR4A═CR4B—, or —O—, —S—, —S(O)—, —S(O)2—, —NR6—, —NR6AC(O), or —C(═O)NR6A—;
- L5 is phenyl;
- L6 is —(CR7R8)s—;
- p=0-4; q=0-3; and s=1
- each R4 is independently H, OH, or —OC1-C6alkyl;
- each R5 is independently selected from is H, OH, or —OC1-C6alkyl;
- each R6 is independently selected from is H or —C1-C6alkyl;
- each R6A is independently selected from H or C1alkyl;
- each R7 is H, —C1alkyl, or —OC1alkyl;
- each R4A and R4B is H;
- each R8 is H, —C1alkyl, or —OC1alkyl.
- In some embodiments, the compounds of Formula IIA-3 are those wherein
- L3 is absent,
- L4 is —(CR4R5)pQ1(CR4R5)q—, wherein Q1 is —O— or —S—,
- L5 is phenyl;
- L6 is —(CR7R8)s—;
- p=1-2; q=0-1; and s=1-2;
- each R4 is independently H, OH, or —OC1-C6alkyl;
- each R5 is independently selected from is H, OH, or —OC1-C6alkyl;
- each R7 is H, —C1alkyl, or —OC1alkyl; and
- each R8 is H, —C1alkyl, or —OC1alkyl.
- In other embodiments, the compounds of Formula IIA-3 are those wherein
- L3 is absent;
- L4 is —(CR4R5)pQ1(CR4R5)q—, wherein Q1 is —O— or —S—;
- L5 is phenyl;
- L6 is —(CR7R8)s—;
- p=1; q=0; and s=1
- each R4 is independently H, OH, or —OC1-C6alkyl;
- each R5 is independently selected from is H, OH, or —OC1-C6alkyl;
- each R7 is H, —C1alkyl, or —OC1alkyl; and
- each R8 is H, —C1alkyl, or —OC1alkyl.
- In other embodiments, the compounds of Formula IIA-3 are those wherein L3 is absent; L4 is —(CR4R5)pQ1(CR4R5)q—, wherein Q1 is —O— or —S—; L5 is phenyl; L6 is —(CR7R8)s—; p=1; q=0; and s=1; each R4 is H; each R5 is H; R7 is H; and R8 is H.
- In some aspects, the disclosure is directed to compounds of Formula IIB:
- or a pharmaceutically acceptable salt or solvate thereof;
- wherein
-
- Q is —O—, —S—, —S(O)—, or —S(O)2—;
- the moiety -W1-W2-W3 is —CR2R2A—CR2R2A—CR2R2A—, —O—CR2BR2C—CR2R2A—, —CR2R2A—CR2BR2C—O—, —S—CR2BR2C—CR2R2A, or —CR2R2A—CR2BR2C—S—;
- R2 and R2A are each independently H, halo, C1-C6alkyl, or R2 and R2A that are attached to the same carbon atom may, together with the carbon atom to which they are both attached, form a C3-C6cycloalkyl ring;
- R2B and R2C are each independently H or C1-C6alkyl, or R2B and R2C may, together with the carbon atom to which they are both attached, form a C3-C6cycloalkyl ring;
- R is halo, —S—C1-C6alkyl, or —O—C1-C6alkyl; n=1 or 2;
- R1 is halo, —CH2—CN, —C1-C6haloalkyl, —OC1-C6haloalkyl, —OC1-C6haloalkyl, —C1-C6alk-OH, —C1-C6alk-O—C1-C6alkyl, —O—C1-C6alk-O—C1-C6alkyl, —C1-C6alk-O—C3-C6cycloalkyl, —C1-C6alk-O—C1-C6haloalkyl, or
-
-
- m=1 or 2
- L3 is absent, or is —NR6S(O)—, —S(═O)2NR6—, —NR6S(O)2—,
- L4 is —(CR4R5)p, (CR4R5)p—CR4A═CR4B—(CR4R5)q, (CR4R5)pO(CR4R5)q, (CR4R5)p—S(═O)2NR6A—(CR4R5)q, (CR4R5)pS(CR4R5)q, (CR4R5)pS(O)(CR4R5)q, (CR4R5)pS(O)2(CR4R5)q, (CR4R5)pC(O)NR6A(CR4R5)q, (CR4R5)pNR6AC(O)(CR4R5)q, or —(CR4R5)p—(CR4A═CR4B)—(CR4R5)q—O—;
- wherein each occurrence of p or q is independently p=0-2 and q=1-5;
- L5 is absent,
- L6 is absent, or is (CR7R8)sO(CR7R8)t, (CR7R8)sNR9(CR7R8>, (CR7R8)sS(CR7R8)t, (CR7R8)sS(O)(CR7R8)t, or (CR7R8)sS(O)2(CR7R8)t;
- wherein each occurrence of s or t is independently s=0-2 and t=0-2;
- each R4 and each R7 is independently selected from H, OH, C1-C6alkyl, C1-C6haloalkyl, —OC1-C6alkyl, —C3-C7cycloalkyl, —OC3-C7cycloalkyl, —CH2—CN, —CN, —N(CH3)2,
-
-
- each R5 and each R8 is independently selected from H, OH, —CH2OH, C1-C6alkyl, —OC1-C6alkyl, —C3-C7cycloalkyl, and —OC3-C7cycloalkyl;
- wherein one R4 and R5 together with the C atom to which they are both attached may optionally form a 3, 4, 5, or 6-membered cycloalkyl ring,
- and
-
- each R9 is independently H or —C1-C6alkyl.
- and each R4A and each R4B is independently selected from H, Me, CF3, and F.
- In some aspects, the disclosure is directed to compounds of Formula IIB-1:
- or a pharmaceutically acceptable salt or solvate thereof;
- wherein
-
- the moiety -W1-W2-W3 is —CR2R2A—CR2R2A—CR2R2A—, —O—CR2BR2C—CR2R2A—, —CR2R2A—CR2BR2C—O—, —S—CR2BR2C—CR2R2A, or —CR2R2A—CR2BR2C—S—;
- R2 and R2A are each independently H, halo, C1-C6alkyl, or R2 and R2A that are attached to the same carbon atom may, together with the carbon atom to which they are both attached, form a C3-C6spirocycloalkyl ring;
- R2B and R2C are each independently H or C1-C6alkyl, or R2B and R2C may, together with the carbon atom to which they are both attached, form a C3-C6spirocycloalkyl ring;
- R is halo, —S—C1-C6alkyl, or —O—C1-C6alkyl; n=1 or 2;
- R1 is halo, —CH2—CN, —C1-C6haloalkyl, —OC1-C6haloalkyl, —OC1-C6haloalkyl, —C1-C6alk-OH, —C1-C6alk-O—C1-C6alkyl, —O—C1-C6alk-O—C1-C6alkyl, —C1-C6alk-O—C3-C6cycloalkyl, —C1-C6alk-O—C1-C6haloalkyl, or
-
-
- m=1 or 2
- L3 is absent, or is —NR6S(O)—, —S(═O)2NR6—, —NR6S(O)2—,
- L4 is —(CR4R5)p, (CR4R5)p—CR4A═CR4B—(CR4R5)q, (CR4R5)pO(CR4R5)q, (CR4R5)p—S(═O)2NR6A—(CR4R5)q, (CR4R5)pS(CR4R5)q, (CR4R5)pS(O)(CR4R5)q, (CR4R5)pS(O)2(CR4R5)q, (CR4R5)pC(O)NR6A(CR4R5)q, (CR4R5)pNR6AC(O)(CR4R5)q, or —(CR4R5)p—(CR4A═CR4B)—(CR4R5)q—O—;
- wherein each occurrence of p or q is independently p=0-2 and q=1-5;
- L5 is absent,
- L6 is absent, or is (CR7R8)sO(CR7R8)t, (CR7R8)sNR9(CR7R8)t, (CR7R8)sS(CR7R8)t, (CR7R8)sS(O)(CR7R8)t, or (CR7R8)sS(O)2(CR7R8)t;
- wherein each occurrence of s or t is independently s=0-2 and t=0-2;
- each R4 and each R7 is independently selected from H, OH, C1-C6alkyl, C1-C6haloalkyl, —OC1-C6alkyl, —C3-C7cycloalkyl, —OC3-C7cycloalkyl, —CH2—CN, —CN, —N(CH3)2,
-
-
- each R5 and each R8 is independently selected from H, OH, —CH2OH, C1-C6alkyl, —OC1-C6alkyl, —C3-C7cycloalkyl, and —OC3-C7cycloalkyl;
- wherein one R4 and R5 together with the C atom to which they are both attached may optionally form a 3, 4, 5, or 6-membered cycloalkyl ring,
- and
-
- each R9 is independently H or —C1-C6alkyl.
- and each R4A and each R4B is independently selected from H, Me, CF3, or F.
- In some aspects, the disclosure is directed to compounds of Formula IIB-2:
- or a pharmaceutically acceptable salt or solvate thereof;
- wherein
-
- R is halo, —S—C1-C6alkyl, or —O—C1-C6alkyl; n=1 or 2;
- R1 is halo, —CH2—CN, —C1-C6haloalkyl, —OC1-C6haloalkyl, —OC1-C6haloalkyl, —C1-C6alk-OH, —C1-C6alk-O—C1-C6alkyl, —O—C1-C6alk-O—C1-C6alkyl, —C1-C6alk-O—C3-C6cycloalkyl, —C1-C6alk-O—C1-C6haloalkyl, or
-
-
- m=1 or 2
- L3 is absent, or is —NR6S(O)—, —S(═O)2NR6—, —NR6S(O)2—,
- L4 is —(CR4R5)p, (CR4R5)p—CR4A═CR4B—(CR4R5)q, (CR4R5)pO(CR4R5)q, (CR4R5)p—S(═O)2NR6A—(CR4R5)q, (CR4R5)pS(CR4R5)q, (CR4R5)pS(O)(CR4R5)q, (CR4R5)pS(O)2(CR4R5)q, (CR4R5)pC(O)NR6A(CR4R5)q, (CR4R5)pNR6AC(O)(CR4R5)q, or —(CR4R5)p—(CR4A═CR4B)—(CR4R5)q—O—;
- wherein each occurrence of p or q is independently p=0-2 and q=1-5;
- L5 is absent,
- L6 is absent, or is (CR7R8)sO(CR7R8)t, (CR7R8)sNR9(CR7R8>, (CR7R8)sS(CR7R8)t, (CR7R8)sS(O)(CR7R8)t, or (CR7R8)sS(O)2(CR7R8)t;
- wherein each occurrence of s or t is independently s=0-2 and t=0-2;
- each R4 and each R7 is independently selected from H, OH, C1-C6alkyl, C1-C6haloalkyl, —OC1-C6alkyl, —C3-C7cycloalkyl, —OC3-C7cycloalkyl, —CH2—CN, —CN, —N(CH3)2,
-
-
- each R5 and each R8 is independently selected from H, OH, —CH2OH, C1-C6alkyl, —OC1-C6alkyl, —C3-C7cycloalkyl, —OC3-C7cycloalkyl;
- wherein one R4 and R5 together with the C atom to which they are both attached may optionally form a 3, 4, 5, or 6-membered cycloalkyl ring,
- and
-
- each R9 is independently H or —C1-C6alkyl.
- and each R4A and each R4B is independently selected from H, Me, CF3, or F.
- In some aspects, the disclosure is directed to compounds of Formula IIB-3:
- or a pharmaceutically acceptable salt or solvate thereof;
- wherein
-
- L3 is absent, or is —NR6S(O)—, —S(═O)2NR6—, —NR6S(O)2—, L4 is —(CR4R5)p, (CR4R5)p—CR4B═CR4B—(CR4R5)q, (CR4R5)pO(CR4R5)q, (CR4R5)p—S(═O)2NR6A—(CR4R5)q, (CR4R5)pS(CR4R5)q, (CR4R5)pS(O)(CR4R5)q, (CR4R5)pS(O)2(CR4R5)q, (CR4R5)pC(O)NR6A(CR4R5)q, (CR4R5)pNR6AC(O)(CR4R5)q, or —(CR4R5)p—(CR4A═CR4B)—(CR4R5)q—O—;
- wherein each occurrence of p or q is independently p=0-2 and q=1-5;
- L5 is absent,
- L6 is absent, or is (CR7R8)sO(CR7R8)t, (CR7R8)sNR9(CR7R8>, (CR7R8)sS(CR7R8)t, (CR7R8)sS(O)(CR7R8)t, or (CR7R8)sS(O)2(CR7R8)t;
- wherein each occurrence of s or t is independently s=0-2 and t=0-2;
- each R4 and each R7 is independently selected from H, OH, C1-C6alkyl, C1-C6haloalkyl, —OC1-C6alkyl, —C3-C7cycloalkyl, and —OC3-C7cycloalkyl;
- each R5 and each R8 is independently selected from H, OH, —CH2OH, C1-C6alkyl, —OC1-C6alkyl, —C3-C7cycloalkyl, and —OC3-C7cycloalkyl;
- wherein one R4 and R5 together with the C atom to which they are both attached may form a 3, 4, 5, or 6-membered cycloalkyl ring; and
- each R4A and each R4B is independently selected from H, Me, CF3 and F; and
- each R9 is independently H or —C1-C6alkyl.
- In some aspects, the disclosure is directed to compounds of Formula IIB-4:
- or a pharmaceutically acceptable salt or solvate thereof;
- wherein
-
- L4 is —(CR4R5)p—CR4A═CR4B—(CR4R5)q—;
- p=1 and q=1-4.
- each R4 is independently selected from H, OH, C1-C6alkyl, C1-C6haloalkyl, —OC1-C6alkyl, —C3-C7cycloalkyl, —OC3-C7cycloalkyl, —CH2—CN, —CN, —N(CH3)2,
-
- each R5 is independently selected from H, OH, —CH2OH, C1-C6alkyl, —OC1-C6alkyl, —C3-C7cycloalkyl, and —OC3-C7cycloalkyl;
- and each R4A and each R4B is independently selected from H, Me, and F.
- In some aspects, the disclosure is directed to compounds of Formula IIB-5:
- or a pharmaceutically acceptable salt or solvate thereof;
- wherein
-
- L4 is —(CR4R5)p—CR4A═CR4B—(CR4R5)q—;
- p=1 and q=1-4;
- R4 is independently H, or —C1-C6alkyl;
- R5 is independently H, or C1-C6alkyl;
- wherein one R4 and one R5, together with the carbon atom to which they are both attached, are
-
- and each R4A and each R4B is independently selected from H, Me, or F.
- In some aspects, the disclosure is directed to compounds of Formula IIB-6:
- or a pharmaceutically acceptable salt or solvate thereof;
- wherein
R1 is halo, —CH2—CN, —C1-C6haloalkyl, —OC1-C6haloalkyl, —OC1-C6haloalkyl, —C1-C6alk-OH, —C1-C6alk-O—C1-C6alkyl, —O—C1-C6alk-O—C1-C6alkyl, —C1-C6alk-O—C3-C6cycloalkyl, —C1-C6alk-O—C1-C6haloalkyl, or - m=1 or 2;
L4 is —(CR4R5)p—CR4A═CR4B—(CR4R5)q—; - p=1 and q=1-4;
- R4 is independently H, —OC1-C6alkyl, or —C1-C6alkyl;
R5 is independently H, —OC1-C6alkyl, or —C1-C6alkyl;
R4A and R4B are H. - In some aspects, the disclosure is directed to compounds of Formula IIB-7:
- or a pharmaceutically acceptable salt or solvate thereof;
- wherein
R is halo, —S—C1-C6alkyl, or —O—C1-C6alkyl;
n=1 or 2;
L4 is —(CR4R5)p—CR4A═CR4B—(CR4R5)q—; - p=1 and q=1-4;
- R4 is independently H, —OC1-C6alkyl, or —C1-C6alkyl;
R5 is independently H, —OC1-C6alkyl, or —C1-C6alkyl;
R4A and R4B are H. - The disclosure is directed to compounds of Formula IIC:
- or a pharmaceutically acceptable salt or solvate thereof;
- wherein
-
- Q is —O—, or —S—;
- R is halo; n=1;
- the moiety -W1-W2-W3 is —CH2—CH2—CH2—, —O—CH2—CH2—, or —CH2—CH2—O—;
- R3 is H, or C1-C6alkyl;
- L1 is —C1-C6alkylene-;
- L2 is C3-C7cycloalkyl, or C4-C7heterocycloalkylene;
- L3 is absent, or is —(CR4R5)p—, —(CR4R5)pO—, —S(O)2—, —C(═O)—, —NR6—;
- L4 is absent or is —(CR4R5)p—CR4A═CR4B—(CR4R5)q, —(CR4R5)pO(CR4R5)q—;
- L5 is a 6-membered arylene, 5-membered heteroarylene, 7-to 10-membered spirocycloalkylene, 7- to 10-spiroheterocycloalkylene, 3- to 7-membered monocyclic cycloalkylene, 3- to 7-membered cycloalkenylene, or a 4- to 7-membered monocyclic heterocycloalkylene group, wherein the spiroheterocycloalkylene or heterocycloalkylene groups have 1, 2, 3 or 4, heteroatoms independently selected from O, or N;
- L6 is absent, or is —(CR7R8)s, (CR7R8)sO(CR7R8>, —(CR7R8)a—CR4A═CR4B—(CR7R8)c, (CR7R8)sC(═O)(CR7R8)t; —(CR7R8)sC(═O)(CR7R8)t—O—, or —(CR7R8)sC(═O)(CR7R8)t—NR6—;
- each R4 is independently H, OH, or —OC1-C6alkyl;
- each R5 is independently selected from is H, OH, or —OC1-C6alkyl;
- or R4 and R5 together with the C atom to which they are both attached may form a 3, 4, 5, 6, or 7-membered cycloalkyl ring;
- each R6 is independently selected from is H or —C1-C6alkyl,
- each R7 is H, OH, —C1-C6alkyl, or —OC1-C6alkyl,
- each R8 is H, OH, —C1-C6alkyl, or —OC1-C6alkyl;
- or R7 and R8 together with the C atom to which they are both attached may form a 3, 4, 5, 6, or 7-membered cycloalkyl ring;
- each R4A and each R4B is independently H, or —OC1-C6alkyl;
- a=0-1; c=0-3; p=0-3; s=0-2, t=0-5; and q=0-2;
- In some aspects, the disclosure is directed to compounds of Formula IIC-1:
- or a pharmaceutically acceptable salt or solvate thereof;
- wherein
-
- L2 is C3-C6cycloalkylene, or heterocycloalkylene;
- L3 is absent, or is —(CR4R5)p—, —(CR4R5)pO—, —S(O)2—, —C(═O)—, —NR6—;
- L4 is absent or is —(CR4R5)p—CR4A═CR4B—(CR4R5)q, —(CR4R5)pO(CR4R5)q—;
- L5 is a 6-membered arylene, or 5-membered heteroarylene, 7- to 10-membered spirocycloalkylene, 7- to 10-spiroheterocycloalkylene, 3- to 7-membered cycloalkylene, 3- to 7-membered cycloalkenylene, or a 4- to 7-membered heterocycloalkylene group, wherein the spiroheterocycloalkylene or heterocycloalkylene groups have 1, 2, 3 or 4, heteroatoms independently selected from O, or N;
- L6 is absent, —(CR7R8)s, (CR7R8)sO(CR7R8)t, —(CR7R8)a—CR4A═CR4B—(CR7R8)c, (CR7R8)sC(═O)(CR7R8)t; —(CR7R8)sC(═O)(CR7R8)t—O—, or —(CR7R8)sC(═O)(CR7R8)t—NR6—;
- a=0-1; c=0-3; p=0-3; s=0-2, t=0-5; and q=0-2;
- each R4 is independently H, OH, or —OC1-C6alkyl;
- each R5 is independently selected from is H, OH, or —OC1-C6alkyl;
- or R4 and R5 together with the C atom to which they are both attached may form a 3, 4, 5, 6, or 7-membered cycloalkyl ring;
- each R4A and each R4B is independently H, or —OC1-C6alkyl;
- each R6 is independently selected from is H or —C1-C6alkyl;
- each R7 is H, OH, —C1-C6alkyl, or —OC1-C6alkyl;
- each R8 is H, OH, —C1-C6alkyl, or —OC1-C6alkyl;
- or R7 and R8 together with the C atom to which they are both attached may form a 3, 4, 5, 6, or 7-membered cycloalkyl ring.
- In some aspects, the disclosure is directed to compounds of Formula IIC-2:
- or a pharmaceutically acceptable salt or solvate thereof;
- wherein
-
- L3 is absent, or is —(CR4R5)p—, —(CR4R5)pO—, —S(O)2—, —C(═O)—, —NR6—;
- L4 is absent or is —(CR4R5)p—CR4A═CR4B—(CR4R5)q, —(CR4R5)pO(CR4R5)q—,
- L5 is a 7- to 10-membered spirocycloalkylene, 7- to 10-spiroheterocycloalkylene, 3- to 7-membered cycloalkylene, 3- to 7-membered cycloalkenylene, or a 4- to 7-membered heterocycloalkylene group, wherein the spiroheterocycloalkylene or heterocycloalkylene groups have 1, 2, 3 or 4, heteroatoms independently selected from O, or N;
- L6 is absent, or is —(CR7R8)s—, (CR7R8)sO(CR7R8)t, or (CR7R8)sC(═O)(CR7R8)t; a=0-1; c=0-3; n=1; p=0-1; s=0-2; t=0-2; and q=0-2;
- each R4 is independently H, OH, or —OC1-C6alkyl;
- each R4A and each R4B is independently H, or —OC1-C6alkyl;
- each R5 is independently selected from is H, OH, or —OC1-C6alkyl;
- each R6 is independently selected from is H or —C1-C6alkyl,
- each R7 is independently H, —C1-C6alkyl, or —OC1-C6alkyl; and
- each R8 is independently H, —C1-C6alkyl, or —OC1-C6alkyl.
- In some aspects, the disclosure is directed to compounds of Formula IIC-3:
- or a pharmaceutically acceptable salt or solvate thereof;
- wherein
-
- L6 is —(CR7R8)a—CR4A═CR4B—(CR7R8)c, (CR7R8)sC(═O)(CR7R8)t; —(CR7R8)sC(═O)(CR7R8)t—O—, or —(CR7R8)sC(═O)(CR7R8)t—NR6—; a=0-1; c=1-3; n=1; s=0-2, t=0-5;
- each R4 is independently H, OH, or —OC1-C6alkyl;
- each R4A and each R4B is H;
- each R5 is independently selected from is H, OH, or —OC1-C6alkyl;
- each R6 is independently selected from is H or —C1-C6alkyl,
- each R7 is independently H, —C1-C6alkyl, or —OC1-C6alkyl,
- each R8 is independently H, —C1-C6alkyl, or —OC1-C6alkyl;
- or R7 and R8, together with the carbon atom to which they are attached, for a C3-C6 cycloalyl ring.
- It will be apparent that the compounds of Formula I and Formula II, including all subgenera described herein, have multiple stereogenic centers. As a result, there exist multiple stereoisomers (enantiomers and diastereomers) of the compounds of Formula I and Formula II (subgenera described herein). The present disclosure contemplates and encompasses each stereoisomer of any compound of Formula I and Formula II (and subgenera described herein), as well as mixtures of said stereoisomers.
- Pharmaceutically acceptable salts and solvates of the compounds of Formula I and Formula II (including all subgenera described herein) are also within the scope of the disclosure.
- Isotopic variants of the compounds of Formula I and Formula II (including all subgenera described herein) are also contemplated by the present disclosure.
- The subject pharmaceutical compositions are typically formulated to provide a therapeutically effective amount of a compound of the present disclosure as the active ingredient, or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof. Where desired, the pharmaceutical compositions contain pharmaceutically acceptable salt and/or coordination complex thereof, and one or more pharmaceutically acceptable excipients, carriers, including inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.
- The subject pharmaceutical compositions can be administered alone or in combination with one or more other agents, which are also typically administered in the form of pharmaceutical compositions. Where desired, the one or more compounds of the invention and other agent(s) may be mixed into a preparation or both components may be formulated into separate preparations to use them in combination separately or at the same time.
- In some embodiments, the concentration of one or more compounds provided in the pharmaceutical compositions of the present invention is less than 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% (or a number in the range defined by and including any two numbers above) w/w, w/v or v/v.
- In some embodiments, the concentration of one or more compounds of the invention is greater than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19.75%, 19.50%, 19.25%, 19%, 18.75%, 18.50%, 18.25% 18%, 17.75%, 17.50%, 17.25% 17%, 16.75%, 16.50%, 16.25%, 16%, 15.75%, 15.50%, 15.25% 15%, 14.75%, 14.50%, 14.25% 14%, 13.75%, 13.50%, 13.25%, 13%, 12.75%, 12.50%, 12.25%, 12%, 11.75%, 11.50%, 11.25% 11%, 10.75%, 10.50%, 10.25% 10%, 9.75%, 9.50%, 9.25%, 9%, 8.75%, 8.50%, 8.25% 8%, 7.75%, 7.50%, 7.25%, 7%, 6.75%, 6.50%, 6.25%, 6%, 5.75%, 5.50%, 5.25%, 5%, 4.75%, 4.50%, 4.25%, 4%, 3.75%, 3.50%, 3.25%, 3%, 2.75%, 2.50%, 2.25%, 2%, 1.75%, 1.50%, 1.25%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% (or a number in the range defined by and including any two numbers above) w/w, w/v, or v/v.
- In some embodiments, the concentration of one or more compounds of the invention is in the range from approximately 0.0001% to approximately 50%, approximately 0.001% to approximately 40%, approximately 0.01% to approximately 30%, approximately 0.02% to approximately 29%, approximately 0.03% to approximately 28%, approximately 0.04% to approximately 27%, approximately 0.05% to approximately 26%, approximately 0.06% to approximately 25%, approximately 0.07% to approximately 24%, approximately 0.08% to approximately 23%, approximately 0.09% to approximately 22%, approximately 0.1% to approximately 21%, approximately 0.2% to approximately 20%, approximately 0.3% to approximately 19%, approximately 0.4% to approximately 18%, approximately 0.5% to approximately 17%, approximately 0.6% to approximately 16%, approximately 0.7% to approximately 15%, approximately 0.8% to approximately 14%, approximately 0.9% to approximately 12%, approximately 1% to approximately 10% w/w, w/v or v/v.
- In some embodiments, the concentration of one or more compounds of the invention is in the range from approximately 0.001% to approximately 10%, approximately 0.01% to approximately 5%, approximately 0.02% to approximately 4.5%, approximately 0.03% to approximately 4%, approximately 0.04% to approximately 3.5%, approximately 0.05% to approximately 3%, approximately 0.06% to approximately 2.5%, approximately 0.07% to approximately 2%, approximately 0.08% to approximately 1.5%, approximately 0.09% to approximately 1%, approximately 0.1% to approximately 0.9% w/w, w/v or v/v.
- In some embodiments, the amount of one or more compounds of the invention is equal to or less than 10 g, 9.5 g, 9.0 g, 8.5 g, 8.0 g, 7.5 g, 7.0 g, 6.5 g, 6.0 g, 5.5 g, 5.0 g, 4.5 g, 4.0 g, 3.5 g, 3.0 g, 2.5 g, 2.0 g, 1.5 g, 1.0 g, 0.95 g, 0.9 g, 0.85 g, 0.8 g, 0.75 g, 0.7 g, 0.65 g, 0.6 g, 0.55 g, 0.5 g, 0.45 g, 0.4 g, 0.35 g, 0.3 g, 0.25 g, 0.2 g, 0.15 g, 0.1 g, 0.09 g, 0.08 g, 0.07 g, 0.06 g, 0.05 g, 0.04 g, 0.03 g, 0.02 g, 0.01 g, 0.009 g, 0.008 g, 0.007 g, 0.006 g, 0.005 g, 0.004 g, 0.003 g, 0.002 g, 0.001 g, 0.0009 g, 0.0008 g, 0.0007 g, 0.0006 g, 0.0005 g, 0.0004 g, 0.0003 g, 0.0002 g, or 0.0001 g (or a number in the range defined by and including any two numbers above).
- In some embodiments, the amount of one or more compounds of the invention is more than 0.0001 g, 0.0002 g, 0.0003 g, 0.0004 g, 0.0005 g, 0.0006 g, 0.0007 g, 0.0008 g, 0.0009 g, 0.001 g, 0.0015 g, 0.002 g, 0.0025 g, 0.003 g, 0.0035 g, 0.004 g, 0.0045 g, 0.005 g, 0.0055 g, 0.006 g, 0.0065 g, 0.007 g, 0.0075 g, 0.008 g, 0.0085 g, 0.009 g, 0.0095 g, 0.01 g, 0.015 g, 0.02 g, 0.025 g, 0.03 g, 0.035 g, 0.04 g, 0.045 g, 0.05 g, 0.055 g, 0.06 g, 0.065 g, 0.07 g, 0.075 g, 0.08 g, 0.085 g, 0.09 g, 0.095 g, 0.1 g, 0.15 g, 0.2 g, 0.25 g, 0.3 g, 0.35 g, 0.4 g, 0.45 g, 0.5 g, 0.55 g, 0.6 g, 0.65 g, 0.7 g, 0.75 g, 0.8 g, 0.85 g, 0.9 g, 0.95 g, 1 g, 1.5 g, 2 g, 2.5, 3 g, 3.5, 4 g, 4.5 g, 5 g, 5.5 g, 6 g, 6.5 g, 7 g, 7.5 g, 8 g, 8.5 g, 9 g, 9.5 g, or 10 g (or a number in the range defined by and including any two numbers above).
- In some embodiments, the amount of one or more compounds of the invention is in the range of 0.0001-10 g, 0.0005-9 g, 0.001-8 g, 0.005-7 g, 0.01-6 g, 0.05-5 g, 0.1-4 g, 0.5-4 g, or 1-3 g.
- The compounds according to the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from 0.01 to 1000 mg, from 0.5 to 100 mg, from 1 to 50 mg per day, and from 5 to 40 mg per day are examples of dosages that may be used. An exemplary dosage is 10 to 30 mg per day. The exact dosage will depend upon the route of administration, the form in which the compound is administered, the subject to be treated, the body weight of the subject to be treated, and the preference and experience of the attending physician.
- A pharmaceutical composition of the invention typically contains an active ingredient (i.e., a compound of the disclosure) of the present invention or a pharmaceutically acceptable salt and/or coordination complex thereof, and one or more pharmaceutically acceptable excipients, carriers, including but not limited to inert solid diluents and fillers, diluents, sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.
- Described below are non-limiting exemplary pharmaceutical compositions and methods for preparing the same.
- In some embodiments, the invention provides a pharmaceutical composition for oral administration containing a compound of the invention, and a pharmaceutical excipient suitable for oral administration.
- In some embodiments, the invention provides a solid pharmaceutical composition for oral administration containing: (i) an effective amount of a compound of the invention; optionally (ii) an effective amount of a second agent; and (iii) a pharmaceutical excipient suitable for oral administration. In some embodiments, the composition further contains: (iv) an effective amount of a third agent.
- In some embodiments, the pharmaceutical composition may be a liquid pharmaceutical composition suitable for oral consumption. Pharmaceutical compositions of the invention suitable for oral administration can be presented as discrete dosage forms, such as capsules, cachets, or tablets, or liquids or aerosol sprays each containing a predetermined amount of an active ingredient as a powder or in granules, a solution, or a suspension in an aqueous or non-aqueous liquid, an oil-in-water emulsion, or a water-in-oil liquid emulsion. Such dosage forms can be prepared by any of the methods of pharmacy, but all methods include the step of bringing the active ingredient into association with the carrier, which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation. For example, a tablet can be prepared by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granules, optionally mixed with an excipient such as, but not limited to, a binder, a lubricant, an inert diluent, and/or a surface active or dispersing agent. Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- This invention further encompasses anhydrous pharmaceutical compositions and dosage forms comprising an active ingredient, since water can facilitate the degradation of some compounds. For example, water may be added (e.g., 5%) in the pharmaceutical arts as a means of simulating long-term storage in order to determine characteristics such as shelf-life or the stability of formulations over time. Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. Pharmaceutical compositions and dosage forms of the invention which contain lactose can be made anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected. An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions may be packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastic or the like, unit dose containers, blister packs, and strip packs.
- An active ingredient can be combined in an intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier can take a wide variety of forms depending on the form of preparation desired for administration. In preparing the compositions for an oral dosage form, any of the usual pharmaceutical media can be employed as carriers, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like in the case of oral liquid preparations (such as suspensions, solutions, and elixirs) or aerosols; or carriers such as starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents can be used in the case of oral solid preparations, in some embodiments without employing the use of lactose. For example, suitable carriers include powders, capsules, and tablets, with the solid oral preparations. If desired, tablets can be coated by standard aqueous or nonaqueous techniques.
- Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, microcrystalline cellulose, and mixtures thereof.
- Examples of suitable fillers for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.
- Disintegrants may be used in the compositions of the invention to provide tablets that disintegrate when exposed to an aqueous environment. Too much of a disintegrant may produce tablets which may disintegrate in the bottle. Too little may be insufficient for disintegration to occur and may thus alter the rate and extent of release of the active ingredient(s) from the dosage form. Thus, a sufficient amount of disintegrant that is neither too little nor too much to detrimentally alter the release of the active ingredient(s) may be used to form the dosage forms of the compounds disclosed herein. The amount of disintegrant used may vary based upon the type of formulation and mode of administration, and may be readily discernible to those of ordinary skill in the art. About 0.5 to about 15 weight percent of disintegrant, or about 1 to about 5 weight percent of disintegrant, may be used in the pharmaceutical composition. Disintegrants that can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums or mixtures thereof.
- Lubricants which can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, or mixtures thereof. Additional lubricants include, for example, a syloid silica gel, a coagulated aerosol of synthetic silica, or mixtures thereof. A lubricant can optionally be added, in an amount of less than about 1 weight percent of the pharmaceutical composition.
- When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying and/or suspending agents, together with such diluents as water, ethanol, propylene glycol, glycerin and various combinations thereof.
- The tablets can be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
- Surfactant which can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. That is, a mixture of hydrophilic surfactants may be employed, a mixture of lipophilic surfactants may be employed, or a mixture of at least one hydrophilic surfactant and at least one lipophilic surfactant may be employed.
- A suitable hydrophilic surfactant may generally have an HLB value of at least 10, while suitable lipophilic surfactants may generally have an HLB value of or less than about 10. An empirical parameter used to characterize the relative hydrophilicity and hydrophobicity of non-ionic amphiphilic compounds is the hydrophilic-lipophilic balance (“HLB” value). Surfactants with lower HLB values are more lipophilic or hydrophobic, and have greater solubility in oils, while surfactants with higher HLB values are more hydrophilic, and have greater solubility in aqueous solutions.
- Hydrophilic surfactants are generally considered to be those compounds having an HLB value greater than about 10, as well as anionic, cationic, or zwitterionic compounds for which the HLB scale is not generally applicable. Similarly, lipophilic (i.e., hydrophobic) surfactants are compounds having an HLB value equal to or less than about 10. However, HLB value of a surfactant is merely a rough guide generally used to enable formulation of industrial, pharmaceutical and cosmetic emulsions.
- Hydrophilic surfactants may be either ionic or non-ionic. Suitable ionic surfactants include, but are not limited to, alkylammonium salts; fusidic acid salts; fatty acid derivatives of amino acids, oligopeptides, and polypeptides; glyceride derivatives of amino acids, oligopeptides, and polypeptides; lecithins and hydrogenated lecithins; lysolecithins and hydrogenated lysolecithins; phospholipids and derivatives thereof; lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkylsulfates; fatty acid salts; sodium docusate; acyl lactylates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides; and mixtures thereof.
- Within the aforementioned group, ionic surfactants include, by way of example: lecithins, lysolecithin, phospholipids, lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkylsulfates; fatty acid salts; sodium docusate; acylactylates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides; and mixtures thereof.
- Ionic surfactants may be the ionized forms of lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, lysophosphatidylserine, PEG-phosphatidylethanolamine, PVP—phosphatidylethanolamine, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, cholylsarcosine, caproate, caprylate, caprate, laurate, myristate, palmitate, oleate, ricinoleate, linoleate, linolenate, stearate, lauryl sulfate, teracecyl sulfate, docusate, lauroyl carnitines, palmitoyl carnitines, myristoyl carnitines, and salts and mixtures thereof.
- Hydrophilic non-ionic surfactants may include, but are not limited to, alkylglucosides; alkylmaltosides; alkylthioglucosides; lauryl macrogolglycerides; polyoxyalkylene alkyl ethers such as polyethylene glycol alkyl ethers; polyoxyalkylene alkylphenols such as polyethylene glycol alkyl phenols; polyoxyalkylene alkyl phenol fatty acid esters such as polyethylene glycol fatty acids monoesters and polyethylene glycol fatty acids diesters; polyethylene glycol glycerol fatty acid esters; polyglycerol fatty acid esters; polyoxyalkylene sorbitan fatty acid esters such as polyethylene glycol sorbitan fatty acid esters; hydrophilic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids, and sterols; polyoxyethylene sterols, derivatives, and analogues thereof; polyoxyethylated vitamins and derivatives thereof; polyoxyethylene-polyoxypropylene block copolymers; and mixtures thereof; polyethylene glycol sorbitan fatty acid esters and hydrophilic transesterification products of a polyol with at least one member of the group consisting of triglycerides, vegetable oils, and hydrogenated vegetable oils. The polyol may be glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, or a saccharide.
- Other hydrophilic-non-ionic surfactants include, without limitation, PEG-10 laurate, PEG-12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, PEG-32 distearate, PEG-40 stearate, PEG-100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-40 castor oil, PEG-35 castor oil, PEG-60 castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-60 corn oil, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, polyglyceryl-10 laurate, PEG-30 cholesterol, PEG-25 phyto sterol, PEG-30 soya sterol, PEG-20 trioleate, PEG-40 sorbitan oleate, PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, POE-20 oleyl ether, POE-20 stearyl ether, tocopheryl PEG-100 succinate, PEG-24 cholesterol, polyglyceryl-lOoleate, Tween 40, Tween 60, sucrose monostearate, sucrose mono laurate, sucrose monopalmitate, PEG 10-100 nonyl phenol series, PEG 15-100 octyl phenol series, and poloxamers.
- Suitable lipophilic surfactants include, by way of example only: fatty alcohols; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acids esters; propylene glycol fatty acid esters; sorbitan fatty acid esters; polyethylene glycol sorbitan fatty acid esters; sterols and sterol derivatives; polyoxyethylated sterols and sterol derivatives; polyethylene glycol alkyl ethers; sugar esters; sugar ethers; lactic acid derivatives of mono- and di-glycerides; hydrophobic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids and sterols; oil-soluble vitamins/vitamin derivatives; and mixtures thereof. Within this group, preferred lipophilic surfactants include glycerol fatty acid esters, propylene glycol fatty acid esters, and mixtures thereof, or are hydrophobic transesterification products of a polyol with at least one member of the group consisting of vegetable oils, hydrogenated vegetable oils, and triglycerides.
- In one embodiment, the composition may include a solubilizer to ensure good solubilization and/or dissolution of the compound of the present invention and to minimize precipitation of the compound of the present invention. This can be especially important for compositions for non-oral use, e.g., compositions for injection. A solubilizer may also be added to increase the solubility of the hydrophilic drug and/or other components, such as surfactants, or to maintain the composition as a stable or homogeneous solution or dispersion.
- Examples of suitable solubilizers include, but are not limited to, the following: alcohols and polyols, such as ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediols and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives; ethers of polyethylene glycols having an average molecular weight of about 200 to about 6000, such as tetrahydrofurfuryl alcohol PEG ether (glycofurol) or methoxy PEG; amides and other nitrogen-containing compounds such as 2-pyrrolidone, 2-piperidone, 8-caprolactam, N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide and polyvinylpyrrolidone; esters such as ethyl propionate, tributyl citrate, acetyl tri ethyl citrate, acetyl tributyl citrate, tri ethyl citrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, ε-caprolactone and isomers thereof, δ-valerolactone and isomers thereof, β-butyrolactone and isomers thereof; and other solubilizers known in the art, such as dimethyl acetamide, dimethyl isosorbide, N-methyl pyrrolidones, monooctanoin, diethylene glycol monoethyl ether, and water.
- Mixtures of solubilizers may also be used. Examples include, but not limited to, triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrins, ethanol, polyethylene glycol 200-100, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide. Particularly preferred solubilizers include sorbitol, glycerol, triacetin, ethyl alcohol, PEG-400, glycofurol and propylene glycol.
- The amount of solubilizer that can be included is not particularly limited. The amount of a given solubilizer may be limited to a bioacceptable amount, which may be readily determined by one of skill in the art. In some circumstances, it may be advantageous to include amounts of solubilizers far in excess of bioacceptable amounts, for example to maximize the concentration of the drug, with excess solubilizer removed prior to providing the composition to a subject using conventional techniques, such as distillation or evaporation. Thus, if present, the solubilizer can be in a weight ratio of 10%, 25% o, 50%), 100% o, or up to about 200%> by weight, based on the combined weight of the drug, and other excipients. If desired, very small amounts of solubilizer may also be used, such as 5%>, 2%>, 1%) or even less. Typically, the solubilizer may be present in an amount of about 1%> to about 100%, more typically about 5%> to about 25%> by weight.
- The composition can further include one or more pharmaceutically acceptable additives and excipients. Such additives and excipients include, without limitation, detackifiers, anti-foaming agents, buffering agents, polymers, antioxidants, preservatives, chelating agents, viscomodulators, toniciflers, flavorants, colorants, odorants, opacifiers, suspending agents, binders, fillers, plasticizers, lubricants, and mixtures thereof.
- In addition, an acid or a base may be incorporated into the composition to facilitate processing, to enhance stability, or for other reasons. Examples of pharmaceutically acceptable bases include amino acids, amino acid esters, ammonium hydroxide, potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, synthetic hydrocalcite, magnesium aluminum hydroxide, diisopropylethylamine, ethanolamine, ethylenediamine, triethanolamine, triethylamine, triisopropanolamine, trimethylamine, tris(hydroxymethyl)aminomethane (TRIS) and the like. Also suitable are bases that are salts of a pharmaceutically acceptable acid, such as acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid, and the like. Salts of polyprotic acids, such as sodium phosphate, disodium hydrogen phosphate, and sodium dihydrogen phosphate can also be used. When the base is a salt, the cation can be any convenient and pharmaceutically acceptable cation, such as ammonium, alkali metals, alkaline earth metals, and the like. Example may include, but not limited to, sodium, potassium, lithium, magnesium, calcium and ammonium.
- Suitable acids are pharmaceutically acceptable organic or inorganic acids. Examples of suitable inorganic acids include hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid, boric acid, phosphoric acid, and the like. Examples of suitable organic acids include acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acids, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid and the like.
- In some embodiments, the invention provides a pharmaceutical composition for injection containing a compound of the present invention and a pharmaceutical excipient suitable for injection. Components and amounts of agents in the compositions are as described herein.
- The forms in which the novel compositions of the present invention may be incorporated for administration by injection include aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles.
- Aqueous solutions in saline are also conventionally used for injection. Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, for the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
- Sterile injectable solutions are prepared by incorporating the compound of the present invention in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, certain desirable methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- Pharmaceutical Compositions for Topical (e.g. Transdermal) Delivery.
- In some embodiments, the invention provides a pharmaceutical composition for transdermal delivery containing a compound of the present invention and a pharmaceutical excipient suitable for transdermal delivery.
- Compositions of the present invention can be formulated into preparations in solid, semisolid, or liquid forms suitable for local or topical administration, such as gels, water soluble jellies, creams, lotions, suspensions, foams, powders, slurries, ointments, solutions, oils, pastes, suppositories, sprays, emulsions, saline solutions, dimethylsulfoxide (DMSO)-based solutions. In general, carriers with higher densities are capable of providing an area with a prolonged exposure to the active ingredients. In contrast, a solution formulation may provide more immediate exposure of the active ingredient to the chosen area.
- The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients, which are compounds that allow increased penetration of, or assist in the delivery of, therapeutic molecules across the stratum corneum permeability barrier of the skin. There are many of these penetration-enhancing molecules known to those trained in the art of topical formulation.
- Examples of such carriers and excipients include, but are not limited to, humectants (e.g., urea), glycols (e.g., propylene glycol), alcohols (e.g., ethanol), fatty acids (e.g., oleic acid), surfactants (e.g., isopropyl myristate and sodium lauryl sulfate), pyrrolidones, glycerol monolaurate, sulfoxides, terpenes (e.g., menthol), amines, amides, alkanes, alkanols, water, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
- Another exemplary formulation for use in the methods of the present invention employs transdermal delivery devices (“patches”). Such transdermal patches may be used to provide continuous or discontinuous infusion of a compound of the present invention in controlled amounts, either with or without another agent.
- The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Pat. Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
- Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a face mask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.
- Pharmaceutical compositions may also be prepared from compositions described herein and one or more pharmaceutically acceptable excipients suitable for sublingual, buccal, rectal, intraosseous, intraocular, intranasal, epidural, or intraspinal administration. Preparations for such pharmaceutical compositions are well-known in the art. See, e.g., Anderson, Philip O.; Knoben, James E.; Troutman, William G, eds., Handbook of Clinical Drug Data, Tenth Edition, McGraw-Hill, 2002; Pratt and Taylor, eds., Principles of Drug Action, Third Edition, Churchill Livingston, N.Y., 1990; Katzung, ed., Basic and Clinical Pharmacology, Ninth Edition, McGraw Hill, 20037ybg; Goodman and Gilman, eds., The Pharmacological Basis of Therapeutics, Tenth Edition, McGraw Hill, 2001; Remingtons Pharmaceutical Sciences, 20th Ed., Lippincott Williams & Wilkins, 2000; Martindale, The Extra Pharmacopoeia, Thirty-Second Edition (The Pharmaceutical Press, London, 1999); all of which are incorporated by reference herein in their entirety.
- Administration of the compounds or pharmaceutical composition of the present invention can be effected by any method that enables delivery of the compounds to the site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, intraarterial, subcutaneous, intramuscular, intravascular, intraperitoneal or infusion), topical (e.g. transdermal application), rectal administration, via local delivery by catheter or stent or through inhalation. Compounds can also be administered intraadiposally or intrathecally.
- In some embodiments, the compounds or pharmaceutical composition of the present invention are administered by intravenous injection.
- The amount of the compound administered will be dependent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician. However, an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to 7 g/day, preferably about 0.05 to about 2.5 g/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, e.g. by dividing such larger doses into several small doses for administration throughout the day.
- In some embodiments, a compound of the invention is administered in a single dose.
- Typically, such administration will be by injection, e.g., intravenous injection, in order to introduce the agent quickly. However, other routes may be used as appropriate. A single dose of a compound of the invention may also be used for treatment of an acute condition.
- In some embodiments, a compound of the invention is administered in multiple doses. Dosing may be about once, twice, three times, four times, five times, six times, or more than six times per day. Dosing may be about once a month, once every two weeks, once a week, or once every other day. In another embodiment a compound of the invention and another agent are administered together about once per day to about 6 times per day. In another embodiment the administration of a compound of the invention and an agent continues for less than about 7 days. In yet another embodiment the administration continues for more than about 6, 10, 14, 28 days, two months, six months, or one year. In some cases, continuous dosing is achieved and maintained as long as necessary.
- Administration of the compounds of the invention may continue as long as necessary. In some embodiments, a compound of the invention is administered for more than 1, 2, 3, 4, 5, 6, 7, 14, or 28 days. In some embodiments, a compound of the invention is administered for less than 28, 14, 7, 6, 5, 4, 3, 2, or 1 day. In some embodiments, a compound of the invention is administered chronically on an ongoing basis, e.g., for the treatment of chronic effects.
- An effective amount of a compound of the invention may be administered in either single or multiple doses by any of the accepted modes of administration of agents having similar utilities, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant.
- The compositions of the invention may also be delivered via an impregnated or coated device such as a stent, for example, or an artery-inserted cylindrical polymer. Such a method of administration may, for example, aid in the prevention or amelioration of restenosis following procedures such as balloon angioplasty. Without being bound by theory, compounds of the invention may slow or inhibit the migration and proliferation of smooth muscle cells in the arterial wall which contribute to restenosis. A compound of the invention may be administered, for example, by local delivery from the struts of a stent, from a stent graft, from grafts, or from the cover or sheath of a stent. In some embodiments, a compound of the invention is admixed with a matrix. Such a matrix may be a polymeric matrix, and may serve to bond the compound to the stent. Polymeric matrices suitable for such use, include, for example, lactone-based polyesters or copolyesters such as polylactide, polycaprolactonglycolide, polyorthoesters, polyanhydrides, polyaminoacids, polysaccharides, polyphosphazenes, poly (ether-ester) copolymers (e.g. PEO-PLLA); polydimethylsiloxane, poly(ethylene-vinylacetate), acrylate-based polymers or copolymers (e.g. polyhydroxyethyl methylmethacrylate, polyvinyl pyrrolidinone), fluorinated polymers such as polytetrafluoroethylene and cellulose esters. Suitable matrices may be nondegrading or may degrade with time, releasing the compound or compounds. Compounds of the invention may be applied to the surface of the stent by various methods such as dip/spin coating, spray coating, dip-coating, and/or brush-coating. The compounds may be applied in a solvent and the solvent may be allowed to evaporate, thus forming a layer of compound onto the stent. Alternatively, the compound may be located in the body of the stent or graft, for example in microchannels or micropores. When implanted, the compound diffuses out of the body of the stent to contact the arterial wall. Such stents may be prepared by dipping a stent manufactured to contain such micropores or microchannels into a solution of the compound of the invention in a suitable solvent, followed by evaporation of the solvent. Excess drug on the surface of the stent may be removed via an additional brief solvent wash. In yet other embodiments, compounds of the invention may be covalently linked to a stent or graft. A covalent linker may be used which degrades in vivo, leading to the release of the compound of the invention. Any bio-labile linkage may be used for such a purpose, such as ester, amide or anhydride linkages. Compounds of the invention may additionally be administered intravascularly from a balloon used during angioplasty. Extravascular administration of the compounds via the pericard or via advential application of formulations of the invention may also be performed to decrease restenosis.
- A variety of stent devices which may be used as described are disclosed, for example, in the following references, all of which are hereby incorporated by reference: U.S. Pat. Nos. 5,451,233; 5,040,548; 5,061,273; 5,496,346; 5,292,331; 5,674,278; 3,657,744; 4,739,762; 5,195,984; 5,292,331; U.S. Pat. Nos. 5,674,278; 5,879,382; 6,344,053.
- The compounds of the invention may be administered in dosages. It is known in the art that due to intersubject variability in compound pharmacokinetics, individualization of dosing regimen is necessary for optimal therapy. Dosing for a compound of the invention may be found by routine experimentation in light of the instant disclosure.
- When a compound of the invention is administered in a composition that comprises one or more agents, and the agent has a shorter half-life than the compound of the invention unit dose forms of the agent and the compound of the invention may be adjusted accordingly.
- The subject pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.
- Exemplary parenteral administration forms include solutions or suspensions of active compound in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.
- The method typically comprises administering to a subject a therapeutically effective amount of a compound of the invention. The therapeutically effective amount of the subject combination of compounds may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The term also applies to a dose that will induce a particular response in target cells, e.g., reduction of proliferation or downregulation of activity of a target protein. The specific dose will vary depending on the particular compounds chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.
- As used herein, the term “IC50” refers to the half maximal inhibitory concentration of an inhibitor in inhibiting biological or biochemical function. This quantitative measure indicates how much of a particular inhibitor is needed to inhibit a given biological process (or component of a process, i.e. an enzyme, cell, cell receptor or microorganism) by half. In other words, it is the half maximal (50%) inhibitory concentration (IC) of a substance (50% IC, or IC50). EC50 refers to the plasma concentration required for obtaining 50%> of a maximum effect in vivo.
- In some embodiments, the subject methods utilize a MCL-1 inhibitor with an IC50 value of about or less than a predetermined value, as ascertained in an in vitro assay. In some embodiments, the MCL-1 inhibitor inhibits MCL-1 a with an IC50 value of about 1 nM or less, 2 nM or less, 5 nM or less, 7 nM or less, 10 nM or less, 20 nM or less, 30 nM or less, 40 nM or less, 50 nM or less, 60 nM or less, 70 nM or less, 80 nM or less, 90 nM or less, 100 nM or less, 120 nM or less, 140 nM or less, 150 nM or less, 160 nM or less, 170 nM or less, 180 nM or less, 190 nM or less, 200 nM or less, 225 nM or less, 250 nM or less, 275 nM or less, 300 nM or less, 325 nM or less, 350 nM or less, 375 nM or less, 400 nM or less, 425 nM or less, 450 nM or less, 475 nM or less, 500 nM or less, 550 nM or less, 600 nM or less, 650 nM or less, 700 nM or less, 750 nM or less, 800 nM or less, 850 nM or less, 900 nM or less, 950 nM or less, 1 μM or less, 1.1 μM or less, 1.2 μM or less, 1.3 μM or less, 1.4 μM or less, 1.5 μM or less, 1.6 μM or less, 1.7 μM or less, 1.8 μM or less, 1.9 μM or less, 2 μM or less, 5 μM or less, 10 μM or less, 15 μM or less, 20 μM or less, 25 μM or less, 30 μM or less, 40 μM or less, 50 μM, 60 μM, 70 μM, 80 μM, 90 μM, 100 μM, 200 μM, 300 μM, 400 μM, or 500 μM, or less, (or a number in the range defined by and including any two numbers above).
- In some embodiments, the MCL-1 inhibitor selectively inhibits MCL-1 a with an IC50 value that is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, or 1000 times less (or a number in the range defined by and including any two numbers above) than its IC50 value against one, two, or three other MCL-1s.
- In some embodiments, the MCL-1 inhibitor selectively inhibits MCL-1 a with an IC50 value that is less than about 1 nM, 2 nM, 5 nM, 7 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, 120 nM, 140 nM, 150 nM, 160 nM, 170 nM, 180 nM, 190 nM, 200 nM, 225 nM, 250 nM, 275 nM, 300 nM, 325 nM, 350 nM, 375 nM, 400 nM, 425 nM, 450 nM, 475 nM, 500 nM, 550 nM, 600 nM, 650 nM, 700 nM, 750 nM, 800 nM, 850 nM, 900 nM, 950 nM, 1 μM, 1.1 μM, 1.2 μM, 1.3 μM, 1.4 μM, 1.5 μM, 1.6 μM, 1.7 μM, 1.8 μM, 1.9 μM, 2 μM, 5 μM, 10 μM, 15 μM, 20 μM, 25 μM, 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, 80 μM, 90 μM, 100 μM, 200 μM, 300 μM, 400 μM, or 500 μM (or in the range defined by and including any two numbers above), and said IC50 value is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, or 1000 times less (or a number in the range defined by and including any two numbers above) than its IC50 value against one, two or three other MCL-1s.
- The subject methods are useful for treating a disease condition associated with MCL-1. Any disease condition that results directly or indirectly from an abnormal activity or expression level of MCL-1 can be an intended disease condition.
- Different disease conditions associated with MCL-1 have been reported. MCL-1 has been implicated, for example, auto-immune diseases, neurodegeneration (such as Parkinson's disease, Alzheimer's disease and ischaemia), inflammatory diseases, viral infections and cancer such as, for example, colon cancer, breast cancer, small-cell lung cancer, non-small-cell lung cancer, bladder cancer, ovarian cancer, prostate cancer, chronic lymphoid leukemia, lymphoma, myeloma, acute myeloid leukemia, or pancreatic cancer.
- Non-limiting examples of such conditions include but are not limited to Acanthoma, Acinic cell carcinoma, Acoustic neuroma, Acral lentiginous melanoma, Acrospiroma, Acute eosinophilic leukemia, Acute lymphoblastic leukemia, Acute lymphocytic leukemia, Acute megakaryoblastic leukemia, Acute monocytic leukemia, Acute myeloblasts leukemia with maturation, Acute myeloid dendritic cell leukemia, Acute myeloid leukemia, Acute myelogenous leukemia, Acute promyelocytic leukemia, Adamantinoma, Adenocarcinoma, Adenoid cystic carcinoma, Adenoma, Adenomatoid odontogenic tumor, Adrenocortical carcinoma, Adult T-cell leukemia, Aggressive NK-cell leukemia, AIDS-Related Cancers, AIDS-related lymphoma, Alveolar soft part sarcoma, Ameloblastic fibroma, Anal cancer, Anaplastic large cell lymphoma, Anaplastic thyroid cancer, Angioimmunoblastic T-cell lymphoma, Angiomyolipoma, Angiosarcoma, Appendix cancer, Astrocytoma, Atypical teratoid rhabdoid tumor, Basal cell carcinoma, Basal-like carcinoma, B-cell leukemia, B-cell lymphoma, Bellini duct carcinoma, Biliary tract cancer, Bladder cancer, Blastoma, Bone Cancer, Bone tumor, Brain Stem Glioma, Brain Tumor, Breast Cancer, Brenner tumor, Bronchial Tumor, Bronchioloalveolar carcinoma, Brown tumor, Burkitt's lymphoma, Cancer of Unknown Primary Site, Carcinoid Tumor, Carcinoma, Carcinoma in situ, Carcinoma of the penis, Carcinoma of Unknown Primary Site, Carcinosarcoma, Castleman's Disease, Central Nervous System Embryonal Tumor, Cerebellar Astrocytoma, Cerebral Astrocytoma, Cervical Cancer, Cholangiocarcinoma, Chondroma, Chondrosarcoma, Chordoma, Choriocarcinoma, Choroid plexus papilloma, Chronic Lymphocytic Leukemia, Chronic monocytic leukemia, Chronic myelogenous leukemia, Chronic Myeloproliferative Disorder, Chronic neutrophilic leukemia, Clear-cell tumor, Colon Cancer, Colorectal cancer, Craniopharyngioma, Cutaneous T-cell lymphoma, Degos disease, Dermatofibrosarcoma protuberans, Dermoid cyst, Desmoplastic small round cell tumor, Diffuse large B cell lymphoma, Dysembryoplastic neuroepithelial tumor, Embryonal carcinoma, Endodermal sinus tumor, Endometrial cancer, Endometrial Uterine Cancer, Endometrioid tumor, Enteropathy-associated T-cell lymphoma, Ependymoblastoma, Ependymoma, Epidermoid cancer, Epithelioid sarcoma, Erythroleukemia, Esophageal cancer, Esthesioneuroblastoma, Ewing Family of Tumor, Ewing Family Sarcoma, Ewing's sarcoma, Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor, Extrahepatic Bile Duct Cancer, Extramammary Paget's disease, Fallopian tube cancer, Fetus in fetu, Fibroma, Fibrosarcoma, Follicular lymphoma, Follicular thyroid cancer, Gallbladder Cancer, Gallbladder cancer, Ganglioglioma, Ganglioneuroma, Gastric Cancer, Gastric lymphoma, Gastrointestinal cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Gastrointestinal stromal tumor, Germ cell tumor, Germinoma, Gestational choriocarcinoma, Gestational Trophoblastic Tumor, Giant cell tumor of bone, Glioblastoma multiforme, Glioma, Gliomatosis cerebri, Glomus tumor, Glucagonoma, Gonadoblastoma, Granulosa cell tumor, Hairy Cell Leukemia, Head and Neck Cancer, Head and neck cancer, Heart cancer, Hemoglobinopathies such as b-thalassemia and sickle cell disease (SCD), Hemangioblastoma, Hemangiopericytoma, Hemangiosarcoma, Hematological malignancy, Hepatocellular carcinoma, Hepatosplenic T-cell lymphoma, Hereditary breast-ovarian cancer syndrome, Hodgkin Lymphoma, Hodgkin's lymphoma, Hypopharyngeal Cancer, Hypothalamic Glioma, Inflammatory breast cancer, Intraocular Melanoma, Islet cell carcinoma, Islet Cell Tumor, Juvenile myelomonocytic leukemia, Kaposi Sarcoma, Kaposi's sarcoma, Kidney Cancer, Klatskin tumor, Krukenberg tumor, Laryngeal Cancer, Laryngeal cancer, Lentigo maligna melanoma, Leukemia, Lip and Oral Cavity Cancer, Liposarcoma, Lung cancer, Luteoma, Lymphangioma, Lymphangiosarcoma, Lymphoepithelioma, Lymphoid leukemia, Lymphoma, Macroglobulinemia, Malignant Fibrous Histiocytoma, Malignant fibrous histiocytoma, Malignant Fibrous Histiocytoma of Bone, Malignant Glioma, Malignant Mesothelioma, Malignant peripheral nerve sheath tumor, Malignant rhabdoid tumor, Malignant triton tumor, MALT lymphoma, Mantle cell lymphoma, Mast cell leukemia, Mastocytosis, Mediastinal germ cell tumor, Mediastinal tumor, Medullary thyroid cancer, Medulloblastoma, Medulloblastoma, Medulloepithelioma, Melanoma, Melanoma, Meningioma, Merkel Cell Carcinoma, Mesothelioma, Mesothelioma, Metastatic Squamous Neck Cancer with Occult Primary, Metastatic urothelial carcinoma, Mixed Mullerian tumor, Monocytic leukemia, Mouth Cancer, Mucinous tumor, Multiple Endocrine Neoplasia Syndrome, Multiple Myeloma, Multiple myeloma, Mycosis Fungoides, Mycosis fungoides, Myelodysplasia Disease, Myelodysplasia Syndromes, Myeloid leukemia, Myeloid sarcoma, Myeloproliferative Disease, Myxoma, Nasal Cavity Cancer, Nasopharyngeal Cancer, Nasopharyngeal carcinoma, Neoplasm, Neurinoma, Neuroblastoma, Neuroblastoma, Neurofibroma, Neuroma, Nodular melanoma, Non-Hodgkin Lymphoma, Non-Hodgkin lymphoma, Nonmelanoma Skin Cancer, Non-Small Cell Lung Cancer, Ocular oncology, Oligoastrocytoma, Oligodendroglioma, Oncocytoma, Optic nerve sheath meningioma, Oral Cancer, Oral cancer, Oropharyngeal Cancer, Osteosarcoma, Osteosarcoma, Ovarian Cancer, Ovarian cancer, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Ovarian Low Malignant Potential Tumor, Paget's disease of the breast, Pancoast tumor, Pancreatic Cancer, Pancreatic cancer, Papillary thyroid cancer, Papillomatosis, Paraganglioma, Paranasal Sinus Cancer, Parathyroid Cancer, Penile Cancer, Perivascular epithelioid cell tumor, Pharyngeal Cancer, Pheochromocytoma, Pineal Parenchymal Tumor of Intermediate Differentiation, Pineoblastoma, Pituicytoma, Pituitary adenoma, Pituitary tumor, Plasma Cell Neoplasm, Pleuropulmonary blastoma, Polyembryoma, Precursor T-lymphoblastic lymphoma, Primary central nervous system lymphoma, Primary effusion lymphoma, Primary Hepatocellular Cancer, Primary Liver Cancer, Primary peritoneal cancer, Primitive neuroectodermal tumor, Prostate cancer, Pseudomyxoma peritonei, Rectal Cancer, Renal cell carcinoma, Respiratory Tract Carcinoma Involving the NUT Gene onChromosome 15, Retinoblastoma, Rhabdomyoma, Rhabdomyosarcoma, Richter's transformation, Sacrococcygeal teratoma, Salivary Gland Cancer, Sarcoma, Schwannomatosis, Sebaceous gland carcinoma, Secondary neoplasm, Seminoma, Serous tumor, Sertoli-Leydig cell tumor, Sex cord-stromal tumor, Sezary Syndrome, Signet ring cell carcinoma, Skin Cancer, Small blue round cell tumor, Small cell carcinoma, Small Cell Lung Cancer, Small cell lymphoma, Small intestine cancer, Soft tissue sarcoma, Somatostatinoma, Soot wart, Spinal Cord Tumor, Spinal tumor, Splenic marginal zone lymphoma, Squamous cell carcinoma, Stomach cancer, Superficial spreading melanoma, Supratentorial Primitive Neuroectodermal Tumor, Surface epithelial-stromal tumor, Synovial sarcoma, T-cell acute lymphoblastic leukemia, T-cell large granular lymphocyte leukemia, T-cell leukemia, T-cell lymphoma, T-cell prolymphocytic leukemia, Teratoma, Terminal lymphatic cancer, Testicular cancer, Thecoma, Throat Cancer, Thymic Carcinoma, Thymoma, Thyroid cancer, Transitional Cell Cancer of Renal Pelvis and Ureter, Transitional cell carcinoma, Urachal cancer, Urethral cancer, Urogenital neoplasm, Uterine sarcoma, Uveal melanoma, Vaginal Cancer, Verner Morrison syndrome, Verrucous carcinoma, Visual Pathway Glioma, Vulvar Cancer, Waldenstrom's macroglobulinemia, Warthin's tumor, Wilms' tumor, or any combination thereof.
- In some embodiments, said method is for treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, eczema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.
- In other embodiments, said method is for treating a disease selected from breast cancer, lung cancer, pancreatic cancer, prostate cancer, colon cancer, ovarian cancer, uterine cancer, or cervical cancer.
- In other embodiments, said method is for treating a disease selected from leukemia such as acute myeloid leukemia (AML), acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, myelodysplasia, myeloproliferative disorders, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), mastocytosis, chronic lymphocytic leukemia (CLL), multiple myeloma (MM), myelodysplastic syndrome (MDS) or epidermoid cancer.
- Compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered to treat any of the described diseases, alone or in combination with a medical therapy. Medical therapies include, for example, surgery and radiotherapy (e.g., gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, systemic radioactive isotopes).
- In other aspects, compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered to treat any of the described diseases, alone or in combination with one or more other agents.
- In other methods, the compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered in combination with agonists of nuclear receptors agents.
- In other methods, the compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered in combination with antagonists of nuclear receptors agents.
- In other methods, the compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered in combination with an anti-proliferative agent.
- For treating cancer and other proliferative diseases, the compounds of the invention can be used in combination with chemotherapeutic agents, agonists or antagonists of nuclear receptors, or other anti-proliferative agents. The compounds of the invention can also be used in combination with a medical therapy such as surgery or radiotherapy, e.g., gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes. Examples of suitable chemotherapeutic agents include any of: abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, all-trans retinoic acid, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bendamustine, bevacizumab, bexarotene, bleomycin, bortezombi, bortezomib, busulfan intravenous, busulfan oral, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, dasatinib, daunorubicin, decitabine, denileukin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone propionate, eculizumab, epirubicin, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib mesylate, interferon alfa 2a, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine, mechlorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, nelarabine, nofetumomab, oxaliplatin, paclitaxel, pamidronate, panobinostat, panitumumab, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pipobroman, plicamycin, procarbazine, quinacrine, rasburicase, rituximab, ruxolitinib, sorafenib, streptozocin, sunitinib, sunitinib maleate, tamoxifen, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinstat and zoledronate.
- In some embodiments, the compounds of the invention can be used in combination with a therapeutic agent that targets an epigenetic regulator. Examples of epigenetic regulators include bromodomain inhibitors, the histone lysine methyltransferase inhibitors, histone arginine methyl transferase inhibitors, histone demethylase inhibitors, histone deacetylase inhibitors, histone acetylase inhibitors, and DNA methyltransferase inhibitors. Histone deacetylase inhibitors include, e.g., vorinostat. Histone arginine methyl transferase inhibitors include inhibitors of protein arginine methyltransferases (PRMTs) such as PRMT5, PRMT1 and PRMT4. DNA methyltransferase inhibitors include inhibitors of DNMT1 and DNMT3.
- For treating cancer and other proliferative diseases, the compounds of the invention can be used in combination with targeted therapies, including JAK kinase inhibitors (e.g. Ruxolitinib), PI3 kinase inhibitors including PI3K-delta selective and broad spectrum PI3K inhibitors, MEK inhibitors, Cyclin Dependent kinase inhibitors, including CDK4/6 inhibitors and CDK9 inhibitors, BRAF inhibitors, mTOR inhibitors, proteasome inhibitors (e.g. Bortezomib, Carfilzomib), HDAC inhibitors (e.g. panobinostat, vorinostat), DNA methyl transferase inhibitors, dexamethasone, bromo and extra terminal family member (BET) inhibitors, BTK inhibitors (e.g. ibrutinib, acalabrutinib), BCL2 inhibitors (e.g. venetoclax), dual BCL2 family inhibitors (e.g. BCL2/BCLxL), PARP inhibitors, FLT3 inhibitors, or LSD 1 inhibitors.
- In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1, e.g., an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), or PDR001. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab. In some embodiments, the anti-PD1 antibody is pembrolizumab. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1, e.g., an anti-PD-L1 monoclonal antibody. In some embodiments, the anti-PD-L1 monoclonal antibody is atezolizumab, durvalumab, or BMS-935559. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab.
- In some embodiments, the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatory agent. Examples of an alkylating agent include cyclophosphamide (CY), melphalan (MEL), and bendamustine. In some embodiments, the proteasome inhibitor is carfilzomib. In some embodiments, the corticosteroid is dexamethasone (DEX). In some embodiments, the immunomodulatory agent is lenalidomide (LEN) or pomalidomide (POM).
- For treating autoimmune or inflammatory conditions, the compound of the invention can be administered in combination with a corticosteroid such as triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, or flumetholone.
- For treating autoimmune or inflammatory conditions, the compound of the invention can be administered in combination with an immune suppressant such as fluocinolone acetonide (Retisert®), rimexolone (AL-2178, Vexol, Alcon), or cyclosporine (Restasis®).
- Compounds of the disclosure also include, for example, the compounds and genera identified m Tables A, B, and C.
-
TABLE B n = 0, 1 or 2 X = H, Me, F X = CHR, O, S, S(O)2, NR R = H or C1-C6alkyl R = H or C1-C6alkyl X = OH, F, OMe, OCF3 R = alkyl, cyclic alkyl, heterocyclic alkyl R = alkyl, cyclic alkyl, heterocyclic alkyl R = alkyl, cyclic alkyl, heterocyclic alkyl R = H or C1-C6alkyl n = 1, 2, 3 R = H or C1-C6alkyl R = H or C1-C6alkyl R = H or C1-C6alkyl n = 0-3 - Compounds of the disclosure also include, for example, the compounds described as Examples below.
- Compounds of the invention can be prepared according to numerous preparatory routes known in the literature. The Schemes below provide general guidance in connection with preparing the compounds of the invention. One skilled in the art would understand that the preparations shown in the Schemes can be modified or optimized using general knowledge of organic chemistry to prepare various compounds of the invention. Example synthetic methods for preparing compounds of the invention are provided in the Schemes below.
- A series of 1,3-diol derivatives of formula 4 (n=0, 1, 2) can be prepared by the methods outlined in Scheme 1. Johnson-Corey-Chaykovsky reaction of the substituted ketone 1 with sulfur ylide can form the corresponding epoxide 2 which can be converted to the aldehyde 3 under Lewis acid (e.g., boron trifluoride diethyl etherate or TiCl4). The aldehyde 3 can be transformed to the 1,3-diol derivative 4 by treatment with formaldehyde under basic conditions (e.g., KOH).
- A series of 1,3-diol derivatives of formula 12 (n=0, 1, 2) can be prepared by the methods outlined in Scheme 2. Compound 7 can be obtained by protecting the alcohol group (e.g., TBS or other silyl group) in 6 obtained from the reduction of the acid 5 using a suitable reductive reagent including, (e.g., BH3, NaBH4, LiBH4, LiAlH4). Lithiation of compound 7 with a suitable agent (e.g., BuLi or another lithium reagent) at low temperature and subsequent reaction of the intermediate with the ketone 8 can afford the alcohol derivative 9. Removal of the protecting group (e.g., TBAF removal of TBS group) followed by intra-molecular Mitsunobo reaction (e.g., DEAD and triphenylphospine) can yield the cyclic ether 11. Removal of the protecting group by treatment of 11 with acid (e.g. pTSA or HCl) can provide the 1,3-diol derivative 12.
- A series of spiro-sulfonamide derivatives of formula 22 (X=CH2, O; n=0, 1, 2) can be prepared by the methods outlined in Scheme 3. Mono-protection of the hydroxyl group 13 can be achieved by reaction of 4 or 12 with substituted benzoyl chloride in the presence of a base (e.g, TEA, DIEA, or NaOH). Oxidation of the hydroxyl group of 13 using a suitable oxidant (e.g., Dess-Martin or Swern oxidation conditions) can afford the corresponding aldehyde 14 which can be transformed into compound 15 by reaction with trimethyl orthoformate in the presence of p-toluenesulfonic acid (p-TsOH). Reaction of compound 15 with 4-fluoro-3-nitrobenzenesulfonamide 16 in the presence of base (e.g., potassium tert-butoxide, sodium tert-butoxide, LiHMDS or NaLiHMDS) can afford the corresponding compound 17. De-protection of the acetal group in 17 to the aldehyde 18 can be achieved under acid conditions (e.g., Amberlyst, p-TsOH, HCl in dioxane or TFA). Reduction of the nitro group in 18 using a suitable reducing agent (e.g., iron in acetic acid, iron and NH4Cl in ethanol) can yield the imine intermediate 19 which can be further reduced to the amine derivative 20 by using suitable reductive reagent (e.g., NaBH4 or NaBH(OAc)3). Alternatively, the amine derivative 20 can be obtained by direct hydrogenation of the nitro compound 18 in the presence of a palladium catalyst (e.g., Pd/C or Pd(OH)2/C in an appropriate solvent such as methanol or ethanol). Reductive amination of the amine derivative 20 can afford the corresponding derivative 21 which can be transformed into the desired product 22 by reaction with the suitable acid using standard amide coupling conditions (e.g., EDCI, CDI, BOP, HATU or HBTU in the presence of a suitable base, TEA or DIEA).
- Alternatively, a series of sulfonamide derivatives of formula 21 (X=CH2, O; n=0, 1, 2) can be prepared by the methods outlined in Scheme 4. Reaction of the sulfonyl chloride 23 with bis-(4-methoxybenzyl)-amine (PMB)2NH 24 can form the corresponding sulfonamide 25 which can be transformed into the derivative 30 in a similar manner as described for compound 15 to compound 21 in the scheme 3. The removal of the PMB protecting groups in 30 to afford the sulfonamide derivative 21 can be achieved by using acid (e.g., TFA in DCM) or hydrogenation conditions (e.g., palladium catalyzed hydrogenation Pd/C with H2).
- A series of macro-cyclic sulfonamide derivatives of formula 36 (X=CH2, O; n=0, 1, 2; m=0, 1, 2) can be prepared by the methods outlined in Scheme 5. The sulfonamide 33 can be obtained by the removal of the protecting groups (e.g. PMB) in 32 under acid conditions (e.g. TFA, HCl) or hydrogenation conditions (e.g., palladium catalyzed hydrogenation Pd/C with H2) following the reductive amination of the sulfonamide 29 with the appropriate aldehyde or ketone 31 (Ros=optional substituent) under suitable conditions (e.g. imine formation followed by treatment with a suitable reducing agent, such as NaBH3(CN) or NaBH(OAc)3). The amide coupling of the sulfonamide 33 with the suitable acid 34 using a coupling agent (e.g. EDC, DCC, or HATU) in the presence of a suitable base (e.g. TEA or DIEA) can yield the macrocyclic precursor 35 which can be then be converted to the corresponding macrocyclic-sulfonamide derivative 36 using a suitable ring closing metathesis (RCM) catalyst (e.g. Grubbs catalyst, Grubbs-II catalyst, Grubbs-III catalyst, Hoveyda-Grubbs catalyst or Zhan catalyst 1B) under standard reaction conditions.
- Similarly, a series of macrocyclic sulfonamide derivatives of formula 39 (X=CH2, O; n=0, 1, 2; m=0, 1, 2) can be prepared by the methods outlined in Scheme 6. The amide coupling of the sulfonamide 33 with the appropriate acid 37 using a coupling agent (e.g. EDC, DCC, or HATU) in the presence of a suitable base (e.g. TEA or DIEA) can provide the sulfonamide derivative 38 which can be then converted to the corresponding macrocyclic sulfonamide derivative 39 in the presence of an RCM catalyst as described in Scheme 4.
- A series of macrocyclic sulfonyl carbamate derivatives of formula 42 (X=CH2, O; n=0, 1, 2; m=0, 1, 2) can be prepared similar methods outlined in Scheme 7. The sulfonamide 33 can react with the appropriate chloroformate derivative 40 in the presence of a suitable base (e.g. DIEA, TEA, or NaOH) to produce the corresponding sulfonyl carbamate 41 which can be transformed into the desired macrocycle of formula 42 in the presence of an RCM catalyst as described in Scheme 4.
- Alternatively, the macrocyclic sulfonamide derivatives of formula 36 (X=CH2, O; n=0, 1, 2; m=0, 1, 2) can be prepared by the methods outlined in Scheme 8. Intermolecular olefin metathesis reaction of compound 33 with the vinyl derivative 43 in the presence of suitable olefin metathesis catalyst, (e.g., Grubbs catalyst, Grubbs-II catalyst, Grubbs-III catalyst, Hoveyda-Grubbs catalyst or Zhan catalyst 1B under suitable reaction conditions) can provide the corresponding olefin compound 44 which can be then hydrolyzed under basic conditions (e.g., LiOH or NaOH) to provide the corresponding acid 45. Intra-molecular amide formation of 45 can afford compound 36 using a suitable amide coupling reagent (e.g., EDCI, CDI, BOP, HATU, or HBTU) and base (e.g., DMAP, Et3N, or Hunig's base).
- In a similar manner, a series of macrocyclic sulfonyl urea derivatives of formula 49 (X=CH2, O; n=0, 1, 2; m=0, 1, 2) can be prepared by the methods outlined in Scheme 9. Grubbs metathesis reaction of compound 33 with the vinyl derivative 46 can provide the corresponding olefin compound 47. Removal the protecting Boc-group in 47 by using acid (e.g., TFA in DCM, HCl in dioxane) can afford the corresponding amine 48. Treatment of 48 with a suitable reagent such as CDI, phosgene or triphosgene and a base (e.g., DMAP, Et3N, or Hunig's base) can provide the macrocyclic sulfonyl urea derivative 49.
- Alternatively, a series of macro-cyclic sulfonyl urea derivatives of formula 49 (X=CH2, O; n=0, 1, 2; m=0, 1, 2) can be prepared by the methods outlined in Scheme 10. The sulfonyl urea derivatives 49 can be obtained by treatment of the sulfonamide 33 with diphenyl carbonate or 4-nitrophenyl chloroformate in the presence of DMAP and triethylamine or Hunig's base, follow by the addition of the appropriate amine 50. Alternatively, treatment of the amine 50 with phosgene, or triphosgene to form the corresponding carbamoyl chloride which can react with the sulfonamide 33 to afford the
sulfonyl urea derivatives 51. RCM reaction of 51 using methods described above can afford macrocycles of formula 49. - A series of macrocyclic sulfonamide derivatives of formula 59 (X=CH2, O; n=0, 1, 2) can be prepared by the methods outlined in Scheme 10. The alcohol derivative 54 can be obtained by hydrolysis of the acetate ester 53 which can be produced by the reductive amination of 29 with the aldehyde 52. Mitsunobo reaction (e.g., DEAD and triphenylphospine) of compound 54 with ester 55 (Ros=optional substituent) can yield the ether derivative 56. Removal of the PMB groups in 56 under acid conditions (e.g. TFA, HCl) or hydrogenation conditions (e.g., palladium catalyzed hydrogenation Pd/C with H2) can give 57, and hydrolysis of the ester group in 57 under basic conditions (e.g., LiOH or NaOH in water/THF) can afford the sulfonamide-acid derivative 58. Intra-molecular amide formation of 58 can form the macro-cyclic sulfonamide derivative 59 by methods provided above.
- A series of spiro-cyclic sulfonamide derivatives of formula 60 can be prepared by the methods outlined in Scheme 12. Alkylation of phenol compound 61 with a bromide 62 can give the corresponding ether 63 in the presence of a base (e.g., NaH or NaOH) which can react with diethyl malonate 64 or other dialkyl malonate in the presence of a suitable palladium catalyst (e.g., Pd(PtButyl)3 or other Pd catalyst) to afford the malonate derivative 65. 1,3-diol derivative 67 can be obtained by reduction (e.g., DIBAL, LAH, or NaBH4) of the diethyl ester 66 provided by treatment of the malonate derivative 65 with 4-nitrobenzenesulfonyl fluoride in the presence of a base (e.g., DBU or DIEA). Asymmetric mono-protecting of the OH-group 68 can be achieved by reaction of 67 with substituted benzoyl chloride in the presence of a suitable chiral catalyst, such as (R,R)-Kang Catalyst. Dess-Martin oxidation or Swern oxidation of the hydroxyl group of 68 can afford the corresponding aldehyde 69 which can be transformed to compound 70 by reaction with trimethyl orthoformate in the presence of acid (e.g., p-TsOH in methanol). Hydrolysis of compound 70 can yield the alcohol 71 which can be transformed into the spiro-cyclic sulfonamide derivatives 60 in a similar manner as the those described above for compound 15 to compound 20 in Scheme 3. Reaction of the alcohol 71 with 4-fluoro-3-nitrobenzenesulfonamide 25 in the presence of base (e.g., potassium tert-butoxide, sodium tert-butoxide, LiHMDS or NaLiHMDS) can afford the corresponding compound 72. De-protection of the acetal group in 72 to the aldehyde 73 can be achieved under acid conditions (e.g., Amberlyst, p-TsOH, HCl in dioxane or TFA). Reduction of the nitro group in 73 by using a suitable reducing agent (e.g., iron in acetic acid, iron or zinc and NH4Cl in ethanol) followed by further reduction of the imine formed in situ with suitable reductive reagent (e.g., NaBH4 or NaBH(OAc)) can afford the spiro-cyclic sulfonamide derivatives of formula 60.
- A series of allyl alcohol derivatives of formula 81 or 82 can be prepared by the methods outlined in Scheme 13. Reductive amination of the spiro-sulfonamide 74 with aldehyde 75 using reductive agent (e.g., NaBH4, NaBH(OAc)3, or NaBCNH3) can afford the corresponding product 76 which can be transformed into the alcohol 77 under saponification conditions (e.g. acid or base). Swern oxidation or Dess-Martin oxidation of the alcohol 77 can afford the aldehyde 78. Alkylation of 78 with a suitable reagent (e.g., vinylmagnesium bromide or vinyllithium) can yield a mixture of the allyl alcohol 79 and 80. The diastereomers can be separated by chromatography (e.g., silica gel column, or preparative HPLC on a Cl8 column, or by SFC using a suitable column) using suitable conditions. Removal of the protecting group PMB in 79 or 80 under acid conditions (e.g., TFA in DCM or HCl in dioxane or phosphoric acid in water) can produce the 81 or 82, respectively.
- Alternatively, the allyl alcohol derivatives of formula 81 or 82 can be prepared by the methods outlined in Scheme 14 via reductive amination of the spiro-sulfonamide 74 with the aldehyde 85 or 86 by methods described in Scheme 13.
- The aldehyde 85 or 86 can be prepared by the methods outlined in Scheme 15. Alkylation of 75 with a suitable agent (e.g., vinylmagnesium bromide or vinyllithium) can produce a mixture of the allyl alcohol 83 or 84 that can be separated by chromatographic methods as described above. Oxidation of 83 or 84 under suitable conditions (e.g., Dess-Martin or Swern conditions) can afford the 85 or 86, respectively.
- A series of carbamate derivatives of formula 92 can be prepared by the methods outlined in Scheme 16. Reaction of the allyl alcohol 81 or 82 with acid 87 can yield the amide 88 under amide coupling conditions (e.g., BOP, HATU, HBTU, or EDCI, and an organic base such as DMAP, Et3N, or Hunig's base). Hydrolysis under basic conditions (e.g., LiOH or NaOH) of 88 can give the alcohol 89. Macrocyclic alcohol 90 can be obtained by a RCM reaction of 89 using RCM reaction conditions described above. Macrocyclic alcohol 90 can be transformed into the desired carbamate derivative 92 by reaction with a suitable dialkylcarbamoyl chloride 93, or by reaction with diphenyl carbonate or CDI followed by treatment with suitable amine RcRdNH.
- Alternative, a series of carbamate derivatives of formula 98 can be prepared by the methods outlined in Scheme 17. Reaction of the allyl alcohol 81 or 82 with 3-allyl-oxazolidine-2,5-dione 94 in the presence of a suitable base (e.g., DBU or DIEA) can afford the amide 95 which can undergo a RCM reaction to yield the corresponding macrocycles 96. Reductive amination of 96 with an aldehyde RCHO with a suitable reducing agent (e.g., NaBH3(CN) or NaBH(OAc)3) can afford 97 which can be transformed into the desired carbamate derivative 98 by methods similar to those shown for conversion of 90 to 92 as described in Scheme 16.
- A series of 2-aminoethylene ether of formula 102 can be prepared by the methods outlined in Scheme 18. Epoxide opening of compound 99 (Ros=optional substituent) with macrocyclic alcohol 90 can give the corresponding alcohol 100 which can be transformed into the ether 102 by a two-step process of activation of the alcohol (e.g., mesylation or tosylation) to yield 101 with a leaving group (Lg) and then displacement of the Lg with an amine RcRdNH to afford 102.
- In a similar manner, a series of aminoalkylene ether of formula 105 can be prepared by the methods outlined in Scheme 19. Reaction of the macrocyclic alcohol 90 with bromoalkyl trifluoromethanesulfonate 103 (Ros=optional substituent, n=1-5) can give the bromide 104 which can be converted to the aminoalkylene ether 105 by reaction with a suitable amine RcRdNH.
- A series of 2-aminoethylene ether of formula 110 and amide derivative of formula 111 can be prepared by the methods outlined in Scheme 20. Reaction of the macrocyclic alcohol 90 with substituted 2-bromoacetic acid 106 (Ros=optional substituent) using a suitable base (e.g. NaH or DBU) can give the acid 107 which can be converted to the isobutyl carbonic anhydride 108 by treatment with isobutyl chloroformate. Reduction of the anhydride 108 with a suitable reducing agent (e.g., DIBAL or NaBH4) at low temperature can provide the aldehyde 109 which can be transformed into the 2-aminoethylene ether 110 by reductive amination with RcRdNH using reductive agent (e.g., NaBH4, NaBH(OAc)3, or NaBCNH3). Alternatively, reaction of the anhydride 108 with amine RcRdNH can yield the corresponding amide 111.
-
-
- To a solution of 6-chlorotetralin-1-one (10.0 g, 55.3 mmol) in DMSO (100 mL) was added trimethylsulfonium iodide (12.4 g, 60.9 mmol) and hydroxypotassium (6.21 g, 110 mmol), the mixture was stirred at 25° C. for 24 hours. The mixture was added to ice water (500 mL), extracted with MTBE (400 mL×3), combined the organic phases, washed with brine (500 mL×2), dried over Na2SO4, filtered and concentrated in vacuum to give 6′-chlorospiro[oxirane-2,1′-tetralin] (10.0 g, 51.3 mmol, 92% yield).
-
- To a solution of 6′-chlorospiro[oxirane-2,1′-tetralin] (10.0 g, 51.3 mmol) in THF (160 mL) was added Boron trifluoride etherate (364 mg, 2.57 mmol) at −8° C., the solution was stirred at −8° C. for 10 mins. The reaction was quenched with sat. NaHCO3 (200 mL) at −8° C., extracted the aqueous with MTBE (400 mL×2), combined the organic phases, washed with brine (400 mL), dried over Na2SO4, filtered and concentrated in vacuum to give 6-chlorotetralin-1-carbaldehyde (11.40 g, 70% purity, 40.995 mmol, 79% yield).
-
- To a solution of 6-chlorotetralin-1-carbaldehyde (11.4 g, 70% purity, 41 mmol) in 2-(2-hydroxyethoxy)ethanol (80 mL, 41 mmol) was added paraformaldehyde (56 mL, 41 mmol), then potassium hydroxide (56 mL, 41 mmol) was added to the mixture at 5° C. The reaction mixture was stirred at 45° C. for 1 h. The reaction mixture was added brine (250 mL), extracted with DCM (300 mL×3), combined the organic phases, dried over Na2SO4, filtered and concentrated in vacuum, the residue was purified by silica gel column chromatography (PE:EA=1.5:1) to give [6-chloro-1-(hydroxymethyl)tetralin-1-yl]methanol (11.2 g, 75% purity, 90% yield). 1H NMR (400 MHz, CDCl3): δ 7.31-7.34 (m, 2H), 7.11-7.14 (m, 2H), 3.87-3.91 (m, 2H), 3.72-3.76 (m, 2H), 2.73-2.76 (m, 2H), 2.11-2.15 (m, 2H), 1.89-1.92 (m, 2H), 1.79-1.83 (m, 2H).
-
- To a solution of [6-chloro-1-(hydroxymethyl)tetralin-1-yl]methanol (11.2 g, 37 mmol) in DCM (150 mL) was added benzoyl chloride (6.26 g, 44 mmol) at 0° C., following by drop-wise addition of DIPEA (7.4 mL, 44 mmol). The mixture stirred at 25° C. 16 h. Added DCM (150 mL) to the mixture, washed with sat. NH4Cl (100 mL) and brine (100 mL), dried over Na2SO4, filtered and concentrated in vacuum, the residue was purified by silica gel column chromatography (PE:EA=9:1) to give 11.65 g of racemic product. 1H NMR (400 MHz, CDCl3): δ 8.00-8.02 (m, 2H), 7.57-7.61 (m, 1H), 7.44-7.48 (m, 3H), 7.14-7.16 (m, 2H), 4.48 (s, 2H), 3.74-3.82 (m, 2H), 2.78-2.81 (m, 2H), 1.83-1.95 (m, 4H).
-
- To a solution of [6-chloro-1-(hydroxymethyl)tetralin-1-yl]methyl benzoate (1.48 g, 4.47 mmol) in DCM (25 mL) was added Dess-Martin periodinane (2.84 g, 6.7 mmol) at 0° C., then the mixture was stirred at 25° C. for 1 h. To the reaction mixture was added a 1:1 mixture of 10% Na2S2O3/sat. NaHCO3solution (100 mL). The mixture was extracted with DCM (100 mL×2). The combined organic phases were washed with brine (15 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by FC on a silica gel column to give (6-chloro-1-formyl-tetralin-1-yl)methyl benzoate (1.24 g, 84% yield). 1H NMR (400 MHz, CDCl3): δ 9.61 (s, 1H), 7.94-7.96 (m, 2H), 7.54-7.58 (m, 1H), 7.41-7.45 (m, 2H), 7.15-7.21 (m, 3H), 4.75 (d, J=11.6 Hz, 1H), 4.55 (d, J=11.6 Hz, 1H), 2.81-2.85 (m, 2H), 2.19-2.23 (m, 1H), 2.00-2.06 (m, 1H), 1.89-1.95 (m, 2H).
-
- To a solution of (6-chloro-1-formyl-tetralin-1-yl)methyl benzoate (1.24 g, 3.77 mmol) in methanol (25 mL) were added p-TsOH H2O (35 mg, 0.19 mmol) and trimethyl orthoformate (1.2 g, 11.3 mmol). The mixture was stirred at 70° C. for 4 h., then concentrated to 50% volume. The residue was diluted with THF (25 mL) and 1 N NaOH (25 mL) was added. The resulting reaction mixture was stirred at 40° C. 4 h. The solvent was removed. The residue was extracted with EA (20 mL×3). The combined organic layers were washed with 1 N NaOH (50 mL) and brine (100 mL), dried over Na2SO4, and concentrated under vacuum. The residue was purified by FC on a silica gel column (PE:EA=9:1) to give [6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methanol (0.98 g, 96% yield). 1H NMR (400 MHz, CDCl3): δ 7.35 (d, J=8.4 Hz, 1H), 7.10-7.13 (m, 2H), 4.49 (s, 1H), 3.90 (dd, J=3.8, 11.2 Hz, 1H), 3.53 (dd, J=8.4, 11.2 Hz, 1H), 3.46 (s, 3H), 3.33 (s, 3H), 2.68-2.76 (m, 2H), 1.99-2.06 (m, 1H), 1.89-1.96 (m, 1H), 1.70-1.86 (m, 2H).
-
- A 100 mL flask with septum containing a mixture of [6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methanol (818 mg, 3.02 mmol) and potassium t-butoxide (779 mg, 6.94 mmol) under N2 was charged with THF (22 mL) giving a tan solution. The solution was stirred for 5 min at 0° C., followed by addition at 0° C. of a solution of 4-Fluoro-3-nitrobenzenesulfonamide (731 mg, 3.32 mmol) in THF (4 mL) over 8 min. The reaction was stirred at 0° C. for 20 min. The reaction mixture was quenched with sat. NH4Cl (10 mL). The reaction mixture was diluted with water (80 mL) and sat. NH4Cl (10 mL), and extracted with EtOAc (100 mL). The organic layer was washed with water (70 mL) and sat. NH4Cl (10 mL), and brine (50 mL). The aqueous layers were combined, and back-extracted with EtOAc (60 mL), washed with water (60 mL), and brine (30 mL). The organic layers were combined, dried over Na2SO4, and filtered and concentrated under reduced pressure to afford 4-[[6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methoxy]-3-nitro-benzenesulfonamide as a yellow foam (1.52 g) and was used directly in the next reaction without further purification. Rf=0.36 (1:1 hexanes:EtOAc); 1H NMR (500 MHz, DMSO-d6) δ 8.28 (d, J=2.3 Hz, 1H), 8.01 (dd, J=2.4, 8.9 Hz, 1H), 7.60 (dd, J=8.7, 16.3 Hz, 2H), 7.50 (s, 2H), 7.19-7.11 (m, 2H), 4.63 (s, 1H), 4.38-4.26 (m, 2H), 3.38 (s, 3H), 3.29 (s, 3H), 2.70 (d, J=6.2 Hz, 2H), 2.04-1.94 (m, 1H), 1.90-1.79 (m, 2H), 1.77-1.67 (m, 1H).
-
- The Amberlyst 16 wet catalyst was rinsed with acetone and dried under high vacuum before use. A 500 mL RBF with septum containing crude 4-[[6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methoxy]-3-nitro-benzenesulfonamide (1.42 g, 3.02 mmol) and pre-treated Amberlyst 16 wet (1 g, ˜7.44 mmol) under N2 was charged with acetone (30 mL). The reaction mixture was heated at 50° C. for 2 h., filtered through cotton and rinsed with DCM. The filtrate was concentrated under reduced pressure to afford 4-[(6-chloro-1-formyl-tetralin-1-yl)methoxy]-3-nitro-benzenesulfonamide as an orange/brown oil (1.7 g) which was used directly in the next reaction without further purification. Rf=0.31 (1:1 hexanes:EtOAc); 1H NMR (500 MHz, DMSO-d6) δ 9.65 (s, 1H), 8.27 (d, J=2.4 Hz, 1H), 8.03 (dd, J=2.4, 8.9 Hz, 1H), 7.63 (d, J=9.0 Hz, 1H), 7.50 (s, 2H), 7.35-7.29 (m, 2H), 7.26 (dd, J=2.4, 8.4 Hz, 1H), 4.77 (d, J=9.6 Hz, 1H), 4.47 (d, J=9.6 Hz, 1H), 2.78 (t, J=6.3 Hz, 2H), 2.19 (ddd, J=3.0, 8.9, 13.2 Hz, 1H), 1.99 (ddd, J=2.8, 8.1, 13.5 Hz, 1H), 1.89-1.80 (m, 1H), 1.80-1.70 (m, 1H).
-
- A solution of crude 4-[(6-chloro-1-formyl-tetralin-1-yl)methoxy]-3-nitro-benzenesulfonamide (assumed 3.02 mmol) in acetic acid (50 mL) was charged with iron powder (1.69 g, 30.2 mmol). The mixture was heated at 70° C. for 3 h. The mixture was charged with Celite, diluted with DCM (50 mL), filtered through a Celite plug, and rinsed with DCM to yield crude 6′-chlorospiro[2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide. Rf=0.24 (1:1 EtOAc/hexanes); LCMS calculated for C18H18ClN2O3S (M+H)+: m/z=377.07/379.07; found: 377.0/379.0.
- The filtrate was concentrated under reduced pressure, dissolved in DCM (30 mL), cooled to 0° C., and charged with sodium triacetoxyborohydride (1.99 g, 9.44 mmol) over 1 min. The reaction mixture was stirred at 0° C. for 1 min, then stirred at RT for 80 min. The reaction mixture was quenched with 10% citric acid (30 mL), diluted with water (30 mL), and extracted with EtOAc (125 mL). The organic layer was washed with 10% citric acid (10 mL) and water (40 mL), washed with brine (2×40 mL), dried over Na2SO4, and filtered. The filtrate was concentrated under reduced pressure to yield 6′-chlorospiro[4,5-dihydro-2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (1.24 g, 2.61 mmol, 86% yield) as a light tan foam. Rf=0.45 (1:1 EtOAc/hexanes). LCMS calculated for C18H20ClN2O3S (M+H)+: m/z=379.09/379.08; found: 379.0/381.0; 1H NMR (500 MHz, DMSO-d6) δ 7.81 (d, J=8.5 Hz, 1H), 7.26 (dd, J=2.4, 8.5 Hz, 1H), 7.18 (dd, J=2.3, 15.2 Hz, 2H), 7.13 (s, 2H), 7.02 (dd, J=2.3, 8.4 Hz, 1H), 6.92 (d, J=8.4 Hz, 1H), 6.20 (t, J=4.1 Hz, 1H), 4.08 (q, J=12.2 Hz, 2H), 3.23 (dd, J=4.7, 13.7 Hz, 1H), 2.77-2.65 (m, 2H), 1.87-1.66 (m, 3H), 1.55 (ddd, J=2.9, 9.7, 12.7 Hz, 1H).
-
-
- To a cooled (−35° C.) solution of 4-Fluoro-3-nitrobenzenesulfonyl chloride (4.89 g, 20.42 mmol) in THF (50 mL) was added Triethylamine (3.13 mL, 22.46 mmol), followed by addition of Bis-(4-methoxybenzyl)amine (4.97 mL, 20.7 mmol) in THF (50 mL) solution over 30 min. while the temperature was kept at −35° C. After completion of the addition, the temperature was allowed slowly to warm to 0° C. over 1 h., and the mixture was stirred at 0° C. for an additional hour. The mixture was neutralized with 1 N HCl to pH about 4-5 and diluted with EtOAc (100 mL). The organic layer was separated, washed with 1 N HCl (10 mL), 7.5% NaHCO3aqueous solution (20 mL), and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was treated with DCM (30 mL), and hexane was added to the suspension until it became cloudy. The resulting suspension was sonicated for 2 min. and left at r.t. for 1 h. The mixture was filtered. and washed with hexane to afford the desired title product (6.85 g) without further purification. The mother liquid was concentrated under reduced pressure. The residue was treated with DCM (5 mL) and hexane was added as the procedures mentioned above to afford the additional 0.51 g of the title product. Total product 4-fluoro-N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-benzenesulfonamide obtained is 7.36 g (78%). 1H NMR (400 MHz, DMSO-d6): δ 8.18-8.23 (m, 2H), 7.75-7.79 (q, 1H), 7.08 (d, 4H), 6.81 (d, 4H), 4.31 (s, 4H), 3.71 (s, 6H). 19F NMR (376 MHz, DMSO-d6): δ −112.54 (s, 1 F). LCMS calculated for C22H22FN2O6S (M+H)+: m/z=461.11; found: 461.1.
-
- Racemic product 6-chloro-1-(hydroxymethyl)tetralin-1-yl]methyl benzoate (intermediate 1, Step 4) was separated by Waters-SFC80 instrument under the separation conditions: Column: AD-H (2.5*25 cm, 10 um); Mobile phase A: Supercritical CO2, Mobile phase B: EtOH, A:B=80/20 at 60 mL/min; Circle Time: 15 min; Sample preparation: Ethanol; Injection Volume: 0.8 mL; Detector Wavelength: 214 nm; Column temperature: 25° C.; Back pressure: 100 bar. The separated products were determined by chiral HPLC. Chiral HPLC conditions: Chiral Column: AD-H, 5 um, 4.6 mm×250 mm (Daicel); Mobile phase: Supercritical C02/EtOH/DEA 70/30/0.06; Flow rate: 2.0 mL/min and Run time: 12 min. to afford [(1S)-6-chloro-1-(hydroxymethyl)tetralin-1-yl]methyl benzoate (P1, Retention time=4.952 min.) and [(1R)-6-chloro-1-(hydroxymethyl)tetralin-1-yl]methyl benzoate (P2, Retention time=6.410 min.). 1H NMR (400 MHz, CDCl3): δ 8.00-8.02 (m, 2H), 7.57-7.61 (m, 1H), 7.44-7.48 (m, 3H), 7.14-7.16 (m, 2H), 4.48 (s, 2H), 3.74-3.82 (m, 2H), 2.78-2.81 (m, 2H), 1.83-1.95 (m, 4H).
-
- This compound was prepared using procedures analogous to those described for Intermediate 1 using [(1S)-6-chloro-1-(hydroxymethyl)tetralin-1-yl]methyl benzoate (Step 2, P1) to replace the racemic [6-chloro-1-(hydroxymethyl)tetralin-1-yl]methyl benzoate in Step 5. 1H NMR (400 MHz, CDCl3): δ 9.61 (s, 1H), 7.94-7.96 (m, 2H), 7.55-7.58 (m, 1H), 7.41-7.45 (m, 2H), 7.15-7.20 (m, 3H), 4.73-4.76 (d, 1H), 4.53-4.56 (d, 1H), 2.82-2.85 (m, 2H), 2.20-2.26 (m, 1H), 2.01-2.07 (m, 1H), 1.90-1.96 (m, 2H).
-
- Method A: This compound was prepared using procedures analogous to those described for Intermediate 1 using [(1R)-6-chloro-1-formyl-tetralin-1-yl]methyl benzoate to replace the racemic (6-chloro-1-formyl-tetralin-1-yl)methyl benzoate in Step 6. 1H NMR (400 MHz, CDCl3+D2O): δ 7.34-7.36 (m, 1H), 7.10-7.12 (m, 2H), 4.49 (s, 1H), 3.89-3.91 (d, 1H), 3.50-3.53 (m, 1H), 3.46 (s, 3H), 3.33 (s, 3H), 2.68-2.76 (m, 2H), 1.99-2.06 (m, 1H), 1.89-1.96 (m, 1H), 1.70-1.86 (m, 2H).
- Method B: The racemic (6-chloro-1-formyl-tetralin-1-yl)methyl benzoate (Intermediate 1 Step 6) was separated by chiral column on Berger MG2 Preparative SFC instrument under the separation conditions: Column: ChiralPak IC (2×25 cm); Mobile phase A: i-PrOH, Mobile phase B: Supercritical CO2, A:B=1/3 at 60 mL/min; Circle Time (Run Time): 5 min injection intervals; Sample preparation: 20 mg/mL iPrOH/DCM; Injection Volume: 0.5 mL; Detector Wavelength: 220 nm; Column temperature: 30° C.; Back pressure: 100 bar. The separated products were determined by chiral HPLC on Berger Analytical SFC. Chiral HPLC conditions: Chiral Column: ChiralPak IC, 5 um, 4.6 mm×250 mm (Daicel); Mobile phase: i-PrOH/Supercritical CO2/EtOH 1/3; Flow rate: 3.0 mL/min and Run time: 7 min.; Detector Wavelength (UV length): 220 nm, 254 nm, and 280 nm; Column temperature: 30° C.; Back pressure: 120 bar. to afford [(1S)-6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methanol (P1, Retention time=1.96 min.) and [(1R)-6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methanol (P2, Retention time=2.69 min.)
-
- To a solution of [(R)-6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methanol (2.96 g, 10.93 mmol, P2) in THF (50 mL) was drop-wised add LiHMDS (11.5 mL, 11.4 mmol) under N2 atmosphere at −40° C., the solution was stirred at −40° C. for 5 mins, then dropwise added 4-fluoro-N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-benzenesulfonamide (7.55 g, 16.4 mmol) (Step 1) in THF (30 mL). The solution was stirred for 5 min. under −40° C., then the mixture was stirred at r.t. for 1 h. The reaction was cooled with ice-water bath, and quenched with sat. NH4Cl aqueous solution (100 mL). The mixture was extracted with EtOAc (100 mL×3). The combined organic layers were washed with sat. NH4Cl solution and brine, dried over Na2SO4, filtered and concentrated in vacuum. The residue was purified by flash chromatography on a silica gel column eluting with ethyl acetate (EA) and petroleum ether (PE) to give N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-4-[[(1R)-6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methoxy]benzenesulfonamide (6.41 g, 82% yield). 1H NMR (400 MHz, DMSO-d6): δ 8.06-8.07 (m, 1H), 7.97-8.00 (m, 1H), 7.60-7.62 (m, 1H), 7.49-7.51 (m, 1H), 7.14-7.17 (m, 2H), 6.99-7.07 (m, 4H), 6.77-6.79 (m, 4H), 4.62 (s, 1H), 4.27-4.36 (m, 2H), 4.24 (s, 4H), 3.70 (s, 6H), 3.39 (s, 3H), 3.30 (s, 3H), 2.68-2.71 (m, 2H), 1.98-2.00 (m, 1H), 1.81-1.85 (m, 2H), 1.71-1.73 (m, 1H).
-
- To a solution of N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-4-[[(1R)-6-chloro-1-(dimethoxymethyl)tetralin-1-yl]methoxy]benzenesulfonamide (6.11 g, 8.59 mmol) in THF (80 mL) and water (20 mL) was added p-TsOH H2O (3.27 g, 17.18 mmol), the mixture was stirred at 70° C. for 16 h. The mixture was cooled to 0° C., and sat. NaHCO3aqueous (100 mL) was added. The mixture was extracted with EA (100 mL×3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with EA and to give N,N-bis[(4-methoxyphenyl) methyl]-3-nitro-4-[[(1R)-6-chloro-1-formyl-tetralin-1-yl]methoxy]benzenesulfonamide (6.11 g, 85% purity, 91% yield).
-
- To a solution of N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-4-[[(1R)-6-chloro-1-formyl-tetralin-1-yl]methoxy]benzenesulfonamide (6.11 g, 7.81 mmol) in ethanol (40 mL) and water (20 mL) was added iron powder (2.18 g, 39 mmol) and NH4Cl (827 mg, 15.6 mmol), the mixture was stirred at 100° C. for 3 h. LCMS showed the reaction completed. The mixture was filtered. The filtrate was added H2O (20 mL), extracted with EA (30 mL×3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give (S)-6′-chloro-N,N-bis(4-methoxybenzyl)-3′,4′-dihydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-sulfonamide (6.11 g, 70% purity, 86% yield) which was directly used in next step reaction without further purification. LCMS calculated for C34H34ClN2O5S (M+H)+: m/z=617.18; found: 617.3.
-
- To a solution of (S)-6′-chloro-N,N-bis(4-methoxybenzyl)-3′,4′-dihydro-2H,2′H-spiro[benzo[b][1,4]oxazepine-3,1′-naphthalene]-7-sulfonamide (6.11 g, 6.73 mmol) (crude product from Step 7, 70% purity) in DCM (80 mL) was portion-wise added NaBH(OAc)3 (7.14 g, 33.67 mmol). The mixture was stirred at 25° C. for 16 h. LCMS showed the reaction worked well. The reaction was added sat. NaHCO3aqueous (80 mL), extracted with DCM (100 mL×3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with EA and PE to give (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[4,5-dihydro-2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (2.30 g, 53% yield). LCMS calculated for C34H36ClN2O5S (M+H)+: m/z=619.2; found: 619.3. 1H NMR (400 MHz, DMSO-d6): δ 7.81-7.83 (m, 1H), 7.24-7.28 (m, 2H), 7.17-7.18 (m, 1H), 6.95-7.06 (m, 6H), 6.78-6.80 (m, 4H), 6.20 (s, 1H), 4.15 (m, 4H), 4.08-4.14 (m, 2H), 3.68 (s, 6H), 3.30-3.36 (m, 1H), 3.23-3.27 (m, 1H), 2.71-2.75 (m, 2H), 1.76-1.86 (m, 3H), 1.56-1.61 (m, 1H).
-
- Step 1: [(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl acetate
- 2,2,2-trifluoroacetic acid (7.0 mL, 92 mmol) was dropwise added to a stirred solution of sodium borohydride (3.48 g, 92.0 mmol) in DCM (200 mL) at 0° C. The resulting mixture was stirred at 0° C. for 10 min. A solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[4,5-dihydro-2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (28.5 g, 46.03 mmol) and [(1R,2R)-2-formylcyclobutyl]methyl acetate (8.63 g, 55.24 mmol) in 200 mL DCM was then dropwise added at 0° C. The resulting mixture was stirred at room temperature for overnight. The reaction was monitored by LC-MS. Another 2 equivalents of sodium borohydride (3.48 g, 92.06 mmol) and 2,2,2-trifluoroacetic acid (7.04 mL, 92.06 mmol) were added to the mixture, followed by the stirring for 3 h. The reaction was quenched by addition of methanol (30 mL), and followed by addition of saturated NaHCO3solution (300 mL) slowly. The resulting mixture was extracted with DCM (300 mL×3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column using EtOAc/Heptanes (5-40%) to afford the desired product [(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl acetate (34.5 g, 45.4 mmol, 98% yield) as a white solid. LC-MS calc. for C40H43ClN2O6S [M+H]+: m/z=759.28/760.28; Found 759.67/760.64.
-
- To a solution of [(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl acetate (54.0 g, 71.1 mmol) in THF (500 mL), methanol (500 mL) and water (500 mL) was added lithium hydroxide monohydrate (14.9 g, 355 mmol). The mixture was stirred at r.t. overnight. The solvent was removed, and the aqueous layer was extracted with DCM (100 mL×3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to afford (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-(hydroxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (52 g, 101% yield) as white solid which was directly used for the next step without further purification. LC-MS calc. for C40H45ClN2O6S [M+H]+: m/z=717.27/718.27; Found 717.6/718.6.
-
- DMSO (20.5 mL, 289 mmol) was slowly added to a cooled (−78° C.) solution of oxalyl chloride (12.4 mL, 144.9 mmol) in DCM (1000 mL). Gas was produced during this addition. The mixture was stirred at −78° C. for 30 min. Then a solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-(hydroxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (52.0 g, 72.4 mmol) in DCM (50 mL) was added over 5 min. The resulting mixture was stirred at −78° C. for 40 min. Then triethylamine (101 mL, 724 mmol) was added. The solution was stirred at −78° C. for additional 10 min, and allowed to warm slowly to 0° C. After the starting material was consumed, water (150 mL) was added. The organic layer were separated. The aqueous layer was extracted with DCM (300 mL×3). The combined organic layers were dried over sodium sulfate and concentrated. The residue was purified by flash chromatography on a silica gel column with EtOAc/Heptanes (5-50%) to afford (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-formylcyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (43 g, 83% yield) as a white solid. LC-MS calc. for C40H43ClN2O6S [M+H]+: m/z=715.25/716.26; Found 715.7/716.7.
-
- Vinylmagnesium bromide (1.0 M solution in THF, 300 mL, 300 mmol) was diluted with THF (200 mL) in a 3 necked round bottom flack under nitrogen. (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-formylcyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (43.0 g, 60.1 mmol) dissolved in THF (400 mL) was introduced dropwise through a dropping funnel over 2 hours at room temperature. The reaction was monitored by LC-MS. After the starting material was consumed, the reaction was then quenched by addition of sat. aqueous solution NH4Cl (300 mL) at 0° C. The organic layer was then separated, and the aqueous layer was extracted with ethyl acetate (300 mL×2). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column using EtOAc/Heptanes (5-40%) to afford two products: P1 (the earlier eluted product: 24.3 g, 40%) and P2 (the latter eluted product: 20 g, 33%).
- P1 was assigned as (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Rt=4.43 min from LC-MS). LC-MS calc. for C42H48ClN2O6S [M+H]+: m/z=743.28/744.29; Found 743.76/744.78. 1H NMR (300 MHz, CDCl3) δ 7.76 (t, J=7.2 Hz, 1H), 7.53 (d, J=1.9 Hz, 1H), 7.24-7.14 (m, 2H), 7.12 (d, J=2.0 Hz, 1H), 7.03-6.97 (m, 5H), 6.79 (t, J=5.7 Hz, 4H), 5.84-5.69 (m, 1H), 5.16 (d, J=17.2 Hz, 1H), 5.05 (d, J=10.4 Hz, 1H), 4.26 (t, J=5.6 Hz, 4H), 4.13 (s, 2H), 3.97 (d, J=4.4 Hz, 1H), 3.80 (d, J=1.8 Hz, 6H), 3.74 (d, J=6.2 Hz, 1H), 3.26 (d, J=14.2 Hz, 1H), 3.09 (dd, J=15.0, 9.3 Hz, 1H), 2.93 (d, J=4.2 Hz, 1H), 2.83-2.75 (m, 2H), 2.48-2.35 (m, 1H), 2.10-1.92 (m, 4H), 1.82 (m, 3H), 1.50 (m, 2H).
- And P2 was assigned as (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Rt=4.13 min from LC-MS). LC-MS calc. for C42H48ClN2O6S [M+H]+: m/z=743.28/745.29; Found 743.8/745.8. 1H NMR (300 MHz, CDCl3) δ 7.75-7.68 (m, 1H), 7.24-7.14 (m, 3H), 7.12 (d, J=2.0 Hz, 1H), 7.01 (t, J=8.3 Hz, 5H), 6.79 (d, J=8.7 Hz, 4H), 5.85 (ddd, J=17.0, 10.4, 6.4 Hz, 1H), 5.29 (dd, J=17.2, 1.2 Hz, 1H), 5.17-5.08 (m, 1H), 4.26 (d, J=8.4 Hz, 4H), 4.14 (d, J=8.0 Hz, 3H), 3.81 (s, 6H), 3.69 (d, J=14.3 Hz, 1H), 3.59 (d, J=12.9 Hz, 1H), 3.31 (d, J=14.3 Hz, 1H), 3.15 (dd, J=14.9, 9.0 Hz, 1H), 2.84-2.76 (m, 2H), 2.67-2.56 (m, 1H), 2.23-2.09 (m, 2H), 2.03 (m, 2H), 1.86-1.73 (m, 3H), 1.59-1.46 (m, 2H).
-
- To a solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (24.3 g, 32.6 mmol, P1, Step 4) and anisole (23.7 mL, 218 mmol) in DCM (240 mL) was added 2,2,2-trifluoroacetic acid (243 mL). The mixture was stirred overnight. The reaction was monitored by LC-MS. Solvents were removed under reduced pressure. The residue was diluted with DCM (200 mL). The mixture was washed with saturated aqueous NaHCO3solution (200 mL×3) and brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with EA/heptane (5%-70%) to afford (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (15.7 g, 31.2 mmol, 95% yield) as a pale white solid. LC-MS calc. for C26H32ClN2O4S [M+H]+: m/z=503.17/505.17; Found 503.5/505.5; 1H NMR (300 MHz, CDCl3) δ 7.74 (d, J=8.5 Hz, 1H), 7.55 (d, J=1.8 Hz, 1H), 7.21 (dd, J=11.4, 4.2 Hz, 2H), 7.12-7.08 (m, 2H), 6.97-6.94 (m, 1H), 6.85 (d, J=8.6 Hz, 1H), 5.90-5.76 (m, 1H), 5.25 (d, J=17.2 Hz, 1H), 5.16-5.08 (m, 1H), 4.11 (s, 2H), 3.88 (d, J=5.1 Hz, 1H), 3.81 (s, 2H), 3.27 (d, J=14.3 Hz, 1H), 3.14 (m, 1H), 2.84-2.75 (m, 2H), 2.51 (dd, J=16.9, 8.5 Hz, 1H), 2.08 (m, 3H), 1.90 (dd, J=15.8, 5.6 Hz, 2H), 1.63 (m, 3H), 1.45 (t, J=12.1 Hz, 1H).
-
- This compound was prepared using procedures analogous to those described for step 5 using P2 Step 4. LC-MS calc. for C26H32ClN2O4S [M+H]+: m/z=503.17/505.17; Found 503.5/505.5; 1H NMR (300 MHz, CDCl3) δ 7.72 (d, J=8.5 Hz, 1H), 7.27-7.16 (m, 3H), 7.12 (s, 1H), 6.99-6.94 (m, 1H), 5.94-5.79 (m, 1H), 5.31 (d, J=17.2 Hz, 1H), 5.19 (d, J=10.5 Hz, 1H), 4.34-4.26 (m, 1H), 4.15-4.08 (m, 2H), 3.70 (d, J=14.5 Hz, 2H), 3.28 (d, J=14.2 Hz, 1H), 3.16 (dd, J=15.1, 9.0 Hz, 1H), 2.79 (dd, J=9.3, 5.0 Hz, 2H), 2.75-2.65 (m, 1H), 2.31-2.21 (m, 1H), 2.05-1.88 (m, 3H), 1.80-1.71 (m, 2H), 1.71-1.59 (m, 2H), 1.50 (t, J=11.4 Hz, 1H).
-
-
- To a stirred solution of (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (1.20 g, 1.61 mmol, Intermediate 3 and 4, Step 4, P1) in DCM (40 mL) was added DMAP (39 mg, 0.32 mmol), triethylamine (0.27 mL, 2.1 mmol) and Ac2O (0.18 mL, 1.8 mmol). The reaction mixture was then stirred at r.t. for 6 h. The reaction was diluted with DCM (40 mL), washed with water (30 mL) and brine. The combined organic layers were dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to afford the desired product (1.26 g) as a light orange colored solid. LC-MS calc. for C44H50ClN2O7S [M+H]+: m/z=785.29/787.29. Found: 785.2/787.4.
- To a stirred solution of [(1S)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] acetate (1.26 g, 1.6 mmol) in DCM (20 mL) was added TFA (20 mL, 137 mmol) dropwise. The reaction was stirred at 40° C. overnight. LC-MS showed the starting material was consumed. The reaction was cooled to r.t. and slowly poured into a 120 mL of saturated K2CO3 solution under an ice bath. The mixture was extracted with DCM (30 mL×3). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The crude product was purified by flash chromatography on a silica gel column (12 g) using EtOAc/Heptanes (2% to 50%) to afford [(1S)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] acetate (680 mg, 77% yield). LC-MS calc. for C28H34ClN2O5S [M+H]+: mz=545.18/547.18. Found: 544.8/546.4.
-
- This compound was prepared using procedures analogous to those described for Intermediate 5 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 3 and 4, Step 4, P2) in Step 1. LC-MS calc. for C28H34ClN2O5S [M+H]+: m/z=545.18/547.18. Found: 544.8/546.6.
-
- Step 1: (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide
- To a cooled (ice-water bath) solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (3.2 g, 4.3 mmol, Intermediate 3 and 4, Step 4, P1) in THF (70 mL) was added sodium hydride (0.52 g, 12.9 mmol). The mixture was stirred for 5 min., then iodomethane (0.8 mL, 12.9 mmol) was added. The mixture was stirred at 50° C. overnight. The reaction was quenched by addition of saturated aqueous ammonium chloride (70 mL) and water (70 mL). The mixture was extracted with EA (70 mL×3). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure to afford the crude product (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (3.1 g, 95% yield) which was directly used in next step directly without further purification. LC-MS calc. for C43H50ClN2O6S [M+H]+: m/z=757.3/759.3. Found: 757.0/759.4.
- This compound was prepared using procedures analogous to those described for Intermediate 5 Step 2 using (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide. LC-MS calc. for C27H34ClN2O4S [M+H]+: m/z=517.2/519.2. Found: 516.8/518.7.
-
- This compound was prepared using procedures analogous to those described for Intermediate 7 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 3 and 4, Step 4, P2) in Step 1. LC-MS calc. for C27H35ClN2O4S [M+H]+: m/z=517.2/519.2. Found: 516.8/518.5.
-
-
- To a stirred solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (0.8 g, 1.08 mmol, Intermediate 3 and 4, Step 4, P1) in THF (10 mL)/Toluene (10 mL) was added N,N-dimethylcarbamoyl chloride (1.16 g, 10.7 mmol). The resulting mixture was cooled to −78° C. and KHMDS (8.15 mL, 0.5 M in Toluene) was added dropwise over 10 min. The reaction was stirred at −78° C. for 10 min. Then the solution was slowly warmed up to r.t. and stirred for 1 h. LC-MS showed the consumption of starting material and the formation of desired product. The reaction was quenched with saturated ammonium chloride solution (20 mL) and extracted with EtOAc (20 mL×3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (20 g) using EtOAc/Heptanes (10% to 60%) to afford [(1S)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] N,N-dimethylcarbamate (0.69 g, 78% yield) as a white solid. LC-MS calc. for C45H53ClN3O7S [M+H]+: m/z=814.3/816.3; Found: 814.8/816.9.
- This compound was prepared using procedures analogous to those described for Intermediate 5 Step 2. LC-MS calc. for C29H37ClN3O5S [M+H]+: m/z=574.2/576.2; Found: 574.6/576.5.
-
-
- This compound was prepared using procedures analogous to those described for Intermediate 9 Step 1 using (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 3 and 4, Step 4 P2) and N,N-dimethylcarbamoyl chloride. LC-MS calc. for C45H53ClN3O7S [M+H]+: m/z=814.3/816.3; Found: 814.7/816.1.
-
- This compound was prepared using procedures analogous to those described for Intermediate 5 Step 2. LC-MS calc. for C29H37ClN3O5S [M+H]+: m/z=574.2/576.2; Found: 574.8/576.7.
-
-
- To a solution of 2-bromo-5-chlorophenol (20.0 g, 96.4 mmol) in NMP (100 mL) was added K2CO3 (26.6 g, 192 mmol) and 2-bromoethoxy-tert-butyldimethylsilane (22.7 mL, 106 mmol). The resulting suspension was stirred at 90° C. for 5 h. After cooling to r.t., the suspension was diluted with water (150 mL), and extracted with ethyl acetate (3×150 mL). The combined organic layers were washed with water (150 mL), brine (150 mL) and dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on a silica gel column with PE/EA (5%) to afford 2-(2-bromo-5-chloro-phenoxy)ethoxy-tert-butyl-dimethyl-silane (32 g, 90% yield) as light yellow oil. 1H NMR (400 MHz, DMSO-d6) δ 7.58 (d, J=8.4 Hz, 1H), 7.24 (d, J=2.4 Hz, 1H), 6.95 (dd, J=8.4, 2.4 Hz, 1H), 4.18-4.16 (m, 2H), 3.94-3.93 (m, 2H), 0.86 (s, 9H), 0.06 (s, 6H).
-
- To a suspension of K3PO4 (21.35 g, 100.6 mmol) and bis(tri-tert-butylphosphine)palladium(0) (1.70 g, 3.34 mmol) in toluene (100 mL), was added 2-(2-bromo-5-chloro-phenoxy)ethoxy-tert-butyl-dimethyl-silane (12.2 g, 33.3 mmol), followed by the addition of diethyl malonate (10.68 g, 66.7 mmol). The resulting suspension was heated at 85° C. for 6 h. under an atmosphere of argon, and then cooled to r.t. The mixture was filtered through a pad of Celite and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on a silica gel column with Hexane/EA (0-10%) to afford diethyl 2-[2-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]-4-chloro-phenyl]propanedioate (7.3 g, 49.2% yield) as a clear oil. 1H NMR: (400 MHz, CDCl3) δ 7.30 (d, J=8.2 Hz, 1H), 6.96 (dd, J=8.3, 2.0 Hz, 1H), 6.92 (d, J=2.0 Hz, 1H), 5.11 (s, 1H), 4.27-4.15 (m, 4H), 4.04 (t, J=5.0 Hz, 2H), 3.94 (t, J=5.1 Hz, 2H), 1.26 (t, J=7.2 Hz, 6H), 0.91 (s, 9H), 0.09 (s, 6H).
-
- To a solution of diethyl 2-[2-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]-4-chloro-phenyl]propanedioate (9.53 g, 21.4 mmol) and DBU (6.52 g, 42.8 mmol) in MeCN (200 mL) under N2 atmosphere was added 4-nitrobenzenesulfonyl fluoride (8.79 g, 42.8 mmol). The resulting solution was stirred at 70° C. for 24 h. After cooling, the solution was concentrated at 35° C. under reduced pressure to remove MeCN. The residue was diluted with water (120 mL) and extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with water (100 mL), 1 N HCl (100 mL), followed by NaHCO3 (500 mL) solution and brine (100 mL). The organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on a silica gel column with Hexane/EA (0-10%) (Rf=0.4 in 10% ethyl acetate in hexane) to afford diethyl 7-chlorochromane-4,4-dicarboxylate (7.400 g, 110.5% yield). 1H NMR: (400 MHz, CDCl3) δ 7.36 (d, J=8.4 Hz, 1H), 6.90 (dd, J=2.0 Hz, 8.4 Hz, 1H), 6.86 (d, J=2.4 Hz, 1H), 4.28-4.19 (m, 6H), 2.54-2.51 (m, 2H), 1.27 (t, J=7.2 Hz, 6H).
-
- To a solution of diethyl 7-chlorochromane-4,4-dicarboxylate (6.30 g, 20.1 mmol) in THF (25 mL) was added diisobutylaluminum hydride (201.4 mL, 201 mmol, 1 M in THF) dropwise at 0° C. The reaction mixture was stirred at r.t. for 18 h. Then it was quenched by the addition of saturated solution of NH4Cl (200 mL) and extracted with ethyl acetate (3×280 mL). The combined organic layers were concentrated under reduced pressure. The crude material was dissolved in THF (100 mL) and water (200 mL), and sodium borohydride (4.4 g, 114.8 mmol) was added. The reaction was stirred at r.t. for 3 h., and then quenched with saturated NH4Cl solution (75 mL). The mixture was extracted with ethyl acetate (2×60 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on a silica gel column with Hexane/EA (0-70%) to afford [7-chloro-4-(hydroxymethyl)chroman-4-yl]methanol (2.80 g, 61% yield). 1H NMR: (400 MHz, CDCl3) δ 7.23 (d, J=9.2 Hz, 1H), 6.87-6.85 (m, 2H), 4.21 (t, J=5.2 Hz, 2H), 3.97 (d, J=10.8 Hz, 2H), 3.78 (d, J=10.8 Hz, 2H), 2.09 (t, J=5.2 Hz, 2H).
-
- To a solution of 2,6-bis((R)-5,5-dibutyl-4-phenyl-4,5-dihydrooxazol-2-yl)pyridine (934 mg, 1.57 mmol) in dry DCM (3 mL) was added CuCl2 (211 mg, 1.57 mmol) and the resulting green solution was stirred at r.t. for 3 h. This solution was added to a solution of [7-chloro-4-(hydroxymethyl)chroman-4-yl]methanol (3.60 g, 15.74 mmol) in dry DCM (60 mL). The resulting solution was cooled to −78° C. A solution of 4-bromobenzoyl chloride (4.15 g, 18.8 mmol) in DCM (5 mL) was then added slowly, followed by the dropwise addition of DIPEA (3.29 mL, 18.8 mmol). The resulting reaction mixture was stirred at −78° C. for 2 h. and then quenched with KH2PO4/H3PO4 buffer solution (70 mL, pH˜3). The reaction was diluted with ethyl acetate (150 mL) and the layers were separated. The organic phase was washed with pH˜3 buffer (1×50 mL), saturated NaHCO3 (2×50 mL) and brine (1×50 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure The residue was purified by column chromatography on a silica gel column eluting with 100% DCM to afford [(4S)-7-chloro-4-(hydroxymethyl)chroman-4-yl]methyl 4-bromobenzoate (4.10 g, 63% yield) (e.r.=92:8). The chiral HPLC: Chiral Column: AD, 2.5 um, 3.0 mm×150 mm; Mobile phase A: Supercritical CO2, Mobile phase B: MeOH (with 0.1% DEA), A:B=50:50; Run time: 20 min.; Detector Wavelength: 254 nm, Instrument: Waters Acouity UPC2. 1H NMR: (400 MHz, CDCl3) δ 7.86 (d, J=8.0 Hz, 1H), 7.84 (s, 1H), 7.60 (d, J=8.4 Hz, 2H), 7.32 (d, J=8.0 Hz, 1H), 6.88 (d, J=8.4 Hz, 2H), 4.53 (d, J=6.0 Hz, 2H), 4.23 (d, J=6.0 Hz, 2H), 3.80 (s, 2H), 2.16-2.09 (m, 1H), 2.02-1.97 (m, 1H).
-
- Dess-Martin periodinane (5.07 g, 11.95 mmol) was added to a stirring solution of [(4S)-7-chloro-4-(hydroxymethyl)chroman-4-yl]methyl 4-bromobenzoate (4.10 g, 9.96 mmol) in DCM (130 mL) at 10° C. After addition, the cooling bath was removed and the reaction mixture was stirred for 30 min. at ambient temperature. Water (17 ml) was then added slowly and the reaction mixture was stirred further at ambient temperature for 30 min. The reaction was cooled to 0° C., quenched with a 1:1 mixture of 10% Na2S2O3 and saturated NaHCO3 (20 mL) solution and stirred further at r.t. for 1 h. The solution was then diluted with ethyl acetate (700 mL) and the aqueous phase was separated. The organic phase was washed with 1:1 mixture of 10% Na2S2O3/saturated NaHCO3solution (200 mL) and brine (20 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure The residue was purified by column chromatography on a silica gel column with eluting with ethylacetate in hexanes (10%) to afford [(4R)-7-chloro-4-formyl-chroman-4-yl]methyl 4-bromobenzoate (3.0 g, 73% yield). 1H NMR: (400 MHz, CDCl3) δ 9.60 (s, 1H), 77.81 (d, J=6.8 Hz, 2H) 7.58 (d, J=8.4 Hz, 2H), 7.13 (dd, J=1.2 Hz, 7.6 Hz, 1H), 6.94 (d, J=8.4 Hz, 2H), 4.84 (d, J=11.2 Hz, 1H), 4.54 (d, J=11.2 Hz, 1H), 4.27-4.24 (m, 2H), 2.52-2.46 (m, 1H), 2.12-2.06 (m, 1H).
-
- To a mixture of [(4R)-7-chloro-4-formyl-chroman-4-yl]methyl 4-bromobenzoate (3.0 g, 7.3 mmol) and trimethyl orthoformate (2.33 g, 21.9 mmol) in anhydrous MeOH (10 mL) was added p-toluenesulfonic acid (63 mg, 0.37 mmol). The reaction was refluxed for 6 h., and concentrated under reduced pressure. The residue was purified by column chromatography on a silica gel column with eluting with ethyl acetate/hexane (10%) to afford [(4R)-7-chloro-4-(dimethoxymethyl)chroman-4-yl]methyl 4-bromobenzoate (2.5 g, 74% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.75 (d, J=8.4 Hz, 1H), 7.74 (s, 1H), 7.56 (d, J=8.4 Hz, 2H), 7.37 (d, J=8.4 Hz, 1H), 6.87-6.83 (m, 1H), 6.51 (d, J=4.4 Hz, 1H), 4.53-4.49 (m, 2H), 4.32-4.29 (m, 1H), 4.20-4.18 (m, 1H), 3.45 (s, 3H), 3.30 (s, 3H), 2.34-2.29 (m, 1H), 2.02-1.97 (m, 1H).
-
- To a mixture of [(4R)-7-chloro-4-(dimethoxymethyl)chroman-4-yl]methyl 4-bromobenzoate (2.50 g, 5.49 mmol) in water (17 mL) and THF (34 mL) was added NaOH (658 mg, 16.4 mmol). The resulting mixture was stirred at r.t. overnight, and then concentrated under reduced pressure. The residue was diluted with EtOAc (50 mL) and washed with water (10 mL), 1 N NaOH (10 mL), water (10 mL) and brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on a silica gel column eluting with PE:EA (2:1) to afford [(4R)-7-chloro-4-(dimethoxymethyl)chroman-4-yl]methanol (1.50 g, 100% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.28-7.26 (m, 1H), 6.86-6.84 (m, 2H), 4.48 (s, 1H), 4.29-4.23 (m, 1H), 4.66-4.11 (m, 1H), 3.98 (d, J=11.2 Hz, 1H), 3.56 (d, J=11.2 Hz, 1H), 3.48 (s, 3H), 3.36 (s, 3H), 2.26-2.20 (m, 1H), 2.08-1.97 (m, 1H).
-
- To a solution of [(4R)-7-chloro-4-(dimethoxymethyl)chroman-4-yl]methanol (1.50 g, 5.5 mmol) in anhydrous THF (50 mL) was added KOBu-t (1.23 g, 11 mmol). After stirring for 5 min at r.t., a solution of 4-fluoro-N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-benzenesulfonamide (3.04 g, 6.6 mmol, Intermediate 2 Step 1) in THF (30 mL) was added dropwise and the resulting mixture was stirred at r.t. for 3 h. The reaction was quenched with saturated NH4Cl solution (50 mL) and extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with NH4Cl (50 mL) and brine (50 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on a silica gel column eluting with ethyl acetate/hexane (20%) to afford N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-4-[[(4R)-7-chloro-4-(dimethoxymethyl)chroman-4-yl]methoxy]benzenesulfonamide (3.35 g, 85% yield) as a yellow semi-solid. 1H NMR (400 MHz, CDCl3) δ 8.04 (d, J=2.4 Hz, 1H), 7.78 (dd, J=2.4, 8.8 Hz, 1H), 7.51 (d, J=8.8 Hz, 1H), 7.00-6.97 (m, 5H), 6.82-6.79 (m, 2H), 6.73-6.70 (m, 4H), 4.68 (s, 1H), 4.28-4.21 (m, 8H), 3.72 (s, 6H), 3.42 (s, 3H), 3.25 (s, 3H), 2.31-2.25 (m, 1H), 1.97-1.84 (m, 1H).
-
- To a solution of N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-4-[[(4R)-7-chloro-4-(dimethoxymethyl)chroman-4-yl]methoxy]benzenesulfonamide (3.35 g, 4.7 mmol) in 1,4-Dioxane (50 mL) and water (17 mL) was added TsOH (1.79 g, 9.39 mmol). The resulting solution was stirred at 105° C. overnight. The reaction was diluted with ethyl acetate (50 mL) and washed with sat. NaHCO3solution (15 mL), water (15 mL) and brine (15 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure The residue was purified by column chromatography on a silica gel column eluting with PE:EA (2:1) to afford N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-4-[[(4R)-7-chloro-4-formyl-chroman-4-yl]methoxy]benzenesulfonamide (2.50 g, 79% yield) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 9.51 (s, 1H), 8.09 (d, J=2.4 Hz, 1H), 6.89-7.86 (m, 1H), 7.12 (d, J=9.2 Hz, 1H), 7.08-7.03 (m, 5H), 6.99-6.93 (m, 2H), 6.81-6.78 (m, 4H), 4.71 (d, J=9.2 Hz, 1H), 4.37-4.35 (m, 1H), 4.30-4.23 (m, 6H), 3.79 (s, 6H), 2.54-2.47 (m, 1H), 2.42-2.36 (m, 1H).
-
- To a solution of N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-4-[[(4R)-7-chloro-4-formyl-chroman-4-yl]methoxy]benzenesulfonamide (2.50 g, 3.75 mmol) and NH4Cl (1.99 g, 37.4 mmol) in ethanol (30 mL) was added zinc (2.45 g, 37.4 mmol) and the resulting solution was stirred at 80° C. under N2 atmosphere overnight. After cooling, the mixture was filtered through a pad of celite. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on a silica gel column eluting with PE:EA (2:1) to afford (3S)-7′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[4,5-dihydro-2H-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide (1.44 g, 58% yield) as a white solid. LC-MS calc. for C33H34ClN2O6S [M+H]+: m/z=621.17/623.17; Found: 621.2/623.2. 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J=8.4 Hz, 1H), 7.21-7.18 (m, 1H), 7.04-6.93 (m, 6H), 6.91 (m, 1H), 6.85 (d, J=2.4 Hz, 1H), 6.78-6.75 (m, 4H), 4.23-4.10 (m, 8H), 3.78 (s, 6H), 3.53 (d, J=12.8 Hz, 1H), 3.40 (d, J=12.8 Hz, 1H), 2.05-2.00 (m, 1H), 1.96-1.92 (m, 1H).
-
-
- This compound was prepared using procedures analogous to those described for Intermediate 3 Step 1-3 using (3S)-7′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[4,5-dihydro-2H-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide (Intermediate 11) and [(1R,2R)-2-formylcyclobutyl]methyl acetate in Step 1. LC-MS: calc. for C39H42ClN2O7S [M+H]+: m/z=717.3/719.3; Found: 717.4/719.2.
-
- This compound was prepared using procedures analogous to those described for Intermediate 3 Step 4 using vinylmagnesium bromide (1.0 M solution THF solution). The reaction was quenched with sat. NH4Cl solution (300 mL) and extracted with (EA 300 mL×3). The organic layer was concentrated and purified by flash chromatography on a silica gel column eluting with EA/Hep (20% to 50%) to afford the two products: P1 (the earlier eluted product) which was assigned to (3S)-7′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide. LC-MS calc. for C41H46ClN2O7S [M+H]+: m/z=745.3/747.3; Found: 745.5/747.4.
- And P2 (the latter eluted product) was assigned to (3S)-7′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide. LC-MS calc. for C41H46ClN2O7S [M+H]+: m/z=745.3/747.3; Found: 745.5/747.4.
-
- This compound was prepared using procedures analogous to those described for Intermediate 3 Step 5 using (3S)-7′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide (P1 Step 2). LC-MS: calcd. for C25H30ClN2O5S [M+H]+: m/z=505.0/507.0; Found: 505.1/507.0.
-
- This compound was prepared using procedures analogous to those described for Intermediate 3 Step 5 using (3S)-7′-chloro-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide (P2 Step 2). LC-MS: calc. for C25H30ClN2O5S [M+H]+: m/z=505.0/507.0; Found: 505.1/507.0.
-
-
- To a suspension of 2-(2-bromo-5-chloro-phenyl)acetic acid (60.0 g, 240 mmol) in THF (300 mL) was added BH3-THF (760 mL, 760 mmol) at 0° C. The reaction mixture was stirred at 25° C. for 4 h., and then quenched by MeOH (300 mL) under N2 at 0° C. The mixture was concentrated to give crude product which was diluted with DCM (100 mL) and washed with 1 M HCl and brine. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduce pressure to afforded 2-(2-bromo-5-chloro-phenyl)ethanol (60 g, 84% yield) as a colorless oil which was used for the next step directly. 1H NMR: (400 MHz, CDCl3) δ 7.46 (d, J=8.4 Hz, 1H), 7.27 (d, J=2.8 Hz, 1H), 7.07 (dd, J=2.8 Hz, 8.8 Hz, 1H), 3.86 (t, J=6.4 Hz, 2H), 2.97 (t, J=6.4 Hz, 2H), 1.88 (s, 1H).
-
- tert-Butylchlorodimethylsilane (25.34 g, 168 mmol) was slowly added to a solution of imidazole (17.34 g, 254 mmol) and 2-(2-bromo-5-chloro-phenyl)ethanol (60.0 g, 254 mmol) in dry DCM (400 mL) at 0° C. over 30 min. After addition, the reaction mixture was stirred at r.t. for 18 h., and treated with 5% of NaHCO3aqueous. The mixture was extracted with EA (200 mL×3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on a silica gel column eluting with PE. EA (0-10%) to give 2-(2-bromo-5-chloro-phenyl)ethoxy-tert-butyl-dimethyl-silane (61 g, 68% yield) as an colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.48 (d, J=8.4 Hz, 1H), 7.30 (d, J=2.8 Hz, 1H), 7.09 (dd, J=8.4, 2.8 Hz, 1H), 3.85 (t, J=6.4 Hz, 2H), 2.97 (t, J=6.4 Hz, 2H), 0.90 (s, 9H), 0.00 (s, 6H).
-
- To a solution of 2-(2-bromo-5-chloro-phenyl)ethoxy-tert-butyl-dimethyl-silane (40.0 g, 114 mmol) in THF (400 mL) was added n-BuLi (54.8 mL, 137 mmol) (2.5 M in hexane) at −78° C. dropwised, and stirred at this temperature for 30 min. To the reaction mixture was added 2,2-dimethyl-1,3-dioxan-5-one (20.8 g, 160 mmol) in THF (15 mL), stirred at −78° C. to −15° C. for 4 h. The mixture was quenched by sat. NH4Cl (150 mL), and extracted with EA (150 mL×3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with PE/EA (2-10%) to give 5-[2-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-4-chloro-phenyl]-2,2-dimethyl-1,3-dioxan-5-ol (30 g, 65% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.65 (d, J=8.4 Hz, 1H), 7.33-7.18 (m, 2H), 4.84 (s, 1H), 4.18 (d, J=11.6 Hz, 2H), 4.03 (d, J=11.6 Hz, 2H), 3.97 (t, J=6.0 Hz, 2H), 3.24 (t, J=6.0 Hz, 2H), 1.62 (s, 3H), 1.52 (s, 3H), 0.88 (s, 9H), 0.01 (s, 6H).
-
- To a solution of 5-[2-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-4-chloro-phenyl]-2,2-dimethyl-1,3-dioxan-5-ol (30.0 g, 74.8 mmol) in THF (150 mL) was slowly added TBAF (97 mL, 97 mmol) (1 M in THF) at 0° C. After addition, the mixture was stirred at 25° C. for 1 h., and diluted with EtOAc (150 mL). The mixture was washed with brine (50 mL) and H2O (50 mL×3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with PE/EA (10-50%) to give 5-(4-chloro-2-(2-hydroxyethyl)phenyl)-2,2-dimethyl-1,3-dioxan-5-ol (21 g, 97% yield) as a colorless oil. TLC (PE/EA=2/1, Rf=0.2). 1H NMR (400 MHz, DMSO-d6) δ 7.61 (d, J=8.4 Hz, 1H), 7.31 (d, J=2.4 Hz, 1H), 7.22 (dd, J=8.4, 2.4 Hz, 1H), 5.44 (s, 1H), 4.75 (t, J=5.0 Hz, 1H), 4.03 (d, J=11.6 Hz, 2H), 3.84 (d, J=11.6 Hz, 2H), 3.62 (dd, J=12.0, 6.8 Hz, 2H), 3.04 (t, J=6.8 Hz, 2H), 1.44 (s, 3H), 1.28 (s, 3H).
-
- To a solution of 5-[4-chloro-2-(2-hydroxyethyl)phenyl]-2,2-dimethyl-1,3-dioxan-5-ol (42.0 g, 146 mmol) in THF (150 mL) was added Ph3P (69.15 g, 263 mmol), and followed by DIAD (52.27 mL, 263.64 mmol) at 0° C. dropwise. The mixture was stirred at 0° C. for 1 h. and 25° C. for 2 h. The reaction was concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with PE/EA (5%) to give (27 g, 68.6% yield) as colorless oil. 1H NMR (400 MHz, DMSO-d6) δ 7.53 (d, J=8.4 Hz, 1H), 7.29-7.25 (m, 2H), 3.92 (d, J=12.4 Hz, 2H), 3.84 (t, J=5.6 Hz, 2H), 3.77 (d, J=12.4 Hz, 2H), 2.75 (t, J=5.6 Hz, 2H), 1.51 (s, 3H), 1.35 (s, 3H).
-
- To a solution of 6′-chloro-2,2-dimethyl-spiro[1,3-dioxane-5,1′-isochromane] (17.0 g, 63.2 mmol) in methanol (25 mL) was added TsOH (0.6 g, 3.16 mmol) and stirred at 25° C. for 18 h. The mixture was quenched by NaHCO3aqueous (20 mL), and extracted with EtOAc (100 mL×3). The combined organic layers were washed with brine and water, dried over Na2SO4, filtered and concentrated under reduced pressure to give (6-chloroisochroman-1,1-diyl)dimethanol (7.6 g, 52.5% yield) as a white solid which was used for next step directly. TLC (silica gel, PE/EA=1/1, R.f.=0.4). 1H NMR (400 MHz, CDCl3) δ 7.20 (dd, J=8.4, 2.4 Hz, 1H), 7.16 (d, J=2.4 Hz, 1H), 7.10 (d, J=8.4 Hz, 1H), 4.01 (t, J=5.6 Hz, 1H), 3.91-3.83 (m, 4H), 2.84 (t, J=5.6 Hz, 1H), 2.20 (s, 2H).
-
- To a solution of R,R-Kang catalyst (2,6-bis((R)-5,5-dibutyl-4-phenyl-4,5-dihydrooxazol-2-yl)pyridine) (908.93 mg, 1.53 mmol) in dry DCM (25 mL) was added Copper(II) chloride (205.79 mg, 1.53 mmol). The resulting green solution was stirred at ambient temperature for 3 h. This solution was transferred via cannula to a solution of 4-bromobenzoyl chloride (5.76 g, 26.2 mmol) in dry DCM (25 mL). The resulting solution was cooled to −78° C. and light green colored precipitation was observed in the reaction after some time. A solution of [6-chloro-1-(hydroxymethyl)isochroman-1-yl]methanol (5.0 g, 21.87 mmol)) in DCM (25 mL) was then added slowly (over 10 min.), followed by the dropwise addition of DIPEA (3.81 mL, 21.8 mmol). The resulting mixture was stirred at −78° C. for 2 h., and quenched by KH2PO4 sat. aqueous solution (100 mL) and allowed to warm to ambient temperature with vigorous stirring. The reaction was diluted with ethyl acetate (400 mL) and the layers were separated. The organic phase was washed with pH˜3 buffer (1×50 mL), saturated NaHCO3 (2×100 mL), and brine (100 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure The crude material was purified by flash chromatography on a silica gel column eluting with EA/PE (5-10%) to give (R)-(6-chloro-1-(hydroxymethyl)isochroman-1-yl)methyl 4-bromobenzoate (5.1 g, 56% yield). The chiral HPLC showed (e.e=93%): Chiral Column: AD, 2.5 um, 3.0 mm×150 mm; Mobile phase A: Supercritical CO2, Mobile phase B: MeOH (with 0.1% DEA), A:B=50:50; Run time: 18 min.; Detector Wavelength: 254 nm, Instrument: Waters Acouity UPC2 0.1H NMR (400 MHz, CDCl3) δ 7.79 (d, J=8.4 Hz, 2H), 7.57 (d, J=8.4 Hz, 2H), 7.26-7.16 (m, 3H), 4.72 (d, J=12.0 Hz, 1H), 4.56 (d, J=12.0 Hz, 1H), 4.13-3.96 (m, 2H), 3.98-3.84 (m, 2H), 2.88-2.78 (m, 2H).
-
- To a solution of (R)-(6-chloro-1-(hydroxymethyl)isochroman-1-yl)methyl 4-bromobenzoate (2.6 g, 6.32 mmol) in DCM (35 mL) was added Dess-Martin periodinane (3.48 g, 8.21 mmol) at 10° C. After addition, the cooling bath was removed. The reaction mixture was stirred for 2 h. at ambient temperature. The reaction was then cooled to 0° C., and diluted with ethyl acetate (100 mL), quenched with a 1:1 mixture of 10% Na2S2O3 and saturated NaHCO3 (100 mL) solution and stirred at r.t. for an additional 0.5 h. The aqueous phase was separated. The organic phase was washed with brine (100 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude material was purified by flash chromatography on a silica gel column eluting with ethyl acetate in hexanes (10%) to afforded [(S)-6-chloro-1-formyl-isochroman-1-yl]methyl 4-bromobenzoate (2.00 g, 77% yield) as light yellow oil. Rf=0.5 in 10% ethyl acetate in hexane. 1H NMR (400 MHz, CDCl3) δ 9.68 (s, 1H), 7.81 (d, J=8.4 Hz, 2H), 7.56 (d, J=8.4 Hz, 2H), 7.26 (m, 2H), 7.21 (s, 1H), 4.85 (d, J=11.6 Hz, 1H), 4.67 (d, J=11.6 Hz, 1H), 4.26-4.12 (m, 1H), 4.09 (m, 1H), 2.98-2.78 (m, 2H).
-
- To a solution of (S)-(6-chloro-1-formylisochroman-1-yl)methyl 4-bromobenzoate (700.0 mg, 1.71 mmol) in anhydrous methanol (15 mL), TsOH (16.25 mg, 0.09 mmol) and trimethyl orthoformate (217 mg, 2.05 mmol) were added and the reaction mixture was refluxed for 4 h. The reaction mixture was then concentrated to 50% volume, diluted with THF (12 mL) and added NaOH (273 mg, 6.83 mmol) in water (2 mL). The resulting mixture was stirred at r.t. overnight, concentrated under reduced pressure. The residue was diluted with diethyl ether (50 mL). The aqueous layer was separated, and the organic layer was washed with 1 N NaOH (10 mL). The combined aqueous layers were extracted with diethyl ether (20 mL). The combined organic layers were washed with 1 N NaOH (10 mL) and brine, dried over sodium sulfate and concentrated under reduced pressure. The crude material was purified by flash chromatography on a silica gel column eluting with ethyl acetate/hexane (20%) to afford (S)-(6-chloro-1-(dimethoxymethyl)isochroman-1-yl)methanol (320 mg, 68% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.40 (d, J=8.5 Hz, 1H), 7.18-7.03 (m, 2H), 4.16-4.13 (m, 1H), 3.96-3.93 (m, 2H), 3.70 (d, J=11.6 Hz, 1H), 3.54 (s, 3H), 3.48 (s, 3H), 2.90-2.69 (m, 2H).
-
- To a solution of tert-butoxypotassium (987.47 mg, 8.8 mmol) in anhydrous THF (3 mL) was cooled to 0° C. and a solution of (S)-(6-chloro-1-(dimethoxymethyl)isochroman-1-yl)methanol (2.0 g, 7.33 mmol) in THF (5 mL) was added dropwise. After 5 min., 4-fluoro-N,N-bis[(4-methoxyphenyl)methyl]-3-nitro-benzenesulfonamide (4390 mg, 9.53 mmol) (1 M in THF) was added dropwise via syringe and the resulting mixture was warmed to r.t. After 1 h the reaction was cooled to 0° C., quenched with saturated NH4CI solution (10 mL) and extracted with ethyl acetate (50 mL). The combined organic layers were washed with NH4CI (10 mL), brine (20 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude material was purified by flash chromatography on a silica gel column eiuting with ethyl acetate/PE (25%) (TLC Rf=0.5 in 30% ethyl acetate in hexane) to afford (S)-4-((6-chloro-1-(dimethoxymethyl)isochroman-1-yl)methoxy)-N,N-bis(4-methoxybenzyl)-3-nitrobenzenesulfonamide (4.2007 g, 80% yield) as a yellow semi-solid. 1H NMR (400 MHz, CDCl3) δ 8.10 (d, J=2.4 Hz, 1H), 7.85 (dd, J=8.8, 2.4 Hz, 1H), 7.50 (d, J=8.6 Hz, 1H), 7.21-7.16 (m, 2H), 7.09-7.04 (m, 5H), 6.82-6.76 (m, 4H), 4.71 (s, 1H), 4.38 (s, 2H), 4.27 (s, 4H), 4.18-4.13 (m, 1H), 4.02-3.92 (m, 1H), 3.79 (s, 6H), 3.54 (d, J=2.0 Hz, 3H), 3.50 (s, 3H), 2.83 (m, 2H).
-
- To a solution (S)-4-((6-chloro-1-(dimethoxymethyl)isochroman-1-yl)methoxy)-N,N-bis(4-methoxybenzyl)-3-nitrobenzenesulfonamide (3.5 g, 4.91 mmol) in 1,4-dioxane (30 mL) was added TsOH (2.53 g, 14.72 mmol) and the suspension was heated to 110° C. for 18 h. Upon completion, the mixture was cooled to r.t., and concentrated under reduced pressure. The residue was dissolved in EtOAc (100 mL) and washed by NaHCO3 (100 mL). The organic layer was concentrated to give (S)-4-((6-chloro-1-formylisochroman-1-yl)methoxy)-N,N-bis(4-methoxybenzyl)-3-nitrobenzenesulfonamide (3.2 g, 78.2% yield) which was used directly in next step. 1H NMR (400 MHz, CDCl3) δ 9.71 (s, 1H), 8.06 (d, J=2.4 Hz, 1H), 7.85 (dd, J=8.8, 2.4 Hz, 1H), 7.26-7.45 (m, 3H), 7.10-7.03 (m, 5H), 6.81-6.77 (m, 4H), 4.59-4.48 (m, 2H), 4.26 (s, 4H), 4.16-4.07 (m, 2H), 3.79 (s, 6H), 3.02-2.85 (m, 2H).
-
- To a solution (S)-4-((6-chloro-1-formylisochroman-1-yl)methoxy)-N,N-bis(4-methoxybenzyl)-3-nitrobenzenesulfonamide (500 mg, 0.75 mmol) in acetic acid (8 mL) was added iron powder (3382 mg, 14.9 mmol) and the suspension was heated to 40° C. for 12 h. Upon completion, the suspension was cooled to r.t. The solid was filtered off and the filtrate was concentrated under reduced pressure. The residue was diluted with DCE (10 mL). To the solution was added NaHB(OAc)3 (795 mg, 3.75 mmol). The reaction mixture was stirred at r.t. for 3 h., and MeOH (10 mL) was added. The resulting mixture was stirred for 1 h., and then concentrated under reduced pressure. The residue was purified by flash chromatograph on a silica gel column to afford (R)-6′-chloro-N,N-bis(4-methoxybenzyl)-4,5-dihydro-2H-spiro[benzo[b][1,4]oxazepine-3,1′-isochroman]-7-sulfonamide (70 mg, 14% yield). LC-MS calc. for C33H34ClN2O6S [M+H]+: m/z=621.18/623.18; Found: 621.1/623.0. 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J=8.4 Hz, 1H), 7.25-7.21 (m, 2H), 7.20 (d, J=2.0 Hz, 1H), 7.08 (d, J=2.4 Hz, 1H), 7.02-6.99 (m, 5H), 6.80-6.76 (m, 4H), 4.38 (dd, J=41.2, 12.6 Hz, 2H), 4.24 (s, 4H), 3.99 (t, J=5.6 Hz, 2H), 3.78-3.75 (m, 7H), 3.51 (d, J=14.0 Hz, 1H), 2.85 (t, J=5.2 Hz, 2H).
-
-
- This compound was prepared using procedures analogous to those described for Intermediate 3 Step 1-3 using (R)-6′-chloro-N,N-bis(4-methoxybenzyl)-4,5-dihydro-2H-spiro[benzo[b][1,4]oxazepine-3,1′-isochroman]-7-sulfonamide (Intermediate 14) and [(1R,2R)-2-formylcyclobutyl]methyl acetate in Step 1. LC-MS: calc. for C39H42ClN2O7S [M+H]+: m/z=717.3/719.3; Found: 717.3/719.3.
-
- This compound was prepared using procedures analogous to those described for Intermediate 3 Step 4 using vinylmagnesium bromide (1.0 M solution THF solution). The reaction was quenched with sat. NH4Cl solution (300 mL) and extracted with (EA 300 mL×3). The organic layer was concentrated and purified by flash chromatography on a silica gel column eluting with EA/Hep (20% to 50%) to afford the two products: P1 (the earlier eluted product) which was assigned to (3R)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-isochromane]-7-sulfonamide. LC-MS calc. for C41H46ClN2O7S [M+H]+: m/z=745.3/747.3; Found: 745.5/747.4.
- And P2 (the latter eluted product) was assigned to (3R)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-isochromane]-7-sulfonamide. LC-MS calc. for C41H46ClN2O7S [M+H]+: m/z=745.3/747.3; Found: 745.5/747.4.
-
- This compound was prepared using procedures analogous to those described for Intermediate 3 Step 5 using (3R)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-isochromane]-7-sulfonamide (P1 Step 2). LC-MS: calcd. for C25H30ClN2O5S [M+H]+: m/z=505.0/507.0; Found: 505.1/507.0.
-
- This compound was prepared using procedures analogous to those described for Intermediate 3 Step 5 using (3R)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-isochromane]-7-sulfonamide (P2 Step 2). LC-MS: calc. for C25H30ClN2O5S [M+H]+: m/z=505.0/507.0; Found: 505.1/507.0.
-
-
- A 20 mL vial with septum under N2 containing a solution of ˜80% pure 6′-chlorospiro[4,5-dihydro-2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 1, 400 mg, 0.84 mmol) in DCM (9 mL) and 2,2,2-trifluoroacetic acid (TFA) (1.5 mL, 19.6 mmol) was charged with cyclobutanecarboxaldehyde (very impure, 262 μL, 3.36 mmol). The solution was stirred at RT for 30 min. The reaction vessel was then placed at 0° C. in an ice-water bath, and charged with sodium borohydride (100 mg, 2.64 mmol) in small portions over 2 min. The reaction was stirred at 0° C. for 1 h. The reaction was quenched by dumping it into sat.NaHCO3 (20 mL, caution:gas evolution), diluting with water (30 mL) and extracting with EtOAc (60 mL). The organic layer was washed with water (20 mL) and sat. NaHCO3 (20 mL), brine (30 mL), dried over Na2SO4, and filtered. The filtrate was concentrated to afford a yellow gum, then turned into a yellow/white solid by repeated concentration after dissolving in DCM and triturating with hexanes. Solids were mostly dissolved in hot DCM (˜10 mL), then charged with hexanes until a cloudy color appeared. The resulting suspension was let cool to RT, then cooled to 0° C. After 2 h, a white/grey precipitate formed. The supernatant was decanted, and the precipitate was washed twice more with DCM/hexanes (2×2 mL, 2:1 ratio). The precipitate was dried under reduced pressure to yield 6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (105 mg, 27.9% yield) as a grey solid.
- The remaining filtrates were combined, dry loaded on Celite, and purified by FCC (40 g SiO2, 0→50% EtOAc in hexanes). Fractions containing pure desired product by TLC were combined and concentrated under reduced pressure and heat (−50° C.) to yield 6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (93.8 mg, 24.8% yield) as a white solid. Combined yield of 52.7%. Rf=0.28 (2:1 hexanes:EtOAc); LCMS calculated for C23H28ClN2O3S (M+H)+: m/z=447.15/449.15; found: 447.0/449.0; 1H NMR (500 MHz, CDCl3) δ 7.67 (d, J=8.5 Hz, 1H), 7.24 (dd, J=2.2, 8.3 Hz, 1H), 7.19-7.14 (m, 2H), 7.09 (d, J=2.3 Hz, 1H), 6.97 (d, J=8.2 Hz, 1H), 4.74 (s, 2H), 4.11 (ABq, 2H), 3.60 (dd, J=1.2, 14.4 Hz, 1H), 3.40-3.26 (m, 3H), 2.84-2.74 (m, 2H), 2.74-2.64 (m, 1H), 2.14-2.04 (m, 2H), 1.97-1.76 (m, 7H), 1.61-1.53 (m, 1H).
-
- A 2 mL microwave vial with septum containing a mixture of solid 6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (18. mg, 0.04 mmol), 4-(dimethylamino)pyridine (0.74 mg, 0.01 mmol), and DCM (1 mL) under N2 was charged with acetyl chloride (5.75 uL, 0.08 mmol), followed by N,N-Diisopropylethylamine (17.54 uL, 0.10 mmol) at r.t. (white vapors appeared). The mixture was shaken then stirred vigorously at 45° C. for 30 min, and shaken occasionally until all solids were dissolved. The reaction solution was quenched by addition of sat. NH4Cl (3 mL). The mixture was extracted with DCM (3 mL), washed with water (2 mL) and sat. NH4Cl (2 mL), brine (4 mL), dried over Na2SO4, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by FCC (12 g SiO2, 0→35% EtOAc in hexanes, wet-loaded in DCM). Fractions containing pure product were combined, and concentrated under reduced pressure and heat (−75° C.) to yield 98% pure N-[6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylacetamide (14.2 mg, 70.6% yield) as a white solid after scratching. LCMS calculated for C25H30ClN4O4S (M+H)+: m/z=489.15/491.15; found: 489.0/491.0. 1H NMR (500 MHz, CDCl3) δ 7.88 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.32 (dd, J=2.2, 8.3 Hz, 1H), 7.29 (d, J=2.3 Hz, 1H), 7.17 (dd, J=2.3, 8.5 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.98 (d, J=8.4 Hz, 1H), 4.13 (s, 2H), 3.60 (d, J=14.7 Hz, 1H), 3.39-3.29 (m, 3H), 2.82-2.74 (m, 2H), 2.70 (dt, J=7.3, 14.0 Hz, 1H), 2.17-2.06 (m, 5H), 1.96-1.71 (m, 8H).
-
-
- To a solution of 6′-chlorospiro[4,5-dihydro-2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 1, 60. mg, 0.16 mmol) in TFA (0.18 mL, 2.38 mmol) and DCM (1 mL) was added cyclopropylcarboxaldehyde (16.65 mg, 0.24 mmol). The mixture was stirred at r.t. for 15 min., then the mixture was cooled by ice-water bath, and sodium borohydride (15 mg, 0.40 mmol) was added slowly (over 15 min). The mixture was stirred at 0° C. for 1 h., then the volatiles were removed under reduced pressure. The residue was diluted with AcOEt (5 mL), and washed with sat. NaHCO3solution (2 mL×2), and brine. The organics was dried over Na2SO4, filtered and concentrated under reduced pressure to afford the crude product 6′-chloro-5-(cyclopropylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (49 mg, 71%) was directly used in next step reaction without further purification. LCMS calculated for C22H26ClN2O3S (M+H)+: m/z=433.13/435.12; found: 433.0/435.0.
-
- To a mixture of 6′-chloro-5-(cyclopropylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (21 mg, 0.05 mmol), acetic acid (0.01 mL, 0.10 mmol) and 4-(dimethylamino)pyridine (12.2 mg, 0.10 mmol) in DCM (2 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (19.1 mg, 0.10 mmol) at r.t. The mixture was stirred at r.t. overnight. The mixture was concentrated under reduced pressure. The residue was purified by FC on a silica gel column eluting with EtOAc/Hex (0-60%) (both contains 0.3% AcOH) to afford the desired product as white solid. LCMS calculated for C24H28ClN2O4S (M+H)+: m/z=475.14/476.14; found: 475.0/477.0. 1H NMR (500 MHz, DMSO-d6) δ 11.90 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.37 (d, J=2.2 Hz, 1H), 7.24 (dd, J=2.4, 8.5 Hz, 1H), 7.19 (dd, J=2.2, 8.3 Hz, 1H), 7.17 (d, J=2.4 Hz, 1H), 7.02 (d, J=8.3 Hz, 1H), 4.09 (s, 2H), 3.56 (d, J=14.4 Hz, 1H), 3.45 (d, J=14.4 Hz, 1H), 3.28 (s, 1H), 3.21 (dd, J=5.9, 14.8 Hz, 1H), 3.09 (dd, J=6.7, 14.8 Hz, 1H), 2.79-2.64 (m, 2H), 2.04-1.91 (m, 1H), 1.90 (s, 3H), 1.76 (d, J=14.5 Hz, 2H), 1.48 (m, 1H), 1.09-0.99 (m, 1H), 0.51 (dq, J=2.1, 8.2 Hz, 2H), 0.33-0.28 (m, 1H), 0.27-0.21 (m, 1H).
-
- This compound was prepared using procedures analogous to those described for Example 2 using cyclohexanecarboxaldehyde to replace cyclopropylcarboxaldehyde in Step I. LCMS calculated for C27H34ClN2O4S (M+H)+: m/z=517.18/519.18; found: 517.1/519.1. 1H NMR (500 MHz, DMSO-d6) δ 11.92 (s, 1H), 7.62 (d, J=8.5 Hz, 1H), 7.23 (dt, J=2.6, 5.8 Hz, 2H), 7.19-7.13 (m, 2H), 7.00 (d, J=8.3 Hz, 1H), 4.08 (q, J=12.2 Hz, 2H), 3.61 (d, J=14.4 Hz, 1H), 3.34 (d, J=14.2 Hz, 1H), 3.18 (dd, J=6.4, 14.8 Hz, 1H), 3.07 (dd, J=7.4, 14.8 Hz, 1H), 2.81-2.64 (m, 2H), 1.99-1.92 (m, 1H), 1.91 (s, 3H), 1.79 (m, 3H), 1.75-1.63 (m, 4H), 1.63-1.56 (m, 1H), 1.52 (m, 1H), 1.13 (m, 3H), 0.96 (m, 2H).
-
- This compound was prepared using procedures analogous to those described for Example 2 using benzaldehyde to replace cyclopropylcarboxaldehyde in Step I. LCMS calculated for C27H28ClN2O4S (M+H)+: m/z=511.14/513.14; found: 511.0/513.0. 1H NMR (500 MHz, DMSO-d6) δ 11.77 (s, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.31 (dd, J=6.8, 8.5 Hz, 2H), 7.27-7.17 (m, 5H), 7.14 (d, J=2.3 Hz, 1H), 7.09-7.01 (m, 2H), 4.64-4.53 (m, 2H), 4.26-4.14 (m, 2H), 3.75 (d, J=14.5 Hz, 1H), 3.41 (d, J=14.4 Hz, 1H), 2.72-2.64 (m, 2H), 1.95 (m, 1H), 1.77 (s, 3H), 1.66 (m, 2H), 1.51 (t, J=12.3 Hz, 1H), 1.22 (m, 2H).
-
- A 4 mL vial with septum containing a suspension of 6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Example 1 Step 1, 40 mg, 0.09 mmol) and 4-(dimethylamino)pyridine (1.5 mg, 0.01 mmol) in DCM (2 mL) and N,N-diisopropylethylamine (40 μL, 0.23 mmol) under N2 was charged with phenylacetyl chloride (18 μL, 0.14 mmol). The vial was heated at 40° C. for 30 min. The reaction mixture was charged with additional phenylacetyl chloride (23 μL, 0.17 mmol) and N,N-diisopropylethylamine (60 uL, 0.34 mmol), and heated at 40° C. for 1 h. The reaction mixture was diluted with EtOAc (40 mL), washed with sat. NH4Cl (20 mL), water (20 mL) and sat. NH4Cl (20 mL), and brine (30 mL). The organic layer was dried over Na2SO4, filtered, concentrated under reduced pressure, and purified by FCC (30 g C18, 10→100% MeCN in water, wet-loaded in DMSO). The fraction containing pure desired product was lyophilized, then further dried under reduced pressure and heat (60° C.) to yield N-[6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-2-phenyl-acetamide (21.5 mg, 97% purity, 41% yield) as a white solid. LCMS calculated for C31H34ClN2O4S (M+H)+: m/z=565.19/567.19; found: 565.2/567.1. 1H NMR (500 MHz, CDCl3) δ 7.76 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.41-7.30 (m, 3H), 7.30-7.26 (m, 2H), 7.20-7.14 (m, 3H), 7.09 (d, J=2.3 Hz, 1H), 6.95 (d, J=8.8 Hz, 1H), 4.13 (s, 2H), 3.63 (s, 2H), 3.59 (d, J=14.3 Hz, 1H), 3.38-3.26 (m, 3H), 2.83-2.71 (m, 2H), 2.68 (p, J=7.2 Hz, 1H), 2.13-2.04 (m, 2H), 1.97-1.71 (m, 8H).
-
- This compound was prepared using procedures analogous to those described for Example 5 using isobutyryl chloride to replace phenylacetyl chloride. The product was purified by FCC (12 g SiO2, 0→20% EtOAc in hexanes with 0.3% AcOH, wet-loaded in DCM to afford N-[6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-2-methyl-propanamide as a white solid. Rf=0.40 (2:1 hexanes:EtOAc). LCMS calculated for C27H34ClN2O4S (M+H)+: m/z=517.19/517.19; found: 517.1/519.1. 1H NMR (500 MHz, CDCl3) δ 7.91 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.33 (dq, J=2.2, 4.4 Hz, 2H), 7.17 (dd, J=2.4, 8.5 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.98-6.95 (m, 1H), 4.13 (s, 2H), 3.60 (d, J=14.3 Hz, 1H), 3.39-3.29 (m, 3H), 2.82-2.66 (m, 3H), 2.43 (hept, J=6.9 Hz, 1H), 2.16-2.06 (m, 2H), 1.97-1.73 (m, 8H), 1.16 (d, J=6.9 Hz, 6H).
-
- This compound was prepared using procedures analogous to those described for Example 5 using 4-chlorobenzoyl chloride to replace phenylacetyl chloride. The product was purified by FCC (12 g SiO2, 0→20% EtOAc in hexanes with 0.3% AcOH, wet-loaded in DCM to afford 4-chloro-N-[6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-benzamide as a white solid. Rf=0.25 (2:1 hexanes:EtOAc); LCMS calculated for C30H31Cl2N204S (M+H)+: m/z=585.14/587.13; found: 585.1/587.1; 1H NMR (500 MHz, CDCl3) δ 8.72 (s, 1H), 7.74 (dt, J=2.0, 2.4, 8.6 Hz, 2H), 7.66 (d, J=8.5 Hz, 1H), 7.48-7.39 (m, 4H), 7.16 (dd, J=2.3, 8.5 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 7.01-6.96 (m, 1H), 4.13 (s, 2H), 3.60 (d, J=14.4 Hz, 1H), 3.42-3.29 (m, 3H), 2.74 (dq, J=5.5, 6.1, 17.8 Hz, 3H), 2.16-2.06 (m, 2H), 1.98-1.70 (m, 8H).
-
- This compound was prepared using procedures analogous to those described for Example 2 using (2R,6S)-2,6-dimethyltetrahydro-2H-pyran-4-carbaldehyde to replace cyclopropylcarboxaldehyde in Step I. LCMS calculated for C28H36ClN2O5S (M+H)+: m/z=547.2/549.19; found: 547.2/549.1. 1H NMR (500 MHz, DMSO-d6) δ 11.91 (s, 1H), 7.62 (d, J=8.5 Hz, 1H), 7.24 (dd, J=2.2, 9.9 Hz, 2H), 7.17 (d, J=2.4 Hz, 1H), 7.15 (dd, J=2.1, 8.3 Hz, 1H), 7.00 (d, J=8.3 Hz, 1H), 4.12-4.04 (m, 2H), 3.64 (d, J=14.4 Hz, 1H), 3.30 (m, 2H) overlap with water signal, 3.16 (qd, J=6.8, 14.8 Hz, 2H), 2.81-2.65 (m, 2H), 2.13 (s, 1H), 2.02-1.92 (m, 2H), 1.90 (s, 3H), 1.85-1.73 (m, 2H), 1.62 (t, J=10.6 Hz, 2H), 1.54-1.40 (m, 2H), 1.05 (dd, J=4.4, 6.2 Hz, 6H), 0.90-0.77 (m, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 2 using 1-methyl-1H-pyrazole-4carboxaldehyde to replace cyclopropylcarboxaldehyde in Step I. LCMS calculated for C25H28ClN4O4S (M+H)+: m/z=515.14/517.14; found: 515.2.0/517.1. 1H NMR (500 MHz, DMSO-d6) δ 11.90 (s, 1H), 7.68 (d, J=8.6 Hz, 1H), 7.65 (s, 1H), 7.38 (s, 1H), 7.33 (d, J=2.2 Hz, 1H), 7.23 (dd, J=2.4, 8.6 Hz, 1H), 7.20-7.14 (m, 2H), 7.00 (d, J=8.3 Hz, 1H), 4.32 (s, 2H), 4.13 (s, 2H), 3.74 (s, 3H), 3.49 (d, J=14.1 Hz, 1H), 3.35 (d, J=14.2 Hz, 1H), 2.69 (d, J=16.0 Hz, 2H), 2.04-1.94 (m, 2H), 1.87 (s, 3H), 1.48 (m, 2H).
-
-
- This compound was prepared using procedures analogous to those described for Example 2 using 1-allylpyrazole-4-carbaldehyde to replace cyclopropylcarboxaldehyde in Step I. LCMS calculated for C25H28ClN4O3S (M+H)+: m/z=499.15/501.15; found: 499.1/501.0. 1H NMR (500 MHz, DMSO-d6) δ 7.66 (t, J=4.3 Hz, 2H), 7.42 (s, 1H), 7.34 (d, J=2.1 Hz, 1H), 7.23 (dd, J=2.4, 8.5 Hz, 1H), 7.19-7.14 (m, 3H), 7.11 (dd, J=2.1, 8.3 Hz, 1H), 6.97 (d, J=8.2 Hz, 1H), 5.94 (ddt, J=5.7, 10.1, 17.2 Hz, 1H), 5.16-5.02 (m, 2H), 4.66 (dt, J=1.6, 5.7 Hz, 2H), 4.39-4.28 (m, 2H), 4.08 (s, 2H), 3.47 (d, J=14.2 Hz, 1H), 3.34 (d, J=15.4 Hz, 1H), 2.69 (dt, J=5.7, 10.1 Hz, 2H), 2.02-1.94 (m, 2H), 1.92-1.84 (m, 1H), 1.67 (d, J=29.4 Hz, 2H), 1.52-1.40 (m, 2H), 1.27 (d, J=13.9 Hz, 2H), 1.16 (t, J=7.3 Hz, 1H), 0.84 (t, J=6.8 Hz, 1H).
-
- This compound was prepared using procedures analogous to those described for Example 2 using 5-hexenoic acid to replace acetic acid in Step 2. LCMS calculated for C31H36ClN404S (M+H)+: m/z=595.21/597.20; found: 595.3/597.2. 1H NMR (500 MHz, DMSO-d6) δ 11.87 (s, 1H), 7.69 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.43 (s, 1H), 7.35 (d, J=2.2 Hz, 1H), 7.23 (dd, J=2.3, 8.5 Hz, 1H), 7.18 (dd, J=2.2, 8.2 Hz, 1H), 7.16 (d, J=2.4 Hz, 1H), 7.01 (d, J=8.3 Hz, 1H), 5.94 (ddt, J=5.7, 10.2, 17.1 Hz, 1H), 5.71 (ddt, J=6.5, 10.1, 16.9 Hz, 1H), 5.12 (dq, J=1.5, 10.2 Hz, 1H), 5.05 (dq, J=1.6, 17.0 Hz, 1H), 4.97-4.88 (m, 2H), 4.65 (dt, J=1.6, 5.8 Hz, 2H), 4.33 (s, 2H), 4.12 (s, 2H), 3.49 (d, J=14.3 Hz, 1H), 3.35 (d, J=14.3 Hz, 1H), 2.69 (m, 2H), 2.17 (t, J=7.4 Hz, 2H), 2.03-1.94 (m, 2H), 1.94-1.83 (m, 2H), 1.50 (p, J=7.4 Hz, 4H).
-
- A solution of N-[5-[(1-allylpyrazol-4-yl)methyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylhex-5-enamide (Example 10, Step 2, 42 mg, 0.07 mmol) in toluene (50 mL) was evacuated and re-charged with nitrogen for three cycles. To the solution was added (1,3-dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride (Hoveyda-Grubbs II, 8.84 mg, 0.01 mmol) in toluene (5 mL). The mixture was then heated at 105° C. for 2 h. Additional Hoveyda-Grubbs II (8.84 mg, 0.01 mmol) was added. The system was evacuated and re-charged with nitrogen for three cycles. The mixture was heated at 105° C. overnight. The mixture was concentrated under reduced pressure. The residue was purified by FC on a silica gel column eluting with EtOAc/Hex (0-60%) (both contains 0.1% AcOH). The desired fractions were collected and concentrated under reduced pressure. The residue was further purified by RP FC on C18 eluting with MeCN/water (10-80%) (both contains 0.2% AcOH) to afford the desired product as slight brown solid which contained 1 eq. AcOH. Based on 1H NMR spectrum, the ratio of the cis- and trans-isomers is about 1:4. Some signals from the cis-isomer could not be distinguished and overlaps with those for the trans-isomer. LCMS calculated for C29H32ClN4O4S (M+H)+: m/z=567.18/569.17; found: 567.1/569.1. 1H NMR (500 MHz, Methanol-d4) δ 7.78 (d, J=8.6 Hz, 1H), 7.46 (d, J=13.9 Hz, 2H), 7.32 (dd, J=2.2, 8.3 Hz, 1H), 7.18 (dd, J=2.4, 8.5 Hz, 1H), 7.11 (dd, J=2.3, 5.0 Hz, 2H), 6.98 (d, J=8.4 Hz, 1H), 5.51 (dt, J=6.2, 14.9 Hz, 0.81H for the 1H in trans-isomer), 5.42 (dt, J=6.9, 14.9 Hz, 0.81H for the 1H in trans-isomer), 5.35 (tt, J=5.0, 1.5 Hz, 0.48H for the 2H in cis-isomer) 4.62-4.56 (m, 2H from trans and 4H from cis), 4.51 (d, J=4.7 Hz, 2H), 4.23 (d, J=4.2 Hz, 2H), 3.79-3.70 (m, 1H), 3.46 (d, J=14.6 Hz, 1H), 2.78 (d, J=5.8 Hz, 2H, overlaps with 2H for cis-isomer), 2.21-2.16 (m, 2H, overlaps with 2H for cis-isomer), 2.03 (m, 2H, overlaps with 2H for cis-isomer), 1.97 (s, 2H, AcOH signal), 1.91-1.85 (m, 2H), 1.68-1.57 (m, 4H).
-
-
- To a solution of rac-(3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[4,5-dihydro-2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 2, 46 mg, 0.07 mmol) in TFA (0.06 mL, 0.74 mmol) and DCM (2 mL) was added cyclobutanecarboxaldehyde (12.5 mg, 0.15 mmol) The mixture was stirred at r.t. for 15 min., then the mixture was cooled by ice-water bath, and sodium borohydride (8.43 mg, 0.22 mmol) was added slowly (over 15 min). The mixture was stirred at 0° C. for 1 h., then the volatile was removed under reduced pressure. The residue was diluted with AcOEt (5 mL) and washed with sat. NaHCO3solution (2 mL×2), and brine. The organics was dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by FC on a silica gel column with EtOAc in hexane (0-50%) to afford the desired product (3S)-6′-chloro-5-(cyclobutylmethyl)-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide. LCMS calculated for C39H44ClN2O5S (M+H)+: m/z=687.26/689.26; found: 688.7.2/689.2.
-
- To a solution of (3S)-6′-chloro-5-(cyclobutylmethyl)-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (48. mg, 0.07 mmol) in DCM (1 mL) was added TFA (0.8 mL, 10.4 mmol). The mixture was stirred at r.t. overnight. and diluted with DCM (5 mL) and carefully neutralized with 7.5% NaHCO3solution to about pH 8. The organic layer was separated. The aqueous layer was extracted with DCM (3 mL). The combined organic layers were washed with 7.5% NaHCO3solution (2 mL), and water (2 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to afford (3S)-6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide which was directly used in next step reaction without further purification. LCMS calculated for C23H28ClN2O3S (M+H)+: m/z=447.14/449.14; found: 447.0/449.0.
-
- To a mixture of (3S)-6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (15 mg, 0.03 mmol), acetic acid (0.5 mL, 0.07 mmol) and 4-(dimethylamino)pyridine (8.2 mg, 0.07 mmol) in DCM (1 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (12.8 mg, 0.07 mmol) at r.t. The mixture was stirred at r.t. for 1 h. The mixture was concentrated under reduced pressure. The residue was purified by FC on a silica gel column eluting with EtOAc/Hex (0-50%). The desired fractions were collected and concentrated under reduced pressure. The residue was diluted with MeCN and water, and was lyophilized to afford the desired product as white solid. LCMS calculated for C25H30ClN4O4S (M+H)+: m/z=489.15/491.15; found: 489.1/491.1. 1H NMR (500 MHz, DMSO-d6) δ 11.90 (s, 1H), 7.63 (d, J=8.6 Hz, 1H), 7.23 (dd, J=2.4, 8.5 Hz, 1H), 7.20-7.15 (m, 3H), 7.03-6.98 (m, 1H), 4.07 (s, 2H), 3.52 (d, J=14.3 Hz, 1H), 3.23-3.36 (m, 3H, overlap with water), 2.80-2.58 (m, 3H), 2.08-1.95 (m, 2H), 1.92 (s, 3H), 1.91-1.84 (m, 1H), 1.77 (m, 6H), 1.51 m, 1H).
-
- To a mixture of (3S)-6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (15 mg, 0.03 mmol), 4-(dimethylamino)pyridine (8.2 mg, 0.07 mmol) and N,N-Diisopropylethylamine (0.01 mL, 0.07 mmol) in DCM (1 mL) was added cyclopentanecarbonyl chloride (6.67 mg, 0.05 mmol) at r.t. The mixture was stirred at r.t. for 2 h. The mixture was concentrated under reduced pressure. The residue was purified by FCC on a silica gel column eluting with EtOAc/Hex (0-50%). The desired fractions were collected and concentrated under reduced pressure. The residue was diluted with MeCN and water and was lyophilized to afford the desired product as white solid. LCMS calculated for C29H36ClN4O3S (M+H)+: m/z=543.2/545.2; found: 543.1/545.1. 1H NMR (500 MHz, DMSO-d6) δ 11.87 (s, 1H), 7.63 (d, J=8.5 Hz, 1H), 7.23 (dd, J=2.4, 8.5 Hz, 1H), 7.19-7.13 (m, 3H), 6.98 (d, J=8.7 Hz, 1H), 4.06 (s, 2H), 3.51 (d, J=14.3 Hz, 1H), 3.29-3.21 (m, 3H), 2.81-2.57 (m, 4H), 2.00 (d, J=6.9 Hz, 2H), 1.90 (d, J=13.9 Hz, 1H), 1.84-1.68 (m, 8H), 1.50 (d, J=29.6 Hz, 7H).
-
- To a mixture of 6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (15.0 mg, 0.03 mmol), Benzyl chloroformate (8.2 mg, 0.07 mmol) and N,N-Diisopropylethylamine (0.01 mL, 0.07 mmol) in DCM (1 mL) was added Benzyl chloroformate (6.67 mg, 0.04 mmol) at r.t. The mixture was stirred at r.t. for 2 h. The mixture was concentrated under reduced pressure. The residue was purified by FC on a silica gel column eluting with EtOAc/Hex (0-50%). The desired fractions were collected and concentrated under reduced pressure. The residue was diluted with MeCN and water, and was lyophilized to afford the desired product as white solid. LCMS calculated for C31H34ClN2O5S (M+H)+: m/z=581.18/583.18; found: 581.3/583.3. 1H NMR (500 MHz, Acetonitrile-d3) δ 9.05 (sbr, 1H), 7.72 (d, J=8.5 Hz, 1H), 7.41-7.32 (m, 3H), 7.32-7.27 (m, 2H), 7.27-7.16 (m, 4H), 6.98 (d, J=8.3 Hz, 1H), 5.12 (s, 2H), 4.14 (s, 2H), 3.64-3.56 (m, 1H), 3.39-3.32 (m, 2H), 3.28 (dd, J=6.1, 14.9 Hz, 1H), 2.86-2.73 (m, 2H), 2.66 (p, J=7.3 Hz, 1H), 2.09-2.02 (m, 3H), 1.92-1.75 (m, 6H), 1.58 m, 1H).
-
- This compound was prepared using procedures analogous to those described for Example 12 using 2-(1,5-dimethylpyrazol-3-yl)acetic acid to replace acetic acid in Step 3. LCMS calculated for C30H36ClN4O4S (M+H)+: m/z=583.21/585.21; found: 583.2/585.2. 1H NMR (500 MHz, Chloroform-d) δ 7.67 (d, J=8.5 Hz, 1H), 7.38-7.32 (m, 2H), 7.17 (dd, J=2.3, 8.5 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.95 (d, J=8.9 Hz, 1H), 5.95 (s, 1H), 4.12 (s, 2H), 3.81 (d, J=8.3 Hz, 3H), 3.61 (s, 2H), 3.38-3.30 (m, 2H), 2.80-2.65 (m, 2H), 2.33-2.20 (m, 5H), 2.16-2.05 (m, 3H), 1.99-1.71 (m, 8H).
-
- This compound was prepared using procedures analogous to those described for Example 12 using 2-(4-thiazolyl)acetic acid to replace acetic acid in Step 3. LCMS calculated for C28H31ClN3O4S 2 (M+H)+: m/z=571.14/573.14; found: 571.2/573.2. 1H NMR (500 MHz, DMSO-d6) δ 12.33 (s, 1H), 9.00 (d, J=2.0 Hz, 1H), 7.68-7.61 (m, 2H), 7.50-7.39 (m, 2H), 7.24 (dd, J=2.4, 8.5 Hz, 1H), 7.21-7.14 (m, 2H), 6.98 (d, J=8.8 Hz, 1H), 4.06 (s, 2H), 3.51 (d, J=14.3 Hz, 1H), 2.82-2.58 (m, 4H), 2.06-1.67 (m, 12H), 1.52 (dd, J=7.0, 14.2 Hz, 1H).
-
- This compound was prepared using procedures analogous to those described for Example 12 using 2-(6-methylpyridin-3-yl)acetic acid to replace acetic acid in Step 3. LCMS calculated for C31H35ClN3O4S (M+H)+: m/z=580.2/582.20; found: 580.3/582.3. 1H NMR (500 MHz, DMSO-d6) δ 12.33 (s, 1H), 8.51 (s, 1H), 8.00 (s, 1H), 7.63 (d, J=8.5 Hz, 2H), 7.29-7.15 (m, 4H), 7.01 (d, J=8.2 Hz, 1H), 4.11-4.03 (m, 2H), 3.77 (s, 2H), 3.51 (d, J=14.3 Hz, 1H), 3.35-3.20 (m, 3H), 2.82-2.67 (m, 2H), 2.58 (s, 3H), 2.04-1.66 (m, 11H), 1.50 (dd, J=5.5, 12.2 Hz, 1H).
-
-
- To a solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[4,5-dihydro-2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 2, 1.20 g, 1.94 mmol) and [(1R,2R)-2-formylcyclobutyl]methyl acetate (0.333 g, 2.13 mmol) in DCM (25 mL) was added 2,2,2-trifluoroacetic acid; TFA (1.2 mL, 15.68 mmol, 8 eq.). The mixture was stirred for 5 min., and then cooled with ice-water bath. To the cooled solution was added sodium borohydride (146.64 mg, 3.88 mmol) in small portion-wise over 15 min. The mixture was stirred at 0° C. for 1.5 h. and was quenched by addition of methanol (1 mL). The reaction mixture was then carefully neutralized with 7.5% NaHCO3 aq. solution to about pH 8. The organic layer was separated and washed with water, dried over Na2SO4, filtered and concentrated under reduced pressure to afford the desired crude product (1.63 g, 90% purity) without further purification. LCMS: m/z=781.3 (M+Na)*.
-
- To a solution of [(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl acetate (1635.0 mg, 1.94 mmol, 90% pure) in methanol (5 mL) and THF (5 mL) was added a solution of lithium hydroxide (100 mg, 4.0 mmol) in water (5 mL). The mixture was stirred at r.t overnight. The volatiles were removed under reduced pressure. The residue was neutralized with 1 N HCl aqueous solution to about pH 7. The mixture was extracted with ethyl acetate (3×5 mL). The combined organic layers were washed with water and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with ethyl acetate in hexane (0-50%) to afford the desired product (1.21 g, 87%).
-
- A 4 mL vial with septum containing triphenylphosphine (36.0 mg, 0.14 mmol) and vacuum-dried (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-(hydroxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (60.9 mg, 0.08 mmol) was charged with 3-hydroxyphenylacetic acid methyl ester (13.5 uL, 0.09 mmol) followed by diisopropyl azodicarboxylate (24.0 μL, 0.12 mmol) dropwise over 1 min at r.t. The reaction mixture was stirred at r.t. for 2 h. The vial was then charged with additional triphenylphosphine (16.5 mg, 0.06 mmol), diisopropyl azodicarboxylate (15.0 μL, 0.08 mmol), and 3-hydroxyphenylacetic acid methyl ester (6.0 μL, 0.04 mmol). The solution was stirred at r.t. for an additional 1 h., then quenched with 2 drops water. The solution was dried under reduced pressure and purified by FCC (12 g SiO2, 0→35% EtOAc in hexanes, wet-loaded in DCM). Fractions containing desired product were combined and concentrated under reduced pressure and heat (˜100° C.) to yield methyl 2-[3-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]phenyl]acetate (53.6 mg, 0.0619 mmol, 72.9% yield) as a slightly white/hazy clear glass. Rf=0.30 (2:1 hexanes:EtOAc); LCMS calcd for C49H54ClN2O8S (M+H)+: m/z=865.33; found: 865.2.
-
- A 4 mL vial with septum containing methyl 2-[3-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]phenyl]acetate (50.0 mg, 0.06 mmol) under N2 was charged with DCM (1 mL) followed by TFA (1.0 mL, 0.06 mmol) and stirred at r.t. overnight. The purple reaction mixture was concentrated under reduced pressure, neutralized with sat. sodium bicarbonate (10 mL), diluted with water (30 mL) and extracted with EtOAc (40 mL). The organic layer was washed with water (40 mL), brine (20 mL), and dried over Na2SO4. The organic layer was filtered, concentrated under reduced pressure, and heat (˜50° C.) to yield methyl 2-[3-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]phenyl]acetate (44.1 mg) as a yellow gum. LCMS calculated for C33H38ClN2O6S (M+H)+: m/z=625.21; found: 625.4.
-
- A 20 mL vial containing methyl 2-[3-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]phenyl]acetate (40 mg, 0.06 mmol) and lithium hydroxide (8.2 mg, 0.33 mmol) was charged with THF (900 μL) and water (300 μL). The vial was purged with N2 and stirred at r.t. for 2 h. The reaction mixture was diluted with EtOAc (30 mL), washed twice with 0.1 M HCl (5 mL) and brine (20 mL), and washed with brine (20 mL). The organic layer was dried over Na2SO4, filtered, concentrated under reduced pressure and heat (−60° C.) to yield crude 2-[3-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]phenyl]acetic acid (37 mg, 0.061 mmol, 95% yield) as an off-white glass. LCMS calculated for C32H36ClN2O5S (M+H)+: m/z=611.20; found: 611.3.
-
- A 20 mL vial with septum containing 2-[3-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]phenyl]acetic acid (26 mg, 0.04 mmol) in DCM (3 mL) was charged with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (25 mg, 0.13 mmol) and 4-(dimethylamino)pyridine (25 mg, 0.20 mmol) in one portion. The reaction mixture was stirred at r.t. for 2 h. The reaction mixture was quenched with 2 drops of water. The reaction mixture was then diluted with EtOAc (30 mL), washed twice with 0.1 M HCl (3 mL) and water (20 mL), and brine (20 mL). The organic layer was dried over Na2SO4, filtered, concentrated under reduced pressure, and purified by FCC (12 g SiO2, 0→40% EtOAc in hexanes, wet-loaded in DCM+hexanes). Fractions containing mostly product were combined and re-purified by FCC (15.5 g C18, 40→95% MeCN in H2O, wet-loaded in DMSO). Fraction of high purity were combined, and concentrated under reduced pressure and heat (−60° C.) to yield 96.3% pure (3R,6R,24S)-6′-chloro-17,17-dioxo-spiro[8,22-dioxa-17λ{circumflex over ( )}6-thia-1,16-diazapentacyclo[16.7.2.1{circumflex over ( )}9,13.0{circumflex over ( )}3,6.0{circumflex over ( )}21,26]octacosa-9(28),10,12,18(27),19,21(26)-hexaene-24,1′-tetralin]-15-one (8.1 mg, 0.013 mmol, 30% yield) as an off-white solid. Rf=0.54 (1:2 hexanes:EtOAc). LCMS calculated for C32H34ClN2O5S (M+H)+: m/z=593.19; found: 593.1; 1H NMR (500 MHz, Acetonitrile-d3) δ 9.40 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.20 (dd, J=2.4, 8.5 Hz, 1H), 7.16 (d, J=2.3 Hz, 1H), 7.13 (dd, J=2.2, 8.3 Hz, 1H), 7.09 (t, J=7.9 Hz, 1H), 6.92 (d, J=2.2 Hz, 1H), 6.83 (t, J=2.1 Hz, 1H), 6.78-6.71 (m, 2H), 6.67 (d, J=7.4 Hz, 1H), 4.13-4.02 (m, 4H), 3.46 (d, J=14.5 Hz, 1H), 3.41 (s, 2H), 3.32 (dd, J=5.4, 14.7 Hz, 2H), 3.19 (dd, J=9.5, 14.7 Hz, 1H), 2.84-2.70 (m, 2H), 2.64 (h, J=7.5, 8.5 Hz, 1H), 2.60-2.51 (m, 1H), 2.03-1.95 (m, 3H), 1.88-1.78 (m, 3H), 1.65-1.55 (m, 2H).
-
- This compound was prepared using procedures analogous to those described for Example 12 using 2-(pyridin-4-yl)acetic acid to replace acetic acid in Step 3. LCMS calculated for C30H33ClN3O4S (M+H)+: m/z=566.18; found: 566.1. 1H NMR (500 MHz, DMSO-d6) δ 12.20 (s, 1H), 8.55 (d, J=5.2 Hz, 1H), 7.62 (d, J=8.6 Hz, 1H), 7.35 (s, 1H), 7.27-7.13 (m, 2H), 7.00 (d, J=8.3 Hz, 1H), 4.06 (s, 1H), 3.71 (s, 1H), 2.82-2.65 (m, 1H), 2.02-1.86 (m, 2H), 1.84-1.68 (m, 4H), 1.50 (d, J=6.8 Hz, 1H).
-
- This compound was prepared using procedures analogous to those described for Example 12 using 2-(pyridin-4-yl)acetic acid to replace acetic acid in Step 3. LCMS calculated for C31H35ClN3O4S (M+H)+: m/z=580.2; found: 580.2. 1H NMR (500 MHz, DMSO-d6) δ 12.33 (s, 1H), 8.51 (s, 1H), 8.00 (s, 1H), 7.63 (d, J=8.5 Hz, 2H), 7.29-7.15 (m, 5H), 7.01 (d, J=8.2 Hz, 1H), 4.11-4.03 (m, 2H), 3.77 (s, 2H), 3.51 (d, J=14.3 Hz, 1H), 3.35-3.20 (m, 3H), 2.82-2.67 (m, 2H), 2.58 (s, 4H), 2.04-1.66 (m, 10H), 1.50 (dd, J=5.5, 12.2 Hz, 1H).
-
- This compound was prepared using procedures analogous to those described for Example 2 using N-Boc-isonipecotic acid to replace acetic acid in Step 2. LCMS calculated for C34H45ClN3O6S (M+H)+: m/z=658.26; found: 657.9.
-
- This compound was prepared using procedures analogous to those described for Example 2 using 2-(1-tert-butoxycarbonyl-4-piperidyl)acetic acid to replace acetic acid in Step 2. LCMS calculated for C35H47ClN3O6S (M+H)+: m/z=672.28; found: 671.9.
-
-
- A solution of tert-butyl (3S)-3-hydroxypiperidine-1-carboxylate (2.01 g, 9.99 mmol) in DCM (20 mL) was cooled to 0° C. and a freshly prepared solution of triphosgene (1.48 g, 4.99 mmol) in 5 mL of DCM was added dropwise over 5 minutes. The mixture was stirred at this temperature for 30 min., then pyridine (0.81 mL, 9.9 mmol) was added dropwise. The mixture was kept stirring at 0° C. for 1 h. Water (30 mL) was added to the mixture and the layers were separated. The organic layer was dried over sodium sulfate and concentrated under reduced pressure to afford the crude product tert-butyl (3S)-3-chlorocarbonyloxypiperidine-1-carboxylate (1.8 g, 68% yield) which was used in next step without further purification.
- A solution of 6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Example 1, Step 1, 15 mg, 0.03 mmol) and potassium carbonate (13.8 mg, 0.10 mmol) in acetone (2 mL) was stirred for 5 min in a sealed tube. Then a solution of tert-butyl (3S)-3-chlorocarbonyloxypiperidine-1-carboxylate (13.3 mg, 0.05 mmol) in acetone was added. The resulting mixture was stirred at 60° C. overnight, and poured into water (5 mL) and extracted with DCM (5 mL×3). The combined organic layer were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by prep-HPLC on C18 column to afford desired product tert-butyl (3S)-3-[[6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylcarbamoyloxy]piperidine-1-carboxylate (12.1 mg, 53% yield) as a white solid. LCMS calculated for C34H45ClN3O7S (M+H)+: m/z=674.26; found: 673.9.
-
- To a solution of pyrrolidine (23.8 mg, 0.34 mmol) in THF (2 mL) was added triphosgene (49.7 mg, 0.17 mmol). The mixture was kept stirring at r.t. for 2 hrs. Then pyridine was added to the solution. The mixture was further kept stirring at r.t. for 1 h. Then the whole solution was transferred to a solution of 6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Example 1, Step 1, 15.0 mg, 0.03 mmol) and potassium carbonate (4.64 mg, 0.03 mmol) in acetone. The mixture was kept stirring at reflux overnight. The mixture was poured into water (5 mL) and the pH of aqueous was adjusted to 7-8 by adding saturated potassium bicarbonate solution. The aqueous layer was extracted with DCM (5 mL×3). The combined organic layer was dried over sodium sulfate and concentrated. The crude product was further purified prep HPLC on C18 column to afford N-[6′-chloro-5-(cyclobutylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylpyrrolidine-1-carboxamide (9 mg, 47% yield) as a yellow solid. LCMS calculated for C28H35ClN3O4S (M+H)+: m/z=544.20; found: 543.8.
-
-
- To a mixture of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-(hydroxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Example 18, Step 2, 44.0 mg, 0.06 mmol), tosyl chloride (16.2 mg, 0.08 mmol) in DCM (0.5 mL) was added TEA (22 uL, 0.16 mmol) at r.t. The reaction mixture was stirred at r.t. for 22 h. The additional tosyl chloride (21.2 mg, 0.11 mmol) and TEA (70 μL, 0.50 mmol) were added, and the reaction mixture was stirred for an additional 3 d at r.t. The reaction mixture was diluted with EtOAc (30 mL), washed with sat. NH4Cl (15 mL) and water (15 mL), 0.05N HCl (30 mL), sat. NaHCO3 (2×20 mL), and brine (20 mL). The organic layer was dried over Na2SO4, filtered, concentrated under reduced pressure to yield crude [(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl 4-methylbenzenesulfonate (65.8 mg) which was directly used in next step reaction without further purification.
-
- A mixture of [(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl 4-methylbenzenesulfonate (65.8 mg), methyl 2-(3-sulfanylphenyl)acetate (26.3 mg, 0.12 mmol), and potassium carbonate (21.5 mg, 0.15 mmol) was purged with N2, and charged with DMF (400 μL). The mixture was stirred at r.t. overnight. LCMS analysis to form two major products. The reaction mixture was diluted with EtOAc (30 mL), washed with 0.1 N HCl (3 mL) and water (30 mL), sat. NaHCO3 (30 mL), and brine (20 mL). The organic layer was dried over Na2SO4, filtered, concentrated under reduced pressure to yield crude methyl 2-[3-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methylsulfanyl]phenyl]acetate (74 mg) as a brown solid. Rf=0.34 (2:1 hexanes:EtOAc)
-
- A solution of methyl 2-[3-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methylsulfanyl]phenyl]acetate (74 mg) in DCM (1.3 mL) and TFA (1.3 mL) was stirred at r.t. for 18 h. The volatiles were removed under reduced pressure. The residue was co-evaporated with DCM twice under reduced pressure, and purified by FCC (12 g SiO2, 10→35% EtOAc in hexanes, wet-loaded in DCM) to yield methyl 2-[3-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methylsulfanyl] phenyl]acetate (19.3 mg with ˜80% pure) as a white solid. Rf=0.18 (2:1 hexanes:EtOAc); LCMS m/z calcd for C33H38ClN2O5S2 (M+H)+: m/z=641.19/643.19; found: 641.2/643.1.
-
- Methyl 2-[3-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methylsulfanyl]phenyl]acetate (19.0 mg, 0.02 mmol) in THF (400 uL) was treated with lithium hydroxide (6.0 mg, 0.24 mmol) in water (130 μL) at r.t. The reaction mixture was stirred at r.t. for 4 h. The mixture was diluted with EtOAc (20 mL), washed with water (5 mL), 0.1 N HCl (4 mL), and brine (15 mL). The aqueous layer was separated and extracted again with EtOAc (20 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to yield 2-[3-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methylsulfanyl]phenyl]acetic acid (29 mg) as an opaque yellow gum. LCMS m/z called for C32H36ClN2O5S2 (M+H)+: m/z=627.17/629.17; found: 627.1/629.1.
- A solution of 2-[3-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl] methylsulfanyl]phenyl]acetic acid (29 mg) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (26.0 mg, 0.14 mmol) in DCM (1.5 mL) was charged with 4-(dimethylamino)pyridine (27.0 mg, 0.22 mmol). The mixture was purged with N2 and stirred at r.t. for 20 h. The reaction mixture was diluted with EtOAc (30 mL), washed twice with 1 N HCl (3 mL) and brine (20 mL). The aqueous layers were combined and back-extracted with DCM (3×20 mL). The organic combined layers were dried over Na2SO4, and filtered, and concentrated under reduced pressure. The residue was purified by FCC (15.5 g C18, 20→100% MeCN in H2O, wet-loaded in DMSO). Fractions containing clean desired product were combined and concentrated under reduced pressure to yield (1S,1′R,2′R)-6-chloro-3,4-dihydro-2H-spiro[naphthalene-1,3′-5,10-dithia-9-aza-1(5,7)-benzo[b][1,4]oxazepina-6(1,3)-benzena-3(1,2)-cyclobutanacyclodecaphan]-8′-one 10′,10′-dioxide (5.5 mg) as a white solid. LCMS m/z calcd for C32H34ClN2O4S2 (M+H)+: m/z=609.16/611.16; found: 609.0/611.0. 1H NMR (500 MHz, Chloroform-d) δ 7.88 (s, 1H), 7.72 (d, J=8.5 Hz, 1H), 7.45 (dd, J=2.1, 8.4 Hz, 1H), 7.28 (d, J=4.2 Hz, 2H), 7.21 (dd, J=2.3, 8.5 Hz, 1H), 7.12 (d, J=2.2 Hz, 1H), 7.07 (s, 1H), 7.03 (t, J=4.7 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 6.86 (d, J=2.2 Hz, 1H), 4.23 (d, J=12.1 Hz, 1H), 4.08 (d, J=12.0 Hz, 1H), 3.61 (ABq, 2H, JAB=14.8 Hz, ΔδAB=0.017 Hz), 3.46 (d, J=14.4 Hz, 1H), 3.38-3.27 (m, 2H), 3.07 (dt, J=6.8, 13.6 Hz, 2H), 2.84-2.73 (m, 3H), 2.26 (ddd, J=7.7, 15.0, 31.3 Hz, 2H), 2.06 (dtd, J=2.6, 8.0, 10.9 Hz, 1H), 1.98-1.75 (m, 3H), 1.66 (p, J=9.0 Hz, 2H), 1.61-1.48 (m, 2H).
-
-
- To a suspension of 1-(aminomethyl)cyclobutanecarboxylic acid hydrochloride salt (500 mg, 3.02 mmol) and sodium bicarbonate (1014 mg, 12.0 mmol) in THF (5 mL) and water (5 mL) was added di-tert-butyl dicarbonate (790 mg, 3.62 mmol). The resulting mixture was heated at 40° C. for 3 h. The reaction was acidified with 0.5 N HCl (to pH 4-5) and extracted with MTBE. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with EtOAc/Hept (15% to 40%) to afford 1-[(tert-butoxycarbonylamino)methyl]cyclobutanecarboxylic acid (520 mg, 75% yield). LCMS: calc. for C11H18NO4 (M−H)−: m/z=228.12; Found: 228.17.
-
- To a solution of 1-[(tert-butoxycarbonylamino)methyl]cyclobutanecarboxylic acid (520 mg, 2.27 mmol) in THF (10 mL) was slowly added sodium hydride (272 mg, 6.8 mmol) at r.t. After 20 min, allyl bromide (411 mg, 3.4 mmol) was added in one portion. The resulting slurry was heated to a gentle reflux for 48 h. The reaction was cool to r.t., concentrated under reduced pressure, charged with EtOAc, and acidified with 0.5 N HCl (to pH 4-5). The layers were separated, and the aqueous phase was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column with EtOAc/Hept (10% to 30%) to afford 1-[[allyl(tert-butoxycarbonyl)amino]methyl]cyclobutanecarboxylic acid (203 mg, 33% yield) as a yellow oil. LCMS: calc. for C14H22NO4 (M−H)−: m/z=268.16, Found: 268.13.
-
- A mixture of (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (120.0 mg, 0.23 mmol, Intermediate 8), 1-[[allyl(tert-butoxycarbonyl)amino]methyl]cyclobutanecarboxylic acid (125 mg, 0.46 mmol), DMAP (170 mg, 1.39 mmol) and EDCI (0.27 mL, 1.39 mmol) was stirred at r.t. for 4 h. The reaction was diluted with CH2C12 and washed with 0.5 N HCl. The organic phase was dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (12 g) using EtOAc/Heptanes (5% to 50%) to afford tert-butyl N-allyl-N-[[1-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylcarbamoyl]cyclobutyl]methyl]carbamate (180 mg) as a colorless oil. LCMS: calc. for C41H55ClN3O7S [M+H]+: m/z=768.34/770.34; Found: 768.14/770.47.
-
- A solution of tert-butyl N-allyl-N-[[1-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylcarbamoyl]cyclobutyl]methyl]carbamate (180 mg, 0.23 mmol) in DCE (90 mL) was bubbled with N2 for 10 min. (1,3-Dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride; Hoveyda-Grubbs II (29.3 mg, 0.05 mmol) was added and the resulting greenish solution was further bubbled with N2 for 5 min, and was heated to reflux under N2 for 16 h. LC-MS analysis indicated the completion of reaction. The reaction was allowed to cool to r.t. while being exposed to air. The reaction was concentrated under reduced pressure, and the residue was purified by flash chromatography on a silica gel column (12 g) using EtOAc/Heptanes (5% to 60%) to afford (3R,6R,7R,8E,23S)-6′-chloro-7-methoxy-11-(tert-butoxycarbonyl)-13,13-(1,3-propylene)-16,16-dioxo-spiro[21-oxa-16-thia-1,11,15-triazatetracyclo[15.7.2.03,6.020,25]hexacosa[8,17(26),18,20(25)]tetraene-23,1′-tetralin]-14-one (140 mg, 80% yield). LC-MS: [M+H]+ calc. for C39H51ClN3O7S: 740.31/742.31; Found: 739.96/742.29.
-
- (3R,6R,7R,8E,23S)-6′-Chloro-7-methoxy-11-(tert-butoxycarbonyl)-13,13-(1,3-propylene)-16,16-dioxo-spiro[21-oxa-16-thia-1,11,15-triazatetracyclo[15.7.2.03,6.020,25]hexacosa[8,17(26),18,20(25)]tetraene-23,1′-tetralin]-14-one (140.0 mg, 0.19 mmol) in 2 N HCl in EtOAc (3 mL) was stirred at r.t. overnight. The reaction was diluted with EtOAc, washed with saturated aqueous NaHCO3solution and brine, dried over Na2SO4, filtered and concentrated under reduced pressure to afford the crude product (120 mg). 40 mg of the crude product was purified by prep-HPLC on C18 column (30×250 mm, 10 m) with 20 to 100% ACN/H2O to afford the desired (3R,6R,7R,8E,23S)-6′-chloro-7-methoxy-13,13-(1,3-propylene)-16,16-dioxo-spiro[21-oxa-16-thia-1,11,15-triazatetracyclo[15.7.2.03,6.020,25]hexacosa[8,17(26),18,20(25)]tetraene-23,1′-tetralin]-14-one (19 mg) as a white solid. LCMS: calc. for C34H43ClN3O5S [M+H]+: m/z=640.26/642.26; Found: 639.96/642.23. 1H NMR (600 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.50 (d, J=8.3 Hz, 1H), 7.27 (d, 1H, overlapped with CDCl3), 7.17 (dd, J=8.5, 2.3 Hz, 1H), 7.07 (d, J=2.3 Hz, 1H), 6.96 (d, J=8.3 Hz, 1H), 5.90 (app s, 1H), 5.62 (dd, J=15.6, 8.0 Hz, 1H), 4.07 (t, J=9.3 Hz, 2H), 3.74 (d, J=14.4 Hz, 1H), 3.54 (app s, 1H), 3.41 (app s, 1H), 3.28 (d, J=14.6 Hz, 1H), 3.25 (s, 3H), 3.18-3.10 (m, 1H), 3.02 (d, J=13.4 Hz, 1H), 2.89-2.71 (m, 2H), 2.63-2.42 (m, 2H), 2.26 (app s, 1H), 2.09-1.77 (m, 8H), 1.62-1.50 (m, 9H).
-
- To a solution of (3R,6R,7R,8E,23S)-6′-chloro-7-methoxy-13,13-(1,3-propylene)-16,16-dioxo-spiro[21-oxa-16-thia-1,11,15-triazatetracyclo[15.7.2.03,6.020,25]hexacosa[8,17(26),18,20(25)]tetraene-23,1′-tetralin]-14-one (40.0 mg, 0.06 mmol, Example 26) in DCM (5 mL) was added acetic acid (0.02 mL, 0.31 mmol) and formaldehyde solution (37% wt %, 51 mg, 0.625 mmol HCHO). After 2 h, the reaction mixture was cooled at 0° C. and sodium borohydride (47.2 mg, 1.25 mmol) was added in portions. The reaction was stirred at r.t. for 3 h, and diluted with DCM and water, filtered through a pad of Celite. The organic layer was washed with saturated aqueous NaHCO3solution and brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC on C18 column (30×250 mm, 10 m) with 20 to 100% ACN/H2O to afford (3R,6R,7R,8E,23S)-6′-chloro-7-methoxy-11-methyl-13,13-(1,3-propylene)-16,16-dioxo-spiro[21-oxa-16-thia-1,11,15-triazatetracyclo[15.7.2.03,6.020,25]hexacosa[8,17(26),18,20(25)]tetraene-23,1′-tetralin]-14-one (20 mg, 48.9% yield). LCMS: calc. for C35H45ClN3O5S [M+H]+: m/z=654.28/656.27; Found: 654.02/656.36. 1H NMR (600 MHz, CDCl3) δ 13.75 (br s, 1H), 7.70 (d, J=8.5 Hz, 1H), 7.54 (dd, J=8.3, 2.1 Hz, 1H), 7.17 (dd, J=8.5, 2.3 Hz, 1H), 7.07 (d, J=2.3 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 6.95 (br s, 1H), 6.12-6.03 (m, 1H), 5.53 (dd, J=15.8, 8.8 Hz, 1H), 4.06 (s, 2H), 3.72 (d, J=14.6 Hz, 1H), 3.60 (t, J=8.5 Hz, 1H), 3.52 (q, J=12.8, 11.3 Hz, 1H), 3.31 (d, J=14.7 Hz, 1H), 3.28 (s, 3H), 3.19 (q, J=13.4, 9.2 Hz, 1H), 3.09 (t, J=11.4 Hz, 1H), 2.96 (dd, J=15.1, 11.2 Hz, 1H), 2.87 (d, J=13.8 Hz, 1H), 2.83-2.66 (m, 3H), 2.60-2.52 (m, 1H), 2.45 (app s, 5H), 2.15-1.58 (m, 13H).
-
-
- NaH (1.03 g, 25.84 mmol) washed by ether (30 mL) was added in one portion to a solution of methyl 1-hydroxycyclopropanecarboxylate (2.0 g, 17.22 mmol) in THF (20 mL). The reaction mixture was stirred at r.t. for 1 h. Allyl bromide (2.08 g, 17.2 mmol) was added, and the reaction mixture was stirred at r.t. for 14 h., then quenched with saturated aqueous NH4Cl (20 mL). The resulting mixture was extracted with ether (3×30 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and filtered. The filtrate was concentrated by decompression distillation at 0° C. to give methyl 1-(allyloxy)cyclopropane-1-carboxylate (1.2 g, 44% yield) as colorless oil. 1H NMR (400 MHz, DMSO-d6) δ 5.91-5.83 (m, 1H), 5.24-5.19 (m, 1H), 5.12-5.09 (m, 1H), 4.096-4.06 (m, 2H), 3.65 (s, 3H), 1.19-1.17 (m, 4H).
-
- NaOH (1.5 g, 37.5 mmol) was added to a solution of methyl 1-allyloxycyclopropanecarboxylate (1.2 g, 7.68 mmol) in methanol (5 mL) and water (5 mL). The reaction mixture was stirred at r.t. for 14 h. To the reaction mixture was added 20 mL of water. The resulting mixture was extracted with DCM (3×20 mL), then adjusted with HCl (3 M) to pH 2˜3, extracted with DCM (5 mL×3). The combined organic layers were dried over anhydrous Na2SO4 and filtered. The filtrate was concentrated to give the crude product 1-allyloxycyclopropanecarboxylic acid (369 mg, 34% yield) which was used directly in next step reaction without further purification. 1H NMR (400 MHz, DMSO-d6) δ 12.54 (br s, 1H), 5.92-5.82 (m, 1H), 5.20 (ddd, J=17.3, 3.8, 1.8 Hz, 1H), 5.09 (ddd, J=10.5, 3.4, 1.5 Hz, 1H), 4.07 (dt, J=5.4, 1.6 Hz, 2H), 1.15-1.14 (m, 2H), 1.11-1.09 (m, 1H).
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and 1-(allyloxy)cyclopropane-1-carboxylic acid in Step 3. LC-MS calc. for C32H38ClN2O6S [M+H]+: m/z=613.2/615.2. Found: 612.8/615.1. 1H NMR (600 MHz, DMSO-d6) δ 11.73 (s, 1H), 7.58 (d, J=8.4 Hz, 1H), 7.33 (d, J=15.7 Hz, 1H), 7.27-7.19 (m, 3H), 7.08 (d, J=14.5 Hz, 1H), 5.66-5.57 (m, 1H), 5.09-5.01 (m, 1H), 4.14 (d, J=11.9 Hz, 1H), 4.09-4.03 (m, 1H), 4.00 (d, J=12.0 Hz, 1H), 3.93 (dd, J=12.7, 9.3 Hz, 1H), 3.52 (d, J=14.2 Hz, 1H), 3.33-3.28 (m, 2H), 3.16-3.05 (m, 2H), 3.02 (s, 3H), 2.84-2.71 (m, 2H), 2.11-2.05 (m, 1H), 2.06-1.97 (m, 1H), 1.88-1.80 (m, 3H), 1.78-1.72 (m, 3H), 1.56 (q, J=9.3 Hz, 1H), 1.40-1.37 (m, 1H), 1.27-1.23 (m, 2H), 1.07-1.05 (m, 2H).
-
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and 1-(allyloxy)cyclopropane-1-carboxylic acid in Step 3. LC-MS calc. for C32H38ClN2O6S [M+H]+: m/z=613.2/615.2. Found: 613.2/615.1. 1H NMR (600 MHz, DMSO-d6) 11.79 (S, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.30 (dd, J=8.5, 2.3 Hz, 1H), 7.25 (d, J=8.4 Hz, 1H), 7.21-7.20 (m, 2H), 7.05 (d, J=8.2 Hz, 1H), 5.67-5.63 (m, 1H), 5.40 (dd, J=15.4, 8.5 Hz, 1H), 4.16-4.05 (m, 3H), 3.80 (dd, J=13.1, 7.2 Hz, 1H), 3.63-3.57 (m, 2H), 3.09-3.05 (m, 4H), 2.83-2.80 (m, 1H), 2.75-2.69 (m, 1H), 2.64-2.59 (m, 1H), 2.29-2.27 (m, 1H), 2.00 (d, J=13.7 Hz, 1H), 1.88-1.82 (m, 3H), 1.76-1.61 (m, 3H), 1.44-1.41 (m, 1H), 1.26-1.14 (m, 3H), 1.06-1.04 (m, 1H).
-
-
- This compound was prepared using procedures analogous to those described for Example 28 Step 1-2 using ethyl 2-hydroxy-2-methyl-propanoate to replace methyl 1-hydroxycyclopropanecarboxylate in Step 1.
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and 1-(allyloxy)cyclopropane-1-carboxylic acid in Step 3. LC-MS calc. for C32H40ClN2O6S [M+H]+: m/z=615.22/617.22. Found: 614.8/617.1. 1H-NMR (600 MHz, CDCl3) δ 9.07 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.51 (d, J=8.2 Hz, 1H), 7.17 (d, J=8.5 Hz, 1H), 7.08 (d, J=2.0 Hz, 1H), 6.99 (dd, J=8.7, 5.1 Hz, 2H), 5.83 (d, J=15.4 Hz, 1H), 5.53 (dd, J=15.6, 8.5 Hz, 1H), 4.11 (dt, J=21.2, 7.1 Hz, 3H), 3.77 (d, J=12.2 Hz, 1H), 3.72 (d, J=14.7 Hz, 1H), 3.59-3.44 (m, 2H), 3.33 (d, J=14.7 Hz, 1H), 3.27 (s, 3H), 3.07 (dd, J=15.0, 9.9 Hz, 1H), 2.84-2.67 (m, 2H), 2.58-2.44 (m, 1H), 2.25-2.13 (m, 1H), 2.04-1.89 (m, 4H), 1.87-1.77 (m, 1H), 1.65-1.52 (m, 3H), 1.42 (s, 3H), 1.38 (s, 3H).
-
-
- To a solution of ethyl 1-aminocyclobutanecarboxylate hydrochloride (501.2 mg, 2.79 mmol) in aqueous sulfuric acid (11.2 mL, 5.6 mmol) at 0° C. was dropwise added a solution of sodium nitrite (980 mg, 14 mmol) in water (3 mL). The reaction was stirred at 0° C. for 1 h and allowed to warm to r.t. After 24 h., the reaction was extracted with MTBE. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo to give ethyl 1-hydroxycyclobutane-1-carboxylate as colorless oil (240 mg). The crude product was used in next step without further purification. TLC: Rf=0.38 (3:7 EtOAc/Hept).
-
- This compound was prepared using procedures analogous to those described for Example 28 Step 1-2 using ethyl 1-hydroxycyclobutane-1-carboxylate to replace methyl 1-hydroxycyclopropanecarboxylate in Step 1. LC-MS calc. for C8H11O3 [M−H]−: m/z=155.1; Found: 155.1.
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and 1-allyloxycyclobutanecarboxylic acid in Step 3. LC-MS calc. for C33H40ClN2O6S [M+H]+: m/z=627.23/629.23. Found: 626.9/629.0. 1H-NMR (400 MHz, CDCl3) δ 10.13 (s, 1H), 7.73 (d, J=8.5 Hz, 1H), 7.53 (d, J=8.5 Hz, 1H), 7.23 (s, 1H), 7.20 (d, J=10.1 Hz, 1H), 7.10 (s, 1H), 6.97 (d, J=8.3 Hz, 1H), 5.90-5.79 (m, 2H), 4.29-3.63 (m, 8H), 3.33 (s, 3H), 3.27 (d, J=14.5 Hz, 1H), 3.00 (dd, J=15.2, 10.5 Hz, 1H), 2.84-2.72 (m, 2H), 2.70-2.59 (m, 1H), 2.37 (s, 2H), 2.10-1.16 (m, 12H).
-
-
- A solution of (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (200.0 mg, 0.40 mmol, Intermediate 3), 2-allyloxy-2-methyl-propanoic acid (171.96 mg, 1.19 mmol, Example 30, Step 1), EDCI (0.47 mL, 2.39 mmol), and DMAP (291.43 mg, 2.39 mmol) in DCM (4 mL) was stirred at r.t. for 16 h. LC-MS indicated the completion of reaction. The reaction was diluted with DCM and washed with 0.5 N HCl. The organic phase was dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (10% to 20%) to afford [(1S)-1-[(1R,2R)-2-[[(3S)-7-[(2-allyloxy-2-methyl-propanoyl)sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] 2-allyloxy-2-methyl-propanoate (300 mg, 99.9% yield). LC-MS: calc. for C40H52ClN2O8S [M+H]+: m/z=755.31/757.31; Found: 755.1/757.4.
-
- A solution of [(1S)-1-[(1R,2R)-2-[[(3S)-7-[(2-allyloxy-2-methyl-propanoyl)sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] 2-allyloxy-2-methyl-propanoate (300 mg, 0.40 mmol) and lithium hydroxide monohydrate (83.3 mg, 1.99 mmol) in THF/MeOH/H2O (0.3 mL each) was heated at 45° C. for 4 h. LC-MS indicated the completion of reaction. The reaction was adjusted with 1 N HCl to pH 3-4 and extracted with DCM. The combined organic layers were washed with saturated aqueous NaHCO3solution and brine, dried over Na2SO4, filtered and concentrated under reduced pressure to afford 2-allyloxy-2-methyl-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-propanamide (175 mg, 70% yield), which was used without further purifications. LCMS: calc. for C33H42ClN2O6S [M+H]+: m/z=629.24/631.24; Found: 628.9/631.2.
- A solution of 2-allyloxy-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-2-methyl-propanamide (1.40 g, 2.23 mmol) in DCE (1230 mL) was bubbled with N2 for 10 min. 1,3-Bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidene[2-(i-propoxy)-5-(N,N-dimethyl aminosulfonyl)phenyl]methyleneruthenium(II) dichloride (Zhan Catalyst 1B) (326 mg, 0.45 mmol) was added and the resulting greenish solution was further bubbled with N2 for 5 min., and was heated at 40° C. under N2 for 2 h. The reaction was concentrated under reduced pressure, and the residue purified by flash column chromatography on a silica gel column with EtOAc/Hept (10% to 70%) to afford two products: P1 (the earlier eluted product, 160 mg, 11% yield) and P2 (the latter eluted product, 647 mg, 47% yield).
- P2 was assigned to (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 32). HPLC: major product, C18 column (4.6×150 mm, 100 Å); flow rate=1 mL/min; mobile phase: 90% MeCN/H2O (with 0.1% HCO2H) 10 min λ=220 nm. tR=3.2 min. LC-MS calc. for C31H38ClN2O6S [M+H]+: m/z=601.21/603.21; Found 601.6/603.6; 1H NMR (300 MHz, CDCl3) δ 9.15 (s, 1H), 7.69 (d, J=8.5 Hz, 1H), 7.53 (dd, J=8.3, 2.1 Hz, 1H), 7.20 (dd, J=8.6, 2.2 Hz, 1H), 7.12 (s, 1H), 7.06 (d, J=1.8 Hz, 1H), 7.02 (d, J=8.3 Hz, 1H), 5.84-5.72 (m, 2H), 4.24 (d, J=3.3 Hz, 1H), 4.13 (t, J=7.2 Hz, 2H), 4.00 (dd, J=13.2, 4.5 Hz, 1H), 3.88 (d, J=12.5 Hz, 1H), 3.72 (d, J=14.6 Hz, 1H), 3.40-3.24 (m, 3H), 2.84-2.71 (m, 3H), 2.43-2.33 (m, 1H), 2.01 (d, J=15.5 Hz, 2H), 1.94-1.81 (m, 4H), 1.75-1.58 (m, 2H), 1.54 (d, J=14.5 Hz, 1H), 1.45 (s, 3H), 1.41 (s, 3H).
- And P1 to (3R,6R,7S,8Z,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 33). P1: minor product, C18 column (4.6×150 mm, 100 Å); flow rate=1 mL/min; mobile phase: 90% MeCN/H2O (with 0.1% HCO2H) 10 min λ=220 nm. tR=4.3 min. LC-MS calc. for C31H38ClN2O6S [M+H]+: m/z=601.21/603.21; Found 601.6/603.6; 1H NMR (300 MHz, CDCl3) δ 9.22 (s, 1H), 7.68 (t, J=8.3 Hz, 1H), 7.55 (dd, J=8.4, 2.1 Hz, 1H), 7.20 (dd, J=8.5, 2.1 Hz, 1H), 7.13 (dd, J=9.6, 2.0 Hz, 2H), 7.03 (d, J=8.4 Hz, 1H), 5.92-5.75 (m, 2H), 4.22-4.14 (m, 1H), 4.00 (dd, J=13.4, 4.9 Hz, 1H), 3.89 (dd, J=13.3, 2.9 Hz, 1H), 3.81-3.61 (m, 4H), 3.33 (d, J=14.5 Hz, 1H), 3.15 (dd, J=15.1, 9.2 Hz, 1H), 2.79 (d, J=9.2 Hz, 2H), 2.53 (d, J=5.2 Hz, 1H), 2.33-2.22 (m, 1H), 2.08-1.92 (m, 4H), 1.81 (dd, J=35.4, 6.4 Hz, 2H), 1.71-1.57 (m, 2H), 1.45 (s, 3H), 1.42 (s, 3H).
-
- To a solution of (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (13.0 mg, 0.02 mmol, Example 32) in THF (0.5 mL) was added sodium hydride (4.3 mg, 0.11 mmol) at r.t. After 10 min, N,N-dimethylcarbamoyl chloride (4.6 mg, 0.04 mmol) was added, and followed by DMAP (5.3 mg, 0.04 mmol). The mixture was stirred at r.t. for 6 h., and diluted with DCM and acidified with 0.5 N HCl to pH 5-6. The organic phase was separated, washed with water and brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC on C18 column (30×250 mm, 10 m) with 20 to 100% ACN/H2O to afford [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate (6 mg, 38% yield) as a white solid. LCMS: calc. for C34H43ClN3O7S [M+H]+: m/z=672.25/674.25; Found: 672.45/674.37. 1H NMR (600 MHz, CDCl3) δ 9.08 (br s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.49 (dd, J=8.3, 2.2 Hz, 1H), 7.17 (dd, J=8.5, 2.4 Hz, 1H), 7.08 (d, J=2.2 Hz, 1H), 7.04-6.95 (m, 2H), 5.86-5.78 (m, 1H), 5.74-5.67 (m, 1H), 5.30 (t, J=4.5 Hz, 1H), 4.15 (d, J=12.2 Hz, 1H), 4.12-4.05 (m, 2H), 3.76-3.72 (m, 1H), 3.70 (d, J=14.8 Hz, 1H), 3.43 (dd, J=15.1, 4.7 Hz, 1H), 3.37 (d, J=14.7 Hz, 1H), 3.21 (dd, J=15.1, 9.3 Hz, 1H), 2.95 (d, J=14.6 Hz, 6H), 2.83-2.73 (m, 3H), 2.37 (dtd, J=15.2, 10.2, 9.7, 5.5 Hz, 1H), 2.06-1.90 (m, 3H), 1.88-1.77 (m, 3H), 1.67-1.60 (m, 2H), 1.56 (s, 2H), 1.43 (s, 6H).
-
- This compound was prepared using procedures analogous to those described for Example 34 using (3R,6R,7S,8Z,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 33) and N,N-dimethylcarbamoyl chloride. LC-MS calc. for C34H43ClN3O7S [M+H]+: m/z=672.24/674.24; Found: 672.6/674.6.
-
- This compound was prepared using procedures analogous to those described for Example 32 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) to replace (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) in Step 2. LC-MS calc. for C31H38ClN2O6S [M+H]+: m/z=601.21/603.21; Found: 600.9/602.8. 1H NMR (600 MHz, DMSO-d6) δ 11.87 (s, 1H), 7.64 (d, J=8.5 Hz, 1H), 7.26 (dd, J=14.2, 5.6 Hz, 2H), 7.18 (d, J=1.9 Hz, 1H), 7.01 (d, J=8.3 Hz, 1H), 6.89 (s, 1H), 5.83 (d, J=12.7 Hz, 1H), 5.49 (dd, J=15.6, 7.9 Hz, 1H), 4.85 (d, J=4.0 Hz, 1H), 4.09 (dd, J=29.6, 12.2 Hz, 2H), 3.99 (dd, J=13.4, 7.4 Hz, 1H), 3.74 (dd, J=11.8, 8.0 Hz, 1H), 3.60 (d, J=14.6 Hz, 1H), 3.45 (d, J=12.5 Hz, 1H), 3.38 (dd, J=21.8, 9.7 Hz, 2H), 3.08 (dd, J=14.8, 10.0 Hz, 1H), 2.81 (d, J=16.9 Hz, 1H), 2.75-2.67 (m, 1H), 2.37-2.30 (m, 1H), 2.03-1.77 (m, 6H), 1.63 (ddd, J=30.2, 19.2, 10.3 Hz, 2H), 1.44 (dd, J=19.1, 9.3 Hz, 1H), 1.34 (s, 3H), 1.21 (s, 3H) ppm.
-
- This compound was prepared using procedures analogous to those described for Example 34 using (3R,6R,7R,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 36) and N,N-dimethylcarbamoyl chloride. LC-MS calc. for C34H43ClN3O7S [M+H]+: m/z=672.24/674.24; Found: 672.0/674.2. 1H NMR (600 MHz, CDCl3) δ 9.27 (br s, 1H), 7.69 (d, J=8.5 Hz, 1H), 7.52 (dd, J=8.3, 2.2 Hz, 1H), 7.18 (dd, J=8.5, 2.4 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 7.04 (d, J=2.2 Hz, 1H), 7.00 (d, J=8.3 Hz, 1H), 5.85 (dt, J=15.6, 4.2 Hz, 1H), 5.80-5.73 (m, 1H), 5.08 (dd, J=7.9, 5.0 Hz, 1H), 4.11 (d, J=12.1 Hz, 1H), 4.06 (d, J=12.1 Hz, 1H), 4.05-3.96 (m, 2H), 3.79 (d, J=14.5 Hz, 1H), 3.73 (dd, J=15.2, 3.8 Hz, 1H), 3.27 (d, J=14.5 Hz, 1H), 3.08 (dd, J=15.3, 9.8 Hz, 1H), 2.96 (s, 3H), 2.92 (s, 3H), 2.77 (dddd, J=22.3, 16.7, 11.4, 4.6 Hz, 3H), 2.54 (td, J=13.0, 11.6, 6.5 Hz, 1H), 2.41 (qd, J=9.4, 4.9 Hz, 1H), 2.05-1.78 (m, 6H), 1.66 (tq, J=14.6, 7.5, 6.4 Hz, 2H), 1.55 (qd, J=10.4, 8.5 Hz, 1H), 1.40 (s, 3H), 1.36 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 32 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 4) and 1-allyloxycyclopropanecarboxylic acid (Example 28, Step 2) in Step 1. LCMS: calc. for C31H36ClN2O6S [M+H]+: m/z=599.20/601.19; Found: 599.4/601.5. 1H NMR (600 MHz, DMSO-d6) δ 11.68 (br, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.29 (dd, J=8.5, 2.3 Hz, 1H), 7.27-7.15 (m, 3H), 7.01 (dd, J=12.3, 5.6 Hz, 1H), 5.58-5.47 (m, 2H), 4.76 (d, J=4.5 Hz, 1H), 4.10 (d, J=12.0 Hz, 1H), 4.04-3.95 (m, 2H), 3.84-3.76 (m, 1H), 3.69-3.57 (m, 2H), 3.03 (d, J=14.5 Hz, 1H), 2.86-2.77 (m, 1H), 2.70 (dt, J=16.9, 8.6 Hz, 1H), 2.05-1.95 (m, 2H), 1.87-1.78 (m, 3H), 1.74-1.68 (m, 2H), 1.62-1.58 (m, 1H), 1.49-1.45 (m, 1H), 1.41 (td, J=15.3, 8.3 Hz, 1H), 1.32-1.10 (m, 6H).
-
- This compound was prepared using procedures analogous to those described for Example 34 using (3R,6R,7R,8E,22S)-6′-Chloro-7-hydroxy-12,12-ethylene-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (Example 38) and N,N-dimethylcarbamoyl chloride. LCMS: calc. for C34H41ClN3O7S [M+H]+: m/z=670.24/672.23; Found: 670.84/672.86. 1H NMR (600 MHz, CDCl3) δ 9.04 (s, 1H), 7.71 (d, J=8.5 Hz, 1H), 7.49 (dd, J=8.3, 2.1 Hz, 1H), 7.29 (d, J=2.2 Hz, 1H), 7.18 (dd, J=8.5, 2.3 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 7.01 (d, J=8.3 Hz, 1H), 5.71 (app q, J=2.6 Hz, 2H), 4.88 (d, J=3.0 Hz, 1H), 4.13 (d, J=12.1 Hz, 1H), 4.05-3.99 (m, 2H), 3.96-3.91 (m, 1H), 3.85 (d, J=14.4 Hz, 1H), 3.82-3.76 (m, 1H), 3.18 (d, J=14.5 Hz, 1H), 3.06 (dd, J=15.3, 5.7 Hz, 1H), 2.91 (s, 3H), 2.84 (s, 3H), 2.76 (dt, J=11.0, 5.4 Hz, 2H), 2.56 (tt, J=10.7, 5.2 Hz, 2H), 2.03-1.85 (m, 4H), 1.83-1.63 (m, 2H), 1.72-1.64 (m, 1H), 1.44 (td, J=13.6, 13.1, 2.6 Hz, 1H), 1.38 (q, J=3.2 Hz, 2H), 1.24-1.19 (m, 1H), 1.18-1.11 (m, 1H).
-
- This compound was prepared using procedures analogous to those described for Example 32 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 3) and 1-allyloxycyclopropanecarboxylic acid (Example 28, Step 2) in Step 1. LCMS: calc. for C31H36ClN2O6S [M+H]+: m/z=599.20/601.19; Found: 599.7/601.6. 1H NMR (300 MHz, CDCl3) δ 9.09 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.52 (d, J=8.2 Hz, 1H), 7.31 (s, 1H), 7.18 (d, J=8.6 Hz, 1H), 7.10 (d, J=1.9 Hz, 1H), 7.02 (d, J=8.4 Hz, 1H), 5.86 (dd, J=15.5, 4.2 Hz, 1H), 5.69-5.51 (m, 1H), 4.19-4.02 (m, 3H), 3.96 (dd, J=12.0, 6.7 Hz, 2H), 3.74 (d, J=14.5 Hz, 1H), 3.54 (dd, J=15.0, 8.1 Hz, 1H), 3.33 (dd, J=17.5, 7.5 Hz, 2H), 2.79 (dd, J=9.1, 5.2 Hz, 2H), 2.64 (dd, J=14.6, 8.3 Hz, 1H), 2.55-2.41 (m, 1H), 2.10-1.77 (m, 3H), 1.65 (ddd, J=35.5, 23.7, 11.9 Hz, 3H), 1.51-1.41 (m, 2H), 1.41-1.31 (m, 2H), 1.23 (ddd, J=17.1, 9.8, 5.4 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 34 using (3R,6R,7S,8E,22S)-6′-Chloro-7-hydroxy-12,12-ethylene-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (Example 40) and N,N-dimethylcarbamoyl chloride. LCMS: calc. for C34H41ClN3O7S [M+H]+: m/z=670.24/672.23; Found: 670.84/672.73. 1H NMR (600 MHz, CDCl3) δ 9.16 (s, 1H), 7.65 (d, J=8.5 Hz, 1H), 7.45 (dd, J=8.3, 2.2 Hz, 1H), 7.25 (d, J=2.3 Hz, 1H), 7.16 (dd, J=8.5, 2.4 Hz, 1H), 7.07 (d, J=2.3 Hz, 1H), 6.96 (d, J=8.3 Hz, 1H), 5.79-5.65 (m, 2H), 5.21-5.17 (m, 1H), 4.15 (d, J=12.2 Hz, 1H), 4.10 (d, J=12.1 Hz, 1H), 4.06-3.98 (m, 2H), 3.63 (d, J=14.7 Hz, 1H), 3.54 (dd, J=15.3, 7.6 Hz, 1H), 3.31 (d, J=14.7 Hz, 1H), 3.22 (dd, J=15.2, 6.5 Hz, 1H), 2.85 (s, 3H), 2.82-2.71 (m, 3H), 2.63 (s, 3H), 2.55 (qd, J=8.8, 6.2 Hz, 1H), 2.09-1.87 (m, 4H), 1.78 (tdd, J=20.5, 10.8, 6.3 Hz, 2H), 1.63 (p, J=9.8 Hz, 1H), 1.50-1.42 (m, 1H), 1.41-1.33 (m, 2H), 1.30-1.23 (m, 1H), 1.20-1.12 (m, 1H).
-
-
- To a stirred solution of 2-((tert-butoxycarbonyl)amino)-2-methylpropanoic acid (2.0 g, 9.84 mmol) in THF (40 mL) was added sodium hydride (0.98 g, 24.6 mmol) in portions under an ice bath. The resulting solution was stirred at r.t. for 10 minutes. Then Allyl bromide (2.13 mL, 24.6 mmol) was added. The reaction was stirred at 50° C. for 24 h. The reaction was quenched with saturated NH4Cl solution (40 mL). The mixture was extracted with EtOAc (40 mL×3). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (40 g) with EtOAc/Heptanes (5% to 80%) to afford 2-[allyl(tert-butoxycarbonyl)amino]-2-methyl-propanoic acid (1.6 g, 66% yield) as a white solid. LC-MS calc. for C12H20NO4 [M−H]−: m/z=242.1; Found: 242.1.
-
- To a stirred solution of 2-((tert-butoxycarbonyl)amino)-2-methylpropanoic acid (176.87 mg, 0.87 mmol) in DCM (5 mL) was added DMAP (212 mg, 1.74 mmol) followed by EDCI (135 mg, 0.87 mmol). The resulting mixture was stirred at r.t. for 10 min. Then (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (150.0 mg, 0.29 mmol, Intermediate 8) was added. The reaction was stirred at 40° C. for 8 h. LC-MS showed full conversion of starting material. The reaction was quenched by HCl (1 M, 10 mL), and was extracted with DCM (10 mL×2). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (20 g) with EtOAc/Heptanes (10% to 80%) to afford tert-butyl N-[1,1-dimethyl-2-oxo-2-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]ethyl]carbamate (159 mg, 78% yield) as a yellow liquid. LC-MS calc. for C36H49ClN3O7S [M+H]+: m/z=702.3/704.3; Found: 702.0/704.3.
-
- tert-Butyl N-[1,1-dimethyl-2-oxo-2-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]ethyl]carbamate (230 mg, 0.33 mmol) was treated with 2M HCl in EA (10.0 mL, 0.33 mmol) at r.t. for 2 h. The solvent was evaporated under reduced pressure to afford the crude product as HCl salt which was used in next step without further purification. LC-MS calc. for C31H41ClN3O5S [M+H]+: m/z=602.2/604.2; Found: 602.0/604.2.
-
- To a stirred solution of 2-amino-2-methyl-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-propanamide hydrochloride (180 mg, 0.28 mmol) in DMF (5 mL) was added sodium hydride (45 mg, 1.13 mmol). The resulting mixture was stirred at r.t. for 5 min. Then allyl bromide (0.02 mL, 0.28 mmol) was added. The reaction was stirred at r.t. for 48 h. LC-MS showed unreacted starting material (˜15%), desired product (˜60%) and dialkylation product (25%). The reaction was quenched by adding water (20 mL). EtOAc (20 mL) was added and the layers were separated. The organic layer was washed with water (20 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column (20 g) with EtOAc/Heptanes (30% to 100%) to afford 2-(allylamino)-2-methyl-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-propanamide (57.5 mg, 31.7% yield) as a white solid. LC-MS calc. for C34H45ClN3O5S [M+H]+: 642.3/644.3; Found: 642.5/644.2.
-
- This compound was prepared using procedures analogous to those described for Example 26 Step 4 using 2-(allylamino)-2-methyl-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-propanamide. LC-MS calc. for C32H41ClN3O5S [M+H]+: 614.2/616.2; Found: 614.3/616.3.
- This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one. LC-MS calc. for C33H43ClN3O5S [M+H]+: m/z=628.3/630.3; Found: 628.0/630.2. 1H NMR (600 MHz, DMSO-d6) δ 9.13 (s, 1H), 7.64 (d, J=8.5 Hz, 1H), 7.25 (dd, J=8.5, 2.4 Hz, 1H), 7.17 (d, J=2.4 Hz, 1H), 7.10 (d, J=8.2 Hz, 1H), 6.83 (d, J=8.2 Hz, 1H), 6.74-6.70 (m, 1H), 6.27 (dd, J=12.4, 6.4 Hz, 1H), 5.62-5.57 (m, 1H), 4.04-3.95 (m, 2H), 3.56 (d, J=14.5 Hz, 1H), 3.53-3.37 (m, 2H), 3.21 (s, 3H), 3.01 (dd, J=15.2, 11.0 Hz, 1H), 2.80 (dt, J=17.0, 4.3 Hz, 1H), 2.71 (ddd, J=16.8, 10.4, 6.5 Hz, 1H), 2.65-2.55 (m, 2H), 2.49-2.25 (m, 3H), 2.03-1.90 (m, 3H), 1.87-1.81 (m, 1H), 1.77-1.70 (m, 2H), 1.54-1.31 (m, 4H), 1.31-1.04 (m, 6H).
-
-
- To a solution of 2-[allyl(tert-butoxycarbonyl)amino]-2-methyl-propanoic acid (4.79 g, 19.6 mmol, Example 83 Step 1) in ethyl acetate (25 mL) was added t-butylchlorodiphenylsilane (3.26 g, 21.6 mmol) at 0° C. followed by addition of triethylamine (TEA) (2.74 mL, 19.6 mmol). White precipitate was formed immediately. The reaction was stirred at 0° C. for 30 min. The white solid was filtered off and rinsed with EtOAc. The filtrate was concentrated under reduced pressure. The residue was dissolved in DCM (25 mL) and followed by addition of oxalyl chloride (2.1 mL, 24 mmol) and DMF (10 drops). Gas was evolved and the reaction was stirred at r.t. overnight. TLC showed a new spot (Rf=0.6, EA:Heptane=1:1) formed. The reaction was concentrated and co-evaporated THF 3 times to remove excess oxalyl chloride. The residue was treated with THF (30 mL) and filtered to provide a stock solution of the desired product (about 0.66 M with 98.6% purity showed by GC at 8.93 min.) which was directly used in next step reaction without further purification.
-
- To a solution of (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (500.0 mg, 0.99 mmol, Intermediate 3) and 3-allyl-4,4-dimethyl-oxazolidine-2,5-dione (3.01 mL, 1.99 mmol) in THF (5 mL) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (298 μL, 1.99 mmol). The resulting mixture was heated to 65° C. for 2 h. The reaction was cooled to r.t. Methanol (8 mL) and water (8 mL) were added, followed by addition of lithium hydroxide monohydrate (500 mg, 11.9 mmol). The reaction was heated to 45° C. for 3 h. THF was removed under reduced pressure. The residue was re-dissolved in DCM, and was quenched with sat. NH4Cl aq. (5 mL). The mixture was extracted with DCM (5 mL×2). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (20 g) with EtOAc/Heptanes (20% to 100%) then MeOH/EtOAc (0% to 50%) to afford 2-(allylamino)-2-methyl-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-propanamide (490 mg, 78.5% yield). LC-MS calc. for C33H43ClN3O5S [M+H]+: m/z=628.3/630.3; Found: 628.8/630.8.
-
- This compound was prepared using procedures analogous to those described for Example 26 Step 4 using 2-(allylamino)-2-methyl-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-propanamide. LC-MS calc. for C31H39ClN3O5S [M+H]+: m/z=600.2/602.2; Found: 600.7/602.7.
- This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one and formaldehyde aqueous solution. LC-MS calc. for C32H41ClN3O5S [M+H]+: m/z=614.24/616.24; Found: 614.8/616.8. 1H NMR (600 MHz, DMSO-d6) δ 7.63 (d, J=8.6 Hz, 1H), 7.25 (dd, J=8.5, 2.4 Hz, 1H), 7.17 (d, J=2.3 Hz, 1H), 7.14-7.10 (m, 1H), 7.08 (br, 1H), 6.86-6.84 (m, 2H), 5.79-5.73 (m, 1H), 5.37-5.31 (m, 1H), 4.09 (d, J=19.1 Hz, 1H), 3.51 (d, J=14.6 Hz, 1H), 3.07 (t, J=12.7 Hz, 1H), 2.84-2.76 (m, 1H), 2.71 (ddd, J=16.8, 10.8, 6.1 Hz, 1H), 2.64-2.60 (m, 1H), 2.17 (d, J=11.4 Hz, 1H), 2.04-2.00 (m, 2H), 1.89-1.82 (m, 3H), 1.67-1.61 (m, 2H), 1.47-1.41 (m, 3H), 1.35-1.33 (m, 2H), 1.27-1.22 (m, 10H), 0.89-0.81 (m, 2H).
-
- This compound was prepared using procedures analogous to those described for Example 34 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 43) and N,N-dimethylcarbamoyl chloride. LC-MS calc. for C35H46ClN4O6S [M+H]+: m/z=685.3/687.3; Found: 685.3/687.3. 1H NMR (400 MHz, DMSO-d6) δ 9.02 (s, 1H), 7.64 (d, J=8.5 Hz, 1H), 7.26 (dd, J=8.5, 2.4 Hz, 1H), 7.17 (d, J=2.3 Hz, 1H), 7.10 (dd, J=8.1, 1.9 Hz, 1H), 6.84 (d, J=8.2 Hz, 1H), 6.77-6.73 (m, 1H), 6.62-6.59 (m, 1H), 6.29-6.26 (m, 1H), 5.91-5.83 (m, 1H), 4.15-3.92 (m, 3H), 3.56 (d, J=14.6 Hz, 1H), 3.29 (d, J=14.4 Hz, 2H), 3.02 (s, 3H), 2.86 (s, 3H), 2.75-2.65 (m, 2H), 2.57-2.51 (m, 4H), 2.43-2.26 (m, 3H), 2.08-1.79 (m, 4H), 1.68 (dt, J=17.5, 8.3 Hz, 2H), 1.57 (t, J=9.0 Hz, 2H), 1.36 (s, 3H), 1.18 (s, 3H).
-
-
- To solution of (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (425 mg, 0.71 mmol, Example 43) in DCE (10 mL) was added formaldehyde-d2 solution (˜20 wt. % in D20) (113 mg, 3.54 mmol). The mixture was stirred at 20° C. for 2 h. LC-MS analysis indicated the starting material was consumed and the iminium intermediate was formed. Sodium cyanoborodeuteride (233 mg, 3.54 mmol) was then added the reaction was stirred for 4 h. LC-MS analysis indicated the reaction was complete. The reaction was quenched with 1M HCl aq. solution (20 mL), and extracted with DCM (20 mL×2). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to afford (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-11-(trideuteriomethyl)spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (393 mg, 89.9% yield) as a light brown colored solid. LC-MS: calc. for C32H38D3ClN3O5S [M+H]+: m/z=617.26/619.26; Found: 617.3/619.1.
- This compound was prepared using procedures analogous to those described for Example 34 (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-11-(trideuteriomethyl)spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one and N,N-dimethylcarbamoyl chloride. LC-MS calc. for C35H43ClD3N3O6S [M+H]+: m/z=688.29/690.29; Found 688.5/690.3. 1H NMR (499 MHz, DMSO-d6) δ 7.62 (d, J=8.6 Hz, 1H), 7.23 (dd, J=8.5, 2.4 Hz, 1H), 7.15 (d, J=2.4 Hz, 1H), 7.09 (dd, J=8.1, 1.9 Hz, 1H), 6.82 (d, J=8.2 Hz, 1H), 6.75 (s, 1H), 6.23 (s, 1H), 5.82 (d, J=15.8 Hz, 1H), 5.22 (s, 1H), 3.98 (q, J=12.2 Hz, 2H), 3.54 (d, J=14.5 Hz, 2H), 3.40 (t, J=11.6 Hz, 3H), 3.06 (dd, J=15.1, 10.8 Hz, 1H), 3.00 (s, 3H), 2.84 (s, 3H), 2.78 (dt, J=16.8, 4.5 Hz, 1H), 2.69 (ddd, J=16.4, 10.6, 5.9 Hz, 2H), 2.39-2.28 (m, 1H), 2.02-1.93 (m, 1H), 1.93-1.76 (m, 3H), 1.68 (dt, J=17.7, 8.4 Hz, 2H), 1.63-1.52 (m, 1H), 1.47-1.36 (m, 1H), 1.34 (s, 3H), 1.16 (s, 3H).
-
-
- To a solution of (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (2.8 g, 4.66 mmol, Example 32) and phenyl chloroformate (3.64 g, 23.2 mmol) in ACN (60 mL) was added pyridine (3.77 mL, 46.5 mmol). The mixture was stirred at r.t. for 1 h. The reaction was monitored by LC-MS. The mixture was carefully neutralized with 0.5 N HCl (80 mL), and extracted with ethyl acetate (40 mL×2). The organic layer was washed with saturated NaHCO3(80 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with EtOAc/10% DCM in Heptanes (5-65%) to afford the desired product phenyl [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.0-3,6.0-19,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] carbonate (1.24 g, 36.9% yield). LC-MS calc. for C38H42ClN2O8S [M+H]+: m/z=721.23.21/723.23; Found 721.8/723.8.
- To a solution of phenyl [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] carbonate (20.0 mg, 0.03 mmol) in MeCN (0.50 mL) was added 1-(2-methoxyethyl)piperazine (12.0 mg, 0.08 mmol). The reaction was heated to 80° C. for 2 h. The reaction was cooled to r.t. and concentrated under reduced pressure. The residue was re-dissolved in DCM (2 mL) and washed with 0.5 N HCl aq. (2 mL). Aqueous layer was extracted with DCM (2 mL) one more time. The combined organic layers were dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC on C18 column (21.2×150 mm, 5 m) using MeCN/H2O (20% to 100% over 18 min) to afford [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-(2-methoxyethyl)piperazine-1-carboxylate (10.6 mg, 48.7% yield). LC-MS calc. for C39H52ClN4O8S [M+H]+: m/z=771.32/773.32; Found: 771.8/773.8. 1H NMR (300 MHz, CDCl3) δ 7.68 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.10 (d, J=2.1 Hz, 1H), 7.02-6.95 (m, 2H), 5.88-5.75 (m, 1H), 5.70 (dd, J=15.7, 4.9 Hz, 1H), 5.34 (s, 1H), 4.11 (dt, J=11.6, 9.0 Hz, 3H), 3.81-3.65 (m, 3H), 3.62-3.43 (m, 5H), 3.43-3.31 (m, 4H), 3.22 (dd, J=15.1, 9.1 Hz, 1H), 2.85-2.67 (m, 2H), 2.60 (t, J=5.5 Hz, 3H), 2.38 (d, J=3.8 Hz, 2H), 2.08-1.89 (m, 5H), 1.89-1.71 (m, 4H), 1.63 (t, J=9.4 Hz, 2H), 1.50 (d, J=12.5 Hz, 2H), 1.44 (s, 3H), 1.37 (s, 3H).
-
- To a solution of DIPEA (232 mg, 1.8 mmol) in MeCN (3 mL) was added 1,1,1-trideuterio-N-(trideuteriomethyl)methanamine hydrochloride (0.3 mL, 1.8 mmol). The resulting mixture was stirred for 5 min at r.t. [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] phenyl carbonate (260 mg, 0.36 mmol, Example 46 Step 1) was then added to the reaction mixture and the resulting solution was stirred at 65° C. for 4 h. LCMS analysis indicated the reaction was complete. The reaction mixture was concentrated under reduced pressure and the residue was purified by prep-HPLC. The desired fractions were collected and concentrated under reduced pressure to afford [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-bis(trideuteriomethyl)carbamate (202 mg, 82.6% yield) as a white solid. LC-MS: calc. for C34H36D6ClN3O7S [M+H]+: m/z=678.3/680.3; Found 678.4/680.4. 1H NMR (300 MHz, CDCl3) δ 9.14 (s, 1H), 7.68 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.2 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 7.02-6.94 (m, 2H), 5.97-5.58 (m, 2H), 5.30 (d, J=5.0 Hz, 1H), 4.17-4.04 (m, 3H), 3.79-3.63 (m, 3H), 3.50-3.32 (m, 2H), 3.19 (dd, J=14.5, 4.9 Hz, 1H), 2.78 (t, J=5.5 Hz, 3H), 2.38 (qd, J=9.0, 3.6 Hz, 1H), 2.06-1.90 (m, 3H), 1.83 (q, J=8.9 Hz, 3H), 1.64 (p, J=9.7 Hz, 1H), 1.45 (s, 3H), 1.37 (s, 3H).
-
-
- To a stirred solution of (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (300 mg, 0.60 mmol) in DMF (3 mL) was added TBSCl (269 mg, 1.79 mmol) followed by imidazole (243 mg, 3.58 mmol). The resulting mixture was stirred at r.t. for 4 h. HCl (aq, 0.5 M, 10 mL) was added followed by 10 mL of EtOAc. The layers were separated, and the organic layer was washed with 10 mL of HCl (0.5 M). The organic layer was dried over sodium sulfate and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column (12 g) using 2% to 35% EtOAc/Heptanes. The desired fractions were collected to afford (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-[tert-butyl(dimethyl)silyl]oxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (260 mg, 70% yield) as a white solid. LC-MS calc. for C32H46ClN2O4SiS [M+H]+: m/z=617.3/619.3; Found: 617.8/619.4.
-
- To a stirred solution of (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-[tert-butyl(dimethyl)silyl]oxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (260 mg, 0.42 mmol) in DCM (10 mL) was added 1-[allyl(tert-butoxycarbonyl)amino]cyclobutanecarboxylic acid (322 mg, 1.26 mmol), 4-(dimethylamino)pyridine (308 mg, 2.53 mmol) and EDCI (0.25 mL, 1.26 mmol) successively. The resulting mixture was stirred at r.t. for 48 hours. HCl (1 M, 30 mL) was added followed by 30 mL of DCM. The layers were separated, and the aqueous layer was extracted with DCM. The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column (12 g) using EtOAc/Heptanes (5% to 80%). The desired fractions were collected to afford tert-butyl N-allyl-N-[1-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-[tert-butyl(dimethyl)silyl]oxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylcarbamoyl]cyclobutyl]carbamate (190 mg, 53% yield) as a white solid. LC-MS calc. for C45H65ClN3O7SiS [M+H]+: m/z=854.4/856.4; Found: 855.0/857.1.
-
- A solution of tert-butyl N-allyl-N-[1-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-[tert-butyl(dimethyl)silyl]oxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylcarbamoyl]cyclobutyl]carbamate (190 mg, 0.22 mmol) in THF (3 mL) and tetrabutylammonium fluoride solution (3.0 mL, 0.22 mmol, 1 M in THF) was stirred at r.t. overnight. The reaction was quenched by adding 10 mL of saturated NH4Cl solution followed by 10 mL of EtOAc. The layers were separated and the aqueous layer was extracted with EtOAc (10 mL×3). The combined organic layers were washed with brine, dried over sodium sulfate and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column (20 g) using 10% to 100% EtOAc/Heptanes then 0% to 50% MeOH/EtOAc. The desired fractions were collected to afford tert-butyl N-allyl-N-[1-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylcarbamoyl]cyclobutyl]carbamate (101 mg, 61% yield) as a white solid. LC-MS: calcd. For C39H51ClN3O7S [M+H]+: m/z=740.3/742.3; Found: 740.8/743.0.
-
- To a stirred solution of tert-butyl N-allyl-N-[1-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylcarbamoyl]cyclobutyl]carbamate (60 mg, 0.08 mmol) in DCE (80 mL) was bubbled with nitrogen for 20 minutes. Then 1,3-Bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidene[2-(i-propoxy)-5-(N,N-dimethyl aminosulfonyl)phenyl]methyleneruthenium(II) dichloride (resin supported) Zhan Catalyst II (11.8 mg, 0.02 mmol) was added under nitrogen. The resulting mixture was further bubbled with nitrogen for 20 minutes. Then the reaction was stirred at 60° C. under nitrogen for 3 hours. LC-MS showed the consumption of the starting material and the formation of desired product. The reaction was cooled to r.t. and stirred under air for 30 minutes to deactivate the catalyst. The solution was concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (12 g) using 20% to 100% EtOAc/Heptanes. The desired fractions were collected to afford (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-tert-butoxycarbonyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (54 mg, 93% yield) as a white solid. LC-MS calc. for C37H47ClN3O7S [M+H]+: m/z=712.3/714.3; Found: 712.9/714.6.
-
- To a stirred solution of (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-tert-butoxycarbonyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (45.0 mg, 0.06 mmol) in DCM (3 mL) was added phosphoric acid (3.0 mL, 43.8 mmol). The resulting mixture was stirred at r.t. for 48 h. The solution was slowly poured into saturated NaHCO3solution (20 mL) under an ice bath. The mixture was extracted with DCM (10 mL×3). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure The crude product (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (37 mg, quantitative yield) was used in next step without further purification. LC-MS calc. for C32H39ClN3O5S [M+H]+: m/z=612.2/614.2; Found: 612.8/614.6.
-
- This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one. LC-MS calc. for C33H41ClN3O5S [M+H]+: m/z=626.2/628.2; Found: 626.9/628.8. 1H NMR (499 MHz, DMSO-d6) δ 7.61 (d, J=8.5 Hz, 1H), 7.23 (dd, J=8.5, 2.4 Hz, 1H), 7.20 (dd, J=8.2, 2.0 Hz, 1H), 7.18 (d, J=2.4 Hz, 1H), 6.99-6.95 (m, 1H), 6.88 (d, J=8.2 Hz, 1H), 5.64-5.56 (m, 1H), 4.84-4.77 (m, 1H), 4.06 (d, J=12.1 Hz, 1H), 4.00-3.84 (m, 2H), 3.49 (d, J=14.3 Hz, 1H), 2.89-2.57 (m, 6H), 2.39-2.21 (m, 4H), 2.07-1.96 (m, 2H), 1.86-1.77 (m, 6H), 1.70-1.64 (m, 1H), 1.61-1.54 (m, 2H), 1.47 (q, J=7.2 Hz, 1H), 1.30-1.23 (m, 5H), 0.89-0.84 (m, 1H).
- This compound was prepared using procedures analogous to those described for Example 34 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one and N,N-dimethylcarbamoyl chloride. LC-MS calc. for C36H46ClN4O6S [M+H]+: m/z=697.3/699.3; Found: 697.9/699.7. 1H NMR (300 MHz, CDCl3) δ 7.67 (d, J=8.5 Hz, 1H), 7.49 (dd, J=8.3, 2.1 Hz, 1H), 7.16 (dd, J=8.5, 2.3 Hz, 1H), 7.06 (d, J=2.3 Hz, 1H), 6.96 (d, J=8.4 Hz, 1H), 6.85 (d, J=2.3 Hz, 1H), 5.79-5.59 (m, 2H), 5.28 (s, 1H), 4.29-3.97 (m, 2H), 3.70 (d, J=14.7 Hz, 1H), 3.53-3.26 (m, 2H), 3.04 (s, 3H), 2.95 (s, 3H), 2.89-2.57 (m, 6H), 2.40 (s, 3H), 2.27 (ddt, J=11.9, 8.2, 3.2 Hz, 2H), 2.19-1.90 (m, 7H), 1.87-1.73 (m, 3H), 1.73-1.55 (m, 3H), 1.41 (t, J=11.8 Hz, 1H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using 3,3-difluoroazetidine hydrochloride and N,N-diisopropylethylamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C35H41ClF2N3O7S [M+H]+: m/z=720.22/722.22; Found 720.8/722.89. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.50 (d, J=8.2 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.10 (d, J=2.1 Hz, 1H), 7.05-6.94 (m, 2H), 5.82 (m, 1H), 5.71 (m, 1H), 5.28 (s, 1H), 4.32 (m, 2H), 4.18-4.05 (m, 3H), 3.81-3.68 (m, 2H), 3.47-3.32 (m, 2H), 3.23 (m, 1H), 2.85-2.69 (m, 3H), 2.46-2.35 (m, 1H), 2.01 (m, 3H), 1.90-1.76 (m, 4H), 1.71-1.58 (m, 3H), 1.46-1.58 (m, 1H), 1.45 (s, 3H), 1.37 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using methylamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C33H41ClN3O7S [M+H]+: m/z=658.23/660.23; Found 658.7/660.7. 1H NMR (300 MHz, CDCl3) δ 7.68 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.3, 1.9 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.10 (d, J=2.1 Hz, 1H), 7.08-7.02 (m, 1H), 7.00 (d, J=8.3 Hz, 1H), 5.88-5.65 (m, 2H), 5.24 (s, 1H), 4.86 (s, 1H), 4.20-4.05 (m, 3H), 3.74 (m, 2H), 3.47 (dd, J=15.1, 4.8 Hz, 1H), 3.34 (d, J=14.6 Hz, 1H), 3.17 (m, 1H), 2.80 (m, 6H), 2.42-2.32 (m, 1H), 1.98 (m, 4H), 1.81 (m, 3H), 1.64 (m, 2H), 1.44 (s, 3H), 1.38 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using 4-methoxypiperidine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C83H49ClN3O8S [M+H]+: m/z=742.29/744.29; Found: 742.7/744.8. 1H NMR (300 MHz, CDCl3) δ 9.08 (s, 1H), 7.68 (d, J=8.5 Hz, 1H), 7.50 (d, J=8.2 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.10 (d, J=2.1 Hz, 1H), 6.99 (d, J=8.2 Hz, 2H), 5.73 (t, J=20.2 Hz, 2H), 5.32 (d, J=3.8 Hz, 1H), 4.22-3.98 (m, 3H), 3.92-3.64 (m, 5H), 3.51-3.29 (m, 6H), 3.22 (dd, J=14.5, 8.9 Hz, 4H), 2.79 (d, J=4.1 Hz, 3H), 2.39 (d, J=6.8 Hz, 1H), 2.10-1.46 (m, 10H), 1.44 (s, 3H), 1.37 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using N,N-dimethylazetidin-3-amine dihydrochloride salt and Hunig's base to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C37H48ClN4O7S [M+H]+: m/z=727.3/729.3; Found: 727.6/729.6. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.51-7.40 (m, 1H), 7.18 (dd, J=8.5, 2.3 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.96 (d, J=8.3 Hz, 1H), 5.81-5.59 (m, 1H), 5.15 (s, 1H), 4.29 (s, 1H), 4.11 (q, J=11.4, 10.7 Hz, 4H), 3.85 (dd, J=9.1, 4.9 Hz, 2H), 3.71 (d, J=14.6 Hz, 2H), 3.40 (t, J=17.2 Hz, 2H), 2.97 (s, 5H), 2.80 (s, 3H), 2.21 (s, 6H), 1.99 (d, J=16.0 Hz, 3H), 1.90-1.73 (m, 3H), 1.73-1.58 (m, 2H), 1.46 (s, 3H), 1.34 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using (3R)—N,N-dimethylpyrrolidin-3-amine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C38H50ClN4O7S [M+H]+: m/z=741.3/743.3; Found: 741.4/743.2. 1H NMR (499 MHz, DMSO-d6) δ 7.67 (d, J=8.5 Hz, 1H), 7.27 (dd, J=8.4, 2.3 Hz, 1H), 7.18 (d, J=2.4 Hz, 1H), 7.11 (dd, J=8.1, 1.9 Hz, 1H), 6.92-6.80 (m, 2H), 6.23 (dd, J=16.5, 7.7 Hz, 1H), 5.54 (dd, J=16.0, 4.1 Hz, 1H), 5.10 (d, J=40.1 Hz, 1H), 4.02 (d, J=7.7 Hz, 3H), 3.88 (dd, J=13.5, 8.0 Hz, 1H), 3.57 (dt, J=12.3, 4.5 Hz, 4H), 3.34-3.26 (m, 4H), 3.08 (td, J=15.2, 9.8 Hz, 2H), 2.75 (dddd, J=33.6, 16.8, 11.5, 5.3 Hz, 3H), 2.39 (d, J=23.1 Hz, 6H), 2.16-1.76 (m, 6H), 1.74-1.56 (m, 3H), 1.49-1.36 (m, 1H), 1.23 (d, J=2.4 Hz, 3H), 1.12 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using 1-methyl-1,4-diazepane to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C38H50ClN4O7S [M+H]+: m/z=741.3/743.3; Found: 741.4/743.2. 1H NMR (300 MHz, CDCl3) δ 7.69 (dd, J=8.5, 3.6 Hz, 1H), 7.54-7.37 (m, 1H), 7.18 (dd, J=8.5, 2.3 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 7.02-6.84 (m, 2H), 6.26-5.60 (m, 1H), 5.28 (s, 1H), 4.31 (d, J=12.4 Hz, 1H), 4.21-3.96 (m, 4H), 3.72 (d, J=14.5 Hz, 2H), 3.52-3.01 (m, 10H), 2.92-2.48 (m, 8H), 2.43 (s, 1H), 2.24 (t, J=9.9 Hz, 1H), 2.06-1.75 (m, 7H), 1.42 (s, 3H), 1.34 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using N,N,N′-trimethylethylenediamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C37H50ClN4O7S [M+H]+: m/z=729.31/731.31; Found: 729.5/731.5. 1H NMR (500 MHz, DMSO-d6) δ 11.62 (s, 1H), 9.39 (s, 1H), 7.64 (d, J=8.4 Hz, 1H), 7.26 (dd, J=8.5, 2.3 Hz, 2H), 7.19 (d, J=2.2 Hz, 1H), 7.02 (d, J=8.2 Hz, 1H), 6.94 (s, 1H), 6.59 (d, J=61.5 Hz, 1H), 5.71 (s, 2H), 5.24 (d, J=88.7 Hz, 1H), 4.34-3.89 (m, 3H), 3.56 (d, J=14.4 Hz, 2H), 3.02-2.62 (m, 13H), 2.12-1.44 (m, 10H), 1.39 (s, 3H), 1.24 (s, 6H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using 3-methoxyazetidine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C36H45ClN3O8S [M+H]+: m/z=714.25/716.25; Found: 714.5/716.5. 1H NMR (499 MHz, DMSO-d6) δ 7.71 (d, J=8.5 Hz, 1H), 7.30 (dd, J=8.5, 2.5 Hz, 1H), 7.21 (d, J=2.4 Hz, 1H), 7.12 (dd, J=8.2, 1.9 Hz, 1H), 6.94-6.80 (m, 2H), 6.30 (d, J=12.0 Hz, 1H), 5.51 (ddd, J=16.0, 3.7, 1.7 Hz, 1H), 5.05 (s, 1H), 4.25 (s, 1H), 4.17-4.10 (m, 1H), 4.08-3.99 (m, 2H), 3.87 (dd, J=13.5, 7.8 Hz, 1H), 3.78 (d, J=7.9 Hz, 1H), 3.65-3.53 (m, 2H), 3.38 (s, 2H), 3.32 (d, J=14.3 Hz, 2H), 3.26 (s, 3H), 3.10 (dd, J=14.9, 10.1 Hz, 1H), 2.89-2.67 (m, 3H), 2.33 (td, J=8.8, 2.8 Hz, 1H), 2.06-1.97 (m, 1H), 1.92-1.83 (m, 3H), 1.69 (ddt, J=17.6, 12.7, 8.1 Hz, 3H), 1.47 (td, J=13.2, 12.1, 3.9 Hz, 1H), 1.30 (s, 1H), 1.24 (s, 3H), 1.13 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using 3-ethoxyazetidine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C37H47ClN3O8S [M+H]+: m/z=728.27/730.27; Found: 728.5/730.5. 1H NMR (499 MHz, DMSO-d6) δ 7.66 (d, J=8.6 Hz, 1H), 7.25 (dd, J=8.5, 2.4 Hz, 1H), 7.16 (d, J=2.4 Hz, 1H), 7.06 (dd, J=8.1, 1.9 Hz, 1H), 6.85 (d, J=2.0 Hz, 1H), 6.79 (d, J=8.1 Hz, 1H), 6.24 (d, J=13.1 Hz, 1H), 5.46 (dt, J=16.1, 2.9 Hz, 1H), 5.00 (s, 1H), 4.28 (q, J=5.3 Hz, 1H), 4.09 (dd, J=9.3, 6.5 Hz, 2H), 4.03-3.93 (m, 2H), 3.85-3.64 (m, 3H), 3.60-3.47 (m, 2H), 3.39 (d, J=6.9 Hz, 1H), 3.26 (d, J=14.3 Hz, 2H), 3.04 (dd, J=14.8, 10.1 Hz, 1H), 2.86-2.60 (m, 3H), 2.28 (qd, J=9.2, 3.0 Hz, 1H), 2.03-1.91 (m, 1H), 1.88-1.75 (m, 3H), 1.71-1.56 (m, 3H), 1.41 (td, J=13.1, 12.2, 4.3 Hz, 1H), 1.30-1.21 (m, 1H), 1.18 (s, 3H), 1.13 (t, J=7.5 Hz, 3H), 1.08 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using (3R)-3-methoxypyrrolidine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C37H47ClN3O8S [M+H]+: m/z=728.27/730.27; Found: 728.5/730.5. 1H NMR (300 MHz, CDCl3) δ 7.68 (d, J=8.5 Hz, 1H), 7.37 (dd, J=8.3, 1.9 Hz, 1H), 7.13 (dd, J=8.4, 2.3 Hz, 1H), 7.06 (d, J=2.3 Hz, 1H), 6.96 (t, J=3.1 Hz, 1H), 6.87 (dd, J=8.3, 3.2 Hz, 1H), 6.08 (d, J=23.0 Hz, 1H), 5.69 (dt, J=15.3, 6.5 Hz, 1H), 5.19 (d, J=15.8 Hz, 1H), 4.08-3.92 (m, 3H), 3.82 (d, J=6.9 Hz, 1H), 3.69-3.58 (m, 2H), 3.48 (dt, J=19.4, 8.9 Hz, 3H), 3.35-3.24 (m, 4H), 3.17-3.05 (m, 2H), 2.75 (s, 3H), 2.56 (q, J=7.2 Hz, 1H), 2.31 (t, J=9.7 Hz, 1H), 2.01-1.89 (m, 3H), 1.78 (s, 3H), 1.60 (t, J=9.1 Hz, 1H), 1.39-1.30 (m, 10H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using (3R)-3-ethoxypyrrolidine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C83H49ClN3O8S [M+H]+: m/z=742.29/744.28; Found: 742.6/744.6. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.37-7.28 (m, 1H), 7.12 (dd, J=8.4, 2.3 Hz, 1H), 7.06 (d, J=2.2 Hz, 1H), 7.00 (d, J=3.4 Hz, 1H), 6.80 (d, J=8.2 Hz, 1H), 6.34-6.07 (m, 1H), 5.70 (dt, J=15.5, 8.1 Hz, 1H), 5.13 (s, 1H), 4.07-3.86 (m, 4H), 3.67-3.38 (m, 7H), 3.22 (d, J=14.4 Hz, 1H), 3.05 (p, J=8.8 Hz, 1H), 2.76-2.74 (m, 2H), 2.68-2.50 (m, 1H), 2.23-2.19 (m, 6H), 2.02-1.70 (m, 8H), 1.63-1.53 (m, 1H), 1.35-1.25 (m, 8H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using 1-(2-methoxyethyl)-1,4-diazepane to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C40H54ClN4O8S [M+H]+: m/z=785.33/787.32; Found: 785.5/787.4; 1H NMR (300 MHz, CDCl3) δ 9.29 (s, 1H, NH), 7.68 (dd, J=8.5, 5.1 Hz, 1H), 7.47 (dd, J=7.1, 5.2 Hz, 1H), 7.19 (d, J=8.4 Hz, 1H), 7.10 (d, J=2.0 Hz, 1H), 7.00 (d, J=8.3 Hz, 1H), 6.87 (d, J=10.0 Hz, 1H), 5.90 (s, 2H), 5.27 (s, 1H), 4.13 (m, 4H), 3.75 (m, 9H), 3.47 (d, J=15.0 Hz, 2H), 3.35 (d, J=12.2 Hz, 6H), 3.25-3.16 (m, 2H), 2.79 (d, J=4.2 Hz, 4H), 2.36 (d, J=8.0 Hz, 2H), 1.98 (d, J=11.1 Hz, 2H), 1.91-1.76 (m, 4H), 1.76-1.63 (m, 2H), 1.46 (s, 3H), 1.36 (d, J=2.4 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using (3S)-tetrahydrofuran-3-amine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C36H45ClN3O8S [M+H]+: m/z=714.2; Found: 714.4. 1H NMR (300 MHz, CDCl3) δ 9.85 (s, 1H), 7.68 (d, J=8.5 Hz, 1H), 7.52 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 7.00 (d, J=8.4 Hz, 2H), 6.02 (m, 1H), 5.65 (m, 2H), 5.17 (s, 1H), 4.27 (m, 2H), 4.21-4.03 (m, 2H), 3.99 (d, J=9.7 Hz, 1H), 3.81-3.59 (m, 6H), 3.47-3.28 (m, 2H), 3.08 (dd, J=15.0, 10.2 Hz, 1H), 2.96-2.69 (m, 3H), 2.37-2.19 (m, 2H), 1.93 (m, 7H), 1.67-1.54 (m, 1H), 1.47 (s, 3H), 1.34 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using (3R)-tetrahydrofuran-3-amine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C36H45ClN3O8S [M+H]+: m/z=714.2; Found: 714.4. 1H NMR (300 MHz, CDCl3) δ 9.08 (s, 1H), 7.68 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.3, 2.0 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 7.07-6.96 (m, 2H), 5.87-5.61 (m, 2H), 5.18 (s, 1H), 4.36-4.01 (m, 6H), 3.97 m, 1H), 3.91-3.66 (m, 5H), 3.47 (dd, J=15.3, 5.0 Hz, 1H), 3.33 (d, J=14.6 Hz, 1H), 3.18 (dd, J=15.2, 8.5 Hz, 1H), 2.78 (m, 3H), 2.48-2.34 (m, 1H), 2.32-2.19 (m, 1H), 2.09-1.70 (m, 7H), 1.63 (t, J=9.4 Hz, 1H), 1.44 (s, 3H), 1.38 (s, 3H).
-
- To a solution of N,O-dimethylhydroxylamine hydrochloride (500 mg, 8.19 mmol) in DCM (10 mL) was added triphosgene (2429 mg, 8.19 mmol), followed by potassium carbonate (4525 mg, 32.7 mmol). The mixture was stirred at r.t. for 1 h. NMR showed that the starting material was consumed. The reaction was then added H2O (15 mL) and extracted with DCM (10 mL×3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The resulting residue N-methoxy-N-methyl-carbamoyl chloride (600 mg, 59% yield) was directly used in the following step without further purification.
- To a solution of (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (40.0 mg, 0.07 mmol, Example 32) and N-methoxy-N-methyl-carbamoyl chloride (41 mg, 0.33 mmol) in toluene (2 mL) was dropwise added KHMDS (0.8 mL, 3.53 mmol) at −30° C. The mixture was then warmed to r.t. and stirred for 4 h. LC-MS showed that most of the starting material was consumed. The mixture was then added 1 N HCl (5 mL) and extracted with ethyl acetate (5 mL×3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC on a C18 column using H2O/ACN (20-100%) to afford the desired product [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methoxy-N-methyl-carbamate (19.7 mg, 43% yield). LC-MS calc. for C34H43ClN3O8S [M+H]+: m/z=688.24/690.24; Found: 688.4/690.5; 1H NMR (300 MHz, CDCl3) δ 9.09 (s, 1H, NH), 7.69 (t, J=7.0 Hz, 1H), 7.51 (dd, J=8.3, 2.0 Hz, 1H), 7.19 (dd, J=8.5, 2.0 Hz, 1H), 7.10 (d, J=1.9 Hz, 1H), 7.01 (dd, J=8.7, 3.2 Hz, 2H), 5.90-5.79 (m, 1H), 5.70 (dd, J=15.6, 5.6 Hz, 1H), 5.32 (d, J=4.0 Hz, 1H), 4.14 (q, J=12.2 Hz, 2H), 4.04 (dd, J=13.9, 5.6 Hz, 1H), 3.77 (d, J=9.1 Hz, 1H), 3.72 (d, J=3.3 Hz, 4H), 3.44-3.34 (m, 2H), 3.28 (dd, J=13.8, 7.7 Hz, 1H), 3.19 (s, 3H), 2.79 (d, J=4.6 Hz, 3H), 2.49-2.39 (m, 1H), 2.00 (dd, J=11.5, 3.6 Hz, 2H), 1.84 (dd, J=16.9, 8.9 Hz, 3H), 1.66-1.60 (m, 3H), 1.45-1.41 (s, 3H), 1.37 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 63 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 32) in Step 2 and (3R)—N-methyltetrahydrofuran-3-amine hydrochloride in Step 1. LC-MS calc. for C37H47ClN3O8S [M+H]+: m/z=728.27/730.27; Found: 728.4/730.3. 1H NMR (300 MHz, CDCl3) δ 9.11 (s, 1H), 7.68 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.2 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 7.00 (d, J=8.4 Hz, 1H), 6.96 (d, J=2.3 Hz, 1H), 5.83 (d, J=4.3 Hz, 1H), 5.73 (dd, J=15.8, 5.3 Hz, 1H), 5.35 (d, J=5.7 Hz, 1H), 4.93 (s, 1H), 4.14 (d, J=6.5 Hz, 2H), 4.08 (d, J=5.4 Hz, 1H), 3.77 (d, J=5.1 Hz, 2H), 3.71 (s, 1H), 3.49-3.34 (m, 2H), 3.23 (dd, J=15.1, 9.4 Hz, 1H), 2.92 (s, 3H), 2.83-2.75 (m, 3H), 2.44-2.36 (m, 1H), 2.28-2.16 (m, 4H), 2.05-1.95 (m, 3H), 1.89-1.75 (m, 4H), 1.65 (t, J=9.4 Hz, 2H), 1.44 (d, J=4.2 Hz, 3H), 1.37 (s, 3H).
-
-
- To a cooled (ice-bath) solution of (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (1.0 g, 1.66 mmol, Example 32) in THF (10 mL) was added sodium hydride (199 mg, 8.32 mmol). After stirring 10 mins at r.t., ethyl bromoacetate (1111 mg, 6.65 mmol) was added. The resulting mixture was stirred at r.t. overnight. The reaction was monitored by LC-MS and quenched with a mixture of cold 1 N HCl aq. (50 mL) and DCM (50 mL). The aqueous layer was extracted with DCM (50 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (20 g) using EA/Heptane (5%-80%) to afford the desired product ethyl 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxyacetate (600 mg, 52.4% yield). LC-MS calc. for C35H44ClN2O8S [M+H]+: m/z=687.20; Found: 687.72.
-
- To a solution of ethyl 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxyacetate (600 mg, 0.87 mmol) in THF (10 mL) and water (10 mL) was added lithium hydroxide monohydrate (183.18 mg, 4.37 mmol). The mixture was stirred at r.t. for 1 h. The mixture was then was quenched with 1N HCl (50 mL), extracted with EA (50 mL×2). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to afford 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]oxyacetic acid (400 mg, 70% yield) which was directly used in next step without purification. LC-MS calc. for C33H40ClN2O6S [M+H]+: m/z=659.22; Found: 659.70. 1H NMR (300 MHz, CDCl3) δ 9.24 (s, 1H, NH), 7.64 (t, J=6.0 Hz, 1H), 7.49 (dd, J=8.3, 2.0 Hz, 1H), 7.18 (dd, J=8.5, 2.2 Hz, 1H), 7.10 (d, J=2.1 Hz, 1H), 7.05 (d, J=2.0 Hz, 1H), 7.02-6.98 (m, 1H), 5.73-5.59 (m, 2H), 4.15-4.03 (m, 4H), 3.94-3.83 (m, 3H), 3.68 (d, J=14.7 Hz, 1H), 3.36 (dd, J=14.4, 8.5 Hz, 3H), 2.85-2.72 (m, 3H), 2.45-2.35 (m, 1H), 2.02 (t, J=7.9 Hz, 3H), 1.95-1.75 (m, 3H), 1.64 (t, J=8.8 Hz, 1H), 1.54 (d, J=11.7 Hz, 1H), 1.46-1.41 (m, 3H), 1.39 (s, 3H).
-
- To a solution 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxyacetic acid (400 mg, 0.60 mmol) in THF (16 mL) cooled with an ice-bath was added triethylamine (0.33 mL, 2.38 mmol) and isobutyl chloroformate (0.27 mL, 2.09 mmol). The reaction mixture was stirred at r.t. for 60 min. and monitored by LC-MS. When LC-MS shows complete reaction, the crude was directly used in further step without work-up and purification. LC-MS calc. for C38H48ClN2O10S [M+H]+: m/z=759.27; Found: 759.87.
-
- To a solution of isobutoxycarbonyl 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxyacetate (456.0 mg, 0.60 mmol) in THF (16 mL) at −78° C. was added diisobutylaluminum hydride (4.0 mL, 6.0 mmol, 1.5 M in toluene). The reaction was stirred for 30 mins at −78° C. The reaction mixture was quenched with 10% Rochelle's salt aqueous solution (40 mL) and the mixture was stirred at r.t. for 1 h. The layers were separated, and the aqueous layer was extracted with EA (2×50 mL). The combined organic layers were dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to afford 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxyacetaldehyde (400 mg, 60%) which was directly used in next step without purification. LC-MS calc. for C33H40ClN2O6S [M+H]+: m/z=643.22; Found: 643.5.
- To a solution of 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxyacetaldehyde (235 mg, 0.37 mmol, 60%) in DCE (5 mL) was added dimethylamine in THF (750.0 μL, 1.5 mmol, 2.0 M THF solution). The mixture was stirred at r.t. for 5 min., followed by adding of sodium triacetoxyborohydride (316 mg, 1.5 mmol). The mixture was then stirred at r.t. for additional 30 min. LC-MS showed that the starting material was consumed. The reaction was quenched by 1N HCl (10 mL) and extracted with DCM (2×10 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC on a C18 column using H2O/ACN (20-100%) to afford the desired product (3R,6R,7S,8E,22S)-6′-chloro-7-[2-(dimethylamino)ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (73 mg, 46% yield). LC-MS calc. for C35H47ClN3O6S [M+H]+: m/z=672.28; Found: 672.4. 1H NMR (300 MHz, DMSO-d6) δ 9.42 (s, 1H, NH), 7.61 (d, J=8.5 Hz, 1H), 7.33-7.16 (m, 3H), 7.03 (t, J=7.5 Hz, 2H), 5.59 (dd, J=15.6, 6.7 Hz, 1H), 5.43 (d, J=14.1 Hz, 1H), 4.08 (dd, J=19.7, 12.1 Hz, 2H), 3.91 (dd, J=14.3, 6.0 Hz, 1H), 3.67-3.60 (m, 2H), 3.32 (m, 5H), 3.15 (dd, J=14.5, 7.5 Hz, 2H), 2.79 (s, 9H), 2.43 (d, J=8.5 Hz, 2H), 1.97 (d, J=10.0 Hz, 1H), 1.86 (t, J=12.2 Hz, 4H), 1.71 (d, J=8.4 Hz, 1H), 1.58 (d, J=9.0 Hz, 2H), 1.43-1.31 (m, 3H), 1.24 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 65 using pyrrolidine to replace dimethylamine in THF (2.0 M) in Step 5. LC-MS calc. for C37H49ClN3O6S [M+H]+: m/z=698.30/700.29; Found: 698.5/700.7; 1H NMR (300 MHz, DMSO-d6) δ 9.56 (s, 1H, NH), 7.66-7.56 (m, 1H), 7.25 (m, 3H), 7.03 (dd, J=9.5, 6.1 Hz, 2H), 5.58 (dd, J=15.5, 6.9 Hz, 1H), 5.40 (d, J=13.6 Hz, 1H), 4.08 (dd, J=19.3, 12.1 Hz, 2H), 3.88 (dd, J=14.4, 6.0 Hz, 1H), 3.66-3.58 (m, 2H), 3.32 (d, J=14.9 Hz, 8H), 3.15 (dd, J=14.5, 7.9 Hz, 2H), 3.04 (s, 3H), 2.79-2.62 (m, 3H), 1.97 (d, J=5.4 Hz, 3H), 1.87 (dd, J=18.6, 5.1 Hz, 6H), 1.72 (d, J=8.4 Hz, 1H), 1.63-1.52 (m, 2H), 1.43-1.30 (m, 3H), 1.24 (s, 3H).
-
- To a solution of (3R,6R,7R,8E,23S)-6′-chloro-7-methoxy-13,13-(1,3-propylene)-16,16-dioxo-spiro[21-oxa-16-thia-1,11,15-triazatetracyclo[15.7.2.03,6.020,25]hexacosa[8,17(26),18,20(25)]tetraene-23,1′-tetralin]-14-one (8.0 mg, 0.01 mmol, Example 26) and triethylamine (0.01 mL, 0.06 mmol) in DCM (1 mL) was added methyl carbonochloridate (4.72 mg, 0.05 mmol) in one portion at r.t. After 10 min, LC-MS indicated the completion of reaction. The reaction was diluted with DCM, washed with saturated aqueous NaHCO3solution and brine, dried over Na2SO4, filtered and concentrated under reduced pressure to afford the desired product (3R,6R,7R,8E,23S)-6′-chloro-7-methoxy-11-methoxycarbonyl-13,13-(1,3-propylene)-16,16-dioxo-spiro[21-oxa-16-thia-1,11,15-triazatetracyclo[15.7.2.03,6.020,25]hexacosa[8,17(26),18,20(25)]tetraene-23,1′-tetralin]-14-one (8 mg, 89.9% yield). LCMS: calc. for C36H45ClN3O7S [M+H]+: m/z=698.27/700.26; Found: 697.97/700.24. 1H NMR (600 MHz, CDCl3) δ 7.66 (d, J=8.5 Hz, 1H), 7.43 (d, J=5.8 Hz, 1H), 7.29 (dd, J=8.3, 2.1 Hz, 1H), 7.16 (dd, J=8.5, 2.4 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 6.90 (d, J=8.2 Hz, 1H), 5.40-5.32 (m, 1H), 5.12 (app s, 1H), 4.18 (d, J=12.0 Hz, 1H), 4.04 (d, J=11.9 Hz, 1H), 3.94-3.81 (m, 2H), 3.67 (app s, 6H), 3.58-3.49 (m, 2H), 3.43-3.21 (m, 4H), 3.15 (m, 1H), 2.84-2.68 (m, 3H), 2.54-2.30 (m, 3H), 2.12-1.77 (m, 9H), 1.63 (ddt, J=26.9, 18.3, 9.5 Hz, 2H), 1.47 (t, J=12.8 Hz, 1H). The sulfonamide NH was not observed due to solvent exchange.
-
- This compound was prepared using procedures analogous to those described for Example 26 using 3-[(tert-butoxycarbonylamino)-2,2-dimethyl-propanoic acid to replace 1-[(tert-butoxycarbonylamino)methyl]cyclobutanecarboxylic acid in Step 2. LCMS: calc. for C33H43ClN3O5S [M+H]+: m/z=628.25/630.25; Found: 628.0/630.2. 1H NMR (300 MHz, CDCl3) δ 8.07 (s, 1H), 7.72 (d, J=8.5 Hz, 1H), 7.43 (dd, J=8.3, 1.7 Hz, 1H), 7.19 (dd, J=8.5, 2.1 Hz, 1H), 7.08 (s, 2H), 6.94 (d, J=8.3 Hz, 1H), 5.99 (dt, J=15.6, 5.5 Hz, 1H), 5.64 (dd, J=15.6, 7.7 Hz, 1H), 4.12-3.99 (m, 2H), 3.81-3.61 (m, 3H), 3.57 (t, J=7.3 Hz, 1H), 3.46 (dd, J=14.8, 4.5 Hz, 1H), 3.27 (s, 3H), 3.01 (dd, J=15.0, 10.3 Hz, 1H), 2.81 (dd, J=24.0, 11.2 Hz, 3H), 2.72-2.52 (m, 2H), 2.32-2.15 (m, 1H), 1.90 (ddd, J=33.7, 25.8, 12.0 Hz, 5H), 1.77-1.54 (m, 4H), 1.40 (t, J=12.1 Hz, 1H), 1.16 (s, 3H), 1.11 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and 1-but-3-enylcyclopropanecarboxylic acid in Step 3. The major product was assigned to Example 69 (3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-12,12-ethylene-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one. LC-MS calc. for C33H40ClN2O5S [M+H]+: m/z=611.23/613.23; Found: 611.0/612.8. Analytic HPLC: C18 column (4.6×150 mm, 100 Å); flow rate=1 mL/min; mobile phase: 5% MeCN/H2O (with 0.1% HCO2H) 1 min, 5% to 95% 7 min, 95% 5 min. λ=230 nm. tR=4.6 min. 1H NMR: (600 MHz, CDCl3) δ 8.18 (br s, 1H), 7.69 (d, J=8.5 Hz, 1H), 7.49 (dd, J=8.3, 2.1 Hz, 1H), 7.41 (d, J=2.2 Hz, 1H), 7.18 (dd, J=8.5, 2.3 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 7.00 (d, J=8.3 Hz, 1H), 5.30 (ddd, J=14.9, 9.9, 4.7 Hz, 1H), 5.08 (dd, J=15.2, 9.0 Hz, 1H), 4.18-4.07 (m, 2H), 3.68-3.56 (m, 2H), 3.32 (d, J=14.5 Hz, 1H), 3.15-3.11 (m, 1H), 3.09 (s, 3H), 2.97 (dd, J=8.8, 2.7 Hz, 1H), 2.82-2.69 (m, 3H), 2.46-2.36 (m, 1H), 2.24-2.14 (m, 1H), 2.09-1.98 (m, 2H), 1.93-1.53 (m, 9H), 1.43 (t, J=13.1 Hz, 1H), 1.39-1.19 (m, 3H).
- And the minor peak was assigned to Example 70 (3R,6R,7R,8Z,22S)-6′-chloro-7-methoxy-12,12-ethylene-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one. LC-MS calc. for C33H40ClN2O5S [M+H]+: m/z=611.23/613.23; Found: 611.0/613.1. Analytic HPLC: C18 column (4.6×150 mm, 100 Å); flow rate=1 mL/min; mobile phase: 5% MeCN/H2O (with 0.1% HCO2H) 1 min, 5% to 95% 7 min, 95% 5 min. λ=230 nm. tR=4.1 min (minor product). 1H NMR: (600 MHz, CDCl3) δ 8.14 (br s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.47-7.45 (m, 1H), 7.33 (d, J=2.2 Hz, 1H), 7.17 (dd, J=8.5, 2.3 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 6.99 (d, J=8.3 Hz, 1H), 5.40 (td, J=10.7, 3.9 Hz, 1H), 5.07 (t, J=10.4 Hz, 1H), 4.15-4.05 (m, 2H), 3.74-3.58 (m, 3H), 3.40 (d, J=14.7 Hz, 1H), 3.28 (dd, J=14.8, 5.3 Hz, 1H), 3.15 (s, 3H), 2.77 (dddd, J=22.5, 16.6, 11.0, 4.9 Hz, 3H), 2.35 (t, J=7.5 Hz, 1H), 2.26-2.18 (m, 1H), 2.10-1.75 (m, 8H), 1.68-1.52 (m, 3H), 1.48 (t, J=12.8 Hz, 1H), 1.34 (dt, J=10.3, 5.7 Hz, 2H), 1.15 (ddd, J=9.7, 6.5, 4.3 Hz, 1H).
-
-
- To a solution of (R)-(+)-4-Phenyl-1,3-oxazolidin-2-one (20.0 g, 122 mmol) in THF (400 mL) was added n-BuLi (53.9 mL, 134 mmol) slowly at −78° C. The reaction solution was stirred at −78° C. for 20 min. Then (E)-but-2-enoyl chloride (14.09 g, 134 mmol) was added slowly. The reaction solution was stirred at −78° C. for 0.5 h and then at 0° C. for 15 mins. The reaction was quenched with saturated NH4Cl solution (20 mL), extracted with EA (200 mL). The organic layer was dried over Na2SO4, filtered and concentrated to give crude mixture which was purified by flash chromatography on a silica gel column with PE/EA=10/1 to give (4R)-4-phenyl-3-[(E)-but-2-enoyl]oxazolidin-2-one (33 g, 58% yield). LC-MS calc. for C13H14NO3 [M+H]+m/z=232.09; Found: 232.0. 1H NMR: (400 MHz, CDCl3) δ 7.43-7.28 (m, 6H), 7.16-7.07 (m, 1H), 5.51 (dd, J=8.8, 4.0 Hz, 1H), 4.72 (t, J=8.8 Hz, 1H), 4.30 (dd, J=8.8, 4.0, Hz, 1H), 1.96 (dd, J=6.8, 1.6 Hz, 3H).
-
- To a solution of (4R)-4-phenyl-3-[(E)-but-2-enoyl]oxazolidin-2-one (11.5 g, 49.73 mmol) in DCM (400 mL) was added TiCl4 (28.3 g, 149.19 mmol) at −78° C. under N2. The solution was stirred at −78° C. for 20 min. Then allyltrimethylsilane (17.0 g, 149 mmol) was added slowly at −78° C. After the addition the reaction solution was stirred at −78° C. for 4 h., and quenched with saturated sodium bicarbonate solution. The organic layer was separated, and the aqueous layer was extracted with EA (200 mL×2). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with PE/EA=10/1 to give (4R)-4-phenyl-3-[(3S)-3-methylhex-5-enoyl]oxazolidin-2-one (5.33 g, 39% yield). The product was purified by recrystallization (n-pentane/Et2O=60/1 with trace CH2C12 at 0° C.) to give (R)-3-((S)-3-methylhex-5-enoyl)-4-phenyloxazolidin-2-one (3 g with dr=97/3). LC-MS calc. for C16H20NO3 [M+H]+ m/z=2734.14; Found: 274.0. 1H NMR: (400 MHz, CDCl3) δ 7.41-7.27 (m, 5H), 5.79-5.69 (m, 1H), 5.43 (dd, J=8.4, 3.6 Hz, 1H), 5.01-4.95 (m, 2H), 4.71-4.66 (m, 1H), 4.29-4.25 (m, 1H), 3.03-2.68 (m, 2H), 2.15-1.91 (m, 3H), 0.92 (d, J=6.4 Hz, 3H).
-
- To a solution of (4R)-4-phenyl-3-[(3S)-3-methylhex-5-enoyl]oxazolidin-2-one (1.6 g, 5.85 mmol) in THF (25 mL) and water (5 mL) was added hydrogen peroxide (2.35 mL, 23 mmol) and LiOH—H2O (0.49 g, 11 mmol) at 0° C. Then the reaction solution was stirred at 0° C. for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was extracted with DCM. The aqueous solution was adjusted pH to 1 with HCl (2 N) and extracted with DCM. The combined organic layers were dried over Na2SO4, filtered and concentrated to give (3S)-3-methylhex-5-enoic acid (600 mg, 80.0% yield). [α]20 D=−4.5 (c=0.79, CHCl3) {lit. [α]22 D=−2.8 (c=1.00, CHCl3), Ref: Angew. Chem., 2009, 48, 8780-8783}. 1H NMR: (400 MHz, CDCl3) δ 5.74-5.83 (m, 1H), 5.04-5.08 (m, 2H), 2.40-2.44 (m, 1H), 2.03-2.20 (m, 4H), 1.01 (d, J=6.4 Hz, 3H).
- This compound was prepared using procedures analogous to those described for Example 30 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (3S)-3-methylhex-5-enoic acid in Step 3. LC-MS calc. for C32H40ClN2O5S [M+H]+: m/z=599.2/601.2; Found 598.9/600.5. 1H NMR (600 MHz, DMSO-d6) 11.76 (s, 1H), 7.58 (d, J=8.5 Hz, 1H), 7.16 (dd, J=8.3, 2.1 Hz, 1H), 7.13 (d, J=2.2 Hz, 1H), 7.11 (d, J=2.4 Hz, 1H), 6.94 (d, J=8.3 Hz, 1H), 5.13-5.06 (m, 1H), 4.78 (dd, J=15.3, 9.0 Hz, 1H), 4.93-3.96 (m, 2H), 3.43 (d, J=14.3 Hz, 2H), 3.01 (dd, J=15.0, 5.3 Hz, 1H), 2.87 (s, 3H), 2.71-2.68 (m, 2H), 2.64-2.56 (m, 2H), 2.21-2.19 (m, 1H), 2.05-1.87 (m, 5H), 1.76-1.64 (m, 4H), 1.54-1.44 (m, 3H), 1.38-1.31 (m, 1H), 0.80 (d, J=6.3 Hz, 3H).
-
-
- To the solution of hex-5-enoic acid (1.0 g, 8.76 mmol) in DCM (10 mL) was added oxalyl chloride (0.62 mL, 8.76 mmol) and DMF (0.10 mL) in one portion. The reaction mixture was stirred at r.t. for 1 h., and concentrated to give hex-5-enoyl chloride (1.16 g, 94.7% yield) which was directly used in next step reaction without further purification.
-
- To a solution of (4R)-4-benzyloxazolidin-2-one (1.55 g, 8.75 mmol) in THF (10 mL) was added LiCl (370 mg, 8.75 mmol) and triethylamine (2.65 g, 26.25 mmol) slowly at 0° C. The reaction solution was stirred at 0° C. for 20 min. Then hex-5-enoyl chloride (1.16 g, 8.75 mmol) was added slowly, and stirred at r.t. overnight. The reaction solution was quenched with water (20 mL) and extracted with EA (40 mL). The organic layer was washed with saturated NaHCO3solution, dried over Na2SO4, filtered and concentrated to give crude mixture which was purified by flash chromatography on a silica gel column with PE/EA=10/1 to give (4R)-4-benzyl-3-hex-5-enoyl-oxazolidin-2-one (500 mg, 21% yield) as a white oil. 1H NMR (400 MHz, CDCl3) δ 7.37-7.27 (m, 3H), 7.24-7.17 (m, 2H), 5.83 (ddt, J=16.9, 10.2, 6.7 Hz, 1H), 5.13-4.95 (m, 2H), 4.68 (ddd, J=10.6, 6.9, 3.3 Hz, 1H), 4.27-4.07 (m, 2H), 3.30 (dd, J=13.4, 3.3 Hz, 1H), 3.07-2.85 (m, 2H), 2.76 (dt, J=18.7, 9.3 Hz, 1H), 2.16 (q, J=7.3 Hz, 2H), 1.89-1.74 (m, 2H).
-
- To a solution of (4R)-4-benzyl-3-hex-5-enoyl-oxazolidin-2-one (500.0 mg, 1.83 mmol) in THF (5 mL) was added NaHMDS (2.5 mL, 1.0 M THF solution, 2.5 mmol) slowly at −78° C. After stirring at −78° C. for 1 h. Iodomethane (778 mg, 5.49 mmol) was added slowly. The mixture was stirred at −78° C. for additional 3 h. The mixture was quenched with CH3COOH (0.1 mL) and warmed up to r.t. Then water (15 mL) was added and extracted with EA (2×20 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The resulting mixture was purified by flash chromatography on a silica gel column with PE/EA=10/1 to give (4R)-4-benzyl-3-[(2R)-2-methylhex-5-enoyl]oxazolidin-2-one (200 mg, 38% yield) as a white oil. 1H NMR (400 MHz, CDCl3) δ 7.36-7.27 (m, 3H), 7.23-7.20 (m, 2H), 5.84-5.74 (m, 1H), 4.70-4.64 (m, 1H), 4.22-4.13 (m, 2H), 3.76-3.71 (m, 1H), 3.26 (dd, J=13.4, 3.3 Hz, 1H), 2.77 (dd, J=13.3, 9.6 Hz, 1H), 2.12-2.06 (m, 2H), 1.93-1.84 (m, 1H), 1.55-1.48 (m, 1H), 1.24 (d, J=6.9 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 41 using (4R)-4-benzyl-3-[(2R)-2-methylhex-5-enoyl]oxazolidin-2-one to replace (4R)-4-phenyl-3-[(3S)-3-methylhex-5-enoyl]oxazolidin-2-one in Step 3. [α]D 20−23.5 (c 0.79, CHCl3) (lit. [α]D 23−25.0 (c 1.07, CHCl3)). (Ref: Tetrahedron 2007 vol. 63 #26 p. 5754-5767). 1H NMR (400 MHz, CDCl3) δ 5.79 (ddt, J=16.9, 10.2, 6.6 Hz, 1H), 5.14-4.86 (m, 2H), 2.58-2.44 (m, 1H), 2.16-2.02 (m, 2H), 1.89-1.71 (m, 1H), 1.53 (dt, J=13.9, 7.6 Hz, 1H), 1.25-1.12 (m, 3H). 13C NMR: (100 MHz, CDCl3) δ 183.2, 137.7, 115.2, 38.7, 32.5, 31.2, 16.8.
- This compound was prepared using procedures analogous to those described for Example 30 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and using (R)-2-methylhex-5-enoic acid in Step 3. LC-MS calc. for C32H40ClN2O5S [M+H]+: m/z=599.2/601.2; Found: 599.0/600.9. 1H NMR (600 MHz, DMSO-d6) δ 11.82 (s, 1H), 7.69 (d, J=8.5 Hz, 1H), 7.31-7.23 (m, 3H), 7.20 (d, J=2.4 Hz, 1H), 7.04 (d, J=8.2 Hz, 1H), 5.26-5.11 (m, 1H), 5.01-4.91 (m, 1H), 4.16 (d, J=12.3 Hz, 1H), 4.01 (d, J=12.3 Hz, 1H), 3.57-3.46 (m, 2H), 3.29 (d, J=14.3 Hz, 1H), 3.05-2.99 (m, 1H), 2.98 (s, 3H), 2.83-2.78 (m, 1H), 2.74-2.68 (m, 1H), 2.22-2.17 (m, 1H), 2.11-2.07 (m, 1H), 2.00 (dt, J=18.9, 6.8 Hz, 1H), 1.93 (d, J=14.0 Hz, 1H), 1.86-1.67 (m, 6H), 1.59-1.51 (m, 2H), 1.44 (td, J=14.9, 6.6 Hz, 2H), 1.34 (dd, J=7.9, 4.4 Hz, 2H), 1.00 (d, J=6.5 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and hept-6-enoic acid in Step 3. LC-MS calc. for C32H40ClN2O5S [M+H]+: m/z=599.23/601.22; Found: 599.0/600.8. 1H NMR (400 MHz, DMSO-d6) δ 11.96 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.29-7.24 (m, 2H), 7.21 (d, J=2.4 Hz, 1H), 7.13 (d, J=2.3 Hz, 1H), 7.02 (d, J=8.3 Hz, 1H), 5.60 (dt, J=15.6, 6.3 Hz, 1H), 5.09 (dd, J=15.6, 8.2 Hz, 1H), 4.21 (d, J=12.1 Hz, 1H), 4.12 (d, J=12.1 Hz, 1H), 3.34-3.30 (m, 1H), 3.27-3.18 (m, 2H), 3.08 (s, 3H), 2.81-2.66 (m, 3H), 2.41 (q, J=7.8 Hz, 1H), 2.29-2.08 (m, 4H), 2.03-1.91 (m, 3H), 1.88-1.92 (m, 4H), 1.61-1.45 (m, 4H), 1.45-1.37 (m, 1H), 1.25-1.20 (m, 3H), 1.15-1.06 (m, 1H).
-
- This compound was prepared using procedures analogous to those described for Example 30 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and pent-4-enoic acid in Step 3. LC-MS calc. for C30H36ClN2O5S [M+H]+: m/z=571.20/573.19; Found: 570.9/572.7. 1H NMR (600 MHz, MeOH-d4) δ 7.63 (d, J=8.3 Hz, 1H), 7.27-7.21 (m, 1H), 7.13 (d, J=2.2 Hz, 1H), 7.09-7.06 (m, 1H), 7.02 (d, J=2.5 Hz, 1H), 6.89 (d, J=8.3 Hz, 1H), 5.05 (s, 1H), 4.91 (dd, J=15.6, 8.2 Hz, 1H), 4.33-4.28 (m, 1H), 3.99-3.96 (m, 1H), 3.66-3.61 (m, 1H), 3.56-3.50 (m, 1H), 3.34-3.27 (m, 3H), 3.02 (s, 3H), 2.78-2.71 (m, 4H), 2.31-2.28 (m, 2H), 2.15-2.02 (m, 3H), 1.85-1.78 (m, 6H), 1.61 (dt, J=10.9, 9.0 Hz, 1H), 1.54-1.43 (m, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and pent-4-enoic acid in Step 3. LC-MS calc. for C30H36ClN2O5S [M+H]+: m/z=571.20/573.19; Found: 570.9/572.8. 1H NMR (600 MHz, Methanol-d4) δ 7.49 (d, J=8.4 Hz, 1H), 7.38 (dd, J=8.3, 2.2 Hz, 1H), 7.04 (ddd, J=12.3, 7.4, 2.3 Hz, 3H), 6.95 (d, J=8.3 Hz, 1H), 5.28 (dd, J=15.6, 8.6 Hz, 1H), 4.54 (t, J=11.8 Hz, 1H), 4.15 (d, J=11.9 Hz, 1H), 3.95 (d, J=11.9 Hz, 1H), 3.60 (dd, J=14.1, 3.3 Hz, 1H), 3.46 (d, J=14.2 Hz, 1H), 3.27 (dd, J=8.7, 2.5 Hz, 1H), 3.04 (s, 3H), 2.88 (dd, J=14.2, 11.1 Hz, 1H), 2.79-2.61 (m, 2H), 2.50 (qd, J=8.3, 4.0 Hz, 2H), 2.41 (dt, J=14.7, 4.4 Hz, 1H), 2.34-2.22 (m, 1H), 2.19-2.03 (m, 3H), 1.92-1.78 (m, 3H), 1.74-1.59 (m, 3H), 1.47 (dq, J=13.0, 9.9, 9.5 Hz, 1H), 1.25-1.17 (m, 1H).
-
- To a stirred solution of (3R,6R,7R,8E,21S)-6′-chloro-7-methoxy-14,14-dioxo-spiro[19-oxa-14-thia-1,13-diazatetracyclo[13.7.2.03,6.018,23]tetracosa-8,15,17,23-tetraene-21,1′-tetralin]-12-one (Example 74, 7.9 mg, 0.01 mmol) was added platinum(IV) oxide anhydrous (0.63 mg). The reaction flask was charged with hydrogen and the reaction mixture was stirred at 20° C. with a hydrogen balloon. LC-MS showed full conversion of starting material after 3 h. The solution was filtered through a pad of Celite and concentrated under reduced pressure The crude product was further purified by Prep-HPLC to afford (3R,6R,7R,21S)-6′-chloro-7-methoxy-14,14-dioxo-spiro[19-oxa-14-thia-1,13-diazatetracyclo[13.7.2.03,6.018,23]tetracosa-15,17,23-triene-21,1′-tetralin]-12-one (2.9 mg, 28.2% yield) as a white solid. LC-MS calc. for C30H38ClN2O5S [M+H]+: m/z=573.21/575.20; Found:572.8/574.6.
-
- This compound was prepared using procedures analogous to those described for Example 46 using (3R,6R,7S,8E,21S)-6′-chloro-7-methoxy-14,14-dioxo-spiro[19-oxa-14-thia-1,13-diazatetracyclo[13.7.2.03,6.018,23]tetracosa-8,15,17,23-tetraene-21,1′-tetralin]-12-one (Example 51). LC-MS calc. for C30H38ClN2O5S [M+H]+: m/z=573.21/575.20; Found:572.8/574.8.
-
-
- To a solution of LiHMDS, 1 M in THF (30.7 mL, 39.9 mmol) in THF (10 mL) was slowly added (R)-3-((S)-3-methylhex-5-enoyl)-4-phenyloxazolidin-2-one (5.46 g, 19.9 mmol, Example 71, Step 2) in THF (1 mL) at −78° C. The mixture was stirred at −78° C. for 1 h. Iodomethane (2.5 mL, 39 mmol) was added slowly. The mixture was stirred at −78° C. for 3 h. Then the mixture was stirred at −35° C. overnight. The mixture was quenched with saturated NH4Cl solution. The organic layer was separated, and the aqueous layer was extracted with EA (3×20 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated to give crude solid. The crude solid was purified by flash chromatography on a silica gel column with PE/EA=10/1 to give (R)-3-((2R,3S)-2,3-dimethylhex-5-enoyl)-4-phenyloxazolidin-2-one (1.4 g, 24% yield) as a white solid. 1H NMR: (400 MHz, CDCl3) δ 7.40-7.27 (m, 1H), 5.82-5.75 (m, 1H), 5.41 (dd, J=3.6 Hz, 8.8 Hz, 1H), 5.02 (t, J=6.8 Hz, 2H), 4.66 (d, J=8.8 Hz, 1H), 4.24 (dd, J=3.6 Hz, 8.8 Hz, 1H), 3.74-3.69 (m, 1H), 2.14-2.09 (m, 1H), 2.01-1.95 (m, 2H), 1.03 (d, J=6.8 Hz, 3H), 0.88 (d, J=6.4 Hz, 3H). 13C NMR: (100 MHz, CDCl3) δ 176.3, 153.4, 139.4, 137.1, 129.2, 128.6, 125.7, 116.1, 69.7, 57.8, 41.9, 40.0, 34.5, 15.5, 13.3.
-
- This compound was prepared using procedures analogous to those described for Example 71 using (R)-3-((2R,3S)-2,3-dimethylhex-5-enoyl)-4-phenyloxazolidin-2-one to replace (4R)-4-phenyl-3-[(3S)-3-methylhex-5-enoyl]oxazolidin-2-one in Step 3. dr=97:3. [α]22 D=−33.8 (c=0.94, CHCl3). 1H NMR: (400 MHz, CDCl3) δ 11.2 (br s, 1H), 5.82-5.73 (m, 1H), 5.06-5.01 (m, 2H), 2.49-2.42 (m, 1H), 2.14-2.09 (m, 1H), 2.04-1.96 (m, 2H), 1.10 (d, J=6.8 Hz, 3H), 0.90 (d, J=6.4 Hz, 3H).
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (2R,3S)-2,3-dimethylhex-5-enoic in Step 3. LC-MS calc. for C33H42ClN2O5S [M+H]+: m/z=613.25/615.25; Found: 612.9/615.0. 1H NMR (400 MHz, DMSO-d6) δ 11.78 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.28 (dd, J=8.5, 2.5 Hz, 1H), 7.27-7.18 (m, 2H), 7.16 (s, 1H), 7.03 (d, J=8.2 Hz, 1H), 5.60-5.51 (m, 1H), 5.08-4.97 (m, 1H), 4.20 (d, J=12.1 Hz, 1H), 4.04 (d, J=12.6 Hz, 1H), 3.27 (d, J=14.0 Hz, 2H), 3.03 (s, 3H), 2.86-2.62 (m, 4H), 2.24-1.98 (m, 4H), 1.95-1.72 (m, 6H), 1.65-1.40 (m, 5H), 1.24 (d, J=3.0 Hz, 3H), 0.84 (d, J=4.2 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and (2R,3S)-2,3-dimethylhex-5-enoic acid (Example 47 Step 2) in Step 3. LC-MS calc. for C33H42ClN2O5S [M+H]+: m/z=613.25/615.25; Found: 613.0/615.0. 1H NMR (600 MHz, MeOH-d4) δ 7.61 (d, J=8.6 Hz, 1H), 7.46-7.41 (m, 2H), 7.19-7.14 (m, 2H), 7.05 (d, J=8.3 Hz, 1H), 5.41-5.33 (m, 2H), 5.17 (s, 1H), 4.23 (d, J=11.8 Hz, 1H), 4.07 (d, J=12.0 Hz, 1H), 3.60 (d, J=12.2 Hz, 1H), 3.53 (d, J=14.3 Hz, 2H), 3.17 (s, 3H), 2.86-2.79 (m, 3H), 2.25-2.18 (m, 3H), 2.05 (d, J=7.0 Hz, 3H), 1.94 (d, J=7.5 Hz, 2H), 1.80 (d, J=15.9 Hz, 2H), 1.63 (d, J=6.0 Hz, 2H), 1.34-1.28 (m, 6H), 1.16 (d, J=6.9 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and hex-5-enoic acid in Step 3. LC-MS calc. for C31H38ClN2O5S [M+H]+: m/z=585.21/587.21; Found: 585.0/586.9. 1H NMR (600 MHz, DMSO-d6) 11.76 (s, 1H), 7.58 (d, J=8.5 Hz, 1H), 7.16 (dd, J=8.3, 2.1 Hz, 1H), 7.13 (d, J=2.2 Hz, 1H), 7.11 (d, J=2.4 Hz, 1H), 6.94 (d, J=8.3 Hz, 1H), 5.13-5.06 (m, 1H), 4.78 (dd, J=15.3, 9.0 Hz, 1H), 4.93-3.96 (m, 2H), 3.43 (d, J=14.3 Hz, 2H), 3.01 (dd, J=15.0, 5.3 Hz, 1H), 2.87 (s, 3H), 2.71-2.68 (m, 2H), 2.64-2.56 (m, 2H), 2.21-2.19 (m, 1H), 2.05-1.87 (m, 5H), 1.76-1.64 (m, 4H), 1.54-1.44 (m, 3H), 1.38-1.31 (m, 1H), 0.80 (d, J=6.3 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 30 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and (R)-2-methylhex-5-enoic acid (Example 72, Step 4) in Step 3. LC-MS calc. for C32H40ClN2O5S [M+H]+: m/z=599.2/601.2; Found: 599.4/601.5. 1H NMR (600 MHz, MeOH-d4) δ 7.58 (d, J=8.4 Hz, 1H), 7.51 (d, J=2.3 Hz, 1H), 7.44 (dd, J=8.4, 2.2 Hz, 1H), 7.20-7.13 (m, 2H), 7.08 (d, J=8.3 Hz, 1H), 5.12 (dd, J=15.4, 8.3 Hz, 1H), 4.99-4.89 (m, 1H), 4.25 (d, J=12.0 Hz, 1H), 4.04 (d, J=11.9 Hz, 1H), 3.68 (dd, J=14.6, 4.3 Hz, 1H), 3.53 (d, J=14.3 Hz, 1H), 3.29 (dd, J=8.9, 2.7 Hz, 1H), 3.13 (s, 3H), 2.88-2.80 (m, 3H), 2.57 (tt, J=9.0, 4.5 Hz, 1H), 2.35 (ddd, J=10.5, 6.7, 3.0 Hz, 1H), 2.21 (dt, J=9.6, 3.3 Hz, 1H), 2.09-1.98 (m, 2H), 1.99-1.90 (m, 2H), 1.88-1.73 (m, 5H), 1.64-1.53 (m, 3H), 1.17 (d, J=7.0 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 30 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and (S)-3-methylhex-5-enoic acid (Example 71, Step 3) in Step 3. LC-MS calc. for C32H40ClN2O5S [M+H]+: m/z=599.2/601.2; Found: 599.3/601.1 1H NMR (600 MHz, MeOH-d4) δ 7.59 (d, J=8.4 Hz, 1H), 7.48-7.41 (m, 2H), 7.18-7.14 (m, 2H), 7.08 (d, J=8.2 Hz, 1H), 5.17 (dd, J=15.4, 7.9 Hz, 1H), 5.09-5.02 (m, 1H), 4.27 (d, J=11.9 Hz, 1H), 4.03 (d, J=11.9 Hz, 1H), 3.74-3.67 (m, 1H), 3.36 (d, J=10.2 Hz, 1H), 3.14 (s, 3H), 3.06 (dd, J=14.1, 11.4 Hz, 1H), 2.87-2.74 (m, 3H), 2.63-2.58 (m, 1H), 2.39 (dd, J=14.7, 2.6 Hz, 1H), 2.25-2.19 (m, 1H), 2.13-1.92 (m, 7H), 1.87-1.67 (m, 5H), 1.62-1.57 (m, 2H), 1.01 (d, J=6.6 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 30 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and hept-6-enoic acid in Step 3. LC-MS calc. for C32H40ClN2O5S [M+H]+: m/z=599.23/601.23; Found: 598.8/601.1. 1H NMR (400 MHz, DMSO-d6) δ 12.00 (s, 1H), 7.59-7.54 (m, 1H), 7.36 (dd, J=8.4, 2.1 Hz, 1H), 7.27 (d, J=2.3 Hz, 1H), 7.24-7.20 (m, 2H), 7.11 (d, J=8.3 Hz, 1H), 5.13 (dd, J=15.6, 8.0 Hz, 1H), 4.85 (ddd, J=14.9, 8.2, 5.2 Hz, 1H), 4.20 (d, J=11.9 Hz, 1H), 3.99 (d, J=12.0 Hz, 1H), 3.61 (dd, J=8.0, 3.5 Hz, 1H), 3.55 (dd, J=14.0, 2.9 Hz, 1H), 3.34-3.24 (m, 2H), 3.10 (s, 3H), 3.04-2.98 (m, 1H), 2.79-2.72 (m, 2H), 2.45 (dt, J=8.6, 4.4 Hz, 1H), 2.40-2.33 (m, 1H), 2.26 (ddd, J=12.4, 8.0, 3.9 Hz, 1H), 2.11 (ddd, J=13.0, 6.3, 3.0 Hz, 1H), 2.06-1.98 (m, 1H), 1.94-1.91 (m, 1H), 1.88-1.70 (m, 5H), 1.70-1.62 (m, 2H), 1.58-1.47 (m, 3H), 1.39 (td, J=9.1, 4.8 Hz, 1H), 1.17-1.10 (m, 1H).
-
-
- This compound was prepared using procedures analogous to those described for Example 71 Step 1-3 using (S)-(+)-4-Phenyl-1,3-oxazolidin-2-one to replace (R)-(+)-4-Phenyl-1,3-oxazolidin-2-one in Step 1. [α]20 D=+3.6 (c=0.74, CHCl3). 1H NMR: (400 z, CDCl3) 5.83-5.74 (m, 1H), 5.10-5.04 (m, 2H), 2.44-2.40 (m, 1H), 2.23-2.03 (m, 4H), 1.01 (d, J=6.0 Hz, 3H).
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and (R)-3-methylhex-5-enoic acid in Step 3. LC-MS calc. for C32H40ClN2O5S [M+H]+: m/z=599.2/601.2; Found: 599.0/601.0. 1H NMR (600 MHz, DMSO-d6) δ 11.94 (s, 1H), 7.61 (d, J=8.5 Hz, 1H), 7.27 (dd, J=8.3, 2.1 Hz, 1H), 7.23 (dd, J=8.4, 2.5 Hz, 1H), 7.21 (d, J=2.5 Hz, 1H), 7.07 (d, J=8.3 Hz, 1H), 7.03 (d, J=2.2 Hz, 1H), 5.14-5.06 (m, 2H), 4.13 (d, J=12.1 Hz, 1H), 4.04 (d, J=12.1 Hz, 1H), 3.52 (dd, J=14.5, 6.4 Hz, 2H), 3.43-3.37 (m, 1H), 3.22-3.13 (m, 1H), 3.07 (s, 3H), 2.80-2.71 (m, 3H), 2.45-2.41 (m, 1H), 2.21 (dd, J=16.7, 7.8 Hz, 1H), 2.18-2.12 (m, 2H), 2.02-1.94 (m, 4H), 1.89-1.82 (m, 3H), 1.78-1.71 (m, 2H), 1.66 (t, J=11.2 Hz, 1H), 1.55 (p, J=9.2 Hz, 1H), 0.89 (d, J=6.9 Hz, 3H).
-
-
- This compound was prepared using procedures analogous to those described for Example 72 Step 2-4 using (4S)-4-benzyl-3-hex-5-enoyl-oxazolidin-2-one to replace (4R)-4-benzyl-3-hex-5-enoyl-oxazolidin-2-one in Step 2. 1H NMR (400 MHz, CDCl3) 5.76-5.86 (m, 1H), 4.99-5.09 (m, 2H), 2.50-2.55 (m, 1H), 2.11-2.16 (m, 2H), 1.79-1.88 (m, 1H), 1.51-1.59 (m, 1H), 1.22 (d, J=7.2 Hz, 3H).
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and (2S)-2-methylhex-5-enoic acid in Step 3. LC-MS calc. for C32H40ClN2O5S [M+H]+: m/z=599.2/601.2; Found: 598.9/600.9. 1H NMR (400 MHz, DMSO-d6) δ 11.94 (s, 1H), 7.62 (d, J=8.5 Hz, 1H), 7.31 (d, J=8.5 Hz, 1H), 7.27-7.19 (m, 2H), 7.06 (d, J=8.3 Hz, 1H), 7.00 (d, J=2.1 Hz, 1H), 5.18-5.07 (m, 2H), 4.16 (d, J=12.1 Hz, 1H), 4.04 (d, J=12.0 Hz, 1H), 3.54-3.43 (m, 3H), 3.07 (s, 3H), 2.82-2.74 (m, 2H), 2.01 (dd, J=14.4, 6.7 Hz, 2H), 1.93-1.79 (m, 5H), 1.73-1.65 (m, 4H), 1.54-1.45 (m, 3H), 1.33-1.17 (m, 4H), 0.96 (d, J=6.8 Hz, 3H).
-
-
- To a solution of diisopropylamine (4.86 g, 48. mmol) in THF (25 mL) was added n-butyllithium (18.3 mL, 45 mmol, 2.5 M in hexane) at −65° C. slowly. After addition, the reaction mixture was allowed to warm slowly to −10° C. and then cooled back to −65° C. Ethyl cyclobutanecarboxylate (5.6 g, 43 mmol) was added dropwise. The resulting mixture was stirred at −65° C. for 1 h., and then 4-bromobut-1-ene (7.08 g, 52 mmol) in N-[bis(dimethylamino)phosphoryl]-N-methyl-methanamine (10 mL, 43 mmol) was added. The reaction was stirred at ambient temperature overnight. The mixture was quenched with water at 0° C., and extracted with MTBE (2×20 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column to afford ethyl 1-but-3-enylcyclobutanecarboxylate (7.78 g, 97% yield).
-
- Ethyl 1-but-3-enylcyclobutanecarboxylate (240.0 mg, 1.32 mmol) in methanol (2 mL) and water (2 mL) was treated with lithium hydroxide monohydrate (226 mg, 5.2 mmol). The reaction was heated and stirred at 50° C. over weekend. After cooling, the reaction was adjusted with 1 N HCl to pH about 2. The mixture was extracted with EA (2×10 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column to afford pure 1-but-3-enylcyclobutanecarboxylic acid (128.7 mg, 63% yield). LC-MS calc. for C8H13O2 [M−H]−: m/z=153.1; Found: 153.0.
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and 1-(but-3-en-1-yl)cyclobutane-1-carboxylic acid in Step 3. LC-MS calc. for C34H42ClN2O5S [M+H]+: m/z=625.24/627.24; Found: 625.0/627.3. 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J=8.5 Hz, 1H), 7.58 (dd, J=8.4, 2.1 Hz, 1H), 7.35 (d, J=1.7 Hz, 1H), 7.18 (dd, J=8.5, 2.2 Hz, 1H), 7.11 (d, J=2.1 Hz, 1H), 7.04 (d, J=8.4 Hz, 1H), 5.27-5.15 (m, 1H), 4.86 (dd, J=15.1, 9.1 Hz, 1H), 4.26 (d, J=11.7 Hz, 1H), 4.15 (d, J=11.9 Hz, 1H), 3.58 (d, J=14.4 Hz, 2H), 3.31 (ddd, J=35.6, 22.1, 11.1 Hz, 3H), 3.11 (d, J=13.4 Hz, 2H), 3.01 (d, J=6.7 Hz, 2H), 2.84-2.70 (m, 2H), 2.63 (d, J=22.6 Hz, 1H), 2.51 (dt, J=16.4, 9.1 Hz, 2H), 2.41-2.29 (m, 2H), 2.13-1.74 (m, 10H), 1.56 (ddd, J=27.7, 19.1, 11.5 Hz, 5H).
-
-
- To a solution of LiHMDS, 1M in THF (179 mL, 179 mmol) was slowly added (4R)-4-phenyl-3-[(3S)-3-methylhex-5-enoyl]oxazolidin-2-one (27.3 g, 99 mmol, Example 41, Step 2) in THF (30 mL) at −78° C. After stirring at −78° C. for 2 h., bromo(methoxy)methane (11 mL, 179 mmol) was slowly added. The reaction mixture was stirred at −78° C. for additional 3 h., and then stirred at −30° C. overnight. The mixture was quenched with saturated NH4Cl aqueous solution. The organic layer was separated and the aqueous layer was extracted with EA (50 mL×3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure The residue solid was purified by silica gel with PE/EA=10/1 to give (R)-3-((2S,3S)-2-(methoxymethyl)-3-methylhex-5-enoyl)-4-phenyloxazolidin-2-one (11.6 g, 36% yield). 1H NMR (400 MHz, CDCl3) δ 7.38-7.27 (m, 5H), 5.80-5.70 (m, 1H), 5.48 (dd, J=8.8, 4.1 Hz, 1H), 5.04-4.99 (m, 2H), 4.65 (t, J=8.8 Hz, 1H), 4.22-4.15 (m, 2H), 3.60-3.50 (m, 2H), 3.16 (s, 3H), 2.20-2.12 (m, 1H), 2.05-1.95 (m, 2H), 0.92 (d, J=8.4 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 71, Step 3 using (4R)-4-phenyl-3-[(2S,3S)-2-(methoxymethyl)-3-methyl-hex-5-enoyl]oxazolidin-2-one. 1H NMR (400 MHz, CDCl3) 5.81-5.71 (m, 1H), 5.07-5.03 (m, 2H), 3.65 (t, J=9.2 Hz, 1H), 3.57-3.54 (m, 1H), 3.12 (s, 3H), 2.64-2.59 (m, 1H), 2.22-2.18 (m, 1H), 2.18-1.97 (m, 1H), 2.06-1.95 (m, 2H), 0.95 (d, J=6.6 Hz, 3H).
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (2S,3S)-2-(methoxymethyl)-3-methylhex-5-enoic acid in Step 3. LC-MS calc. for C34H44ClN2O6S [M+H]+: m/z=643.25/645.25; Found: 642.9/645.2. 1H NMR (400 MHz, DMSO-d6) δ 11.89 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.28 (dd, J=8.5, 2.4 Hz, 1H), 7.22 (d, J=2.3 Hz, 2H), 7.14 (s, 1H), 7.03 (d, J=8.2 Hz, 1H), 5.60-5.52 (m, 1H), 5.08-4.99 (m, 1H), 4.19-4.12 (m, 4H), 3.45 (t, J=9.2 Hz, 2H), 3.33-3.25 (m, 2H), 3.19-3.11 (m, 3H), 3.04 (s, 3H), 2.86-2.65 (m, 4H), 2.55 (s, 3H), 2.09 (q, J=6.2, 5.2 Hz, 2H), 2.01 (q, J=6.8, 6.1 Hz, 1H), 1.88-1.80 (m, 5H), 1.64-1.36 (m, 5H).
-
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3 S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 4) and (2S,3S)-2-(methoxymethyl)-3-methylhex-5-enoic acid in Step 3. LC-MS calc. for C33H42ClN2O6S [M+H]+: m/z=629.2/631.2; Found: 628.9/631.1. 1H NMR (600 MHz, DMSO-d6) δ 11.69 (s, 1H), 7.65 (d, J=8.5 Hz, 2H), 7.32-7.19 (m, 4H), 7.15 (s, 1H), 7.00 (d, J=7.7 Hz, 1H), 5.52 (s, 1H), 5.27 (s, 1H), 4.53 (d, J=3.4 Hz, 1H), 4.27-3.93 (m, 3H), 3.55 (s, 2H), 3.43 (t, J=9.2 Hz, 2H), 3.34 (s, 12H), 3.21 (dd, J=32.9, 8.9 Hz, 5H), 2.94 (d, J=11.3 Hz, 1H), 2.85-2.68 (m, 3H), 2.11-1.97 (m, 3H), 1.90 (d, J=13.2 Hz, 2H), 1.79 (d, J=19.7 Hz, 5H), 1.66-1.36 (m, 5H), 0.60 (s, 4H).
-
-
- To a mixture of (4R)-4-phenyl-3-[(3S)-3-methylhex-5-enoyl]oxazolidin-2-one (Example 71 Step 2, 20.0 g, 73.2 mmol) in THF (150 mL) at −78° C. was added the solution of NaHMDS (2 M in THF) (54.8 mL, 109 mmol) dropwise. The mixture was stirred at −78° C. for 3.5 h. Then t-butyl bromoacetate (21.4 g, 109 mmol) was added dropwise. The mixture was stirred at −78° C. for 30 min., and then allowed to warm to −40° C. and stirred at −40° C. for 1 h. The mixture was quenched with 50 mL of saturated NH4Cl aqueous solution, extracted with ethyl acetate (3×200 mL). The organic layer was dried and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with PE/EA=10:1 to get tert-butyl-(3R,4S)-4-methyl-3-[-(4R)-2-oxo-4-phenyl-oxazolidine-3-carbonyl]hept-6-enoate (8 g, 27.2% yield) as white solid. 1H NMR (400 MHz, CDCl3) δ 7.41-7.27 (m, 5H), 5.89-5.70 (m, 1H), 5.45-5.35 (m, 1H), 5.09-4.96 (m, 2H), 4.75-4.61 (m, 1H), 4.29-4.20 (m, 2H), 2.67 (dd, J=16.9, 11.7 Hz, 1H), 2.30 (dd, J=16.9, 3.4 Hz, 1H), 2.18 (dd, J=15.5, 8.6 Hz, 1H), 2.08-1.93 (m, 2H), 1.32-1.19 (m, 9H), 0.87 (dd, J=19.0, 6.6 Hz, 3H).
-
- To a mixture of tert-butyl-(3R,4S)-4-methyl-3-[(4R)-2-oxo-4-phenyl-oxazolidine-3-carbonyl]hept-6-enoate (9.6 g, 24.7 mmol) in 50 mL of DCM was added trifluoroacetic acid (73 mL, 991 mmol). The mixture was stirred at r.t. for 12 h. LC-MS showed the reaction was complete. The mixture was concentrated under reduced pressure. To the residue was added water (60 mL). The mixture was adjusted to pH ˜ 7 with saturated NaHCO3aqueous solution (100 mL), and extracted with ethyl acetate (100 mL). The organic layer was dried and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with PE/EA=2:1 to afford (3R,4S)-4-methyl-3-[(4R)-2-oxo-4-phenyl-oxazolidine-3-carbonyl]hept-6-enoic acid (6.6 g, 79% yield) as a pale yellow solid. LC-MS calc. for C18H22NO5 [M+H]+: m/z=332.14; Found: 332.2. 1H NMR (400 MHz, DMSO-d6) δ 12.17 (s, 1H), 7.26-7.36 (m, 5H), 5.74-5.84 (m, 1H), 5.49 (dd, J=2.8, 8.4 Hz, 1H), 5.01-5.08 (m, 2H), 4.76 (t, J=8.4 Hz, 1H), 4.17 (dt, J=3.2, 11.6 Hz, 1H), 4.10 (dd, J=2.8, 8.8 Hz, 1H), 2.54 (dd, J=12.0, 17.2 Hz, 1H), 2.34 (dd, J=3.2, 17.2 Hz, 1H), 1.99-2.13 (m, 3H), 0.76 (d, J=6.4 Hz, 3H).
-
- To a mixture of (3R,4S)-4-methyl-3-[(4R)-2-oxo-4-phenyl-oxazolidine-3-carbonyl]hept-6-enoic acid (3.0 g, 9.05 mmol) and triethylamine (3.7 g, 36 mmol) in 100 mL of dry THF at −40° C. was added isobutyl chloroformate (2.47 g, 18.11 mmol). The mixture was stirred at −40° C. for 1 h. Then sodium borohydride (1.37 g, 36.21 mmol) in 30 mL of water was added. The mixture was stirred at −40° C. for 2 h. The reaction mixture was treated with 3 N HCl (80 mL) and allowed to warm to r.t. The organic solvent was removed under reduced pressure, and the aqueous solution was extracted with DCM (100 mL). The organic layer was dried and concentrated to afford the crude product (4R)-4-phenyl-3-[(2R,3S)-2-(2-hydroxyethyl)-3-methyl-hex-5-enoyl]oxazolidin-2-one (5.6 g) which was directly used in next step reaction without further purification. LC-MS calc. for C18H24NO4 [M+H]+: m/z=318.16; Found: 318.2.
-
- To a mixture of (4R)-4-phenyl-3-[(2R,3S)-2-(2-hydroxyethyl)-3-methyl-hex-5-enoyl]oxazolidin-2-one (600 mg, 1.89 mmol) in 20 mL of dry DCM was added trimethyloxonium tetrafluoroborate (279 mg, 1.89 mmol) and proton sponge (1,8-bis(dimethylamino)naphthalene) (405 mg, 1.89 mmol). The mixture was stirred at r.t. for 2 d. The mixture was concentrated under reduced pressure and the residue was dissolved in ethyl acetate (50 mL). The mixture was washed with 3 M HCl (30 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column with PE/EA=10:1 to afford (4R)-4-phenyl-3-[(2R,3S)-2-(2-methoxyethyl)-3-methyl-hex-5-enoyl]oxazolidin-2-one (320 mg, 50% yield) as a colorless oil. LC-MS calc. for C19H26NO4 [M+H]+: m/z=332.18; Found: 332.2.
-
- To a mixture of (4R)-4-phenyl-3-[(2R,3S)-2-(2-methoxyethyl)-3-methyl-hex-5-enoyl]oxazolidin-2-one (320 mg, 0.97 mmol) in 15 mL of THF and 3 mL of water at 0° C. was added hydrogen peroxide (30% in water) (0.39 mL, 3.8 mmol) and lithium hydroxide (46 mg, 1.9 mmol). The mixture was stirred at 0° C. for 1 h and then allowed to warm to r.t. and stirred at r.t. for 12 h. The organic solvent was removed and the aqueous solution was added 10 mL of water, adjusted to pH 3.0 with con. HCl, extracted with ethyl acetate (30 mL). The organic layer was dried and concentrated to get (2R,3S)-2-(2-methoxyethyl)-3-methyl-hex-5-enoic acid (90 mg, 47% yield) as a colorless oil. LC-MS calc. for C10H19O3 [M+H]+: m/z=187.13; Found: 169.2 ([M−H2O+H]+). 1H NMR (400 MHz, CDCl3) δ 0.94 (d, J=6.4 Hz, 3H), 1.71-1.79 (m, 1H), 1.85-1.92 (m, 1H), 1.93-2.01 (m, 2H), 2.13-2.21 (m, 1H), 2.44-2.49 (m, 1H), 3.33 (s, 3H), 3.37-3.47 (m, 2H), 5.02 (s, 1H), 5.05-5.06 (m, 1H), 5.71-5.82 (m, 1H).
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (2R,3S)-2-(2-methoxyethyl)-3-methyl-hex-5-enoic acid in Step 3. LC-MS calc. for C35H46ClN2O6S [M+H]+: m/z=657.28/659.28; Found: 657.1/658.8.
-
-
- This compound was prepared using procedures analogous to those described for Example 71 Step 3 using tert-butyl (3R,4S)-4-methyl-3-((R)-2-oxo-4-phenyloxazolidine-3-carbonyl)hept-6-enoate (Example 89 Step 1). 1H NMR (400 MHz, CDCl3) δ 0.91 (d, J=6.4 Hz, 3H), 1.44 (s, 9H), 1.94-2.08 (m, 2H), 2.10-2.16 (m, 1H), 2.31 (dd, J=4.0 Hz, 16.8 Hz, 1H), 2.61 (m, J=11.2 Hz, 16.8 Hz, 1H), 2.88 (m, J=4.0 Hz, 11.2 Hz, 1H), 5.02-5.03 (m, 1H), 5.06 (m, J=1.2 Hz, 1H), 5.71-5.81 (m, 1H).
-
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (2R,3S)-2-(2-(tert-butoxy)-2-oxoethyl)-3-methylhex-5-enoic acid in Step 3. LC-MS calc. for C38H50ClN2O7S [M+H]+: m/z=713.3/715.3; Found: 712.9/715.2.
-
- A solution of tert-butyl 2-[(3R,6R,7R,8E,11S,12R,22S)-6′-chloro-7-methoxy-11-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-12-yl]acetate (25.0 mg, 0.04 mmol) in CH2Cl2 (1 mL) at 0° C. was treated with 2,2,2-trifluoroacetic acid (TFA) (0.5 mL) drop-wise. The reaction was stirred at r.t. overnight. The volatile components are removed under vacuum to afford the crude product 2-[(3R,6R,7R,8E,11S,12R,22S)-6′-chloro-7-methoxy-11-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-12-yl]acetic acid (21 mg) which was directly used in next step without further purification. LC-MS: calc. for C34H42ClN2O7S [M+H]+: m/z=657.2/659.2; Found: 657.0/659.3.
- A mixture of 2-[(3R,6R,7R,8E,11S,12R,22S)-6′-chloro-7-methoxy-11-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-12-yl]acetic acid (20.0 mg, 0.03 mmol), 3,3-difluoroazetidine hydrochloride (7.94 mg, 0.06 mmol), and HATU (34.71 mg, 0.09 mmol) in DCM (1 mL) was stirred at 0° C. for 1 h., and then diisopropylethylamine (11.78 mg, 0.09 mmol) was added. The mixture was stirred at r.t. overnight. LC-MS analysis indicated complete conversion. The reaction was quenched with 0.5M HCl (1.0 mL) and volatile components were removed under reduced pressure. The residue was purified by prep-HPLC on a C18 column with ACN and water to afforded (3R,6R,7R,8E,11S,12R,22S)-6′-chloro-12-[2-(3,3-difluoroazetidin-1-yl)-2-oxo-ethyl]-7-methoxy-11-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (2 mg, 9.0% yield). LC-MS calc. for C37H45ClF2N3O6S [M+H]+: m/z=732.2/734.2; Found: 732.0/734.3.
-
- This compound was prepared using procedures analogous to those described for Example 149 Step 4 using dimethylamine HCl salt. LC-MS: calc. for C36H47ClN3O6S [M+H]=684.2/686.2; Found: 684.0/686.3.
-
- This compound was prepared using procedures analogous to those described for Example 149 Step 4 using morpholine. LC-MS: calc. for C38H49ClN3O7S [M+H]=726.3/728.3; Found: 726.7/728.1.
-
-
- This compound was prepared using procedures analogous to those described for Example 88 Step 1-2 using (4R)-4-phenyl-3-[(3S)-3-methylhex-5-enoyl]oxazolidin-2-one (Example 86 Step 2) and 1-(chloromethoxy)-2-methoxy-ethane in Step 1. 1H NMR (400 MHz, CDCl3) δ 5.81-5.72 (m, 1H), 5.06-5.03 (m, 2H), 3.74 (t, J=9.2 Hz 1H), 3.67-3.60 (m, 3H), 3.56-3.52 (m, 2H), 3.38 (s, 3H), 2.67-2.65 (m, 1H), 2.21-2.19 (m, 1H), 2.03-1.96 (m, 2H), 0.96 (d, J=6.4 Hz, 3H).
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (2S,3S)-2-(2-methoxyethoxymethyl)-3-methyl-hex-5-enoic acid in Step 3. LC-MS calc. for C36H47ClN2O7S [M+H]+: m/z=687.28/689.28; Found:
-
-
- This compound was prepared using procedures analogous to those described for Example 88 Step 1-2 using (4R)-4-phenyl-3-[(3S)-3-methylhex-5-enoyl]oxazolidin-2-one (Example 86 Step 2) and (2-(chloromethoxy)ethyl)trimethylsilane in Step 1. 1H NMR (400 MHz, CDCl3) δ 5.78-5.71 (m, 1H), 5.06-5.02 (m, 2H), 3.66-3.51 (m, 4H), 2.60-2.57 (m, 1H), 2.30-2.11 (m, 1H), 2.03-1.96 (m, 2H), 1.01-0.85 (m, 5H), 0.01 (s, 9H).
-
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (2S,3S)-3-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)hex-5-enoic acid in Step 3. LC-MS calc. for C38H54ClN2O6SiS [M+H]+: m/z=729.31; Found: 729.7.
- To a solution of (3R,6R,7R,8E,11S,12S,22S)-6′-chloro-7-methoxy-11-methyl-15,15-dioxo-12-(2-trimethylsilylethoxymethyl)spiro[20-oxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (10 mg) in DCM (1 mL) was added 50% TFA (1 mL). The resulting mixture was stirred at r.t. for 2 h. The mixture was concentrated under reduced pressure. The residue was purified on C18 column with MeCN/H2O (30-100%) to afford the desired product (5 mg). LC-MS calc. for C33H42ClN2O6S [M+H]+: m/z=629.24; Found: 629.0.
-
-
- To a solution of (R)-(−)-phenyl-2-oxazolidinone (15.0 g, 93 mmol) in THF (500 mL) was added n-BuLi (80.9 mL, 202 mmol) slowly at −78° C. The reaction solution was stirred at −78° C. for 20 min. Then hex-5-enoyl chloride (26.8 g, 202 mmol) was added slowly. The reaction was stirred at −78° C. for 0.5 h and allowed to warm to ambient temperature overnight. The reaction was quenched with saturated NH4Cl solution (100 mL), and extracted with EA (100 mL×2). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to give crude mixture which was purified by flash chromatography on a silica gel column with PE/EA (10/1) to give (4R)-3-hex-5-enoyl-4-phenyl-oxazolidin-2-one (15 g, 31% yield). 1H NMR: (400 MHz, CDCl3) 7.29-7.43 (m, 5H), 5.73-5.83 (m, 1H), 5.43-5.46 (m, 1H), 4.96-5.04 (m, 2H), 4.71 (t, J=8.8 Hz, 1H), 4.28-4.31 (m, 1H), 2.95-2.99 (m, 2H), 2.06-2.12 (m, 2H), 1.70-1.77 (m, 2H).
-
- This compound was prepared using procedures analogous to those described for Example 88 Step 1-2 using (4R)-3-hex-5-enoyl-4-phenyl-oxazolidin-2-one and (2-(chloromethoxy)ethyl)trimethylsilane in Step 1. 1H NMR (400 MHz, CDCl3) δ 5.78 (ddt, J=16.9, 10.2, 6.6 Hz, 1H), 5.09-4.88 (m, 2H), 3.58-3.39 (m, 4H), 2.67 (ddd, J=15.5, 7.8, 5.6 Hz, 1H), 2.23-2.07 (m, 2H), 1.81 (ddd, J=21.5, 11.5, 5.8 Hz, 1H), 1.68-1.52 (m, 1H), 0.99-0.81 (m, 2H), 0.04-−0.01 (m, 9H).
- This compound was prepared using procedures analogous to those described for Example 94 Step 2-3 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (S)-2-((2-(trimethylsilyl)ethoxy)methyl)hex-5-enoic acid. LC-MS calc. for C32H40ClN2O6S [M+H]+: m/z=615.22; Found: 615.0.
-
-
- This compound was prepared using procedures analogous to those described for Example 88 Step 1-2 using (4R)-3-hex-5-enoyl-4-phenyl-oxazolidin-2-one and bromo(methoxy)methane in Step 1. 1H NMR (400 MHz, CDCl3) δ 5.84-5.74 (m, 1H), 5.08-4.98 (m, 2H), 3.59 (dd, J=9.2, 8.0 Hz, 1H), 3.52 (dd, J=9.2, 5.2 Hz, 1H), 3.37 (s, 3H), 2.74-2.67 (m, 2H), 2.17-2.10 (m, 2H), 1.85-1.74 (m, 1H), 1.66-1.57 (m, 1H).
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (S)-2-(methoxymethyl)hex-5-enoic acid in Step 3. LC-MS calc. for C33H42ClN2O6S [M+H]+: m/z=629.24/631.24; Found:
-
-
- This compound was prepared using procedures analogous to those described for Example 88 Step 1-2 using (4R)-3-hex-5-enoyl-4-phenyl-oxazolidin-2-one and 1-(chloromethoxy)-2-methoxyethane in Step 1. 1H NMR (400 MHz, CDCl3) δ 5.85-5.75 (m, 1H), 5.09-4.98 (m, 2H), 3.72-3.69 (m, 1H), 3.67-3.60 (m, 3H), 3.56-3.52 (m, 2H), 3.36 (s, 3H), 2.78-2.71 (m, 1H), 2.19-2.09 (m, 2H), 1.81-1.71 (m, 1H), 1.69-1.59 (m, 1H).
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (S)-2-((2-methoxyethoxy)methyl)hex-5-enoic acid in Step 3. LC-MS calc. for C35H46ClN2O7S [M+H]+: m/z=673.26/675.26; Found:
-
- To a solution of (3R,6R,24S)-6′-chloro-17,17-dioxo-spiro[22-oxa-8,17-dithia-1,16-diazapentacyclo[16.7.2.19,13.03,6.021,26]octacosa-9(28),10,12,18(27),19,21(26)-hexaene-24,1′-tetralin]-15-one (3.5 mg, Example 25) in DCM (0.50 mL) was added m-CPBA (77 wt %) (2.0 mg, 0.01 mmol) under N2, and stirred at r.t. for 18 h. The reaction mixture was concentrated under reduced pressure. The residue (white solid) was purified by FCC (15.5 g C18, 20→100% MeCN in H2O, wet-loaded in DMSO). Fractions containing pure product were combined and concentrated under reduced pressure to afford (3R,6R,24S)-6′-chloro-8,8,17,17-tetraoxo-spiro[22-oxa-8,17-dithia-1,16-diazapentacyclo[16.7.2.19,13.03,6.021,26]octacosa-9(28),10,12,18(27),19,21(26)-hexaene-24,1′-tetralin]-15-one (1.66 mg) as a white solid. LCMS m/z calc. for C32H34ClN2O6S2 [M+H]+: m/z=641.15/643.15; Found: 641.1/643.1.
-
-
- A solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-(hydroxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (56.8 mg, 0.08 mmol, Example 18 Step 2) in DMF (0.5 mL) was charged with sodium hydride (60% dispersion in mineral oil, 14 mg, 0.36 mmol) (caution: evolves H2) at r.t. and was purged with N2. After 1 min., the mixture was charged with allyl bromide (27 uL, 0.32 mmol) and stirred at r.t. for 22 h. The reaction mixture was quenched with water (1 mL) (caution: evolves H2), diluted with sat. NH4Cl (20 mL) and extracted with EtOAc (30 mL). The organic layer was separated, washed with water (2×20 mL) and brine (2×20 mL). The organic layer was dried over Na2SO4, filtered, concentrated under reduced pressure to yield (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-(allyloxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (67 mg) without further purification.
-
- The crude (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-(allyloxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (67 mg) was dissolved in DCM (800 μL). The flask was purged with N2, then charged with TFA (800 μL), and stirred at r.t. for 22 h. The reaction mixture was co-evaporated with DCM twice under reduced pressure, and diluted with EtOAc (30 mL), washed with sat. NaHCO3(20 mL), water (20 mL), and brine (20 mL). The organic layer was dried over Na2SO4, filtered, concentrated under reduced pressure to yield (3S)-6′-chloro-5-[[(1R,2R)-2-(allyloxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (62.1 mg) as a yellow/white solid. LCMS m/z calc. for C27H34ClN2O4S [M+H]+: m/z=517.19/519.19; Found: 517.1/519.2.
-
- A mixture of (3S)-6′-chloro-5-[[(1R,2R)-2-(allyloxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (40.95 mg, 0.08 mmol), 4-(dimethylamino)pyridine (DMAP) (48.38 mg, 0.40 mmol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) (53.14 mg, 0.28 mmol) under N2 was dissolved in DCM (1 mL). To the solution was added 4-pentenoic acid (24 uL, 0.24 mmol). The mixture was stirred at r.t. for 2.5 h. The reaction mixture was diluted with EtOAc (30 mL), washed twice with brine (20 mL) and 0.1 N HCl (5 mL), and washed with brine (20 mL). The organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure to yield N-[(3S)-6′-chloro-5-[[(1R,2R)-2-(allyloxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylpent-4-enamide (36 mg, 76% yield) as a clear yellow glass (36 mg). Rf=0.44 (2:1 hexanes:EtOAc); LCMS m/z calc. for C32H40ClN2O5S [M+H]+: m/z=599.23/601.23; Found: 599.3/601.2.
- A solution of N-[(3S)-6′-chloro-5-[[(1R,2R)-2-(allyloxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylpent-4-enamide (28.0 mg, 0.05 mmol) in DCM (2 mL) was purged with N2 and was charged with a solution of (1,3-dimesitylimidazolidin-2-ylidene)(2-isopropoxybenzylidene)ruthenium(VI) chloride (Hoveyda-Grubbs II) (2.9 mg) in DCM (1 mL). The reaction mixture was stirred at r.t. for 1 d. The reaction mixture was charged with 3 drops DMSO, concentrated under reduced pressure, and purified by FCC (15.5 g C18, 40→100% MeCN in H2O, wet-loaded in DMSO). Fractions containing pure product were combined and concentrated under reduced pressure and heat (−50° C.) to yield the desired (3R,6R,10E,23S)-6′-chloro-16,16-dioxo-spiro[8,21-dioxa-16-thia-1,15-diazatetracyclo[15.7.2.03,6.020,25]hexacosa-10,17(26),18,20(25)-tetraene-23,1′-tetralin]-14-one (14.4 mg, 51% yield) as a white solid. LCMS m/z calc. for C30H35ClN2O5S [M+H]+: m/z=571.20/573.20; Found: 571.1/573.0; 1H NMR (500 MHz, MeCN-d3) δ 9.31 (s, 1H), 7.66 (d, J=8.4 Hz, 1H), 7.36 (dd, J=2.2, 8.4 Hz, 1H), 7.20 (d, J=2.2 Hz, 1H), 7.19-7.13 (m, 2H), 6.98 (d, J=8.4 Hz, 1H), 5.48-5.38 (m, 1H), 4.95 (dt, J=5.5, 15.8 Hz, 1H), 4.35 (d, J=11.9 Hz, 1H), 4.02 (d, J=11.9 Hz, 1H), 3.64 (dd, J=5.9, 13.0 Hz, 1H), 3.59 (dd, J=4.6, 14.4 Hz, 1H), 3.54 (dt, J=1.5, 5.0, 12.7 Hz, 1H), 3.50 (d, J=14.6 Hz, 1H), 3.35 (d, J=14.4 Hz, 1H), 3.29 (dd, J=6.3, 9.8 Hz, 1H), 3.19 (dd, J=4.1, 9.8 Hz, 1H), 3.08 (dd, J=10.5, 14.5 Hz, 1H), 2.85 (td, J=4.3, 9.4 Hz, 1H), 2.77 (q, J=6.6, 7.8 Hz, 2H), 2.46-2.40 (m, 1H), 2.40-2.34 (m, 1H), 2.27-2.18 (m, 3H), 2.08-2.04 (m, 1H), 2.01-1.96 (m, 1H), 1.88-1.82 (m, 3H), 1.71-1.52 (m, 3H).
-
-
- To a solution of L-proline methyl ester hydrochloride (6.64 g, 40.0 mmol) in DMF (80 mL) was added Et3N (223 mL, 160 mmol) and Allyl bromide (9.7 g, 80 mmol) at 0° C. The mixture was stirred at ambient temperature for 12 h. The reaction mixture was poured into water, and extracted with ethyl acetate (3×30 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and evaporated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (EtOAc/hexane=1:3) to give methyl (2S)-1-allylpyrrolidine-2-carboxylate (5.4 g, 79% yield) as a colorless liquid. 1H NMR (400 MHz, CDCl3) δ 6.04-5.94 (m, 1H), 5.20 (dd, J=16.8, 1.6 Hz, 1H), 5.16 (d, J=10.0 Hz, 1H), 3.71 (s, 3H), 3.33-3.28 (m, 1H), 3.16-3.11 (m, 3H), 2.39-2.37 (m, 1H), 2.17-2.04 (m, 1H), 1.95-1.90 (m, 2H), 1.82-1.79 (m, 1H).
-
- To a solution of methyl (2S)-1-allylpyrrolidine-2-carboxylate (2.0 g, 11 mmol) in THF (10 mL) and water (5 mL) was added NaOH (945 mg, 23 mmol). After stirring for 18 h at rt., the reaction mixture was added water (10 mL) and washed with ethyl acetate (2×20 mL). The aqueous layer was acidified with 1 N HCl (10 mL) and washed with ethyl acetate (10 mL). The aqueous layer was concentrated under reduced pressure. The residue was dissolved in DCM/MeOH (1:1, 20 mL). The salt was removed by filtration and the filtrate was evaporated under reduced pressure to afford (2S)-1-allylpyrrolidine-2-carboxylic acid HCl salt (1.9 g, 84% yield) as a white solid. [a]D 20=−74.0 (c=1.0, MeOH). 1H NMR (400 MHz, MeOH-d4) δ 5.98-5.94 (m, 1H), 5.60 (dd, J=17.2, 1.2 Hz, 1H), 5.51 (d, J=10.0 Hz, 1H), 4.09-4.05 (m, 1H), 3.95-3.90 (m, 1H), 3.86-3.81 (m, 1H), 3.74-3.68 (m, 1H), 3.23-3.18 (m, 1H), 2.54-2.48 (m, 1H), 2.20-2.11 (m, 2H), 2.03-1.96 (m, 1H).
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and allylpyrrolidine-2-carboxylic acid in Step 3. LC-MS calc. for C33H41ClN3O5S [M+H]+: m/z=626.24/628.24; Found: 626.0/628.0. 1H NMR (600 MHz, DMSO-d6) δ 8.85 (s, 1H), 7.61 (d, J=8.5 Hz, 1H), 7.27 (d, J=2.0 Hz, 1H), 7.24 (dd, J=8.5, 2.4 Hz, 1H), 7.19 (d, J=2.4 Hz, 1H), 7.12 (dd, J=8.2, 1.9 Hz, 1H), 6.86 (d, J=8.2 Hz, 1H), 5.71 (dd, J=15.4, 6.5 Hz, 1H), 5.14-5.00 (m, 1H), 4.02 (d, J=12.0 Hz, 1H), 3.97 (d, J=12.1 Hz, 1H), 3.77 (d, J=8.7 Hz, 2H), 3.59 (d, J=18.3 Hz, 2H), 3.54 (d, J=14.2 Hz, 1H), 3.39 (dd, J=14.4, 5.4 Hz, 1H), 3.26 (d, J=14.4 Hz, 2H), 3.03 (s, 3H), 2.86-2.78 (m, 1H), 2.77-2.70 (m, 2H), 2.45-2.38 (m, 1H), 2.34-2.30 (m, 1H), 2.08-1.93 (m, 5H), 1.88-1.80 (m, 3H), 1.79-1.71 (m, 2H), 1.63-1.44 (m, 3H).
-
-
- To a solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-(hydroxymethyl)cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (300.0 mg, 0.42 mmol, Intermediate 3 Step 2) in DCM (5 mL) was added triphosgene (62 mg, 0.21 mmol) and pyridine (0.03 mL, 0.42 mmol) at r.t. The reaction was stirred for 1 h. Water was added and extracted with DCM. The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was used directly without further purification.
-
- To a solution of [(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl carbonochloridate (161 mg, 0.21 mmol) in MeCN (2 mL) was added potassium carbonate (285 mg, 2.07 mmol) and tert-butyl (3R)-3-(methylamino)pyrrolidine-1-carboxylate (124 mg, 0.62 mmol). The reaction mixture was stirred at r.t. for 2 d. After the reaction was completed, Water was added and extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with EtOAc in Hexane (0-50%) to afford tert-butyl (3R)-3-[[(1R,2R)-2-[[rac-(3 S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxycarbonylamino]pyrrolidine-1-carboxylate (105 mg, 54% yield)
-
- To a solution of tert-butyl (3R)-3-[methyl-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxycarbonyl]amino]pyrrolidine-1-carboxylate (105.0 mg, 0.11 mmol) in DCM (0.50 mL) was added 2,2,2-trifluoroacetic acid (1.0 mL, 13.07 mmol). The reaction mixture was stirred at r.t. overnight. The mixture was neutralized by sat. NaHCO3 aq. and extracted with DCM. The combined organic layers were dried over Na2SO4, filtered and evaporated under reduced pressure. The residue was purified by prep-HPLC with MeCN/H2O to afford [(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl N-methyl-N-[(3R)-pyrrolidin-3-yl]carbamate (47.5 mg, 70.78% yield).
-
- To a solution of [(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl N-methyl-N-[(3R)-pyrrolidin-3-yl]carbamate (47.4 mg, 0.08 mmol) in THF (0.50 mL) was added 1,1′-carbonyldiimidazole (14.0 mg, 0.09 mmol). The reaction was heated to 55° C. for 30 min. The resulting mixture was quenched with water and extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered and evaporated under reduced pressure to afford the crude product which was used directly in next step without further purification.
- To a solution of [(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methyl N-methyl-N-[(3R)-1-(pyrrole-1-carbonyl)pyrrolidin-3-yl]carbamate (52.2 mg, 0.07 mmol) in MeCN (0.50 mL) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (34.24 mg, 0.22 mmol). The reaction was heated to 85° C. overnight. The reaction was quenched with water (2 mL) and the mixture was extracted with DCM (2×2 mL). The combined organic layers were dried over Na2SO4, filtered and evaporated under reduced pressure. The residue was purified by prep-HPLC on C18 column (30×250 mm, 10 μm) using MeCN/H2O (20% to 100%) to afford (3R,6R,11R,24S)-6′-chloro-10-methyl-17,17-dioxo-spiro[8,22-dioxa-17-thia-1,10,14,16-tetrazapentacyclo[16.7.2.111,14.03,6.021,26]octacosa-18(27),19,21(26)-triene-24,1′-tetralin]-9,15-dione (7 mg, 14% yield). LC-MS: calc. for C31H38ClN4O6S [M+H]+: m/z=629.21/631.21; Found: 628.9/631.1. 1H NMR (400 MHz, DMSO-d6) δ 7.66 (d, J=8.4 Hz, 1H), 7.30-7.21 (m, 1H), 7.19 (d, J=2.1 Hz, 1H), 7.11 (d, J=18.0 Hz, 1H), 6.93 (d, J=7.8 Hz, 1H), 6.57 (s, 1H), 4.21-3.90 (m, 4H), 3.88-3.29 (m, 10H), 3.23 (dd, J=25.3, 21.5 Hz, 3H), 2.87-2.56 (m, 4H), 2.40-1.74 (m, 6H), 1.58 (d, J=47.6 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 101 Step 2-5 using tert-butyl (3R)-3-aminopyrrolidine-1-carboxylate to replace (3R)-3-(methylamino)pyrrolidine-1-carboxylate in Step 2. LC-MS calc. for C30H36ClN4O6S [M+H]+: 615.22/617.22; Found: 614.9/616.7. 1H NMR (400 MHz, DMSO-d6) δ 7.65 (d, J=8.1 Hz, 1H), 7.26 (d, J=8.8 Hz, 1H), 7.20 (s, 1H), 7.12 (s, 1H), 6.97 (dd, J=16.3, 8.5 Hz, 1H), 6.82 (d, J=8.7 Hz, 1H), 6.57 (s, 1H), 4.22 (s, 1H), 4.05 (s, 1H), 3.80 (d, J=16.1 Hz, 1H), 3.71 (d, J=2.6 Hz, 1H), 3.12 (s, 2H), 2.84-2.62 (m, 2H), 2.37-2.27 (m, 1H), 1.68 (ddd, J=134.6, 64.0, 36.5 Hz, 10H).
-
- This compound was prepared using procedures analogous to those described for Example 101 Step 2-5 using (3S)-3-(methylamino)pyrrolidine-1-carboxylate to replace (3R)-3-(methylamino)pyrrolidine-1-carboxylate in Step 2. LC-MS: calc. for C31H38ClN4O6S [M+H]+: m/z=629.2/631.2; Found: 628.9/631.1. 1H NMR (600 MHz, MeOH-d4) δ 7.72 (d, J=8.5 Hz, 1H), 7.32 (d, J=6.4 Hz, 1H), 7.21-7.18 (m, 1H), 7.17 (s, 1H), 7.14 (s, 1H), 6.96 (d, J=8.0 Hz, 1H), 4.24-4.03 (m, 6H), 3.71 (s, 2H), 3.62-3.36 (m, 3H), 2.94 (s, 2H), 2.81 (dt, J=16.9, 13.1 Hz, 3H), 2.70 (s, 1H), 2.46 (s, 1H), 2.22-2.09 (m, 3H), 2.00 (s, 2H), 1.91 (d, J=6.6 Hz, 3H), 1.67 (d, J=28.3 Hz, 3H), 1.33 (d, J=27.8 Hz, 2H).
-
-
- To a solution of CBr4 (388.35 mg, 1.17 mmol) in DCM (25 mL) under an atmosphere of nitrogen was added triphenylphosphine (307 mg, 1.17 mmol) and stirred for 30 mins. To this was added the (3S)-6′-chloro-5-[[2-(hydroxymethyl)cyclobutyl]methyl]-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Example 18, Step 2, 420 mg, 0.59 mmol). The reaction was stirred at r.t. for 14 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column using 0-30% EtOAc in hexane to give (3S)-5-[[2-(bromomethyl)cyclobutyl]methyl]-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (300 mg, 65% yield). 1H NMR (500 MHz, CDCl3) δ 7.67 (d, J=8.5 Hz, 1H), 7.24-7.08 (m, 3H), 7.06-6.96 (m, 6H), 6.84-6.75 (m, 4H), 4.29 (d, J=5.7 Hz, 4H), 4.11 (d, J=1.7 Hz, 2H), 3.79 (d, J=7.5 Hz, 8H), 3.70-3.55 (m, 2H), 3.40-3.19 (m, 4H), 2.78 (d, J=12.2 Hz, 2H), 2.46-2.29 (m, 2H), 2.05-1.80 (m, 4H), 1.70-1.48 (m, 2H).
-
- To (3S)-5-[[2-(bromomethyl)cyclobutyl]methyl]-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (300.0 mg, 0.38 mmol) in MeCN (20 mL) was added the potassium carbonate (215 mg, 1.54 mmol), and methyl 2-(5-hydroxy-3-pyridyl)acetate (128 mg, 0.77 mmol). The reaction was heated at 80° C. overnight, filtered and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column using 0-40% EtOAc in hexane to give methyl 2-[5-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]-3-pyridyl]acetate (170 mg, 51% yield). LC-MS calc. for C48H53ClN3O8S [M+H]+: m/z=866.3; found 866.5. 1H NMR (500 MHz, CDCl3) δ 8.13 (s, 2H), 7.68 (d, J=8.4 Hz, 1H), 7.47 (s, 1H), 7.19 (dd, J=2.3, 8.5 Hz, 1H), 7.15-7.10 (m, 2H), 7.05 (d, J=2.1 Hz, 1H), 6.98 (d, J=8.2 Hz, 1H), 6.93 (d, J=8.7 Hz, 4H), 6.76 (d, J=8.6 Hz, 4H), 4.13 (d, J=15.2 Hz, 8H), 3.99-3.90 (m, 2H), 3.78 (s, 7H), 3.71 (s, 4H), 3.64 (s, 4H), 3.34-3.19 (m, 2H), 2.79 (s, 2H), 2.49 (s, 2H).
-
- To methyl 2-[5-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]-3-pyridyl]acetate (170 mg, 0.20 mmol) in DCM (3 mL) was added the 2,2,2-trifluoroacetic acid (TFA) (1.5 mL). The reaction stirred at r.t. for 16 h. The reaction was concentrated under vacuum, extracted with DCM, the organic layer was washed with water, saturated sodium bicarbonate, and dried over sodium sulfate. The DCM layer was filtered, concentrated under reduced pressure, and purified by flash chromatography on a silica gel column using 0-10% methanol in DCM to give methyl 2-[5-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]-3-pyridyl]acetate (99 mg, 80.6% yield).
-
- To methyl 2-[5-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]-3-pyridyl]acetate (99.0 mg, 0.16 mmol) in THF (3 mL) and water (3 mL) was added the lithium hydroxide (18.0 mg, 0.72 mmol) and stirred at r.t. for 2 h. The reaction mixture was concentrated and the residue neutralized with 0.25 N HCl, extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over sodium sulfate, filtered and concentrated to give 2-[5-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]-3-pyridyl]acetic acid (92 mg, 80% yield). LC-MS calc. for C33H35ClF3N308S [M+H]+: m/z=612.2; found 612.4.
- To 2-[5-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]-3-pyridyl]acetic acid (72.0 mg, 0.12 mmol) in DCM (9 mL) and DMF (1 mL) was added the EDCI (67 mg, 0.35 mmol) and DMAP (67 mg, 0.55 mmol) and stirred at r.t. for 16 h. The reaction was diluted with water, extracted with ethyl acetate. The ethyl acetate layer was washed with water brine, dried over sodium sulfate, filtered and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column using 0-15% MeOH in DCM to give (3R,6R,24S)-6′-chloro-17,17-dioxo-spiro[8,22-dioxa-17-thia-1,11,16-triazapentacyclo[16.7.2.19,13.03,6.021,26]octacosa-9(28),10,12,18(27),19,21(26)-hexaene-24,1′-tetralin]-15-one (20 mg, 28% yield). LC-MS calc. for C31H33ClN3O5S [M+H]+: m/z=594.2; Found 594.3. 1H NMR (500 MHz, MeCN-d3) δ 8.04 (d, J=2.6 Hz, 1H), 7.90 (d, J=1.7 Hz, 1H), 7.68 (d, J=8.5 Hz, 1H), 7.30 (t, J=2.2 Hz, 1H), 7.23-7.07 (m, 3H), 6.98 (d, J=2.2 Hz, 1H), 6.75 (d, J=8.3 Hz, 1H), 4.17-3.98 (m, 4H), 3.53 (d, J=14.5 Hz, 1H), 3.45-3.20 (m, 7H), 2.84-2.69 (m, 3H), 2.55 (d, J=12.0 Hz, 3H), 1.90-1.47 (m, 5H).
-
-
- This compound was prepared using procedure analogous to that described for Example 18 Step 3 using methyl 2-(3,5-dihydroxyphenyl)acetate to replace methyl 3-hydroxyphenylacetate. Rf=0.73 (1:1 hexanes:EtOAc).
-
- A mixture of methyl 2-[3-hydroxy-5-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]phenyl]acetate (72 mg, 0.08 mmol), and triphenylphosphine (37.0 mg, 0.14 mmol) were evacuated and recharged with N2 (×2). Then N-(2-hydroxyethyl)morpholine (15.0 μL, 0.12 mmol) in DCM (3 mL) was added. To the mixture was added a solution of di-tert-butyl azodicarboxylate (25.0 mg, 0.11 mmol) in DCM (850 μL) dropwise over 2 min at r.t. The reaction mixture was stirred at r.t. overnight. An additional triphenylphosphine (9.0 mg, 0.03 mmol) was added, followed by diisopropyl azodicarboxylate (9.0 μL, 0.05 mmol). The mixture was stirred at r.t. for 1 h., concentrated under reduced pressure and purified by flash chromatography on a silica gel column with EtOAc in hexanes (10-100%) and then MeOH in DCM (2%) (with 0.2% NH4OH) to afford methyl 2-[3-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]-5-(2-morpholinoethoxy)phenyl]acetate (44 mg, 54% yield). LCMS m/z calc. for C55H65ClN3O10S [M+H]+: m/z=994.41; Found: 994.5.
- This compound was prepared as TFA salt using procedures analogous to those described for Example 18 Step 4-6 using methyl 2-[3-[[(1R,2R)-2-[[(3 S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]-5-(2-morpholinoethoxy)phenyl]acetate. LCMS m/z calc. for C38H45ClN3O7S [M+H]+: m/z=722.27; found: 722.5. 1H NMR (500 MHz, DMSO-d6) δ 12.05 (s, 1H), 9.94 (s, 1H), 7.60 (d, J=8.6 Hz, 1H), 7.27 (dd, J=2.4, 8.5 Hz, 1H), 7.21 (d, J=2.3 Hz, 1H), 7.07 (dd, J=2.1, 8.3 Hz, 1H), 6.92-6.86 (m, 1H), 6.82 (d, J=8.3 Hz, 1H), 6.64 (s, 1H), 6.51 (bs, 2H), 6.35 (d, J=2.2 Hz, 1H), 6.28 (s, 1H), 4.21 (q, J=5.0, 6.2 Hz, 2H), 4.11-4.03 (m, 2H), 4.03-3.95 (m, 4H), 3.74-3.65 (m, 2H), 3.48 (d, J=7.8 Hz, 1H), 3.41 (t, J=13.7 Hz, 1H), 3.39-3.25 (m, 4H), 3.20 (q, J=11.5, 14.9 Hz, 3H), 2.83-2.69 (m, 2H), 2.63 (s, 1H), 2.01-1.86 (m, 3H), 1.83-1.73 (m, 3H), 1.60 (q, J=10.4 Hz, 1H), 1.56-1.49 (m, 1H).
-
-
- To a stirred solution of (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (100 mg, 0.19 mmol, Intermediate 8) in MeCN (3 mL) was added TEA (0.1 mL, 0.58 mmol) and phenyl chloroformate (0.07 mL, 0.58 mmol). The resulting mixture was stirred at r.t. for 10 min. LCMS indicated the starting material was consumed. But-3-en-1-amine (16.5 mg, 0.23 mmol) was then added to the reaction mixture and the resulting solution was stirred overnight. The reaction was quenched by water (5 mL), extracted with EtOAc (3×10 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (12 g) using EtOAc/Heptanes (2% to 60%) to afford 1-but-3-enyl-3-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-urea (91 mg, 76% yield) as a white solid. LC-MS calc. for C32H41ClN3O5S [M+H]+: m/z=614.25/616.25. Found: 613.9/615.4.
- A solution of 1-but-3-enyl-3-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-urea (91.0 mg, 0.15 mmol) in DCE (100 mL) was bubbled with N2 for 30 min. Hoveyda-Grubbs II (18.5 mg, 0.03 mmol) was added and the reaction mixture was further bubbled with N2 for 30 min., and was stirred at 80° C. under N2 overnight. The reaction was concentrated under reduced pressure, and the residue was purified by flash chromatography on a silica gel column (12 g) using EtOAc/Heptanes (2% to 60%). The desired fractions were collected, concentrated under reduced pressure, and further purified by Prep-HPLC on C18 column (30×250 mm, 10 m) with 20 to 100% CH3CN/H2O (tR=23 min) to afford (3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-15,15-dioxo-spiro[20-oxa-15-thia-1,12,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (38 mg, 43% yield) as a white solid. LC-MS calc. for C30H37ClN3O5S [M+H]+: m/z=586.21/588.21; Found 586.1/587.9. 1H NMR (600 MHz, CDCl3) δ 7.68 (d, J=8.5 Hz, 1H), 7.18 (dt, J=8.7, 2.4 Hz, 1H), 7.08 (d, J=2.1 Hz, 1H), 7.02 (s, 1H), 6.99 (s, 1H), 6.96 (d, J=8.3 Hz, 1H), 5.88 (dt, J=14.2, 6.5 Hz, 1H), 5.48 (dd, J=15.7, 8.3 Hz, 1H), 4.09 (s, 2H), 3.80 (d, J=14.6 Hz, 1H), 3.67 (d, J=15.0 Hz, 1H), 3.49 (t, J=8.2 Hz, 2H), 3.42-3.30 (m, 2H), 3.26 (s, 3H), 3.02 (dd, J=15.1, 10.7 Hz, 1H), 2.89-2.67 (m, 2H), 2.57 (d, J=10.2 Hz, 1H), 2.38 (s, 2H), 2.29-2.12 (m, 1H), 2.10-1.91 (m, 3H), 1.84 (d, J=12.9 Hz, 1H), 1.67 (p, J=9.5 Hz, 3H), 1.42 (t, J=13.1 Hz, 1H), 1.39-1.21 (m, 2H).
-
- This compound was prepared using procedures analogous to those described for Example 106 using N-methylbut-3-en-1-amine hydrochloride to replace but-3-en-1-amine in Step 1. LC-MS calc. for C31H39ClN3O5S [M+H]+: m/z=600.22/602.22; Found 600.1/602.0. 1H NMR (600 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.52-7.30 (m, 2H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.08 (t, J=1.6 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 5.53-5.11 (m, 2H), 4.13 (d, J=12.2 Hz, 1H), 4.03 (d, J=12.1 Hz, 1H), 3.76-3.58 (m, 3H), 3.31 (d, J=14.6 Hz, 1H), 3.17-3.00 (m, 5H), 2.85 (s, 3H), 2.82-2.68 (m, 3H), 2.43-2.15 (m, 3H), 2.02-1.94 (m, 1H), 1.91-1.69 (m, 5H), 1.43 (q, J=16.1, 11.8 Hz, 2H), 1.36-1.18 (m, 1H).
-
- This compound was prepared using procedures analogous to those described for Example 106 using N-methylprop-2-en-1-amine hydrochloride to replace but-3-en-1-amine in Step 1. LC-MS: calc. for C30H37ClN3O5S [M+H]+: m/z=586.2/588.2; Found: 586.0/587.8. 1H NMR (600 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.48-7.32 (m, 1H), 7.22-7.13 (m, 1H), 7.07 (d, J=2.2 Hz, 1H), 7.01 (s, 1H), 6.93 (s, 1H), 5.85 (d, J=16.0 Hz, 1H), 5.69 (s, 1H), 4.25 (d, J=18.4 Hz, 1H), 4.07 (s, 2H), 3.76 (d, J=14.4 Hz, 3H), 3.61 (t, J=7.0 Hz, 1H), 3.32-3.22 (m, 4H), 3.13-2.95 (m, 3H), 2.85-2.67 (m, 2H), 2.52 (t, J=8.9 Hz, 1H), 2.09-1.97 (m, 2H), 1.91 (s, 2H), 1.87-1.76 (m, 1H), 1.66 (p, J=9.4 Hz, 2H), 1.57-1.46 (m, 1H), 1.40 (t, J=13.0 Hz, 1H), 1.28-1.22 (m, 1H).
-
-
- To a solution of (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (175 mg, 0.29 mmol, Example 32) in DCM (17 mL) was added Dess-Martin periodinane (144 mg, 0.34 mmol) at 0° C. (ice-water bath). The mixture was stirred at r.t. for 30 min., and then quenched with 10% sodium thiosulfate (5 mL) and stirred for additional 30 min. The resulting mixture was extracted with DCM (10 mL×2). The combined organic layers were washed with saturated NaHCO3(10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with EtOAc/Heptanes (5-90%) to afford the desired product (3R,6R,8E,22S)-6′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7,13-dione (100 mg, 57% yield). LC-MS calc. for C31H36ClN2O6S [M+H]+: m/z=599.19/601.19; Found 599.5/601.5.
-
- To a solution of (3R,6R,8E,22S)-6′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7,13-dione (100 mg, 0.17 mmol) in DMSO (8 mL) and THF (2 mL) was added trimethylsulfonium iodide (51 mg, 0.25 mmol), followed by potassium t-butoxide (1.OM in THF) (46 mg, 0.42 mmol) at 0° C. in ice-water bath. The mixture was then stirred at r.t. for 3 h. The reaction was monitored by LC-MS. The reaction was quenched with 1 drop acetic acid and stirred for 1 min. The mixture was poured into ethyl acetate (20 mL) and washed with water (20 mL). The aqueous layer was extracted with EA (20 mL×2). The combined organic layers were washed with water (50 mL), brine (50 mL) and dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with EtOAc/Heptanes (5-90%) to afford the desired product (3R,6R,8E,22S)-6′-chloro-7,7-(1-oxa-ethylene)-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (50 mg, 48% yield). LC-MS calc. for C32H38ClN2O6S [M+H]+: m/z=613.21/615.20; Found 613.7/615.7.
- To a solution of (3R,6R,8E,22S)-6′-chloro-7,7-(1-oxa-ethylene)-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (10.0 mg, 0.02 mmol) and 1-isopropylpiperazine (3.1 mg, 0.02 mmol) in THF (2 mL) was added potassium t-butoxide (1.0 M in THF) (3.6 mg, 0.03 mmol). The mixture was stirred at 65° C. for 3 d. and monitored by LC-MS. The reaction mixture was neutralized with 1-2 drops of 2 N HCl in ethyl acetate. The solvent was then removed and the residue was purified through Prep-HPLC on C18 column to afford (3R,6R,8E,22S)-6′-chloro-7-hydroxy-7-[(4-isopropylpiperazin-1-yl)methyl]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (2.8 mg, 23% yield) as a white solid. LC-MS calc. for C39H54ClN4O6S [M+H]+: m/z=741.34/743.33; Found 741.8/743.8.
-
-
- To a stirred solution of 2-bromo-2-methyl-propanoic acid (500 mg, 2.99 mmol) in MeCN (3 mL) was added tert-butyl N-(2-hydroxyethyl)-N-methyl-carbamate (786 mg, 4.49 mmol) and DIPEA (1.15 mL, 6.59 mmol) at 40° C. The resulting solution was stirred at 40° C. for 3 h. LC-MS analysis indicated the reaction was complete. The reaction mixture was adjusted with 1 N HCl to pH 1-2, and then extracted with EtOAc (2×20 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to afford 2-[2-[tert-butoxycarbonyl(methyl)amino]ethoxy]-2-methyl-propanoic acid (160 mg, 20% yield) as a colorless oil. LC-MS calc. for C12H22NO5 [M−H]−: m/z=260.3; Found: 260.2.
-
- To a suspension of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-formylcyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (1450.0 mg, 2.03 mmol, Intermediate 3 Step 3) in 1-butanol (5 mL) and 2-methylbut-2-ene (5.0 mL, 47.2 mmol) was added sodium chlorite (458 mg, 4.05 mmol) and the solution of sodium phosphate monobasic monohydrate (559 mg, 4.05 mmol) in water (5 mL). The reaction was stirred at r.t. for 3 h. LC-MS showed reaction was completed. The reaction was quenched with 10% Na2S2O3 aq. (5 mL) and the mixture was extracted with EtOAc (2×2 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to afford the crude product (500 mg) which was used directly in next step reaction without further purification.
-
- To a solution of (1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarboxylic acid (500 mg, 0.68 mmol) in DMF (5 mL) was added iodomethane (116 mg, 0.82 mmol) and potassium carbonate (141 mg, 1.03 mmol). The reaction was stirred overnight and then quenched with water (20 mL), and extracted with MTBE (2×10 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to afford the crude product which was used without further purification.
-
- To a solution of methyl (1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarboxylate (850 mg, 1.14 mmol) in DCM (2 mL) was added anisole (0.5 mL, 4.6 mmol) and 2,2,2-trifluoroacetic acid (TFA) (2.0 mL, 26.14 mmol). The reaction was stirred at r.t. overnight. Upon completion of the reaction, the mixture was concentrated under reduced pressure. The residue was re-dissolved in DCM and washed with sat. Na2CO3 aq. The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to afford the crude product which was used without further purification.
-
- To a stirred solution of methyl (1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl] (50 mg, 0.10 mmol) in DCM (1 mL) was added DMAP (48 mg, 0.40 mmol) and EDCI (38 mg, 0.20 mmol) at 20° C. The resulting solution was stirred at 20° C. for 3 h. LCMS analysis indicated the reaction was complete. The reaction mixture was quenched with 1 N HCl solution and extracted with EtOAc (5 mL×3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column using EtOAc/Heptanes (5-90%) to afford methyl (1R,2R)-2-[[(3S)-7-[[2-[2-[tert-butoxycarbonyl(methyl)amino]ethoxy]-2-methyl-propanoyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarboxylate (37 mg, 50% yield) as a light orange solid. LC-MS calc. for C37H51ClN3O9S [M+H]+: m/z=748.3/750.3; Found: 748.5/750.3.
-
- To a solution of methyl (1R,2R)-2-[[(3S)-7-[[2-[2-[tert-butoxycarbonyl(methyl)amino]ethoxy]-2-methyl-propanoyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarboxylate (40 mg, 0.05 mmol) in DCM (0.50 mL) was added phosphoric acid (0.67 mL, 11 mmol). The resulting solution was vigorously stirred at 40° C. for 3 h. LCMS analysis indicated the reaction was complete. The reaction mixture was quenched with 1 M NaOH aqueous solution to pH 8 and extracted with 2×4 mL DCM. The combined organic layers were concentrated under reduced pressure to afford methyl (1R,2R)-2-[[(3S)-6′-chloro-7-[[2-methyl-2-[2-(methylamino)ethoxy]propanoyl]sulfamoyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarboxylate (19 mg, 55% yield) as a white solid. LC-MS calc. for C32H43ClN3O7S [M+H]+: m/z=648.2/650.2; Found: 648.3/650.3.
-
- To a solution of methyl (1R,2R)-2-[[(3S)-6′-chloro-7-[[2-methyl-2-[2-(methylamino)ethoxy]propanoyl]sulfamoyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarboxylate (19.0 mg, 0.03 mmol) in methanol (0.50 mL) and THF (0.50 mL) was added lithium hydroxide monohydrate (3.7 mg, 0.09 mmol) in water (0.50 mL). The resulting solution was stirred at 40° C. for 2 h. LCMS analysis indicated the reaction was complete. The reaction mixture was quenched with 1 M HCl aqueous solution to pH 5-6 and extracted with EtOAc (2×10 mL). The combined organic layers were concentrated under reduced pressure to afford (1R,2R)-2-[[(3S)-6′-chloro-7-[[2-methyl-2-[2-(methylamino)ethoxy]propanoyl]sulfamoyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarboxylic acid (16 mg, 86% yield) as a white solid. LC-MS calc. for C31H41ClN3O7S [M+H]+: m/z=634.2/636.2; Found: 634.6/636.7.
- To a solution of (1R,2R)-2-[[(3S)-6′-chloro-7-[[2-methyl-2-[2-(methylamino)ethoxy]propanoyl]sulfamoyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarboxylic acid (16 mg, 0.03 mmol) in DMF (5 mL) was added HATU (2.1 mg, 0.05 mmol) and DIPEA (0.01 mL, 0.05 mmol). The resulting solution was stirred at 20° C. for 1 h. LCMS analysis indicated the reaction was complete. The reaction mixture was quenched with water and extracted with EtOAc (2×10 mL). The combined organic layers were concentrated under reduced pressure and the residue was purified by prep-HPLC on C18 column (30×250 mm, 10 m) using MeCN/H2O (20 to 100%) to afford (3R,6R,22S)-6′-chloro-8,12,12-trimethyl-15,15-dioxo-spiro[11,20-dioxa-thia-1,8,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-16(25),17,19(24)-triene-22,1′-tetralin]-7,13-dione (4 mg, 25% yield) as a white solid. LC-MS calc. for C31H39ClN306S [M+H]+: m/z=616.2/618.2; Found 616.6/618.6. 1H NMR (300 MHz, CDCl3) δ 7.74 (d, J=8.5 Hz, 1H), 7.51-7.31 (m, 2H), 7.22-7.04 (m, 2H), 6.94 (d, J=8.4 Hz, 1H), 4.10 (s, 2H), 4.03-3.89 (m, 1H), 3.89-3.77 (m, 1H), 3.73-3.63 (m, 1H), 3.56 (t, J=6.5 Hz, 1H), 3.29 (d, J=14.5 Hz, 2H), 3.11 (s, 5H), 2.77 (q, J=5.5, 5.0 Hz, 2H), 2.30-2.15 (m, 1H), 2.06-1.67 (m, 9H), 1.41 (s, 3H), 1.34 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and 2-(allyloxy)acetic acid in Step 3. LC-MS calc. for C30H36ClN2O6S [M+H]+: m/z=587.19/589.19; Found: 586.8/588.9. 1H NMR (600 MHz, DMSO-d6) δ 12.01 (s, 1H), 7.62 (d, J=8.5 Hz, 1H), 7.29 (dd, J=8.3, 2.1 Hz, 1H), 7.24 (dd, J=8.5, 2.4 Hz, 1H), 7.21 (d, J=2.4 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 7.06 (d, J=8.3 Hz, 1H), 5.43 (ddt, J=15.6, 7.6, 1.4 Hz, 1H), 5.20-5.09 (m, 1H), 4.13 (d, J=12.0 Hz, 1H), 4.06 (d, J=12.0 Hz, 1H), 4.01-3.90 (m, 4H), 3.55-3.47 (m, 2H), 3.39 (dd, J=7.5, 3.1 Hz, 1H), 3.20-3.12 (m, 1H), 3.05 (s, 3H), 2.80-2.73 (m, 2H), 2.02 (ddd, J=14.2, 6.4, 2.8 Hz, 1H), 1.91 (ddt, J=11.2, 7.6, 3.8 Hz, 1H), 1.89-1.80 (m, 2H), 1.79-1.71 (m, 2H), 1.66 (ddd, J=13.8, 10.3, 3.2 Hz, 1H), 1.58-1.50 (m, 1H), 1.30-1.20 (m, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and 2-(allyloxy)acetic acid in Step 3. LC-MS calc. for C30H36ClN2O6S [M+H]+: m/z=587.19/589.19; Found: 586.8/589.0. 1H NMR (600 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.26-7.21 (m, 1H), 7.13 (d, J=8.3 Hz, 1H), 7.07 (s, 1H), 6.83 (d, J=63.8 Hz, 1H), 6.05 (s, 1H), 5.34 (qd, J=11.1, 6.0 Hz, 1H), 5.17 (dd, J=99.9, 13.5 Hz, 1H), 4.52 (s, 1H), 4.19-3.88 (m, 4H), 3.78 (dt, J=31.6, 15.8 Hz, 2H), 3.34 (s, 3H), 3.28 (d, J=14.7 Hz, 1H), 3.00 (dd, J=29.7, 15.2 Hz, 1H), 2.83-2.68 (m, 2H), 2.64 (s, 1H), 2.33 (d, J=31.7 Hz, 2H), 2.08-1.95 (m, 3H), 1.74-1.54 (m, 3H), 1.34 (dd, J=28.1, 12.4 Hz, 3H).
-
-
- This compound was prepared using procedures analogous to those described for Example 28 Step 1-2 using ethyl (2S)-2-hydroxypropanoate to replace methyl 1-hydroxycyclopropanecarboxylate in Step 1. TLC Rf=0.25 (EA:Hep=2:1).
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using [(1S)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] acetate (Intermediate 5) and (2S)-2-allyloxypropanoic acid in Step 3. LC-MS calc. for C32H38ClN2O7S [M+H]+: m/z=629.20/631.20; Found: 629.0/630.8. 1H NMR (600 MHz, CDCl3) δ 8.95 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.55-7.48 (m, 1H), 7.17 (dd, J=8.5, 2.3 Hz, 1H), 7.12 (d, J=2.2 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.99 (d, J=8.3 Hz, 1H), 5.59 (q, J=3.7 Hz, 2H), 5.41-5.28 (m, 1H), 5.21 (t, J=4.3 Hz, 1H), 4.39-4.29 (m, 1H), 4.24 (d, J=12.2 Hz, 1H), 4.13 (d, J=12.2 Hz, 1H), 3.83-3.70 (m, 2H), 3.66 (d, J=14.6 Hz, 1H), 3.48-3.31 (m, 2H), 3.23 (dd, J=15.0, 8.1 Hz, 1H), 2.87-2.72 (m, 3H), 2.53 (dt, J=13.7, 8.8 Hz, 1H), 2.07 (s, 3H), 2.07-1.72 (m, 5H), 1.60 (td, J=18.9, 17.8, 11.1 Hz, 2H), 1.41 (d, J=6.8 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (2S)-2-allyloxypropanoic acid (Example 113 Step 1) in Step 3. LC-MS calc. for C33H38ClN2O6S [M+H]+: m/z=601.2/603.2; Found: 601.0/602.8. 1H NMR (400 MHz, DMSO-d6) δ 12.00 (s, 1H), 7.63 (dd, J=30.8, 26.0 Hz, 1H), 7.29 (dd, J=8.5, 2.2 Hz, 1H), 7.26-7.21 (m, 3H), 7.05 (d, J=7.4 Hz, 1H), 5.38-5.20 (m, 1H), 4.21 (d, J=12.9 Hz, 1H), 4.11 (d, J=12.2 Hz, 1H), 4.01 (d, J=12.3 Hz, 1H), 3.80-3.52 (m, 4H), 3.07-2.94 (m, 3H), 2.87-2.65 (m, 3H), 2.33 (dd, J=11.1, 9.2 Hz, 1H), 2.05-1.92 (m, 1H), 1.88-1.54 (m, 6H), 1.42 (dd, J=22.3, 11.3 Hz, 1H), 1.30-1.21 (m, 5H) ppm.
-
-
- 1 This compound was prepared using procedures analogous to those described for Example 28 Step 1-2 using ethyl (2R)-2-hydroxypropanoate to replace methyl 1-hydroxycyclopropanecarboxylate in Step 1. TLC Rf=0.3 (50% EA in Hep).
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (2R)-2-allyloxypropanoic acid in Step 3. LC-MS calc. for C33H38ClN2O6S [M+H]+: m/z=601.2/603.2; Found: 600.8/603.0. 1H NMR (400 MHz, DMSO-d6) δ 12.09 (s, 1H), 7.67 (d, J=8.6 Hz, 1H), 7.30-7.23 (m, 2H), 7.19 (d, J=2.2 Hz, 1H), 7.02 (d, J=8.3 Hz, 2H), 5.70-5.61 (m, 1H), 5.13 (dd, J=15.6, 8.0 Hz, 1H), 4.25 (d, J=12.1 Hz, 1H), 4.06 (d, J=12.1 Hz, 1H), 3.97 (dd, J=12.8, 6.2 Hz, 2H), 3.78 (dd, J=14.4, 6.8 Hz, 1H), 3.52 (d, J=14.4 Hz, 1H), 3.39 (t, J=6.5 Hz, 2H), 3.30 (d, J=7.3 Hz, 2H), 3.09 (s, 2H), 2.84-2.65 (m, 3H), 2.30 (dd, J=16.0, 10.6 Hz, 2H), 2.06-1.96 (m, 2H), 1.95-1.76 (m, 4H), 1.62-1.42 (m, 4H), 1.24 (d, J=6.6 Hz, 3H).
-
-
- To a solution of ethyl 1-aminocyclobutanecarboxylate hydrochloride (1.00 g, 5.57 mmol) and sodium bicarbonate (1.43 g, 16.7 mmol) in THF (5 mL) and water (5 mL) was added di-tert butyl dicarbonate (1.46 g, 6.68 mmol). The resulting mixture was stirred at r.t. for 10 min. and briefly heated in a hot water bath at 50° C. for 10 min. diluted with water, and extracted with MTBE. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure to afford the crude product which was used without further purifications. LC-MS calc. for C12H22NO4 [M+H]+: m/z=244.15; Found 244.0.
-
- To a suspension of sodium hydride (60%, 446 mg, 11.5 mmol) in DMF (15 mL) was added ethyl 1-(tert-butoxycarbonylamino)cyclobutanecarboxylate (1.35 g, 5.57 mmol) in DMF (5 mL) at 0° C. After 20 min., allyl bromide (1.01 g, 8.36 mmol) was added in one portion. The reaction was stirred at ambient temperature overnight, quenched with saturated aqueous NH4Cl and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (3% to 8% EtOAc/Hept) to afford ethyl 1-[allyl(tert-butoxycarbonyl)amino]cyclobutanecarboxylate (1.42 g, 90% yield) as a colorless oil. TLC (10% EtOAc/Hept) Rf=0.48.
-
- A solution of ethyl 1-[allyl(tert-butoxycarbonyl)amino]cyclobutanecarboxylate (1.40 g, 4.94 mmol) and lithium hydroxide monohydrate (1.03 g, 24.7 mmol) in MeOH/THF/H2O (5 mL, 5 mL, 8 mL) was heated at 45° C. overnight. The reaction was cooled to 0° C., acidified with 2 N HCl, and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column (10% to 30% EtOAc/Hept) to afford 1-[allyl(tert-butoxycarbonyl)amino]cyclobutanecarboxylic acid (0.790 g, 62.6% yield). LC-MS calc. for C13H20NO4 [M−H]−. m/z=254.14; Found 254.1.
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-5 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and 1-[allyl(tert-butoxycarbonyl)amino]cyclobutanecarboxylic acid in Step 3. LC-MS calc. for C33H41ClN3O5S [M+H]+: m/z=626.24/628.24; Found: 626.0/628.2. 1H NMR (600 MHz, CDCl3) δ 7.68 (d, J=8.5 Hz, 1H), 7.42 (dd, J=8.6, 2.1 Hz, 1H), 7.26 (app s, 1H, overlapped with CHCl3), 7.17 (dd, J=8.5, 2.3 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 5.37-5.24 (m, 2H), 4.11 (d, J=12.1 Hz, 1H), 4.06 (d, J=12.2 Hz, 1H), 3.70 (d, J=14.6 Hz, 1H), 3.65 (dd, J=14.4, 7.0 Hz, 1H), 3.40 (dd, J=14.7, 4.3 Hz, 1H), 3.31 (d, J=14.6 Hz, 1H), 3.13 (s, 3H), 3.09 (d, J=5.6 Hz, 1H), 3.02 (dd, J=15.1, 7.1 Hz, 1H), 2.94 (d, J=13.1 Hz, 1H), 2.82-2.71 (m, 2H), 2.59 (dqd, J=16.2, 8.8, 8.2, 2.6 Hz, 2H), 2.45 (tt, J=8.4, 3.3 Hz, 1H), 2.28 (d, J=8.1 Hz, 1H), 2.08-1.77 (m, 10H), 1.76-1.69 (m, 1H), 1.68-1.60 (m, 1H), 1.44-1.37 (m, 1H).
-
-
- This compound was prepared using procedures analogous to those described for Example 116 Step 2-3 using methyl (2S)-2-(tert-butoxycarbonylamino)propanoate to replace ethyl 1-(tert-butoxycarbonylamino)cyclobutanecarboxylate in Step 2.
-
- This compound was prepared using procedures analogous to those described for Example 26 Step 3 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl] cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (2S)-2-[allyl(tert-butoxycarbonyl)amino]propanoic acid.
-
- This compound was prepared using procedures analogous to those described for Example 26 Step 4 using tert-butyl N-allyl-N-[(1S)-1-methyl-2-oxo-2-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]ethyl]carbamate (81.3 mg, 0.11 mmol) in DCE (110 mL) at 80° C. overnight and purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (2% to 50%) to afford two products: P1 (the earlier eluted product, 29.8 mg, 38.1% yield) and P2 (the latter eluted product, 21.7 mg, 27% yield).
- P1 was assigned to tert-butyl (3R,6R,7R,8Z,12S,22S)-6′-chloro-7-methoxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-11-carboxylate, and P2 was assigned to tert-butyl (3R,6R,7R,8E,12S,22S)-6′-chloro-7-methoxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-11-carboxylate.
- tert-butyl (3R,6R,7R,8E,12S,22S)-6′-chloro-7-methoxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-11-carboxylate (21.7 mg, 0.03 mmol, P2 Step 4) was treated with 2 N HCl in EA (0.5 mL). The reaction mixture was stirred at r.t. overnight and quenched with sat. NaHCO3 aq. solution. The mixture was extracted with DCM (2 mL×2). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC on C18 column (30×250 mm, 10 m) using MeCN/H2O (20% to 100%) to afford (3R,6R,7R,8E,12S,22S)-6′-chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (9.4 mg, 48.7% yield). LC-MS calc. for C31H39ClN3O5S [M+H]+: m/z=600.22/602.22; Found=599.9/601.7. 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J=8.5 Hz, 1H), 7.32 (s, 1H), 7.15 (s, 1H), 7.10 (d, J=1.8 Hz, 1H), 6.93 (d, J=8.1 Hz, 1H), 5.45 (dd, J=15.3, 8.8 Hz, 2H), 5.39-5.24 (m, 2H), 4.13 (d, J=12.0 Hz, 1H), 4.01 (d, J=12.3 Hz, 1H), 3.87-3.65 (m, 2H), 3.65-3.48 (m, 2H), 3.48-3.38 (m, 1H), 3.32 (d, J=14.6 Hz, 2H), 3.23 (s, 1H), 3.13 (d, J=8.2 Hz, 1H), 3.03 (dd, J=15.2, 6.0 Hz, 2H), 2.87-2.68 (m, 1H), 2.64 (s, 4H), 2.31 (d, J=3.4 Hz, 2H), 2.02 (d, J=13.6 Hz, 2H), 1.97-1.53 (m, 3H), 1.53-1.22 (m, 2H), 1.16 (dd, J=6.0, 3.4 Hz, 2H).
-
- This compound was prepared using procedures analogous to those described for Example 117 using tert-butyl (3R,6R,7R,8Z,12S,22S)-6′-chloro-7-methoxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-11-carboxylate (P1, Example 117, step 4) in Step 5. LC-MS calc. for C31H39ClN3O5S [M+H]+: m/z=600.22/602.22; Found: 600.9/602.1. 1H NMR (400 MHz, CDCl3) δ 7.68 (d, J=8.5 Hz, 1H), 7.41 (dd, J=8.3, 1.7 Hz, 1H), 7.18 (dd, J=8.8, 2.4 Hz, 2H), 7.08 (d, J=2.1 Hz, 1H), 6.94 (d, J=8.3 Hz, 1H), 5.58 (d, J=5.1 Hz, 2H), 4.08 (s, 2H), 3.78-3.55 (m, 3H), 3.48-3.25 (m, 4H), 3.22 (s, 2H), 3.07 (dd, J=15.2, 8.0 Hz, 1H), 2.85-2.65 (m, 2H), 2.65-2.50 (m, 5H), 2.40-2.30 (m, 1H), 2.01 (d, J=14.6 Hz, 1H), 1.87 (ddd, J=32.6, 16.9, 6.0 Hz, 4H), 1.65-1.49 (m, 2H), 1.49-1.34 (m, 3H).
-
-
- This compound was prepared using procedures analogous to those described for Example 116 Step 2-3 using ethyl 1-(tert-butoxycarbonylamino)cyclopropanecarboxylate to replace ethyl 1-(tert-butoxycarbonylamino)cyclobutanecarboxylate in Step 2.
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-5 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl] cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and 1-(allyl(tert-butoxycarbonyl)amino)cyclopropane-1-carboxylic acid in Step 3. LC-MS calc. for C32H39ClN3O5S [M+H]+: m/z=612.22/614.22; Found: 611.9/614.2. 1H NMR (600 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.46 (d, J=7.9 Hz, 1H), 7.31 (s, 1H), 7.18 (dd, J=8.5, 2.0 Hz, 1H), 7.08 (d, J=2.0 Hz, 1H), 6.98 (d, J=8.3 Hz, 1H), 5.40 (d, J=4.0 Hz, 2H), 4.08 (dd, J=37.7, 12.1 Hz, 2H), 3.79-3.67 (m, 2H), 3.29 (dd, J=34.7, 13.2 Hz, 2H), 3.20-3.07 (m, 5H), 3.04 (dd, J=15.2, 6.4 Hz, 1H), 2.84-2.63 (m, 3H), 2.37 (s, 1H), 2.00 (d, J=13.3 Hz, 1H), 1.95-1.72 (m, 4H), 1.69-1.49 (m, 4H), 1.44-1.35 (m, 2H), 1.17-1.11 (m, 1H), 1.08 (dd, J=12.8, 8.7 Hz, 1H), 0.95 (tdd, J=15.5, 9.4, 6.0 Hz, 1H).
-
- This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (Example 116) and formaldehyde aqueous solution (37%). LC-MS calc. for C34H43ClN3O5S [M+H]+: m/z=640.25/642.25; Found: 640.0/642.2. 1H NMR (600 MHz, CDCl3) δ 7.67 (d, J=8.5 Hz, 1H), 7.45 (d, J=16.9 Hz, 1H), 7.16 (d, J=7.7 Hz, 1H), 7.08 (t, J=4.6 Hz, 1H), 6.90 (s, 2H), 5.41 (dd, J=14.8, 9.0 Hz, 1H), 4.07 (dd, J=33.9, 11.7 Hz, 2H), 3.71 (d, J=14.7 Hz, 1H), 3.48 (s, 1H), 3.34 (d, J=15.0 Hz, 1H), 3.26 (s, 3H), 2.97 (dd, J=34.6, 21.1 Hz, 1H), 2.85-2.66 (m, 2H), 2.49 (s, 1H), 2.42 (s, 3H), 2.29 (s, 1H), 2.17 (s, 1H), 2.11-1.88 (m, 6H), 1.83 (d, J=8.0 Hz, 1H), 1.65 (s, 9H), 1.40 (t, J=12.9 Hz, 1H), 0.95-0.73 (m, 1H).
-
-
- This compound was prepared using procedures analogous to those described for Example 116 Step 2-3 using methyl (2R)-2-(tert-butoxycarbonylamino)propanoate to replace ethyl 1-(tert-butoxycarbonylamino)cyclobutanecarboxylate in Step 2.
-
- These two compounds were prepared using procedures analogous to those described for Example 117 Step 2-3 using (2R)-2-[allyl(tert-butoxycarbonyl)amino]propanoic acid to replace (2S)-2-[allyl(tert-butoxycarbonyl)amino]propanoic acid in Step 2. P1 (the earlier eluted product) was assigned to the cis-isomer and P2 (the earlier eluted product) was assigned to the trans-isomer.
- This compound was prepared using procedures analogous to those described for Example 117 Step 5 using tert-butyl (3R,6R,7R,8E,12R,22S)-6′-chloro-7-methoxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-11-carboxylate (P2). LC-MS calc. for C31H39ClN3O5S [M+H]+: m/z=600.22/602.22; Found: 599.9/602.0. 1H NMR (600 MHz, CDCl3) δ 7.68 (d, J=8.5 Hz, 1H), 7.34 (d, J=8.3 Hz, 1H), 7.30 (s, 1H), 7.16 (d, J=8.4 Hz, 1H), 7.08 (s, 1H), 6.95 (d, J=8.3 Hz, 1H), 5.42-5.26 (m, 2H), 4.12 (d, J=12.1 Hz, 1H), 4.04 (d, J=12.1 Hz, 1H), 3.77-3.63 (m, 3H), 3.31 (d, J=14.5 Hz, 1H), 3.16 (d, J=6.9 Hz, 1H), 3.12 (s, 3H), 3.03 (dd, J=15.1, 6.4 Hz, 3H), 2.85-2.71 (m, 2H), 2.71-2.59 (m, 1H), 2.28 (td, J=14.0, 9.1 Hz, 1H), 2.00 (t, J=6.8 Hz, 2H), 1.94-1.69 (m, 7H), 1.64 (dd, J=19.0, 9.5 Hz, 2H), 1.40 (d, J=7.0 Hz, 2H).
-
- This compound was prepared using procedures analogous to those described for Example 117 Step 5 using tert-butyl (3R,6R,7R,8Z,12R,22S)-6′-chloro-7-methoxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]-pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-11-carboxylate (P1, Example 121 Step 2). LC-MS calc. for C31H39ClN3O5S [M+H]+: m/z=600.22/602.22; Found: 599.9/602.0. 1H NMR (600 MHz, CDCl3) δ 7.68 (d, J=8.5 Hz, 1H), 7.44 (d, J=7.9 Hz, 1H), 7.17 (d, J=6.6 Hz, 2H), 7.08 (d, J=1.7 Hz, 1H), 6.94 (d, J=8.2 Hz, 1H), 5.53 (s, 2H), 4.11-4.03 (m, 2H), 3.75 (d, J=9.6 Hz, 1H), 3.69 (d, J=14.5 Hz, 1H), 3.53 (d, J=14.6 Hz, 1H), 3.33 (dd, J=42.0, 19.1 Hz, 4H), 3.21 (s, 3H), 3.06 (dd, J=14.8, 7.7 Hz, 1H), 2.82-2.69 (m, 2H), 2.60-2.51 (m, 1H), 2.40-2.32 (m, 1H), 2.01 (dd, J=15.3, 8.8 Hz, 1H), 1.86 (ddd, J=42.9, 24.7, 5.6 Hz, 5H), 1.65-1.53 (m, 2H), 1.41 (t, J=9.9 Hz, 4H), 1.27 (d, J=18.2 Hz, 1H).
-
- This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7R,8E,12R,22S)-6′-chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 121). LC-MS calc. for C32H41ClN3O5S [M+H]+: m/z=614.24/616.24; Found: 614.0/615.8. 1H NMR (600 MHz, CDCl3) δ 7.68 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.4, 2.0 Hz, 1H), 7.18 (dd, J=8.5, 2.1 Hz, 1H), 7.08 (d, J=2.1 Hz, 1H), 6.97 (d, J=8.4 Hz, 2H), 5.74-5.67 (m, 1H), 5.44 (dd, J=15.7, 8.7 Hz, 1H), 4.09 (dd, J=24.3, 12.1 Hz, 2H), 3.71 (d, J=14.6 Hz, 1H), 3.50 (d, J=8.8 Hz, 1H), 3.44-3.37 (m, 1H), 3.35 (d, J=14.7 Hz, 1H), 3.23 (d, J=15.4 Hz, 2H), 3.09-3.02 (m, 2H), 2.97 (dd, J=14.9, 7.3 Hz, 1H), 2.87 (dd, J=14.9, 4.3 Hz, 1H), 2.81 (s, 1H), 2.80-2.72 (m, 2H), 2.55-2.46 (m, 2H), 2.37 (d, J=10.0 Hz, 2H), 2.15 (dd, J=15.0, 7.4 Hz, 1H), 2.06-1.89 (m, 4H), 1.83 (d, J=7.6 Hz, 2H), 1.72-1.36 (m, 2H), 1.35-1.19 (m, 2H), 0.97-0.76 (m, 2H).
-
- This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7R,8Z,12R,22S)-6′-chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 122). LC-MS calc. for C32H41ClN3O5S [M+H]+: m/z=614.24/616.24; Found: 614.0/615.8. 1H NMR (600 MHz, CDCl3) δ 7.93 (d, J=7.9 Hz, 1H), 7.70 (d, J=8.7 Hz, 2H), 7.45 (dd, J=15.8, 7.4 Hz, 2H), 7.35 (d, J=8.5 Hz, 1H), 7.18 (dd, J=27.6, 9.5 Hz, 3H), 7.06 (dd, J=16.6, 8.7 Hz, 3H), 6.97 (s, 2H), 6.77 (dd, J=28.8, 20.2 Hz, 4H), 6.61 (s, 1H), 6.05 (s, 1H), 5.80-5.61 (m, 3H), 5.46 (s, 1H), 5.31 (dd, J=15.4, 8.3 Hz, 1H), 5.19 (s, 1H), 5.07 (s, 2H), 4.29 (d, J=11.2 Hz, 2H), 4.06 (d, J=10.7 Hz, 3H), 3.85-3.71 (m, 3H), 3.71-3.18 (m, 20H), 2.87 (ddt, J=92.3, 76.4, 36.2 Hz, 20H), 2.47 (d, J=30.6 Hz, 4H), 2.23 (t, J=38.8 Hz, 10H), 2.11-1.74 (m, 20H), 1.74-1.45 (m, 10H), 1.45-1.18 (m, 12H), 1.18-0.95 (m, 10H), 0.89 (ddd, J=29.8, 15.5, 8.0 Hz, 4H).
-
-
- Mg(ClO4)2 (819 mg, 3.67 mmol) was added to methyl (2S)-oxirane-2-carboxylate (1.5 g, 14.69 mmol) in methanol (2 mL) under stirring vigorously. The reaction mixture was heated to 80° C. for 20 h. After the reaction was completed (monitored by GC, GC: SM Rt=4.68 min, product Rt=6.0 min), the mixture was cooled to r.t., filtered and concentrated under reduced pressure. The residue was re-dissolved in heptane, filtered again and concentrated to remove MeOH completely. The residue (1.97 g) was used for next step directly.
-
- Allyl bromide (3.55 g, 29 mmol) was added to methyl (2S)-2-hydroxy-3-methoxy-propanoate (1.97 g, 14 mmol) in tert-butyl methyl ether (40 mL) and followed by addition of silver(I) oxide (6.8 g, 29 mmol) for 3 d. The reaction was filtered through a pad of Celite and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (20 g) using EtOAc/Heptanes (2% to 30%) to afford methyl (2S)-2-allyloxy-3-methoxy-propanoate (810.9 mg, 31.7% yield).
-
- This compound was prepared using procedures analogous to those described for Example 86 Step 2 using methyl (2S)-2-allyloxy-3-methoxy-propanoate and LiOH.
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide and (2S)-2-allyloxy-3-methoxy-propanoic acid. LC-MS calc. for C32H40ClN2O7S [M+H]+: m/z=631.22/633.21; Found: 631.0/632.8. 1H NMR (600 MHz, CDCl3) δ 7.67 (d, J=8.5 Hz, 1H), 7.41 (d, J=7.8 Hz, 1H), 7.24 (s, 1H), 7.18 (d, J=8.2 Hz, 1H), 7.09 (d, J=1.8 Hz, 1H), 6.99 (d, J=8.2 Hz, 1H), 5.46 (d, J=15.6 Hz, 1H), 5.39 (dd, J=15.6, 8.3 Hz, 1H), 4.51-4.43 (m, 1H), 4.12 (dd, J=23.8, 11.9 Hz, 2H), 3.84-3.75 (m, 2H), 3.69 (d, J=13.8 Hz, 2H), 3.60 (dd, J=10.3, 5.6 Hz, 1H), 3.56-3.46 (m, 1H), 3.40 (s, 3H), 3.35 (d, J=14.6 Hz, 1H), 3.23-3.13 (m, 2H), 3.11 (s, 3H), 2.83-2.63 (m, 3H), 2.35-2.25 (m, 1H), 2.06-1.97 (m, 1H), 1.97-1.77 (m, 4H), 1.77-1.66 (m, 1H), 1.63 (dt, J=18.8, 9.5 Hz, 2H), 1.45 (t, J=12.5 Hz, 1H).
-
-
- To a suspension of (2S)-2-(tert-butoxycarbonylamino)-2-cyclopropyl-acetic acid (1500 mg, 6.97 mmol) in THF (20 mL) was added sodium hydride (60% in oil) (351 mg, 14.6 mmol) and the reaction mixture was stirred at r.t. for 20 min. Allyl bromide (927 mg, 7.67 mmol) was added drop-wise. After addition, the reaction was stirred at 50° C. overnight. The reaction was quenched with 10 mL saturated aqueous NH4Cl and extracted with EtOAc (2×20 mL). The combined organic extracts were washed with water and brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with EtOAc/Hept (3% to 8%) to afford (2S)-2-[allyl(tert-butoxycarbonyl)amino]-2-cyclopropyl-acetic acid (840 mg, 47% yield) as a colorless oil.
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-5 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl] cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (S)-2-(allyl(tert-butoxycarbonyl)amino)-2-cyclopropylacetic acid in Step 3. LC-MS calc. for C33H41ClN3O5S [M+H]+: m/z=626.24/628.23; Found: 626.0/628.2. 1H NMR (600 MHz, CDCl3) δ 7.68 (d, J=8.5 Hz, 1H), 7.37 (dd, J=8.3, 2.1 Hz, 1H), 7.32 (s, 1H), 7.17 (dd, J=8.5, 2.3 Hz, 1H), 7.11-7.06 (m, 1H), 6.97 (d, J=8.3 Hz, 1H), 5.39-5.32 (m, 1H), 5.28 (d, J=5.6 Hz, 1H), 4.14-4.01 (m, 2H), 3.71 (d, J=14.6 Hz, 1H), 3.69-3.59 (m, 2H), 3.31 (d, J=14.6 Hz, 1H), 3.12 (s, 3H), 3.02 (dd, J=14.9, 6.7 Hz, 2H), 2.88 (d, J=13.5 Hz, 1H), 2.83-2.70 (m, 2H), 2.65 (q, J=8.3 Hz, 1H), 2.32-2.18 (m, 2H), 2.00 (d, J=13.5 Hz, 2H), 1.94-1.78 (m, 4H), 1.80-1.69 (m, 2H), 1.64 (p, J=11.1, 10.4 Hz, 2H), 1.46-1.37 (m, 1H), 1.02 (d, J=7.2 Hz, 1H), 0.73-0.54 (m, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7R,8E,12S,22S)-6′-chloro-12-cyclopropyl-7-methoxy-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.0˜3,6.0˜19,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 126). LC-MS calc. for C34H42ClN3O5S [M+H]+: m/z=640.3/642.3; Found: 640.0/642.2. 1H NMR (600 MHz, DMSO-d6) δ 7.65 (d, J=8.5 Hz, 1H), 7.26 (dd, J=8.5, 2.3 Hz, 1H), 7.17 (d, J=2.3 Hz, 1H), 7.13 (dd, J=8.2, 1.9 Hz, 1H), 6.85 (d, J=8.1 Hz, 1H), 6.82 (d, J=2.0 Hz, 1H), 6.08 (dd, J=13.4, 6.9 Hz, 1H), 5.70-5.58 (m, 1H), 4.00 (s, 2H), 3.55 (t, J=12.7 Hz, 2H), 3.33 (s, 6H), 3.19 (s, 3H), 3.04 (dd, J=15.2, 10.0 Hz, 1H), 2.78 (s, 4H), 2.13-2.04 (m, 1H), 2.04-1.94 (m, 2H), 1.94-1.87 (m, 2H), 1.84 (dq, J=10.2, 5.5, 4.7 Hz, 2H), 1.69 (p, J=10.2 Hz, 2H), 1.39 (q, J=6.9 Hz, 1H), 1.04 (ddt, J=13.4, 9.2, 4.5 Hz, 1H), 0.89-0.83 (m, 1H), 0.70 (td, J=8.6, 7.5, 4.0 Hz, 1H), 0.60 (tt, J=8.8, 3.4 Hz, 1H), 0.56-0.47 (m, 2H).
-
-
- This compound was prepared using procedures analogous to those described for Example 116 Step 2-3 using methyl (2S)-2-(tert-butoxycarbonylamino)-3-methyl-butanoate to replace ethyl 1-(tert-butoxycarbonylamino)cyclobutanecarboxylate in Step 2.
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-5 using (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl] cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 8) and (S)-2-(allyl(tert-butoxycarbonyl)amino)butanoic acid in Step 3. LC-MS calc. for C33H43ClN3O5S [M+H]+: m/z=628.25/630.25; Found: 628.1/629.8. 1H NMR (600 MHz, CDCl3) δ 7.68 (dd, J=8.6, 3.9 Hz, 1H), 7.38 (s, 1H), 7.26 (s, 1H), 7.16 (d, J=9.6 Hz, 1H), 7.11-7.01 (m, 1H), 6.91 (s, 1H), 5.58-5.17 (m, 2H), 4.19-3.92 (m, 2H), 3.77-3.60 (m, 2H), 3.32 (d, J=14.6 Hz, 1H), 3.15 (d, J=25.0 Hz, 3H), 3.02 (dd, J=15.0, 6.7 Hz, 1H), 2.94 (s, 1H), 2.86-2.69 (m, 2H), 2.65 (s, 1H), 2.23 (dd, J=18.4, 10.8 Hz, 1H), 2.11-1.95 (m, 2H), 1.95-1.69 (m, 4H), 1.62 (dq, J=28.8, 9.6 Hz, 2H), 1.45-1.35 (m, 1H), 1.35-1.21 (m, 3H), 1.09-0.97 (m, 4H), 0.94 (d, J=6.9 Hz, 1H), 0.88 (t, J=6.9 Hz, 1H).
-
- This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7R,8E,12S,22S)-6′-chloro-7-methoxy-12-isopropyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 128). LC-MS calc. for C34H45ClN3O5S [M+H]+: m/z=642.27/644.27; Found: 642.0/643.8. 1H NMR (400 MHz, CDCl3) δ 7.70 (d, J=8.5 Hz, 1H), 7.52 (dd, J=8.4, 2.1 Hz, 1H), 7.28 (s, 1H), 7.20 (dd, J=8.5, 2.4 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 7.05-6.93 (m, 1H), 6.07-5.16 (m, 2H), 4.28-3.97 (m, 2H), 3.82-3.68 (m, 1H), 3.53-3.26 (m, 4H), 3.20-2.91 (m, 2H), 2.91-2.66 (m, 3H), 2.58-2.14 (m, 4H), 2.14-1.90 (m, 5H), 1.91-1.54 (m, 5H), 1.54-1.37 (m, 3H), 1.32-1.20 (m, 6H).
-
-
- To a stirred solution of (3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (120.0 mg, 0.23 mmol, Intermediate 8) in MeCN (5 mL) was added triethylamine (0.19 mL, 1.39 mmol) followed by phenyl chloroformate (0.09 mL, 0.70 mmol). The resulting mixture was stirred at r.t. for 20 min. LC-MS showed the consumption of starting material. Allylamine (0.35 mL, 4.6 mmol) was added and the reaction was stirred at r.t. overnight. Water (10 mL) was added, and extracted with EtOAc (10 mL×3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (20% to 100%) to afford 1-allyl-3-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-urea (127 mg, 91% yield) as a white solid. LC-MS calc. for C31H39ClN3O5S [M+H]+: m/z=600.2/602.2; Found: 599.9/602.0.
- To a stirred solution of 1-allyl-3-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1R)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-urea (108.0 mg, 0.18 mmol) in DCE (180 mL) was bubbled with nitrogen for 20 min. Then Hoveyda-Grubbs II (22.5 mg, 0.04 mmol) was added under nitrogen. The reaction was further bubbled with nitrogen for 10 min. The reaction was stirred at 80° C. under nitrogen overnight. The reaction was cooled to r.t. and bubbled with air for 30 min. to deactivate the catalyst. The residue was purified by flash chromatography on a silica gel column (12 g) using EtOAc/Heptanes (20% to 100%). The desired fractions were collected, concentrated and re-purified by prep-HPLC on C18 column (30×250 mm, 10 m) using MeCN/H2O (20% to 100%) to afford two products: P1 as a white solid (the earlier eluted product, 7.4 mg, 7.2%) and P2 as a white solid (the latter eluted product, 32.4 mg, 31% yield).
- PIwas assigned to the cis-isomer Example 130 (3R,6R,7R,8Z,21S)-6′-chloro-7-methoxy-14,14-dioxo-spiro[19-oxa-14-thia-1,11,13-triazatetracyclo[13.7.2.03,6.018,23]tetracosa-8,15,17,23-tetraene-21,1′-tetralin]-12-one. LC-MS calc. for C29H35ClN3O5S [M+H]+: m/z=572.2/574.2; Found: 572.0/573.8. HPLC (cis isomer): C18 column (4.6×150 mm, 5 m); flow rate=1 mL/min; mobile phase: 60% MeCN/H2O (with 0.1% TFA) 1 min, 60% to 95% 7 min, 95% 7 min; λ=220 nm. tR=6.7 min. 1H NMR (600 MHz, DMSO-d6) δ 10.58 (s, 1H), 7.63 (d, J=8.6 Hz, 1H), 7.33 (d, J=7.8 Hz, 1H), 7.29-7.24 (m, 1H), 7.19 (dd, J=8.5, 2.7 Hz, 1H), 7.12-7.05 (m, 1H), 7.02-6.94 (m, 2H), 5.76-5.71 (m, 1H), 5.42 (dd, J=15.9, 7.8 Hz, 1H), 4.22 (q, J=11.5, 11.0 Hz, 1H), 4.14-3.96 (m, 3H), 3.67 (d, J=14.5 Hz, 1H), 3.54-3.47 (m, 1H), 3.47-3.39 (m, 2H), 3.11 (s, 3H), 2.80 (dq, J=16.4, 6.6, 5.5 Hz, 1H), 2.72 (ddt, J=16.6, 10.9, 4.9 Hz, 2H), 2.07-1.95 (m, 3H), 1.95-1.82 (m, 4H), 1.73-1.59 (m, 2H), 1.46 (t, J=12.1 Hz, 2H).
- P2 was assigned to the trans-isomer Example 131 and (3R,6R,7R,8E,21S)-6′-chloro-7-methoxy-14,14-dioxo-spiro[19-oxa-14-thia-1,11,13-triazatetracyclo[13.7.2.03,6.018,23]tetracosa-8,15,17,23-tetraene-21,1′-tetralin]-12-one. LC-MS calc. for C29H35ClN3O5S [M+H]+: m/z=572.2/574.2; Found: 571.9/573.7. HPLC (trans isomer): C18 column (4.6×150 mm, 5 m); flow rate=1 mL/min; mobile phase: 60% MeCN/H2O (with 0.1% TFA) 1 min, 60% to 95% 7 min, 95% 7 min; λ=220 nm. tR=9.6 min. 1H NMR (600 MHz, DMSO-d6) δ 10.54 (s, 1H), 7.68 (d, J=8.6 Hz, 1H), 7.27 (dd, J=8.5, 2.4 Hz, 1H), 7.21-7.11 (m, 3H), 7.05 (d, J=8.3 Hz, 1H), 6.99 (d, J=2.2 Hz, 1H), 5.66 (dt, J=15.8, 3.9 Hz, 1H), 5.40 (ddt, J=15.7, 7.5, 1.9 Hz, 1H), 4.20 (d, J=12.2 Hz, 1H), 4.07 (d, J=12.1 Hz, 1H), 3.88-3.73 (m, 2H), 3.63 (d, J=14.5 Hz, 1H), 3.52 (dd, J=7.4, 5.1 Hz, 1H), 3.42-3.30 (m, 3H), 3.25 (dd, J=14.9, 9.2 Hz, 1H), 3.11 (s, 3H), 2.85-2.77 (m, 1H), 2.73 (q, J=8.3 Hz, 1H), 2.22 (dq, J=8.8, 3.6 Hz, 1H), 2.03 (dt, J=13.5, 4.2 Hz, 1H), 1.92-1.83 (m, 4H), 1.71-1.60 (m, 1H), 1.56-1.42 (m, 2H).
-
- This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7R,8E,12R,22S)-6′-chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 121) and acetaldehyde. LC-MS calc. for C33H43ClN3O5S [M+H]+: m/z=628.25/630.25; Found: 628.0/630.2. 1H NMR (300 MHz, CDCl3) δ 7.70 (d, J=8.5 Hz, 1H), 7.54 (dd, J=8.4, 2.0 Hz, 1H), 7.19 (dd, J=8.5, 2.3 Hz, 1H), 7.09 (d, J=2.0 Hz, 1H), 7.03 (s, 1H), 6.99 (d, J=8.4 Hz, 1H), 5.84-5.68 (m, 1H), 5.48 (dd, J=15.4, 8.5 Hz, 1H), 4.10 (s, 2H), 3.81-3.67 (m, 1H), 3.59 (d, J=14.6 Hz, 2H), 3.48-3.37 (m, 1H), 3.37-3.28 (m, 2H), 3.26 (s, 3H), 3.23-3.13 (m, 1H), 3.05 (dd, J=15.2, 9.3 Hz, 1H), 2.88 (d, J=5.5 Hz, 1H), 2.85-2.64 (m, 4H), 2.51 (d, J=4.0 Hz, 1H), 2.30-2.14 (m, 1H), 1.90 (ddd, J=16.7, 13.7, 6.3 Hz, 4H), 1.74-1.53 (m, 2H), 1.48-1.36 (m, 1H), 1.28 (d, J=7.0 Hz, 4H), 1.10 (t, J=7.1 Hz, 3H).
-
- To a solution of (3R,6R,7R,8E,12R,22S)-6′-chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 87) (32.4 mg, 0.04 mmol) in DCM (0.50 mL) was added acetyl chloride (10.0 μL, 0.14 mmol) at r.t. The mixture was stirred for 10 min. and LC-MS indicated the reaction was completed. The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC on C18 column (30×250 mm, 10 m) with MeCN/H2O (20% to 100%) (w/0.1% TFA) to afford the title product (9.9 mg, 35% yield). LC-MS calc. for C33H41ClN3O6S [M+H]+: m/z=642.23/644.23; Found: 642.0/644.2. 1H NMR (300 MHz, CDCl3) δ 9.62 (d, J=13.2 Hz, 1H), 7.69 (d, J=8.5 Hz, 1H), 7.50 (d, J=8.3 Hz, 1H), 7.37 (d, J=1.9 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.10 (d, J=2.0 Hz, 1H), 7.01 (d, J=8.4 Hz, 1H), 5.44 (dd, J=15.3, 7.2 Hz, 1H), 5.20 (d, J=4.2 Hz, 1H), 5.00 (s, 1H), 4.14 (d, J=9.1 Hz, 2H), 3.84 (ddd, J=23.1, 15.6, 9.4 Hz, 3H), 3.66 (t, J=14.1 Hz, 2H), 3.40-3.19 (m, 3H), 3.19-3.04 (m, 4H), 2.89-2.50 (m, 4H), 2.36 (d, J=5.5 Hz, 1H), 2.15 (d, J=20.1 Hz, 3H), 2.08-1.54 (m, 4H), 1.45 (t, J=11.1 Hz, 4H).
-
- This compound was prepared using procedures analogous to those described for Example 133 using (3R,6R,7R,8E,12R,22S)-6′-chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 121) and methyl chloroformate. LC-MS calc. for C33H41ClN3O7S [M+H]+: m/z=658.23/660.23; Found: 658.4/660.3. 1H NMR (600 MHz, CDCl3) δ 7.68 (d, J=8.5 Hz, 1H), 7.49 (s, 1H), 7.29 (d, J=15.1 Hz, 1H), 7.17 (d, J=8.5 Hz, 1H), 7.08 (d, J=1.9 Hz, 1H), 6.99 (s, 1H), 5.48 (s, 1H), 4.57 (s, 1H), 4.09 (dd, J=30.4, 11.9 Hz, 2H), 3.90-3.80 (m, 1H), 3.80-3.60 (m, 6H), 3.25 (dd, J=27.0, 13.3 Hz, 2H), 3.19-3.09 (m, 2H), 3.07 (s, 1H), 2.84-2.69 (m, 2H), 2.65 (s, 1H), 2.35 (d, J=21.3 Hz, 1H), 1.99 (d, J=11.0 Hz, 1H), 1.97-1.86 (m, 2H), 1.80 (ddd, J=19.4, 16.4, 9.7 Hz, 2H), 1.64 (ddd, J=36.5, 19.0, 9.2 Hz, 5H), 1.45-1.36 (m, 3H), 1.35-1.28 (m, 1H).
-
- This compound was prepared using procedures analogous to those described for Example 133 using (3R,6R,7R,8E,12R,22S)-6′-chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 121) and methanesulfonyl chloride. LC-MS calc. for C32H41ClN3O7S2 [M+H]+: m/z=678.2/680.2; Found: 678.4/680.3.
-
-
- This compound was prepared using procedures analogous to those described for Example 43 Step 2 using (3R)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 7) and 3-allyl-4,4-dimethyl-oxazolidine-2,5-dione (Example 43 Step 1). LC-MS calc. for C34H45ClN30SS [M+H]+: m/z=642.28/644.28; Found: 642.9/644.8.
- This compound was prepared using procedures analogous to those described for Example 26 Step 4 using 2-(allylamino)-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-methoxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-2-methyl-propanamide. LC-MS calc. for C32H41ClN3O5S [M+H]+: m/z=614.24/616.24; Found: 614.8/616.7. 1H NMR (600 MHz, DMSO-d6) δ 7.60 (d, J=8.5 Hz, 1H), 7.22 (dd, J=8.5, 2.3 Hz, 1H), 7.17 (d, J=2.2 Hz, 1H), 7.16 (d, J=1.8 Hz, 1H), 6.96 (s, 1H), 6.85 (d, J=8.2 Hz, 1H), 5.74 (s, 1H), 5.58 (dd, J=15.8, 6.0 Hz, 1H), 4.08-3.85 (m, 3H), 3.48 (d, J=14.3 Hz, 2H), 3.38 (dd, J=14.6, 7.9 Hz, 1H), 3.29-3.24 (m, 2H), 3.20 (s, 3H), 3.15 (dt, J=14.5, 5.0 Hz, 1H), 2.83-2.76 (m, 1H), 2.75-2.68 (m, 1H), 2.64-2.56 (m, 1H), 2.41-2.29 (m, 1H), 2.01 (ddt, J=13.7, 9.0, 4.5 Hz, 2H), 1.91-1.77 (m, 3H), 1.75-1.41 (m, 4H), 1.32 (s, 3H), 1.23 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7S,8E,22S)-6′-chloro-7-methoxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 136) and formaldehyde aqueous solution (37%). LC-MS calc. for C33H43ClN3O5S [M+H]+: m/z=628.25/630.25; Found: 628.7/630.5. 1H NMR (600 MHz, CDCl3) δ 7.66 (d, J=8.5 Hz, 1H), 7.53-7.43 (m, 1H), 7.16 (dd, J=8.5, 2.3 Hz, 1H), 7.07 (d, J=2.3 Hz, 1H), 6.95 (d, J=8.3 Hz, 1H), 6.92-6.85 (m, 1H), 5.83 (s, 1H), 5.54 (dd, J=15.6, 5.3 Hz, 1H), 5.45-5.19 (m, 1H), 4.07 (q, J=11.9 Hz, 2H), 3.71 (d, J=14.8 Hz, 1H), 3.63 (d, J=5.1 Hz, 1H), 3.35 (s, 4H), 3.07 (dd, J=15.1, 10.3 Hz, 1H), 2.78 (dqt, J=22.2, 10.8, 5.1 Hz, 5H), 2.28 (s, 3H), 2.22 (t, J=7.7 Hz, 1H), 2.03-1.89 (m, 6H), 1.89-1.80 (m, 2H), 1.76 (q, J=8.9 Hz, 2H), 1.63 (ddd, J=18.1, 11.7, 5.4 Hz, 2H), 1.49-1.39 (m, 2H).
-
-
- This compound was prepared using procedures analogous to those described for Example 26 Step 3-4 using [(1R)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] acetate (Intermediate 6) and 1-[allyl(tert-butoxycarbonyl)amino]cyclobutanecarboxylic acid (Example 116 Step 3) in Step 3. LC-MS calc. for C39H49ClN3O8S [M+H]+: m/z=754.29/756.28; Found: 754.0/756.4.
-
- (3R,6R,7R,8E,22S)-6′-chloro-7-acetoxy-11-tert-butoxycarbonyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (40 mg, 0.05 mmol) was stirred in 2 N HCl in EtOAc (3 mL) at r.t. overnight. The reaction was diluted with EtOAc, washed with saturated aqueous NaHCO3solution and brine. The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to afford (3R,6R,7R,8E,22S)-6′-chloro-7-acetoxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (35 mg, 100% yield) which was used for the next step without further purification. LC-MS calc. for C34H41ClN3O6S [M+H]+: m/z=654.23/656.23; Found 654.0/656.2.
-
- To a solution of (3R,6R,7R,8E,22S)-6′-chloro-7-acetoxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (35 mg, 0.05 mmol) in DCE (2 mL) was added two drops of formaldehyde aqueous solution (37% wt %, ca. 22 mg, 0.26 mmol HCHO). After 30 min., sodium cyanoborohydride (16.8 mg, 0.27 mmol) was added in one portion, and stirred at r.t. for 4 h. The reaction was diluted with DCM and water, and filtered through a pad of Celite. The organic layer was washed with saturated aqueous NaHCO3solution and brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by Prep-HPLC on C18 column (30×250 mm, 10 m) with 20 to 100% ACN/H2O (tR=24 min) to afford (3R,6R,7R,8E,22S)-6′-chloro-7-acetoxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (14 mg, 39% yield) as a white product. LC-MS calc. for C35H43ClN3O6S [M+H]+: m/z=668.26/670.25; Found: 668.0/670.3.
- To a solution of (3R,6R,7R,8E,22S)-6′-chloro-7-acetoxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (14.0 mg, 0.02 mmol) in MeOH (0.5 mL) and THF (0.2 mL) was added a solution of potassium carbonate (28.95 mg, 0.21 mmol) in water (0.5 mL) at r.t. After 16 h, LC-MS indicated the completion of reaction. The reaction was extracted with DCM, washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure to afford (3R,6R,7R,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (10 mg, 76% yield), which was sufficiently pure without further purifications. LC-MS calc. for C33H41ClN3O5S [M+H]+: m/z=626.25/628.24; Found: 626.0/628.2. 1H NMR (600 MHz, CDCl3) δ 7.67 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.4, 2.2 Hz, 1H), 7.17 (dd, J=8.5, 2.4 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 6.98 (app d, J=8.3 Hz, 2H), 5.70 (app s, 1H), 5.64-5.55 (m, 1H), 4.12 (d, J=12.2 Hz, 1H), 4.07 (d, J=12.1 Hz, 1H), 4.00 (t, J=7.8 Hz, 1H), 3.73 (d, J=14.7 Hz, 1H), 3.51 (app s, 1H), 3.33 (d, J=14.8 Hz, 1H), 3.05 (dd, J=15.2, 10.0 Hz, 1H), 2.90-2.64 (m, 4H), 2.49 (s, 1H), 2.42 (s, 3H), 2.31-2.23 (m, 1H), 2.18-2.09 (m, 3H), 2.04-1.91 (m, 5H), 1.88-1.78 (m, 1H), 1.75-1.60 (m, 3H), 1.49-1.39 (m, 1H).
-
- This compound was prepared using procedures analogous to those described for Example 34 using (3R,6R,7R,8E,22S)-6′-Chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (Example 138) and N,N-dimethylcarbamoyl chloride. LC-MS calc. for C36H46ClN4O6S [M+H]+: m/z=697.27/699.27; Found 697.9/699.7. 1H NMR (600 MHz, CDCl3) δ 7.70 (d, J=8.5 Hz, 1H), 7.50 (d, J=8.3 Hz, 1H), 7.18 (dd, J=8.5, 2.3 Hz, 1H), 7.07 (d, J=2.3 Hz, 1H), 6.99 (d, J=8.4 Hz, 2H), 5.75 (s, 1H), 5.57 (s, 1H), 5.38-5.31 (m, 1H), 5.01 (s, 1H), 4.12-4.02 (m, 2H), 3.78 (d, J=14.5 Hz, 1H), 3.67 (s, 1H), 3.26 (d, J=14.6 Hz, 1H), 3.02 (dd, J=15.2, 9.9 Hz, 2H), 2.92 (d, J=13.5 Hz, 5H), 2.80-2.71 (m, 2H), 2.52 (s, 1H), 2.37 (s, 3H), 2.27 (s, 1H), 2.22 (t, J=7.7 Hz, 1H), 2.15 (d, J=20.7 Hz, 1H), 2.07-1.98 (m, 4H), 1.98-1.90 (m, 3H), 1.90-1.76 (m, 4H), 1.41 (t, J=12.7 Hz, 2H).
-
- To a solution of (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (20 mg, 0.03 mmol, Example 32) in THF (0.25 mL) was added NaH (5.3 mg, 0.13 mmol, 60% suspension on mineral oil). The reaction was stirred at 0° C. for 30 min., and 2-bromo-N,N-dimethyl-acetamide (33 mg, 0.20 mmol) was added. The reaction was slowly warmed to r.t. over 4 h. The reaction was quenched with saturated NH4Cl and diluted with EtOAc (3.0 mL). The organic layer separated, washed with water and brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by Prep-HPLC on a C18 column with H2O:MeCN (20% to 100%) to afford 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxy-N,N-dimethyl-acetamide (12 mg, 52% yield). LC-MS calc. for C35H45ClN3O7S [M+H]+: m/z=686.2/688.2; Found: 686.8/688.8.
-
- This compound was prepared using procedures analogous to those described for Example 140 using (3R,6R,7R,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 36). LC-MS calc. for C35H45ClN3O7S [M+H]+: m/z=686.2/688.2; Found: 686.7/688.8.
-
- This compound was prepared using procedures analogous to those described for Example 140 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-ethylene-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 40). LC-MS calc. for C35H43ClN3O7S [M+H]+: m/z=684.2/686.2; Found: 684.7/686.9.
-
- This compound was prepared using procedures analogous to those described for Example 140 using (3R,6R,7R,8E,22S)-6′-chloro-7-hydroxy-12,12-ethylene-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 38). LC-MS calc. for C35H43ClN3O7S [M+H]+: m/z=684.2/686.2; Found: 684.7/687.0.
-
- Step 1: (3S)-5-[[(1R,2R)-2-[(S)-f-[tert-butyl(dimethyl)silyl]oxyallyl]cyclobutyl]methyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide
- To a stirred solution of (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl] spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (300 mg, 0.60 mmol, Intermediate 3) in DMF (5 mL) was added TBSCl (224 mg, 1.49 mmol) and imidazole (203 mg, 2.98 mmol). The resulting solution was stirred at 20° C. overnight. The reaction was quenched with water (15 mL), and extracted with EtOAc (20 mL×3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (2% to 75%) to afford (3S)-5-[[(1R,2R)-2-[(1S)-1-[tert-butyl(dimethyl)silyl]oxyallyl]cyclobutyl]methyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (315 mg, 85% yield) as a white solid. LC-MS calc. for C32H46ClN204SiS [M+H]+: m/z=617.3/619.3; Found 617.5/619.8.
-
- A solution of (3S)-5-[[(1R,2R)-2-[(1S)-1-[tert-butyl(dimethyl)silyl]oxyallyl]cyclobutyl]methyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (315 mg, 0.51 mmol), (2R)-2-[allyl(tert-butoxycarbonyl)amino]propanoic acid (233 mg, 1.02 mmol, Example 121 Step 1) in DCM (3 mL) was added DMAP (206 mg, 2.04 mmol) and EDCI (195 mg, 1.02 mmol) at r.t. The mixture was stirred for 3 h. The reaction was diluted with DCM (10 mL), washed with 1 N HCl (3 mL) and brine, dried over Na2SO4, filtered and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (2% to 50%) to afford tert-butyl N-allyl-N-[(1R)-2-[[(3S)-5-[[(1R,2R)-2-[(1S)-1-[tert-butyl(dimethyl)silyl]oxyallyl]cyclobutyl]methyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]-1-methyl-2-oxo-ethyl]carbamate (264 mg, 62% yield) as a white solid. LC-MS calc. for C43H63ClN3O7SiS [M+H]+: m/z=828.4/830.4; Found 828.9/830.9.
-
- To a stirred solution of tert-butyl N-allyl-N-[(1R)-2-[[(3S)-5-[[(1R,2R)-2-[(1S)-1-[tert-butyl(dimethyl)silyl]oxyallyl]cyclobutyl]methyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]-1-methyl-2-oxo-ethyl]carbamate (230 mg, 0.28 mmol) in THF (10 mL) was added TBAF (725 mg, 2.78 mmol, 1 M in THF, pre-treated with molecular sieve). The resulting solution was stirred at 20° C. overnight. The reaction was quenched with sat. NH4Cl aq. Solution (10 mL), and extracted with EtOAc (20 mL×3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (2% to 60%) to afford tert-butyl N-allyl-N-[(1R)-2-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]-1-methyl-2-oxo-ethyl]carbamate (190 mg, 95% yield). LC-MS calc. for C37H49ClN3O7S [M+H]+: m/z=714.3/716.3; Found 714.8/717.0.
-
- A solution of tert-butyl N-allyl-N-[(1R)-2-[[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]-1-methyl-2-oxo-ethyl]carbamate (260 mg, 0.36 mmol) in DCE (200 mL) was bubbled with N2 for 30 min. 1,3-Bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidene[2-(i-propoxy)-5-(N,N-dimethylaminosulfonyl)phenyl]-methyleneruthenium(II)dichloride (Zhan-catalyst-1B) (53.42 mg, 0.07 mmol) was added and the reaction mixture was further bubbled with N2 for 30 min, and was heated to 40° C. under N2 for 3 h. LC-MS analysis indicated the completion of reaction. The reaction was cool to r.t. while being exposed to air. The reaction was concentrated under reduced pressure, and the residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (2% to 50%) to afford two products: P1 (the earlier eluted product, 110 mg, 44.0% yield) as a light brown colored solid and P2 (the latter eluted product, 90 mg, 0.13 mmol, 36% yield) as a light brown colored solid.
- P1 was assigned to the trans-isomer tert-butyl (3R,6R,7S,8E,12R,22S)-6′-chloro-7-hydroxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-11-carboxylate. LC-MS calc. for C35H45ClN3O7S [M+H]+: m/z=686.3/688.3; Found: 686.8/688.3.
- And P2 was assigned to the cis-isomer tert-butyl (3R,6R,7S,8Z,12R,22S)-6′-chloro-7-hydroxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-11-carboxylate. LC-MS calc. for C35H45ClN3O7S [M+H]+: m/z=686.3/688.3; Found: 686.8/688.3.
-
- A solution of tert-butyl (3R,6R,7S,8E,12R,22S)-6′-chloro-7-hydroxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-11-carboxylate (110.0 mg, 0.16 mmol, P1 from Step 4) in DCE (2 mL) was added phosphoric acid (3.0 mL, 51 mmol) and the resulting solution was stirred at 20° C. overnight. LC-MS analysis indicated the completion of reaction. The reaction was quenched with aq. 1M NaOH solution (20 mL) and extracted with DCM (10 mL×2). The combined organic layers were concentrated under reduced pressure to afford (3R,6R,7S,8E,12R,22S)-6′-chloro-7-hydroxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.0˜3,6.0˜19,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (87 mg, 92% yield) as a light brown colored solid. LC-MS calc. for C30H37ClN3O5S [M+H]+: m/z=586.2/588.2; Found: 586.7/588.6.
- This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7S,8E,12R,22S)-6′-chloro-7-hydroxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one and formaldehyde aqueous solution (37%). LC-MS calc. for C31H39ClN3O5S [M+H]+: m/z=600.2/602.2; Found: 600.6/602.8. 1H NMR (600 MHz, CDCl3) δ 7.69 (s, 1H), 7.01 (d, J=28.3 Hz, 2H), 6.69 (d, J=141.3 Hz, 2H), 6.20 (s, 1H), 5.63 (d, J=15.5 Hz, 1H), 5.43-5.24 (m, 1H), 4.11 (s, 1H), 4.05-3.69 (m, 3H), 3.59-3.46 (m, 1H), 3.25-3.06 (m, 2H), 2.79 (d, J=83.6 Hz, 5H), 2.31 (s, 3H), 2.24-2.19 (m, 1H), 2.08-1.93 (m, 3H), 1.83 (s, 3H), 1.59 (d, J=56.9 Hz, 4H), 1.44 (d, J=7.6 Hz, 2H).
-
- This compound was prepared using procedures analogous to those described for Example 34 using (3R,6R,7S,8E,12R,22S)-6′-chloro-7-hydroxy-11,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one and N,N-dimethylcarbamoyl chloride. LC-MS calc. for C34H44ClN4O6S [M+H]+: m/z=671.3/673.3; Found: 671.7/673.9. 1H NMR (300 MHz, CDCl3) δ 7.65 (d, J=8.6 Hz, 1H), 7.51 (d, J=8.3 Hz, 1H), 7.18 (dd, J=8.5, 2.3 Hz, 1H), 7.13-6.88 (m, 3H), 5.84-5.46 (m, 2H), 5.30 (d, J=4.3 Hz, 1H), 4.32-3.97 (m, 3H), 3.67 (d, J=14.5 Hz, 2H), 3.42-3.28 (m, 2H), 2.95 (d, J=6.1 Hz, 6H), 2.79 (p, J=6.2, 4.7 Hz, 3H), 2.64 (s, 3H), 2.54-2.36 (m, 2H), 2.16-1.73 (m, 7H), 1.68-1.48 (m, 3H), 1.35 (s, 3H).
-
-
- This compound was prepared using procedures analogous to those described for Example 34 using tert-butyl (3R,6R,7S,8E,12R,22S)-6′-chloro-7-hydroxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-11-carboxylate (P1 Example 144 Step 4) and N,N-dimethylcarbamoyl chloride. LC-MS calc. for C38H50ClN4O8S [M+H]+: m/z=757.30/759.30; Found: 758.04/760.12.
- This compound was prepared using procedures analogous to those described for Example 144 Step 5 using tert-butyl (3R,6R,7S,8E,12R,22S)-6′-chloro-7-(dimethylcarbamoyloxy)-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-11-carboxylate and phosphoric acid. LC-MS calc. for C33H42ClN4O6S [M+H]+: m/z=657.24/659.24; Found: 657.73/659.70. 1H NMR (300 MHz, CDCl3) δ 7.67 (dd, J=8.6, 4.5 Hz, 1H), 7.43-7.33 (m, 1H), 7.29 (s, 1H), 7.20-7.06 (m, 3H), 6.94 (dd, J=8.4, 4.6 Hz, 1H), 5.76-5.52 (m, 2H), 5.15 (t, J=4.6 Hz, 1H), 4.23-3.97 (m, 2H), 3.63 (dd, J=14.5, 9.7 Hz, 2H), 3.54-3.25 (m, 5H), 2.86 (s, 3H), 2.80-2.72 (m, 4H), 2.67-2.47 (m, 3H), 2.23 (t, J=7.4 Hz, 2H), 2.02-1.75 (m, 6H), 1.47 (d, J=6.7 Hz, 4H).
-
-
- The compounds were prepared using procedures analogous to those described for Example 32 Step 1-3 using (3S)6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 3) and (2S)-2-[allyl(tert butoxycarbonyl)amino]propanoic acid (Example 85 Step 1) in Step 1. The reaction mixture was purified by flash chromatography on a silica gel column with EtOAc/Heptanes (3% to 50%) to afford two products: P1 (the earlier eluted product) was assigned to the Z-isomer tert-butyl (3R,6R,7S,8Z,12S,22S)-6′-chloro-7-hydroxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-11-carboxylate and P2 (the latter eluted product) was assigned to the E-isomer tert-butyl (3R,6R,7S,8E,12S,22S)-6′-chloro-7-hydroxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-11-carboxylate. LC-MS calc. for C35H45ClN3O7S [M+H]+: m/z=686.2/688.2; Found: 686.7/688.1.
-
- This compound was prepared using procedures analogous to those described for Example 144 Step 5 using tert-butyl(3R,6R,7S,8E,12S,22S)-6′-chloro-7-hydroxy-12-methyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-11-carboxylate (P2 Step 1) and phosphoric acid (85% solution in water). LC-MS calc. for C30H37ClN30SS [M+H]+: m/z=586.2/588.2; Found: 586.6/588.6.
-
- The compounds were prepared using procedures analogous to those described for Example 27using (3R,6R,7S,8E,12S,22S)-6′-chloro-7-hydroxy-12-methyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one and formaldehyde aqueous solution (37%). LC-MS calc. for C31H39ClN3O5S [M+H]+: m/z=600.2/602.2; Found: 600.8/602.6.
- The compounds were prepared using procedures analogous to those described for Example 34 using (3R,6R,7S,8E,12S,22S)-6′-chloro-7-hydroxy-11,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one and N,N-dimethylcarbamoyl chloride. LC-MS calc. for C34H44ClN4O6S [M+H]+: m/z=671.26/673.26; Found: 671.7/673.8.
-
- This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (2.8 g, 4.66 mmol, Example 32) in Step 1 and 2-piperazin-1-ylethanol in Step 2. LC-MS calc. for C38H50ClN4O8S [M+H]+: m/z=757.30/759.30; Found: 757.7/759.7. 1H NMR (300 MHz, CDCl3) δ 7.68 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.0 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.10 (d, J=2.0 Hz, 1H), 6.98 (dd, J=7.6, 5.2 Hz, 2H), 5.91-5.78 (m, 1H), 5.71 (dd, J=15.7, 4.9 Hz, 1H), 5.33 (d, J=9.1 Hz, 1H), 4.12 (dt, J=13.9, 9.6 Hz, 4H), 3.80-3.67 (m, 2H), 3.67-3.61 (m, 2H), 3.47 (d, J=4.4 Hz, 1H), 3.41 (s, 1H), 3.37 (d, J=14.6 Hz, 1H), 3.21 (dd, J=15.0, 9.3 Hz, 2H), 2.87-2.67 (m, 5H), 2.61-2.55 (m, 3H), 2.45-2.33 (m, 3H), 1.99 (dd, J=24.2, 8.9 Hz, 4H), 1.89-1.72 (m, 4H), 1.64 (t, J=9.4 Hz, 2H), 1.50 (d, J=12.7 Hz, 1H), 1.45 (s, 3H), 1.37 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using 2-(4-methylpiperazin-1-yl)ethanamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LC-MS calc. for C39H53ClN5O7S [M+H]+: m/z=770.34/772.34; Found: 770.7/772.7. 1H NMVR (300 MHz, CDCl3) δ 7.71 (d, J=8.5 Hz, 1H), 7.39 (d, J=8.3 Hz, 1H), 7.19 (dd, J=8.5, 2.1 Hz, 1H), 7.09 (s, 2H), 6.93 (d, J=8.3 Hz, 1H), 6.82 (d, J=8.3 Hz, 1H), 6.49 (s, 1H), 6.18 (d, J=15.2 Hz, 1H), 5.58 (d, J=15.6 Hz, 1H), 5.18 (s, 1H), 4.20-4.02 (m, 4H), 3.66 (dd, J=34.7, 13.8 Hz, 3H), 3.30 (dd, J=17.0, 9.0 Hz, 2H), 3.01 (d, J=14.9 Hz, 5H), 2.80 (d, J=12.3 Hz, 7H), 2.39 (s, 3H), 2.32-2.18 (m, 2H), 1.88 (ddd, J=27.1, 21.1, 12.4 Hz, 6H), 1.59 (dd, J=18.3, 8.8 Hz, 3H), 1.39 (d, J=2.5 Hz, 6H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using 1-(2-aminoethyl)piperidin-4-ol to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C39H52ClN4O8S [M+H]+: m/z=771.32/773.32; Found: 771.8/773.8. 1H NMR (300 MHz, CDCl3) δ 7.73 (d, J=8.5 Hz, 1H), 7.30 (d, J=8.4 Hz, 1H), 7.18 (dd, J=8.4, 2.1 Hz, 2H), 7.14-7.06 (m, 2H), 6.88 (d, J=8.2 Hz, 1H), 6.82 (d, J=8.0 Hz, 1H), 6.41-6.26 (m, 1H), 5.50 (d, J=15.8 Hz, 1H), 5.14 (s, 1H), 4.30 (dd, J=14.9, 4.9 Hz, 1H), 4.23-4.08 (m, 2H), 4.04 (d, J=12.6 Hz, 2H), 3.84 (dd, J=15.6, 10.5 Hz, 2H), 3.77-3.63 (m, 3H), 3.30 (dd, J=39.0, 12.7 Hz, 3H), 2.97 (dt, J=25.5, 13.4 Hz, 5H), 2.85-2.32 (m, 4H), 2.19 (dd, J=17.7, 8.8 Hz, 2H), 1.94 (dt, J=22.0, 14.6 Hz, 6H), 1.85-1.68 (m, 4H), 1.67-1.48 (m, 3H), 1.37 (d, J=8.6 Hz, 6H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using (3S)-1-methylpyrrolidin-3-amine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C37H48ClN4O7S [M+H]+: m/z=727.3/729.3; Found: 727.5/729.2. 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J=8.5 Hz, 1H), 7.31 (dd, J=8.3, 2.0 Hz, 1H), 7.17 (dd, J=8.5, 2.2 Hz, 1H), 7.07 (dd, J=4.2, 2.2 Hz, 2H), 6.87 (d, J=8.2 Hz, 1H), 6.42-6.12 (m, 1H), 5.47 (dd, J=15.8, 2.6 Hz, 1H), 5.08 (s, 1H), 4.47-4.28 (m, 2H), 4.13-4.00 (m, 3H), 3.87 (d, J=11.6 Hz, 1H), 3.77-3.59 (m, 2H), 3.21 (d, J=14.3 Hz, 1H), 3.07-2.85 (m, 6H), 2.80-2.66 (m, 7H), 2.48 (ddd, J=14.3, 7.1, 3.1 Hz, 1H), 2.21-2.13 (m, 2H), 2.05-1.85 (m, 3H), 1.77 (td, J=9.3, 8.9, 3.0 Hz, 2H), 1.59-1.48 (m, 1H), 1.36 (s, 3H), 1.33 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using (3R)-1-methylpyrrolidin-3-amine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C37H48ClN4O7S [M+H]+: m/z=727.3/729.3; Found: 727.6/729.3. 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J=8.4 Hz, 1H), 7.32 (dd, J=8.1, 2.1 Hz, 1H), 7.17 (dd, J=8.5, 2.4 Hz, 1H), 7.11-7.03 (m, 2H), 6.87 (d, J=8.2 Hz, 1H), 6.27 (dd, J=14.3, 6.9 Hz, 1H), 5.63-5.38 (m, 1H), 5.06 (s, 1H), 4.31 (td, J=13.4, 12.5, 5.2 Hz, 2H), 4.19-3.97 (m, 3H), 3.81-3.57 (m, 3H), 3.22 (d, J=14.4 Hz, 1H), 3.03-2.33 (m, 17H), 2.18 (q, J=8.9, 7.3 Hz, 1H), 2.04-1.72 (m, 5H), 1.54 (p, J=9.2 Hz, 1H), 1.37 (s, 3H), 1.34 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using 3-hydroxyazetidine-1-carboxylate to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C35H43ClN3O8S [M+H]+: m/z=700.24/702.24; Found: 700.3/702.0. 1H NMR (300 MHz, CDCl3) δ 7.66 (d, J=8.5 Hz, 1H), 7.48-7.31 (m, 1H), 7.20-7.02 (m, 2H), 6.99-6.75 (m, 2H), 6.26 (s, 1H), 5.64 (d, J=15.2 Hz, 1H), 5.09 (s, 1H), 4.55 (s, 1H), 4.43-4.16 (m, 2H), 4.10-4.00 (m, 4H), 3.81 (d, J=12.8 Hz, 1H), 3.70 (d, J=14.7 Hz, 1H), 3.62-3.44 (m, 1H), 3.41-3.34 (m, 2H), 3.01 (q, J=7.4 Hz, 2H), 2.75 (d, J=10.5 Hz, 4H), 2.20 (q, J=7.3, 5.5 Hz, 1H), 1.99-1.75 (m, 4H), 1.61 (q, J=9.3 Hz, 1H), 1.40-1.27 (m, 9H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using (3S)—N,N-dimethylpyrrolidin-3-amine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C35H50ClN4O7S [M+H]+: m/z=741.3/743.3; Found: 741.4/743.2. 1H NMR (499 MHz, DMSO-d6) δ 7.67 (dd, J=8.6, 3.4 Hz, 1H), 7.27 (dt, J=8.6, 2.0 Hz, 1H), 7.18 (d, J=2.4 Hz, 1H), 7.10 (dd, J=8.2, 2.0 Hz, 1H), 6.92-6.79 (m, 2H), 6.22 (s, 1H), 5.71-5.21 (m, 2H), 5.10 (d, J=32.3 Hz, 1H), 4.02 (d, J=5.9 Hz, 2H), 3.87 (d, J=9.4 Hz, 1H), 3.57 (d, J=13.5 Hz, 6H), 3.13-2.99 (m, 2H), 2.86-2.64 (m, 4H), 2.29 (d, J=35.6 Hz, 5H), 2.13-1.91 (m, 4H), 1.86 (d, J=7.5 Hz, 4H), 1.67 (dd, J=21.5, 12.4 Hz, 3H), 1.45 (q, J=12.9, 10.8 Hz, 2H), 1.22 (s, 3H), 1.12 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using N′,N′-dimethylethane-1,2-diamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C36H48ClN4O7S [M+H]+: m/z=715.29/717.29; Found: 715.4/717.2. 1H NMR (499 MHz, DMSO-d6) δ 7.67 (d, J=8.6 Hz, 1H), 7.28 (dd, J=8.5, 2.4 Hz, 1H), 7.18 (d, J=2.4 Hz, 1H), 7.15-7.00 (m, 2H), 6.95 (d, J=2.1 Hz, 1H), 6.85 (d, J=8.1 Hz, 1H), 6.28 (s, 1H), 5.48 (dd, J=16.1, 3.7 Hz, 1H), 4.92 (s, 1H), 4.10-3.95 (m, 2H), 3.89 (dd, J=14.0, 7.7 Hz, 1H), 3.77 (s, 1H), 3.55 (d, J=14.2 Hz, 2H), 3.27-3.12 (m, 4H), 3.12-3.00 (m, 2H), 2.86-2.56 (m, 7H), 2.44-2.24 (m, 2H), 2.15-1.90 (m, 2H), 1.84 (dd, J=14.0, 7.6 Hz, 3H), 1.67 (ddd, J=43.0, 21.1, 12.2 Hz, 3H), 1.45 (dt, J=26.0, 9.4 Hz, 2H), 1.21 (s, 3H), 1.13 (s, 3H).
-
-
- This compound was prepared using procedures analogous to those described for Example 46 using tert-butyl N-(azetidin-3-yl)-N-methyl-carbamate to replace 1-(2-methoxyethyl)piperazine in Step 2. The reaction mixture was concentrated under reduced pressure and the residue was directly used for the next step. LC-MS: calcd. for C41H54ClN409S [M+H]+: m/z=813.3/815.3; Found: 813.7/815.5.
- To a solution of [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.0-3,6.0˜-19,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-[tert-butoxycarbonyl(methyl)amino]azetidine-1-carboxylate (30.0 mg, 0.04 mmol) in IPA (1 mL) and DCM (0.10 mL) was added phosphoric acid (0.5 mL, 8.6 mmol). The resulting solution was vigorously stirred at 20° C. for 3 h. The reaction mixture was quenched with 1M NaOH aqueous solution and extracted with DCM (2×2 mL). The combined organic layers were concentrated under reduced pressure. The residue was purified by prep-HPLC on C18 column (30×250 mm, 10 m) with MeOH/H2O (15% to 100%) to afford [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-(methylamino)azetidine-1-carboxylate (16.8 mg, 63.9% yield) as a white solid. LCMS calc. for C36H46ClN4O7S [M+H]+: m/z=713.28/715.28; Found: 713.4/715.3. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.53-7.37 (m, 1H), 7.22-7.05 (m, 3H), 7.00-6.78 (m, 2H), 5.67 (dd, J=15.9, 4.2 Hz, 1H), 5.11 (s, 1H), 4.32-4.00 (m, 6H), 3.85-3.66 (m, 3H), 3.59 (s, 2H), 3.39 (t, J=17.0 Hz, 3H), 3.22-3.07 (m, 3H), 2.79 (s, 3H), 2.56-2.35 (m, 3H), 2.23 (t, J=7.6 Hz, 1H), 2.09-1.72 (m, 6H), 1.45 (s, 3H), 1.33 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 156 using tert-butyl N-(2-aminoethyl)-N-methyl-carbamate to replace 4-amino-1-boc-piperidine in Step 1. LCMS calc. for C35H46ClN4O7S [M+H]+: m/z=701.28/703.28; Found 701.4/703.3. 1H NMR (499 MHz, DMSO-d6) δ 7.65 (dd, J=8.8, 4.1 Hz, 1H), 7.27 (dd, J=8.5, 2.4 Hz, 1H), 7.17 (d, J=2.2 Hz, 1H), 7.06 (dd, J=8.2, 1.9 Hz, 1H), 7.02-6.87 (m, 2H), 6.84 (d, J=8.1 Hz, 1H), 6.55-6.15 (m, 1H), 5.65-4.77 (m, 2H), 4.00 (s, 2H), 3.89 (d, J=6.0 Hz, 2H), 3.66-3.50 (m, 2H), 3.19 (dd, J=24.7, 13.1 Hz, 3H), 3.11-2.93 (m, 3H), 2.80 (d, J=18.4 Hz, 2H), 2.76-2.59 (m, 4H), 2.29 (d, J=8.7 Hz, 1H), 2.00 (ddd, J=21.8, 12.3, 6.1 Hz, 2H), 1.90-1.76 (m, 3H), 1.76-1.56 (m, 3H), 1.49-1.34 (m, 2H), 1.23-1.18 (m, 3H), 1.12 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using 2,2-dimethylmorpholine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C37H45ClN3O8S [M+H]+: m/z=742.29/744.29; Found: 742.6/744.6. 1H NMR (499 MHz, DMSO-d6) δ 7.64 (d, J=8.6 Hz, 1H), 7.25 (ddd, J=8.5, 6.1, 2.3 Hz, 2H), 7.18 (d, J=2.4 Hz, 1H), 7.06-6.92 (m, 2H), 6.51 (s, 1H), 5.67 (s, 1H), 5.33 (td, J=4.5, 2.2 Hz, 1H), 5.18 (s, 1H), 4.18-4.03 (m, 3H), 4.01-3.86 (m, 1H), 3.64-3.49 (m, 4H), 3.31-3.15 (m, 2H), 2.83-2.62 (m, 3H), 2.41-2.14 (m, 1H), 2.05-1.94 (m, 4H), 1.83 (d, J=4.7 Hz, 3H), 1.68 (ddt, J=44.8, 18.3, 8.4 Hz, 3H), 1.55-1.43 (m, 3H), 1.39 (s, 2H), 1.22 (s, 3H), 1,14-1.07 (m, 5H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using 2-methoxy-N-methyl-ethanamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C36H47ClN3O8S [M+H]+: m/z=716.27/718.27; Found: 716.6/718.6. 1H NMR (499 MHz, DMSO-d6) δ 7.69-7.62 (m, 1H), 7.33-7.23 (m, 2H), 7.20 (dd, J=5.6, 2.4 Hz, 2H), 6.94 (s, 2H), 5.73 (d, J=39.4 Hz, 1H), 5.39-5.05 (m, 1H), 4.23-3.83 (m, 3H), 3.66-3.52 (m, 2H), 3.46 (s, 3H), 3.25 (d, J=12.2 Hz, 4H), 3.16-3.07 (m, 1H), 2.97 (d, J=21.7 Hz, 1H), 2.91-2.63 (m, 5H), 2.60 (s, 1H), 2.47-2.20 (m, 2H), 2.01 (dt, J=18.3, 7.8 Hz, 3H), 1.86 (s, 3H), 1.78-1.59 (m, 3H), 1.57-1.42 (m, 2H), 1.42-1.33 (m, 2H), 1.20-1.12 (m, 2H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using (2S)-2-(methoxymethyl)pyrrolidine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C38H49ClN3O8S [M+H]+: m/z=742.29/744.28; Found: 742.5/744.5. 1H NMR (499 MHz, DMSO-d6) δ 7.64 (d, J=8.5 Hz, 1H), 7.28-7.21 (m, 2H), 7.19-7.16 (m, 1H), 7.02 (d, J=8.3 Hz, 1H), 6.98-6.94 (m, 1H), 6.65 (s, 1H), 5.72-5.67 (m, 1H), 5.21-5.15 (m, 1H), 4.09 (t, J=15.3 Hz, 2H), 3.94 (d, J=15.4 Hz, 1H), 3.86-3.83 (m, 1H), 3.56 (d, J=14.9 Hz, 1H), 3.28-3.15 (m, 7H), 2.80-2.72 (m, 2H), 2.04-1.94 (m, 5H), 1.83-1.77 (m, 6H), 1.49-1.46 (m, 2H), 1.42-1.38 (m, 2H), 1.28-1.22 (m, 10H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using (2R)-2-(methoxymethyl)pyrrolidine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C38H49ClN3O8S [M+H]+: m/z=742.29/744.28; Found: 742.5/744.5.
-
- This compound was prepared using procedures analogous to those described for Example 46 using (3S)-3-ethoxypyrrolidine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C83H49ClN3O8S [M+H]+: m/z=742.29/744.28; Found: 742.6/744.6. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.34 (t, J=7.2 Hz, 1H), 7.13 (dt, J=8.6, 2.2 Hz, 1H), 7.06 (d, J=2.2 Hz, 1H), 6.99 (s, 1H), 6.84 (dd, J=8.3, 4.0 Hz, 1H), 6.13 (s, 1H), 5.70 (dt, J=14.7, 6.4 Hz, 1H), 5.17 (d, J=4.6 Hz, 1H), 4.08-3.93 (m, 4H), 3.84 (d, J=13.0 Hz, 1H), 3.67 (d, J=14.4 Hz, 1H), 3.50-3.42 (m, 7H), 3.25 (d, J=14.3 Hz, 1H), 3.15-3.01 (m, 1H), 2.75 (q, J=5.2 Hz, 2H), 2.37-2.30 (m, 1H), 2.21 (t, J=7.6 Hz, 1H), 2.02-1.86 (m, 5H), 1.81-1.75 (m, 3H), 1.62-1.54 (m, 1H), 1.34-1.15 (m, 11H).
-
- This compound was prepared using procedures analogous to those described for Example 156 using tert-butyl N-methyl-N-[(3S)-pyrrolidin-3-yl]carbamate to replace 4-amino-1-boc-piperidine in Step 1. LCMS calc. for C37H48ClN4O7S [M+H]+: m/z=727.3/729.3; Found: 727.5/729.3. 1H NMR (300 MHz, CDCl3) δ 7.70 (d, J=8.5 Hz, 1H), 7.40 (dd, J=8.3, 2.0 Hz, 1H), 7.16 (dd, J=8.5, 2.3 Hz, 1H), 7.06 (d, J=2.3 Hz, 1H), 6.89 (d, J=8.3 Hz, 1H), 6.81 (d, J=2.2 Hz, 1H), 6.29 (td, J=10.4, 9.0, 4.9 Hz, 1H), 5.64 (dt, J=15.9, 2.7 Hz, 1H), 5.09 (s, 1H), 4.36 (d, J=12.4 Hz, 1H), 4.17-3.97 (m, 3H), 3.84 (d, J=13.4 Hz, 1H), 3.76-3.07 (m, 14H), 2.98-2.89 (m, 1H), 2.78 (d, J=8.6 Hz, 3H), 2.34-2.11 (m, 3H), 1.92-1.85 (m, 5H), 1.61 (d, J=6.6 Hz, 1H), 1.38 (s, 3H), 1.32 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 156 using tert-butyl N-methyl-N-[(3R)-pyrrolidin-3-yl]carbamate to replace 4-amino-1-boc-piperidine in Step 1. LCMS calc. for C37H48ClN4O7S [M+H]+: m/z=727.3/729.3; Found: 727.3/729.1. 1H NMR (499 MHz, DMSO-d6) δ 7.65 (d, J=8.5 Hz, 1H), 7.26 (dd, J=8.5, 2.4 Hz, 1H), 7.20-7.13 (m, 1H), 7.10-6.99 (m, 1H), 6.91-6.73 (m, 2H), 6.22-6.17 (m, 1H), 5.54-5.46 (m, 1H), 4.91 (s, 1H), 4.11-3.94 (m, 3H), 3.90-3.78 (m, 2H), 3.70-3.65 (m, 4H), 3.01 (dd, J=16.0, 10.5 Hz, 2H), 2.88-2.67 (m, 4H), 2.67-2.55 (m, 3H), 2.29 (dq, J=15.3, 7.5, 6.3 Hz, 1H), 2.22-2.07 (m, 2H), 2.03-1.92 (m, 2H), 1.89-1.81 (m, 3H), 1.70-1.63 (m, 3H), 1.47-1.34 (m, 1H), 1.24 (s, 3H), 1.18 (s, 3H), 1.08 (d, J=8.4 Hz, 2H) ppm.
-
- This compound was prepared using procedures analogous to those described for Example 46 using 3-Fluoroazetidine hydrochloride and Hunig's Base to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C35H42ClFN3O7S [M+H]+: m/z=702.23/704.23; Found: 702.7/704.7. 1H NMR (300 MHz, CDCl3) δ 9.13 (s, 1H, NH), 7.69 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.10 (d, J=2.1 Hz, 1H), 7.02-6.98 (m, 1H), 6.96 (d, J=1.8 Hz, 1H), 5.88-5.79 (m, 1H), 5.70 (dd, J=15.6, 4.9 Hz, 1H), 5.38 (m, 1H), 5.23 (m, 2H), 4.14 (m, 4H), 3.74 (dd, J=14.1, 8.3 Hz, 2H), 3.37 (d, J=14.5 Hz, 2H), 3.22 (dd, J=15.0, 9.3 Hz, 1H), 2.79 (d, J=4.1 Hz, 3H), 2.41-2.33 (m, 1H), 2.16 (s, 4H), 2.01 (dd, J=16.7, 9.0 Hz, 3H), 1.83 (d, J=8.4 Hz, 2H), 1.64 (dt, J=18.8, 9.3 Hz, 2H), 1.46 (s, 3H), 1.37 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using 3,3-Difluoropyrrolidine hydrochloride and Hunig's base to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C36H43ClF2N3O7S [M+H]+: m/z=734.24/736.24; Found: 734.7/735.7. 1H NMR (600 MHz, DMSO-d6) δ 7.64 (d, J=8.5 Hz, 1H), 7.25 (d, J=8.3 Hz, 2H), 7.18 (s, 1H), 7.05-6.99 (m, 1H), 6.91 (s, 1H), 6.69-6.48 (m, 1H), 5.92-5.62 (m, 2H), 4.15-3.98 (m, 4H), 3.81 (m, 2H), 2.80 (d, J=16.8 Hz, 2H), 2.75-2.64 (m, 6H), 2.44 (s, 2H), 2.06-1.93 (m, 3H), 1.84 (d, J=4.0 Hz, 2H), 1.72 (s, 1H), 1.65 (s, 2H), 1.52-1.44 (m, 2H), 1.38 (s, 3H), 1.22 (s, 3H).
-
- To a solution of (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (30.0 mg, 0.10 mmol, Example 32) in MeCN (3 mL) was added 1,1′-carbonyldiimidazole (24.23 mg, 0.30 mmol). The mixture was stirred at 45° C. for 3 h. LCMS showed that the starting material was consumed. The mixture was concentrated, and the residue was re-dissolved in MeCN (1 mL) and water (1 mL). To the solution was added methoxyamine which was in-situ generated from methoxyamine hydrochloride (10.15 mg, 0.22 mmol) by treatment with 2 drops of 2N NaOH solution. The mixture was stirred at 45° C. overnight. The mixture was cooled down to r.t., 2 drops of 2 N HCl in EA was added and concentrated under reduced pressure. The residue was purified by prep-HPLC on a C18 column using H2O/ACN (20-100%) to afford the desired product [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]N-methoxycarbamate (7.8 mg, 26.8% yield). LCMS calc. for C33H41ClN3O8S [M+H]+: m/z=674.22/675.23; Found: 674.3/674.2; 1H NMR (300 MHz, CDCl3) δ 9.13 (s, 1H, NH), 7.68 (d, J=8.5 Hz, 1H), 7.52 (dt, J=8.5, 2.5 Hz, 1H), 7.19 (d, J=8.5 Hz, 1H), 7.10 (d, J=2.0 Hz, 1H), 7.07-6.97 (m, 2H), 5.78 (t, J=5.8 Hz, 1H), 4.15 (m, 3H), 4.02-3.83 (m, 2H), 3.75 (d, J=8.2 Hz, 2H), 3.50-3.23 (m, 3H), 2.88-2.70 (m, 3H), 2.45-2.33 (m, 1H), 2.10-1.95 (m, 3H), 1.91 (dd, J=12.9, 6.4 Hz, 2H), 1.87-1.80 (m, 3H), 1.69-1.59 (m, 2H), 1.58-1.49 (m, 2H), 1.44 (d, J=3.4 Hz, 3H), 1.38 (d, J=6.2 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using N,N-dimethyl-1-[(2S)-pyrrolidin-2-yl]methanamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C39H52ClN4O7S [M+H]+: m/z=755.32/757.31; Found: 755.5/757.4. 1H NMR (600 MHz, DMSO-d6) δ 9.11 (s, 1H, NH), 7.70 (d, J=8.6 Hz, 1H), 7.32 (td, J=8.0, 2.1 Hz, 2H), 7.25 (d, J=2.2 Hz, 1H), 7.08 (d, J=8.3 Hz, 1H), 7.01 (d, J=19.4 Hz, 1H), 5.75 (s, 2H), 5.24 (s, 1H), 4.17 (dd, J=27.1, 12.1 Hz, 3H), 3.99 (d, J=13.3 Hz, 1H), 3.59 (m, 3H), 3.36-3.22 (m, 5H), 3.15 (s, 1H), 2.92 (s, 3H), 2.87 (s, 3H), 2.85-2.71 (m, 4H), 2.05 (dt, J=12.0, 7.2 Hz, 2H), 1.93 (m, 4H), 1.80 (dd, J=24.4, 7.6 Hz, 2H), 1.69 (m, 2H), 1.62-1.49 (m, 2H), 1.43 (s, 3H), 1.28 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using N,N-dimethyl-1-[(2R)-pyrrolidin-2-yl]methanamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C39H52ClN4O7S [M+H]+: m/z=755.32/757.31; Found: 755.6/757.5. 1H NMR (600 MHz, DMSO-d6) δ 9.14 (s, 1H, NH), 7.65 (d, J=8.5 Hz, 1H), 7.26 (d, J=8.4 Hz, 2H), 7.19 (d, J=1.5 Hz, 1H), 7.02 (d, J=8.4 Hz, 1H), 6.92 (s, 1H), 5.84-5.66 (m, 2H), 5.12 (s, 1H), 4.10 (dd, J=23.8, 12.3 Hz, 3H), 3.96 (dt, J=28.1, 14.1 Hz, 1H), 3.62-3.53 (m, 2H), 3.32-3.20 (m, 6H), 3.14-3.10 (m, 1H), 2.88 (t, J=8.8 Hz, 3H), 2.86-2.82 (m, 3H), 2.80 (dd, J=12.3, 4.1 Hz, 2H), 2.76-2.69 (m, 2H), 2.05-1.96 (m, 2H), 1.86 (m, 6H), 1.76-1.69 (m, 2H), 1.65 (dd, J=18.7, 9.5 Hz, 1H), 1.52-1.46 (m, 1H), 1.38 (d, J=8.7 Hz, 3H), 1.23 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using (1R,5S)-3-oxa-8-azabicyclo[3.2.1]octane hydrochloride and N,N-diisopropylethylaamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C38H47ClN3O8S [M+H]+: m/z=740.27/742.27; Found: 740.5/742.3. 1H NMR (600 MHz, DMSO-d6) δ 7.63 (t, J=8.3 Hz, 1H), 7.25 (d, J=8.2 Hz, 2H), 7.19 (s, 1H), 6.98 (m, 2H), 6.60 (d, J=77.3 Hz, 1H), 5.84-5.51 (m, 2H), 4.26 (m, 2H), 4.09 (dd, J=38.2, 12.5 Hz, 2H), 4.03-3.85 (m, 1H), 3.71-3.46 (m, 4H), 3.25 (s, 3H), 3.06-2.96 (m, 1H), 2.80 (d, J=16.6 Hz, 1H), 2.76-2.64 (m, 2H), 2.05-1.94 (m, 3H), 1.83 (s, 3H), 1.75 (t, J=20.1 Hz, 2H), 1.68-1.57 (m, 4H), 1.52-1.44 (m, 2H), 1.24 (s, 6H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using (9aS)-1,3,4,6,7,8,9,9a-octahydropyrazino[2,1-c][1,4]oxazine; dihydrochloride and diisopropylethylamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C39H50ClN4O8S [M+H]+: m/z=769.3/771.3; Found 769.5/771.5. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.4, 2.2 Hz, 1H), 7.18 (d, J=8.5 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.99 (d, J=8.4 Hz, 2H), 5.90-5.62 (m, 2H), 5.43-5.27 (m, 1H), 4.16-4.00 (m, 4H), 3.95-3.63 (m, 6H), 3.40 (dd, J=22.9, 15.5 Hz, 2H), 3.21 (dd, J=15.4, 9.0 Hz, 2H), 3.06 (t, J=12.7 Hz, 1H), 2.84-2.62 (m, 6H), 2.38 (qd, J=8.9, 3.4 Hz, 2H), 2.25 (q, J=9.2, 7.1 Hz, 2H), 1.99 (tdd, J=14.5, 11.1, 6.4 Hz, 3H), 1.89-1.78 (m, 3H), 1.65 (q, J=9.1 Hz, 2H), 1.44 (s, 3H), 1.37 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using morpholine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C36H45ClN3O8S [M+H]+: m/z=714.26/716.26; Found: 714.7/716.7. 1H NMR (600 MHz, CDCl3) δ 9.03 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.49 (dd, J=8.3, 2.1 Hz, 1H), 7.18 (dd, J=8.5, 2.2 Hz, 1H), 7.09 (d, J=2.0 Hz, 1H), 6.97 (dd, J=17.3, 5.2 Hz, 2H), 5.91-5.63 (m, 2H), 5.35 (s, 1H), 4.27-4.03 (m, 3H), 3.87-3.11 (m, 12H), 2.77 (dd, J=11.1, 5.2 Hz, 3H), 2.39 (dd, J=8.7, 3.3 Hz, 1H), 2.09-1.91 (m, 3H), 1.81 (ddd, J=29.9, 18.4, 9.7 Hz, 3H), 1.70-1.58 (m, 3H), 1.44 (s, 3H), 1.36 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using pyrrolidine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C36H45ClN3O7S [M+H]+: m/z=698.26/700.26; Found: 698.4/700.4. 1H NMR (500 MHz, CDCl3) δ 9.07 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.52-7.44 (m, 1H), 7.17 (dd, J=8.5, 2.3 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 6.98 (dd, J=5.3, 3.0 Hz, 2H), 5.77 (ddd, J=20.5, 16.0, 8.3 Hz, 2H), 5.37-5.33 (m, 2H), 5.30 (s, 1H), 4.07 (dd, J=13.7, 5.9 Hz, 1H), 3.84-3.65 (m, 2H), 3.51-3.44 (m, 2H), 3.37 (d, J=14.9 Hz, 2H), 3.21 (dd, J=14.9, 9.3 Hz, 1H), 2.85-2.71 (m, 3H), 2.36 (dd, J=9.0, 3.7 Hz, 1H), 2.26-2.17 (m, 2H), 2.01 (d, J=6.5 Hz, 4H), 1.89-1.80 (m, 6H), 1.65 (d, J=5.7 Hz, 2H), 1.43 (s, 3H), 1.35 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using azetidine hydrochloride and hunig's base to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C35H41ClN3O7S [M−H]+: m/z=682.24/684.24; Found: 682.7/684.7. 1H NMR (600 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.41 (d, J=28.7 Hz, 1H), 7.15 (d, J=8.4 Hz, 1H), 7.07 (d, J=1.6 Hz, 1H), 6.99 (s, 1H), 6.88 (s, 1H), 6.02 (s, 1H), 5.69 (dd, J=15.6, 5.6 Hz, 1H), 5.34 (d, J=2.9 Hz, 1H), 5.16 (s, 1H), 4.02 (ddd, J=21.9, 18.8, 7.6 Hz, 6H), 3.82 (s, 1H), 3.68 (d, J=14.5 Hz, 1H), 3.49 (s, 1H), 3.39-2.96 (m, 2H), 2.81-2.72 (m, 2H), 2.63 (d, J=10.3 Hz, 1H), 2.34 (qd, J=9.5, 3.2 Hz, 1H), 2.26-2.18 (m, 2H), 2.03-1.96 (m, 4H), 1.91 (dd, J=8.8, 4.0 Hz, 2H), 1.82-1.74 (m, 3H), 1.38 (s, 3H), 1.25 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using (2R)-2-methylpiperazine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C37H48ClN4O7S [M+H]+: m/z=727.29/729.28; Found: 727.5/729.5. 1H NMR (600 MHz, CDCl3) δ 9.65 (s, 1H), 7.63 (dd, J=34.1, 7.2 Hz, 1H), 7.41 (d, J=25.4 Hz, 1H), 7.19-7.04 (m, 2H), 6.93 (d, J=35.6 Hz, 2H), 5.85 (dd, J=202.2, 33.8 Hz, 1H), 5.48-5.05 (m, 1H), 4.31-3.64 (m, 7H), 3.61-3.41 (m, 1H), 3.31 (d, J=14.6 Hz, 1H), 3.19-2.98 (m, 2H), 2.76 (ddd, J=22.2, 17.3, 4.6 Hz, 5H), 2.34 (d, J=7.6 Hz, 2H), 2.27-2.18 (m, 1H), 2.03-1.88 (m, 4H), 1.84-1.70 (m, 4H), 1.63 (d, J=9.9 Hz, 2H), 1.38 (s, 3H), 1.26 (d, J=8.7 Hz, 3H), 1.10 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using (2S)-2-methylpiperazine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C37H48ClN4O7S [M+H]+: m/z=727.29/729.28; Found: 727.5/729.5. 1H NMR (500 MHz, CDCl3) δ 7.67 (d, J=8.5 Hz, 1H), 7.48 (d, J=7.1 Hz, 1H), 7.16 (d, J=8.4 Hz, 1H), 7.09 (dd, J=6.9, 2.2 Hz, 1H), 6.97 (d, J=8.1 Hz, 2H), 5.71 (s, 2H), 5.35 (dd, J=5.7, 3.9 Hz, 2H), 4.13 (t, J=11.9 Hz, 2H), 4.03 (dd, J=22.2, 8.6 Hz, 2H), 3.83-3.64 (m, 2H), 3.44 (d, J=14.9 Hz, 1H), 3.35 (d, J=14.6 Hz, 1H), 3.26-3.12 (m, 1H), 3.00 (d, J=15.0 Hz, 1H), 2.82-2.72 (m, 4H), 2.54 (s, 1H), 2.38 (s, 1H), 2.26-2.15 (m, 1H), 1.97 (dd, J=42.5, 8.6 Hz, 4H), 1.86-1.74 (m, 4H), 1.63 (dd, J=19.1, 9.7 Hz, 2H), 1.48 (t, J=12.2 Hz, 1H), 1.42 (s, 3H), 1.35 (s, 3H), 1.07 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using 1-(2-pyridyl)piperazine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C41H49ClN507S [M+H]+: m/z=790.3/792.3; Found: 790.3/792.3. 1H NMR (600 MHz, CDCl3) δ 9.13 (s, 1H), 8.28 (d, J=4.8 Hz, 1H), 7.82-7.73 (m, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.49 (dd, J=8.3, 2.2 Hz, 1H), 7.18 (dd, J=8.5, 2.2 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 7.00 (d, J=8.3 Hz, 1H), 6.94 (d, J=2.0 Hz, 1H), 6.90-6.77 (m, 2H), 6.01-5.67 (m, 2H), 5.56-5.21 (m, 2H), 4.29-4.02 (m, 3H), 3.83-3.70 (m, 6H), 3.51-3.31 (m, 2H), 3.21 (dd, J=15.1, 9.7 Hz, 1H), 2.84-2.73 (m, 4H), 2.48-2.31 (m, 1H), 2.28-2.19 (m, 1H), 2.10-1.91 (m, 4H), 1.83 (ddd, J=25.5, 18.9, 9.2 Hz, 3H), 1.72-1.59 (m, 2H), 1.44 (s, 3H), 1.36 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using 3-(2-aminoethyl)pyridine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C39H46ClN4O7S [M+H]+: m/z=749.28/751.28; Found: 749.5/751.4. 1H NMR (500 MHz, DMSO-d6) δ 8.58 (s, 2H), 7.96 (d, J=7.4 Hz, 1H), 7.62 (dd, J=22.2, 7.3 Hz, 2H), 7.33-7.23 (m, 2H), 7.19 (d, J=1.9 Hz, 1H), 7.12 (t, J=5.6 Hz, 1H), 7.06-6.96 (m, 2H), 6.92 (s, 1H), 5.81-5.26 (m, 2H), 5.01 (d, J=91.1 Hz, 1H), 4.11 (dd, J=43.7, 12.2 Hz, 3H), 3.90 (dd, J=14.3, 5.9 Hz, 2H), 2.95-2.60 (m, 6H), 2.17-1.45 (m, 10H), 1.40 (s, 3H), 1.24 (s, 6H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using 2,2-difluoroethanamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C34H41ClF2N3O7S [M+H]+: m/z=708.23/710.23; Found: 708.4/710.3. 1H NMR (500 MHz, DMSO-d6) δ 11.66 (s, 1H), 7.65 (d, J=8.4 Hz, 1H), 7.44 (d, J=7.2 Hz, 1H), 7.35-7.13 (m, 4H), 7.05 (t, J=19.8 Hz, 2H), 6.51 (s, 1H), 6.27-5.57 (m, 2H), 5.33 (t, J=4.7 Hz, 1H), 5.04 (s, 1H), 4.33-3.72 (m, 3H), 2.85-2.64 (m, 3H), 2.15-1.44 (m, 10H), 1.39 (s, 2H), 1.24 (s, 8H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using 4-(2-aminoethyl)morpholine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C38H50ClN4O8S [M+H]+: m/z=757.31/759.30; Found: 757.5/759.2.
-
- This compound was prepared using procedures analogous to those described for Example 46 using isopropylamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C35H45ClN3O7S [M+H]+: m/z=686.26/688.26; Found: 686.8/688.8. 1H NMR (600 MHz, CDCl3) δ 8.97 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.1 Hz, 1H), 7.17 (dd, J=8.5, 2.2 Hz, 1H), 7.08 (d, J=1.7 Hz, 2H), 6.99 (d, J=8.3 Hz, 1H), 5.82-5.60 (m, 2H), 5.15 (s, 1H), 4.64 (d, J=7.0 Hz, 1H), 4.13 (dd, J=26.0, 12.2 Hz, 3H), 3.80 (s, 3H), 3.52-3.07 (m, 3H), 2.86-2.63 (m, 3H), 2.35 (d, J=40.1 Hz, 1H), 2.07-1.71 (m, 7H), 1.64 (d, J=10.1 Hz, 1H), 1.42 (s, 3H), 1.37 (s, 3H), 1.17 (d, J=6.3 Hz, 6H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using isobutylamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C36H47ClN3O7S [M+H]+: m/z=700.27/702.27; Found: 700.8/702.6. 1H NMR (600 MHz, CDCl3) δ 9.00 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.1 Hz, 1H), 7.17 (dd, J=8.5, 2.2 Hz, 1H), 7.07 (dd, J=10.3, 1.9 Hz, 2H), 6.99 (d, J=8.3 Hz, 1H), 5.88-5.57 (m, 2H), 5.20 (s, 1H), 4.91 (t, J=5.6 Hz, 1H), 4.27-4.04 (m, 3H), 3.85-3.64 (m, 2H), 3.52-3.28 (m, 2H), 3.23-3.12 (m, 1H), 3.01 (dd, J=13.5, 6.9 Hz, 2H), 2.77 (dd, J=10.5, 5.2 Hz, 3H), 2.37 (dd, J=8.7, 3.9 Hz, 1H), 2.08-1.70 (m, 7H), 1.62 (d, J=9.6 Hz, 2H), 1.42 (s, 3H), 1.37 (s, 3H), 0.92 (d, J=6.7 Hz, 6H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using cyclopropylmethylamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C36H45ClN3O7S [M+H]+: m/z=698.27/700.27; Found: 698.3/700.1.
-
- This compound was prepared using procedures analogous to those described for Example 46 using cyclobutylamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C36H45ClN3O7S [M+H]+: m/z=698.27/700.27; Found: 698.4/700.3. 1H NMR (600 MHz, CDCl3) δ 9.00 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.1 Hz, 1H), 7.17 (dd, J=8.5, 2.2 Hz, 1H), 7.07 (dd, J=10.3, 1.9 Hz, 2H), 6.99 (d, J=8.3 Hz, 1H), 5.88-5.57 (m, 2H), 5.20 (s, 1H), 4.91 (t, J=5.6 Hz, 1H), 4.27-4.04 (m, 3H), 3.85-3.64 (m, 2H), 3.52-3.28 (m, 2H), 3.23-3.12 (m, 1H), 3.01 (dd, J=13.5, 6.9 Hz, 2H), 2.77 (dd, J=10.5, 5.2 Hz, 3H), 2.37 (dd, J=8.7, 3.9 Hz, 1H), 2.08-1.70 (m, 7H), 1.62 (d, J=9.6 Hz, 2H), 1.42 (s, 3H), 1.37 (s, 3H), 0.92 (d, J=6.7 Hz, 6H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using 4-aminotetrahydropyran to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C37H47ClN3O8S [M+H]+: m/z=728.28/730.28; Found: 728.3/730.0. 1H NMR (600 MHz, DMSO-d6) δ 11.66 (s, 1H), 7.65 (d, J=8.5 Hz, 1H), 7.40-6.73 (m, 7H), 6.53 (s, 1H), 5.51 (dd, J=178.9, 11.3 Hz, 2H), 5.02 (s, 1H), 4.28-3.72 (m, 6H), 3.55 (s, 1H), 2.73 (dd, J=24.8, 16.6 Hz, 3H), 2.12-1.49 (m, 12H), 1.43-1.09 (m, 11H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using 1-isopropylpiperazine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C39H52ClN4O7S [M+H]+: m/z=755.32/757.31; Found: 755.5/757.4. 1H NMR (600 MHz, CDCl3) δ 12.87 (s, 1H), 9.15 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.47 (d, J=7.6 Hz, 1H), 7.18 (dd, J=8.5, 2.0 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 7.00 (d, J=8.3 Hz, 1H), 6.86 (s, 1H), 5.90 (t, J=20.4 Hz, 2H), 5.43-5.18 (m, 1H), 4.47-4.01 (m, 5H), 3.89-3.28 (m, 9H), 3.25-2.59 (m, 6H), 2.29 (dt, J=15.3, 8.3 Hz, 2H), 2.17-1.91 (m, 4H), 1.89-1.80 (m, 4H), 1.35 (s, 10H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using 1-(oxetan-3-yl)piperazine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C39H50ClN4O8S [M+H]+: m/z=769.30/71.29; Found: 769.7/771.6. 1H NMR (600 MHz, CDCl3) δ 9.13 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.52-7.40 (m, 1H), 7.18 (dd, J=8.5, 2.2 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.99 (d, J=8.3 Hz, 1H), 6.88 (d, J=2.0 Hz, 1H), 6.01-5.74 (m, 2H), 5.54-5.25 (m, 4H), 4.77 (ddd, J=42.9, 9.0, 4.2 Hz, 3H), 4.31-4.07 (m, 4H), 3.93 (dd, J=33.3, 27.0 Hz, 3H), 3.82-3.29 (m, 7H), 3.19 (dd, J=15.2, 10.0 Hz, 1H), 3.03-2.57 (m, 7H), 2.44-2.18 (m, 5H), 1.45 (s, 6H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using cyclopropylamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C35H43ClN3O7S [M+H]+: m/z=684.24/686.24; Found: 684.4/686.1. 1H NMR (300 MHz, CDCl3) δ 9.04 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.49 (dd, J=8.3, 2.1 Hz, 1H), 7.17 (dd, J=8.5, 2.3 Hz, 1H), 7.11-6.89 (m, 3H), 5.67 (dd, J=16.0, 3.5 Hz, 2H), 5.10 (d, J=55.9 Hz, 1H), 4.32-3.97 (m, 3H), 3.90-3.01 (m, 6H), 2.93-2.16 (m, 5H), 2.08-1.72 (m, 7H), 1.64 (s, 1H), 1.43 (s, 3H), 1.36 (s, 3H), 0.72 (dd, J=6.7, 5.0 Hz, 2H), 0.54 (s, 2H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using methylpiperazine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C37H48ClN4O7S [M+H]+: m/z=727.30/729.29; Found: 727.6/729.2. 1H NMR (499 MHz, CDCl3) δ 7.67 (d, J=8.5 Hz, 1H), 7.54-7.41 (m, 1H), 7.17 (dd, J=8.5, 2.3 Hz, 1H), 7.13-7.04 (m, 1H), 6.98 (t, J=6.1 Hz, 2H), 6.17-5.55 (m, 2H), 5.32 (s, 2H), 4.12 (dd, J=25.4, 12.1 Hz, 3H), 3.85-3.08 (m, 9H), 2.93-2.64 (m, 3H), 2.60-2.14 (m, 9H), 2.09-1.92 (m, 5H), 1.82 (s, 2H), 1.43 (s, 3H), 1.36 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using piperidin-4-ol to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C37H47ClN3O8S [M+H]+: m/z=728.28/730.28; Found: 728.4/729.9. 1H NMR (500 MHz, DMSO-d6) δ 11.69 (s, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.20 (ddd, J=109.1, 20.0, 12.8 Hz, 6H), 6.57 (s, 1H), 5.74 (s, 2H), 5.20 (s, 1H), 4.77 (d, J=3.5 Hz, 1H), 3.92 (ddd, J=188.7, 35.2, 15.1 Hz, 8H), 2.96-2.68 (m, 4H), 1.84 (dd, J=111.2, 52.7 Hz, 11H), 1.31 (t, J=57.5 Hz, 10H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using 2-methoxyethylamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C35H45ClN3O8S [M+H]+: m/z=702.26/704.26; Found: 702.4/704.3. 1H NMR (500 MHz, DMSO-d6) δ 11.72 (s, 1H), 7.70 (d, J=8.6 Hz, 1H), 7.40-7.19 (m, 3H), 7.05 (d, J=48.1 Hz, 3H), 6.57 (s, 1H), 5.95-5.33 (m, 2H), 5.07 (s, 1H), 4.39-3.76 (m, 4H), 3.59 (d, J=14.9 Hz, 2H), 3.28 (s, 3H), 3.16 (s, 2H), 2.96-2.64 (m, 3H), 2.16-1.50 (m, 9H), 1.44 (s, 2H), 1.25 (d, J=43.6 Hz, 7H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using oxetan-3-amine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C35H43ClN3O8S [M+H]+: m/z=700.24/702.24; Found: 700.3/702.3. 1H NMR (600 MHz, CDCl3) δ 8.97 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.49 (dd, J=26.7, 25.2 Hz, 1H), 7.18 (dd, J=8.5, 2.2 Hz, 1H), 7.07 (d, J=13.5 Hz, 2H), 7.01 (d, J=8.3 Hz, 1H), 5.94-5.64 (m, 2H), 5.56-5.12 (m, 4H), 4.98-4.79 (m, 3H), 4.56 (d, J=6.0 Hz, 2H), 4.13 (dd, J=27.7, 12.2 Hz, 3H), 3.75 (dd, J=53.1, 12.3 Hz, 2H), 3.53-3.10 (m, 2H), 2.90-2.65 (m, 3H), 2.49-2.28 (m, 1H), 2.29-2.14 (m, 2H), 2.01 (d, J=5.4 Hz, 4H), 1.86 (d, J=10.0 Hz, 1H), 1.43 (s, 3H), 1.37 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using 1-(2-aminoethyl)-piperidine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C39H52ClN4O7S [M+H]+: m/z=755.33/757.32; Found: 755.5/757.4. 1H NMR (600 MHz, CDCl3) δ 12.22 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.49 (d, J=7.7 Hz, 1H), 7.17 (dd, J=8.5, 2.2 Hz, 1H), 7.08 (s, 1H), 7.03-6.86 (m, 2H), 5.81 (s, 1H), 5.63 (dd, J=15.4, 4.6 Hz, 1H), 5.42-5.24 (m, 2H), 5.18 (s, 1H), 4.12 (dd, J=24.6, 12.2 Hz, 3H), 4.04-3.79 (m, 2H), 3.78-3.55 (m, 5H), 3.50-2.98 (m, 5H), 2.93-2.53 (m, 6H), 2.49-2.28 (m, 1H), 2.28-2.12 (m, 2H), 2.08-1.96 (m, 6H), 1.40 (s, 4H), 1.36 (s, 5H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using N1,N2-dimethylethane-1,2-diamine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C36H48ClN4O7S [M+H]+: m/z=715.30/717.29; Found: 715.5/717.5. 1H NMR (500 MHz, DMSO-d6) δ 11.61 (s, 1H), 8.42 (s, 2H), 7.65 (d, J=8.3 Hz, 1H), 7.26 (dd, J=8.4, 2.3 Hz, 2H), 7.19 (d, J=2.0 Hz, 1H), 7.02 (d, J=8.2 Hz, 1H), 6.95 (s, 1H), 5.69 (s, 2H), 5.29 (dd, J=49.6, 44.7 Hz, 1H), 4.32-3.87 (m, 3H), 3.56 (d, J=14.5 Hz, 2H), 2.82 (ddd, J=56.1, 35.7, 24.1 Hz, 9H), 2.59 (s, 3H), 2.16-1.57 (m, 8H), 1.39 (s, 4H), 1.23 (d, J=10.5 Hz, 6H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using (3S)-3-methoxypyrrolidine to replace 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C37H47ClN3O8S [M+H]+: m/z=728.27/730.27; Found: 728.5/730.5. 1H NMR (300 MHz, CDCl3) δ 7.68 (d, J=8.5 Hz, 1H), 7.36 (d, J=8.5 Hz, 1H), 7.13 (dd, J=8.4, 2.4 Hz, 1H), 7.06 (d, J=2.2 Hz, 1H), 6.97 (d, J=2.2 Hz, 1H), 6.85 (d, J=8.2 Hz, 1H), 6.10 (br, 1H), 5.70 (ddd, J=15.8, 10.4, 5.4 Hz, 1H), 5.22-5.14 (m, 1H), 4.12-3.92 (m, 4H), 3.86 (d, J=16.1 Hz, 2H), 3.66 (t, J=13.7 Hz, 2H), 3.52-3.40 (m, 4H), 3.34 (s, 3H), 3.28 (s, 2H), 3.09 (q, J=12.3 Hz, 2H), 2.78-2.70 (m, 4H), 2.31 (d, J=8.0 Hz, 1H), 2.01-1.92 (m, 4H), 1.80-1.72 (m, 3H), 1.36 (s, 3H), 1.31 (s, 3H).
-
-
- To a solution of (3S)-6′-chloro-5-[[(1R,2R)-2-(hydroxymethyl)cyclobutyl]methyl]-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (300.0 mg, 0.42 mmol, Intermediate 3 Step 2) in THF (15 mL) was added potassium tert-butoxide (93.86 mg, 0.84 mmol) at 20° C. The mixture was stirred at r.t. for 30 min., and t-butyl bromoacetate (163.15 mg, 0.84 mmol) was then added. The resulting mixture was stirred at r.t. overnight. LCMS showed full conversion of starting material. The reaction was quenched by water (5 mL), and extracted with EtOAc (20 mL×3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (3% to 40%) to afford tert-butyl 2-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetate (280 mg, 80.5% yield) as a white solid. LCMS calc. for C46H56ClN2O8S [M+H]+: m/z=831.34/833.34; Found: 831.06/832.45.
-
- To a solution of tert-butyl 2-[[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetate (280.0 mg, 0.34 mmol) in DCM (3 mL) was added TFA (3.0 mL, 39.2 mmol) at 40° C. The reaction mixture was stirred for 4 h. LCMS analysis indicated the completion of reaction. The reaction was diluted with EtOAc (10 mL), and adjusted to 7-8 pH with saturated aqueous Na2CO3 solution. The layers were separated, and the aqueous layer was extracted with EtOAc (10 mL×3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting solution was concentrated under reduced pressure and the residue was purified by flash chromatography system on a silica gel column (12 g) with EtOAc/Heptanes (3% to 60%) to afford 2-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetic acid (152 mg, 84.4% yield) as a white solid. LCMS calc. for C26H32ClN2O6S [M+H]+: m/z=535.16/537.16; Found: 534.8/536.6.
-
- To a stirred solution of 2-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetic acid (195.0 mg, 0.36 mmol) in DMF (5 mL) was added K2CO3 (100.59 mg, 0.73 mmol) and iodomethane (103.46 mg, 0.73 mmol). The resulting mixture was stirred at r.t. for 4 h. LCMS showed full conversion of starting material. EtOAc (10 mL) was added and the layers were separated, then the aqueous layer was adjusted pH to 1-2 with aq. HCl (1 N), and extracted with EtOAc (20 mL×2). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (2% to 50%) to afford methyl 2-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetate (159 mg, 79.5% yield) as a white solid. LCMS calc. for C27H34ClN2O6S [M+H]+: m/z=549.17/551.17; Found: 548.9/550.6.
-
- A mixture of (2S)-2-[tert-butoxycarbonyl(methyl)amino]propanoic acid (77.73 mg, 0.38 mmol), methyl 2-[[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetate (70.0 mg, 0.13 mmol), EDCI (73.32 mg, 0.38 mmol) and DMAP (77.4 mg, 0.76 mmol) in DCM (3 mL) was stirred at r.t. overnight. LCMS analysis indicated the completion of reaction. The reaction was diluted with DCM (10 mL), washed with 1 N HCl (2 mL) and brine, dried over Na2SO4, filtered and concentrated under reduced pressure The residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (3% to 60%) to afford methyl 2-[[(1R,2R)-2-[[(3S)-7-[[(2S)-2-[tert-butoxycarbonyl(methyl)amino]propanoyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetate (75 mg, 80.1% yield) as a white solid. LCMS calc. for C36H49ClN3O9S [M+H]+: m/z=734.28/736.28; Found: 733.9/736.3.
-
- To a stirred solution of methyl 2-[[(1R,2R)-2-[[(3S)-7-[[(2S)-2-[tert-butoxycarbonyl(methyl)amino]propanoyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetate (75.0 mg, 0.10 mmol) in THF (0.50 mL) and methanol (0.50 mL) was added lithium hydroxide monohydrate (12.87 mg, 0.31 mmol) in water (0.50 mL). The resulting mixture was stirred at r.t. for 4 h. LCMS showed full conversion of starting material. THF and MeOH were partially removed on a rotary evaporator, and the aqueous layer was adjusted pH to 1-2 with aq. HCl (1 N) and extracted with EtOAc (10 mL×3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to afford 2-[[(1R,2R)-2-[[(3S)-7-[[(2S)-2-[tert-butoxycarbonyl(methyl)amino]propanoyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetic acid (64 mg, 87% yield) as a white solid. LCMS calc. for C35H47ClN3O9S [M+H]+: m/z=720.26/722.26; Found: 720.0/721.6.
-
- 2-[[(1R,2R)-2-[[(3S)-7-[[(2S)-2-[tert-butoxycarbonyl(methyl)amino]propanoyl]-sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]-cyclobutyl]methoxy]acetic acid (64.0 mg, 0.09 mmol) was dissolved in 2N HCl in EtOAc solution (0.0 mL, 0.09 mmol), and stirred at r.t. for 6 h. The reaction was concentrated under reduced pressure, and the residue was added lithium hydroxide monohydrate (3.73 mg, 0.09 mmol) in THF (0.50 mL), water (0.50 mL) and methanol (0.50 mL). After 2 h, LCMS analysis indicated the completion of reaction. The reaction mixture was concentrated under reduced pressure to afford 2-[[(1R,2R)-2-[[(3S)-6′-chloro-7-[[(2S)-2-(methylamino)propanoyl]sulfamoyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]methoxy]acetic acid (51 mg, 92.6% yield) as a white solid. LCMS calc. for C30H39ClN3O7S [M+H]+: m/z=620.22/622.22; Found: 619.9/622.1.
- To a stirred solution of 2-[[(1R,2R)-2-[[(3S)-6′-chloro-7-[[(2S)-2-(methylamino)-propanoyl]sulfamoyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]-cyclobutyl]methoxy]acetic acid (26.0 mg, 0.04 mmol) in DMF (2 mL) was added HATU (31.88 mg, 0.08 mmol) and DIPEA (0.01 mL, 0.08 mmol) at 20° C. After 1 h, LCMS analysis indicated the full conversion of starting material to the desired product. The reaction was quenched by water (5 mL), and extracted with EtOAc (10 mL×3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (2% to 60%). The desired fractions were collected, and further purified by prep-HPLC on a C18 column (30×250 mm, 10 μm) with MeCN/H2O (20 to 100%) to afford (3R,6R,12S,22S)-6′-chloro-11,12-dimethyl-15,15-dioxo-spiro[8,20-dioxa-15-thia-1,11,14-triazatetracyclo-[14.7.2.03,6.019,24]pentacosa-16,18,24-triene-22,1′-tetralin]-10,13-dione (6.2 mg, 0.0103 mmol, 24.56% yield) as a white solid. LCMS calc 602.20/604.20; Found 602.28/604.25.
-
- This compound was prepared using procedures analogous to those described for Example 196 Step 4-7 using (2S)-2-(tert-butoxycarbonylamino)propanoic acid to replace (2S)-2-[tert-butoxycarbonyl(methyl)amino]propanoic acid in Step 4. LCMS calc. for C29H35ClN3O6S [M+H]+: m/z=588.19/590.19; Found 588.6/590.6. 1H NMR (400 MHz, CDCl3) δ 7.68 (d, J=8.5 Hz, 1H), 7.52 (d, J=8.1 Hz, 1H), 7.22 (s, 1H), 7.13 (dd, J=8.2, 2.2 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 6.80 (d, J=8.1 Hz, 1H), 5.48-5.23 (m, 1H), 4.39 (d, J=8.6 Hz, 1H), 4.06-3.82 (m, 4H), 3.75 (d, J=14.2 Hz, 2H), 3.46 (s, 2H), 3.34 (d, J=14.4 Hz, 1H), 3.09 (d, J=13.5 Hz, 1H), 2.81 (d, J=25.2 Hz, 2H), 1.97 (s, 3H), 1.72 (ddd, J=42.0, 16.7, 8.4 Hz, 5H), 1.37 (d, J=7.2 Hz, 5H).
-
-
- This compound was prepared using procedures analogous to those described for Example 42 Step 2 using [(1R)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] N,N-dimethylcarbamate (Intermediate 10) and 3-allyl-4,4-dimethyl-oxazolidine-2,5-dione (Example 42 Step 1). LC-MS: calc. for C36H48ClN4O6S [M+H]+: m/z=699.3/701.3; Found: 699.5/701.5.
-
- This compound was prepared using procedures analogous to those described for Example 26 Step 4 using [(1R)-1-[(1R,2R)-2-[[(3S)-7-[[2-(allylamino)-2-methyl-propanoyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] N,N-dimethylcarbamate. LCMS calc. for C34H44ClN4O6S [M+H]+: m/z=671.3/673.3; Found: 671.9/673.8.
-
-
- To a solution of (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (680.0 mg, 1.11 mmol, Example 43) in pyridine (0.89 mL, 11.07 mmol) was added phenyl chloroformate (0.69 mL, 5.54 mmol). The mixture was stirred at r.t. for 1 h. LCMS showed the full conversion of the starting material into the desired product. The mixture was concentrated under reduced pressure and the residue was purified by flash chromatography on a silica gel column with EA:Hep (50% to 100%) to afford [(3R,6R,7S,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl] phenyl carbonate (810 mg, 99.6% yield).
- To a solution of [(3R,6R,7S,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl] phenyl carbonate (40.0 mg, 0.05 mmol) in MeCN (1 mL) was added morpholine (47.46 mg, 0.54 mmol). Reaction was stirred for 14 h at 75° C. LCMS showed the conversion of the starting material into the desired product. The mixture was concentrated and purified by prep-HPLC on a C18 column (15% to 100% MeCN/H2O) to afford [(3R,6R,7S,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] morpholine-4-carboxylate (15 mg, 37.9% yield). LCMS calcd. for C37H48ClN4O7S [M+H]+: m/z=727.29/729.29; Found 727.4/729.4. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.53-7.43 (m, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.96 (d, J=8.3 Hz, 1H), 6.83 (s, 1H), 5.86 (s, 1H), 5.70 (d, J=15.7 Hz, 1H), 5.39 (s, 1H), 4.17 (d, J=12.2 Hz, 1H), 4.06 (d, J=12.1 Hz, 1H), 3.72 (d, J=5.6 Hz, 6H), 3.50 (m 6H), 3.35 (d, J=14.8 Hz, 1H), 3.09 (dd, J=15.0, 10.9 Hz, 1H), 2.87-2.73 (m, 3H), 2.29 (s, 3H), 1.99 (d, J=12.4 Hz, 2H), 1.83 (q, J=10.1, 9.5 Hz, 2H), 1.68 (dt, J=18.6, 9.5 Hz, 1H), 1.45 (d, J=12.8 Hz, 1H), 1.31 (d, J=24.9 Hz, 6H), 1.12 (s, 3H).
-
- To a solution of [(3R,6R,7R,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.0˜3,6.0˜19,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate (10.0 mg, 0.01 mmol, Example 197) in DCE (0.50 mL) was added 37% formaldehyde aqueous solution (0.01 mL, 0.30 mmol). The mixture was stirred at r.t. for 2 h., then NaBH3CN (11.27 mg, 0.30 mmol) in methanol (0.10 mL) was added. The reaction mixture was stirred at r.t. for 6 h. The reaction was quenched by sat. NH4Cl aqueous solution (5 mL), and extracted with EtOAc (10 mL×3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC on a C18 column with MeCN/H2O (20% to 100%) to afford [(3R,6R,7R,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate (6.3 mg, 61.7% yield) as a white solid. LCMS calc. for C35H46ClN4O6S [M+H]+: m/z=685.3/687.3; Found 685.8/687.3. 1H NMR (600 MHz, CDCl3) δ 7.68 (d, J=8.5 Hz, 1H), 7.52 (d, J=15.5 Hz, 1H), 7.18 (dd, J=8.6, 2.3 Hz, 1H), 7.07 (d, J=2.3 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 6.83 (s, 1H), 5.92 (dt, J=12.7, 6.0 Hz, 1H), 5.41-5.25 (m, 1H), 5.07 (s, 1H), 4.08 (t, J=16.8 Hz, 2H), 3.73 (d, J=14.7 Hz, 1H), 3.36 (s, 1H), 3.06 (dd, J=15.2, 10.7 Hz, 1H), 2.92 (s, 4H), 2.84-2.72 (m, 3H), 2.52 (s, 1H), 2.28 (s, 2H), 2.22 (t, J=7.7 Hz, 1H), 2.08-1.90 (m, 5H), 1.83 (s, 3H), 1.72-1.61 (m, 3H), 1.43 (t, J=13.1 Hz, 2H), 1.32 (d, J=12.4 Hz, 3H), 1.26 (d, J=8.6 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 199 Step 2 using cyclobutylamine to replace morpholine. LCMS calc. for C37H48ClN4O6S [M+H]+: m/z=711.30/713.30; Found: 711.7/713.8. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.52 (dd, J=8.3, 2.0 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.09 (d, J=2.1 Hz, 1H), 6.98 (d, J=8.4 Hz, 1H), 6.89 (s, 1H), 5.89 (d, J=15.5 Hz, 1H), 5.67 (d, J=14.4 Hz, 1H), 5.44 (s, 1H), 5.28 (d, J=17.7 Hz, 1H), 4.14 (dt, J=35.4, 10.4 Hz, 3H), 3.70 (d, J=14.7 Hz, 1H), 3.39 (dd, J=28.7, 14.8 Hz, 2H), 3.14-2.97 (m, 1H), 2.81 (dd, J=15.8, 8.0 Hz, 5H), 2.46-2.13 (m, 5H), 2.09-1.89 (m, 5H), 1.89-1.77 (m, 4H), 1.77-1.52 (m, 4H), 1.45 (d, J=12.6 Hz, 1H), 1.35 (s, 3H), 1.11 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 63 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 32) in Step 2 and (3S)—N-methyltetrahydrofuran-3-amine hydrochloride in Step 1. LCMS calc. for C37H47ClN3O8S [M+H]+: m/z=728.27/730.27; Found: 728.4/730.1. 1H NMR (300 MHz, CDCl3) δ 9.12 (s, 1H), 7.69 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.6, 2.2 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 7.01 (s, 1H), 6.99-6.95 (m, 1H), 5.83 (dd, J=5.9, 3.4 Hz, 1H), 5.73 (dd, J=15.7, 5.2 Hz, 1H), 5.33 (q, J=4.3, 3.9 Hz, 1H), 4.91 (s, 1H), 4.12 (t, J=6.3 Hz, 2H), 4.09-4.04 (m, 1H), 3.78 (s, 2H), 3.69 (d, J=8.3 Hz, 1H), 3.50-3.32 (m, 2H), 3.23 (dd, J=15.1, 9.3 Hz, 1H), 2.90 (s, 3H), 2.81-2.76 (m, 3H), 2.40 (dd, J=8.9, 3.5 Hz, 1H), 2.24 (dd, J=9.5, 5.5 Hz, 1H), 2.04 (d, J=8.6 Hz, 1H), 1.95 (d, J=10.1 Hz, 2H), 1.87-1.74 (m, 5H), 1.71-1.62 (m, 3H), 1.51 (d, J=12.6 Hz, 1H), 1.44 (s, 3H), 1.37 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 199 Step 2 using methylamine (40% in water) to replace morpholine. LCMS calc. for C34H44ClN4O6S [M+H]+: m/z=671.27/673.27; Found: 671.7/673.6. 1H NMR (499 MHz, DMSO-d6) δ 7.63 (dd, J=8.5, 2.5 Hz, 1H), 7.25 (dd, J=8.5, 2.4 Hz, 1H), 7.19-7.07 (m, 2H), 6.88-6.84 (m, 2H), 6.07 (br, 1H), 5.81-5.66 (m, 1H), 5.17-5.12 (m, 1H), 3.58-3.49 (m, 1H), 3.31-3.25 (m, 6H), 3.19-3.06 (m, 1H), 2.86-2.64 (m, 4H), 2.60 (d, J=4.6 Hz, 2H), 2.55 (s, 3H), 2.37 (dt, J=3.8, 2.0 Hz, 1H), 2.00 (dt, J=12.2, 3.9 Hz, 1H), 1.85 (s, 3H), 1.77-1.61 (m, 3H), 1.48-1.44 (m, 1H), 1.35 (s, 3H), 1.28-1.10 (m, 5H).
-
- This compound was prepared using procedures analogous to those described for Example 199 Step 2 using ethylamine (66-72% in water) to replace morpholine. LCMS calc. for C35H46ClN4O6S [M+H]+: m/z=685.28/687.28; Found: 685.7/687.7. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.09 (d, J=2.0 Hz, 1H), 6.98 (d, J=8.3 Hz, 1H), 6.88 (s, 1H), 5.90 (d, J=15.4 Hz, 1H), 5.68 (d, J=15.7 Hz, 1H), 5.28 (s, 1H), 5.21 (s, 1H), 4.12 (dd, J=36.0, 12.1 Hz, 2H), 3.70 (d, J=14.5 Hz, 1H), 3.50-3.35 (m, 2H), 3.27 (dd, J=13.5, 7.0 Hz, 2H), 3.16-2.97 (m, 1H), 2.81 (dd, J=14.7, 8.2 Hz, 4H), 2.28 (s, 4H), 2.06-1.92 (m, 4H), 1.85 (s, 4H), 1.63 (dd, J=18.6, 9.6 Hz, 1H), 1.45 (d, J=12.8 Hz, 1H), 1.35 (s, 3H), 1.22 (dd, J=16.2, 9.0 Hz, 3H), 1.11 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 199 Step 2 using cyclopropyl methylamine to replace morpholine. LCMS calc. for C37H48ClN4O6S [M+H]+: m/z=711.30/713.30; Found: 711.8/713.8. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.3, 2.0 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.09 (d, J=2.0 Hz, 1H), 6.98 (d, J=8.3 Hz, 1H), 6.89 (s, 1H), 5.93 (d, J=15.4 Hz, 1H), 5.68 (d, J=15.4 Hz, 1H), 5.40 (s, 1H), 5.26 (s, 1H), 4.12 (dd, J=36.4, 12.1 Hz, 2H), 3.70 (d, J=14.8 Hz, 1H), 3.39 (dd, J=25.6, 14.9 Hz, 3H), 3.17-2.98 (m, 3H), 2.92-2.68 (m, 4H), 2.29 (s, 4H), 1.99 (d, J=11.2 Hz, 4H), 1.87 (d, J=16.2 Hz, 4H), 1.63 (dd, J=18.8, 9.3 Hz, 1H), 1.45 (d, J=12.4 Hz, 1H), 1.35 (s, 3H), 1.10 (d, J=10.9 Hz, 3H), 0.57-0.47 (m, 2H), 0.27 (q, J=4.7 Hz, 2H).
-
- This compound was prepared using procedures analogous to those described for Example 199 Step 2 using cyclopropylamine to replace morpholine. LCMS calc. for C36H46ClN4O6S [M+H]+: m/z=697.28/699.28; Found: 697.7/699.8. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.0 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.09 (d, J=2.0 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 6.85 (d, J=1.7 Hz, 1H), 5.85 (s, 1H), 5.68 (d, J=16.0 Hz, 1H), 5.43 (s, 1H), 5.29 (s, 1H), 4.11 (dd, J=35.5, 12.1 Hz, 2H), 3.70 (d, J=14.2 Hz, 1H), 3.38 (dd, J=25.8, 14.4 Hz, 2H), 3.15-2.99 (m, 2H), 2.96-2.73 (m, 4H), 2.67 (s, 1H), 2.29 (s, 4H), 2.07-1.89 (m, 4H), 1.85 (d, J=8.6 Hz, 4H), 1.63 (d, J=8.2 Hz, 1H), 1.45 (d, J=12.5 Hz, 1H), 1.36 (s, 3H), 1.11 (s, 3H), 0.77 (d, J=5.4 Hz, 2H), 0.59 (d, J=4.8 Hz, 2H).
-
- This compound was prepared using procedures analogous to those described for Example 199 Step 2 using propan-2-amine to replace morpholine. LCMS calc. for C36H48ClN4O6S [M+H]+: m/z=699.30/701.30; Found: 699.8/701.7. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.3, 2.0 Hz, 1H), 7.19 (dd, J=8.6, 2.1 Hz, 1H), 7.09 (d, J=1.9 Hz, 1H), 6.98 (d, J=8.4 Hz, 1H), 6.89 (s, 1H), 5.89 (d, J=15.6 Hz, 1H), 5.68 (d, J=14.9 Hz, 1H), 5.24 (s, 1H), 5.12 (s, 1H), 4.12 (dd, J=35.8, 12.1 Hz, 2H), 3.86 (dd, J=13.6, 6.5 Hz, 1H), 3.70 (d, J=14.6 Hz, 1H), 3.39 (dd, J=28.1, 14.5 Hz, 2H), 3.13-2.99 (m, 1H), 2.80 (t, J=10.4 Hz, 6H), 2.28 (s, 3H), 2.08-1.91 (m, 3H), 1.84 (d, J=4.3 Hz, 3H), 1.63 (dd, J=18.9, 9.6 Hz, 1H), 1.45 (d, J=13.0 Hz, 1H), 1.35 (s, 3H), 1.23 (dd, J=11.4, 6.6 Hz, 7H), 1.11 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 199 Step 2 by replacement of morpholine with (9aS)-1,3,4,6,7,8,9,9a-octahydropyrazino[2,1-c][1,4]oxazine which was prepared in THF solution as following: a solution of (9aS)-1,3,4,6,7,8,9,9a-octahydropyrazino[2,1-c][1,4]oxazine dihydrochloride (500.0 mg, 2.32 mmol) in methanol (1 mL) was treated NaOMe (105.9 mg, 1.96 mmol) for 30 min. at r.t., concentrated under reduced pressure, re-dissolved in THF (1 mL) and filtered. LCMS calc. for C40H53ClN5O7S [M+H]+: m/z=782.33/784.33; Found 782.5/784.4. 1H NMR (300 MHz, CDCl3) δ 7.69 (dd, J=7.8, 4.1 Hz, 1H), 7.50 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.6, 2.4 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 6.81 (s, 1H), 5.91-5.62 (m, 2H), 5.40 (s, 1H), 4.22-4.00 (m, 4H), 3.88-3.65 (m, 5H), 3.48-3.22 (m, 4H), 3.10 (q, J=13.6, 11.8 Hz, 3H), 2.89-2.70 (m, 7H), 2.28 (d, J=9.6 Hz, 6H), 1.99 (d, J=12.2 Hz, 4H), 1.91-1.75 (m, 4H), 1.35 (s, 3H), 1.10 (s, 3H).
-
-
- This compound was prepared using procedures analogous to those described for Example 42 Step 2 using [(1S)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] N,N-dimethylcarbamate (Intermediate 9) and 3-allyl-4,4-dimethyl-oxazolidine-2,5-dione (Example 42 Step 1). LCMS calc. for C36H48ClN4O6S [M+H]+: m/z=699.3/701.3; Found: 699.9/701.8.
- This compound was prepared using procedures analogous to those described for Example 26 Step 4 using [(1S)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] N,N-dimethylcarbamate. LCMS calc. for C34H44ClN4O6S [M+H]+: m/z=671.3/673.3; Found: 671.8/673.2.
-
- This compound was prepared using procedures analogous to those described for Example 27 using [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate (Example 204) and acetaldehyde. LCMS calc. for C36H48ClN4O6S [M+H]+: m/z=699.30/701.30; Found: 699.69/701.66. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.2 Hz, 1H), 7.09 (d, J=2.1 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 6.84 (d, J=2.0 Hz, 1H), 5.90 (dd, J=15.5, 8.3 Hz, 1H), 5.67 (d, J=15.5 Hz, 1H), 5.28 (s, 1H), 4.12 (dd, J=37.4, 12.1 Hz, 2H), 3.73 (d, J=14.7 Hz, 1H), 3.41 (dd, J=20.8, 15.1 Hz, 2H), 3.12 (s, 3H), 3.00 (d, J=7.3 Hz, 3H), 2.93-2.74 (m, 4H), 2.73-2.58 (m, 1H), 2.29-2.14 (m, 2H), 1.99 (d, J=10.6 Hz, 4H), 1.91-1.74 (m, 4H), 1.66 (dd, J=18.7, 9.3 Hz, 2H), 1.41 (d, J=7.3 Hz, 5H), 1.18 (s, 3H), 1.06 (t, J=7.1 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 27 using [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate (Example 204) and propionaldehyde. LCMS calc. for C36H48ClN4O6S [M+H]+: m/z=699.30/701.30; Found: 699.7/701.7. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 1.9 Hz, 1H), 7.19 (dd, J=8.5, 2.1 Hz, 1H), 7.09 (d, J=1.9 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 6.84 (d, J=1.9 Hz, 1H), 5.93 (dd, J=15.4, 8.5 Hz, 1H), 5.65 (d, J=15.7 Hz, 1H), 5.28 (s, 1H), 4.12 (dd, J=37.7, 12.1 Hz, 2H), 3.73 (d, J=14.7 Hz, 1H), 3.41 (t, J=16.2 Hz, 3H), 3.08 (dd, J=20.9, 10.1 Hz, 4H), 3.02-2.90 (m, 4H), 2.78 (dt, J=15.9, 14.5 Hz, 4H), 2.48-2.36 (m, 1H), 2.22 (d, J=8.4 Hz, 1H), 1.99 (d, J=10.9 Hz, 3H), 1.83 (dd, J=8.8, 4.5 Hz, 3H), 1.68-1.59 (m, 2H), 1.48 (dt, J=11.9, 6.1 Hz, 3H), 1.38 (s, 3H), 1.16 (s, 3H), 0.90 (t, J=7.3 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 199 Step 2 using (3S)-tetrahydrofuran-3-amine to replace morpholine. LCMS calc. for C37H48ClN4O7S [M+H]+: m/z=727.29/729.29; Found: 727.4/729.5. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.08 (d, J=2.3 Hz, 1H), 7.02-6.87 (m, 2H), 6.09 (t, J=11.5 Hz, 1H), 5.90 (s, 1H), 5.66 (d, J=16.1 Hz, 1H), 5.19 (s, 1H), 4.40-4.13 (m, 4H), 4.04 (d, J=12.1 Hz, 1H), 3.95 (d, J=9.5 Hz, 1H), 3.85-3.60 (m, 3H), 3.42 (d, J=13.5 Hz, 1H), 3.31 (d, J=14.7 Hz, 1H), 3.10-2.67 (m, 6H), 2.43-2.13 (m, 4H), 2.09-1.70 (m, 5H), 1.61 (q, J=9.0 Hz, 1H), 1.33 (d, J=38.8 Hz, 5H), 1.12 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 199 Step 2 using N,N,N′-trimethylethylenediamine to replace morpholine. LCMS calc. for C38H53ClN5O6S [M+H]+: m/z=742.33/744.33; Found: 742.8/744.8. 1H NMR (300 MHz, CDCl3) δ 7.70 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.96 (dd, J=8.3, 2.3 Hz, 1H), 6.84 (d, J=2.3 Hz, 1H), 6.06-5.85 (m, 1H), 5.78-5.65 (m, 1H), 5.31 (d, J=16.4 Hz, 1H), 4.16 (d, J=12.2 Hz, 1H), 4.11-4.00 (m, 1H), 3.78-3.56 (m, 2H), 3.51-3.23 (m, 3H), 3.15-2.86 (m, 10H), 2.88-2.73 (m, 6H), 2.64-2.38 (m, 1H), 2.35-2.17 (m, 6H), 2.01 (dt, J=10.8, 5.6 Hz, 3H), 1.66 (q, J=8.9, 8.5 Hz, 1H), 1.51-1.23 (m, 6H), 1.13 (d, J=3.5 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 199 using 3-dimethylamino azetidine 2HCl salt and Hunig's base to replace morpholine. LCMS calc. for C38H51ClN5O6S [M+H]+: m/z=740.32/742.31; Found: 740.6/742.6. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.3, 2.0 Hz, 1H), 7.19 (dd, J=8.6, 2.3 Hz, 1H), 7.08 (d, J=2.1 Hz, 1H), 6.95 (d, J=8.3 Hz, 1H), 6.82 (s, 1H), 6.05-5.78 (m, 1H), 5.68 (dd, J=15.7, 2.8 Hz, 1H), 5.25 (s, 1H), 4.22-3.99 (m, 3H), 3.99-3.85 (m, 3H), 3.71 (d, J=14.7 Hz, 2H), 3.38 (dd, J=14.9, 8.9 Hz, 2H), 3.20-2.67 (m, 6H), 2.32-2.15 (m, 8H), 2.04-1.90 (m, 3H), 1.83 (dq, J=9.4, 4.9 Hz, 3H), 1.65 (q, J=9.4 Hz, 1H), 1.52-1.23 (m, 6H), 1.12 (d, J=6.4 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 199 Step 2 using (3R)-3-methoxypyrrolidine to replace morpholine. LCMS calc. for C38H50ClN4O7S [M+H]+: m/z=741.33/743.33; Found: 741.5/743.5. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.63-7.45 (m, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.09 (d, J=2.2 Hz, 1H), 6.96 (dd, J=8.4, 1.1 Hz, 1H), 6.85 (dd, J=5.4, 2.2 Hz, 1H), 6.00-5.62 (m, 2H), 5.40-5.25 (m, 1H), 4.17 (d, J=12.2 Hz, 1H), 4.12-3.94 (m, 2H), 3.86 (d, J=13.2 Hz, 1H), 3.72 (d, J=14.7 Hz, 1H), 3.67-3.26 (m, 8H), 3.09 (ddd, J=14.7, 11.0, 3.2 Hz, 1H), 2.82 (ddd, J=15.4, 10.3, 5.9 Hz, 6H), 2.28 (s, 3H), 1.95 (dddd, J=46.8, 27.6, 9.1, 5.6 Hz, 6H), 1.79-1.54 (m, 1H), 1.50-1.23 (m, 6H), 1.11 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 199 Step 2 using azetidine hydrochloride salt and Hunig's base to replace morpholine. LCMS calc. for C36H46ClN4O6S [M+H]+: m/z=697.27/699.27; Found: 697.4/699.5. 1H NMR (300 MHz, CDCl3) δ 7.70 (d, J=8.5 Hz, 1H), 7.52-7.42 (m, 1H), 7.24-7.05 (m, 2H), 7.01-6.90 (m, 1H), 6.86 (s, 1H), 5.92 (s, 1H), 5.72-5.60 (m, 1H), 5.22 (s, 1H), 4.39-3.87 (m, 4H), 3.72 (d, J=14.6 Hz, 1H), 3.47 (d, J=15.0 Hz, 1H), 3.34 (d, J=14.8 Hz, 1H), 3.15-2.98 (m, 1H), 2.89 (s, 2H), 2.78 (d, J=10.5 Hz, 3H), 2.28 (s, 6H), 1.99 (d, J=12.0 Hz, 2H), 1.84 (d, J=15.0 Hz, 4H), 1.65 (q, J=9.5 Hz, 1H), 1.30 (d, J=22.5 Hz, 5H), 1.17-0.98 (m, 4H).
-
- This compound was prepared using procedures analogous to those described for Example 199 Step 2 using 3-methoxyazetidine hydrochloride salt and Hunig's base to replace morpholine. LCMS calc. for C37H48ClN4O7S [M+H]+: m/z=727.29/729.29; Found: 727.4/729.5. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 6.82 (d, J=2.2 Hz, 1H), 5.86 (s, 1H), 5.67 (d, J=15.9 Hz, 1H), 5.26 (s, 1H), 4.24 (s, 3H), 4.18 (d, J=12.2 Hz, 1H), 4.05 (d, J=12.1 Hz, 1H), 3.97 (d, J=7.9 Hz, 2H), 3.72 (d, J=14.7 Hz, 1H), 3.37 (d, J=14.7 Hz, 3H), 3.35-3.27 (m, 3H), 3.07 (dd, J=15.0, 11.1 Hz, 1H), 2.81 (s, 5H), 2.88-2.73 (m, 1H), 2.28 (s, 3H), 2.01 (s, 1H), 1.82 (s, 4H), 1.65 (q, J=9.4 Hz, 1H), 1.37 (s, 3H), 1.27 (d, J=4.3 Hz, 1H), 1.11 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 63 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 43) in Step 2 and (3R)—N-methyltetrahydrofuran-3-amine hydrochloride in Step 1. LCMS calc. for C38H50ClN4O7S [M+H]+: m/z=741.30/743.30; Found: 741.4/743.3. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.4, 2.1 Hz, 1H), 7.19 (dd, J=8.6, 2.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.98 (d, J=8.3 Hz, 1H), 6.84 (d, J=2.2 Hz, 1H), 5.85-5.77 (m, 1H), 5.76-5.67 (m, 1H), 5.36 (s, 1H), 5.00 (s, 1H), 4.18 (d, J=12.2 Hz, 1H), 4.10-4.03 (m, 2H), 3.74 (d, J=15.1 Hz, 2H), 3.46 (d, J=14.8 Hz, 1H), 3.37 (d, J=14.7 Hz, 1H), 3.15-3.08 (m, 1H), 3.06-2.95 (m, 3H), 2.82 (t, J=9.4 Hz, 4H), 2.28 (s, 6H), 1.99 (d, J=11.0 Hz, 2H), 1.90-1.61 (m, 9H), 1.35 (s, 3H), 1.27 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 27 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 43, Step 3) and acetaldehyde. LCMS calc. for C33H43ClN3O5S [M+H]+: m/z=628.25/630.25; Found: 628.4/630.4. 1H NMR (600 MHz, DMSO-d6) δ 7.64 (d, J=8.6 Hz, 1H), 7.25 (dd, J=8.4, 2.4 Hz, 1H), 7.25-7.15 (m, 3H), 7.10 (d, J=8.1 Hz, 1H), 6.76 (s, 1H), 5.72 (s, 1H), 5.33 (t, J=5.0 Hz, 1H), 4.88-4.84 (m, 1H), 3.99 (t, J=10.4 Hz, 2H), 3.51 (s, 1H), 3.02 (s, 2H), 2.80 (d, J=16.8 Hz, 1H), 2.72 (dd, J=11.1, 6.1 Hz, 1H), 2.54 (s, 4H), 2.00 (dt, J=19.0, 7.0 Hz, 5H), 1.85 (s, 5H), 1.85-1.81 (m, 1H), 1.64 (d, J=8.2 Hz, 2H), 1.56 (s, 1H), 1.46 (p, J=7.2 Hz, 2H), 1.39 (s, 2H), 1.30 (s, 2H), 1.15 (s, 1H), 0.86 (t, J=6.8 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 199 using (3R,6R,7S,8E,22S)-6′-chloro-11-ethyl-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo [14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 219) in Step 1 and 4-aminotetrahydropyran in Step 2. LCMS calcd. for C39H52ClN4O7S [M+H]+: m/z=755.32/757.32; Found: 755.5/757.6. 1H NMR (600 MHz, DMSO-d6) δ 7.65 (d, J=8.5 Hz, 1H), 7.26 (dd, J=8.5, 2.4 Hz, 1H), 7.19 (dd, J=9.9, 5.1 Hz, 2H), 6.96 (dd, J=14.4, 7.0 Hz, 2H), 5.59 (s, 1H), 4.99 (d, J=4.0 Hz, 1H), 4.11 (d, J=12.3 Hz, 1H), 4.05 (d, J=11.6 Hz, 1H), 3.68 (s, 3H), 3.58-3.12 (m, 9H), 2.82-2.76 (m, 1H), 2.72 (q, J=8.4 Hz, 2H), 2.65 (s, 7H), 2.43 (s, 1H), 1.98 (dt, J=13.8, 4.6 Hz, 1H), 1.83 (h, J=6.0, 4.9 Hz, 3H), 1.71 (q, J=8.6 Hz, 2H), 1.63-1.53 (m, 1H), 1.48 (dd, J=14.5, 7.6 Hz, 1H), 1.31 (s, 3H), 1.27-1.21 (m, 2H), 1.19 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 199 using (3R,6R,7S,8E,22S)-6′-chloro-11-ethyl-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo [14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 219) in Step 1 and morpholine in Step 2. LCMS calc. for C38H49ClN4O7S [M+H]+: m/z=741.3/743.37; Found 741.6/741.6. 1H NMR (300 MHz, CDCl3) δ 7.67 (d, J=8.5 Hz, 1H), 7.59-7.47 (m, 1H), 7.24-7.07 (m, 2H), 7.05-6.90 (m, 2H), 5.89 (s, 1H), 5.64 (d, J=16.5 Hz, 1H), 5.36 (s, 1H), 4.19 (d, J=12.2 Hz, 1H), 4.06 (d, J=12.0 Hz, 1H), 3.70 (d, J=13.1 Hz, 6H), 3.35 (d, J=14.6 Hz, 3H), 3.09 (s, 6H), 2.81 (m, 10H), 2.31 (d, J=9.3 Hz, 1H), 2.07-1.94 (m, 3H), 1.84 (t, J=9.2 Hz, 2H), 1.31 (s, 6H).
-
- This compound was prepared using procedures analogous to those described for Example 199 using (3R,6R,7S,8E,22S)-6′-chloro-11-ethyl-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo [14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 219) in Step 1 and 4-methoxypiperidine in Step 2. LCMS calc. for C40H54ClN4O7S [M+H]+: m/z=769.34/771.34; Found 769.7/771.8. 1H NMR (300 MHz, CDCl3) δ 7.63 (dd, J=19.7, 8.5 Hz, 1H), 7.52 (dd, J=8.3, 2.1 Hz, 1H), 7.24-7.06 (m, 3H), 7.00 (d, J=8.4 Hz, 1H), 5.86 (s, 2H), 5.61 (s, 1H), 4.19 (d, J=12.1 Hz, 1H), 5.32 (s, 2H), 4.06 (d, J=12.1 Hz, 1H), 3.90 (m, 16H), 3.70 (d, J=14.7 Hz, 1H), 3.35 (d, J=16.0 Hz, 7H), 3.11 (s, 1H), 1.97 (t, J=10.3 Hz, 1H), 1.80 (dt, J=18.6, 8.5 Hz, 1H), 1.67-1.54 (m, 1H), 1.36-1.21 (m, 10H).
-
- This compound was prepared using procedures analogous to those described for Example 199 using (3R,6R,7S,8E,22S)-6′-chloro-11-ethyl-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo [14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (30.0 mg, Example 219) in Step 1 and tert-butyl N-(azetidin-3-yl)-N-methyl-carbamate (74.67 mg, 0.40 mmol) in Step 2. The reaction mixture was concentrated under reduced pressure The residue was dissolved in IPA (0.50 mL) and DCM (0.50 mL), and treated with phosphoric acid (0.5 mL, 8.6 mmol). The resulting mixture was stirred for 16 h., and quenched with sat. NaHCO3(aq) (1 mL). The mixture was extracted with DCM (1 mL×3). The organic layer was concentrated and the residue was purified by prep-HPLC on a C18 column with MeCN/H2O (15% to 100%) to afford the title compound (6 mg, 20.2% yield). LCMS calc. for C38H51ClN5O6S [M+H]+: m/z=740.32/742.32; Found 740.5/742.6. 1H NMR (600 MHz, DMSO-d6) δ 7.64 (d, J=8.5 Hz, 1H), 7.26 (dd, J=8.5, 2.3 Hz, 1H), 7.17 (d, J=2.3 Hz, 1H), 7.09 (d, J=8.4 Hz, 1H), 6.84 (d, J=8.2 Hz, 1H), 6.72 (s, 1H), 6.41 (t, J=12.5 Hz, 1H), 5.80 (d, J=15.7 Hz, 1H), 5.11 (s, 1H), 3.99 (q, J=12.2 Hz, 3H), 3.74-3.65 (m, 2H), 3.56 (d, J=14.5 Hz, 1H), 3.31-3.24 (m, 1H), 3.03 (dd, J=15.2, 11.1 Hz, 1H), 2.96 (dd, J=12.6, 6.8 Hz, 1H), 2.83-2.76 (m, 1H), 2.70 (ddd, J=17.2, 11.3, 6.2 Hz, 2H), 2.51 (s, 1H), 2.32 (q, J=8.8 Hz, 1H), 2.24 (s, 3H), 1.99 (ddt, J=17.6, 12.2, 5.6 Hz, 2H), 1.93-1.77 (m, 3H), 1.73-1.63 (m, 3H), 1.41 (s, 3H), 1.32-1.28 (m, 1H), 1.30-1.18 (m, 10H), 0.86 (t, J=6.9 Hz, 1H).
-
- This compound was prepared using procedures analogous to those described for Example 199 using (3R,6R,7S,8E,22S)-6′-chloro-11-ethyl-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo [14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 219) in Step 1 and N,N-dimethylazetidin-3-amine in Step 2. LCMS calc. for C39H53ClN5O6S [M+H]+: m/z=754.33/756.43; Found 756.5/758.6. 1H NMR (300 MHz, CDCl3) δ 7.70 (d, J=8.5 Hz, 1H), 7.63-7.45 (m, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.10 (dd, J=9.3, 2.2 Hz, 1H), 6.94 (d, J=8.4 Hz, 1H), 6.80 (s, 1H), 6.18 (s, 1H), 5.69 (d, J=14.6 Hz, 1H), 5.18 (s, 1H), 4.38 (s, 1H), 4.16 (d, J=12.3 Hz, 1H), 4.03 (d, J=10.9 Hz, 2H), 3.86 (s, 1H), 3.71 (d, J=14.6 Hz, 1H), 3.36 (d, J=14.7 Hz, 1H), 3.25-3.09 (m, 1H), 3.01 (m, 15H), 2.79 (m, 4H), 2.20 (d, J=16.2 Hz, 7H), 1.98 (d, J=12.3 Hz, 1H), 1.64 (q, J=9.3 Hz, 1H), 1.46 (d, J=30.9 Hz, 3H), 1.23 (q, J=7.8, 7.2 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 199 using (3R,6R,7S,8E,22S)-6′-chloro-11-ethyl-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo [14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 219) in Step 1 and 1-(2-methoxyethyl)piperazine in Step 2. LCMS calc. for C41H57ClN507S [M+H]+: m/z=798.36/800.36; Found: 799.1/801.1.
-
- This compound was prepared using procedures analogous to those described for Example 63 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 43) in Step 2 and (3S)—N-methyltetrahydrofuran-3-amine hydrochloride in Step 1. LCMS calc. for C38H50ClN4O7S [M+H]+: m/z=741.30/743.30; Found: 741.4/743.3. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.51 (d, J=8.5 Hz, 1H), 7.19 (dd, J=8.5, 2.3 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 7.03-6.95 (m, 1H), 6.89-6.75 (m, 1H), 5.94-5.62 (m, 2H), 5.38 (s, 1H), 4.97 (s, 1H), 4.18 (d, J=12.1 Hz, 1H), 4.13-3.96 (m, 2H), 3.90-3.62 (m, 4H), 3.41 (dd, J=25.6, 15.3 Hz, 2H), 3.06 (dd, J=39.0, 17.3 Hz, 4H), 2.81 (t, J=12.5 Hz, 5H), 2.26 (d, J=14.2 Hz, 5H), 2.12-1.56 (m, 10H), 1.35 (s, 4H), 1.27 (s, 2H).
-
- This compound was prepared using procedures analogous to those described for Example 46 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-ethylene-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.0˜3,6.0˜19,24]pentacosa[8,16(25),17,19(24)]tetraene-22,1′-tetralin]-13-one (Example 40) in Step 1 and methylamine (40% in water) in Step 2. LCMS calc. for C33H39ClN3O7S [M+H]+: m/z=656.22/658.22; Found: 656.6/658.5. 1H NMR (300 MHz, CDCl3) δ 9.02 (s, 1H), 7.64 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.0 Hz, 1H), 7.37 (d, J=1.6 Hz, 1H), 7.17 (dd, J=8.5, 2.1 Hz, 1H), 7.09 (d, J=2.1 Hz, 1H), 7.00 (d, J=8.3 Hz, 1H), 5.81-5.56 (m, 2H), 5.09 (d, J=6.6 Hz, 1H), 4.46 (s, 1H), 4.14 (s, 2H), 4.07 (dd, J=13.3, 5.2 Hz, 1H), 3.95 (dd, J=13.0, 7.5 Hz, 1H), 3.67 (t, J=10.3 Hz, 1H), 3.60 (d, J=7.4 Hz, 1H), 3.30 (d, J=14.6 Hz, 1H), 3.17 (dd, J=15.3, 4.7 Hz, 1H), 2.76 (d, J=4.8 Hz, 4H), 2.72-2.61 (m, 1H), 2.56 (dd, J=16.5, 8.3 Hz, 1H), 2.05-1.85 (m, 3H), 1.81 (dd, J=10.7, 7.7 Hz, 1H), 1.70 (dd, J=11.7, 7.0 Hz, 2H), 1.62 (d, J=12.4 Hz, 2H), 1.55-1.30 (m, 3H), 1.22 (ddd, J=13.3, 11.2, 4.6 Hz, 2H).
-
-
- A mixture of (3S)-6′-chloro-5-[[(1R,2R)-2-[1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (3.0 g, 5.96 mmol), 1-allyloxycyclobutanecarboxylic acid (3.26 g, 20.87 mmol), DMAP (5.83 g, 47.71 mmol) and EDC (5.72 g, 29.82 mmol) in DCM (30 mL) was stirred at 30° C. for 2 h. LCMS showed the conversion of the starting material into the desired product. The mixture was quenched with sat. NH4Cl(aq) (20 mL) and extracted with DCM (20 mL×3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was dissolved in THF (10 mL), water (10 mL) and methanol (10 mL), and treated with LiOH (1.29 g, 30.79 mmol). The mixture was stirred at 30° C. overnight, and quenched with 1M HCl (20 mL). The mixture was extracted with EtOAc (20 mL×3). The combined organic layers were washed with sat. NaHCO3(aq) (20 mL) and brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with EA:Hep (5% to 30%) to afford 1-allyloxy-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-cyclobutanecarboxamide (2.35 g, 71.4% yield).
-
- A solution of 1-allyloxy-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl] methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-cyclobutanecarboxamide (2.35 g, 3.66 mmol) in DCE (2.5 L) was bubbled with N2 gas for 15 min., then Hoveyda-Grubbs 11(0.46 g, 0.73 mmol) was added and the mixture was bubbled with N2 gas for an additional 15 min. The mixture was stirred for 2 h. at 40° C. under N2. LCMS showed the conversion of the starting material into the desired product. The mixture was then exposed to air and stirred for 30 min before it was concentrated under reduced pressure. The reside was purified by flash chromatography on a silica gel column eluting with EA:Hep (10% to 60%) to afford (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo [14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (1.49 g, 66.3% yield).
- This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one in Step 1 and (3R)-3-ethoxypyrrolidine in Step 2. LCMS calc. for C39H49ClN3O8S [M+H]+: m/z=754.29/756.29; Found: 754.4/756.4. 1H NMR (300 MHz, CDCl3) δ 7.70 (dd, J=8.5, 4.3 Hz, 1H), 7.51 (d, J=8.2 Hz, 1H), 7.18 (d, J=8.4 Hz, 1H), 7.10-6.91 (m, 3H), 5.96 (s, 1H), 5.62 (ddd, J=15.6, 9.3, 5.4 Hz, 1H), 5.17 (d, J=4.8 Hz, 1H), 4.08 (m, 4H), 3.76-3.60 (m, 3H), 3.59-3.32 (m, 3H), 3.32-3.12 (m, 2H), 2.81-2.63 (m, 2H), 2.44 (m, 1H), 2.09 (dd, J=58.7, 11.5 Hz, 7H), 1.82 (t, J=8.0 Hz, 3H), 1.63 (q, J=9.4 Hz, 1H), 1.33-1.18 (m, 9H), 1.09 (dd, J=8.8, 6.3 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 228 Step 2) in Step 1 and (3R)-3-methoxypyrrolidine HCl and DIPEA in Step 2. LCMS calc. for C39H53ClN5O6S [M+H]+: m/z=740.28/742.27; Found: 740.4/742.5. 1H NMR (300 MHz, CDCl3) δ 7.68 (dd, J=8.5, 5.3 Hz, 1H), 7.48 (dd, J=8.3, 2.1 Hz, 1H), 7.18 (d, J=8.8 Hz, 1H), 7.13-6.99 (m, 2H), 6.97 (dd, J=8.3, 2.6 Hz, 1H), 5.80 (d, J=15.9 Hz, 1H), 5.64 (td, J=15.6, 13.8, 5.0 Hz, 1H), 5.23 (s, 1H), 4.23-4.01 (m, 3H), 3.75-3.46 (m, 2H), 3.47-3.29 (m, 5H), 3.29-3.08 (m, 1H), 2.78 (s, 3H), 2.67-2.48 (m, 1H), 2.42 (d, J=7.4 Hz, 2H), 2.35-2.17 (m, 1H), 2.10 (q, J=10.4, 9.9 Hz, 1H), 1.97 (dd, J=14.7, 6.0 Hz, 2H), 1.87 (dd, J=27.0, 5.2 Hz, 2H), 1.70-1.40 (m, 2H), 1.29 (d, J=16.4 Hz, 3H), 1.10 (d, J=6.6 Hz, 8H).
-
- This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 228 Step 2) in Step 1 and 3-ethoxyazetidine in Step 2. LCMS calc. for C38H47ClN3O8S [M+H]+: m/z=740.27/742.27; Found:740.4/742.4; 1H NMR (300 MHz, CDCl3) δ 7.68 (d, J=8.5 Hz, 1H), 7.45 (dd, J=8.3, 2.0 Hz, 1H), 7.16 (dd, J=8.5, 2.4 Hz, 1H), 7.05 (dd, J=13.4, 2.3 Hz, 2H), 6.94 (d, J=8.3 Hz, 1H), 5.83 (s, 1H), 5.60 (dd, J=15.7, 5.4 Hz, 1H), 5.12 (s, 1H), 4.28-3.98 (m, 7H), 3.67 (m, 3H), 3.48-3.37 (m, 4H), 3.29 (d, J=14.5 Hz, 1H), 2.76 (d, J=5.0 Hz, 2H), 2.27-2.16 (m, 3H), 2.10-1.93 (m, 7H), 1.80-1.64 (m, 6H), 1.21-1.18 (m, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 228 Step 2) in Step 1 and dimethylamine (2.0 M in THF) in Step 2. LCMS calc. for C35H43ClN3O7S [M+H]+: m/z=684.24/686.24; Found: 684.3/686.2; 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.45 (dd, J=8.3, 2.0 Hz, 1H), 7.16 (dd, J=8.5, 2.4 Hz, 1H), 7.04 (dd, J=18.7, 2.2 Hz, 2H), 6.93 (d, J=8.3 Hz, 1H), 6.10-5.97 (m, 1H), 5.62 (dd, J=15.7, 5.8 Hz, 1H), 5.13 (t, J=5.0 Hz, 1H), 4.07 (d, J=3.8 Hz, 1H), 3.99 (dd, J=14.0, 6.3 Hz, 1H), 3.80-3.68 (m, 2H), 3.65 (s, 1H), 3.51 (d, J=14.1 Hz, 1H), 3.24 (d, J=14.4 Hz, 1H), 3.14 (dd, J=15.0, 8.8 Hz, 1H), 2.94-2.82 (m, 6H), 2.75-2.69 (m, 3H), 2.67 (s, 3H), 2.14-1.92 (m, 6H), 1.76-1.66 (m, 6H).
-
- This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 228 Step 2) in Step 1 and azetidine hydrochloride and DIPEA in Step 2. LCMS calc. for C37H45ClN3O6S [M+H]+: m/z=696.24/698.24; Found: 696.3/698.4; 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.15 (dd, J=8.5, 2.3 Hz, 2H), 7.09-7.00 (m, 2H), 6.91 (d, J=8.3 Hz, 1H), 5.63 (dd, J=15.4, 5.8 Hz, 1H), 5.37-5.31 (m, 1H), 5.12 (s, 1H), 4.10-3.88 (m, 7H), 3.66-3.64 (m, 2H), 3.24-3.20 (m, 1H), 2.76 (s, 2H), 2.40-2.31 (m, 4H), 2.21-2.08 (m, 5H), 2.06-1.93 (m, 6H), 1.76-1.62 (m, 7H).
-
- This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 228 Step 2) in Step 1 and N,N,N′-trimethylethylenediamine in Step 2. LCMS calc. for C38H50ClN4O7S [M+H]+: m/z=741.30/743.30; Found:741.4/743.3; 1H NMR (300 MHz, CDCl3) δ 7.71 (d, J=8.5 Hz, 1H), 7.46 (d, J=8.2 Hz, 1H), 7.18 (dd, J=8.5, 2.4 Hz, 2H), 7.09 (s, 1H), 6.94 (d, J=8.3 Hz, 1H), 6.41 (s, 1H), 6.07 (s, 1H), 5.66 (d, J=15.0 Hz, 1H), 5.34 (d, J=11.5 Hz, 1H), 4.98 (s, 1H), 4.69 (s, 1H), 4.20-4.00 (m, 4H), 3.71 (d, J=15.5 Hz, 3H), 3.50 (d, J=14.1 Hz, 2H), 3.37-3.26 (m, 2H), 3.03-2.95 (m, 4H), 2.85 (s, 3H), 2.78 (s, 2H), 2.74 (s, 1H), 2.41 (s, 3H), 2.23-2.20 (m, 4H), 1.99-1.87 (m, 4H), 1.82-1.75 (m, 4H).
-
- This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 228 Step 2) in Step 2 and (3R)—N-methyltetrahydrofuran-3-amine hydrochloride in Step 1. LCMS calc. for C38H47ClN3O8S [M+H]+: m/z=740.27/742.27; Found: 740.4/742.2. 1H NMR (300 MHz, CDCl3) δ 7.67 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.3, 2.1 Hz, 1H), 7.18 (dd, J=8.5, 2.4 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 7.05 (d, J=2.2 Hz, 1H), 7.00 (d, J=8.3 Hz, 1H), 5.66 (d, J=2.8 Hz, 2H), 5.30-5.19 (m, 1H), 4.89 (s, 1H), 4.20 (d, J=12.1 Hz, 1H), 4.12 (s, 1H), 4.08 (d, J=3.4 Hz, 1H), 4.01 (dd, J=8.6, 4.8 Hz, 1H), 3.76 (d, J=5.9 Hz, 2H), 3.70 (d, J=7.5 Hz, 1H), 3.66 (s, 1H), 3.56 (d, J=13.8 Hz, 1H), 3.38 (s, 1H), 3.32 (d, J=6.5 Hz, 2H), 2.86 (s, 3H), 2.79-2.72 (m, 4H), 2.04-1.70 (m, 12H), 1.67-1.49 (m, 4H).
-
- This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 228 Step 2) in Step 2 and N-methyloxetan-3-amine in Step 1. LCMS calc. for C37H45ClN3O8S [M+H]+: m/z=726.26/728.26; Found: 726.4.4/728.6. 1H NMR (300 MHz, CDCl3) δ 7.68 (dq, J=12.6, 8.1 Hz, 2H), 7.51 (dd, J=8.3, 2.1 Hz, 1H), 7.18-7.00 (m, 3H), 5.88 (tdd, J=16.8, 10.4, 5.5 Hz, 1H), 5.64 (s, 2H), 5.38-5.01 (m, 3H), 4.77 (dt, J=13.4, 7.0 Hz, 2H), 4.25-4.02 (m, 3H), 3.97-3.84 (m, 1H), 3.83-3.52 (m, 3H), 3.29 (d, J=20.3 Hz, 3H), 3.06 (s, 3H), 2.78 (s, 4H), 2.57-2.05 (m, 3H), 2.09-1.77 (m, 2H), 1.60 (dd, J=20.4, 10.9 Hz, 2H), 1.47-1.23 (m, 5H).
-
- This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 228 Step 2) in Step 2 and N-methyltetrahydropyran-4-amine in Step 1. LCMS calc. for C39H49ClN3O8S [M+H]+: m/z=754.29/756.29; Found: 754.4/756.5. 1H NMR (300 MHz, CDCl3) δ 8.81 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.51 (dd, J=8.4, 2.1 Hz, 1H), 7.21-6.92 (m, 4H), 5.64 (s, 2H), 5.25 (s, 1H), 4.25-4.05 (m, 2H), 4.01 (d, J=10.4 Hz, 6H), 3.73 (dd, J=30.6, 14.2 Hz, 1H), 3.56 (d, J=13.7 Hz, 1H), 3.48-3.29 (m, 8H), 2.84-2.68 (m, 7H), 2.56-2.44 (m, 1H), 2.45-2.20 (m, 1H), 2.24-1.98 (m, 1H), 2.04-1.83 (m, 1H), 1.82 (q, J=10.4, 7.9 Hz, 4H), 1.57 (s, 1H), 1.29 (d, J=16.1 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-12,12-(1,3-propylene)-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 228 Step 2) in Step 2 and (3S)-tetrahydrofuran-3-amine in Step 1. LCMS calc. for C37H45ClN3O8S [M+H]+: m/z=726.26/728/26; Found: 726.4/728.4.
-
- This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 48 Step 8) in Step 1 and 3-methoxyazetidine hydrochloride and DIPEA in Step 2. LCMS calc. for C38H48ClN4O7S [M+H]+: m/z=739.2/741.2; Found: 739.4/741.5. 1H NMR (300 MHz, CDCl3) δ 7.70 (d, J=8.5 Hz, 1H), 7.53 (dd, J=8.4, 2.3, 1H), 7.23-7.18 (m, 1H), 7.10 (d, J=2.3 Hz, 1H), 7.00 (dd, J=8.3, 1.0 Hz, 1H), 6.87 (d, J=2.2 Hz, 1H), 5.72-5.67 (m, 2H), 5.24 (br, 1H), 4.23-4.06 (m, 4H), 3.96 (d, J=8.3 Hz, 1H), 3.73 (d, J=14.8 Hz, 1H), 3.45-3.40 (m, 2H), 3.33 (s, 3H), 3.12 (dd, J=14.9, 10.6 Hz, 1H), 2.89-2.66 (m, 5H), 2.44 (s, 3H), 2.35-2.15 (m, 4H), 2.04-1.92 (m, 4H), 1.85-1.64 (m, 7H), 1.34-1.30 (m, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 48 Step 8) in Step 2 and N-methyltetrahydropyran-4-amine in Step 1. LCMS calc. for C40H52ClN4O7S [M+H]+: m/z=767.32/769.32; Found: 767.5/769.8. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, J=8.5 Hz, 1H), 7.52 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.99 (d, J=8.3 Hz, 1H), 6.86 (d, J=2.2 Hz, 1H), 5.72 (s, 2H), 5.33 (s, 1H), 4.27 (s, 1H), 4.17 (d, J=12.2 Hz, 1H), 4.06 (d, J=12.2 Hz, 1H), 3.73 (d, J=14.7 Hz, 1H), 3.55-3.40 (m, 4H), 3.36 (d, J=14.4 Hz, 1H), 3.13 (t, J=12.8 Hz, 1H), 2.90 (d, J=11.8 Hz, 3H), 2.89-2.63 (m, 7H), 2.58-2.43 (m, 1H), 2.42 (s, 3H), 2.36-2.05 (m, 1H), 2.01 (s, 2H), 2.00-1.84 (m, 1H), 1.85-1.52 (m, 8H), 1.44 (t, J=12.0 Hz, 1H), 1.36-1.20 (m, 4H).
-
- This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 48 Step 8) in Step 2 and N-methyloxetan-3-amine in Step 1. LCMS calc. for C38H48ClN4O7S [M+H]+: m/z=739.29/741.29; Found: 739.5/741.5.
-
- This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 48 Step 8) in Step 2 and (3S)—N-methyltetrahydrofuran-3-amine hydrochloride in Step 1. LCMS calc. for C39H49ClN3O8S [M+H]+: m/z=753.31/755.31; Found: 753.4/755.4. 1H NMR (300 MHz, Chloroform-d) δ 7.69 (d, J=8.6 Hz, 1H), 7.52 (dd, J=8.4, 2.1 Hz, 1H), 7.24-7.16 (m, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.99 (d, J=8.4 Hz, 1H), 6.86 (d, J=2.2 Hz, 1H), 5.72 (d, J=2.7 Hz, 2H), 5.33 (s, 1H), 4.96 (s, 1H), 4.17 (d, J=12.2 Hz, 1H), 4.10-3.98 (m, 2H), 3.85-3.67 (m, 5H), 3.50-3.41 (m, 1H), 3.36 (d, J=14.8 Hz, 1H), 3.13 (dd, J=15.0, 10.5 Hz, 1H), 2.94 (d, J=8.5 Hz, 3H), 2.79 (q, J=6.1, 5.7 Hz, 4H), 2.72 (s, 2H), 2.43 (s, 3H), 2.08-1.92 (m, 7H), 1.85-1.62 (m, 7H), 1.46 (d, J=12.9 Hz, 1H).
-
- This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 48 Step 8) in Step 2 and (3R)—N-methyltetrahydrofuran-3-amine hydrochloride in Step 1. LCMS calc. for C39H50ClN4O7S [M+H]+: m/z=753.31/755.31; Found: 753.4/755.4. 1H NMR (300 MHz, Chloroform-d) δ 7.69 (d, J=8.5 Hz, 1H), 7.52 (dd, J=8.4, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.99 (d, J=8.3 Hz, 1H), 6.86 (d, J=2.3 Hz, 1H), 5.72 (d, J=1.8 Hz, 2H), 5.40-5.29 (m, 1H), 4.97 (s, 1H), 4.17 (d, J=12.1 Hz, 1H), 4.06 (d, J=12.1 Hz, 2H), 3.86-3.74 (m, 3H), 3.71 (s, 2H), 3.50-3.40 (m, 1H), 3.36 (d, J=14.7 Hz, 1H), 3.12 (dd, J=15.0, 10.6 Hz, 1H), 2.95 (d, J=8.1 Hz, 3H), 2.79 (q, J=5.8, 5.1 Hz, 4H), 2.71 (s, 1H), 2.43 (s, 3H), 2.09-1.89 (m, 7H), 1.89-1.76 (m, 4H), 1.75-1.61 (m, 4H), 1.46 (d, J=13.0 Hz, 1H).
-
- This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 48 Step 8) in Step 2 and (3R)-tetrahydrofuran-3-amine in Step 1. LCMS calc. for C38H48ClN4O7S [M+H]+: m/z=739.29/741.29; Found: 739.3/741.3.
-
- This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 48 Step 8) in Step 1 and 3-ethoxyazetidine; hydrochloride and DIPEA in Step 2. LCMS calc. for C39H50ClN4O7S [M+H]+: m/z=753.30/755.30; Found: 753.6/755.3. 1H NMR (300 MHz, CDCl3) δ 7.70 (d, J=8.5 Hz, 1H), 7.52 (dd, J=8.4, 2.0 Hz, 1H), 7.20 (dd, J=8.5, 2.4 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 6.99 (d, J=8.3 Hz, 1H), 6.88 (d, J=2.2 Hz, 1H), 5.72-5.66 (m, 2H), 5.24 (br, 1H), 4.22-4.13 (m, 6H), 3.73 (d, J=14.7 Hz, 1H), 3.48-3.33 (m, 4H), 3.12 (dd, J=15.0, 10.5 Hz, 1H), 2.84-2.71 (m, 4H), 2.44 (s, 3H), 2.32-2.27 (m, 3H), 2.06-1.95 (m, 4H), 1.85-1.80 (m, 3H), 1.67-1.61 (m, 2H), 1.45 (t, J=11.8 Hz, 1H), 1.27-1.16 (m, 8H).
-
- This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 48 Step 8) in Step 1 and 4-methoxypiperidine in Step 2. LC-MS: calc. for C40H52ClN4O7S [M+H]+: m/z=767.32/769.32; Found 767.4/769.4.
-
- This compound was prepared using procedures analogous to those described for Example 32 Step 1-3 using (3S)-7′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,4′-chromane]-7-sulfonamide (Intermediate 12) and 2-allyloxy-2-methyl-propanoic acid (Example 30 Step 1). LC-MS: calc. for C30H36ClN2O7S [M+H]+: m/z=603.2/605.2; Found: 603.2/605.2. HPLC: C18 column (4.6×150 mm, 100 Å); flow rate=1 mL/min; mobile phase: 5% MeCN/H2O (with 0.1% TFA) 2 min, 5% to 95% 6 min, 95% 2 min. λ=220 nm. tR=6.813 min. 1H NMR (499 MHz, DMSO-d6) δ 11.71 (s, 1H), 7.55 (d, J=8.5 Hz, 1H), 7.38-7.20 (m, 1H), 7.15-7.00 (m, 2H), 6.97 (dd, J=8.5, 2.3 Hz, 1H), 6.89 (t, J=2.4 Hz, 1H), 5.67-5.37 (m, 2H), 4.69 (d, J=4.1 Hz, 1H), 4.33-4.17 (m, 3H), 4.05 (d, J=12.1 Hz, 1H), 3.97-3.82 (m, 2H), 3.59 (d, J=14.5 Hz, 1H), 3.45 (t, J=15.4 Hz, 2H), 3.17 (dd, J=14.5, 7.4 Hz, 1H), 2.60 (q, J=7.8, 6.0 Hz, 1H), 2.34-2.20 (m, 1H), 2.17-1.95 (m, 2H), 1.84 (tdt, J=25.5, 16.6, 7.4 Hz, 3H), 1.73-1.51 (m, 2H), 1.36 (s, 3H), 1.23 (s, 3H).
-
- To a stirred solution of (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (22.0 mg, 0.04 mmol, Example 246) in MeCN (10 ml) was added CDI (18.11 mg, 0.11 mmol). The mixture was stirred at 45° C. for 2 h. LCMS analysis indicated the starting material was fully consumed. Dimethylamine in THF (35 uL, 0.07 mmol, 2.0 N) was added. The reaction mixture was stirred at 45° C. for 2 h. HCl (1.0 M, 2 mL) was added. The mixture was extracted with DCM (5 mL×3). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC on a C18 column to afford [(3R,6R,7S,8E,22S)-7′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-7-yl] N,N-dimethylcarbamate (5.8 mg, 23.6% yield) as a white solid. LCMS calc. for C33H41ClN308S [M−H]*: m/z=674.2/676.2; Found: 674.4/676.4. 1H NMR (499 MHz, DMSO-d6) δ 11.69 (s, 1H), 7.57 (d, J=8.5 Hz, 1H), 7.33-7.18 (m, 1H), 7.05-6.94 (m, 3H), 6.88 (d, J=2.2 Hz, 1H), 5.66 (s, 2H), 5.10 (t, J=3.5 Hz, 1H), 4.35-4.15 (m, 3H), 4.07 (d, J=12.1 Hz, 1H), 3.94 (d, J=13.7 Hz, 1H), 3.63 (d, J=14.5 Hz, 1H), 3.41 (d, J=14.5 Hz, 1H), 3.25 (d, J=6.7 Hz, 2H), 2.92 (s, 3H), 2.83 (s, 3H), 2.69 (q, J=7.9 Hz, 1H), 2.43 (s, 1H), 2.11-1.97 (m, 1H), 1.89-1.79 (m, 2H), 1.77-1.60 (m, 3H), 1.37 (s, 3H), 1.21 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 1 and morpholine in Step 2. LC-MS: calc. for C35H43ClN3O9S [M+H]+: m/z=716.2/718.2; Found: 716.3/718.3. 1H NMR (300 MHz, CDCl3) δ 7.78 (d, J=7.5 Hz, 1H), 7.57 (dd, J=8.4, 1.1 Hz, 1H), 7.39 (d, J=7.6 Hz, 1H), 7.13-7.01 (m, 2H), 6.94 (ddd, J=8.4, 2.3, 1.2 Hz, 1H), 5.97-5.64 (m, 2H), 5.34 (t, J=4.3 Hz, 1H), 4.57 (td, J=11.5, 10.4, 6.4 Hz, 1H), 4.40-3.94 (m, 5H), 3.80-3.62 (m, 4H), 3.54-3.26 (m, 4H), 3.03-2.87 (m, 1H), 2.80 (d, J=7.1 Hz, 3H), 2.08-1.80 (m, 6H), 1.65 (dd, J=12.2, 6.6 Hz, 2H), 1.46 (s, 3H), 1.37 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 32 Step 1-3 using (3R)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-isochromane]-7-sulfonamide (Intermediate 15) and 2-allyloxy-2-methyl-propanoic acid (Example 30 Step 1). LC-MS: calc. for C30H36ClN2O7S [M+H]+: m/z=603.2/605.2; Found: 603.2/605.2. 1H NMR (300 MHz, CDCl3) δ 7.60-7.45 (m, 2H), 7.25-7.14 (m, 3H), 7.02 (dd, J=8.4, 1.4 Hz, 1H), 5.86-5.51 (m, 2H), 4.38-4.29 (m, 1H), 4.17 (d, J=12.1 Hz, 2H), 4.09-3.96 (m, 2H), 3.84-3.52 (m, 6H), 3.28 (dd, J=14.8, 7.3 Hz, 1H), 2.94 (ddt, J=24.3, 16.0, 7.8 Hz, 2H), 2.80-2.68 (m, 1H), 2.40 (q, J=9.1 Hz, 1H), 2.14-1.78 (m, 4H), 1.42 (s, 3H), 1.39 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22R)-6′-Chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-isochromane]-13-one (Example 249) in Step 1 and dimethylamine in THF solution (2.0 N) in Step 2. LC-MS: calc. for C33H41ClN3O8S [M+H]+: m/z=674.2/676.2; Found: 674.3/676.3. 1H NMR (300 MHz, CDCl3) δ 7.50 (d, J=8.5 Hz, 1H), 7.43 (dd, J=8.3, 2.0 Hz, 1H), 7.27-7.21 (m, 1H), 7.16 (d, J=2.2 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 6.94 (dd, J=8.3, 0.9 Hz, 1H), 6.09 (ddd, J=15.8, 6.4, 4.1 Hz, 1H), 5.69 (dd, J=15.7, 5.5 Hz, 1H), 5.25 (t, J=4.2 Hz, 1H), 4.31 (d, J=11.8 Hz, 1H), 4.13 (d, J=11.8 Hz, 1H), 4.02-3.95 (m, 2H), 3.80-3.71 (m, 1H), 3.66 (d, J=11.6 Hz, 2H), 3.50-3.38 (m, 2H), 3.03 (s, 3H), 2.95 (s, 3H), 2.72 (s, 5H), 2.37 (qd, J=9.0, 2.9 Hz, 1H), 2.04 (qt, J=7.5, 3.0 Hz, 1H), 1.84 (q, J=9.0 Hz, 2H), 1.71-1.57 (m, 1H), 1.40 (s, 3H), 1.33 (s, 3H).
-
-
- To a solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-formylcyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (1000.0 mg, 1.4 mmol, Intermediate 3 Step 3) in DCM (20 mL) was added copper sulfate (669.41 mg, 4.19 mmol) followed by the addition of (S)-2-methylpropane-2-sulfinamide (254.16 mg, 2.1 mmol). The reaction mixture was stirred at r.t. overnight. The reaction was filtered through a pad of Celite and washed with DCM. The filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column EtOAc/Hep (3% to 60%) to afford (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(E)-[(S)-tert-butylsulfinyl]iminomethyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (980 mg, 85.6% yield). LCMS calcd. for C44H53ClN3O6S2 [M+H]+: m/z=818.31/820.30; Found: 819.0/821.0.
-
- To a cooled (−78° C.) solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(E)-[(S)-tert-butylsulfinyl]iminomethyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (980.0 mg, 1.2 mmol) in THF (20 mL) was added dropwise vinylmagnesium bromide (1.8 mL, 1.8 mmol, 1.OM THF solution) over 10 min. After addition, the reaction mixture was allowed to warm to r.t. over 1 h. LCMS showed full conversion of starting material and the formation of desired product. The reaction was quenched with sat. NH4Cl(aq) (20 mL) and extracted with EtOAc (20 mL×3). The organic layer was dried over NaSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column EA:Hep (3% to 100%) to afford two products: P1 (the earlier eluted product, 410 mg, 40.4%) which was assigned to (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-[[(S)-tert-butylsulfinyl]amino]allyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide and P2 (the latter eluted product, 190 mg, 18.7%) which was assigned to (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-[[(S)-tert-butylsulfinyl]amino]allyl] cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide. LCMS calcd. for C46H57ClN3O6S2 [M+H]+: m/z=846.34/848.33; Found: 847.1/849.2.
-
- (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-[[(S)-tert-butylsulfinyl]amino]allyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (400.0 mg, 0.47 mmol, P1 Step 2) in 1,4-dioxane (10 mL) was treated with 6 M HCl in IPA solution (1.5 mL, 9.45 mmol). The reaction mixture was stirred for 1 h. LCMS showed full consume of starting material. The reaction was quenched with sat. NaHCO3(aq) (10 mL) and extracted with EtOAc (10 mL×3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to yield (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-aminoallyl] cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (312 mg, 88.9% yield) which was used in the next step without further purification. LCMS calc. for C42H48ClN3O5S [M+H]+: m/z=742.31/744.31; Found: 742.7/744.1.
-
- To a solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1R)-1-aminoallyl] cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (312.0 mg, 0.42 mmol) in DCM (5 mL) was added methyl chloroformate (0.05 mL, 0.63 mmol) and triethylamine (0.09 mL, 0.67 mmol). The mixture was stirred for 4 h. The reaction was quenched with MeOH (1 mL) and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column EtOAc/Heptanes (3% to 50%) to afford methyl N-[(1R)-1-[(1R,2R)-2-[[(3 S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] carbamate (252 mg, 74.9% yield). LCMS calc. for C44H51ClN3O7S [M+H]+: m/z=800.31/802.31; Found: 800.8/803.0.
-
- Methyl N-[(1R)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl) methyl] sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl] cyclobutyl]allyl]carbamate (180.0 mg, 0.22 mmol) was dissolved in 2,2,2-trifluoroacetic acid (2.0 mL, 25.96 mmol) and DCM (8 mL). The mixture was stirred at r.t. overnight 16 h. The mixture was quenched by sat. NaHCO3(aq) (10 mL) and extracted with EtOAc (10 mL×3). The combined organic layers were concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column EtOAc/Heptanes (10% to 50%) to afford methyl N-[(1R)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]carbamate (116 mg, 92.1% yield). LCMS calc. for C28H35ClN3O5S [M+H]+: m/z=560.20/562.20; Found: 560.8/562.7.
-
- To a solution of methyl N-[(1R)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]carbamate (48.0 mg, 0.09 mmol) and 2-allyloxy-2-methyl-propanoic acid (24.71 mg, 0.17 mmol, Example 30 Step 1) in DCM (2 mL) was added sequentially DMAP (41.88 mg, 0.34 mmol), and EDCI (32.86 mg, 0.17 mmol). The mixture was stirred at r.t. overnight. The mixture was diluted with DCM (1 mL) and washed with 1 M HCl(aq) (1 mL). The organic layer was concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column EtOAc/Heptanes (10% to 50%) to afford methyl N-[(1R)-1-[(1R,2R)-2-[[(3S)-7-[(2-allyloxy-2-methyl-propanoyl) sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl] methyl]cyclobutyl]allyl]carbamate (51 mg, 86.7% yield). LCMS calc. for C35H46ClN4O6S [M+H]+: m/z=685.28/687.28; Found: 685.8/687.2.
- A solution of methyl N-[(1R)-1-[(1R,2R)-2-[[(3S)-7-[(2-allyloxy-2-methyl-propanoyl) sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]carbamate (51.07 mg, 0.07 mmol) in DCE (60 mL) was bubbled with N2 gas for 10 min., then Hoveyda-Grubbs II (9.33 mg, 0.01 mmol) was added. The reaction mixture was re-bubbled with N2 for an additional 10 min. The mixture was then stirred at 40° C. under N2 overnight. The reaction was exposed to air for 30 min. before concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column EA:Hep (5% to 60%), and further purified by prep-HPLC H2O:MeCN (10% to 100%) to afford methyl N-[(3R,6R,7R,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]carbamate (9 mg, 18.4% yield). LCMS calc. for C33H41ClN3O7S [M+H]+: m/z=658.24/660.23; Found: 658.68/660.8. HPLC: C18 column (4.6×150 mm, 5 m); flow rate=1 mL/min; mobile phase: MeCN/H2O (with 0.1% TFA) 50% to 95% 6 min, 95% 4 min; λ=220 nm. tR=6.741 min. 1H NMR (300 MHz, CDCl3) δ 7.68 (d, J=8.5 Hz, 1H), 7.52 (d, J=8.4 Hz, 1H), 7.09-6.98 (m, 4H), 5.62 (dd, J=15.4, 7.2 Hz, 1H), 4.11-3.92 (m, 3H), 3.81-3.72 (m, 5H), 3.54 (d, J=14.6 Hz, 1H), 3.33 (d, J=14.5 Hz, 1H), 3.16 (t, J=12.2 Hz, 1H), 2.79 (s, 2H), 2.57 (s, 1H), 2.22 (q, J=6.8, 6.0 Hz, 1H), 2.04-1.89 (m, 4H), 1.65 (s, 3H), 1.50-1.23 (m, 7H), 0.89 (t, J=6.5 Hz, 1H).
-
-
- This compound was prepared using procedures analogous to those described for Example 251 Step 4 using ethyl chloroformate to replace methyl chloroformate. LCMS calc. for C45H53ClN3O7S [M+H]+: m/z=814.33/816.33; Found: 815.0/816.9.
-
- To a solution of ethyl N-[(1R)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl) methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl] methyl]cyclobutyl]allyl]carbamate (371.0 mg, 0.46 mmol) in DMF (6 mL) was added sodium hydride (60% o, dispersion in paraffin liquid) (54.66 mg, 1.37 mmol), followed by iodomethane (0.11 mL, 1.82 mmol). The reaction was stirred at r.t. for 4 h. The reaction was quenched with sat. NH4Cl (aq) and extracted with EtOAc (10 mL×3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to afford the crude product which was used in the next step without further purification. LCMS calc. for C46H55ClN3O7S [M+H]+: m/z=828.34/830.33; Found: 828.8/830.2.
- This compound was prepared using procedures analogous to those described for Example 251 Step 5-7 using ethyl N-methyl-N-[(1R)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]carbamate in Step 5 and 2-allyloxy-2-methyl-propanoic acid (Example 30 Step 1) in Step 6. LCMS calcd. for C35H45ClN3O7S (M+H)+: m/z=686.27/688.26; Found: 686.3/688.3. HPLC: C18 column (4.6×150 mm, 5 m); flow rate=1 mL/min; mobile phase: MeCN/H2O (with 0.1% TFA) 50% to 95% 6 min, 95% 4 min; λ=220 nm. tR=8.004 min.
-
-
- This compound was prepared using procedures analogous to those described for Example 251 Step 5-7 using ethyl N-methyl-N-[(1R)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]carbamate (Example 252, Step 2) in Step 5 and 3-allyl-4,4-dimethyl-oxazolidine-2,5-dione (Example 43 Step 1) in Step 6. LCMS calcd. for C35H46ClN4O6S (M+H)+: m/z=685.27/686.26; Found: 685.3/687.3.
- This compound was prepared using procedures analogous to those described for Example 138 Step 3 using ethyl N-methyl-N-[(3R,6R,7R,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo [14.7.2.03,6.019,24] pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]carbamate and formaldehyde aqueous solution (37%). LCMS calcd. for C36H48ClN4O6S [M+H]+: m/z=699.30/701.30; Found: 699.4/701.5.
-
-
- This compound was prepared using procedures analogous to those described for Example 251 Step 3 using (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-[(1S)-1-[[(S)-tert-butylsulfinyl]amino]allyl] cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (P2 Example 251 Step 2). LCMS calc. for C42H48ClN3O5S [M+H]+: m/z=742.31/744.31; Found: 742.7/744.1.
-
- To a solution of 2,2,2-trifluoro-N-[(1S)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]acetamide (0.82 g, 1.1 mmol) in DCM (10 mL) was added trifluoroacetic anhydride (0.28 mL, 2.21 mmol) and triethylamine (0.62 mL, 4.42 mmol). The mixture was stirred for 16 h. The reaction was concentrated under reduced pressure to afford 2,2,2-trifluoro-N-[(1S)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl] sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]acetamide (1.6 g) which was used in the next step without further purification. LCMS calc. for C44H48ClF3N3O6S [M+H]+: m/z=838.29/840.29; Found: 838.8/840.0.
-
- This compound was prepared using procedures analogous to those described for Example 251 Step 5-7 using 2,2,2-trifluoro-N-[(1S)-1-[(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl]acetamide in Step 5 and 2-allyloxy-2-methyl-propanoic acid (Example 30 Step 1) in Step 6. LCMS calc. for C33H38ClF3N3O6S [M+H]+: m/z=696.21/698.21; Found: 696.3/698.3.
-
- To a solution of 2,2,2-trifluoro-N-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24] pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]acetamide (134.0 mg, 0.19 mmol) in methanol (10 mL) and water (5 mL) was added potassium carbonate (265.62 mg, 1.92 mmol). The mixture was stirred at 50° C. overnight. The mixture was quenched with NH4Cl(aq) (10 mL) and extracted with EtOAc (10 mL×3). The combined organic layers were concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column EA:Hep (10% to 100%) to afford (3R,6R,7S,8E,22S)-7-amino-6′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (120 mg). LCMS calc. for C31H39ClN3O5S [M+H]+: m/z=600.22/602.22; Found: 600.5/602.5.
-
- This compound was prepared using procedures analogous to those described for Example 251 Step 4 using (3R,6R,7S,8E,22S)-7-amino-6′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one and methyl chloroformate. LCMS calc. for C33H40ClN3O7S [M+H]+: m/z=658.23/660.22; Found: 658.4/660.4.
-
- This compound was prepared using procedures analogous to those described for Example 252 Step 2 using methyl N-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24] pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]carbamate and iodomethane. LCMS calc. for C34H43ClN3O7S [M+H]+: m/z=672.25/674.25; Found: 672.4/674.4; HPLC: C18 column (4.6×150 mm, 5 m); flow rate=1 mL/min; mobile phase: MeCN/H2O (with 0.1% TFA) 50% to 95% 6 min, 95% 4 min; λ=220 nm. tR=7.321 min. 1H NMR (600 MHz, DMSO-d6) δ 7.65 (d, J=8.5 Hz, 1H), 7.30 (s, 1H), 7.23-7.18 (m, 2H), 7.09 (s, 1H), 6.85 (s, 1H), 6.66 (s, 1H), 5.63 (s, 1H), 5.33 (t, J=4.9 Hz, 1H), 4.17 (s, 1H), 3.96 (d, J=12.7 Hz, 1H), 3.89 (s, 1H), 3.70 (s, 1H), 3.52 (s, 3H), 2.80-2.70 (m, 1H), 2.65 (s, 2H), 2.00 (tt, J=13.1, 5.7 Hz, 3H), 1.86 (s, 2H), 1.80 (s, 3H), 1.54 (d, J=9.6 Hz, 1H), 1.46 (t, J=7.1 Hz, 2H), 1.29 (d, J=6.4 Hz, 1H), 1.26-1.19 (m, 4H), 1.14 (d, J=10.6 Hz, 3H), 0.86 (t, J=6.8 Hz, 3H).
-
-
- This compound was prepared using procedures analogous to those described for Example 251 Step 4 using (3R,6R,7S,8E,22S)-7-amino-6′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 254 Step 4) and acetyl chloride. LCMS calcd. for C33H41ClN3O6S [M+H]+: m/z=642.24/644.24; Found: 642.4/642.3.
- This compound was prepared using procedures analogous to those described for Example 252 Step 2 using N-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]acetamide and iodomethane. LCMS calcd. for C34H43ClN3O6S (M+H)+: m/z=656.26/658.25; Found: 656.4/658.5. 1H NMR (600 MHz, CDCl3) δ 7.75-7.70 (m, 1H), 7.60-7.38 (m, 1H), 7.16 (dd, J=8.7, 2.4 Hz, 1H), 7.13-7.06 (m, 2H), 7.02 (s, 1H), 6.91 (s, 1H), 5.82 (s, 1H), 5.39 (s, 1H), 5.25 (s, 1H), 5.03 (s, 1H), 4.18 (d, J=13.7 Hz, 2H), 4.07 (s, 3H), 3.94 (dd, J=13.6, 8.5 Hz, 1H), 3.70 (s, 2H), 3.23 (d, J=14.3 Hz, 1H), 2.79 (d, J=5.9 Hz, 1H), 2.78-2.69 (m, 4H), 2.52-2.32 (m, 1H), 2.24-2.19 (m, 3H), 2.06-1.94 (m, 4H), 1.92-1.87 (m, 1H), 1.86-1.81 (m, 4H), 1.45 (d, J=9.8 Hz, 2H), 0.87 (h, J=7.5, 6.5 Hz, 3H).
-
-
- This compound was prepared using procedures analogous to those described for Example 251 Step 4 using (3R,6R,7S,8E,22S)-7-amino-6′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 254 Step 4) and methanesulfonyl chloride. LCMS calcd. for C32H41ClN3O7S2 (M+H)+: m/z=678.21/680.20; found: 678.4/660.1.
- This compound was prepared using procedures analogous to those described for Example 252 Step 2 using N-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]methanesulfonamide and iodomethane. LCMS calcd. for C33H43ClN3O7S2 [M+H]+: m/z=692.22/692.42; found: 692.7/694.7. 1H NMR (300 MHz, CDCl3) δ 8.81 (s, 1H), 7.64 (d, J=8.6 Hz, 1H), 7.49 (d, J=8.4 Hz, 1H), 7.21-6.91 (m, 4H), 5.84 (dd, J=15.3, 8.7 Hz, 1H), 5.33 (s, 1H), 4.17 (s, 3H), 3.95 (s, 2H), 3.69-3.52 (m, 3H), 3.37 (d, J=14.4 Hz, 1H), 3.23 (s, 1H), 2.75 (m, 8H), 2.37-1.61 (m, 5H), 1.45 (d, J=12.0 Hz, 6H), 1.36-1.23 (m, 3H).
-
-
- This compound was prepared using procedures analogous to those described for Example 251 Step 4 using (3R,6R,7S,8E,22S)-7-amino-6′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 254 Step 4) and N,N-dimethylcarbamoyl chloride. LCMS calcd. for C34H44ClN4O6S (M+H)+: m/z=671.27/673.26; found: 671.5/673.4.
- This compound was prepared using procedures analogous to those described for Example 252 Step 2 using 1,1-dimethyl-3-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24] pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl]urea and iodomethane. LCMS calcd. for C35H46ClN4O6S [M+H]+: m/z=685.28/687.28; found: 685.7/687.7. 1H NMR (500 MHz, CDCl3) δ 9.07 (s, 1H), 7.67-7.55 (m, 2H), 7.18-7.10 (m, 1H), 7.03 (s, 2H), 6.84 (d, J=8.4 Hz, 1H), 5.89 (d, J=10.0 Hz, 1H), 5.56 (d, J=15.1 Hz, 1H), 5.42 (s, 1H), 4.14 (d, J=10.7 Hz, 3H), 4.06 (d, J=11.8 Hz, 1H), 4.01-3.89 (m, 3H), 3.86 (d, J=12.9 Hz, 2H), 3.47 (d, J=15.2 Hz, 2H), 3.26 (d, J=19.2 Hz, 2H), 2.98 (d, J=14.6 Hz, 1H), 2.66 (s, 2H), 2.58 (s, 3H), 2.37 (d, J=8.4 Hz, 1H), 2.13 (s, 1H), 2.06-1.99 (m, 2H), 1.85 (s, 3H), 1.44 (d, J=14.9 Hz, 4H), 1.31 (s, 6H).
-
- This compound was prepared using procedures analogous to those described for Example 65 using 3,3-difluoroazetidine hydrochloride to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C36H45ClN3O6S [M+H]+: m/z=720.26/722.26; Found: 720.5/722.6.
-
- This compound was prepared using procedures analogous to those described for Example 65 using methylpiperazine to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C38H52ClN4O6S [M+H]+: m/z=727.32/729.32; Found: 727.5/729.7; 1H NMR (600 MHz, DMSO-d6) δ 7.63-7.59 (m, 1H), 7.30 (dd, J=8.3, 2.1 Hz, 1H), 7.24 (dd, J=8.5, 2.3 Hz, 1H), 7.20 (d, J=2.3 Hz, 1H), 7.07-7.04 (m, 2H), 5.56 (dd, J=15.7, 7.2 Hz, 1H), 5.36 (s, 1H), 4.07 (dt, J=27.4, 13.7 Hz, 3H), 3.91-3.85 (m, 2H), 3.32 (m, 6H), 3.15 (m, 3H), 2.80-2.76 (m, 2H), 2.74 (s, 4H), 2.65 (dd, J=3.9, 1.9 Hz, 1H), 2.47-2.38 (m, 2H), 2.34-2.23 (m, 1H), 2.04-1.93 (m, 3H), 1.91-1.76 (m, 5H), 1.74-1.69 (m, 1H), 1.61-1.55 (m, 2H), 1.47 (d, J=6.6 Hz, 1H), 1.38 (s, 3H), 1.26 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 65 using (R)-3-methoxypyrrolidine to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C38H51ClN3O7S [M+H]+: m/z=728.31/730.30; Found: 728.5/730.7; 1H NMR (300 MHz, DMSO-d6) δ 9.95 (s, 1H, NH), 7.61 (d, J=8.5 Hz, 1H), 7.32-7.17 (m, 3H), 7.03 (t, J=7.7 Hz, 2H), 5.57 (dd, J=15.7, 6.8 Hz, 1H), 5.46-5.31 (m, 1H), 4.08 (m, 3H), 3.87 (dd, J=14.2, 5.8 Hz, 1H), 3.68-3.58 (m, 3H), 3.32 (m, 6H), 3.23 (m, 4H), 3.20-3.08 (m, 4H), 2.79-2.62 (m, 3H), 2.28-2.18 (m, 1H), 1.96 (dd, J=18.5, 9.0 Hz, 2H), 1.84 (s, 4H), 1.77-1.61 (m, 2H), 1.58 (d, J=8.2 Hz, 2H), 1.37 (s, 3H), 1.24 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 65 using -methoxyazetidine hydrochloride to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C37H49ClN3O7S [M+H]+: m/z=714.29/716.29; Found: 714.5/716.7; 1H NMR (300 MHz, DMSO-d6) δ 7.61 (d, J=8.5 Hz, 1H), 7.31-7.15 (m, 3H), 7.02 (dd, J=9.3, 5.7 Hz, 2H), 5.56 (dd, J=15.6, 6.1 Hz, 1H), 5.48 (s, 1H), 4.36 (s, 1H), 4.27-4.13 (m, 2H), 4.11-4.02 (m, 2H), 3.90 (m, 2H), 3.63 (s, 1H), 3.53 (d, J=8.2 Hz, 2H), 3.32 (m, 5H), 3.22 (d, J=7.3 Hz, 4H), 3.19-3.09 (m, 2H), 2.76 (dd, J=21.0, 12.7 Hz, 2H), 2.66 (s, 1H), 2.41 (s, 2H), 1.96 (d, J=13.3 Hz, 1H), 1.84 (d, J=4.1 Hz, 4H), 1.71 (d, J=8.3 Hz, 1H), 1.55 (d, J=7.0 Hz, 2H), 1.37 (s, 3H), 1.24 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 65 using azetidine hydrochloride to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C37H47ClN3O6S [M+H]+: m/z=684.28/686.28; Found: 684.4/686.2; 1H NMR (300 MHz, CDCl3) δ 10.60 (s, 1H, NH), 7.68 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.0 Hz, 1H), 7.18 (dd, J=8.5, 2.0 Hz, 1H), 7.09 (d, J=2.0 Hz, 1H), 7.01-6.96 (m, 1H), 6.87 (t, J=4.3 Hz, 1H), 6.01 (dd, J=15.7, 3.9 Hz, 1H), 5.70 (dd, J=15.6, 5.4 Hz, 1H), 4.14-3.94 (m, 5H), 3.76 (dd, J=14.2, 5.2 Hz, 3H), 3.57-3.45 (m, 3H), 3.38 (d, J=14.9 Hz, 3H), 3.11 (dd, J=15.0, 11.0 Hz, 2H), 2.76 (M, 4H), 2.28 (d, J=7.5 Hz, 1H), 2.23-2.05 (m, 2H), 2.00 (dd, J=14.1, 5.9 Hz, 4H), 1.81 (dd, J=16.2, 8.1 Hz, 2H), 1.73-1.58 (m, 2H), 1.50 (d, J=10.2 Hz, 3H), 1.34 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 65 using piperidine to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C37H51ClN3O6S [M+H]+: m/z=712.31/714.31; Found: 712.4/714.3; 1H NMR (300 MHz, CDCl3) δ 9.53 (s, 1H, NH), 7.67 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.0 Hz, 1H), 7.18 (dd, J=8.5, 2.1 Hz, 1H), 7.10 (d, J=2.0 Hz, 1H), 7.02-6.98 (m, 1H), 6.94 (t, J=3.4 Hz, 1H), 5.89 (dd, J=15.6, 3.3 Hz, 1H), 5.64 (dd, J=15.6, 6.1 Hz, 1H), 4.12 (d, J=5.8 Hz, 2H), 4.03 (dd, J=13.0, 5.2 Hz, 2H), 3.71 (d, J=15.0 Hz, 6H), 3.36 (d, J=14.5 Hz, 4H), 3.18 (dd, J=15.1, 9.6 Hz, 1H), 2.79 (d, J=4.0 Hz, 5H), 2.27-2.18 (m, 1H), 2.02-1.77 (m, 12H), 1.66 (dd, J=17.9, 8.9 Hz, 2H), 1.47 (s, 3H), 1.36 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 65 using (3R)-3-fluoropyrrolidine hydrochloride to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C37H48ClFN3O6S [M+H]+: m/z=716.3/718.3. Found: 716.4/718.2. 1H NMR (300 MHz, CDCl3) δ 7.70 (d, J=8.5 Hz, 1H), 7.47 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.99 (d, J=8.3 Hz, 1H), 6.83 (d, J=2.2 Hz, 1H), 6.08-5.89 (m, 1H), 5.75 (dd, J=15.6, 6.7 Hz, 1H), 5.36 (d, J=53.3 Hz, 1H), 4.66-4.24 (m, 2H), 4.20-3.96 (m, 4H), 3.84-3.69 (m, 3H), 3.46 (qd, J=24.9, 22.1, 13.2 Hz, 7H), 3.14 (dd, J=15.0, 10.7 Hz, 2H), 2.85-2.65 (m, 3H), 2.36-2.09 (m, 5H), 1.89-1.66 (m, 5H), 1.49 (s, 3H), 1.32 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 65 using (3S)-3-fluoropyrrolidine hydrochloride to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C37H48ClFN3O6S [M+H]+: m/z=716.3/718.3. Found: 716.4/718.2. 1H NMR (300 MHz, CDCl3) δ 7.68 (d, J=8.5 Hz, 1H), 7.48 (dd, J=8.3, 2.1 Hz, 1H), 7.18 (dd, J=8.5, 2.4 Hz, 1H), 7.09 (d, J=2.3 Hz, 1H), 6.99 (d, J=8.3 Hz, 1H), 6.89 (d, J=2.2 Hz, 1H), 6.08-5.84 (m, 1H), 5.72 (dd, J=15.7, 6.3 Hz, 1H), 5.33 (d, J=53.0 Hz, 1H), 4.26 (t, J=9.1 Hz, 2H), 4.17-4.02 (m, 4H), 3.77 (t, J=14.1 Hz, 3H), 3.59-3.33 (m, 7H), 3.16 (dd, J=15.1, 10.3 Hz, 2H), 2.82-2.74 (m, 3H), 2.28 (ddd, J=35.2, 19.4, 11.1 Hz, 5H), 1.95-1.64 (m, 5H), 1.49 (s, 3H), 1.35 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 1 and (3R)-3-methoxypyrrolidine hydrochloride in Step 2. LC-MS: calc. for C36H43ClN3O9S [M+H]−: m/z=728.2/730.2; Found: 728.5/730.5. 1H NMR (300 MHz, CDCl3) δ 7.56 (d, J=8.5 Hz, 1H), 7.48 (ddd, J=7.8, 5.4, 2.1 Hz, 1H), 7.05 (dd, J=4.8, 2.2 Hz, 1H), 6.97 (d, J=8.3 Hz, 1H), 6.92 (dd, J=8.4, 2.2 Hz, 1H), 6.85 (d, J=2.1 Hz, 1H), 6.15-5.77 (m, 1H), 5.77-5.51 (m, 1H), 5.23 (d, J=8.3 Hz, 1H), 4.24 (dtd, J=31.1, 11.4, 8.1 Hz, 3H), 4.11-3.91 (m, 4H), 3.74-3.62 (m, 4H), 3.44 (q, J=7.4, 6.2 Hz, 3H), 3.36 (s, 3H), 3.32 (s, 2H), 3.20-3.09 (m, 1H), 2.79 (q, J=7.2 Hz, 2H), 2.06-1.95 (m, 3H), 1.85-1.77 (m, 2H), 1.60 (p, J=9.2 Hz, 1H), 1.42 (s, 3H), 1.33 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 65 using N,O-dimethylhydroxylamine hydrochloride to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C35H47ClFN3O6S [M+H]+: m/z=688.3/690.3; Found: 688.3/690.3. 1H NMR (300 MHz, CDCl3) δ 7.66 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 7.03-6.92 (m, 2H), 5.87 (d, J=16.2 Hz, 1H), 5.66 (dd, J=15.6, 6.5 Hz, 1H), 5.36 (d, J=1.0 Hz, 1H), 4.37 (s, 3H), 4.18-3.99 (m, 4H), 3.84 (s, 3H), 3.74 (d, J=5.3 Hz, 1H), 3.68 (s, 1H), 3.62-3.54 (m, 1H), 3.47-3.32 (m, 4H), 3.20 (dd, J=15.0, 9.5 Hz, 1H), 3.09 (s, 3H), 2.79 (d, J=4.5 Hz, 3H), 2.32-2.21 (m, 1H), 2.01-1.90 (m, 3H), 1.79 (q, J=9.4, 8.9 Hz, 2H), 1.47 (s, 3H), 1.37 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 65 using diethylamine in THF (2.0 M) to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C37H51ClFN3O6S [M+H]+: m/z=700.3/702.3. Found: 700.3/702.3.
-
- This compound was prepared using procedures analogous to those described for Example 65 using (3S,4R)-3,4-difluoropyrrolidine hydrochloride to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C37H47ClF2N3O6S [M+H]+: m/z=734.3/736.3. Found: 734.3/736.3.
-
- This compound was prepared using procedures analogous to those described for Example 65 using morpholine to replace dimethylamine in THF (2.0 M) in Step 5. LCMS calc. for C37H49ClN3O7S [M+H]+: m/z=714.29/716.29; Found: 714.7/716.8.
-
- This compound was prepared using procedures analogous to those described for Example 65 Step 1-5 using (3R,6R,7R,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 36) in Step 1 and morpholine in Step 5. LCMS calc. for C37H49ClN3O7S [M+H]+: m/z=714.29/716.29; Found: 714.7/716.8. 1H NMR (300 MHz, CDCl3) δ 9.43 (s, 1H), 7.70 (d, J=8.5 Hz, 1H), 7.54 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 7.05-6.93 (m, 2H), 5.92 (dt, J=15.7, 4.5 Hz, 1H), 5.73 (dd, J=15.7, 8.5 Hz, 1H), 4.10 (d, J=2.0 Hz, 2H), 3.99 (m, 2H), 3.87 (d, J=6.5 Hz, 1H), 3.71 (dt, J=24.9, 14.9 Hz, 6H), 3.36-3.22 (m, 4H), 3.01 (m, 3H), 2.79 (m, 2H), 2.45 (m, 1H), 2.40-2.32 (m, 1H), 2.24 (m, 1H), 1.99 (m, 3H), 1.84 (m, 3H), 1.71-1.62 (m, 1H), 1.47 (m, 1H), 1.41 (d, J=15.2 Hz, 6H), 1.35-1.25 (m, 2H).
-
- This compound was prepared using procedures analogous to those described for Example 65 Step 1-5 using (3R,6R,7R,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 36) in Step 1 and 3,3-difluoroazetidine hydrochloride in Step 5. LCMS calc. for C36H45ClF2N3O6S [M+H]+: m/z=720.27/722.27; Found: 720.7/722.7. 1H NMR (300 MHz, CDCl3) δ 9.47 (s, 1H), 7.70 (d, J=8.5 Hz, 1H), 7.54 (dd, J=8.3, 2.1 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 7.01 (d, J=8.3 Hz, 1H), 6.93 (d, J=2.2 Hz, 1H), 5.91 (dt, J=15.7, 4.6 Hz, 1H), 5.71 (dd, J=15.7, 8.6 Hz, 1H), 4.11 (s, 2H), 3.99 (m, 2H), 3.91 (m, 1H), 3.87 (d, J=6.5 Hz, 1H), 3.77 (d, J=14.4 Hz, 1H), 3.70 (dd, J=8.6, 4.9 Hz, 1H), 3.60 (m, 2H), 3.52 (m, 3H), 3.27 (m, 2H), 3.07 (dd, J=15.1, 10.1 Hz, 1H), 2.78 (m, 2H), 2.46 (t, J=9.1 Hz, 1H), 2.31 (dt, J=15.5, 9.8 Hz, 1H), 2.11-1.92 (m, 3H), 1.91-1.79 (m, 2H), 1.68 (m, 2H), 1.50 (m, 1H), 1.41 (d, J=11.1 Hz, 6H), 1.30 (m, 2H).
-
- This compound was prepared using procedures analogous to those described for Example 65 Step 1-5 using (3R,6R,7R,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 36) in Step 1 and dimethylamine in THF (2 M) in Step 5. LCMS calc. for C35H47ClN3O6S [M+H]+: m/z=672.3/674.3; Found: 672.4/674.3. 1H NMR (600 MHz, DMSO-d6) δ 9.24 (s, 1H), 7.63 (d, J=8.6 Hz, 1H), 7.26 (dd, J=8.5, 2.3 Hz, 2H), 7.19 (d, J=2.4 Hz, 1H), 7.02 (d, J=8.4 Hz, 1H), 6.82 (d, J=2.3 Hz, 1H), 6.08 (d, J=13.9 Hz, 1H), 5.43 (dd, J=16.0, 8.7 Hz, 1H), 4.14-4.03 (m, 3H), 3.74-3.66 (m, 2H), 3.61 (d, J=14.6 Hz, 1H), 3.54 (m, 1H), 3.47 (m, 2H), 3.24 (m, 3H), 3.11 (dd, J=15.3, 10.2 Hz, 1H), 2.79 (m, 7H), 2.73 (m, 1H), 2.39 (d, J=1.9 Hz, 1H), 2.10 (m, 1H), 1.98 (m, 4H), 1.85 (m, 2H), 1.73-1.69 (m, 1H), 1.47 (m, 1H), 1.35 (s, 3H), 1.23 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 65 Step 1-5 using (3R,6R,7R,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 36) in Step 1 and pyrrolidine in Step 5. LCMS calc. for C37H48ClN3O6S [M+H]+: m/z=698.3/700.3; Found: 698.4/700.3. 1H NMR (600 MHz, DMSO-d6) δ 9.37 (s, 1H), 7.64 (d, J=8.5 Hz, 1H), 7.26 (dd, J=8.5, 2.3 Hz, 2H), 7.23-7.16 (m, 1H), 7.05-6.99 (m, 1H), 6.83 (d, J=2.2 Hz, 1H), 6.07 (d, J=16.2 Hz, 1H), 5.44 (dd, J=15.9, 8.8 Hz, 1H), 4.09 (m, 3H), 3.67 (m, 1H), 3.61 (d, J=14.6 Hz, 1H), 3.55-3.41 (m, 6H), 3.19-2.95 (m, 5H), 2.89-2.64 (m, 3H), 2.13-2.06 (m, 1H), 1.99 (m, 6H), 1.84 (m, 4H), 1.71 (m, 2H), 1.47 (d, J=7.9 Hz, 1H), 1.36 (s, 3H), 1.23 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 65 Step 1-5 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 43) in Step 1 and 3-fluoroazetidine hydrochloride in Step 5. LCMS calc. for C37H49ClFN4O5S [M+H]+: m/z=715.31/717.31; Found: 715.4/717.4.
-
- This compound was prepared using procedures analogous to those described for Example 65 Step 1-5 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 43) in Step 1 and (3R)-3-fluoropyrrolidine hydrochloride in Step 5. LCMS calc. for C38H51ClFN4O5S [M+H]+: m/z=729.32/731.31; Found: 729.5/731.5.
-
- This compound was prepared using procedures analogous to those described for Example 65 Step 1-5 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 43) in Step 1 and 1-(2-methoxyethyl)-1,4-diazepane in Step 5. LCMS calc. for C42H61ClN5O6S [M+H]+: m/z=798.40/800.40; Found: 798.5/800.5.
-
- To a solution of isobutoxycarbonyl 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxyacetate (40.0 mg, 0.05 mmol, Example 65 Step 3) in THF (4 mL) was added triethylamine (0.07 mL, 0.50 mmol). The mixture was stirred at r.t. for 5 min, followed by adding of 3,3-difluoroazetidine hydrochloride (65.2 mg, 0.50 mmol). The mixture was then stirred at r.t. for an additional 4 h. LCMS showed that the starting material was consumed. The reaction was quenched by 1N HCl (2 mL), and extracted with DCM (3 mL×2). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC on a C18 column using H2O/ACN (20-100%) to afford (3R,6R,7S,8E,22S)-6′-chloro-7-[2-(3,3-difluoroazetidin-1-yl)-2-oxo-ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (9 mg, 21% yield). LCMS calc. for C36H43ClF2N3O7S [M+H]+: m/z=734.2; Found: 734.5. 1H NMR (300 MHz, CDCl3) δ 9.08 (s, 1H), 7.72-7.58 (m, 1H), 7.52 (m, 1H), 7.37 (dd, J=4.3, 2.0 Hz, 1H), 7.20 (dd, J=8.5, 2.4 Hz, 1H), 7.12 (d, J=2.9 Hz, 1H), 7.02 (dd, J=8.5, 3.4 Hz, 1H), 5.85-5.48 (m, 2H), 4.66 (m, 2H), 4.39 (m, 2H), 4.27-4.07 (m, 3H), 4.03-3.90 (m, 2H), 3.88-3.64 (m, 3H), 3.52 (m, 1H), 3.42-3.28 (m, 2H), 2.89-2.63 (m, 3H), 2.41 (m, 1H), 2.11-1.76 (m, 6H), 1.72-1.53 (m, 2H), 1.49-1.33 (m, 6H).
-
- This compound was prepared using procedures analogous to those described for Example 278 using azetidine hydrochloride to replace 3,3-difluoroazetidine hydrochloride. LCMS calc. for C36H45ClN3O7S [M+H]+: m/z=698.2; Found: 698.3. 1H NMR (300 MHz, CDCl3) δ 9.17 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.52 (dd, J=8.3, 2.1 Hz, 1H), 7.20 (dd, J=8.5, 2.3 Hz, 1H), 7.13 (m, 2H), 7.00 (m, 1H), 6.83 (d, J=8.2 Hz, 1H), 5.77 (m, 1H), 5.61 (dd, J=15.7, 6.4 Hz, 1H), 4.48-4.26 (m, 2H), 4.23-4.03 (m, 5H), 4.01-3.65 (m, 5H), 3.46-3.33 (m, 2H), 3.26 (m, 2H), 2.80 (m, 2H), 2.33 (m, 2H), 2.06-1.91 (m, 3H), 1.86 (m, 2H), 1.64 (s, 3H), 1.43 (d, J=20.2 Hz, 6H).
-
- This compound was prepared using procedures analogous to those described for Example 278 using 3-methoxyazetidine hydrochloride to replace 3,3-difluoroazetidine hydrochloride. LCMS calc. for C37H47ClN3O7S [M+H]+: m/z=728.2; Found: 728.3. 1H NMR (300 MHz, CDCl3) δ 9.17 (s, 1H), 7.67 (dd, J=8.5, 3.9 Hz, 1H), 7.52 (dd, J=8.4, 1.9 Hz, 1H), 7.20-7.10 (m, 2H), 7.08-6.94 (m, 2H), 6.83 (d, J=8.3 Hz, 1H), 5.85-5.46 (m, 2H), 4.65-4.39 (m, 1H), 4.39-4.17 (m, 3H), 4.15-3.84 (m, 6H), 3.82-3.67 (m, 2H), 3.55 (q, J=6.9 Hz, 1H), 3.45-3.33 (m, 2H), 3.31 (d, J=10.4 Hz, 3H), 3.23 (d, J=15.0 Hz, 1H), 2.83-2.69 (m, 2H), 2.45-2.29 (m, 1H), 2.29-2.14 (m, 1H), 2.07-1.78 (m, 7H), 1.59-1.50 (m, 1H), 1.52-1.33 (m, 6H).
-
- This compound was prepared using procedures analogous to those described for Example 278 using 3-fluoroazetidine hydrochloride to replace 3,3-difluoroazetidine hydrochloride. LCMS calc. for C36H44ClFN3O7S [M+H]+: m/z=716.2; Found: 716.3. 1H NMR (300 MHz, CDCl3) δ 9.16 (d, J=22.6 Hz, 1H), 7.67 (t, J=7.7 Hz, 1H), 7.52 (dd, J=8.3, 2.0 Hz, 1H), 7.23-7.11 (m, 2H), 7.11-6.93 (m, 2H), 6.83 (d, J=7.8 Hz, 1H), 5.94-5.52 (m, 2H), 5.33 (d, J=57.0 Hz, 1H), 4.89-4.57 (m, 1H), 4.46 (m, 2H), 4.25-4.01 (m, 5H), 3.94-3.54 (m, 4H), 3.49-3.09 (m, 3H), 2.79 (m, 2H), 2.36 (m, 1H), 2.12-1.76 (m, 5H), 1.65 (m, 3H), 1.56-1.34 (m, 6H).
-
- This compound was prepared using procedures analogous to those described for Example 278 using 4-aminotetrahydropyran to replace 3,3-difluoroazetidine hydrochloride. LCMS calc. for C83H49ClN3O8S [M+H]+: m/z=742.29/744.28; Found: 742.4/744.3; 1H NMR (300 MHz, CDCl3) δ 7.65 (d, J=8.4 Hz, 1H), 7.43 (s, 1H), 7.15 (d, J=8.7 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 7.03 (d, J=2.1 Hz, 1H), 6.89 (s, 1H), 6.46 (s, 1H), 5.60 (dd, J=15.4, 6.6 Hz, 1H), 4.10-3.78 (m, 10H), 3.68 (d, J=14.4 Hz, 1H), 3.40-3.36 (m, 5H), 2.75 (d, J=18.9 Hz, 3H), 2.37 (d, J=9.6 Hz, 1H), 1.91-1.84 (m, 9H), 1.66 (d, J=9.1 Hz, 1H), 1.50-1.48 (m, 2H), 1.39 (s, 3H), 1.35 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 278 using pyrrolidine to replace 3,3-difluoroazetidine hydrochloride. LCMS calc. for C36H43ClF2N3O7S [M+H]+: m/z=712.2; Found: 712.4. 1H NMR (300 MHz, CDCl3) δ 9.16 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.52 (dd, J=8.3, 2.1 Hz, 1H), 7.23-7.16 (m, 1H), 7.11 (d, J=2.3 Hz, 1H), 7.08-6.95 (m, 2H), 5.74 (dt, J=15.7, 4.6 Hz, 1H), 5.62 (dd, J=15.7, 6.7 Hz, 1H), 4.19 (m, 2H), 4.13 (m, 2H), 4.01 (d, J=14.0 Hz, 1H), 3.92-3.84 (m, 2H), 3.70 (d, J=14.6 Hz, 1H), 3.51 (m, 3H), 3.41 (m, 1H), 3.29 (dd, J=14.9, 8.4 Hz, 1H), 2.87-2.63 (m, 3H), 2.44 (dt, J=9.6, 4.8 Hz, 1H), 1.92 (m, 8H), 1.60 (m, 2H), 1.42 (d, J=9.5 Hz, 6H).
-
- This compound was prepared using procedures analogous to those described for Example 278 using (3R)-tetrahydrofuran-3-amine to replace 3,3-difluoroazetidine hydrochloride. LCMS calc. for C37H47ClN3O8S [M+H]+: m/z=728.3/730.3; Found: 728.4/730.4. 1H NMR (300 MHz, CDCl3) δ 9.38 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.53 (dd, J=8.3, 2.1 Hz, 1H), 7.20 (dd, J=8.5, 2.3 Hz, 1H), 7.11 (d, J=2.3 Hz, 1H), 7.05-6.98 (m, 2H), 6.89 (d, J=7.7 Hz, 1H), 5.80 (ddd, J=16.0, 6.9, 3.3 Hz, 1H), 5.63 (dd, J=15.8, 5.9 Hz, 1H), 4.56 (ddt, J=10.5, 7.5, 3.2 Hz, 1H), 4.19-3.95 (m, 6H), 3.87-3.74 (m, 6H), 3.42-3.20 (m, 3H), 2.80 (dt, J=12.3, 6.4 Hz, 3H), 2.41-2.19 (m, 2H), 2.09-1.80 (m, 7H), 1.67 (t, J=9.3 Hz, 1H), 1.47 (s, 3H), 1.39 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 278 using (3S)-tetrahydrofuran-3-amine to replace 3,3-difluoroazetidine hydrochloride. LCMS calc. for C37H47ClN3O8S [M+H]+: m/z=728.3/730.3; Found: 728.4/730.4. 1H NMR (300 MHz, CDCl3) δ 9.44 (s, 1H), 7.66 (d, J=8.5 Hz, 1H), 7.53 (dd, J=8.4, 2.0 Hz, 1H), 7.20 (dd, J=8.5, 2.2 Hz, 1H), 7.11 (d, J=2.2 Hz, 1H), 7.04-6.98 (m, 2H), 5.81 (ddd, J=15.9, 6.7, 3.6 Hz, 1H), 5.66 (dd, J=15.9, 6.1 Hz, 1H), 5.35-5.27 (m, 1H), 4.58 (tt, J=7.3, 3.7 Hz, 1H), 4.19-3.94 (m, 6H), 3.88-3.65 (m, 6H), 3.47-3.21 (m, 3H), 2.78 (dt, J=19.1, 5.7 Hz, 3H), 2.45-2.23 (m, 2H), 2.10-1.80 (m, 7H), 1.67 (t, J=9.3 Hz, 1H), 1.46 (s, 3H), 1.39 (s, 3H).
-
- To a solution of (3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate (35.0 mg, 0.05 mmol, Example 34) in ethyl acetate (3 mL) was added platinum(IV) oxide (2.36 mg, 0.01 mmol). The mixture was then purged by H2 gas in balloon for 2 times, and stirred at r.t. for 2 h under H2 atmosphere. LCMS showed that most of the starting material was consumed. The mixture was filtered through Celite and concentrated under reduced pressure. The resulting residue was then purified by prep-HPLC on a C18 column using H2O/ACN (20-100%) to provide [(3R,6R,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-16,18,24-triene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate (7.4 mg, 21.1% yield) as a white solid. LCMS calc. for C34H43ClN3O7S [M+H]+: m/z=674.26/677.26; Found: 674.7/679.6; 1H NMR (600 MHz, DMSO-d6) δ 7.61 (q, J=8.0 Hz, 1H), 7.31-7.16 (m, 4H), 7.00 (dt, J=17.3, 8.5 Hz, 1H), 4.76-4.64 (m, 1H), 4.14-4.09 (m, 1H), 4.06-4.00 (m, 1H), 3.54-3.43 (m, 3H), 3.25 (t, J=14.6 Hz, 2H), 3.10-2.96 (m, 2H), 2.85-2.74 (m, 3H), 2.74-2.65 (m, 3H), 2.58 (d, J=14.1 Hz, 2H), 2.24 (s, 1H), 1.96-1.89 (m, 2H), 1.85-1.73 (m, 3H), 1.73-1.52 (m, 5H), 1.49-1.35 (m, 2H), 1.28 (s, 3H), 1.23 (d, J=16.5 Hz, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 65 Step 1-5 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 43) in Step 1 and 3,3-difluoroazetidine hydrochloride in Step 5. LCMS calc. for C37H48ClF2N4O5S [M+H]+: m/z=733.30/735.30; Found: 733.3/735.1. 1H NMR (300 MHz, CDCl3) δ 7.74-7.45 (m, 2H), 7.22-7.18 (m, 2H), 7.09 (s, 1H), 7.03-6.89 (m, 1H), 6.02 (s, 1H), 5.71-5.46 (m, 1H), 5.36 (s, 1H), 4.23-3.94 (m, 4H), 3.87 (d, J=18.4 Hz, 1H), 3.69 (s, 3H), 3.33 (d, J=15.2 Hz, 2H), 3.06 (s, 1H), 2.79 (s, 3H), 2.46 (s, 2H), 2.25 (t, J=7.7 Hz, 2H), 1.64 (d, J=7.4 Hz, 1H), 1.46 (s, 3H), 1.33 (s, 16H).
-
- This compound was prepared using procedures analogous to those described for Example 65 Step 1-5 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 43) in Step 1 and 3,3-difluoropyrrolidine hydrochloride in Step 5. LCMS calc. for C38H50ClF2N4O5S [M+H]+: m/z=747.32/749.31; Found: 747.4/749.3. 1H NMR (300 MHz, CDCl3) δ 7.71-7.49 (m, 1H), 7.39-7.12 (m, 4H), 7.08-6.84 (m, 1H), 6.00 (s, 2H), 5.61 (d, J=17.9 Hz, 2H), 5.37 (s, 2H), 3.72 (d, J=14.2 Hz, 4H), 3.52 (s, 3H), 3.11 (s, 1H), 2.80 (s, 1H), 2.62 (m, 15H), 2.54 (s, 2H), 2.39-2.21 (m, 3H), 2.04 (s, 5H), 1.66 (d, J=7.4 Hz, 2H).
-
- This compound was prepared using procedures analogous to those described for Example 65 Step 1-5 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (Example 43) in Step 1 and piperidine in Step 5. LCMS calc. for C39H54ClN4O5S [M+H]+: m/z=725.35/727.35; Found: 725.3/727.6. 1H NMR (300 MHz, CDCl3) δ 11.57 (s, 1H), 7.67 (d, J=8.5 Hz, 1H), 7.52 (dd, J=8.3, 2.0 Hz, 1H), 7.09 (d, J=2.3 Hz, 2H), 7.02-6.88 (m, 2H), 5.95 (d, J=45.7 Hz, 2H), 5.60 (d, J=15.9 Hz, 1H), 5.42-5.28 (m, 1H), 4.20-4.00 (m, 3H), 3.72 (dd, J=24.6, 13.3 Hz, 4H), 3.31 (d, J=14.6 Hz, 1H), 3.06 (s, 2H), 2.53 (s, 3H), 2.38-2.20 (m, 2H), 2.00 (d, J=7.1 Hz, 1H), 1.84 (s, 3H), 1.69-1.24 (m, 23H).
-
- This compound was prepared using procedures analogous to those described for Example 278 using (3R,4R)-3,4-difluoropyrrolidine to replace 3,3-difluoroazetidine hydrochloride. LCMS calc. for C37H45ClF2N3O7S [M+H]+: m/z=748.3/750.3; Found: 748.4/750.4. 1H NMR (300 MHz, CDCl3) δ 7.66 (d, J=8.5 Hz, 1H), 7.49 (dt, J=8.4, 1.7 Hz, 1H), 7.18 (dt, J=8.5, 1.8 Hz, 1H), 7.09 (t, J=1.8 Hz, 1H), 7.05-6.95 (m, 2H), 5.82-5.53 (m, 2H), 5.19 (ddd, J=50.3, 15.9, 4.2 Hz, 2H), 4.11-3.64 (m, 12H), 3.44-3.22 (m, 3H), 2.84-2.69 (m, 3H), 2.37 (dd, J=9.2, 3.1 Hz, 1H), 2.03-1.78 (m, 7H), 1.63 (d, J=17.3 Hz, 1H), 1.42 (s, 3H), 1.37 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 278 using (3R,4S)-3,4-difluoropyrrolidine to replace 3,3-difluoroazetidine hydrochloride. C37H45ClF2N3O7S [M+H]+: m/z=748.3/750.3; Found: 748.4/750.4. 1H NMR (300 MHz, CDCl3) δ 7.65 (dd, J=8.5, 2.7 Hz, 1H), 7.48 (dt, J=8.4, 1.7 Hz, 1H), 7.18 (dt, J=8.5, 1.9 Hz, 1H), 7.09 (d, J=2.1 Hz, 1H), 7.00 (ddd, J=8.4, 4.1, 1.7 Hz, 2H), 5.85-5.56 (m, 2H), 5.26-4.95 (m, 2H), 4.17-3.66 (m, 12H), 3.45-3.17 (m, 3H), 2.85-2.66 (m, 3H), 2.38 (dq, J=10.6, 5.4, 3.0 Hz, 1H), 2.07-1.78 (m, 7H), 1.64 (t, J=8.7 Hz, 1H), 1.43 (s, 3H), 1.38 (s, 3H).
-
-
- To a solution of but-3-en-2-ol (410.0 mg, 5.69 mmol) and DIPEA (1.98 mL, 11.37 mmol) in MeCN (5 mL) was added 2-bromo-2-methyl-propanoic acid (636.18 mg, 3.81 mmol). The reaction mixture was stirred at 50° C. overnight. Upon completion, the solvent was removed under reduced pressure. The residue was dissolved in DCM (10 mL) and washed with 1 N HCl solution (10 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to yield 2-methyl-2-(1-methylallyloxy)propanoic acid (450 mg, 50.0% yield), which was used for the next reaction without further purification. TLC: Rf=0.1 (Heptane:EtOAc=1:1).
-
- To a solution of (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]-methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (180.0 mg, 0.36 mmol, Intermediate 3) and 2-methyl-2-(1-methylallyloxy)propanoic acid (169.81 mg, 1.07 mmol) in DCM (4 mL) was added 4-(dimethylamino)pyridine (262.28 mg, 2.15 mmol), followed by the addition of EDCI (274.37 mg, 1.43 mmol). The reaction mixture was stirred at r.t. overnight. The reaction was diluted with DCM (5 mL) and washed with 1N HCl solution (5 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to yield [1-[(1R,2R)-2-[[(3S)-6′-chloro-7-[[2-methyl-2-(1-methylallyloxy)propanoyl]sulfamoyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]-1-methyl-allyl] 2-methyl-2-(1-methylallyloxy)propanoate (295 mg, 103.4% yield), which was used for the next reaction without further purification. LCMS calc. for C43H58ClN2O8S [M+H]+: m/z=783.34/785.34; Found: 783.6/785.5.
-
- To a solution of [(1S)-1-[(1R,2R)-2-[[(3S)-6′-chloro-7-[[2-methyl-2-(1-methylallyloxy)propanoyl]sulfamoyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]allyl] 2-methyl-2-(1-methylallyloxy)propanoate (295.0 mg, 0.38 mmol) in THF (0.50 mL), methanol (0.50 mL) and water (0.50 mL) was added lithium hydroxide monohydrate (158.15 mg, 3.77 mmol). The reaction mixture was stirred at 45° C. for 2 h. The solvent was removed under reduced pressure. The residue was dissolved in DCM (5 mL) and washed with sat. NaHCO3solution (5 mL) and brine (5 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with EtOAc/Heptanes (5-30%) to afford the desired product N-[(3 S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-2-methyl-2-(1-methylallyloxy)propanamide (124 mg, 51.2% yield). LCMS calc. for C34H44ClN2O6S [M+H]+: m/z=643.24/645.24; Found: 643.4/645.3.
-
- To a solution of N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]-methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-2-methyl-2-(1-methylallyloxy)propanamide (124.0 mg, 0.19 mmol) in DCE (90 mL) was bubbled with N2 for 20 min. Then Zhan catalyst (28.26 mg, 0.04 mmol) was added and was bubbled with N2 for another 5 min. The reaction mixture was stirred at 45° C. for 2 h. The solvent was removed under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with EtOAc/Heptanes with 0.2% HOAc (5-65%) to afford two products: P1 (18 mg, the earlier eluted product) and P2 (74 mg, the latter eluted product). The first fraction P1 was assigned to cis-isomer (3R,6R,7S,8Z,22S)-6′-chloro-7-hydroxy-10,12,12-trimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (18 mg, 15.2% yield). The P2 was assigned to the trans-isomer (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-10,12,12-trimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (74 mg, 62.4% yield). LCMS calc. for C32H40ClN2O6S [M+H]+: m/z=615.22/617.22; Found: 615.3/617.2.
- To a solution of (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-10,12,12-trimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (15.0 mg, 0.02 mmol) in MeCN (1 mL) was added CDI (11.86 mg, 0.07 mmol). The reaction mixture was stirred at 45° C. for 2 h., and then cooled to r.t. Dimethylamine (0.025 mL, 0.05 mmol) (2.0 M in THF solution) was added. The reaction mixture was stirred at r.t. for 2 h. The reaction was concentrated under reduced pressure. The residue was purified by Prep-HPLC on a C18 column eluting with ACN/H2O (20%˜100%) to afford a mixture of the two desired products: Fraction 1 (3.8 mg) contained about 39% of Product 2 (Product 1/Product 2=55:35, Rt (P1)=8.02 min, Rt (P2)=8.18 min), and Fraction 2 (3.6 mg) contained 30% of Product 1 (Product 1/Product 2=29:67, Rt (P1)=8.02 min, Rt (P2)=8.18 min). [(3R,6R,7S,8E,22S)-6′-chloro-10,12,12-trimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate (3.8 mg, 21.8% yield). LCMS calc. for C35H45ClN3O7S [M+H]+: m/z=686.26/688.26; Found: 686.4/688.4. 1H NMR (600 MHz, DMSO-d6) δ 7.64 (dd, J=8.6, 4.5 Hz, 1H), 7.29-7.26 (m, 1H), 7.25 (d, J=2.5 Hz, 1H), 7.24 (d, J=2.4 Hz, 1H), 7.18 (dd, J=5.9, 2.4 Hz, 1H), 7.04 (s, 1H), 5.66 (d, J=14.2 Hz, 1H), 5.17 (s, 1H), 4.19 (s, 1H), 4.00 (d, J=12.2 Hz, 1H), 3.59 (d, J=14.3 Hz, 3H), 3.12 (s, 1H), 2.98 (s, 1H), 2.85 (s, 2H), 2.75 (s, 6H), 2.62 (s, 1H), 2.03-1.95 (m, 2H), 1.89-1.79 (m, 3H), 1.77-1.69 (m, 2H), 1.66-1.59 (m, 1H), 1.52-1.50 (m, 1H), 1.47-1.40 (m, 1H), 1.32 (s, 6H), 1.24 (s, 3H).
-
-
- To a suspension of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]-5-[[(1R,2R)-2-formylcyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (1450.0 mg, 2.03 mmol, Intermediate 3 Step 3) in 1-butanol (5 mL) and 2-methylbut-2-ene (5.0 mL, 47.2 mmol) was added sodium chlorite (458.34 mg, 4.05 mmol) and the solution of sodium phosphate monobasic monohydrate (559.45 mg, 4.05 mmol) in water (5 mL). The reaction was stirred at r.t. for 3 h. LCMS showed reaction was completed. The reaction was quenched with aq. 10% Na2S2O3(5 mL) and the mixture was extracted with ethyl acetate (2 mL×2). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was used directly without further purification. LCMS calc. for C40H42ClN2O7S [M−H]−: m/z=730.24/732.24; Found: 730.8/732.7.
-
- To a solution of [(1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutanecarbonyl]oxysodium (300.0 mg, 0.40 mmol) and N,O-dimethylhydroxylamine hydrochloride (77.69 mg, 0.80 mmol) in DCM (4 mL) was added DIPEA (0.28 mL, 1.59 mmol), followed by the addition of 1-[bis(dimethylamino)-methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (302.86 mg, 0.80 mmol) at 0° C. The reaction mixture was stirred at r.t. for 2 h. The reaction was diluted with DCM (5 mL) and washed with 1 N HCl solution (5 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with EtOAc/Heptanes (5-50%) to afford the desired product (1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]-N-methoxy-N-methyl-cyclobutanecarboxamide (232 mg, 75.2% yield). LCMS calc. for C42H49ClN3O7S [M+H]+: m/z=774.29/776.29; Found: 774.5/776.3.
-
- To a solution of methylmagnesium chloride THF solution (3 M in THF, 1.0 mL, 3 mmol) was added a solution of (1R,2R)-2-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]-N-methoxy-N-methyl-cyclobutanecarboxamide (232.0 mg, 0.30 mmol) in THF (2 mL) dropwise at 0° C. After addition, the reaction mixture was stirred at r.t. for 2 h. The reaction was quenched with aq. NH4Cl solution (5 mL) at 0° C. and extracted with ethyl acetate (5 mL×3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to afford the crude (3S)-5-[[(1R,2R)-2-acetylcyclobutyl]methyl]-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (300 mg) which contaminated with some inorganic salt and was used for the next reaction without further purification. LCMS calc. for C41H46ClN2O6S [M+H]+: m/z=729.27/731.27; Found: 729.5/731.4.
-
- To a solution of (3S)-5-[[(1R,2R)-2-acetylcyclobutyl]methyl]-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (300.0 mg, 0.41 mmol) in DCM (3 mL) was added Anisole (0.3 mL, 2.76 mmol) and TFA (3.0 mL, 39.2 mmol). The reaction mixture was stirred at r.t. overnight. The solvent was removed under reduced pressure. The residue was dissolved in DCM (5 mL) and washed with sat. NaHCO3solution (5 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with EtOAc/Heptanes (5-70%) to afford the desired product (3S)-5-[[(1R,2R)-2-acetylcyclobutyl]methyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (220 mg). LCMS calc. for C25H30ClN204S [M+H]+: m/z=489.15/491.15; Found: 489.2/491.4.
-
- To a solution of vinylmagnesium bromide THF solution (1.0 M in THF, 4.5 mL, 4.5 mmol) was added a solution of (3S)-5-[[(1R,2R)-2-acetylcyclobutyl]methyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (220.0 mg, 0.45 mmol) in THF (1 mL) dropwise at 0° C. After addition, the reaction mixture was stirred at r.t. for 2 h. The reaction was quenched by aq. NH4Cl (5 mL) and extracted with ethyl acetate (5 mL×3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with EtOAc/Heptanes (5-70%) to afford the desired product (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxy-1-methyl-allyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (85 mg, 36.5% yield). LCMS calc. for C27H33ClN2O4S [M+H]+: m/z=517.18/519.18; Found: 517.2/519.3.
-
- To a mixture of (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxy-1-methyl-allyl]-cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (85.0 mg, 0.16 mmol) and 2-allyloxy-2-methyl-propanoic acid (71.1 mg, 0.49 mmol, Example 30 Step 1) in DCM (1 mL) was added DMAP (120.5 mg, 0.99 mmol), followed by the addition of EDCI (126.05 mg, 0.66 mmol). The reaction mixture was stirred at r.t. overnight, and then diluted with DCM (5 mL). The mixture was and washed with 1N HCl solution (5 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to yield [(1S)-1-[(1R,2R)-2-[[(3S)-7-[(2-allyloxy-2-methyl-propanoyl)sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]-1-methyl-allyl] 2-allyloxy-2-methyl-propanoate (136 mg) which was directly used for the next reaction without further purification. LCMS calc. for C41H54ClN208S [M+H]+: m/z=769.32/771.32; Found: 769.5/771.5.
-
- To a solution of [(1S)-1-[(1R,2R)-2-[[(3S)-7-[(2-allyloxy-2-methyl-propanoyl)sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]cyclobutyl]-1-methyl-allyl] 2-allyloxy-2-methyl-propanoate (136.0 mg, 0.18 mmol) in THF (0.50 mL), methanol (0.50 mL) and water (0.50 mL) was added lithium hydroxide monohydrate (74.24 mg, 1.77 mmol). The reaction mixture was stirred at 45° C. for 6 h. The solvent was removed under reduced pressure. The residue was dissolved in DCM (5 mL) and washed with 1N HCl solution (5 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with EtOAc/Heptanes (5-60%) to afford the desired product 2-allyloxy-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxy-1-methyl-allyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-2-methyl-propanamide (83 mg, 73.0% yield). LCMS calc. for C34H44ClN2O6S [M+H]+: m/z=643.25/645.25; Found: 643.4/645.5.
-
- To a solution of 2-allyloxy-N-[(3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxy-1-methyl-allyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonyl-2-methyl-propanamide (83.0 mg, 0.13 mmol) in DCE (80 mL) was bubbled with N2 for 20 min. Then Zhan catalyst (18.92 mg, 0.03 mmol) was added and was bubbled with N2 for another 5 min. The reaction mixture was stirred at 45° C. for 2 h. Upon completion, the solvent was removed under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with EtOAc/Heptanes (5-60%), and further purified with Prep-HPLC on a C18 column eluting with ACN/H2O (20%˜100%) to afford the desired product (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-7,12,12-trimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one (2.6 mg, 3.3% yield). LCMS calc. for C32H40ClN2O6S [M+H]+: m/z=615.23/617.23; Found: 615.4/617.5. 1H NMR (300 MHz, CDCl3) δ 7.68 (d, J=8.5 Hz, 1H), 7.47 (s, 1H), 7.18 (d, J=9.2 Hz, 1H), 7.07 (d, J=2.3 Hz, 1H), 6.95 (s, 1H), 6.89 (d, J=2.2 Hz, 1H), 6.05 (s, 1H), 5.78 (d, J=15.4 Hz, 1H), 4.09 (s, 3H), 3.85-3.67 (m, 2H), 3.46 (d, J=14.5 Hz, 1H), 3.39-3.29 (m, 1H), 3.02 (d, J=14.2 Hz, 1H), 2.74 (d, J=19.5 Hz, 3H), 2.03-1.89 (m, 3H), 1.81 (t, J=8.5 Hz, 2H), 1.69 (s, 4H), 1.41 (s, 3H), 1.36 (s, 3H), 1.24 (d, J=7.2 Hz, 3H).
- This compound was prepared using procedures analogous to those described for Example 34 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-7,12,12-trimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one and dimethylcarbamoyl chloride. LCMS calc. for C35H45ClN3O7S [M+H]+: m/z=686.26/688.26; Found: 686.4/688.4. 1H NMR (300 MHz, CDCl3) δ 7.70 (d, J=8.5 Hz, 1H), 7.48 (dd, J=8.3, 2.2 Hz, 1H), 7.19 (dd, J=8.5, 2.4 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 6.98 (d, J=8.4 Hz, 1H), 6.93 (d, J=2.1 Hz, 1H), 6.04 (d, J=15.8 Hz, 1H), 5.85-5.71 (m, 1H), 4.09 (d, J=3.7 Hz, 2H), 3.92-3.83 (m, 1H), 3.78 (d, J=14.6 Hz, 1H), 3.59 (d, J=15.1 Hz, 1H), 3.34 (d, J=14.3 Hz, 1H), 3.10 (dd, J=15.1, 10.8 Hz, 1H), 2.94 (d, J=5.1 Hz, 6H), 2.79 (s, 2H), 2.24 (t, J=9.1 Hz, 1H), 2.01 (d, J=6.3 Hz, 2H), 1.85 (d, J=8.9 Hz, 1H), 1.65 (d, J=8.8 Hz, 7H), 1.61 (s, 3H), 1.43 (s, 3H), 1.36 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 292 Step 2-5 using (2S)-1-allylpyrrolidine-2-carboxylic acid HCl (Example 100 Step 2) and (3S)-6′-chloro-5-[[(1R,2R)-2-[(1S)-1-hydroxyallyl]cyclobutyl]methyl]spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (Intermediate 3) in Step 2, and dimethylcarbamoyl chloride in Step 5. LCMS calc. for C35H44ClN5O6S [M+H]+: m/z=683.26/685.26; Found: 683.4/685.4. 1H NMR (300 MHz, DMSO-d6) δ 8.96 (s, 1H), 7.62 (dd, J=8.6, 1.8 Hz, 1H), 7.29 (dd, J=8.5, 2.3 Hz, 1H), 7.16 (dd, J=3.7, 2.1 Hz, 2H), 6.99 (dd, J=8.1, 1.8 Hz, 1H), 6.76 (dd, J=8.2, 1.7 Hz, 1H), 5.88 (dd, J=15.6, 3.0 Hz, 1H), 5.18 (d, J=10.9 Hz, 1H), 5.08-4.93 (m, 1H), 4.05 (d, J=12.2 Hz, 1H), 3.92 (d, J=12.3 Hz, 1H), 3.75-3.58 (m, 3H), 3.57-3.42 (m, 3H), 3.17 (s, 1H), 3.14-3.08 (m, 1H), 3.05 (d, J=4.4 Hz, 1H), 2.96 (d, J=6.6 Hz, 1H), 2.78-2.70 (m, 1H), 2.66 (s, 3H), 2.51 (s, 3H), 2.41 (t, J=8.0 Hz, 2H), 2.33-2.24 (m, 1H), 2.15-1.85 (m, 5H), 1.79-1.59 (m, 5H), 1.38 (d, J=10.2 Hz, 1H).
-
- This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-6′-chloro-7-hydroxy-11-methyl-12,12-(1,3-propylene)-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one (Example 48 Step 8) in Step 2 and (3S)-tetrahydrofuran-3-amine in Step 1. LCMS calc. for C38H48ClN4O7S [M+H]+: m/z=739.29/741.29; Found: 739.3/741.4.
-
-
- To a mixture of ethyl 2-(1H-pyrazol-3-yl)acetate (1.0 g, 6.49 mmol) and cesium carbonate (4.25 g, 12.97 mmol) in DMF (35 mL) was added t-butyl bromoacetate (1.9 g, 9.73 mmol) dropwise. The mixture was stirred at r.t. overnight. The mixture was diluted with ethyl acetate (50 mL), washed with water (30 mL×3). The organic layer was dried over Na2SO4, filtered, and concentrated. The residue was purified with reverse phase HPLC (0.01% ammonia in water and acetonitrile) to get ethyl 2-[1-(2-tert-butoxy-2-oxo-ethyl)pyrazol-3-yl]acetate (370.5 mg, 20.6% yield) as a pale yellow oil. LCMS calc. for C13H21N2O4 [M+H]+: m/z=269.14; Found: 269.1. 1H NMR (400 MHz, CDCl3-d) δ 1.26 (t, J=7.2 Hz, 3H), 1.47 (s, 9H), 3.69 (s, 2H), 4.17 (q, J=6.8 Hz, 2H), 4.77 (s, 2H), 6.30 (d, J=2.4 Hz, 1H), 7.41 (d, J=2.4 Hz, 1H).
-
- To a stirred solution of ethyl 2-[1-(2-tert-butoxy-2-oxo-ethyl)pyrazol-3-yl]acetate (128.0 mg, 0.48 mmol) in THF (1 mL), water (1 mL) and methanol (1 mL) was added lithium hydroxide monohydrate (22.02 mg, 0.52 mmol). The resulting mixture was stirred at r.t. overnight. LCMS indicated the consumption of starting material and the formation of desired product. Water (5 mL) was added followed by 5 mL of DCM. The pH of aqueous layer was adjusted to 2˜3 by adding 0.1 M HCl. The layers were separated, and the aqueous layer was extracted with EtOAc (10 mL×3). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (20% to 100%) to afford 2-[1-(2-tert-butoxy-2-oxo-ethyl)pyrazol-3-yl]acetic acid (115 mg) as a light yellow solid. LCMS calc. for C11H15N2O4S [M−H]−: m/z=239.1; Found: 239.2.
-
- To a stirred solution of (3S)-6′-chloro-N,N-bis[(4-methoxyphenyl)methyl]spiro[4,5-dihydro-2H-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (1.0 g, 1.62 mmol, Intermediate 2) in DCM (3 mL) was added tert-butyl 3-formylpyrrolidine-1-carboxylate (0.39 g, 1.94 mmol). The resulting mixture was then cooled to 0° C. TFA (1.24 mL, 16.15 mmol) was added to this solution followed by sodium borohydride (1.22 g, 32.3 mmol). The resulting mixture was further stirred at 0° C. for 30 min., then slowly warmed up to r.t. LCMS showed the consumption of starting material and the formation of desired product. MeOH (2 mL) was added to quench the reaction. Water (10 mL) was added followed by 10 mL of DCM. The pH of aqueous layer was adjusted to 7-8 by adding saturated sodium bicarbonate solution. The layers were separated, and the aqueous layer was extracted with DCM (10 mL×2). The combined organic layers were dried over Na2SO4, filtered and concentrated to afford tert-butyl 3-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]pyrrolidine-1-carboxylate (660 mg, 50.9% yield) which was used in next step without further purification. LCMS calc. for C44H53ClN3O7S [M+H]+: m/z=802.3/804.3; Found: 802.5/804.6.
-
- To a stirred solution of tert-butyl 3-[[(3S)-7-[bis[(4-methoxyphenyl)methyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]pyrrolidine-1-carboxylate (0.66 g, 0.82 mmol) in DCM (10 mL) was added TFA slowly. The resulting mixture was kept stirring at r.t. overnight. The reaction was slowly poured into 100 mL of saturated sodium carbonate solution under an ice bath. Then the mixture was extracted with DCM (50 mL×3). The combined organic layers were dried over Na2SO4, filtered and concentrated to afford (3S)-6′-chloro-5-(pyrrolidin-3-ylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (400 mg) as a white solid. The crude product was used in next step without further purification. LCMS calc. for C23H29ClN3O3S [M+H]+: m/z=462.2/464.2; Found: 462.6/464.5.
-
- To a solution of (3S)-6′-chloro-5-(pyrrolidin-3-ylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-sulfonamide (160.0 mg, 0.35 mmol) in methanol (5 mL) was added di-tert butyl dicarbonate (113.38 mg, 0.52 mmol). The resulting mixture was stirred at r.t. LCMS indicated the consumption of starting material and the formation of desired product. Water (20 mL) was added and extracted with DCM (20 mL×3). The combined organic layers were dried over Na2SO4, filtered and concentrated. The residue was purified by flash chromatography on a silica gel column (12 g) with EtOAc/Heptanes (20% to 100%) to afford tert-butyl 3-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]pyrrolidine-1-carboxylate (103 mg, 52.9% yield) as a colorless oil. LCMS calc. for C28H37ClN3O5S [M+H]+: m/z=562.2/564.2; Found: 562.5/564.7.
-
- To a stirred solution of tert-butyl 3-[[(3S)-6′-chloro-7-sulfamoyl-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]pyrrolidine-1-carboxylate (80.0 mg, 0.14 mmol) in DCM (2 mL) was added 2-[1-(2-tert-butoxy-2-oxo-ethyl)pyrazol-3-yl]acetic acid (68.39 mg, 0.28 mmol) followed by EDCI (0.06 mL, 0.28 mmol) and DMAP (69.55 mg, 0.57 mmol). The resulting mixture was stirred at r.t. overnight. The reaction was quenched by adding 5 mL of 1 M HCl (5 mL) and extracted with DCM (5 mL×3). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC on a C18 column (30×250 mm, 10 m) with MeCN/H2O (20% to 100%) to afford tert-butyl 3-[[(3S)-7-[[2-[1-(2-tert-butoxy-2-oxo-ethyl)pyrazol-3-yl]acetyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]pyrrolidine-1-carboxylate (62 mg, 55.5% yield) as a white solid. LCMS calc. for C39H51ClN5O8S [M+H]+: m/z=784.3/786.3; Found: 784.5/786.5.
-
- To a stirred solution of tert-butyl 3-[[(3S)-7-[[2-[1-(2-tert-butoxy-2-oxo-ethyl)pyrazol-3-yl]acetyl]sulfamoyl]-6′-chloro-spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-5-yl]methyl]pyrrolidine-1-carboxylate (62.0 mg, 0.08 mmol) in DCM (2 mL) was added phosphoric acid (0.05 mL, 0.79 mmol). The resulting mixture was stirred at r.t. for 24 h. The solution was slowly poured into a 30 mL of saturated sodium bicarbonate solution and the pH of aqueous layer was adjusted to ˜4-5 by adding 1 M HCl. The mixture was extracted with EtOAc (10 mL×3). The combined organic layers were dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC on a C18 column (30×250 mm, 10 m) with MeCN/H2O (20% to 100%) to afford 2-[3-[2-oxo-2-[[(3S)-6′-chloro-5-(pyrrolidin-3-ylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]ethyl]pyrazol-1-yl]acetic acid (31 mg, 50.0% yield) as a white solid. LCMS calc. for C30H35ClN5O6S [M+H]+: m/z=628.2/630.2; Found: 628.4/630.5.
- To a stirred solution of 2-[3-[2-oxo-2-[[(3S)-6′-chloro-5-(pyrrolidin-3-ylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]ethyl]pyrazol-1-yl]acetic acid (31.0 mg, 0.05 mmol) in DMF (25 mL) was added HATU (56.3 mg, 0.15 mmol) followed by DIPEA (0.03 mL, 0.15 mmol). The resulting solution was stirred at r.t. for 2 h. Water (50 mL) was added, and extracted with ethyl acetate (25 mL×3). The combined organic layers were washed with water (25 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC on a C18 column (30×250 mm, 10 m) with MeCN/H2O (20% to 100%) to afford (23S)-6′-chloro-16,16-dioxo-spiro[21-oxa-16-thia-1,6,12,15,27-pentazapentacyclo[15.7.2.13,6.19,12.020,25]octacosa-9(27),10,17,19,25-pentaene-23,1′-tetralin]-7,14-dione (9.1 mg, 30.2% yield) as a white solid. LCMS calc. for C30H33ClN5O5S [M+H]+: m/z=610.2/612.2; Found: 610.4/612.3.
-
-
- This compound was prepared using procedures analogous to those described for Example 296 Step 1-2 using tert-butyl 2-(1H-pyrazol-3-yl)acetate and ethyl bromoacetate in Step 1. LCMS calc. for C9H14N204 [M+H]+: m/z=213.1; Found: 213.2.
-
- This compound was prepared using procedures analogous to those described for Example 296 Step 6-7 using 2-[1-(2-ethoxy-2-oxo-ethyl)pyrazol-3-yl]acetic acid to replace 2-[1-(2-tert-butoxy-2-oxo-ethyl)pyrazol-3-yl]acetic acid in Step 6. LCMS calc. for C32H39ClN5O6S [M+H]+: m/z=656.2/658.2; Found: 656.4/658.4.
-
- To a solution of ethyl 2-[3-[2-[[(3S)-6′-chloro-5-(pyrrolidin-3-ylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]-2-oxo-ethyl]pyrazol-1-yl]acetate (25.0 mg, 0.04 mmol) in methanol (0.50 mL) and THF (0.50 mL) was added lithium hydroxide monohydrate (4.8 mg, 0.11 mmol) in water (0.50 mL). The resulting solution was stirred at 40° C. for 2 h. The reaction mixture was quenched with 1M HCl aqueous solution to pH 5-6 and extracted with EtOAc. The combined organic layers were concentrated under reduced pressure to afford 2-[3-[2-[[(3S)-6′-chloro-5-(pyrrolidin-3-ylmethyl)spiro[2,4-dihydro-1,5-benzoxazepine-3,1′-tetralin]-7-yl]sulfonylamino]-2-oxo-ethyl]pyrazol-1-yl]acetic acid (21 mg, 87.7% yield) as a white solid. LC-MS: calc. for C30H35ClN5O6S [M+H]+: m/z=628.1/630.2; Found: 628.3/630.2.
- This compound was prepared using procedures analogous to those described for Example 296 Step. LCMS calc. for C30H33ClN5O5S [M+H]+: m/z=610.2/612.2; Found 610.2/612.2.
-
- This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22R)-6′-Chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-isochromane]-13-one (Example 249) in Step 2 and N-methyloxetan-3-amine in Step 1. LCMS calc. for C35H43ClN3O9S [M+H]+: m/z=716.23/718.23; Found: 716.0/718.1. 1H NMR (300 MHz, Chloroform-d) δ 7.54 (dd, J=8.3, 2.1 Hz, 1H), 7.49 (d, J=8.5 Hz, 1H), 7.25 (d, J=2.3 Hz, 1H), 7.17 (d, J=2.2 Hz, 1H), 7.10 (d, J=2.3 Hz, 1H), 7.01 (dd, J=8.4, 1.1 Hz, 1H), 5.93-5.83 (m, 1H), 5.67 (dd, J=15.6, 5.9 Hz, 1H), 4.92-4.74 (m, 5H), 4.33 (d, J=11.8 Hz, 1H), 4.16 (d, J=11.8 Hz, 1H), 4.05-3.93 (m, 3H), 3.66 (td, J=15.5, 14.8, 4.6 Hz, 4H), 3.34 (dd, J=15.0, 5.2 Hz, 1H), 3.16 (s, 3H), 2.96 (dd, J=9.1, 6.0 Hz, 1H), 2.83-2.70 (m, 2H), 2.47-2.35 (m, 1H), 2.16-2.05 (m, 1H), 1.88 (q, J=10.6, 9.9 Hz, 2H), 1.65 (d, J=9.5 Hz, 2H), 1.43 (s, 3H), 1.35 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22R)-6′-Chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-isochromane]-13-one (Example 249) in Step 2 and and (3R)—N-methyltetrahydrofuran-3-amine hydrochloride in Step 1. LCMS calc. for C36H45ClN3O9S [M+H]+: m/z=730.25/732.25; Found: 730.0/732.2. 1H NMR (300 MHz, Chloroform-d) δ 7.53 (dd, J=8.3, 2.1 Hz, 1H), 7.49 (d, J=8.4 Hz, 1H), 7.26 (dd, J=8.4, 2.2 Hz, 1H), 7.17 (d, J=2.2 Hz, 1H), 7.10 (d, J=2.2 Hz, 1H), 7.01 (d, J=8.4 Hz, 1H), 5.93-5.82 (m, 1H), 5.67 (dd, J=15.7, 5.6 Hz, 1H), 5.34 (s, 1H), 4.96 (s, 1H), 4.33 (d, J=11.8 Hz, 1H), 4.16 (d, J=11.8 Hz, 1H), 4.10-3.91 (m, 4H), 3.80 (s, 2H), 3.74-3.50 (m, 5H), 3.37 (d, J=5.1 Hz, 1H), 2.95 (s, 3H), 2.90-2.82 (m, 1H), 2.81-2.69 (m, 1H), 2.48-2.36 (m, 1H), 2.26 (ddd, J=13.1, 8.9, 4.8 Hz, 1H), 2.17-2.00 (m, 2H), 1.89 (dq, J=19.4, 9.4 Hz, 3H), 1.66 (t, J=9.4 Hz, 2H), 1.44 (s, 3H), 1.35 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22R)-6′-Chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-isochromane]-13-one (Example 249) in Step 2 and N-methyltetrahydropyran-4-amine in Step 1. LCMS calc. for C37H47ClN3O9S [M+H]+: m/z=744.26/746.26; Found: 744.1/746.2. 1H NMR (300 MHz, Chloroform-d) δ 7.59-7.44 (m, 2H), 7.26 (dd, J=8.4, 2.2 Hz, 1H), 7.17 (d, J=2.2 Hz, 1H), 7.12 (d, J=2.3 Hz, 1H), 7.01 (d, J=8.4 Hz, 1H), 5.86 (d, J=16.0 Hz, 1H), 5.66 (d, J=16.1 Hz, 1H), 5.34 (s, 1H), 4.33 (d, J=11.8 Hz, 1H), 4.17 (d, J=11.9 Hz, 1H), 4.10-3.88 (m, 5H), 3.75-3.59 (m, 4H), 3.46 (d, J=11.9 Hz, 1H), 3.35 (dd, J=15.0, 5.4 Hz, 1H), 3.05-2.95 (m, 1H), 2.88 (d, J=17.0 Hz, 3H), 2.76 (dt, J=16.3, 3.8 Hz, 1H), 2.50-2.34 (m, 1H), 2.15-1.99 (m, 1H), 1.88 (dd, J=21.4, 10.2 Hz, 4H), 1.66 (t, J=9.0 Hz, 6H), 1.43 (s, 3H), 1.35 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 2 and (3R)—N-methyltetrahydrofuran-3-amine hydrochloride in Step 1. LCMS calc. for C36H45ClN3O9S [M+H]+: m/z=730.25/732.25; Found: 730.1/732.1. 1H NMR (300 MHz, CDCl3) δ 9.10 (s, 1H), 7.60-7.48 (m, 2H), 7.06-6.99 (m, 2H), 6.93 (dt, J=8.5, 1.6 Hz, 1H), 6.86 (d, J=2.1 Hz, 1H), 5.87-5.63 (m, 2H), 5.27 (d, J=16.4 Hz, 2H), 4.91 (s, 1H), 4.36-4.00 (m, 7H), 3.84-3.68 (m, 5H), 3.49-3.32 (m, 2H), 3.23 (dd, J=15.0, 8.9 Hz, 1H), 2.91 (s, 3H), 2.41 (qd, J=9.3, 3.3 Hz, 1H), 2.27 (dtd, J=13.3, 8.4, 4.8 Hz, 1H), 2.09-1.98 (m, 2H), 1.91-1.77 (m, 3H), 1.66 (q, J=9.4 Hz, 1H), 1.44 (s, 3H), 1.36 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 1 and (3R)-tetrahydrofuran-3-amine in Step 2. LCMS calc. for C35H43ClN3O9S [M+H]+: m/z=716.23/718.23; Found: 716.52/718.09. 1H NMR (300 MHz, CDCl3) δ 9.05 (s, 1H), 7.54 (t, J=14.5 Hz, 2H), 7.14 (s, 1H), 7.05 (d, J=8.3 Hz, 1H), 6.95 (dd, J=8.4, 2.0 Hz, 1H), 6.88 (d, J=1.9 Hz, 1H), 5.83-5.64 (m, 2H), 5.18 (s, 1H), 4.26 (m, 3H), 4.16-4.07 (m, 2H), 4.03-3.95 (m, 1H), 3.86 (d, J=5.8 Hz, 2H), 3.77 (d, J=13.5 Hz, 2H), 3.44 (t, J=12.4 Hz, 2H), 3.22 (d, J=6.9 Hz, 3H), 2.79 (d, J=6.4 Hz, 1H), 2.40 (s, 1H), 2.32-2.20 (m, 1H), 2.11-1.99 (m, 2H), 1.83 (dd, J=32.2, 8.6 Hz, 4H), 1.69-1.60 (m, 1H), 1.44 (s, 3H), 1.39 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 2 and N-methyloxetan-3-amine in Step 1. LCMS calc. for C35H41ClN3O9S [M−H]−: m/z=714.2/716.2; Found 713.8/715.8. 1H NMR (300 MHz, CDCl3) δ 7.56 (dd, J=8.4, 2.1 Hz, 2H), 7.05 (dd, J=8.3, 1.8 Hz, 2H), 6.95 (dd, J=8.6, 2.2 Hz, 1H), 6.88 (d, J=2.2 Hz, 1H), 5.74 (t, J=8.0 Hz, 2H), 5.28 (d, J=4.6 Hz, 1H), 4.89-4.73 (m, 3H), 4.43-3.98 (m, 6H), 3.87-3.69 (m, 3H), 3.50-3.20 (m, 3H), 3.12 (s, 3H), 2.50-2.32 (m, 1H), 2.25 (t, J=7.6 Hz, 1H), 2.17-1.76 (m, 7H), 1.46 (s, 3H), 1.37 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 2 and N-methyltetrahydropyran-4-amine in Step 1. LCMS calc. for C37H47ClN3O9S [M+H]+: m/z=744.26/746.26; Found: 744.2/746.2. 1H NMR (300 MHz, CDCl3) δ 9.04 (s, 1H), 7.60-7.46 (m, 2H), 7.09-6.99 (m, 2H), 6.93 (dd, J=8.4, 2.2 Hz, 1H), 6.86 (d, J=2.1 Hz, 1H), 5.84-5.63 (m, 2H), 5.31 (t, J=4.3 Hz, 1H), 4.39-3.92 (m, 9H), 3.76 (t, J=12.2 Hz, 2H), 3.52-3.34 (m, 4H), 3.27 (d, J=8.8 Hz, 1H), 2.85 (s, 3H), 2.51-2.35 (m, 1H), 2.12-1.98 (m, 2H), 1.81 (q, J=12.0, 10.8 Hz, 4H), 1.65 (d, J=6.8 Hz, 4H), 1.44 (s, 3H), 1.36 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 1 and tetrahydropyran-4-amine in Step 2. LCMS calc. for C36H45ClN3O9S [M+H]+: m/z=730.25/732.25; Found: 730.2/732.2. 1H NMR (300 MHz, CDCl3) δ 9.02 (s, 1H), 7.61-7.53 (m, 2H), 7.15 (s, 1H), 7.05 (d, J=8.3 Hz, 1H), 6.94 (dd, J=8.4, 2.1 Hz, 1H), 6.88 (d, J=2.0 Hz, 1H), 5.79-5.67 (m, 2H), 5.18 (s, 1H), 4.30 (d, J=7.7 Hz, 1H), 4.22 (d, J=16.7 Hz, 2H), 4.14 (d, J=12.0 Hz, 2H), 4.02 (d, J=11.3 Hz, 2H), 3.84-3.74 (m, 2H), 3.54-3.43 (m, 4H), 3.19 (m, 2H), 2.83-2.72 (m, 1H), 2.41 (s, 1H), 2.04 (dd, J=10.7, 6.1 Hz, 2H), 2.00-1.80 (m, 6H), 1.54 (dd, J=12.4, 3.9 Hz, 2H), 1.45 (s, 3H), 1.39 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 63 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 2 and N,O-dimethylhydroxylamine hydrochloride in Step 1. LCMS calc. for C33H41ClN3O9S [M+H]+: m/z=690.22/692.22; Found: 690.0/692.0. 1H NMR (300 MHz, CDCl3) δ 9.05 (s, 1H), 7.56 (dd, J=8.4, 2.0 Hz, 2H), 7.10 (d, J=2.2 Hz, 1H), 7.04 (dd, J=8.4, 0.9 Hz, 1H), 6.94 (dd, J=8.5, 2.2 Hz, 1H), 6.88 (d, J=2.2 Hz, 1H), 5.82-5.61 (m, 2H), 5.35-5.17 (m, 1H), 4.30-3.99 (m, 5H), 3.77 (dd, J=14.7, 6.0 Hz, 2H), 3.71 (s, 3H), 3.51-3.30 (m, 3H), 3.19 (s, 3H), 2.80 (d, J=7.9 Hz, 1H), 2.47 (tt, J=8.9, 4.9 Hz, 1H), 2.01-1.81 (m, 4H), 1.66 (q, J=9.6 Hz, 2H), 1.45 (s, 3H), 1.38 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 1 and N,N,N′-trimethylethylenediamine in Step 2. LCMS calc. for C36H49ClN4O8S [M+H]+: m/z=731.28/733.28; Found: 731.2/733.3. 1H NMR (300 MHz, CDCl3) δ 7.57 (d, J=8.4 Hz, 2H), 7.04 (d, J=8.1 Hz, 2H), 6.95 (dd, J=8.3, 1.9 Hz, 1H), 6.88 (d, J=2.0 Hz, 1H), 5.80 (d, J=37.2 Hz, 2H), 5.26 (s, 1H), 4.32 (s, 1H), 4.25-4.17 (m, 2H), 4.13 (d, J=12.2 Hz, 2H), 3.79 (d, J=14.5 Hz, 2H), 3.44 (d, J=14.7 Hz, 2H), 3.26 (s, 2H), 3.02 (s, 3H), 2.94 (s, 4H), 2.51-2.34 (m, 2H), 2.05 (d, J=8.3 Hz, 2H), 1.97-1.77 (m, 4H), 1.65 (s, 2H), 1.47 (m, 3H), 1.37 (s, 3H), 1.28 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 1 and (3R)-3-ethoxypyrrolidine in Step 2. LCMS calc. for C37H47ClN3O9S [M+H]+: m/z=744.26/746.26; Found: 744.15/746.26; 1H NMR (300 MHz, CDCl3) δ 9.49-9.09 (m, 1H), 7.55 (dd, J=8.4, 3.0 Hz, 2H), 7.02 (d, J=6.3 Hz, 2H), 6.93 (d, J=8.4 Hz, 1H), 6.86 (d, J=1.9 Hz, 1H), 5.82 (d, J=14.2 Hz, 1H), 5.73-5.62 (m, 1H), 5.27 (s, 1H), 4.29 (d, J=10.0 Hz, 1H), 4.25-4.15 (m, 2H), 4.08 (dd, J=16.0, 9.3 Hz, 3H), 3.82-3.72 (m, 2H), 3.71-3.61 (m, 4H), 3.42 (dd, J=13.4, 5.8 Hz, 4H), 3.25-3.17 (m, 1H), 2.83 (s, 1H), 2.38 (d, J=8.2 Hz, 1H), 2.13-1.98 (m, 4H), 1.86 (dd, J=14.6, 5.6 Hz, 3H), 1.67-1.60 (m, 1H), 1.45 (s, 3H), 1.35 (s, 3H), 1.29-1.22 (m, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 1 and 3-methoxyazetidine in Step 2. LCMS calc. for C35H43ClN3O9S [M+H]+: m/z=716.23/718.23; Found: 716.2/718.3. 1H NMR (300 MHz, CDCl3) δ 9.12 (s, 1H), 7.55 (d, J=8.4 Hz, 2H), 7.02 (d, J=8.3 Hz, 2H), 6.93 (dd, J=8.5, 2.0 Hz, 1H), 6.86 (d, J=1.9 Hz, 1H), 5.79 (d, J=15.5 Hz, 1H), 5.70-5.60 (m, 1H), 5.21 (s, 1H), 4.31-4.27 (m, 1H), 4.20 (d, J=8.4 Hz, 3H), 4.13 (s, 1H), 4.10-4.01 (m, 2H), 3.91 (d, J=6.8 Hz, 1H), 3.75 (t, J=12.1 Hz, 2H), 3.42 (s, 2H), 3.38 (s, 1H), 3.31 (s, 3H), 3.22 (dd, J=14.9, 8.9 Hz, 2H), 2.79 (d, J=6.1 Hz, 1H), 2.37 (d, J=5.7 Hz, 1H), 2.09-1.98 (m, 2H), 1.95-1.78 (m, 3H), 1.68-1.59 (m, 1H), 1.45 (s, 3H), 1.36 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 1 and (3R)—N,N-dimethylpyrrolidin-3-amine in Step 2. LCMS calc. for C37H48ClN4O8S [M+H]+: m/z=743.28/745.28; Found: 743.2/745.2. 1H NMR (300 MHz, CDCl3) δ 9.20 (s, 1H), 7.53 (dd, J=16.3, 8.7 Hz, 2H), 7.03 (d, J=8.3 Hz, 1H), 6.97-6.88 (m, 2H), 6.86 (d, J=2.0 Hz, 1H), 6.00-5.73 (m, 2H), 5.30 (s, 1H), 4.33 (d, J=11.4 Hz, 1H), 4.29-4.13 (m, 4H), 4.09 (d, J=12.0 Hz, 1H), 3.88 (d, J=14.8 Hz, 1H), 3.75 (d, J=12.1 Hz, 3H), 3.63 (s, 2H), 3.44 (d, J=14.7 Hz, 2H), 3.17-3.06 (m, 1H), 2.87 (d, J=18.8 Hz, 7H), 2.45-2.24 (m, 3H), 2.18 (s, 1H), 2.02 (d, J=14.3 Hz, 1H), 1.88 (s, 3H), 1.71-1.62 (m, 1H), 1.44 (s, 3H), 1.35 (s, 3H).
-
- This compound was prepared using procedures analogous to those described for Example 46 Step 1-2 using (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (Example 246) in Step 1 and N,N-dimethylazetidin-3-amine dihydrochloride salt and Hunig's base in Step 2. LCMS calc. for C36H46ClN4O8S [M+H]+: m/z=729.26/731.26; Found:729.2/731.5. 1H NMR (300 MHz, CDCl3) δ 7.53 (dd, J=18.2, 10.3 Hz, 2H), 7.02 (d, J=8.2 Hz, 1H), 6.97-6.89 (m, 2H), 6.86 (d, J=1.7 Hz, 1H), 6.10 (s, 1H), 5.71 (s, 1H), 5.30 (s, 1H), 4.34 (d, J=11.2 Hz, 2H), 4.26 (d, J=12.1 Hz, 2H), 4.20 (d, J=10.9 Hz, 2H), 4.07 (d, J=12.0 Hz, 1H), 3.80 (d, J=14.7 Hz, 2H), 3.73 (s, 2H), 3.43 (d, J=14.4 Hz, 2H), 3.02 (s, 2H), 2.83 (s, 6H), 2.27 (s, 1H), 2.02 (d, J=14.1 Hz, 2H), 1.85 (s, 3H), 1.65 (d, J=9.2 Hz, 2H), 1.36 (s, 3H), 1.27 (s, 3H).
-
-
- A suspension of lithium aluminium deuteride (2.0 g, 46.5 mmol) in ether (20 mL) was cooled at −78° C. under N2. 2-Propenoyl chloride (4.0 mL, 39.44 mmol) in ether (20 mL) was added dropwise over 1 h. at −78° C. The mixture was then allowed to slowly warm to r.t. and stirred overnight. The mixture was carefully quenched at −10° C. with water (4 mL), followed by 15% NaOH (4 mL). The mixture was diluted with water (12 mL), and stirred for 1 h. The mixture was filtered. The filtrate was dried over Na2SO4, filtered and the solvent was partially removed under reduced pressure. The crude product (0.25 g, 4.19 mmol) and 2-bromo-2-methyl-propanoic acid (1.0 g, 5.99 mmol) was dissolved in MeCN (3 mL). DIPEA (2.3 g, 18 mmol) was added and the mixture was stirred at 50° C. overnight. The mixture was quenched with 1 M HCl (20 mL) and extracted with EtOAc (20 mL×2). The organic layer was concentrated. The residue was purified with flash chromatography on a silica gel column with EtOAc:Heptane (0% to 40%) to afford 2-(1,1-dideuterioallyloxy)-2-methyl-propanoic acid (500 mg, 40.% yield).
-
- This compound was prepared using procedures analogous to those described for Example 32 Step 1-2 using 2-(1,1-dideuterioallyloxy)-2-methyl-propanoic acid to replace 2-allyloxy-2-methyl-propanoic acid in Step 1. LCMS calc. for C31H36D2ClN2O6S [M+H]+: m/z=603.23/604.23; Found: 602.9.1/604.4.
- This compound was prepared using procedures analogous to those described for Example 34. LCMS calc. for C34H41D2ClN3O7S [M+H]+: m/z=674.26/675.26; Found: 674.1/675.4.
-
-
- To a solution of (3R,6R,7S,8E,22S)-7′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,4′-chromane]-13-one (130 mg, 0.22 mmol, Example 246) in toluene (4 mL) was added 2,6-ditert-butylpyridine (412 mg, 2.2 mmol) followed by 2-bromoethyl trifluoromethanesulfonate (554 mg, 2.2 mmol). The resulting mixture was stirred at 90° C. overnight. The reaction was quenched with 1N HCl aq. solution (1 mL) and extracted with EtOAc. The combined organic extracts were washed with water and brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column with EtOAc/Heptanes (3% to 60%) to afford (3R,6R,7S,8E,22S)-7-(2-bromoethoxy)-7′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,4′-chromane]-13-one (105 mg, 68.6% yield) as a white solid. LC-MS: calc. for C32H39BrClN2O7S [M+H]+: m/z=709.1/711.1; Found: 709.0/710.8.
- To a stirred solution of (3R,6R,7S,8E,22S)-7-(2-bromoethoxy)-7′-chloro-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,4′-chromane]-13-one (30 mg, 0.04 mmol) in DMSO (1 mL) was added potassium iodide (35 mg, 0.21 mmol) and dimethylamine (2 M in THF) (9.5 mg, 0.21 mmol). The resulting solution was stirred at 35° C. for 1 h. The reaction mixture was directly purified by prep-HPLC on C18 column (30×250 mm, 10 m) with MeOH/H2O (15% to 100%) to afford (3R,6R,7S,8E,22S)-7′-chloro-7-[2-(dimethylamino)ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one (11 mg, 38.6% yield) as a white solid. LC-MS calc. for C34H45ClN3O7S [M+H]+: m/z=674.26/676.26; Found: 674.2/676.4.
-
- This compound was prepared using procedures analogous to those described for Example 313 Step 2 using diethylamine (2 M in THF) to replace dimethylamine (2 M in THF). LC-MS calc. for C36H49ClN3O7S [M+H]+: m/z=702.29/704.29; Found: 702.0/703.5.
-
- This compound was prepared using procedures analogous to those described for Example 313 Step 2 using pyrrolidine to replace dimethylamine (2 M in THF). LC-MS calc. for C36H47ClN3O7S [M+H]+: m/z=700.27/702.27; Found: 700.2/702.6. Single-Crystal X-ray Analysis of Example 34
- A saturated solution of Example 34 in ethanol/methyl tert-butyl ether (4/1) was stored at 23-25° C., and after 4 days, cubic crystals were observed. A crystal of approximate dimensions 0.197 mm×0.250 mm×0.345 mm, was used for the X-ray crystallographic analysis. The X-ray intensity data were measured.
- The total exposure time was 3.45 hours. The frames were integrated with the Bruker SAINT software package using a narrow-frame algorithm. The integration of the data using an orthorhombic unit cell yielded a total of 26210 reflections to a maximum 0 angle of 75.550 (0.80 Å resolution), of which 8525 were independent (average redundancy 3.074, completeness=98.9%, Rint=4.77%, Rsig=4.89%) and 7840 (91.96%) were greater than 2σ(F2). The final cell constants of a=9.1529(13) Å, b=11.1812(17) Å, c=41.054(7) Å, volume=4201.5(11) Å3, are based upon the refinement of the XYZ-centroids of 9678 reflections above 20 σ(I) with 6.463°<2θ<150.8°. Data were corrected for absorption effects using the Multi-Scan method (SADABS). The ratio of minimum to maximum apparent transmission was 0.838. The calculated minimum and maximum transmission coefficients (based on crystal size) are 0.5830 and 0.7240.
-
FIG. 1 shows an ORTEP representation of the compound of Example 34. The structure was solved and refined using the Bruker SHELXTL Software Package, using the space group P 21 21 21, with Z=4 for the formula unit, C40H60ClN3O10S. The final anisotropic full-matrix least-squares refinement on F2 with 504 variables converged at R1=7.06%, for the observed data and wR2=20.53% for all data. The goodness-of-fit was 1.151. The largest peak in the final difference electron density synthesis was 0.445 e−/Å3 and the largest hole was −0.447 e−/Å3 with an RMS deviation of 0.091 e−/Å3. On the basis of the final model, the calculated density was 1.281 g/cm3 and F (000), 1736 e−. -
TABLE E1 Sample and crystal data for Example 34. Identification code Example 34 Chemical formula C40H60ClN3O10S (includes 3 ethanols) Formula weight 810.42 g/mol Temperature 150(2) K Wavelength 1.54178 Å Crystal size 0.197 × 0.250 × 0.345 mm Crystal system orthorhombic Space group P 21 21 21 Unit cell dimensions a = 9.1529(13) Å α = 90° b = 11.1812(17) Å β = 90° c = 41.054(7) Å γ = 90° Volume 4201.5(11) Å3 Z 4 Density (calculated) 1.281 g/cm3 Absorption 1.752 mm−1 coefficient F(000) 1736 -
TABLE E2 Data collection and structure refinement for Example 34. Theta range for 2.15 to 75.55° data collection Index ranges −11 <= h <= 11, −13 <= k <= 13, −51 <= l <= 51 Reflections 26210 collected Independent 8525 [R(int) = 0.0477] reflections Coverage of 98.9% independent reflections Absorption correction Multi-Scan Max. and min. 0.7240 and 0.5830 transmission Structure solution direct methods technique Structure solution XT, VERSION 2014/5 program Refinement method Full-matrix least-squares on F2 Refinement program SHELXL-2018/3 (Sheldrick, 2018) Function minimized Σ w(Fo 2 − Fc 2)2 Data/restraints/ 8525/0/504 parameters Goodness-of-fit 1.151 on F2 Δ/σmax 0.001 Final R indices 7840 data; I > 2σ(I) R1 = 0.0706, wR2 = 0.2010 all data R1 = 0.0740, wR2 = 0.2053 Weighting scheme w = 1/[σ2(Fo 2) + (0.1199P)2 + 1.8325P] where P = (Fo 2 + 2Fc 2)/3 Absolute structure 0.002 (11) parameter Extinction 0.0048(6) coefficient Largest diff. 0.445 and −0.447 eÅ−3 peak and hole R.M.S. deviation 0.091 eÅ−3 from mean Biological Assays Cell free Mcl-1: Bim affinity assay (Mcl-1 Bim) - The binding affinity of each compound was measured via a fluorescence polarization competition assay, in which the compound competes for the same binding site with the ligand, and thus leads to a dose-dependent anisotropy reduction. The tracer ligand utilized was a fluorescein isothiocyanate labelled peptide (FITC-ARIAQELRRIGDEFNETYTR) derived from Bim (GenScript).
- The assay was carried out in black half-area 96-well NBS plate (Corning), containing 15 nM of MCL-1 (BPS Bioscience), 5 nM of FITC-Bim and 3-fold serial diluted test compounds in a total volume of 50 μL of assay buffer (20 mM HEPES, 50 mM NaCl, 0.002% Tween 20, 1 mM TCEP, and 1% DMSO). The reaction plate was incubated for 1 hour at room temperature. The change of anisotropy is measured with an Envision multimode plate reader (PerkinElmer) at emission wavelength 535 nm. Fluorescence polarization was calculated in mP unit and the percentage inhibition was calculated by % inhibition=100×(mPDMSO-mP)/(mPDMSO-mPPc), in which mPDMSO is the DMSO control, and mPPc is the positive control. IC50 values were determined from a 10-point dose response curve by fitting the percent inhibition against compound concentration using the GraphPad Prism software. The inhibition constant Ki was subsequently calculated according to the Nikolovska-Coleska's equation (Anal. Biochem., 2004, 332, 261),
-
-
- where [I]50 is the concentration of the free inhibitor at 50% inhibition, [L]50 is the concentration of the free labeled ligand at 50% inhibition, [P]0 is the concentration of the free protein at 0% inhibition, and Kd is the dissociation constant of the protein-ligand complex. See Table F.
- Dispense 10 μL aliquot of prepared H929 cells (1:1 ratio of cells:Trypan Blue (#1450013, Bio-Rad)) onto cell counting slide (#145-0011, Bio-Rad) and obtain cell density and cell viability using cell counter (TC20, Bio-Rad). Remove appropriate volume of resuspended cells from culture flask to accommodate 2000 cells/well @ 5 μL/well. Transfer H929 cells to 50 mL conical (#430290, Corning) for each of the FBS concentration to be assayed (10%, 0.1%). Spin down at 1000 rpm for 5 min. using tabletop centrifuge (SPINCHRON 15, Beckman). Discard supernatant and resuspend cell pellet in modified RPMI 1640 (#10-040-CV, Corning) cell culture media containing sodium pyruvate (100 mM) (#25-000-CL, Corning), HEPES buffer (1 M) (#25-060-CL, Corning) and glucose (200 g/L) (A24940-01, Gibco) with appropriate FBS (F2422-500 ML, Sigma) concentration to a cell density of 400,000 cells/mL. Dispense 5 μL of resuspended H929 cells per well in 384-well small volume TC treated plate (#784080, Greiner Bio-one) using standard cassette (#50950372, Thermo Scientific) on Multidrop Combi (#5840310, Thermo Scientific) in laminar flow cabinet. Dispense compounds onto plates using digital liquid dispenser (D300E, Tecan). Incubate plates in humidified tissue culture incubator @ 37° C. for 4 hours. Add 5 μL of prepared Caspase-Glo® 3/7 detection buffer (G8093, Promega) to each well of 384-well plate using small tube cassette (#24073295, Thermo Scientific) on Combi multi-drop, incubate @ RT for 30-60 min. Read plates with microplate reader (PheraStar, BMG Labtech) using 384 well luminescence mode.
- Dispense 10 μL aliquot of prepared H929 cells (1:1 ratio of cells:Trypan Blue (#1450013, Bio-Rad)) onto cell counting slide (#145-0011, Bio-Rad) and obtain cell density and cell viability using cell counter (TC20, Bio-Rad). Remove appropriate volume of resuspended cells from culture flask to accommodate 4000 cells/well @ 10 μL/well. Transfer H929 cells to 50 mL conical (#430290, Corning). Spin down at 1000 rpm for 5 min using tabletop centrifuge (SPINCHRON 15, Beckman). Discard supernatant and resuspend cell pellet in modified RPMI 1640 (#10-040-CV, Corning) cell culture media containing 10% FBS (F2422-500 ML, Sigma), sodium pyruvate (100 mM) (#25-000-CL, Corning), HEPES buffer (1 M) (#25-060-CL, Corning) and glucose (200 g/L) (A24940-01, Gibco) to a cell density of 400,000 cells/mL. Dispense 10 μL of resuspended H929 cells per well in 384-well small volume TC treated plate (#784080, Greiner Bio-one) using standard cassette (#50950372, Thermo Scientific) on Multi-drop Combi (#5840310, Thermo Scientific) in laminar flow cabinet. Dispense compounds onto plates using digital liquid dispenser (D300E, Tecan). Incubate plates in humidified tissue culture incubator @ 37° C. for 24 hours. Add 10 μL of prepared CellTiTer-Glo® detection buffer (G7570, Promega) or ATPlite 1 Step detection reagent (#6016731, Perkin Elmer) to each well of 384-well plate using small tube cassette (#24073295, Thermo Scientific) on Combi multi drop, incubate @ RT for 30-60 min. Read plates with microplate reader (PheraStar, BMG Labtech) using 384 well luminescence mode.
- Cytotoxicity studies were conducted in NCI-H929 multiple myeloma cell line. Cells were maintained in RPMI 1640 (Corning Cellgro, Catalog #: 10-040-CV) supplemented with 10% v/v FBS (GE Healthcare, Catalog #: SH30910.03), 10 mM HEPES (Corning, Catalog #: 25-060-CI), 1 mM sodium pyruvate (Corning Cellgro, Catalog #: 25-000-CI and 2500 mg/L glucose (Gibco, Catalog #: A24940-01). Cells were seeded in 96-well plates at a density of 75000 cells/well. Compounds dissolved in DMSO were plated in duplicate using a digital dispenser (Tecan D300E) and tested on a 9-point 3-fold serial dilution. Cells were incubated for 24 hr in a 37° C. incubator at 5% CO2. Cell viability was measured using the Cell Counting Kit-8 (CCK-8, Jojindo, CK04-13) as per manufacturer's instructions. Cells were incubated for 4 hours at 37° C. 5% CO2 following addition of reagent and OD450 values were measured with a microplate reader (iMark microplate reader, Bio-Rad). Background from media only wells were averaged and subtracted from all readings. OD450 values were then normalized to DMSO controls to obtain percentage of viable cells, relative to DMSO vehicle control and plotted in Graphpad Prism ([Inhibitor] vs. normalized response—Variable slope; equation: Y=100/(1+(X{circumflex over ( )}HillSlope)/(IC50{circumflex over ( )}HillSlope))) to determine IC50 values (the concentration of compound inhibiting half of the maximal activity).
-
TABLE F Cell free Mcl-1: Bim affinity assay (Mcl-1 Bim) and Cell viability assay (H929_10FBS) Ex BIM_Ki H929_10FBS IC50 No. (nM) (nM) 1 45.6 # 2 179 # 3 143 # 4 207 # 5 37.3 # 6 35.7 # 7 227 NT 8 424 # 9 1640 # 10 1430 # 11 503 # 12 15.8 # 13 22 # 14 222 NT 15 8.7 # 16 9 # 17 7.4 # 18 1.4 # 19 9.3 # 20 21.8 # 21 53.3 # 22 57 # 23 73.6 # 24 6.0 # 25 9.0 # 26 ++ # 27 ++ # 28 +++ # 29 +++ ## 30 +++ ## 31 ++ # 32 +++ ### 33 +++ ### 34 +++ ### 35 ++ # 36 +++ ## 37 +++ ### 38 +++ ### 39 +++ ## 40 +++ ### 41 +++ ### 42 ++ ### 43 ++ # 44 +++ ### 45 +++ ### 46 +++ ### 47 +++ ### 48 +++ ### 49 +++ ### 50 +++ ### 51 +++ ### 52 +++ ### 53 +++ ### 54 +++ ### 55 +++ ### 56 +++ ### 57 +++ ### 58 +++ ### 59 +++ ### 60 +++ ### 61 +++ ### 62 +++ ### 63 +++ ### 64 +++ ### 65 +++ ### 66 +++ ### 67 ++ # 68 ++ # 69 ++ # 70 ++ # 71 ++ # 72 ++ # 73 ++ # 74 +++ # 75 ++ # 76 ++ # 77 ++ # 78 ++ # 79 ++ # 80 ++ # 81 ++ # 82 ++ # 83 ++ # 84 ++ # 85 ++ # 86 ++ # 87 +++ ## 88 +++ ## 89 ++ # 90 +++ # 91 ++ # 92 +++ ## 93 ++ # 94 +++ # 95 ++ # 96 +++ # 97 +++ # 98 ++ # 99 ++ # 100 ++ # 101 +++ # 102 ++ # 103 +++ # 104 +++ # 105 ++ # 106 ++ ## 107 ++ ## 108 ++ # 109 ++ # 110 ++ # 111 ++ # 112 ++ # 113 +++ ## 114 +++ ## 115 ++ # 116 ++ ## 117 ++ # 118 ++ # 119 ++ ## 120 ++ ## 121 ++ # 122 ++ # 123 ++ ## 124 ++ ## 125 +++ # 126 ++ # 127 ++ ## 128 ++ # 129 ++ # 130 ++ # 131 ++ # 132 ++ ### 133 ++ # 134 ++ # 135 ++ # 136 ++ # 137 ++ ## 138 ++ ## 139 ++ ## 140 +++ ### 141 +++ ### 142 +++ ## 143 +++ ### 144 ++ # 145 +++ ### 146 ++ ### 147 +++ ### 148 +++ ### 149 +++ ### 150 +++ ## 151 +++ ### 152 +++ ### 153 +++ ### 154 +++ ### 155 +++ ### 156 +++ ### 157 +++ ### 158 +++ ### 159 +++ ### 160 +++ ### 161 +++ ## 162 +++ ### 163 +++ ### 164 +++ ### 165 +++ ### 166 +++ ### 167 +++ ### 168 +++ ### 169 +++ ### 170 +++ ## 171 +++ ### 172 +++ ### 173 +++ ### 174 +++ ### 175 +++ ### 176 +++ ### 177 ++ ### 178 +++ ### 179 +++ ### 180 +++ ### 181 +++ ### 182 +++ ### 183 +++ ### 184 +++ ### 185 +++ ### 186 +++ ### 187 +++ ### 188 +++ ### 189 +++ ### 190 +++ ### 191 +++ ### 192 +++ ### 193 ++ ### 194 +++ ### 195 +++ ### 196 ++ # 197 ++ # 198 +++ ### 199 +++ ### 200 ++ ### 201 +++ ### 202 +++ ### 203 +++ ### 204 +++ ### 205 ++ ### 206 +++ ### 207 +++ ### 208 ++ ### 209 +++ ### 210 +++ ### 211 +++ ### 212 +++ ### 213 +++ ### 214 +++ ### 215 +++ ### 216 +++ ### 217 +++ ### 218 +++ ### 219 ++ ### 220 +++ ### 221 +++ ### 222 +++ ### 223 +++ ### 224 +++ ### 225 ++ ### 226 +++ ### 227 +++ ### 228 +++ ### 229 +++ ### 230 +++ ### 231 +++ ### 232 +++ ### 233 +++ ### 234 +++ ### 235 +++ ### 236 +++ ### 237 +++ ### 238 +++ ### 239 +++ ### 240 +++ ### 241 +++ ### 242 +++ ### 243 +++ ### 244 +++ ### 245 +++ ### 246 ++ # 247 +++ ### 248 +++ # 249 ++ # 250 +++ ### 251 ++ # 252 ++ # 253 ++ # 254 ++ # 255 ++ # 256 ++ # 257 ++ # 258 +++ ### 259 +++ ### 260 +++ ### 261 +++ ### 262 +++ ### 263 +++ ### 264 +++ ### 265 ++ ### 266 +++ ### 267 ++ ## 268 +++ ### 269 +++ ### 270 +++ ### 271 +++ ### 272 +++ ### 273 +++ ## 274 +++ ## 275 ++ ### 276 +++ ## 277 ++ # 278 +++ ### 279 +++ ### 280 +++ ### 281 +++ ### 282 +++ ### 283 +++ ### 284 +++ ### 285 +++ ### 286 ++ # 287 +++ ### 288 ++ # 289 ++ # 290 +++ ### 291 +++ ## 292 +++ ### 293 +++ ### 294 ++ ### 295 ++ # 296 ++ ### 297 ++ # 298 +++ ## 299 +++ ## 300 +++ ## 301 +++ ### 302 +++ ### 303 +++ ### 304 +++ ### 305 +++ ### 306 +++ ### 307 +++ ### 308 +++ ### 309 +++ ## 310 +++ ### 311 +++ ### 312 +++ ### 313 NT NT 314 NT NT 315 NT NT +++ Ki < 1 nM; ++ Ki = 1 nM-100 nM; ### IC50 < 500 nM; ## IC50 < 1000 nM; # IC50 > 1000 nM; NT = not tested - In some embodiments, the invention is directed to the following aspects:
- Aspect 1. A compound of Formula I:
-
- or a pharmaceutically acceptable salt or solvate thereof;
- wherein
- Z is CH or N;
- Q is —O—, —S—, —S(O)—, or —S(O)2—;
- the moiety -W1-W2-W3 is —CR2R2A—CR2R2A—CR2R2A—, —O—CR2BR2C—CR2R2A—, —CR2R2A—CR2BR2C—O—, —NR2B—CR2BR2C—CR2R2A—, —CR2R2A—CR2BR2C— NR2B—, —S—CR2BR2C—CR2R2A, or —CR2R2A—CR2BR2C—S—;
- L1 is absent or is optionally substituted —C1-C6alkylene-;
- L2 is absent or is optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, or optionally substituted heteroarylene;
- L3 is absent, or is —(CR4R5)p—, —(CR4R5)pO—, —O—, —S—, —S(O)—, —S(O)2—, —C(═O)—, —NR6—, —OC(═O)—, —C(═O)O—, —NR6AC(O)—, —C(═O)NR6A—, —OC(═O)N(R6A)—, —NR6AC(O)O—, —S(═O)NR6A—, —NR6AS(O)—, —S(═O)2NR6A—, or —NR6AS(O)2—;
- L4 is absent, or is —(CR4R5)pQ1(CR4R5)q—, wherein Q1 is absent, —CR4A═CR4B—, —O—, —S—, —S(O)—, —S(O)2—, —C(═O)—, —NR6—, —OC(═O)—, —C(═O)O—, —NR6AC(O)—, —C(═O)NR6A—, —NR6AC(O)R6B—, —OC(═O)N(R6A)—, —NR6AC(O)O—, —S(═O)NR6A—, —NR6AS(O)—, —S(═O)2NR6A—, or —NR6AS(O)2—; or is —(CR4R5)p—(CR4A═CR4B)—(CR4R5)q—O—;
- L5 is absent, or is —C1-C6 alkylene-, —C2-C6 alkenylene-, —C2-C6 alkynylene-, -arylene-, -heteroarylene-, -cycloalkenylene-, -cycloalkylene-, -heterocycloalkylene-, wherein said C1-C6 alkylene, C2-C6 alkenylene, C2-C6 alkynylene, arylene, heteroarylene, cycloalkenylene, cycloalkylene, or heterocycloalkylene groups are optionally substituted;
- L6 is absent, or is —(CR7R8)s—, —(CR7R8)sO(CR7R8)t—, —(CR7R8)sNR9(CR7R8)t—, —(CR7R8)sS(CR7R8)t—, —(CR7R8)sS(O)(CR7R8)t—, —(CR7R8)sS(O)2(CR7R8)t—, —(CR7R8)sNR9AC(O)(CR7R8)t—, —(CR7R8)sOC(O)NR9A(CR7R8)t—, —(CR7R8)SNR9AC(O)O(CR7R8)t—, —(CR7R8)sNR9AC(O)NR9B(CR7R8)t—, —(CR7R8)SNR9AS(O)(CR7R8)t—, —(CR7R8)sNR9AS(O)2(CR7R8)t—; —(CR7R8)s—CR4A═CR4B—(CR7R8)t—, —(CR7R8)sC(═O)(CR7R8)t—; —(CR7R8)sC(═O)(CR7R8)t—O—, or —(CR7R8)sC(═O)(CR7R8)t—NR6—;
- each n is independently 0-3;
- each m is independently 0-2;
- each p is independently 0-4;
- each q is independently 0-4;
- each s is independently 0-3;
- each t is independently 0-4;
- each R is independently -D, -halo, —CN, —NO2, —C1-C6alkyl, —C2-C6alkenyl, —C1-C6alkoxy, -cycloalkyl, —ORa, —SRa, —C(O)Rb, —C(O)ORa, —NRcRd, —C(O)NRcRd, or —S(O)2Ra; wherein said —C1-C6alkyl, —C2-C6alkenyl, —C1-C6alkoxy, or -cycloalkyl is optionally substituted;
- each R1 is independently -D, -halo, —CN, —NO2, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —ORa, —SRa, —NRcRd, —C(O)Rb, —OC(O)Rb, —C(O)ORa, —C(O)NRcRd, —S(O)2Ra; -aryl, -heteroaryl, -cycloalkyl, or -heterocycloalkyl, wherein said —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, -cycloalkyl, -heterocycloalkyl, -aryl, or -heteroaryl is optionally substituted;
- each R2, R2A, or R2a is independently H, D, halo, ORa, optionally substituted C1-C6alkyl, or R2 and R2A that are attached to the same carbon atom may, together with the carbon atom to which they are both attached, form an optionally substituted cycloalkyl ring;
- each R2B and R2C is independently H, D, optionally substituted C1-C6alkyl, or R2B and R2C may, together with the carbon atom to which they are both attached, form an optionally substituted cycloalkyl ring;
- R3 is H, D, —C1-C6alkyl, —C3-C6alkenyl, —C3-C6alkynyl, cycloalkyl, heterocycloalkyl, C(O)Rb, C(O)ORa, or C(O)NRcRd; wherein said C1-C6alkyl, —C3-C6alkenyl, —C3-C6alkynyl, cycloalkyl, or heterocycloalkyl is optionally substituted; or R3 is —C1-C6alkyl substituted at the C1 carbon atom with —OR3A wherein R3A is C1-C6alkyl, —PO3H, —C(O)OR2C, or —C(O)NR3AR3B wherein R3A and R3B are each independently H, D, optionally substituted C1-C6alkyl;
- each R4 or R7 is independently H, D, halo, —OH, —CN, —NO2, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, —ORa, —SRa, —NRcRd, —NRaRc, —C(O)Rb, —OC(O)Ra, —C(O)ORa, —C(O)NRcRd, —S(O)Rb, or —S(O)2Rb, wherein said C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkenyl, or heterocycloalkyl is optionally substituted;
- each R4A or R4B is independently H, D, -Me, —CF3 or —F;
- each R5 or R8 is independently H, D, fluoro, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —C(O)Rb, —C(O)ORa, —C(O)NRcRd, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein said C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted;
- or R4 and R5 together with the C atom to which they are attached form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted;
- or an R4 and an R5 attached to adjacent carbon atoms, together with the C atoms to which they are attached, form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted;
- or R7 and R8 together with the C atom to which they are both attached form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted, each optionally substituted;
- or an R7 and an R8 attached to adjacent carbon atoms, together with the C atoms to which they are attached, form a cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, each optionally substituted;
- each R6 or R9 is independently H, D, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —OC1-C6alkyl, —C(O)Rb, —C(O)ORa, —C(O)NRcRd, —S(O)Rb or —S(O)2Rb, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group, wherein said C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —OC1-C6alkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl ring, is optionally substituted;
- or R9 together with either an R7 or an R8 forms an optionally substituted heterocyclic alkylene;
- each R6A, R6B, R9A, or R9B is independently H, D, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein said C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted;
- or R6A and R6B together with the N atoms to which they are attached form an optionally substituted heterocycloalkyl or heterocycloalkenyl ring;
- or R9A and R9B together with the N atoms to which they are attached form an optionally substituted heterocycloalkyl or heterocycloalkenyl ring;
- each Ra is independently H, D, —C(O)Rb, —C(O)ORc, —C(O)NRcRd, —P(ORc)2, —P(O)RcRb, —P(O)ORcORb, —S(O)Rb, —S(O)NRcRd, —S(O)2Rb, —S(O)2NRcRd, —B(ORc)(ORb), SiRb 3, —C1-C10alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl wherein said C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted;
- each Rb, is independently H, D, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl wherein said —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, aryl, cycloalkyl, cycloalkeneyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl is optionally substituted;
- each Rc or Rd is independently H, D, —C1-C10 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —OC1-C6alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein said C1-C10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, —OC1-C6alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl are each optionally substituted;
- or Rc and Rd, together with the N atom to which they are both attached, form an optionally substituted monocyclic or multicyclic heterocycloalkyl, or optionally substituted monocyclic or multicyclic heterocycloalkenyl group.
- Aspect 2. The compound according to aspect 1 having the Formula IA-0,
-
- or a pharmaceutically acceptable salt or solvate thereof;
wherein - Z is CH or N;
- Q is —O—, —S—, —S(O)—, or —S(O)2—;
- the moiety -W1-W2-W3 is —CR2R2A—CR2R2A—CR2R2A—, —O—CR2BR2C—CR2R2A—, —CR2R2A—CR2BR2C—O—, —NR2B—CR2BR2C—CR2R2A—, —CR2R2A—CR2BR2C— NR2B—, —S—CR2BR2C—CR2R2A—, or —CR2R2A—CR2BR2C—S—;
- L1 is optionally substituted —C1-C6alkylene-;
- L2 is optionally substituted 3-7 membered cycloalkylene, optionally substituted 4-7 membered heterocycloalkylene, optionally substituted arylene, or optionally substituted heteroarylene;
- L3 is absent, or is —(CR4R5)p—, —(CR4R5)pO—, —O—, —S—, —S(O)—, —S(O)2—, —C(═O)—, —NR6—, —OC(═O)—, —C(═O)O—, —NR6AC(O)—, —C(═O)NR6A—, —OC(═O)N(R6A)—, —NR6AC(O)O—, —S(═O)NR6A—, —NR6AS(O)—, —S(═O)2NR6A—, or —NR6AS(O)2—;
- L4 is absent, or is —(CR4R5)pQ1(CR4R5)q—, wherein Q1 is absent, —CR4A═CR4B—, —O—, —S—, —S(O)—, —S(O)2—, —C(═O)—, —NR6—, —OC(═O)—, —C(═O)O—, —NR6AC(O)—, —C(═O)NR6A—, —NR6AC(O)R6B—, —OC(═O)N(R6A)—, —NR6AC(O)O—, —S(═O)NR6A—, —NR6AS(O)—, —S(═O)2NR6A—, or —NR6AS(O)2—; or is —(CR4R5)p—(CR4A═CR4B)—(CR4R5)q—O—;
- L5 is absent, or is —C1-C6 alkylene-, —C2-C6 alkenylene-, —C2-C6 alkynylene-, a 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, or 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene group, wherein said C1-C6 alkylene, C2-C6 alkenylene, C2-C6 alkynylene, a 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, or 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene groups are optionally substituted;
- L6 is absent, or is —(CR7R8)s—, —O(CR7R8)t—, —NR9(CR7R8)t—, —S(CR7R8)t—, —S(O)(CR7R8)t—, —S(O)2(CR7R8)t—, —NR9AC(O)(CR7R8)t—, —C(O)NR9A(CR7R8)t—, —R9AC(O)O(CR7R8)t—, —NR9AC(O)NR9B(CR7R8)t—, —NR9AS(O)(CR7R8)t—, —NR9AS(O)2(CR7R8)t—; —CR4A═CR4B—(CR7R8)t—, —C(═O)(CR7R8)t—; —C(═O)(CR7R8)t—O—, or —C(═O)(CR7R8)t—NR6—;
- each n is independently 0-3;
- each m is independently 0-2;
- each p is independently 0-4;
- each q is independently 0-4;
- each s is independently 0-3;
- each t is independently 0-4;
- each R is independently D, halo, —CN, —NO2, C1-C6alkyl, C2-C6alkenyl, C1-C6alkoxy, C3-C6cycloalkyl, —ORa, —SRa, —C(O)Rb, —C(O)ORa, —NRcRd, —C(O)NRcRd, or —S(O)2Ra; wherein said C1-C6alkyl, C2-C6alkenyl, C1-C6alkoxy, or C3-C6cycloalkyl is optionally substituted;
- each R1 is independently D, halo, —CN, —NO2, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —ORa, —SRa, —NRcRd, —C(O)Rb, —OC(O)Rb, —C(O)ORa, —C(O)NRcRd, —S(O)2Ra; aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein said C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, is optionally substituted;
- each R2, R2A, or R2a is independently H, D, halo, —ORa, optionally substituted —C1-C6alkyl, or R2 and R2A, that are attached to the same carbon atom may, together with the carbon atom to which they are both attached, form an optionally substituted 3-7 membered cycloalkyl ring;
- R2B and R2C are each independently H, D, optionally substituted C1-C6alkyl, or R2B and R2C may, together with the carbon atom to which they are both attached, form an optionally substituted 3-7 membered cycloalkyl ring;
- R3 is H, D, —C1-C6alkyl, —C3-C6alkenyl, —C3-C6alkynyl, 3-7 membered cycloalkyl, -4-7 membered heterocycloalkyl, —C(O)Rb, —C(O)ORa, or —C(O)NRcRd; wherein said C1-C6alkyl, —C3-C6alkenyl, —C3-C6alkynyl, cycloalkyl, and heterocycloalkyl is optionally substituted; or R3 is —C1-C6alkyl substituted at the C1 carbon atom with —OR3A wherein R3A is C1-C6alkyl, —PO3H, —C(O)OR2C, or —C(O)NR3AR3B wherein R3A and R3B are each independently H, D, optionally substituted C1-C6alkyl;
- each R4 or R7 is independently H, D, halo, —OH, —CN, —NO2, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, 3-7 membered cycloalkyl, —ORa, —SRa, —NRcRd, —NRaRc, —C(O)Rb, —OC(O)Ra, —C(O)ORa, —C(O)NRcRd, —S(O)Rb, —S(O)2Rb, aryl, heteroaryl, or heterocycloalkyl, wherein said C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl is optionally substituted;
- each R4A or R4B is independently H, D, -Me, —CF3 or —F;
- each R5 or R8 is independently H, D, fluoro, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —C(O)Rc, —C(O)ORc, —C(O)NRcRd, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein said C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl is optionally substituted;
- or R4 and R5 together with the C atom to which they are attached form a cycloalkyl or heterocycloalkyl ring, each optionally substituted;
- or R7 and R8 together with the C atom to which they are attached form a cycloalkyl or heterocycloalkyl ring, each optionally substituted;
- each R6 or R9 is independently H, D, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —OC1-C6alkyl, —C(O)Rb, —C(O)ORa, —C(O)NRcRd, —S(O)Rb or —S(O)2Rb, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group, wherein said C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —OC1-C6alkyl, -aryl, heteroaryl, cycloalkyl, or heterocycloalkyl is optionally substituted;
- each R6A, R6B, R9A, or R9B is independently H, D, C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, 3-7 membered cycloalkyl, 4-7 membered heterocycloalkyl, wherein said C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, 3-7 membered cycloalkyl, or 4-7 membered heterocycloalkyl is optionally substituted;
- or R6A and R6B together with the atoms to which they are attached form an optionally substituted heterocycloalkyl ring;
- or R9A and R9B together with the N atom to which they are attached form an optionally substituted heterocycloalkyl ring;
- each Ra is independently H, D, —C(O)Rb, —C(O)ORe, —C(O)NRcRd, —P(ORc)2, —P(O)RcRb, —P(O)ORcORb, —S(O)Rb, —S(O)NRcRd, —S(O)2Rb, —S(O)2NRcRd, —B(ORc)(ORb), —SiRb3, —C1-C10alkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, wherein said C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted;
- each Rb is independently H, D, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, wherein said C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted;
- each Rc or Rd is independently H, D, C1-C10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, —OC1-C6alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, wherein said C1-C10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, —OC1-C6alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, is optionally substituted;
- or Rc and Rd, together with the N atom to which they are both attached, form an optionally substituted monocyclic or multi cyclic -4-10 membered heterocycloalkyl group.
- or a pharmaceutically acceptable salt or solvate thereof;
- Aspect 3. The compound according to either aspect 1 or aspect 2, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound has the Formula IA:
-
- wherein W1 is —CH2— and W3 is —O—, or W1 is —O— and W3 is —CH2—, or W1 is —CH2— and W3 is —S—, or W1 is —S— and W3 is —CH2—, or W1 is —CH2— and W3 is —NR2B—, or W1 is —NR2B— and W3 is —CH2—, or W1 is —CH2— and W3 is —CH2—.
- Aspect 4. The compound according to aspect 3, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound has the Formula IA-1:
- Aspect 5. The compound according to aspect 4, wherein W1 is —CH2— or —O—.
- Aspect 6. A compound according to aspect 3, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound has the Formula IA-2:
- Aspect 7. The compound according to aspect 6, wherein W3 is —CH2— or —O—.
- Aspect 8. The compound according to aspect 3, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound has the Formula IA-3:
- wherein W1 is —CH2— and W3 is O, or W1 is —O— and W3 is —CH2—, or W1 is —CH2— and W3 is —CH2—.
- Aspect 9. The compound according to any one of aspects 1-8, wherein L1 is optionally substituted C1alkylene.
- Aspect 10. The compound according to aspect 9, wherein L1 is —CH2—.
- Aspect 11. The compound according to any one of aspects 1-10, wherein L2 is optionally substituted cycloalkylene or optionally substituted heterocycloalkylene.
- Aspect 12. The compound according to aspect 11, wherein L1 is —CH2—; and L2 is optionally substituted cyclobutylene or optionally substituted pyrrolidine.
- Aspect 13. The compound according to any one of aspects 1-12, wherein said compound is a compound of Formula IA-4:
-
- or a pharmaceutically acceptable salt or solvate thereof; wherein
- W1 is —CH2— and W3 is O, or W1 is —O— and W3 is —CH2—, or W1 is —CH2— and W3 is —CH2—;
- L3 is absent, or is —(CR4R5)p—, —(CR4R5)pO—, —S(O)—, —S(O)2—, —C(═O)—, —C(═O)O—, —C(═O)NR6A—, —NR6AC(O)O—, —S(═O)NR6A—, —NR6AS(O)—, —S(═O)2NR6A—, or —NR6AS(O)2—;
- L4 is absent, or —(CR4R5)pQ1(CR4R5)q—, wherein Q1 is absent, —CR4A═CR4B—, —O—, —S—, —S(O)—, —S(O)2—, —C(═O)—, —NR6—, —OC(═O)—, —C(═O)O—, —NR6AC(O), —C(═O)NR6A—, —NR6AC(O)R6B—, —OC(═O)N(R6A)—, —NR6AC(O)O—, —S(═O)NR6A—, —NR6AS(O)—, —S(═O)2NR6A—, or —NR6AS(O)2—;
- L5 is absent, or is a 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 12-membered cycloalkenylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, a 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene group, wherein the 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 12-membered cycloalkenylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, a 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene group is optionally substituted; and
- L6 is absent, or is —(CR7R8)s—, —O(CR7R8)t—, —NR9(CR7R8)t—, —S(CR7R8)t—, —S(O)(CR7R8)t—, —S(O)2(CR7R8)t—, —NR9AC(O)(CR7R8)t—, —C(O)NR9A(CR7R8)t—, —R9AC(O)O(CR7R8)t—, —NR9AC(O)NR9B(CR7R8)t—, —NR9AS(O)(CR7R8)t—, —NR9AS(O)2(CR7R8)t—; —CR4A═CR4B—(CR7R8)t—, —C(═O)(CR7R8)t—; —C(═O)(CR7R8)t—O—, or —C(═O)(CR7R8)t—NR6—.
- or a pharmaceutically acceptable salt or solvate thereof; wherein
- Aspect 14. The compound according to any one of aspects 1-13, or a pharmaceutically acceptable salt or solvate thereof; wherein
- L3 absent;
- L4 is —(CR4R5)pQ1(CR4R5)q—, wherein Q1 is absent, —CR4A═CR4B—, —O—, —S—, —S(O)—, —S(O)2—, —C(═O)—, —NR6—, —OC(═O)—, —C(═O)O—, —NR6AC(O), —C(═O)NR6A—, —NR6AC(O)R6B—, —OC(═O)N(R6A)—, —NR6AC(O)O—, —S(═O)NR6A—, —NR6AS(O)—, —S(═O)2NR6A—, or —NR6AS(O)2—;
- L5 is absent; and
- L6 is absent, or is —(CR7R8)s—, —O(CR7R8)t—, —NR9(CR7R8)t—, —S(CR7R8)t—, —S(O)(CR7R8)t—, —S(O)2(CR7R8)t—, —NR9AC(O)(CR7R8)t—, —C(O)NR9A(CR7R8)t—, —R9AC(O)O(CR7R8)t—, —NR9AC(O)NR9B(CR7R8)t—, —NR9AS(O)(CR7R8)t—, —NR9AS(O)2(CR7R8)t—; —CR4A═CR4B—(CR7R8)t—, —C(═O)(CR7R8)t—; —C(═O)(CR7R8)t—O—, or —C(═O)(CR7R8)t—NR6—.
- Aspect 15. The compound according to any one of aspects 1-14, wherein
- L4 is —(CR4R5)pQ1(CR4R5)q—, wherein Q1 is —CR4A═CR4B—; and
- L6 is absent, —O(CR7R8)t—, or —NR9(CR7R8)t—.
- Aspect 16. The compound according to any one of aspects 1-15, wherein
- p=1;
- q=1-4; and
- t=1.
- Aspect 17. The compound according to any one of aspects 1-13, or a pharmaceutically acceptable salt or solvate thereof; wherein
- L3 absent;
- L4 is —(CR4R5)pQ1(CR4R5)q—, wherein Q1 is absent, —CR4A═CR4B—, —O—, —S—, —S(O)—, —S(O)2—, —C(═O)—, —NR6—, —OC(═O)—, —C(═O)O—, —NR6AC(O), —C(═O)NR6A—, —NR6AC(O)R6B—, —OC(═O)N(R6A)—, —NR6AC(O)O—, —S(═O)NR6A—, —NR6AS(O)—, —S(═O)2NR6A—, or —NR6AS(═O)2—;
- L5 is a 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 12-membered cycloalkenylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, a 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene group, wherein the 6- to 10-membered arylene, 5- to 10-membered heteroaryl ene, a 3- to 12-membered cycloalkenylene, a 3- to 12-membered cycloalkenylene, a 3- to 7-membered monocyclic cycloalkylene, a 6- to 12 bicyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, or 6- to 12-membered bicyclic heterocycloalkylene group is optionally substituted; and
- L6 is absent, or is —(CR7R8)s—.
- Aspect 18. The compound according to any one of aspects 1-13 or 17, wherein
- L4 is —(CR4R5)pQ1(CR4R5)q—, wherein Q1 is —CR4A═CR4B—, —O—, —S—, —S(O)—, —S(O)2—, —C(═O)—, —OC(═O)—, —C(═O)O—, —OC(═O)N(R6A)—, or —NR6AC(O)O—;
- L5 is a 6- to 10-membered arylene, 5- to 10-membered heteroaryl ene, a 3- to 7-membered monocyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene, wherein the 6- to 10-membered arylene, 5- to 10-membered heteroarylene, a 3- to 7-membered monocyclic cycloalkylene, a 3- to 7-membered monocyclic heterocycloalkylene is optionally substituted; and
- L6 is absent, or is —(CR7R8)s—.
- Aspect 19. The compound according to any one of aspects 1 to 14, or a pharmaceutically acceptable salt or solvate thereof; wherein L4 is —(CR4R5)pQ1(CR4R5)q— wherein p=1; q=1-3, Q1 is absent, or —CR4A═CR4B—; L6 is (CR7R8)s wherein s=1-2, —O(CR7R8)t—, —NR9(CR7R8)t—, —S(CR7R8)t—, —S(O)(CR7R8)t—, or —S(O)2(CR7R8)t—, wherein t=1.
- Aspect 20. The compound according to any one of aspects 1-14 or 19, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound is a compound of Formula IA-8:
-
- wherein X is O, NR9, CR7R8, S, S(O), SO2;
- R is halo or C1-C6alkyl;
- represents a carbon-carbon single bond in which each carbon atom in the bond is substituted with R4 and R5, an (E)-carbon-carbon double bond, or a (Z)-carbon-carbon double bond;
- Ra* is Ra wherein Ra is H, —C(O)Rb, —C(O)ORc, —C(O)NRcRd, P(ORc)2, P(O)RcRb, P(O)ORcORb, S(O)Rb, S(O)NRcRd, S(O)2Rb, S(O)2NRcRd, B(ORc)(ORb), SiRb3, C1-C10alkyl, C2-C10 alkenyl, C2-C10 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, wherein said C1-C10 alkyl, C2-C10alkenyl, C2-C10 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted;
- Rc* is Rc wherein Rc is H, D, —C1-C10 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —OC1-C6alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, wherein said C1-C10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, —OC1-C6alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl are each optionally substituted.
- Aspect 21. The compound according to aspect 20, wherein represents a carbon-carbon single bond in which each carbon atom in the bond is substituted with R4 and R5.
- Aspect 22. The compound according to aspect 20, wherein represents a carbon-carbon double bond substituted with R4A and R4B.
- Aspect 23. The compound according to aspect 22, wherein represents a (E)-carbon-carbon double bond substituted with R4A and R4B.
- Aspect 24. The compound according to any one of aspects 20-23, wherein X is —O—, —NR9—, or —CR7R8—.
- Aspect 25. The compound according to any one of aspects 20-24, wherein Ra* is Ra wherein Ra is H, —C(O)Rb, —C(O)ORc, —C(O)NRcRd, —S(O)2Rb, or optionally substituted C1-C6alkyl; and Rc* is Rc wherein Rc is H or optionally substituted C1-C10alkyl.
- Aspect 26. The compound according to any one of aspects 20-25, wherein R is —Cl.
- Aspect 27. The compound according to any one of aspects 20-26, wherein each R4 and R5 is independently H or C1-C6alkyl.
- Aspect 28. The compound according to any one of aspects 1-14 or 19, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound is a compound of Formula IA-5:
-
- wherein X is —O—, —NR9—, —CR7R8—, —S—, —S(O)—, —SO2—; R is halo or C1-C6alkyl;
- represents a carbon-carbon single bond in which each carbon atom in the bond is substituted with R4 and R5, an (E)-carbon-carbon double bond substituted with R4A and R4B, or a (Z)-carbon-carbon double bond substituted with R4A and R4B; and Ra* is Ra wherein Ra is H, —C(O)Rb, —C(O)ORc, —C(O)NRcRd, P(ORc)2, P(O)RcRb, P(O)ORcORb, S(O)Rb, S(O)NRcRd, S(O)2Rb, S(O)2NRcRd, B(ORc)(ORb), SiRb 3, C1-C10alkyl, C2-C10 alkenyl, C2-C10 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, wherein said C1-C10 alkyl, C2-C10alkenyl, C2-C10 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted.
- Aspect 29. The compound according to aspect 28, wherein represents a carbon-carbon single bond in which each carbon atom in the bond is substituted with R4 and R5.
- Aspect 30. The compound according to aspect 28, wherein represents a carbon-carbon double bond substituted with R4A and R4B.
- Aspect 31. The compound according to any one of aspects 28-30wherein X is —O—, —NR9—, or —CR7R8—.
- Aspect 32. The compound according to any one of aspects 28-31, wherein Ra* is Ra wherein Ra is H, —C(O)Rb, —C(O)NRcRd, optionally substituted C1-C10alkyl, optionally substituted C2-C10alkenyl, optionally substituted C2-C10 alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl.
- Aspect 33. The compound according to aspect 30, having the structure IA-6:
-
- or a pharmaceutically acceptable salt or solvate thereof;
- wherein X is —O—, —NR9—, or —CR7R8—; and
- W1 is —CH2— and W3 is O, or W1 is —O— and W3 is —CH2—, or W1 is —CH2— and W3 is —CH2—.
- or a pharmaceutically acceptable salt or solvate thereof;
- Aspect 34. The compound according to any one of aspects 28-33, wherein each R4 or R5 is independently H, D, or C1-C6alkyl.
- Aspect 35. The compound according to any one of aspects 20-34, wherein X is —CR7R8—.
- Aspect 36. The compound according to any one of aspects 20-34, wherein X is —O—.
- Aspect 37. The compound according to any one of aspects 20-34, wherein X is —NR9—.
- Aspect 38. The compound according to aspect 37, wherein X is —NR9— wherein R9 is H; optionally substituted —C1-C6alkyl; optionally substituted —C(O)OC1-C6alkyl; optionally substituted —SO2C1-C6alkyl; optionally substituted —C(O)C1-C6alkyl; optionally substituted —C(O)NRcRd; or wherein R9 together with either R7 or R8 form an optionally substituted C1-C6alkylene group.
- Aspect 39. The compound according to aspect 38, wherein X is —NR9— wherein R9 is H; —C1-C6alkyl, optionally substituted with deuterium; —C(O)OC1-C6alkyl; —SO2C1-C6alkyl; —C(O)C1-C6alkyl; or wherein R9 together with either R7 or R8 form a C1-C6alkylene group.
- Aspect 40. The compound according to aspect 39, wherein X is —NR9— wherein R9 is H; —CH3; —CH2CH3, —CH2CH2CH3, —CD3, —C(O)OCH3; —C(O)OC(CH3)3, —SO2CH3; or —C(O)CH3.
- Aspect 41. The compound according to anyone of aspects 20-40, wherein each R7 and each R8 is independently H, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted —C1-C6alkyl;
- or R7 and R8 attached to the same carbon atom, together with that carbon atom, form an optionally substituted cycloalkyl ring or an optionally substituted heterocycloalkyl ring;
- or R7 and R8 attached to adjacent carbon atoms, together with those carbon atoms, form an optionally substituted cycloalkyl ring or and optionally substituted heterocycloalkyl ring.
- Aspect 42. The compound of aspect 41, wherein each R7 and each R8 is independently H, optionally substituted 3-7 membered cycloalkyl, 4-7 membered heterocycloalkyl, or optionally substituted —C1-C6alkyl;
- or wherein R7 and R8 attached to the same carbon atom, together with that carbon atom, form an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocycloalkyl ring;
- or R7 and R8 attached to adjacent carbon atoms, together with those carbon atoms, form an optionally substituted 3-7 membered cycloalkyl ring or an optionally substituted 4-7 membered heterocycloalkyl ring.
- Aspect 43. The compound of aspect 42, wherein R7 and R8 attached to the same carbon atom, together with that carbon atom, form a 3-7 membered cycloalkyl ring or 4-7 membered heterocycloalkyl ring;
- or R7 and R8 attached to adjacent carbon atoms, together with the atoms to which they are attached, form a 3-7 membered cycloalkyl ring or 4-7 membered heterocycloalkyl ring.
- Aspect 44. The compound of aspect 42, wherein R7 or R8 are each independently H, —CH3, -cyclopropyl, —CH2CH3, or —CH(CH3)2.
- Aspect 45. The compound of aspect 42, wherein R7 and R8 attached to the same carbon atom, together with that carbon atom, form a cyclopropyl ring, a cyclobutyl ring, or azetidinyl ring.
- Aspect 46. The compound of aspect 41, wherein each R7 and each R8 is independently H, or a —C1-C6alkyl group optionally substituted with —OH; optionally substituted —OC1-C6alkyl; optionally substituted —(CH2CH2O)oC1-C6alkyl wherein o is 1-10; or —C(O)NRc1Rd1 wherein Rc1 and Rd1 are independently H, optionally substituted —C1-C6alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl; or wherein or Rc1 and Rd1, together with the N atom to which they are both attached, form an optionally substituted monocyclic or multicyclic heterocycloalkyl ring.
- Aspect 47. The compound of aspect 46, wherein the —C1-C6alkyl group is optionally substituted with —OH; —OC1-C6alkyl; —(CH2CH2O)oC1-C6alkyl wherein o is 1-10; or —C(O)NRc1Rd1 wherein Rc1 and Rd1 are independently H, C1-C6alkyl, or 4-7 membered heterocycloalkyl; or wherein or Rc1 and Rd1, together with the N atom to which they are both attached, form a monocyclic or multicyclic 4-7 membered heterocycloalkyl ring optionally substituted with halo; —OC1-C6alkyl; or —C1-C6alkyl optionally substituted with —OH or —OC1-C6alkyl.
- Aspect 48. The compound of any one of aspects 28-47, wherein Ra* is Ra wherein Ra is H.
- Aspect 49. The compound of any one of aspects 28-47, wherein Ra* is Ra wherein Ra is —C(O)Rb.
- Aspect 50. The compound of any one of aspects 28-47, wherein Ra* is Ra wherein Ra is —C(O)Rb wherein Rb is optionally substituted —C1-C6alkyl.
-
Aspect 51. The compound of aspect 50, wherein Ra* is Ra wherein Ra is —C(O)Rb wherein Rb is —C1-C6alkyl. - Aspect 52. The compound of
aspect 51, wherein Ra* is Ra wherein Ra is —C(O)Rb wherein Rb is —CH3. - Aspect 53. The compound of any one of aspects 28-47, wherein Ra* is Ra wherein Ra is —C(O)NRcRd.
- Aspect 54. The compound of any one of aspects 28-47, wherein Ra* is Ra wherein Ra is —C(O)NRcRd wherein Rc and Rd are independently H; optionally substituted —OC1-C6alkyl; optionally substituted cycloalkyl; optionally substituted —C1-C6alkyl, or optionally substituted heterocycloalkyl.
- Aspect 55. The compound of aspect 54, wherein Ra* is Ra wherein Ra is —C(O)NRcRd wherein Rc and Rd are independently H; optionally substituted 3-7 membered cycloalkyl; —OC1-C6alkyl; —C1-C6alkyl (optionally substituted with deuterium, halo, optionally substituted cycloalkyl, optionally substituted —OC1-C6alkyl, —NRc1Rd1 wherein Rc1 and Rd1 are independently H or optionally substituted —C1-C6alkyl, optionally substituted 4-7 membered heterocycloalkyl, or optionally substituted 5-6 membered heteroaryl); or optionally substituted 4-7 membered heterocycloalkyl.
- Aspect 56. The compound aspect 54, wherein Ra* is Ra wherein Ra is —C(O)NRcRd wherein Rc and Rd are independently H; 3-7 membered cycloalkyl; —C1-C6alkyl (optionally substituted with deuterium, halo, —OC1-C6alkyl, cycloalkyl, —NRc1Rd1 wherein Rc1 and Rd1 are independently H or —C1-C6alkyl, 4-7 membered heterocycloalkyl (optionally substituted with halo, —C1-C6alkyl, —OH, or —OC1-C6alkyl), or -5-6 membered heteroaryl), —OC1-C6alkyl; or -4-7 membered heterocycloalkyl optionally substituted with —C1-C6alkyl or —OH.
- Aspect 57. The compound of any one of aspects 33-39, wherein Ra* is Ra wherein Ra is —C(O)NRcRd wherein Rc and Rd, together with the nitrogen atom to which they are both attached, form an optionally substituted monocyclic or multicyclic heterocycloalkyl group.
- Aspect 58. The compound of aspect 47, wherein Ra* is Ra wherein Ra is —C(O)NRcRd wherein Rc and Rd, together with the nitrogen atom to which they are both attached, form a monocyclic or multicyclic heterocycloalkyl group optionally substituted with -halo, —OH, optionally substituted -4-7 membered heterocycle, optionally substituted 5-6 membered heteroaryl, optionally substituted —OC1-C6alkyl, optionally substituted —C1-C6alkyl; or —NRc1Rd1 wherein Rc1 and Rd1 are independently H or optionally substituted C1-C6alkyl,
- Aspect 59. The compound of aspect 28-47, wherein Ra* is Ra wherein Ra is —C(O)NRcRd wherein Rc and Rd, together with the nitrogen atom to which they are both attached, form a monocyclic or multicyclic -4-10 membered heterocycloalkyl group optionally substituted with -halo, —OH, -4-7 membered heterocycle, 5-6 membered heteroaryl, —OC1-C6alkyl, —C1-C6alkyl (optionally substituted with —OH, —OC1-C6alkyl, or NRc1Rd1 wherein Rc1 and Rd1 are independently H or C1-C6alkyl); or —NRc1Rd1 wherein Rc1 and Rd1 are independently H or C1-C6alkyl.
- Aspect 60. The compound according to any one of aspects 28-47, wherein Ra* is Ra wherein Ra is optionally substituted —C1-C6alkyl.
- Aspect 61. The compound of aspect 60, wherein Ra* is Ra wherein Ra is —C1-C10alkyl optionally substituted with —C(O)NRc1Rd1, wherein Rc1 and Rd1 are independently H, optionally substituted C1-C6alkyl, or optionally substituted heterocyclyl; or wherein or Rc1 and Rd1, together with the N atom to which they are both attached, form an optionally substituted monocyclic or multicyclic -4-10 membered heterocycloalkyl group; —NRc1Rd1 wherein Rc1 and Rd1 are independently H, optionally substituted C1-C6alkyl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl; optionally substituted heteroaryl; —C(O)OH; or optionally substituted -heterocycloalkyl.
- Aspect 62. The compound of aspect 61, wherein Ra* is Ra wherein Ra is —C1-C10alkyl optionally substituted with —C(O)NRc1Rd1, wherein Rc1 and Rd1 are independently H, C1-C6alkyl (optionally substituted with —OC1-C6alkyl), or 4-7 membered heterocycloalkyl; or wherein or Rc1 and Rd1, together with the N atom to which they are both attached, form a monocyclic or multicyclic -4-10 membered heterocycloalkyl group (optionally substituted with halo, —OC i-C6alkyl, or —C1-C6alkyl (optionally substituted with —OH or —OC1-C6alkyl)); —NRc1Rd1 wherein Rc1 and Rd1 are independently H, or optionally substituted C1-C6alkyl; —C4-C5heteroaryl; —C(O)OH; or -4-7 membered heterocycloalkyl optionally substituted with halo, C1-C6alkyl, or —OC1-C6alkyl.
- Aspect 63. The compound according to any one of aspects 28-62, wherein the compound has the structure (IA-7):
- wherein W1 is —CH2— and W3 is —O—; or W1 is —O— and W3 is —CH2—; or W1 is —CH2— and W3 is —CH2-.
- Aspect 64. The compound according to aspect 63, wherein W1 is —CH2— and W3 is —CH2-.
- Aspect 65. A compound, or a pharmaceutically acceptable salt or solvate thereof, wherein said compound is:
- (3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-12,12-ethylene-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one;
- (3R,6R,7R,8E,12S,22S)-6′-chloro-7-methoxy-12-methyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one;
- (3R,6R,7R,8E,12R,22S)-6′-chloro-7-methoxy-11,12-dimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-13-one;
- (3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one;
- (3R,6R,7R,8E,22S)-6′-chloro-7-hydroxy-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one;
- (3R,6R,7R,8E,22S)-6′-chloro-7-methoxy-11,12,12-trimethyl-15,15-dioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one;
- [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;
- [(3R,6R,7S,8E,22S)-6′-Chloro-12,12-ethylene-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;
- [(3R,6R,7S,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;
- [(3R,6R,7S,8E,22S)-6′-chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;
- [(3R,6R,7S,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methylcarbamate;
- [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-11-(trideuteriomethyl)spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;
- [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-(dimethylamino)azetidine-1-carboxylate;
- [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-(dimethylamino)pyrrolidine-1-carboxylate;
- [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-methyl-1,4-diazepane-1-carboxylate;
- [(3R,6R,7S,8E,22S)-6′-chloro-11-ethyl-12,12-dimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]N,N-dimethylcarbamate;
- [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-11-propyl-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]N,N-dimethylcarbamate;
- [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-methoxypiperidine-1-carboxylate;
- [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[2-(dimethylamino)ethyl]-N-methyl-carbamate;
- [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-methoxyazetidine-1-carboxylate;
- [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-1-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 3-ethoxyazetidine-1-carboxylate;
- [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-methoxypyrrolidine-1-carboxylate;
- [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-ethoxypyrrolidine-1-carboxylate;
- [(3R,6R,7S,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]morpholine-4-carboxylate;
- [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] 4-(2-m ethoxy ethyl)-1,4-diazepane-1-carboxylate;
- [(3R,6R,7S,8E,22S)-7′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-7-yl] N,N-dimethylcarbamate;
- [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[(3R)-tetrahydrofuran-3-yl]carbamate;
- [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[(3S)-tetrahydrofuran-3-yl]carbamate;
- (3R,6R,7S,8E,22S)-6′-chloro-7-[2-(dimethylamino)ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one;
- (3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-15,15-dioxo-7-(2-pyrrolidin-1-ylethoxy)spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-13-one;
- [(3R,6R,7S,8E,22S)-6′-chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-methoxypyrrolidine-1-carboxylate;
- [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methoxy-N-methyl-carbamate;
- [(3R,6R,7S,8E,22S)-6′-chloro-12,12-1,3-propylene-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16(25),17,19(24)-tetraene-22,1′-tetralin]-7-yl] N-methyl-N[2-(dimethylamino)ethyl] carbamate;
- [(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-[(3R)-tetrahydrofuran-3-yl]carbamate;
- [(3R,6R,7S,8E,22S)-6′-chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-[(3R)-tetrahydrofuran-3-yl]carbamate;
- [(3R,6R,7S,8E,22S)-6′-chloro-11,12,12-trimethyl-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-[(3R)-tetrahydrofuran-3-yl]carbamate;
- [(3R,6R,7S,8E, 22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-bis(trideuteriomethyl)carbamate;
- 2-[(3R,6R,7S,8E,22S)-6′-chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl]oxy-N-tetrahydropyran-4-yl-acetamide;
- [(3R,6R,7S,8E,22S)-6′-chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-(oxetan-3-yl)carbamate;
- [(3R,6R,7S,8E,22S)-6′-chloro-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-tetrahydropyran-4-yl-carbamate;
- [(3R,6R,7S,8E,22S)-6′-chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-tetrahydropyran-4-yl-carbamate;
- [(3R,6R,7S,8E,22S)-6′-chloro-10,12,12-trimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;
- [(3R,6R,7S,8E,22S)-6′-chloro-7,12,12-trimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;
- [(3R,6R,7S,8E,22S)-7′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-7-yl] N-methyl-N-[(3R)-tetrahydrofuran-3-yl]carbamate;
- [(3R,6R,7S,8E,22S)-7′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-7-yl] N-methoxy-N-methyl-carbamate;
- [(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-[2-(dimethylamino)ethyl]-N-methyl-carbamate;
- [(3R,6R,7S,8E,22S)-6′-Chloro-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] (3R)-3-ethoxypyrrolidine-1-carboxylate;
- [(3R,6R,7S,8E,22S)-6′-Chloro-10,10-dideuterio-12,12-dimethyl-13,15,15-trioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N,N-dimethylcarbamate;
- (3R,6R,7S,8E,22S)-7′-chloro-7-[2-(dimethylamino)ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one;
- (3R,6R,7S,8E,22S)-7′-chloro-7-[2-(diethylamino)ethoxy]-12,12-dimethyl-15,15-dioxo-spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one;
- (3R,6R,7S,8E,22S)-7′-chloro-12,12-dimethyl-15,15-dioxo-7-(2-pyrrolidin-1-ylethoxy)spiro[11,20-dioxa-15-thia-1,14-diazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,4′-chromane]-13-one;
- [(3R,6R,7S,8E,22S)-6′-chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-(oxetan-3-yl)carbamate; or
- [(3R,6R,7S,8E,22S)-6′-chloro-11-methyl-12,12-(1,3-propylene)-13,15,15-trioxo-spiro[20-oxa-15-thia-1,11,14-triazatetracyclo[14.7.2.03,6.019,24]pentacosa-8,16,18,24-tetraene-22,1′-tetralin]-7-yl] N-methyl-N-[(3R)-tetrahydrofuran-3-yl]carbamate.
- Aspect 66. A pharmaceutical composition comprising a compound according to any one of aspects 1 to 65 and a pharmaceutically acceptable excipient.
- Aspect 67. A method of inhibiting an MCL-1 enzyme comprising contacting the MCL-1 enzyme with an effective amount of a compound of any one of aspects 1 to 65.
- Aspect 68. A method of treating a disease or disorder associated with aberrant MCL-1 activity in a subject comprising administering to the subject, a compound of any one of aspects 1 to 65.
- Aspect 69. The method of aspect 68, wherein the disease or disorder associated with aberrant MCL-1 activity is colon cancer, breast cancer, small-cell lung cancer, non-small-cell lung cancer, bladder cancer, ovarian cancer, prostate cancer, chronic lymphoid leukemia, lymphoma, myeloma, acute myeloid leukemia, or pancreatic cancer.
Claims (22)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/404,808 US20230010358A1 (en) | 2018-11-09 | 2021-08-17 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862758202P | 2018-11-09 | 2018-11-09 | |
US201962907451P | 2019-09-27 | 2019-09-27 | |
US201962909635P | 2019-10-02 | 2019-10-02 | |
US16/679,105 US11130769B2 (en) | 2018-11-09 | 2019-11-08 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein |
US17/404,808 US20230010358A1 (en) | 2018-11-09 | 2021-08-17 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/679,105 Continuation US11130769B2 (en) | 2018-11-09 | 2019-11-08 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230010358A1 true US20230010358A1 (en) | 2023-01-12 |
Family
ID=68808529
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/679,105 Active US11130769B2 (en) | 2018-11-09 | 2019-11-08 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein |
US17/404,808 Abandoned US20230010358A1 (en) | 2018-11-09 | 2021-08-17 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/679,105 Active US11130769B2 (en) | 2018-11-09 | 2019-11-08 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein |
Country Status (12)
Country | Link |
---|---|
US (2) | US11130769B2 (en) |
EP (1) | EP3877390A1 (en) |
JP (1) | JP2022506973A (en) |
KR (1) | KR20210089662A (en) |
CN (1) | CN113166173A (en) |
AU (1) | AU2019374907A1 (en) |
BR (1) | BR112021008796A2 (en) |
CA (1) | CA3118919A1 (en) |
IL (1) | IL283078A (en) |
MA (1) | MA54157A (en) |
MX (1) | MX2021005463A (en) |
WO (1) | WO2020097577A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2020012137A (en) | 2018-05-14 | 2021-01-29 | Gilead Sciences Inc | Mcl-1 inhibitors. |
CA3144558A1 (en) | 2019-07-09 | 2021-01-14 | Janssen Pharmaceutica Nv | Macrocyclic spirocycle derivatives as mcl-1 inhibitors |
WO2021032591A1 (en) * | 2019-08-16 | 2021-02-25 | Inflazome Limited | Macrocyclic sulfonylurea derivatives useful as nlrp3 inhibitors |
US20220389031A1 (en) * | 2019-08-16 | 2022-12-08 | Inflazome Limited | Macrocyclic sulfonylamide derivatives useful as nlrp3 inhibitors |
TWI778443B (en) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1 inhibitors |
KR20220105661A (en) | 2019-11-26 | 2022-07-27 | 길리애드 사이언시즈, 인코포레이티드 | Methods and intermediates for preparing MCL1 inhibitors |
US20230357275A1 (en) * | 2020-05-13 | 2023-11-09 | Prelude Therapeutics, Incorporated | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein |
EP4165050A1 (en) | 2020-06-10 | 2023-04-19 | JANSSEN Pharmaceutica NV | Macrocyclic 2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1 |
MX2023007297A (en) | 2020-12-17 | 2023-07-04 | Janssen Pharmaceutica Nv | Macrocyclic branched 3-fluoro-but-3-enamides as inhibitors of mcl-1. |
BR112023020877A2 (en) | 2021-04-26 | 2023-12-12 | Janssen Pharmaceutica Nv | MACROCYCLIC 2-ALLYLTETRAHYDROFURANS AS MCL-1 INHIBITORS |
EP4351657A1 (en) | 2021-06-11 | 2024-04-17 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
CA3222269A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
CN115677616A (en) * | 2021-11-03 | 2023-02-03 | 中国药科大学 | Macrocyclic sulfonamide compound, preparation method and medical application thereof |
AU2022391938A1 (en) | 2021-11-16 | 2024-07-04 | Janssen Pharmaceutica Nv | Macrocyclic 2-amino-but-3-enamides as inhibitors of mcl-1 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
US5350395A (en) | 1986-04-15 | 1994-09-27 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
US4748982A (en) | 1987-01-06 | 1988-06-07 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
CA1322628C (en) | 1988-10-04 | 1993-10-05 | Richard A. Schatz | Expandable intraluminal graft |
US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
US5292331A (en) | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
EA035929B1 (en) * | 2013-01-15 | 2020-09-02 | Инсайт Холдингс Корпорейшн | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDES USEFUL AS Pim KINASE INHIBITORS |
JO3474B1 (en) | 2014-08-29 | 2020-07-05 | Amgen Inc | Tetrahydronaphthalene derivatives that inhibit mcl-1 protein |
WO2017147410A1 (en) | 2016-02-25 | 2017-08-31 | Amgen Inc. | Compounds that inhibit mcl-1 protein |
CN106565706B (en) * | 2016-10-27 | 2018-05-01 | 广东东阳光药业有限公司 | A kind of sulfamide derivative and its application in pharmacy |
JP6453507B2 (en) * | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Compound that inhibits MCL-1 protein |
-
2019
- 2019-11-08 MA MA054157A patent/MA54157A/en unknown
- 2019-11-08 CA CA3118919A patent/CA3118919A1/en active Pending
- 2019-11-08 JP JP2021525143A patent/JP2022506973A/en active Pending
- 2019-11-08 BR BR112021008796-6A patent/BR112021008796A2/en unknown
- 2019-11-08 WO PCT/US2019/060638 patent/WO2020097577A1/en unknown
- 2019-11-08 MX MX2021005463A patent/MX2021005463A/en unknown
- 2019-11-08 US US16/679,105 patent/US11130769B2/en active Active
- 2019-11-08 CN CN201980073752.1A patent/CN113166173A/en active Pending
- 2019-11-08 KR KR1020217013796A patent/KR20210089662A/en active Search and Examination
- 2019-11-08 AU AU2019374907A patent/AU2019374907A1/en active Pending
- 2019-11-08 EP EP19816994.8A patent/EP3877390A1/en active Pending
-
2021
- 2021-05-09 IL IL283078A patent/IL283078A/en unknown
- 2021-08-17 US US17/404,808 patent/US20230010358A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2020097577A1 (en) | 2020-05-14 |
MA54157A (en) | 2021-09-15 |
US11130769B2 (en) | 2021-09-28 |
JP2022506973A (en) | 2022-01-17 |
EP3877390A1 (en) | 2021-09-15 |
IL283078A (en) | 2021-06-30 |
MX2021005463A (en) | 2021-06-18 |
AU2019374907A1 (en) | 2021-06-03 |
CA3118919A1 (en) | 2020-05-14 |
BR112021008796A2 (en) | 2021-08-03 |
KR20210089662A (en) | 2021-07-16 |
CN113166173A (en) | 2021-07-23 |
US20200148705A1 (en) | 2020-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11130769B2 (en) | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein | |
CN114901277B (en) | Isoindolinone and indazole compounds for EGFR degradation | |
US10711007B2 (en) | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | |
US11702423B2 (en) | BRM targeting compounds and associated methods of use | |
US11254683B2 (en) | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | |
TW202334138A (en) | Methods for treatment of cancer | |
US20220267345A1 (en) | CDK Inhibitors And Their Use As Pharmaceuticals | |
US20230212191A1 (en) | Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein | |
US20230265083A1 (en) | Heterocycle CDK Inhibitors And Their Use Thereof | |
US20230365576A1 (en) | BRM Targeting Compounds And Associated Methods Of Use | |
US20230357275A1 (en) | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein | |
US11939340B2 (en) | CDK inhibitors and their use as pharmaceuticals | |
US20230257394A1 (en) | CDK Inhibitors And Their Use As Pharmaceuticals | |
US20240150340A1 (en) | CDK Inhibitors And Their Use As Pharmaceuticals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: PRELUDE THERAPEUTICS, INCORPORATED, DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AFFINITY RESEARCH CHEMICALS, INC.;REEL/FRAME:063076/0349 Effective date: 20210423 Owner name: AFFINITY RESEARCH CHEMICALS, INC., DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WEI, PENG;REEL/FRAME:063076/0227 Effective date: 20210423 Owner name: PRELUDE THERAPEUTICS, INCORPORATED, DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZHOU, JINCONG;LEAL, RAUL A.;SHETTY, RUPA;AND OTHERS;SIGNING DATES FROM 20200714 TO 20200715;REEL/FRAME:063076/0033 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: AWAITING TC RESP., ISSUE FEE NOT PAID |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |